

PN	WO2000066629-A1.	
XX		
FD	09-NOV-2000.	
XX		
PF	28-APR-2000; 2000WO-US011814.	
XX		
PR	30-APR-1999; 99US-0132018P.	
XX		
PA	(AMYL-) AMYLIN PHARM INC.	
XX		
PI	Young A, Prickett K;	
XX		
DR	WPI; 2000-672834/65.	
XX		
PT	Modified extendin or an extendin agonist linked to one or more polyethylene	
PT	glycol (PEG) polymers, modulate plasma glucose levels, useful for	
PT	treating disorders such as diabetes and obesity.	
XX		
PS	Disclosure; Fig 3; 119pp; English.	
XX		
CC	The present invention relates to extendings and their agonists which have	
CC	been modified with molecular weight increasing agents such as	
CC	polyethylene glycol (PEG). These can be used in the treatment of	
CC	diabetes, obesity, impaired glucose tolerance, postprandial dumping	
CC	syndrome, postprandial hyperglycaemia, eating disorders, insulin	
CC	resistance syndrome, dyslipidaemia and to suppress glucagon secretion	
XX		
SQ	Sequence 18 AA;	
AA52873	Length: 18 February 4, 2005 13:04	Type: P Check: 3037 ..
Found using 'seq3'	(mohamed337.key)	

```

1      KGFTSLGFIETPPPS      18
1
-----
1      1 match found in sequence:
      aab52874 ; Extendin agonist compound #2.
      (from "seq3ags.pep")
      TOIG of: aab52874 check: 3492 from: 1 to: 18

ID      AAB52874 standard; peptide; 18 AA.
XX
AC      AAB52874;
XX
XX
DT      28-FEB-2001 (first entry)
XX
XX      Extendin agonist compound #2.
DE
XX
XX      Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW      insulin-resistance syndrome; food intake.
XX
XX      Heloderma sp.
OS
XX      WO200066629-A1.
FN
XX
XX
PD      09-NOV-2000.
PD
XX
XX      28-APR-2000; 2000WO-US011814.
PF
XX
XX      30-APR-1999; 99US-0132018P.
PR
XX      (AMYL-) AMYLIN PHARM INC.
PA
XX
XX      Young A, Prickett K;
PI
XX      WPI; 2000-672834/65.
XX
XX      Modified extendin or an extendin agonist linked to one or more polyethylene
PT      glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT      treating disorders such as diabetes and obesity.
XX

```

```

PS Disclosure; Fig 3; 119pp; English.
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 18 AA;
SQ
AAB52874 Length: 18 February 4, 2005 13:04 Type: P Check: 3492 ..
Found using 'seq3' (mohamed337.key)
|-----|
1 HGEFTSMLMXIEWPPPPS 18
-----
1 match found in sequence:
aab52875 ; Extendin agonist compound #3.
(from "seq3ags.pep")
TOIG of: aab52875 check: 3455 from: 1 to: 18
ID AAB52875 standard; peptide; 18 AA.
XX AC AAB52876;
XX XX
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #4.
XX XX
XX XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX XN WPI; 2000-672834/65.
DR Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
PT OS Heloderma sp.
PS Disclosure; Fig 3; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
XX polyethylene glycol (PEG). These can be used in the treatment of
XX diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 18 AA;
SQ
AAB52875 Length: 18 February 4, 2005 13:04 Type: P Check: 3455 ..
Found using 'seq3' (mohamed337.key)
|-----|
1 HGEFTSMLMFVEWPPPPS 18
-----
1 match found in sequence:
aab52877 ; Extendin agonist compound #5.
(from "seq3ags.pep")
TOIG of: aab52877 check: 3477 from: 1 to: 18
ID AAB52877 standard; peptide; 18 AA.
XX AC AAB52877;
XX XX
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #5.
XX XX
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX XN insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
OS

```

```
XX PN WO200066629-A1.
XX PS
XX PD
XX PF 09-NOV-2000.
XX PP 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PP (AMYL-) AMYLIN PHARM INC.
XX PA
XX PI Young A, Prickett K;
XX PS WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 3; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX CC Sequence 18 AA;
XX SQ
AAB52877 Length: 18 February 4, 2005 13:04 Type: P Check: 3477 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTSDFXEWPPPPS 18
1 |-----|
1 match found in sequence:
aab52878 ; Extendin agonist compound #6.
(from "seq3ags.pep")
TOIG of: aab52878 check: 3247 from: 1 to: 18
ID AAB52878 standard; peptide; 18 AA.
XX AC AAB52878;
XX XX
XX DT 28-FEB-2001 (first entry)
XX DE
XX DE Extendin agonist compound #6.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX AC
XX AC AAB52878;
XX DT 28-FEB-2001 (first entry)
XX DE
XX DE Extendin agonist compound #6.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX XX Heloderma sp.
XX OS
XX PN WO200066629-A1.
XX PS
XX PD 09-NOV-2000.
XX PP 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PP (AMYL-) AMYLIN PHARM INC.
XX PA
XX PI Young A, Prickett K;
XX PS WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
```

```
XX PS Disclosure; Fig 3; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX CC Sequence 18 AA;
XX SQ
AAB52878 Length: 18 February 4, 2005 13:04 Type: P Check: 3247 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTSDFXEWPPPPS 18
1 |-----|
1 match found in sequence:
aab52879 ; Extendin agonist compound #7.
(from "seq3ags.pep")
TOIG of: aab52879 check: 3300 from: 1 to: 18
ID AAB52879 standard; peptide; 18 AA.
XX AC AAB52879;
XX XX
XX DT 28-FEB-2001 (first entry)
XX DE
XX DE Extendin agonist compound #7.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX AC
XX AC AAB52879;
XX DT 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PP (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX PS WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 3; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX CC Sequence 18 AA;
XX SQ
AAB52879 Length: 18 February 4, 2005 13:04 Type: P Check: 3300 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTSDFXEWPPPPS 18
1 |-----|
```

```

1 match found in sequence:
aab52880 ; Extendin agonist compound #8.
(from "seq3ags.pep")
TOIG of: aab52880 check: 3070 from: 1 to: 18

ID AAB52880 standard; peptide; 18 AA.
XX
AC AAB52880;
XX
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin agonist compound #8.
XX
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
OS
PN WO200066629-A1.
XX
XX 09-NOV-2000.
PD
XX
XX 28-APR-2000; 2000WO-US011814.
PF
XX
XX 30-APR-1999; 99US-0132018P.
PR
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
PI
XX
XX WPI; 2000-672834/65.
DR
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 3; 119pp; English.
PS
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 18 AA;
SQ

AAB52880 Length: 18 February 4, 2005 13:04 Type: P Check: 3070 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
  HAEFTSDLLFIEFPFPPPS
  1 18

-----
1 match found in sequence:
aab52881 ; Extendin agonist compound #9.
(from "seq3ags.pep")
TOIG of: aab52881 check: 3312 from: 1 to: 18

ID AAB52881 standard; peptide; 18 AA.
XX
XX AAB52881;
XX
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin agonist compound #9.
XX
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX

```

```
PT treating disorders such as diabetes and obesity.
PS Disclosure; Fig 3; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 18 AA;

AAB52882 Length: 18 February 4, 2005 13:04 Type: P Check: 3312 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
  HGEFTSDFLMFIEWPPPPS 18
  1

-----
1 match found in sequence:
aab52883 ; Extendin agonist compound #11.
(from "seq3ags.pep")
TOIG of: aab52883 check: 3312 from: 1 to: 18

ID AAB52883 standard; peptide; 18 AA.
XX
AC AAB52883;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin agonist compound #11.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX
PI WPI; 2000-672834/65.
XX
DR Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
PS Disclosure; Fig 3; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 18 AA;

AAB52883 Length: 18 February 4, 2005 13:04 Type: P Check: 3312 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
  HGEFTSDFLMFIEWPPPPS 18
  1

-----
1 match found in sequence:
aab52883 ; Extendin agonist compound #11.
(from "seq3ags.pep")
TOIG of: aab52883 check: 3312 from: 1 to: 18

ID AAB52883 standard; peptide; 18 AA.
XX
AC AAB52883;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin agonist compound #11.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX
PI WPI; 2000-672834/65.
XX
DR Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
PS Disclosure; Fig 3; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 18 AA;

AAB52884 Length: 18 February 4, 2005 13:04 Type: P Check: 3312 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
  HGEFTSDFLMFIEWPPPPS 18
  1

-----
1 match found in sequence:
aab52884 ; Extendin agonist compound #12.
(from "seq3ags.pep")
TOIG of: aab52884 check: 3312 from: 1 to: 18

ID AAB52884 standard; peptide; 18 AA.
XX
AC AAB52884;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin agonist compound #12.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX
PI WPI; 2000-672834/65.
XX
DR Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
PS Disclosure; Fig 3; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 18 AA;

AAB52885 Length: 18 February 4, 2005 13:04 Type: P Check: 3312 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
  HGEFTSDFLMFIEWPPPPS 18
  1

-----
1 match found in sequence:
aab52885 ; Extendin agonist compound #13.
(from "seq3ags.pep")
TOIG of: aab52885 check: 3082 from: 1 to: 18

ID AAB52885 standard; peptide; 18 AA.
XX
AC AAB52885;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin agonist compound #13.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
```



```
1 HGEFTSDFLMEFWAAAAS 18
-----
1 match found in sequence:
aab52888 ; Extending agonist compound #16.
(from "seq3ags.pep")
TOIG of: aab52888 check: 2592 from: 1 to: 18

ID AAB52888 standard; peptide; 18 AA.
XX
AC AAB52888;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #16.
XX
KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX
DR WPI; 2000-672834/65.
XX
PT Modified extendin or an extendin agonist linked to one or more polyethylene
glycol (PEG) polymers, modulate plasma glucose levels, useful for
treating disorders such as diabetes and obesity.
XX
PS Disclosure; Fig 3; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
been modified with molecular weight increasing agents such as
polyethylene glycol (PEG). These can be used in the treatment of
diabetes, obesity, impaired glucose tolerance, postprandial dumping
syndrome, postprandial hyperglycaemia, eating disorders, insulin
resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 18 AA;

AAB52889 Length: 18 February 4, 2005 13:04 Type: P Check: 2152 ..
Found using 'seq3' (mohamed337.key)

1 HGEFTSDFLMEFWAAAAS 18
-----
1 match found in sequence:
aaw47550 ; Extending agonist (1).
(from "seq3ags.pep")
TOIG of: aaw47550 check: 3082 from: 1 to: 18

ID AAW47550 standard; peptide; 18 AA.
XX
AC AAW47550;
XX
DT 03-JUL-1998 (first entry)
XX
DE Extending agonist (1).
XX
KW Extending agonist; gastric motility; gastric emptying; treatment; spasm;
postprandial dumping syndrome; postprandial hyperglycaemia;
type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
Gila monster venom.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 18
FT /note= "amidated"
XX
PN WO9805351-A1.
XX
PD 12-FEB-1998.
XX
PF 08-AUG-1997; 97WO-US014199.
XX
PR 08-AUG-1996; 96US-00694954.
XX
```

```
1 HGEFTSDFLMEFWAAAAS 18
-----
1 match found in sequence:
aab52889 ; Extending agonist compound #17.
(from "seq3ags.pep")
TOIG of: aab52889 check: 2152 from: 1 to: 18

ID AAB52889 standard; peptide; 18 AA.
XX
AC AAB52889;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #17.
XX
KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX
```


PT glucose tolerance etc., also in diagnostic investigations.

XX Example 6; Fig 8; 70pp; English.

XX The present sequence is an extendin agonist, which reduces gastric motility and delays gastric emptying. It can be used to treat spasm (where associated with acute diverticulitis or disorders of the biliary tract or sphincter of Oddi), postprandial dumping syndrome and hyperglycaemia (particularly associated with type 2 diabetes), type 1 diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist is administered to prevent stomach contents passing into the intestines, then the stomach pumped) and obesity. It can also be administered to subjects undergoing gastrointestinal diagnostic investigation, particularly radiological or by magnetic resonance imaging. Extendins, components of Gila monster venom, have some sequence similarity to glucagon-like peptides (GLP). They are GLP agonists and have been suggested (US5424286) for treatment of diabetes and prevention of hyperglycaemia

XX Sequence 18 AA;

AAW47552 Length: 18 February 4, 2005 13:04 Type: P Check: 3091 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
1 HGEFTSDFIEFPPPPS 18

1 match found in sequence:
aaw47553 ; Extendin agonist (4).
(from "seq3ags.pep")
TOIG of: aaw47553 check: 3329 from: 1 to: 18

ID AAW47553 standard; peptide; 18 AA.

XX AC AAW47553;

XX 03-JUL-1998 (first entry)

XX Extendin agonist (4).

XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
KW postprandial dumping syndrome; postprandial hyperglycaemia;
KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
KW Gila monster venom.

XX Synthetic.

XX Key Location/Qualifiers
FT Modified-site 18
FT /note= "amidated"

XX WO9805351-A1.

XX 12-FEB-1998.

XX 08-AUG-1997; 97WO-US014199.

XX 08-AUG-1996; 96US-00694954.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Gedulin B, Beeley NRA, Prickett KS;

XX WPI; 1998-145351/13.

XX Regulating gastrointestinal motility using extendins or their agonists -
PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
PT glucose tolerance etc., also in diagnostic investigations.

XX Example 7; Fig 8; 70pp; English.

XX

CC The present sequence is an extendin agonist, which reduces gastric motility and delays gastric emptying. It can be used to treat spasm (where associated with acute diverticulitis or disorders of the biliary tract or sphincter of Oddi), postprandial dumping syndrome and hyperglycaemia (particularly associated with type 2 diabetes), type 1 diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist is administered to prevent stomach contents passing into the intestines, then the stomach pumped) and obesity. It can also be administered to subjects undergoing gastrointestinal diagnostic investigation, particularly radiological or by magnetic resonance imaging. Extendins, components of Gila monster venom, have some sequence similarity to glucagon-like peptides (GLP). They are GLP agonists and have been suggested (US5424286) for treatment of diabetes and prevention of hyperglycaemia

XX Sequence 18 AA;

AAW47553 Length: 18 February 4, 2005 13:04 Type: P Check: 3329 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
1 YGEFTSDFIEFPPPPS 18

1 match found in sequence:
aaw47554 ; Extendin agonist (5).
(from "seq3ags.pep")
TOIG of: aaw47554 check: 3420 from: 1 to: 18

ID AAW47554 standard; peptide; 18 AA.

XX AC AAW47554;

XX 03-JUL-1998 (first entry)

XX Extendin agonist (5).

XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
KW postprandial dumping syndrome; postprandial hyperglycaemia;
KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
KW Gila monster venom.

XX Synthetic.

XX Key Location/Qualifiers
FT Modified-site 18
FT /note= "amidated"

XX WO9805351-A1.

XX 12-FEB-1998.

XX 08-AUG-1997; 97WO-US014199.

XX 08-AUG-1996; 96US-00694954.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Gedulin B, Beeley NRA, Prickett KS;

XX WPI; 1998-145351/13.

XX Regulating gastrointestinal motility using extendins or their agonists -
PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
PT glucose tolerance etc., also in diagnostic investigations.

XX Example 8; Fig 8; 70pp; English.

XX The present sequence is an extendin agonist, which reduces gastric motility and delays gastric emptying. It can be used to treat spasm (where associated with acute diverticulitis or disorders of the biliary tract or sphincter of Oddi), postprandial dumping syndrome and

CC hyperglycaemia (particularly associated with type 2 diabetes), type 1
CC diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
CC is administered to prevent stomach contents passing into the intestines,
CC then the stomach pumped) and obesity. It can also be administered to
CC subjects undergoing gastrointestinal diagnostic investigation.
CC particularly radiological or by magnetic resonance imaging. Extendins,
CC components of Gila monster venom, have some sequence similarity to
CC glucagon-like peptides (GLP). They are GLP agonists and have been
CC suggested (US5424286) for treatment of diabetes and prevention of
CC hyperglycaemia
XX
SQ Sequence 18 AA;
AAW47554 Length: 18 February 4, 2005 13:04 Type: P Check: 3420 ..
Found using 'seq3' (mohamed337.key)
1 HGFDTSLMFIWPPPPY 18
|-----|
1 match found in sequence:
aaw47555 : Extendin agonist (6).
(from "seq3ags.pep")
TOIG of: aaw47555 check: 3309 from: 1 to: 18
ID AAW47555 standard; peptide; 18 AA.
XX
AC AAW47555;
XX
DT 03-JUL-1998 (first entry)
XX
DE Extendin agonist (6).
XX
KW Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
KW postprandial dumping syndrome; postprandial hyperglycaemia;
KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
KW Gila monster venom.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 18 /note= "amidated"
FT
FT
FT
FN WO9805351-A1.
XX
PD 12-FEB-1998.
XX
PF 08-AUG-1997; 97WO-US014199.
XX
PR 08-AUG-1996; 96US-00694954.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX
DR WPI; 1998-145351/13.
XX
PT Regulating gastrointestinal motility using extendins or their agonists -
PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
PT glucose tolerance etc., also in diagnostic investigations.
XX
PS Example 9; Fig 8; 70pp; English.
XX
CC The present sequence is an extendin agonist, which reduces gastric
CC motility and delays gastric emptying. It can be used to treat spasm
CC (where associated with acute diverticulitis or disorders of the biliary
CC tract or sphincter of Oddi), postprandial dumping syndrome and
CC hyperglycaemia (particularly associated with type 2 diabetes), type 1
CC diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
CC is administered to prevent stomach contents passing into the intestines,
CC then the stomach pumped) and obesity. It can also be administered to
CC subjects undergoing gastrointestinal diagnostic investigation.
CC particularly radiological or by magnetic resonance imaging. Extendins,
CC components of Gila monster venom, have some sequence similarity to
CC glucagon-like peptides (GLP). They are GLP agonists and have been
CC suggested (US5424286) for treatment of diabetes and prevention of
CC hyperglycaemia

CC subjects undergoing gastrointestinal diagnostic investigation,
CC particularly radiological or by magnetic resonance imaging. Extendins,
CC components of Gila monster venom, have some sequence similarity to
CC glucagon-like peptides (GLP). They are GLP agonists and have been
CC suggested (US5424286) for treatment of diabetes and prevention of
CC hyperglycaemia
XX
SQ Sequence 18 AA;
AAW47555 Length: 18 February 4, 2005 13:04 Type: P Check: 3309 ..
Found using 'seq3' (mohamed337.key)
1 HGFDTSLMFIWPPPPY 18
|-----|
1 match found in sequence:
aaw47556 : Extendin agonist (7).
(from "seq3ags.pep")
TOIG of: aaw47556 check: 3384 from: 1 to: 18
ID AAW47556 standard; peptide; 18 AA.
XX
AC AAW47556;
XX
DT 03-JUL-1998 (first entry)
XX
DE Extendin agonist (7).
XX
KW Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
KW postprandial dumping syndrome; postprandial hyperglycaemia;
KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
KW Gila monster venom.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 4 /label= Nal
FT Modified-site 18 /note= "amidated"
FT
FT
FN WO9805351-A1.
XX
PD 12-FEB-1998.
XX
PF 08-AUG-1997; 97WO-US014199.
XX
PR 08-AUG-1996; 96US-00694954.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX
DR WPI; 1998-145351/13.
XX
PT Regulating gastrointestinal motility using extendins or their agonists -
PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
PT glucose tolerance etc., also in diagnostic investigations.
XX
PS Example 10; Fig 8; 70pp; English.
XX
CC The present sequence is an extendin agonist, which reduces gastric
CC motility and delays gastric emptying. It can be used to treat spasm
CC (where associated with acute diverticulitis or disorders of the biliary
CC tract or sphincter of Oddi), postprandial dumping syndrome and
CC hyperglycaemia (particularly associated with type 2 diabetes), type 1
CC diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
CC is administered to prevent stomach contents passing into the intestines,
CC then the stomach pumped) and obesity. It can also be administered to
CC subjects undergoing gastrointestinal diagnostic investigation.
CC particularly radiological or by magnetic resonance imaging. Extendins,
CC components of Gila monster venom, have some sequence similarity to
CC glucagon-like peptides (GLP). They are GLP agonists and have been
CC suggested (US5424286) for treatment of diabetes and prevention of
CC hyperglycaemia

CC components of Gila monster venom, have some sequence similarity to
 CC glucagon-like peptides (GLP). They are GLP agonists and have been
 CC suggested (US5424286) for treatment of diabetes and prevention of
 CC hyperglycaemia
 XX
 SQ Sequence 18 AA;

AAW47556 Length: 18 February 4, 2005 13:04 Type: P Check: 3384 ..
 Found using 'seq3' (mohamed337.key)

1 HGEFSDLMFIEWPPPPS
 1 18

 1 match found in sequence:
 aaw47557 : Exendin agonist (8).
 (from "seq3ags.pep")
 TOIG of: aaw47557 check: 3307 from: 1 to: 18

ID AAW47557 standard; peptide; 18 AA.
 XX
 AC AAW47557;
 XX
 DT 03-JUL-1998 (first entry)
 XX
 DE Exendin agonist (8).
 XX
 KW Exendin agonist; gastric motility; gastric emptying; treatment; spasm;
 KW postprandial dumping syndrome; postprandial hyperglycaemia;
 KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
 KW Gila monster venom.
 XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT Modified-site 18
 FT /note= "amidated"

XX WO9805351-A1.
 XX 12-FEB-1998.
 XX
 XX 08-AUG-1997; 97WO-US014199.
 XX
 XX 08-AUG-1996; 96US-00694954.
 XX
 XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
 XX WPI; 1998-145351/13.

XX Regulating gastrointestinal motility using exendins or their agonists -
 PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
 PT glucose tolerance etc., also in diagnostic investigations.

XX Example 11; Fig 8; 70pp; English.

XX The present sequence is an exendin agonist, which reduces gastric
 CC motility and delays gastric emptying. It can be used to treat spasm
 CC (where associated with acute diverticulitis or disorders of the biliary
 CC tract or sphincter of Oddi), postprandial dumping syndrome and
 CC hyperglycaemia (particularly associated with type 2 diabetes), type 1
 CC diabetes, impaired glucose tolerance, toxin ingestion (an exendin agonist
 CC is administered to prevent stomach contents passing into the intestines,
 CC then the stomach pumped) and obesity. It can also be administered to
 CC subjects undergoing gastrointestinal diagnostic investigation,
 CC particularly radiological or by magnetic resonance imaging. Exendins,
 CC components of Gila monster venom, have some sequence similarity to
 CC glucagon-like peptides (GLP). They are GLP agonists and have been
 CC suggested (US5424286) for treatment of diabetes and prevention of
 CC hyperglycaemia

XX Sequence 18 AA;
 SQ
 AAW47557 Length: 18 February 4, 2005 13:04 Type: P Check: 3307 ..
 Found using 'seq3' (mohamed337.key)

1 HGEFSDLMFIEWPPPPS
 1 18

 1 match found in sequence:
 aaw47558 : Exendin agonist (9).
 (from "seq3ags.pep")
 TOIG of: aaw47558 check: 3313 from: 1 to: 18

ID AAW47558 standard; peptide; 18 AA.
 XX
 AC AAW47558;
 XX
 DT 03-JUL-1998 (first entry)
 XX
 DE Exendin agonist (9).
 XX

KW Exendin agonist; gastric motility; gastric emptying; treatment; spasm;
 KW postprandial dumping syndrome; postprandial hyperglycaemia;
 KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
 KW Gila monster venom.

XX Synthetic.

XX Key Location/Qualifiers
 FT Modified-site 18
 FT /note= "amidated"

XX WO9805351-A1.
 XX 12-FEB-1998.
 XX
 XX 08-AUG-1997; 97WO-US014199.
 XX
 XX 08-AUG-1996; 96US-00694954.
 XX
 XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
 XX WPI; 1998-145351/13.

XX Regulating gastrointestinal motility using exendins or their agonists -
 PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
 PT glucose tolerance etc., also in diagnostic investigations.

XX Example 12; Fig 8; 70pp; English.

XX The present sequence is an exendin agonist, which reduces gastric
 CC motility and delays gastric emptying. It can be used to treat spasm
 CC (where associated with acute diverticulitis or disorders of the biliary
 CC tract or sphincter of Oddi), postprandial dumping syndrome and
 CC hyperglycaemia (particularly associated with type 2 diabetes), type 1
 CC diabetes, impaired glucose tolerance, toxin ingestion (an exendin agonist
 CC is administered to prevent stomach contents passing into the intestines,
 CC then the stomach pumped) and obesity. It can also be administered to
 CC subjects undergoing gastrointestinal diagnostic investigation,
 CC particularly radiological or by magnetic resonance imaging. Exendins,
 CC components of Gila monster venom, have some sequence similarity to
 CC glucagon-like peptides (GLP). They are GLP agonists and have been
 CC suggested (US5424286) for treatment of diabetes and prevention of
 CC hyperglycaemia

XX Sequence 18 AA;

AAW47558 Length: 18 February 4, 2005 13:04 Type: P Check: 3313 ..

aaw47561 ; Exendin agonist (12).
 (from "seq3ags.pep")
 TOIG of: aaw47561 check: 3399 from: 1 to: 18
 AAW47561 standard; peptide; 18 AA.

ID XX
 AC AAW47561;
 XX
 DT 03-JUL-1998 (first entry)
 XX
 DE Exendin agonist (12).
 XX
 KW Exendin agonist; gastric motility; gastric emptying; treatment; spasm;
 KW postprandial dumping syndrome; postprandial hyperglycaemia;
 KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
 KW Gila monster venom.
 XX
 OS Synthetic.

Key Location/Qualifiers
 FT Modified-site 8
 FT Modified-site /note= "pentylglycine"
 FT Modified-site 18
 FT Modified-site /note= "amidated"

PN WO9805351-A1.

PD 12-FEB-1998.

PF 08-AUG-1997; 97WO-US014199.

PR 08-AUG-1996; 96US-00694954.

PA (AMYL-) AMYLIN PHARM INC.

PI Young AA, Gedulin B, Beeley NRA, Prickett KS;

DR WPI; 1998-145351/13.

Regulating gastrointestinal motility using exendins or their agonists -
 for treating spasm, diabetic postprandial hyperglycaemia, impaired
 glucose tolerance etc., also in diagnostic investigations.

PS Example 15; Fig 8; 70pp; English.

CC The present sequence is an exendin agonist, which reduces gastric
 motility and delays gastric emptying. It can be used to treat spasm
 (where associated with acute diverticulitis or disorders of the biliary
 tract or sphincter of Oddi), postprandial dumping syndrome and
 hyperglycaemia (particularly associated with type 2 diabetes), type 1
 diabetes, impaired glucose tolerance, toxin ingestion (an exendin agonist
 is administered to prevent stomach contents passing into the intestines,
 then the stomach pumped) and obesity. It can also be administered to
 subjects undergoing gastrointestinal diagnostic investigation, Exendins,
 particularly radiological or by magnetic resonance imaging. Exendins,
 components of Gila monster venom, have some sequence similarity to
 glucagon-like peptides (GLP). They are GLP agonists and have been
 suggested (US5424286) for treatment of diabetes and prevention of
 hyperglycaemia

SQ Sequence 18 AA;

AAW47561 Length: 18 February 4, 2005 13:04 Type: P Check: 3399 ..
 Found using 'seq3' (mohamed337.key)

1 HGEFTSDXLFIWFPPPPS
 18

1 match found in sequence:
 aaw47562 ; Exendin agonist (13).
 (from "seq3ags.pep")

TOIG of: aaw47562 check: 3178 from: 1 to: 18
 AAW47562 standard; peptide; 18 AA.

ID XX
 AC AAW47562;
 XX
 DT 03-JUL-1998 (first entry)
 XX
 DE Exendin agonist (13).
 XX
 KW Exendin agonist; gastric motility; gastric emptying; treatment; spasm;
 KW postprandial dumping syndrome; postprandial hyperglycaemia;
 KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
 KW Gila monster venom.
 XX
 OS Synthetic.

Key Location/Qualifiers
 FT Modified-site 8
 FT Modified-site /note= "pentylglycine"
 FT Modified-site 18
 FT Modified-site /note= "amidated"

PN WO9805351-A1.

PD 12-FEB-1998.

PF 08-AUG-1997; 97WO-US014199.

PR 08-AUG-1996; 96US-00694954.

PA (AMYL-) AMYLIN PHARM INC.

PI Young AA, Gedulin B, Beeley NRA, Prickett KS;

DR WPI; 1998-145351/13.

Regulating gastrointestinal motility using exendins or their agonists -
 for treating spasm, diabetic postprandial hyperglycaemia, impaired
 glucose tolerance etc., also in diagnostic investigations.

PS Example 16; Fig 8; 70pp; English.

CC The present sequence is an exendin agonist, which reduces gastric
 motility and delays gastric emptying. It can be used to treat spasm
 (where associated with acute diverticulitis or disorders of the biliary
 tract or sphincter of Oddi), postprandial dumping syndrome and
 hyperglycaemia (particularly associated with type 2 diabetes), type 1
 diabetes, impaired glucose tolerance, toxin ingestion (an exendin agonist
 is administered to prevent stomach contents passing into the intestines,
 then the stomach pumped) and obesity. It can also be administered to
 subjects undergoing gastrointestinal diagnostic investigation, Exendins,
 particularly radiological or by magnetic resonance imaging. Exendins,
 components of Gila monster venom, have some sequence similarity to
 glucagon-like peptides (GLP). They are GLP agonists and have been
 suggested (US5424286) for treatment of diabetes and prevention of
 hyperglycaemia

SQ Sequence 18 AA;

AAW47562 Length: 18 February 4, 2005 13:04 Type: P Check: 3178 ..
 Found using 'seq3' (mohamed337.key)

1 HGEFTSDXLFIWFPPPPS
 18

1 match found in sequence:
 aaw47563 ; Exendin agonist (14).
 (from "seq3ags.pep")

TOIG of: aaw47563 check: 3411 from: 1 to: 18

KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
 KW Gila monster venom.
 XX
 OS Synthetic.

XX Key Location/Qualifiers
 XX FT FH
 XX Modified-site 18
 XX FT /note= "amidated"

XX PN WO9805351-A1.

XX PD 12-FEB-1998.

XX PF 08-AUG-1997; 97WO-US014199.

XX PR 08-AUG-1996; 96US-00694954.

XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Young AA, Gedulin B, Beeley NRA, Prickett KS;
 XX DR WPI; 1998-145351/13.

XX PT Regulating gastrointestinal motility using extendins or their agonists -
 XX FT for treating spasm, diabetic postprandial hyperglycaemia, impaired
 XX PT glucose tolerance etc., also in diagnostic investigations.

XX PS Example 21; Fig 8; 70pp; English.

XX CC The present sequence is an extendin agonist, which reduces gastric
 CC motility and delays gastric emptying. It can be used to treat spasm
 CC (where associated with acute diverticulitis or disorders of the biliary
 CC tract or sphincter of Oddi), postprandial dumping syndrome and
 CC hyperglycaemia (particularly associated with type 2 diabetes), type 1
 CC diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
 CC is administered to prevent stomach contents passing into the intestines,
 CC then the stomach pumped) and obesity. It can also be administered to
 CC subjects undergoing gastrointestinal diagnostic investigation.
 CC particularly radiological or by magnetic resonance imaging. Extendins,
 CC components of Gila monster venom, have some sequence similarity to
 CC glucagon-like peptides (GLP). They are GLP agonists and have been
 CC suggested (US5424286) for treatment of diabetes and prevention of
 CC hyperglycaemia

XX SQ Sequence 18 AA;

AAW47567 Length: 18 February 4, 2005 13:04 Type: P Check: 3225 ..

Found using 'seq3' (mohamed337.key)

```

1 |-----|
  | HGEFTSLLVFVEPPPPS 18
  1
-----
1 match found in sequence:
aaw47568 ; Extendin agonist (19).
(from "seq3ags.pep")
TOIG of: aaw47568 check: 3477 from: 1 to: 18

```

ID AAW47568 standard; peptide; 18 AA.
 XX
 AC AAW47568;
 XX
 DT 03-JUL-1998 (first entry)
 XX
 DE Extendin agonist (19).

XX
 KW Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
 KW postprandial dumping syndrome; postprandial hyperglycaemia;
 KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
 KW Gila monster venom.
 XX
 OS Synthetic.

XX Key Location/Qualifiers
 XX FT FH
 XX Modified-site 11
 XX FT /note= "tert-butylglycine"
 XX FT Modified-site 18
 XX FT /note= "amidated"

XX PN WO9805351-A1.

XX PD 12-FEB-1998.

XX PF 08-AUG-1997; 97WO-US014199.

XX PR 08-AUG-1996; 96US-00694954.

XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Young AA, Gedulin B, Beeley NRA, Prickett KS;
 XX DR WPI; 1998-145351/13.

XX PT Regulating gastrointestinal motility using extendins or their agonists -
 XX FT for treating spasm, diabetic postprandial hyperglycaemia, impaired
 XX PT glucose tolerance etc., also in diagnostic investigations.
 XX PS Example 22; Fig 8; 70pp; English.

XX CC The present sequence is an extendin agonist, which reduces gastric
 CC motility and delays gastric emptying. It can be used to treat spasm
 CC (where associated with acute diverticulitis or disorders of the biliary
 CC tract or sphincter of Oddi), postprandial dumping syndrome and
 CC hyperglycaemia (particularly associated with type 2 diabetes), type 1
 CC diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
 CC is administered to prevent stomach contents passing into the intestines,
 CC then the stomach pumped) and obesity. It can also be administered to
 CC subjects undergoing gastrointestinal diagnostic investigation.
 CC particularly radiological or by magnetic resonance imaging. Extendins,
 CC components of Gila monster venom, have some sequence similarity to
 CC glucagon-like peptides (GLP). They are GLP agonists and have been
 CC suggested (US5424286) for treatment of diabetes and prevention of
 CC hyperglycaemia

XX SQ Sequence 18 AA;

AAW47568 Length: 18 February 4, 2005 13:04 Type: P Check: 3477 ..

Found using 'seq3' (mohamed337.key)

```

1 |-----|
  | HGEFTSLLVFVEPPPPS 18
  1
-----
1 match found in sequence:
aaw47569 ; Extendin agonist (20).
(from "seq3ags.pep")
TOIG of: aaw47569 check: 3247 from: 1 to: 18

```

ID AAW47569 standard; peptide; 18 AA.
 XX
 AC AAW47569;
 XX
 DT 03-JUL-1998 (first entry)
 XX
 DE Extendin agonist (20).

XX
 KW Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
 KW postprandial dumping syndrome; postprandial hyperglycaemia;
 KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
 KW Gila monster venom.
 XX
 OS Synthetic.
 XX Key Location/Qualifiers

```

FT Modified-site 11
FT FT /note= "tert-butylglycine"
FT Modified-site 18
FT FT /note= "amidated"
XX
XX WO9805351-A1.
XX
XX 12-FEB-1998.
XX
XX 08-AUG-1997; 97WO-US014199.
XX
XX 08-AUG-1996; 96US-00694954.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX
XX Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX
XX Example 23; Fig 8; 70pp; English.
XX
XX The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation,
XX particularly radiological or by magnetic resonance imaging. Extendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX
XX Sequence 18 AA;
XX
AAW47569 Length: 18 February 4, 2005 13:04 Type: P Check: 3247 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTSDDLFXRPPPPPS 18
1 -----|
1 match found in sequence:
aaw47570 ; Extendin agonist (21).
(from "seq3ags.pep")
TOIG of: aaw47570 check: 3300 from: 1 to: 18
-----
ID AAW47570 standard; peptide; 18 AA.
XX
XX AAW47570;
XX
XX 03-JUL-1998 (first entry)
XX
XX Extendin agonist (21).
XX
XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX postprandial dumping syndrome; postprandial hyperglycaemia;
XX type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX Gila monster venom.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 18 /note= "amidated"
XX
XX WO9805351-A1.
XX
XX 12-FEB-1998.
XX

```

```

XX WO9805351-A1.
XX
XX 12-FEB-1998.
XX
XX 08-AUG-1997; 97WO-US014199.
XX
XX 08-AUG-1996; 96US-00694954.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX
XX Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX
XX Example 24; Fig 8; 70pp; English.
XX
XX The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation,
XX particularly radiological or by magnetic resonance imaging. Extendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX
XX Sequence 18 AA;
XX
AAW47570 Length: 18 February 4, 2005 13:04 Type: P Check: 3300 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTSDDLFXRPPPPPS 18
1 -----|
1 match found in sequence:
aaw47571 ; Extendin agonist (22).
(from "seq3ags.pep")
TOIG of: aaw47571 check: 3070 from: 1 to: 18
-----
ID AAW47571 standard; peptide; 18 AA.
XX
XX AAW47571;
XX
XX 03-JUL-1998 (first entry)
XX
XX Extendin agonist (22).
XX
XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX postprandial dumping syndrome; postprandial hyperglycaemia;
XX type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX Gila monster venom.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 18 /note= "amidated"
XX
XX WO9805351-A1.
XX
XX 12-FEB-1998.
XX

```

```

XX 08-AUG-1997; 97WO-US014199.
PF 08-AUG-1996; 96US-00694954.
PR (AMYL-) AMYLIN PHARM INC.
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX Example 25; Fig 8; 70pp; English.
XX The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation,
XX particularly radiological or by magnetic resonance imaging. Extendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX Sequence 18 AA;
XX
AAW47571 Length: 18 February 4, 2005 13:04 Type: P Check: 3070
Found using 'seq3' (mohamed337.key)
1 |-----|
1 HAEFTSLLFIEFPFPPPS 18
-----
1 match found in sequence:
aaw47572 ; Extendin agonist (23).
(from "seq3ags.pep")
TOIG of: aaw47572 check: 3808 from: 1 to: 18
ID AAW47572 standard; peptide; 18 AA.
XX AAW47572;
XX 03-JUL-1998 (first entry)
XX Extendin agonist (23).
XX
XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX postprandial dumping syndrome; postprandial hyperglycaemia;
XX type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX Gila monster venom.
XX Synthetic.
XX Key Location/Qualifiers
XX Modified-site 14 /note= "thioproline"
XX Modified-site 15 /note= "thioproline"
XX Modified-site 16 /note= "thioproline"
XX Modified-site 17 /note= "thioproline"
XX Modified-site 18 /note= "amidated"
XX

```

```

XX WO9805351-A1.
XX 12-FEB-1998.
XX 08-AUG-1997; 97WO-US014199.
XX 08-AUG-1996; 96US-00694954.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX Example 26; Fig 8; 70pp; English.
XX The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation,
XX particularly radiological or by magnetic resonance imaging. Extendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX Sequence 18 AA;
XX
AAW47572 Length: 18 February 4, 2005 13:04 Type: P Check: 3808
Found using 'seq3' (mohamed337.key)
1 |-----|
1 HGFTSLLMFIEWXXXXS 18
-----
1 match found in sequence:
aaw47573 ; Extendin agonist (24).
(from "seq3ags.pep")
TOIG of: aaw47573 check: 3696 from: 1 to: 18
ID AAW47573 standard; peptide; 18 AA.
XX AAW47573;
XX 03-JUL-1998 (first entry)
XX Extendin agonist (24).
XX
XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX postprandial dumping syndrome; postprandial hyperglycaemia;
XX type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX Gila monster venom.
XX Synthetic.
XX Key Location/Qualifiers
XX Modified-site 15 /note= "thioproline"
XX Modified-site 16 /note= "thioproline"
XX Modified-site 17 /note= "thioproline"
XX Modified-site 17 /note= "thioproline"
XX

```

```

FT Modified-site 18 /note= "amidated"
XX
XX PN WO9805351-A1.
XX
XX PD 12-FEB-1998.
XX
XX PF 08-AUG-1997; 97WO-US0141199.
XX
XX PR 08-AUG-1996; 96US-00694954.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX
XX DR WPI; 1998-145351/13.
XX
XX PT Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX
XX PS Example 27; Fig 8; 70pp; English.
XX
XX CC The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation,
XX particularly radiological or by magnetic resonance imaging. Exendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX
XX SQ Sequence 18 AA;
AAW47573 Length: 18 February 4, 2005 13:04 Type: P Check: 3696
Found using 'seq3' (mohamed337.key)
1 HGEFTSDFMFIEWPXXXS 18
1 match found in sequence:
aaw47574 ; Exendin agonist (25).
(from "seq3ags.pep")
TOIG of: aaw47574 check: 3312 from: 1 to: 18

ID AAW47574 standard; peptide; 18 AA.
XX
XX AC AAW47574;
XX
XX DT 03-JUL-1998 (first entry)
XX
XX DE Exendin agonist (25).
XX
XX KW Exendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX postprandial dumping syndrome; postprandial hyperglycaemia;
XX type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX Gila monster venom.
XX
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 14
XX /label= Hyp
XX Modified-site 15
XX /label= Hyp

```

```

FT Modified-site 16 /label= Hyp
XX
XX FT Modified-site 17 /label= Hyp
XX
XX FT Modified-site 18 /note= "amidated"
XX
XX PN WO9805351-A1.
XX
XX PD 12-FEB-1998.
XX
XX PF 08-AUG-1997; 97WO-US0141199.
XX
XX PR 08-AUG-1996; 96US-00694954.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX
XX DR WPI; 1998-145351/13.
XX
XX PT Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX
XX PS Example 28; Fig 8; 70pp; English.
XX
XX CC The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation,
XX particularly radiological or by magnetic resonance imaging. Exendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX
XX SQ Sequence 18 AA;
AAW47574 Length: 18 February 4, 2005 13:04 Type: P Check: 3312
Found using 'seq3' (mohamed337.key)
1 HGEFTSDFMFIEWPPPPS 18
1 match found in sequence:
aaw47575 ; Exendin agonist (26).
(from "seq3ags.pep")
TOIG of: aaw47575 check: 3312 from: 1 to: 18

ID AAW47575 standard; peptide; 18 AA.
XX
XX AC AAW47575;
XX
XX DT 03-JUL-1998 (first entry)
XX
XX DE Exendin agonist (26).
XX
XX KW Exendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX postprandial dumping syndrome; postprandial hyperglycaemia;
XX type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX Gila monster venom.
XX
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX

```

```

XX FT Modified-site 15 /label= Hyp
XX FT Modified-site 16 /label= Hyp
XX FT Modified-site 17 /label= Hyp
XX FT Modified-site 18 /note= "amidated"
XX PN WO9805351-A1.
XX PD 12-FEB-1998.
XX PF 08-AUG-1997; 97WO-US014199.
XX PR 08-AUG-1996; 96US-00694954.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX DR Regulating gastrointestinal motility using extendins or their agonists -
XX PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX PT glucose tolerance etc., also in diagnostic investigations.
XX PS Example 29; Fig 8; 70pp; English.
XX CC The present sequence is an extendin agonist, which reduces gastric
XX CC motility and delays gastric emptying. It can be used to treat spasm
XX CC (where associated with acute diverticulitis or disorders of the biliary
XX CC tract or sphincter of Oddi), postprandial dumping syndrome and
XX CC hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX CC diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX CC is administered to prevent stomach contents passing into the intestines,
XX CC then the stomach pumped) and obesity. It can also be administered to
XX CC subjects undergoing gastrointestinal diagnostic investigation,
XX CC particularly radiological or by magnetic resonance imaging. Extendins,
XX CC components of Gila monster venom, have some sequence similarity to
XX CC glucagon-like peptides (GLP). They are GLP agonists and have been
XX CC suggested (US5424286) for treatment of diabetes and prevention of
XX CC hyperglycaemia
XX SQ Sequence 18 AA;

AAW47575 Length: 18 February 4, 2005 13:04 Type: P Check: 3312 ..
Found using 'seq3' (mohamed337.key)

1 HGEFTSMLMFIEWPPPPS 18
1 -----|-----|
1 match found in sequence:
aaw47576 ; Extendin agonist (27).
(from "seq3aggs-pep")
TOIG of: aaw47576 check: 3578 from: 1 to: 18

ID AAW47576 standard; peptide; 18 AA.
XX AAW47576;
XX AC
XX DT 03-JUL-1998 (first entry)
XX DE Extendin agonist (27).
XX KW Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX KW postprandial dumping syndrome; postprandial hyperglycaemia;
XX KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX KW Gila monster venom.
XX OS Synthetic.

XX FT Modified-site 14 /note= "thioprolin"
XX FT Modified-site 15 /note= "thioprolin"
XX FT Modified-site 16 /note= "thioprolin"
XX FT Modified-site 17 /note= "thioprolin"
XX FT Modified-site 18 /note= "amidated"
XX PN WO9805351-A1.
XX PD 12-FEB-1998.
XX PF 08-AUG-1997; 97WO-US014199.
XX PR 08-AUG-1996; 96US-00694954.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX DR Regulating gastrointestinal motility using extendins or their agonists -
XX PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX PT glucose tolerance etc., also in diagnostic investigations.
XX PS Example 30; Fig 8; 70pp; English.
XX CC The present sequence is an extendin agonist, which reduces gastric
XX CC motility and delays gastric emptying. It can be used to treat spasm
XX CC (where associated with acute diverticulitis or disorders of the biliary
XX CC tract or sphincter of Oddi), postprandial dumping syndrome and
XX CC hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX CC diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX CC is administered to prevent stomach contents passing into the intestines,
XX CC then the stomach pumped) and obesity. It can also be administered to
XX CC subjects undergoing gastrointestinal diagnostic investigation,
XX CC particularly radiological or by magnetic resonance imaging. Extendins,
XX CC components of Gila monster venom, have some sequence similarity to
XX CC glucagon-like peptides (GLP). They are GLP agonists and have been
XX CC suggested (US5424286) for treatment of diabetes and prevention of
XX CC hyperglycaemia
XX SQ Sequence 18 AA;

AAW47576 Length: 18 February 4, 2005 13:04 Type: P Check: 3578 ..
Found using 'seq3' (mohamed337.key)

1 HGEFTSDDLFIIFEXXKS 18
1 -----|-----|
1 match found in sequence:
aaw47577 ; Extendin agonist (28).
(from "seq3aggs-pep")
TOIG of: aaw47577 check: 3082 from: 1 to: 18

ID AAW47577 standard; peptide; 18 AA.
XX AAW47577;
XX AC
XX DT 03-JUL-1998 (first entry)
XX DE Extendin agonist (28).
XX KW Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX KW postprandial dumping syndrome; postprandial hyperglycaemia;

```

```

KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
KW Gila monster venom.
OS Synthetic.
FH Key Location/Qualifiers
FT Modified-site 14 /label= Hyp
FT Modified-site 15 /label= Hyp
FT Modified-site 16 /label= Hyp
FT Modified-site 17 /label= Hyp
FT Modified-site 18 /label= Hyp
FT Modified-site 18 /note= "amidated"
XX WO9805351-A1.
XX 12-FEB-1998.
XX 08-AUG-1997; 97WO-US014199.
XX 08-AUG-1996; 96US-00694954.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX Example 31; Fig 8; 70pp; English.
XX The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation,
XX particularly radiological or by magnetic resonance imaging. Extendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX Sequence 18 AA;
AAW47577 Length: 18 February 4, 2005 13:04 Type: P Check: 3082 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTSDDLFIIEPPPPS 18
|-----|
1 match found in sequence:
aaw47578 ; Extendin agonist (29).
(from "seq3ags.pep")
TOIG of: aaw47578 check: 2382 from: 1 to: 18

ID AAW47578 standard; peptide; 18 AA.
XX AAW47578;
XX 03-JUL-1998 (first entry)
XX

```

```

DE Extendin agonist (29).
XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
KW postprandial dumping syndrome; postprandial hyperglycaemia;
KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
KW Gila monster venom.
OS Synthetic.
FH Key Location/Qualifiers
FT Modified-site 14 /label= Meala
FT Modified-site 15 /label= Meala
FT Modified-site 16 /label= Meala
FT Modified-site 17 /label= Meala
FT Modified-site 18 /label= Meala
FT Modified-site 18 /note= "amidated"
XX WO9805351-A1.
XX 12-FEB-1998.
XX 08-AUG-1997; 97WO-US014199.
XX 08-AUG-1996; 96US-00694954.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX Regulating gastrointestinal motility using extendins or their agonists -
XX for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX glucose tolerance etc., also in diagnostic investigations.
XX Example 32; Fig 8; 70pp; English.
XX The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation,
XX particularly radiological or by magnetic resonance imaging. Extendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX Sequence 18 AA;
AAW47578 Length: 18 February 4, 2005 13:04 Type: P Check: 2382 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTSDDLFIIEWAAAAAS 18
|-----|
1 match found in sequence:
aaw47579 ; Extendin agonist (30).
(from "seq3ags.pep")
TOIG of: aaw47579 check: 2592 from: 1 to: 18

ID AAW47579 standard; peptide; 18 AA.
XX

```

```

AC AAW47579;
XX
XX
DT 03-JUL-1998 (first entry)
XX
XX
DE Extendin agonist (30).
XX
XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
KW postprandial dumping syndrome; postprandial hyperglycaemia;
KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
KW Gila monster venom.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 15 /label= MeAla
FT Modified-site 16 /label= MeAla
FT Modified-site 17 /label= MeAla
FT Modified-site 18 /note= "amidated"
FT
FT
XX WO9805351-A1.
XX
XX 12-FEB-1998.
XX
XX 08-AUG-1997; 97WO-US014199.
XX
XX 08-AUG-1996; 96US-00694954.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX
XX Regulating gastrointestinal motility using extendins or their agonists -
PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
PT glucose tolerance etc., also in diagnostic investigations.
XX
XX Example 33; Fig 8; 70pp; English.
XX
XX The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation.
XX particularly radiological or by magnetic resonance imaging. Extendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX
XX Sequence 18 AA;
XX
AAW47579 Length: 18 February 4, 2005 13:04 Type: P Check: 2592
Found using 'seq3' (mohamed337.key)
1 HGEFTSDFLFIWFPAAS 18
1
-----
1 match found in sequence:
aaw47580; Extendin agonist (31).
(from "seq3ags.pgp")
TOIG of: aaw47580 check: 2152 from: 1 to: 18

```

```

ID
XX
XX AAW47580 standard; peptide; 18 AA.
AC
XX AAW47580;
XX
XX 03-JUL-1998 (first entry)
DT
XX
XX Extendin agonist (31).
DE
XX
XX Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
KW postprandial dumping syndrome; postprandial hyperglycaemia;
KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
KW Gila monster venom.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 14 /label= MeAla
FT Modified-site 15 /label= MeAla
FT Modified-site 16 /label= MeAla
FT Modified-site 17 /label= MeAla
FT Modified-site 18 /label= MeAla
FT Modified-site 18 /note= "amidated"
FT
FT
XX WO9805351-A1.
XX
XX 12-FEB-1998.
XX
XX 08-AUG-1997; 97WO-US014199.
XX
XX 08-AUG-1996; 96US-00694954.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Gedulin B, Beeley NRA, Prickett KS;
XX WPI; 1998-145351/13.
XX
XX Regulating gastrointestinal motility using extendins or their agonists -
PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
PT glucose tolerance etc., also in diagnostic investigations.
XX
XX Example 34; Fig 8; 70pp; English.
XX
XX The present sequence is an extendin agonist, which reduces gastric
XX motility and delays gastric emptying. It can be used to treat spasm
XX (where associated with acute diverticulitis or disorders of the biliary
XX tract or sphincter of Oddi), postprandial dumping syndrome and
XX hyperglycaemia (particularly associated with type 2 diabetes), type 1
XX diabetes, impaired glucose tolerance, toxin ingestion (an extendin agonist
XX is administered to prevent stomach contents passing into the intestines,
XX then the stomach pumped) and obesity. It can also be administered to
XX subjects undergoing gastrointestinal diagnostic investigation.
XX particularly radiological or by magnetic resonance imaging. Extendins,
XX components of Gila monster venom, have some sequence similarity to
XX glucagon-like peptides (GLP). They are GLP agonists and have been
XX suggested (US5424286) for treatment of diabetes and prevention of
XX hyperglycaemia
XX
XX Sequence 18 AA;
XX
AAW47580 Length: 18 February 4, 2005 13:04 Type: P Check: 2152
Found using 'seq3' (mohamed337.key)
1 HGEFTSDFLFIWFPAAS 18
1
-----
1 match found in sequence:

```

```

ay03721 ; Exendin agonist compound 1.
(from "seq3ags.pep")
TOIG of: aay03721 check: 3082 from: 1 to: 18

ID AAY03721 standard; peptide; 18 AA.
XX
AC AAY03721;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 1.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 18
FT /note= "C-terminal amide"
XX
PN WO9907404-A1.
XX
PD 18-FEB-1999.
XX
PP 06-AUG-1998; 98WO-US016387.
XX
PR 08-AUG-1997; 97US-0055404P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-180403/15.
XX
New exendin agonists - useful in the treatment of Type I and II diabetes.
XX
Claim 17; Fig 1A-B; 70pp; English.
XX
The invention relates to exendin agonists which slow gastric emptying and
lower plasma glucose levels. The exendin agonists are used to treat Type
I and II diabetes, disorders which would be benefited by agents which
lower plasma glucose levels, and disorders which would be benefited by
agents useful in delaying and/or slowing gastric emptying. Delayed
gastric emptying is a useful diagnostic aid in gastro-intestinal
radiological examinations. Sequences AAY03721-51 represent specifically
claimed examples of the exendin agonist compounds of the invention. (Also
see AAY03720 for exendin generic peptide formula and description)
XX
SQ Sequence 18 AA;

AAY03722 Length: 18 February 4, 2005 13:04 Type: P Check: 3303 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
  1 HGFTSDLLFIEWPPPPS 18

-----
1 match found in sequence:
ay03723 ; Exendin agonist compound 3.
(from "seq3ags.pep")
TOIG of: aay03723 check: 3091 from: 1 to: 18

ID AAY03723 standard; peptide; 18 AA.
XX
AC AAY03723;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 3.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 18
FT /note= "C-terminal amide"
XX
PN WO9907404-A1.
XX
PD 18-FEB-1999.
XX
PP 06-AUG-1998; 98WO-US016387.

```

```

ay03721 ; Exendin agonist compound 1.
(from "seq3ags.pep")
TOIG of: aay03721 check: 3082 from: 1 to: 18

ID AAY03721 standard; peptide; 18 AA.
XX
AC AAY03721;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 1.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 18
FT /note= "C-terminal amide"
XX
PN WO9907404-A1.
XX
PD 18-FEB-1999.
XX
PP 06-AUG-1998; 98WO-US016387.
XX
PR 08-AUG-1997; 97US-0055404P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-180403/15.
XX
New exendin agonists - useful in the treatment of Type I and II diabetes.
XX
Claim 17; Fig 1A-B; 70pp; English.
XX
The invention relates to exendin agonists which slow gastric emptying and
lower plasma glucose levels. The exendin agonists are used to treat Type
I and II diabetes, disorders which would be benefited by agents which
lower plasma glucose levels, and disorders which would be benefited by
agents useful in delaying and/or slowing gastric emptying. Delayed
gastric emptying is a useful diagnostic aid in gastro-intestinal
radiological examinations. Sequences AAY03721-51 represent specifically
claimed examples of the exendin agonist compounds of the invention. (Also
see AAY03720 for exendin generic peptide formula and description)
XX
SQ Sequence 18 AA;

AAY03721 Length: 18 February 4, 2005 13:04 Type: P Check: 3082 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
  1 HGFTSDLLFIEWPPPPS 18

-----
1 match found in sequence:
ay03722 ; Exendin agonist compound 2.
(from "seq3ags.pep")
TOIG of: aay03722 check: 3303 from: 1 to: 18

ID AAY03722 standard; peptide; 18 AA.
XX
AC AAY03722;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 2.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;

```


Found using 'seq3' (mohamed337.key)

```
1 |-----|
  HGFTSDFLEWPPPP 18
```

1 match found in sequence:

ay03726 ; Exendin agonist compound 6.

(from "seq3ags.pep")

TOIG of: ay03726 check: 3309 from: 1 to: 18

ID AAY03726 standard; peptide; 18 AA.

XX AC

XX AAY03726;

XX DT 08-JUN-1999 (first entry)

XX DE Exendin agonist compound 6.

XX EX

XX Exendin; agonist; diabetes; disorder; plasma glucose; gastric;

KW diagnostic; gastro-intestinal; radiological.

XX OS Synthetic.

XX FT

XX Key Location/Qualifiers

FT Modified-site 18

FT /note= "C-terminal amide"

XX PN

XX WO9907404-A1.

XX PD

XX 18-FEB-1999.

XX PF

XX 06-AUG-1998; 98WO-US016387.

XX PR

XX 08-AUG-1997; 97US-0055404P.

XX PA

XX (AMYL-) AMYLIN PHARM INC.

XX PI

XX Beeley NRA, Prickett KS;

XX DR

XX WPI; 1999-180403/15.

XX PT

XX New exendin agonists - useful in the treatment of Type I and II diabetes.

XX PS

XX Claim 17; Fig 1A-B; 70pp; English.

XX CC

XX The invention relates to exendin agonists which slow gastric emptying and

CC lower plasma glucose levels. The exendin agonists are used to treat Type

CC I and II diabetes, disorders which would be benefited by agents which

CC lower plasma glucose levels, and disorders which would be benefited by

CC agents useful in delaying and/or slowing gastric emptying. Delayed

CC gastric emptying is a useful diagnostic aid in gastro-intestinal

CC radiological examinations. Sequences AAY03721-51 represent specifically

CC claimed examples of the exendin agonist compounds of the invention. (Also

CC see AAY03720 for exendin generic peptide formula and description)

XX SQ

XX Sequence 18 AA;

XX AAY03726 Length: 18 February 4, 2005 13:04 Type: P Check: 3309

XX Found using 'seq3' (mohamed337.key)

```
1 |-----|
  HGFTSDFLEWPPPPS 18
```

1 match found in sequence:

ay03727 ; Exendin agonist compound 7.

(from "seq3ags.pep")

TOIG of: ay03727 check: 3384 from: 1 to: 18

ID AAY03727 standard; peptide; 18 AA.

XX AC

XX AAY03727;

XX DT 08-JUN-1999 (first entry)

XX DE Exendin agonist compound 7.

XX EX

XX Exendin; agonist; diabetes; disorder; plasma glucose; gastric;

KW diagnostic; gastro-intestinal; radiological.

XX OS Synthetic.

XX AAY03727;

XX DT 08-JUN-1999 (first entry)

XX DE Exendin agonist compound 7.

XX EX

XX Exendin; agonist; diabetes; disorder; plasma glucose; gastric;

KW diagnostic; gastro-intestinal; radiological.

XX OS Synthetic.

XX FT

XX Key Location/Qualifiers

FT Modified-site 4

FT /note= "naphthylalanine"

FT Modified-site 18

FT /note= "C-terminal amide"

XX PN

XX WO9907404-A1.

XX PD

XX 18-FEB-1999.

XX PF

XX 06-AUG-1998; 98WO-US016387.

XX PR

XX 08-AUG-1997; 97US-0055404P.

XX PA

XX (AMYL-) AMYLIN PHARM INC.

XX PI

XX Beeley NRA, Prickett KS;

XX DR

XX WPI; 1999-180403/15.

XX PT

XX New exendin agonists - useful in the treatment of Type I and II diabetes.

XX PS

XX Claim 17; Fig 1A-B; 70pp; English.

XX CC

XX The invention relates to exendin agonists which slow gastric emptying and

CC lower plasma glucose levels. The exendin agonists are used to treat Type

CC I and II diabetes, disorders which would be benefited by agents which

CC lower plasma glucose levels, and disorders which would be benefited by

CC agents useful in delaying and/or slowing gastric emptying. Delayed

CC gastric emptying is a useful diagnostic aid in gastro-intestinal

CC radiological examinations. Sequences AAY03721-51 represent specifically

CC claimed examples of the exendin agonist compounds of the invention. (Also

CC see AAY03720 for exendin generic peptide formula and description)

XX SQ

XX Sequence 18 AA;

XX AAY03727 Length: 18 February 4, 2005 13:04 Type: P Check: 3384

XX Found using 'seq3' (mohamed337.key)

```
1 |-----|
  HGEXTSDFLEWPPPPS 18
```

1 match found in sequence:

ay03728 ; Exendin agonist compound 8.

(from "seq3ags.pep")

TOIG of: ay03728 check: 3307 from: 1 to: 18

ID AAY03728 standard; peptide; 18 AA.

XX AC

XX AAY03728;

XX DT 08-JUN-1999 (first entry)

XX DE Exendin agonist compound 8.

XX EX

XX Exendin; agonist; diabetes; disorder; plasma glucose; gastric;

KW diagnostic; gastro-intestinal; radiological.

XX OS Synthetic.

CC lower plasma glucose levels, and disorders which would be benefited by
 CC agents useful in delaying and/or slowing gastric emptying. Delayed
 CC gastric emptying is a useful diagnostic aid in gastro-intestinal
 CC radiological examinations. Sequences AAY03721-51 represent specifically
 CC claimed examples of the extendin agonist compounds of the invention. (Also
 CC see AAY03720 for extendin generic peptide formula and description)
 XX
 SQ Sequence 18 AA;

AAY03730 Length: 18 February 4, 2005 13:04 Type: P Check: 3318 ..
 Found using 'seq3' (mohamed337.key)

1 |-----|
 1 HGEFTDLMFIEWPPPPS 18

 1 match found in sequence:
 aay03731 ; Extendin agonist compound 11.
 (from "seq3ags.pep")
 TOIG of: aay03731 check: 3319 from: 1 to: 18

ID AAY03731 standard; peptide; 18 AA.
 AC AAY03731;
 XX
 DT 08-JUN-1999 (first entry)
 DE Extendin agonist compound 11.
 XX
 XX Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
 KW diagnostic; gastro-intestinal; radiological.
 OS Synthetic.

Key Location/Qualifiers
 FT Modified-site 18 /note= "C-terminal amide"
 FT
 PN WO9907404-A1.
 XX
 PD 18-FEB-1999.

XX 06-AUG-1998; 98WO-US016387.
 XX 08-AUG-1997; 97US-0055404P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-180403/15.

XX New extendin agonists - useful in the treatment of Type I and II diabetes.
 XX
 PS Claim 17; Fig 1A-B; 70pp; English.

CC The invention relates to extendin agonists which slow gastric emptying and
 CC lower plasma glucose levels. The extendin agonists are used to treat Type
 CC I and II diabetes, disorders which would be benefited by agents which
 CC lower plasma glucose levels, and disorders which would be benefited by
 CC agents useful in delaying and/or slowing gastric emptying. Delayed
 CC gastric emptying is a useful diagnostic aid in gastro-intestinal
 CC radiological examinations. Sequences AAY03721-51 represent specifically
 CC claimed examples of the extendin agonist compounds of the invention. (Also
 CC see AAY03720 for extendin generic peptide formula and description)
 XX
 SQ Sequence 18 AA;

AAY03731 Length: 18 February 4, 2005 13:04 Type: P Check: 3319 ..
 Found using 'seq3' (mohamed337.key)

1 |-----|

1 HGEFTSELMFIEWPPPPS 18
 1 match found in sequence:
 aay03732 ; Extendin agonist compound 12.
 (from "seq3ags.pep")
 TOIG of: aay03732 check: 3408 from: 1 to: 18

ID AAY03732 standard; peptide; 18 AA.
 AC AAY03732;
 XX
 DT 08-JUN-1999 (first entry)
 DE Extendin agonist compound 12.
 XX
 XX Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
 KW diagnostic; gastro-intestinal; radiological.
 OS Synthetic.

Key Location/Qualifiers
 FT Modified-site 8 /note= "pentylglycine"
 FT Modified-site 18
 FT /note= "C-terminal amide"
 XX
 PN WO9907404-A1.

XX 18-FEB-1999.
 XX 06-AUG-1998; 98WO-US016387.
 XX 08-AUG-1997; 97US-0055404P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-180403/15.

XX New extendin agonists - useful in the treatment of Type I and II diabetes.
 XX
 PS Claim 17; Fig 1A-B; 70pp; English.

CC The invention relates to extendin agonists which slow gastric emptying and
 CC lower plasma glucose levels. The extendin agonists are used to treat Type
 CC I and II diabetes, disorders which would be benefited by agents which
 CC lower plasma glucose levels, and disorders which would be benefited by
 CC agents useful in delaying and/or slowing gastric emptying. Delayed
 CC gastric emptying is a useful diagnostic aid in gastro-intestinal
 CC radiological examinations. Sequences AAY03721-51 represent specifically
 CC claimed examples of the extendin agonist compounds of the invention. (Also
 CC see AAY03720 for extendin generic peptide formula and description)
 XX
 SQ Sequence 18 AA;

AAY03732 Length: 18 February 4, 2005 13:04 Type: P Check: 3408 ..
 Found using 'seq3' (mohamed337.key)

1 |-----|
 1 HGEFTSDXMFIEWPPPPS 18

 1 match found in sequence:
 aay03733 ; Extendin agonist compound 13.
 (from "seq3ags.pep")
 TOIG of: aay03733 check: 3178 from: 1 to: 18

ID AAY03733 standard; peptide; 18 AA.
 XX

```

AC AAY03733;
XX
XX 08-JUN-1999 (first entry)
DT
XX
XX Extendin agonist compound 13.
DE
XX
XX Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
XX Synthetic.
OS
XX
XX
XX Key Location/Qualifiers
FH Modified-site 8
FT /note= "pentylglycine"
FT
FT Modified-site 18
FT /note= "C-terminal amide"
XX
XX WO9907404-A1.
PN
XX
XX 18-FEB-1999.
PD
XX
XX 06-AUG-1998; 98WO-US016387.
PF
XX
XX 08-AUG-1997; 97US-0055404P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Beeley NRA, Prickett KS;
PI
XX WPI; 1999-180403/15.
DR
XX
XX New extendin agonists - useful in the treatment of Type I and II diabetes.
PT
XX Claim 17; Fig 1A-B; 70pp; English.
PS
XX
XX The invention relates to extendin agonists which slow gastric emptying and
CC lower plasma glucose levels. The extendin agonists are used to treat Type
CC I and II diabetes, disorders which would be benefited by agents which
CC lower plasma glucose levels, and disorders which would be benefited by
CC agents useful in delaying and/or slowing gastric emptying. Delayed
CC gastric emptying is a useful diagnostic aid in gastro-intestinal
CC radiological examinations. Sequences AAY03721-51 represent specifically
CC claimed examples of the extendin agonist compounds of the invention. (Also
CC see AAY03720 for extendin generic peptide formula and description)
XX
XX Sequence 18 AA;
SQ
AAY03733 Length: 18 February 4, 2005 13:04 Type: P Check: 3178 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
  HGEFTSDXLFIETPPPPS 18
  1

-----
1 match found in sequence:
aay03733 ; Extendin agonist compound 14.
(from "seq3ags.pep")
TOIG of: aay03734 check: 3411 from: 1 to: 18

ID AAY03734 standard; peptide; 18 AA.
XX
XX AAY03734;
AC
XX
XX 08-JUN-1999 (first entry)
DT
XX
XX Extendin agonist compound 14.
DE
XX
XX Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
XX Synthetic.
OS
XX

```

```

FH Key Location/Qualifiers
FT Modified-site 9
FT /note= "pentylglycine"
FT Modified-site 18
FT /note= "C-terminal amide"
XX
XX WO9907404-A1.
PN
XX
XX 18-FEB-1999.
PD
XX
XX 06-AUG-1998; 98WO-US016387.
PF
XX
XX 08-AUG-1997; 97US-0055404P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Beeley NRA, Prickett KS;
PI
XX WPI; 1999-180403/15.
DR
XX
XX New extendin agonists - useful in the treatment of Type I and II diabetes.
PT
XX Claim 17; Fig 1A-B; 70pp; English.
PS
XX
XX The invention relates to extendin agonists which slow gastric emptying and
CC lower plasma glucose levels. The extendin agonists are used to treat Type
CC I and II diabetes, disorders which would be benefited by agents which
CC lower plasma glucose levels, and disorders which would be benefited by
CC agents useful in delaying and/or slowing gastric emptying. Delayed
CC gastric emptying is a useful diagnostic aid in gastro-intestinal
CC radiological examinations. Sequences AAY03721-51 represent specifically
CC claimed examples of the extendin agonist compounds of the invention. (Also
CC see AAY03720 for extendin generic peptide formula and description)
XX
XX Sequence 18 AA;
SQ
AAY03734 Length: 18 February 4, 2005 13:04 Type: P Check: 3411 ..
Found using 'seq3' (mohamed337.key)

1 |-----|
  HGEFTSDXLFIETPPPPS 18
  1

-----
1 match found in sequence:
aay03735 ; Extendin agonist compound 15.
(from "seq3ags.pep")
TOIG of: aay03735 check: 3190 from: 1 to: 18

ID AAY03735 standard; peptide; 18 AA.
XX
XX AAY03735;
AC
XX
XX 08-JUN-1999 (first entry)
DT
XX
XX Extendin agonist compound 15.
DE
XX
XX Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 9
FT /note= "pentylglycine"
FT Modified-site 18
FT /note= "C-terminal amide"
XX
XX WO9907404-A1.
PN
XX
XX 18-FEB-1999.
PD
XX
XX 06-AUG-1998; 98WO-US016387.
PF

```

XX 08-AUG-1997; 97US-0055404P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-180403/15.
XX
XX New extendin agonists - useful in the treatment of Type I and II diabetes.
XX
XX Claim 17; Fig 1D-E; 70pp; English.
XX
XX The invention relates to extendin agonists which slow gastric emptying and
XX lower plasma glucose levels. The extendin agonists are used to treat Type
XX I and II diabetes, disorders which would be benefited by agents which
XX lower plasma glucose levels, and disorders which would be benefited by
XX agents useful in delaying and/or slowing gastric emptying. Delayed
XX gastric emptying is a useful diagnostic aid in gastro-intestinal
XX radiological examinations. Sequences AAY03721-51 represent specifically
XX claimed examples of the extendin agonist compounds of the invention. (Also
XX see AAY03720 for extendin generic peptide formula and description)
XX
XX Sequence 18 AA;
XX
XX The invention relates to extendin agonists which slow gastric emptying and
XX lower plasma glucose levels. The extendin agonists are used to treat Type
XX I and II diabetes, disorders which would be benefited by agents which
XX lower plasma glucose levels, and disorders which would be benefited by
XX agents useful in delaying and/or slowing gastric emptying. Delayed
XX gastric emptying is a useful diagnostic aid in gastro-intestinal
XX radiological examinations. Sequences AAY03721-51 represent specifically
XX claimed examples of the extendin agonist compounds of the invention. (Also
XX see AAY03720 for extendin generic peptide formula and description)
XX
XX Sequence 18 AA;
XX
XX AAY03735 Length: 18 February 4, 2005 13:04 Type: P Check: 3190 ..
XX Found using 'seq3' (mohamed337.key)
XX
1 |-----|
1 HGEFTS D L X F I E F P P P P S 18

1 match found in sequence:
aay03736; Extendin agonist compound 16.
(from "seq3ags.pep")
TOIG of: aay03736 check: 3492 from: 1 to: 18

ID AAY03736 standard; peptide; 18 AA.
XX
XX AAY03736;
AC
XX
XX 08-JUN-1999 (first entry)
DT
XX
XX Extendin agonist compound 16.
DE
XX
XX Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
KW
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 10
FT Modified-site 18 /note= "naphthylalanine"
FT Modified-site 18 /note= "C-terminal amide"
FT
XX
XX WO9907404-A1.
PN
XX
XX 18-FEB-1999.
PD
XX
XX 06-AUG-1998; 98WO-US016387.
PF
XX
XX 08-AUG-1997; 97US-0055404P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Beeley NRA, Prickett KS;
PI
XX
XX WPI; 1999-180403/15.
DR
XX
XX New extendin agonists - useful in the treatment of Type I and II diabetes.
XX
XX

PS Claim 17; Fig 1D-E; 70pp; English.
XX
XX The invention relates to extendin agonists which slow gastric emptying and
XX lower plasma glucose levels. The extendin agonists are used to treat Type
XX I and II diabetes, disorders which would be benefited by agents which
XX lower plasma glucose levels, and disorders which would be benefited by
XX agents useful in delaying and/or slowing gastric emptying. Delayed
XX gastric emptying is a useful diagnostic aid in gastro-intestinal
XX radiological examinations. Sequences AAY03721-51 represent specifically
XX claimed examples of the extendin agonist compounds of the invention. (Also
XX see AAY03720 for extendin generic peptide formula and description)
XX
XX Sequence 18 AA;
XX
XX AAY03736 Length: 18 February 4, 2005 13:04 Type: P Check: 3492 ..
XX Found using 'seq3' (mohamed337.key)
XX
1 |-----|
1 HGEFTS D L X F I E F P P P P S 18

1 match found in sequence:
aay03737; Extendin agonist compound 17.
(from "seq3ags.pep")
TOIG of: aay03737 check: 3455 from: 1 to: 18

ID AAY03737 standard; peptide; 18 AA.
XX
XX AAY03737;
AC
XX
XX 08-JUN-1999 (first entry)
DT
XX
XX Extendin agonist compound 17.
DE
XX
XX Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
KW
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 18
FT Modified-site 18 /note= "C-terminal amide"
FT
XX
XX WO9907404-A1.
PN
XX
XX 18-FEB-1999.
PD
XX
XX 06-AUG-1998; 98WO-US016387.
PF
XX
XX 08-AUG-1997; 97US-0055404P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Beeley NRA, Prickett KS;
PI
XX
XX WPI; 1999-180403/15.
DR
XX
XX New extendin agonists - useful in the treatment of Type I and II diabetes.
XX
XX Claim 17; Fig 1D-E; 70pp; English.
XX
XX The invention relates to extendin agonists which slow gastric emptying and
XX lower plasma glucose levels. The extendin agonists are used to treat Type
XX I and II diabetes, disorders which would be benefited by agents which
XX lower plasma glucose levels, and disorders which would be benefited by
XX agents useful in delaying and/or slowing gastric emptying. Delayed
XX gastric emptying is a useful diagnostic aid in gastro-intestinal
XX radiological examinations. Sequences AAY03721-51 represent specifically
XX claimed examples of the extendin agonist compounds of the invention. (Also
XX see AAY03720 for extendin generic peptide formula and description)
XX
XX Sequence 18 AA;
XX
XX

```

AYY03737 Length: 18 February 4, 2005 13:04 Type: P Check: 3455 ..
Found using 'seq3' (mohamed337.key)

1 HGEFTSLLMFVEWPPPPS
  1
-----
1 match found in sequence:
aay03738 ; Exendin agonist compound 18.
(from "seq3ags.pep")
TOIG of: aay03738 Check: 3225 from: 1 to: 18

ID AAY03738 standard; peptide; 18 AA.
XX
AC AAY03738;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 18.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 18
FT Modified-site 18 /note= "C-terminal amide"
FT
XX
PN W09907404-A1.
XX
PD 18-FEB-1999.
XX
PF 06-AUG-1998; 98WO-US016387.
XX
PR 08-AUG-1997; 97US-0055404P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-180403/15.
XX
XX New exendin agonists - useful in the treatment of Type I and II diabetes.
XX
XX Claim 17; Fig 1D-E; 70pp; English.
XX
XX The invention relates to exendin agonists which slow gastric emptying and
XX lower plasma glucose levels. The exendin agonists are used to treat Type
XX I and II diabetes, disorders which would be benefited by agents which
XX lower plasma glucose levels, and disorders which would be benefited by
XX agents useful in delaying and/or slowing gastric emptying. Delayed
XX gastric emptying is a useful diagnostic aid in gastro-intestinal
XX radiological examinations. Sequences AAY03721-51 represent specifically
XX claimed examples of the exendin agonist compounds of the invention. (Also
XX see AAY03720 for exendin generic peptide formula and description)
XX
XX Sequence 18 AA;
XX
AYY03738 Length: 18 February 4, 2005 13:04 Type: P Check: 3225 ..
Found using 'seq3' (mohamed337.key)

1 HGEFTSLLMFVEWPPPPS
  1
-----
1 match found in sequence:
aay03739 ; Exendin agonist compound 19.
(from "seq3ags.pep")
TOIG of: aay03739 Check: 3477 from: 1 to: 18

```

```

ID AAY03739 standard; peptide; 18 AA.
XX
AC AAY03739;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 19.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 11
FT Modified-site 18 /note= "tert-butylglycine"
FT Modified-site 18 /note= "C-terminal amide"
FT
XX
PN W09907404-A1.
XX
PD 18-FEB-1999.
XX
PF 06-AUG-1998; 98WO-US016387.
XX
PR 08-AUG-1997; 97US-0055404P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
XX
XX WPI; 1999-180403/15.
XX
XX New exendin agonists - useful in the treatment of Type I and II diabetes.
XX
XX Claim 17; Fig 1D-E; 70pp; English.
XX
XX The invention relates to exendin agonists which slow gastric emptying and
XX lower plasma glucose levels. The exendin agonists are used to treat Type
XX I and II diabetes, disorders which would be benefited by agents which
XX lower plasma glucose levels, and disorders which would be benefited by
XX agents useful in delaying and/or slowing gastric emptying. Delayed
XX gastric emptying is a useful diagnostic aid in gastro-intestinal
XX radiological examinations. Sequences AAY03721-51 represent specifically
XX claimed examples of the exendin agonist compounds of the invention. (Also
XX see AAY03720 for exendin generic peptide formula and description)
XX
XX Sequence 18 AA;
XX
AYY03739 Length: 18 February 4, 2005 13:04 Type: P Check: 3477 ..
Found using 'seq3' (mohamed337.key)

1 HGEFTSLLMFVEWPPPPS
  1
-----
1 match found in sequence:
aay03740 ; Exendin agonist compound 20.
(from "seq3ags.pep")
TOIG of: aay03740 Check: 3247 from: 1 to: 18

ID AAY03740 standard; peptide; 18 AA.
XX
AC AAY03740;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 20.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.

```

```

XX OS Synthetic.
XX FH Key
XX FT Modified-site
XX FT Modified-site
XX FT Modified-site
XX PN WO9907404-A1.
XX PD 18-FEB-1999.
XX PF 06-AUG-1998; 98WO-US016387.
XX PR 08-AUG-1997; 97US-0055404P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-180403/15.
XX PT New extendin agonists - useful in the treatment of Type I and II diabetes.
XX PS Claim 17; Fig 1D-E; 70pp; English.
XX CC The invention relates to extendin agonists which slow gastric emptying and
XX CC lower plasma glucose levels. The extendin agonists are used to treat Type
XX CC I and II diabetes, disorders which would be benefited by agents which
XX CC lower plasma glucose levels, and disorders which would be benefited by
XX CC agents useful in delaying and/or slowing gastric emptying. Delayed
XX CC gastric emptying is a useful diagnostic aid in gastro-intestinal
XX CC radiological examinations. Sequences AAY03721-51 represent specifically
XX CC claimed examples of the extendin agonist compounds of the invention. (Also
XX CC see AAY03720 for extendin generic peptide formula and description)
XX SQ Sequence 18 AA;

AAY03740 Length: 18 February 4, 2005 13:04 Type: P Check: 3247 ..
Found using 'seq3' (mohamed337.key)
1 |-----|
1 HGEFTSDDLFXEFPFPPPS 18
-----
1 match found in sequence:
aay03741 ; Extendin agonist compound 21.
(from "seq3ags.pep")
TOIG of: aay03741 check: 3300 from: 1 to: 18

ID AAY03741 standard; peptide; 18 AA.
XX AC AAY03741;
XX DT 08-JUN-1999 (first entry)
XX DE Extendin agonist compound 21.
XX OS Synthetic.
XX FH Key
XX FT Modified-site
XX FT Modified-site
XX PN WO9907404-A1.
XX PD 18-FEB-1999.
XX PF 06-AUG-1998; 98WO-US016387.
XX PR 08-AUG-1997; 97US-0055404P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-180403/15.
XX PT New extendin agonists - useful in the treatment of Type I and II diabetes.
XX PS Claim 17; Fig 1D-E; 70pp; English.
XX CC The invention relates to extendin agonists which slow gastric emptying and
XX CC lower plasma glucose levels. The extendin agonists are used to treat Type
XX CC I and II diabetes, disorders which would be benefited by agents which
XX CC lower plasma glucose levels, and disorders which would be benefited by
XX CC agents useful in delaying and/or slowing gastric emptying. Delayed
XX CC gastric emptying is a useful diagnostic aid in gastro-intestinal
XX CC radiological examinations. Sequences AAY03721-51 represent specifically
XX CC claimed examples of the extendin agonist compounds of the invention. (Also
XX CC see AAY03720 for extendin generic peptide formula and description)
XX SQ Sequence 18 AA;

AAY03741 Length: 18 February 4, 2005 13:04 Type: P Check: 3300 ..
Found using 'seq3' (mohamed337.key)
1 |-----|
1 HGEFTSDDLFXEFPFPPPS 18
-----
1 match found in sequence:
aay03742 ; Extendin agonist compound 22.
(from "seq3ags.pep")
TOIG of: aay03742 check: 3091 from: 1 to: 18

ID AAY03742 standard; peptide; 18 AA.
XX AC AAY03742;
XX DT 08-JUN-1999 (first entry)
XX DE Extendin agonist compound 22.
XX OS Synthetic.
XX FH Key
XX FT Modified-site
XX FT Modified-site
XX PN WO9907404-A1.
XX PD 18-FEB-1999.
XX PF 06-AUG-1998; 98WO-US016387.
XX PR 08-AUG-1997; 97US-0055404P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-180403/15.
XX PT New extendin agonists - useful in the treatment of Type I and II diabetes.
XX PS Claim 17; Fig 1D-E; 70pp; English.

```

XX The invention relates to exendin agonists which slow gastric emptying and
 CC lower plasma glucose levels. The exendin agonists are used to treat Type
 CC I and II diabetes, disorders which would be benefited by agents which
 CC lower plasma glucose levels, and disorders which would be benefited by
 CC agents useful in delaying and/or slowing gastric emptying. Delayed
 CC gastric emptying is a useful diagnostic aid in gastro-intestinal
 CC radiological examinations. Sequences AAY03721-51 represent specifically
 CC claimed examples of the exendin agonist compounds of the invention. (Also
 CC see AAY03720 for exendin generic peptide formula and description)
 XX

SQ Sequence 18 AA;
 AAY03742 Length: 18 February 4, 2005 13:04 Type: P Check: 3091 ..
 Found using 'seq3' (mohamed337.key)

1 HGEFTSGLMFIEFPFPPPS 18
 1 HGEFTSGLMFIEFPFPPPS 18

 1 match found in sequence:
 aay03743 ; Exendin agonist compound 23.
 (from "seq3ags.pep")
 TOIG of: aay03743 check: 3808 from: 1 to: 18

 ID AAY03743 standard; peptide; 18 AA.
 XX
 AC AAY03743;
 XX
 DT 08-JUN-1999 (first entry)
 XX
 DE Exendin agonist compound 23.
 XX
 EX Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
 KW diagnostic; gastro-intestinal; radiological.
 KW
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 14..17
 FT Modified-site /note= "thio proline"
 FT Modified-site 18
 FT Modified-site /note= "C-terminal amide"
 FT
 FT
 FT
 PN WO9907404-A1.
 XX
 PD 18-FEB-1999.
 XX
 PF 06-AUG-1998; 98WO-US016387.
 XX
 PR 08-AUG-1997; 97US-0055404P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-180403/15.
 XX
 PS New exendin agonists - useful in the treatment of Type I and II diabetes.
 XX
 PS Claim 17; Fig 1D-E; 70pp; English.
 XX
 CC The invention relates to exendin agonists which slow gastric emptying and
 CC lower plasma glucose levels. The exendin agonists are used to treat Type
 CC I and II diabetes, disorders which would be benefited by agents which
 CC lower plasma glucose levels, and disorders which would be benefited by
 CC agents useful in delaying and/or slowing gastric emptying. Delayed
 CC gastric emptying is a useful diagnostic aid in gastro-intestinal
 CC radiological examinations. Sequences AAY03721-51 represent specifically
 CC claimed examples of the exendin agonist compounds of the invention. (Also
 CC see AAY03720 for exendin generic peptide formula and description)
 XX

SQ Sequence 18 AA;
 AAY03743 Length: 18 February 4, 2005 13:04 Type: P Check: 3808 ..
 Found using 'seq3' (mohamed337.key)

1 HGEFTSGLMFIEFPFPPPS 18
 1 HGEFTSGLMFIEFPFPPPS 18

 1 match found in sequence:
 aay03744 ; Exendin agonist compound 24.
 (from "seq3ags.pep")
 TOIG of: aay03744 check: 3696 from: 1 to: 18

 ID AAY03744 standard; peptide; 18 AA.
 XX
 AC AAY03744;
 XX
 DT 08-JUN-1999 (first entry)
 XX
 DE Exendin agonist compound 24.
 XX
 EX Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
 KW diagnostic; gastro-intestinal; radiological.
 KW
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 15..17
 FT Modified-site /note= "thio proline"
 FT Modified-site 18
 FT Modified-site /note= "C-terminal amide"
 FT
 FT
 FT
 PN WO9907404-A1.
 XX
 PD 18-FEB-1999.
 XX
 PF 06-AUG-1998; 98WO-US016387.
 XX
 PR 08-AUG-1997; 97US-0055404P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-180403/15.
 XX
 PS New exendin agonists - useful in the treatment of Type I and II diabetes.
 XX
 PS Claim 17; Fig 1D-E; 70pp; English.
 XX
 CC The invention relates to exendin agonists which slow gastric emptying and
 CC lower plasma glucose levels. The exendin agonists are used to treat Type
 CC I and II diabetes, disorders which would be benefited by agents which
 CC lower plasma glucose levels, and disorders which would be benefited by
 CC agents useful in delaying and/or slowing gastric emptying. Delayed
 CC gastric emptying is a useful diagnostic aid in gastro-intestinal
 CC radiological examinations. Sequences AAY03721-51 represent specifically
 CC claimed examples of the exendin agonist compounds of the invention. (Also
 CC see AAY03720 for exendin generic peptide formula and description)
 XX

SQ Sequence 18 AA;
 AAY03744 Length: 18 February 4, 2005 13:04 Type: P Check: 3696 ..
 Found using 'seq3' (mohamed337.key)

1 HGEFTSGLMFIEFPFPPPS 18
 1 HGEFTSGLMFIEFPFPPPS 18

 1 match found in sequence:

```

aay03745 ; Exendin agonist compound 25.
(from "seq3ags.pep")
TOIG of: aay03745 check: 3808 from: 1 to: 18

ID AAY03745 standard; peptide; 18 AA.
XX
AC AAY03745;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 25.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 14..17
FT Modified-site /note= "homo proline"
FT Modified-site 18
FT Modified-site /note= "C-terminal amide"
XX
PN WO9907404-A1.
XX
PD 18-FEB-1999.
XX
PF 06-AUG-1998; 98WO-US016387.
XX
PR 08-AUG-1997; 97US-0055404P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-180403/15.
XX
New exendin agonists - useful in the treatment of Type I and II diabetes.
Claim 17; Fig 1D-E; 70pp; English.
XX
The invention relates to exendin agonists which slow gastric emptying and
lower plasma glucose levels. The exendin agonists are used to treat Type
I and II diabetes, disorders which would be benefited by agents which
lower plasma glucose levels, and disorders which would be benefited by
agents useful in delaying and/or slowing gastric emptying. Delayed
gastric emptying is a useful diagnostic aid in gastro-intestinal
radiological examinations. Sequences AAY03721-51 represent specifically
claimed examples of the exendin agonist compounds of the invention. (Also
see AAY03720 for exendin generic peptide formula and description)
XX
SQ Sequence 18 AA;
AAY03745 Length: 18 February 4, 2005 13:04 Type: P Check: 3808 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTSDLMFIEWPXXXX 18
-----
1 match found in sequence:
aay03747 ; Exendin agonist compound 26.
(from "seq3ags.pep")
TOIG of: aay03746 check: 3696 from: 1 to: 18

ID AAY03746 standard; peptide; 18 AA.
XX
AC AAY03746;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 26.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 14..17
FT Modified-site /note= "homo proline"
FT Modified-site 18
FT Modified-site /note= "C-terminal amide"
XX
PN WO9907404-A1.
XX
PD 18-FEB-1999.
XX
PF 06-AUG-1998; 98WO-US016387.
XX
PR 08-AUG-1997; 97US-0055404P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-180403/15.
XX
New exendin agonists - useful in the treatment of Type I and II diabetes.
Claim 17; Fig 1D-E; 70pp; English.
XX
The invention relates to exendin agonists which slow gastric emptying and
lower plasma glucose levels. The exendin agonists are used to treat Type
I and II diabetes, disorders which would be benefited by agents which
lower plasma glucose levels, and disorders which would be benefited by
agents useful in delaying and/or slowing gastric emptying. Delayed
gastric emptying is a useful diagnostic aid in gastro-intestinal
radiological examinations. Sequences AAY03721-51 represent specifically
claimed examples of the exendin agonist compounds of the invention. (Also
see AAY03720 for exendin generic peptide formula and description)
XX
SQ Sequence 18 AA;
aay03745 Length: 18 February 4, 2005 13:04 Type: P Check: 3696 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTSDLMFIEWPXXXX 18
-----
1 match found in sequence:
aay03747 ; Exendin agonist compound 27.
(from "seq3ags.pep")
TOIG of: aay03747 check: 3578 from: 1 to: 18

ID AAY03747 standard; peptide; 18 AA.
XX
AC AAY03747;
XX
DT 08-JUN-1999 (first entry)
XX
DE Exendin agonist compound 27.
XX
KW Exendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 14..17
FT Modified-site /note= "thio proline"
FT Modified-site 18
FT Modified-site /note= "C-terminal amide"
XX
```

XX WO9907404-A1.
PN 18-FEB-1999.
XX
XX
XX PD 06-AUG-1998; 98WO-US016387.
PF
XX
XX PD 08-AUG-1997; 97US-0055404P.
PF
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Beeley NRA, Prickett KS;
PI
XX WPI; 1999-180403/15.
XX
XX New extendin agonists - useful in the treatment of Type I and II diabetes.
PT
XX
XX Claim 17; Fig 1D-E; 70pp; English.
PS
XX The invention relates to extendin agonists which slow gastric emptying and
CC lower plasma glucose levels. The extendin agonists are used to treat Type
CC I and II diabetes, disorders which would be benefited by agents which
CC lower plasma glucose levels, and disorders which would be benefited by
CC agents useful in delaying and/or slowing gastric emptying. Delayed
CC gastric emptying is a useful diagnostic aid in gastro-intestinal
CC radiological examinations. Sequences AAY03721-51 represent specifically
CC claimed examples of the extendin agonist compounds of the invention. (Also
CC see AAY03720 for extendin generic peptide formula and description)
XX
XX Sequence 18 AA;
SQ
AAY03747 Length: 18 February 4, 2005 13:04 Type: P Check: 3578 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTS DLLFI EFXXXXX 18
|-----|
1 match found in sequence:
aay03748 ; Extendin agonist compound 28.
(from "seq3ags.pep")
TOIG of: aay03748 check: 3578 from: 1 to: 18

ID AAY03748 standard; peptide; 18 AA.
XX
XX AC AAY03748;
AC
XX
XX DT 08-JUN-1999 (first entry)
DT
XX
XX DE Extendin agonist compound 29.
DE
XX
XX KW Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
XX OS Synthetic.
OS
XX
XX FH Key Location/Qualifiers
FH Modified-site 14..17
FT Modified-site /note= "homo proline"
FT Modified-site 18
FT Modified-site /note= "C-terminal amide"
XX
XX PN WO9907404-A1.
PN
XX
XX PD 18-FEB-1999.
PD
XX
XX PF 06-AUG-1998; 98WO-US016387.
PF
XX
XX PR 08-AUG-1997; 97US-0055404P.
PR
XX
XX PA (AMYL-) AMYLIN PHARM INC.
PA
XX
XX PI Beeley NRA, Prickett KS;
PI
XX
XX DR WPI; 1999-180403/15.
DR
XX
XX PT New extendin agonists - useful in the treatment of Type I and II diabetes.
PT
XX
XX PS Claim 17; Fig 1D-E; 70pp; English.
PS
XX The invention relates to extendin agonists which slow gastric emptying and
CC lower plasma glucose levels. The extendin agonists are used to treat Type
CC I and II diabetes, disorders which would be benefited by agents which
CC lower plasma glucose levels, and disorders which would be benefited by
CC agents useful in delaying and/or slowing gastric emptying. Delayed
CC gastric emptying is a useful diagnostic aid in gastro-intestinal
CC radiological examinations. Sequences AAY03721-51 represent specifically
CC claimed examples of the extendin agonist compounds of the invention. (Also
CC see AAY03720 for extendin generic peptide formula and description)
XX
XX Sequence 18 AA;
SQ
AAY03747 Length: 18 February 4, 2005 13:04 Type: P Check: 3578 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTS DLLFI EFXXXXX 18
|-----|
1 match found in sequence:
aay03748 ; Extendin agonist compound 28.
(from "seq3ags.pep")
TOIG of: aay03748 check: 3578 from: 1 to: 18

ID AAY03748 standard; peptide; 18 AA.
XX
XX AC AAY03748;
AC
XX
XX DT 08-JUN-1999 (first entry)
DT
XX
XX DE Extendin agonist compound 28.
DE
XX
XX KW Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
XX OS Synthetic.
OS
XX
XX FH Key Location/Qualifiers
FH Modified-site 14..17
FT Modified-site /note= "homo proline"
FT Modified-site 18
FT Modified-site /note= "C-terminal amide"
XX
XX PN WO9907404-A1.
PN
XX
XX PD 18-FEB-1999.
PD
XX
XX PF 06-AUG-1998; 98WO-US016387.
PF
XX
XX PR 08-AUG-1997; 97US-0055404P.
PR
XX
XX PA (AMYL-) AMYLIN PHARM INC.
PA
XX
XX

PI Beeley NRA, Prickett KS;
XX
XX DR WPI; 1999-180403/15.
XX
XX PT New extendin agonists - useful in the treatment of Type I and II diabetes.
PT
XX
XX PS Claim 17; Fig 1D-E; 70pp; English.
PS
XX The invention relates to extendin agonists which slow gastric emptying and
CC lower plasma glucose levels. The extendin agonists are used to treat Type
CC I and II diabetes, disorders which would be benefited by agents which
CC lower plasma glucose levels, and disorders which would be benefited by
CC agents useful in delaying and/or slowing gastric emptying. Delayed
CC gastric emptying is a useful diagnostic aid in gastro-intestinal
CC radiological examinations. Sequences AAY03721-51 represent specifically
CC claimed examples of the extendin agonist compounds of the invention. (Also
CC see AAY03720 for extendin generic peptide formula and description)
XX
XX Sequence 18 AA;
SQ
AAY03748 Length: 18 February 4, 2005 13:04 Type: P Check: 3578 ..
Found using 'seq3' (mohamed337.key)
1 HGEFTS DLLFI EFXXXXX 18
|-----|
1 match found in sequence:
aay03749 ; Extendin agonist compound 29.
(from "seq3ags.pep")
TOIG of: aay03749 check: 2382 from: 1 to: 18

ID AAY03749 standard; peptide; 18 AA.
XX
XX AC AAY03749;
AC
XX
XX DT 08-JUN-1999 (first entry)
DT
XX
XX DE Extendin agonist compound 29.
DE
XX
XX KW Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
KW diagnostic; gastro-intestinal; radiological.
XX
XX OS Synthetic.
OS
XX
XX FH Key Location/Qualifiers
FH Modified-site 14..17
FT Modified-site /note= "methylaniline"
FT Modified-site 18
FT Modified-site /note= "C-terminal amide"
XX
XX PN WO9907404-A1.
PN
XX
XX PD 18-FEB-1999.
PD
XX
XX PF 06-AUG-1998; 98WO-US016387.
PF
XX
XX PR 08-AUG-1997; 97US-0055404P.
PR
XX
XX PA (AMYL-) AMYLIN PHARM INC.
PA
XX
XX PI Beeley NRA, Prickett KS;
PI
XX
XX DR WPI; 1999-180403/15.
DR
XX
XX PT New extendin agonists - useful in the treatment of Type I and II diabetes.
PT
XX
XX PS Claim 17; Fig 1D-E; 70pp; English.
PS
XX The invention relates to extendin agonists which slow gastric emptying and
CC lower plasma glucose levels. The extendin agonists are used to treat Type
CC I and II diabetes, disorders which would be benefited by agents which
CC lower plasma glucose levels. The extendin agonists are used to treat Type
CC I and II diabetes, disorders which would be benefited by agents which
CC

CC lower plasma glucose levels, and disorders which would be benefited by
CC agents useful in delaying and/or slowing gastric emptying. Delayed
CC gastric emptying is a useful diagnostic aid in gastro-intestinal
CC radiological examinations. Sequences AAY03721-51 represent specifically
CC claimed examples of the extendin agonist compounds of the invention. (Also
CC see AAY03720 for extendin generic peptide formula and description)

XX Sequence 18 AA;

AAY03749 Length: 18 February 4, 2005 13:04 Type: P Check: 2382 ..
Found using 'seq3' (mohamed337.key)

1 HGEFTSDFLEWFAAAAS
18

1 match found in sequence:
aay03750 ; Extendin agonist compound 30:
(from "seq3ags.pep")
TOIG of: aay03750 check: 2592 from: 1 to: 18

ID AAY03750 standard; peptide; 18 AA.

XX AC AAY03750;

XX DT 08-JUN-1999 (first entry)

XX DE Extendin agonist compound 30.

XX KW Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
XX diagnostic; gastro-intestinal; radiological.

XX OS Synthetic.

XX FH Key Location/Qualifiers
FT Modified-site 15..17

FT /note= "methylalanine"

FT Modified-site 18

FT /note= "C-terminal amide"

XX PN WO9907404-A1.

XX PD 18-FEB-1999.

XX PF 06-AUG-1998; 98WO-US016387.

XX PR 08-AUG-1997; 97US-0055404P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett KS;

XX DR WPI; 1999-180403/15.

XX PT New extendin agonists - useful in the treatment of Type I and II diabetes.

XX PS Claim 17; Fig 1D-E; 70pp; English.

XX CC The invention relates to extendin agonists which slow gastric emptying and
CC lower plasma glucose levels. The extendin agonists are used to treat Type
CC I and II diabetes, disorders which would be benefited by agents which
CC lower plasma glucose levels, and disorders which would be benefited by
CC agents useful in delaying and/or slowing gastric emptying. Delayed
CC gastric emptying is a useful diagnostic aid in gastro-intestinal
CC radiological examinations. Sequences AAY03721-51 represent specifically
CC claimed examples of the extendin agonist compounds of the invention. (Also
CC see AAY03720 for extendin generic peptide formula and description)

XX Sequence 18 AA;

AAY03750 Length: 18 February 4, 2005 13:04 Type: P Check: 2592 ..
Found using 'seq3' (mohamed337.key)

1 HGEFTSDFLEWFAAAAS
18

1 match found in sequence:
aay03751 ; Extendin agonist compound 31:
(from "seq3ags.pep")
TOIG of: aay03751 check: 2152 from: 1 to: 18

ID AAY03751 standard; peptide; 18 AA.

XX AC AAY03751;

XX DT 08-JUN-1999 (first entry)

XX DE Extendin agonist compound 31.

XX KW Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
XX diagnostic; gastro-intestinal; radiological.

XX OS Synthetic.

XX FH Key Location/Qualifiers
FT Modified-site 14..17

FT /note= "methylalanine"

FT Modified-site 18

FT /note= "C-terminal amide"

XX PN WO9907404-A1.

XX PD 18-FEB-1999.

XX PF 06-AUG-1998; 98WO-US016387.

XX PR 08-AUG-1997; 97US-0055404P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett KS;

XX DR WPI; 1999-180403/15.

XX PT New extendin agonists - useful in the treatment of Type I and II diabetes.

XX PS Claim 17; Fig 1D-E; 70pp; English.

XX CC The invention relates to extendin agonists which slow gastric emptying and
CC lower plasma glucose levels. The extendin agonists are used to treat Type
CC I and II diabetes, disorders which would be benefited by agents which
CC lower plasma glucose levels, and disorders which would be benefited by
CC agents useful in delaying and/or slowing gastric emptying. Delayed
CC gastric emptying is a useful diagnostic aid in gastro-intestinal
CC radiological examinations. Sequences AAY03721-51 represent specifically
CC claimed examples of the extendin agonist compounds of the invention. (Also
CC see AAY03720 for extendin generic peptide formula and description)

XX Sequence 18 AA;

AAY03751 Length: 18 February 4, 2005 13:04 Type: P Check: 2152 ..
Found using 'seq3' (mohamed337.key)

1 HGEFTSDFLEWFAAAAS
18

Times: -- Search Statistics --
CPU 00:00:00.01 Total Elapsed
00:00:01.00

Number of sequences searched: 79
Number of sequence hits: 79
Number of separate matches: 79
Number of sequence hits saved: 0

```

> O <
O | O IntelliGenetics
> O <

Quest - Quick User-directed Expression Search Tool
Release 5.4

-- Outline of search "seq3_pir" --

Selected search type is key against sequence data banks or files.
Selected scope is Sequence.
Selected sequence key from "mohamed337.key":
seq3 (AA) ID seq3 AA preliminary pattern
followed by
1 h or r or y
2 . s or g or a or t
2 d or e
2 any character
2 t or s
2 t or s
2 d or e
2 any character
2 any character
2 any character
2 any character
2 d or e
2 any character
2 any character
2 any character
2 any character
2 s or t or y
2

Selected files:
File : seq3pir.pep

-- Output Parameters --

Format Options:
Nucleic acid code matching Exact Indirect file No
Find non-matching hits only No Sequence or key file No
Report key used Yes List of hits Yes
Note position of hit Yes Hit display Yes
Display full annotations Yes Name and annotations Yes
Sequence context 50

Run mode Batch
Time to start comparison now
Notify at end of run No

-----
1 match found in sequence:
ah0476 ; TOIG of: ah0476 check: 8 from: 1 to: 466
(from "seq3pir.pep")
TOIG of: ah0476 check: 8 from: 1 to: 466

P1:AH0476 - NAD(P) transhydrogenase (B-specific) (EC 1.6.1.1) [imported] -
Versinia pestis (strain CO92)
C:Species: Versinia pestis
C>Date: 02-Nov-2001 #sequence_revision 02-Nov-2001 #text_change 09-Jul-2004
C:Accession: AH0476
R:Parkhill, J.; Wren, B.W.; Thomson, N.R.; Titball, R.W.; Holden, M.T.G.;
Prentice, M.B.; Sabathia, M.; James, K.D.; Churcher, C.; Mungall, K.L.; Baker,
S.; Basham, D.B.; Bentley, S.D.; Brooks, K.; Cerdeno-Tarraga, A.M.;
Chillingworth, T.; Cronin, A.; Davies, R.M.; Davis, P.; Dougan, G.; Feltwell,
T.; Hamlin, N.; Holroyd, S.; Jagels, K.; Leather, S.; Karlyshev, A.V.; Moulle,
S.; Oyston, P.C.F.; Quail, M.; Rutherford, K.; Simmonds, M.; Skelton, J.;
Stevens, K.; Whitehead, S.; Barrall, B.G.
Nature 413, 523-527, 2001

-----
1 match found in sequence:
ah0476 ; TOIG of: ah0476 check: 8 from: 1 to: 466
(from "seq3pir.pep")
TOIG of: ah0476 check: 8 from: 1 to: 466

P1:AH0476 - NAD(P) transhydrogenase (B-specific) (EC 1.6.1.1) [imported] -
Versinia pestis (strain CO92)
C:Species: Versinia pestis
C>Date: 02-Nov-2001 #sequence_revision 02-Nov-2001 #text_change 09-Jul-2004
C:Accession: AH0476
R:Parkhill, J.; Wren, B.W.; Thomson, N.R.; Titball, R.W.; Holden, M.T.G.;
Prentice, M.B.; Sabathia, M.; James, K.D.; Churcher, C.; Mungall, K.L.; Baker,
S.; Basham, D.B.; Bentley, S.D.; Brooks, K.; Cerdeno-Tarraga, A.M.;
Chillingworth, T.; Cronin, A.; Davies, R.M.; Davis, P.; Dougan, G.; Feltwell,
T.; Hamlin, N.; Holroyd, S.; Jagels, K.; Leather, S.; Karlyshev, A.V.; Moulle,
S.; Oyston, P.C.F.; Quail, M.; Rutherford, K.; Simmonds, M.; Skelton, J.;
Stevens, K.; Whitehead, S.; Barrall, B.G.
Nature 413, 523-527, 2001

-----
1 match found in sequence:
c96601 ; TOIG of: c96601 check: 9036 from: 1 to: 309
(from "seq3pir.pep")
TOIG of: c96601 check: 9036 from: 1 to: 309

P1:C96601 - hypothetical protein T6H22.19 [imported] - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cress)
C>Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 09-Jul-2004
C:Accession: C96601
O.:Alonso, J.; Altar, H.; Araujo, R.; Bowman, C.L.; Brooks, S.Y.; Buehler, E.
R.; Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White,
Chan, A.; Chao, Q.; Chen, H.; Cheuk, R.F.; Chin, C.W.; Chung, M.K.; Conn, L.;
Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.; Dunn, P.; Etgu, P.;
Feldblyum, T.V.; Feng, J.; Fong, B.; Fujii, C.Y.; Gill, J.E.; Goldsmith, A.D.;
Haas, B.; Hansen, N.F.; Hughes, B.; Huizar, L.
Nature 408, 816-820, 2000
A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin,
E.; Kim, C.J.; Koo, H.L.; Kremenetskaia, I.; Kurtz, D.B.; Kwan, A.; Lam, B.;
Langin-Hooper, S.; Lee, A.; Lee, J.M.; Lenz, C.A.; Li, J.H.; Li, Y.; Lin, X.;
Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziani, A.; Miltschker, J.;
Miranda, M.; Nguyen, M.; Nierman, W.C.; Osborne, B.I.; Pai, G.; Peterson, J.;
Pham, P.K.; Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.;
Tallon, L.J.; Tambunga, G.; Toriumi, M.J.; Town, C.D.; Utterback, T.; van Aken,
S.; Vaysberg, M.; Vysotskaia, V.S.; Walker, M.; Wu, D.; Yu, G.; Fraser, C.M.;
Venter, J.C.; Davis, R.W.
A:Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A:Reference number: A86141; MUID:21016719; PMID:11130712
A:Accession: C96601
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-309 <STO>
A:Cross-references: UNIPROT:Q9SGS9; GB:AE005173; NID:g6056383; PIDN:AAF02847.1;
GSPDB:GN00141
C:Genetics:
A:Gene: T6H22.19
A:Map position: 1

-----
1 match found in sequence:
c96601 ; TOIG of: c96601 check: 9036 from: 1 to: 309
(from "seq3pir.pep")
TOIG of: c96601 check: 9036 from: 1 to: 309

P1:C96601 - hypothetical protein T6H22.19 [imported] - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cress)
C>Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 09-Jul-2004
C:Accession: C96601
O.:Alonso, J.; Altar, H.; Araujo, R.; Bowman, C.L.; Brooks, S.Y.; Buehler, E.
R.; Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White,
Chan, A.; Chao, Q.; Chen, H.; Cheuk, R.F.; Chin, C.W.; Chung, M.K.; Conn, L.;
Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.; Dunn, P.; Etgu, P.;
Feldblyum, T.V.; Feng, J.; Fong, B.; Fujii, C.Y.; Gill, J.E.; Goldsmith, A.D.;
Haas, B.; Hansen, N.F.; Hughes, B.; Huizar, L.
Nature 408, 816-820, 2000
A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin,
E.; Kim, C.J.; Koo, H.L.; Kremenetskaia, I.; Kurtz, D.B.; Kwan, A.; Lam, B.;
Langin-Hooper, S.; Lee, A.; Lee, J.M.; Lenz, C.A.; Li, J.H.; Li, Y.; Lin, X.;
Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziani, A.; Miltschker, J.;
Miranda, M.; Nguyen, M.; Nierman, W.C.; Osborne, B.I.; Pai, G.; Peterson, J.;
Pham, P.K.; Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.;
Tallon, L.J.; Tambunga, G.; Toriumi, M.J.; Town, C.D.; Utterback, T.; van Aken,
S.; Vaysberg, M.; Vysotskaia, V.S.; Walker, M.; Wu, D.; Yu, G.; Fraser, C.M.;
Venter, J.C.; Davis, R.W.
A:Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A:Reference number: A86141; MUID:21016719; PMID:11130712
A:Accession: C96601
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-309 <STO>
A:Cross-references: UNIPROT:Q9SGS9; GB:AE005173; NID:g6056383; PIDN:AAF02847.1;
GSPDB:GN00141
C:Genetics:
A:Gene: T6H22.19
A:Map position: 1

-----
1 match found in sequence:
c96601 ; TOIG of: c96601 check: 9036 from: 1 to: 309
(from "seq3pir.pep")
TOIG of: c96601 check: 9036 from: 1 to: 309

P1:C96601 - hypothetical protein T6H22.19 [imported] - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cress)
C>Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 09-Jul-2004
C:Accession: C96601
O.:Alonso, J.; Altar, H.; Araujo, R.; Bowman, C.L.; Brooks, S.Y.; Buehler, E.
R.; Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White,
Chan, A.; Chao, Q.; Chen, H.; Cheuk, R.F.; Chin, C.W.; Chung, M.K.; Conn, L.;
Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.; Dunn, P.; Etgu, P.;
Feldblyum, T.V.; Feng, J.; Fong, B.; Fujii, C.Y.; Gill, J.E.; Goldsmith, A.D.;
Haas, B.; Hansen, N.F.; Hughes, B.; Huizar, L.
Nature 408, 816-820, 2000
A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin,
E.; Kim, C.J.; Koo, H.L.; Kremenetskaia, I.; Kurtz, D.B.; Kwan, A.; Lam, B.;
Langin-Hooper, S.; Lee, A.; Lee, J.M.; Lenz, C.A.; Li, J.H.; Li, Y.; Lin, X.;
Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziani, A.; Miltschker, J.;
Miranda, M.; Nguyen, M.; Nierman, W.C.; Osborne, B.I.; Pai, G.; Peterson, J.;
Pham, P.K.; Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.
A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.;
Tallon, L.J.; Tambunga, G.; Toriumi, M.J.; Town, C.D.; Utterback, T.; van Aken,
S.; Vaysberg, M.; Vysotskaia, V.S.; Walker, M.; Wu, D.; Yu, G.; Fraser, C.M.;
Venter, J.C.; Davis, R.W.
A:Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A:Reference number: A86141; MUID:21016719; PMID:11130712
A:Accession: C96601
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-309 <STO>
A:Cross-references: UNIPROT:Q9SGS9; GB:AE005173; NID:g6056383; PIDN:AAF02847.1;
GSPDB:GN00141
C:Genetics:
A:Gene: T6H22.19
A:Map position: 1

-----
1 match found in sequence:
c96601 ; TOIG of: c96601 check: 9036 from: 1 to: 309
(from "seq3pir.pep")
TOIG of: c96601 check: 9036 from: 1 to: 309

P1:C96601 - hypothetical protein T6H22.19 [imported] - Arabidopsis thaliana
C:Species: Arabidopsis thaliana (mouse-ear cress)
C>Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 09-Jul-2004
C:Accession: C96601
O.:Alonso, J.; Altar, H.; Araujo, R.; Bowman, C.L.; Brooks, S.Y.; Buehler, E.
R.; Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White,
Chan, A.; Chao, Q.; Chen, H.; Cheuk, R.F.; Chin, C.W.; Chung, M.K.; Conn, L.;
Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.; Dunn, P.; Etgu, P.;
Feldblyum, T.V.; Feng, J.; Fong, B.; Fujii, C.Y.; Gill, J.E.; Goldsmith, A.D.;
```

Fri Feb 4 14:12:15 2005

238 NPNFLTGGASATLTGLDSCSDQWLVRLALLSQLTKIDSLGPKESQSYGEGSSSLL
288

-----|-----
298 TDIGIPSTWNC
305

1 match found in sequence:
t29492 ; TOIG of: t29492 check: 4006 from: 1 to: 358
(from "seq3pir.pep")
TOIG of: t29492 check: 4006 from: 1 to: 358
P1:T29492 - hypothetical protein D1005.3 - Caenorhabditis elegans
C:Species: Caenorhabditis elegans
C>Date: 15-Oct-1999 #sequence_revision 15-Oct-1999 #text_change 09-Jul-2004
C/Accession: T29492
R:Wohldmann, F.; Hawkins, J.
Submitted to the EMBL Data Library, May 1996
A;Description: The sequence of C. elegans cosmid D1005.
A;Reference number: Z20627
A;Accession: T29492
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-358 <WOH>
A;Cross-references: UNIPROT:Q18909; EMBL:U58727; PIDN:AB00581.1;
GSPDB:GN00028; CESP:D1005.3
A;Experimental source: strain Bristol N2; clone D1005
C;Genetics:
A;Gene: CESP.D1005.3
A;Map position: X
A;Introns: 36/2; 90/3; 339/2
T29492 Length: 358 February 4, 2005 13:17 Type: P Check: 4006 ..
Found using 'seq3' (mohamed337.key)

...
169 YGTGYRVPGDYDQGYKQNCVKAETDFGATKTRAVKRPVPYDDYQKEYSESSDMDT
219

-----|-----
229 NDCSVDSYEPFKSKTKSAGLENFKPQTRARKYKLKADBEKAEPYKLYKXARNNDV
236

...

-- Search Statistics --

Times:	CPU	Total Elapsed
	00:00:00.00	00:00:00.00

Number of sequences searched:	3
Number of sequence hits:	3
Number of separate matches:	3
Number of sequence hits saved:	0

```

> O <
> | |< IntelliGenetics
> O <

Quest - Quick User-directed Expression Search Tool
Release 5.4

-- Outline of search "seq3_uni" --

Selected search type is key against sequence data banks or files.
Selected scope is Sequence.
Selected sequence key from "mohamed337 key":
seq3 (AA) ID seq3 AA preliminary pattern
followed by
1 h or r or y
2 s or g or a or t
2 d or e
2 any character
2 t or s
2 t or s
2 d or e
2 any character
2 any character
2 any character
2 any character
2 d or e
2 any character
2 any character
2 any character
2 any character
2 any character
2 s or t or y

Selected files:
File : seq3uni.pep

-- Output Parameters --

Format Options:
Nucleic acid code matching Exact Indirect file No
Find non-matching hits only No Sequence or key file No
Report key used Yes List of hits Yes
Note position of hit Yes Hit display Yes
Display full annotations Yes Name and annotations Yes
Sequence context 50

Run mode Batch
Time to start comparison now
Notify at end of run No

-----
1 match found in sequence:
na22arath ; NAC-domain containing protein 21/22 (ANAC021) (ANAC022).
(from "seq3uni.pep")
TOIG of: na22_arath check: 4353 from: 1 to: 324

ID NA22 ARATH STANDARD; PRT; 324 AA.
AC Q84TE6; Q9SE10; Q9SGS9;
DT 25-OCT-2004 (Rel. 45, Created)
DT 25-OCT-2004 (Rel. 45, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE NAC-domain containing protein 21/22 (ANAC021) (ANAC022).
GN Name=NAC1; OrderedLocusNames=AC1956010; ORFNAMES=F14J16.32, T6H22.19;
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsis.
OX NCBI_TaxID=3702;
RN [1]

```

```

RP SEQUENCE FROM N.A., FUNCTION, TISSUE SPECIFICITY, AND INDUCTION
RP (ISOFORM 1).
RC STRAIN=cv. Landsberg erecta;
RX PubMed=11114891; DOI=10.1101/gad.852200;
RA Xie Q., Frugis G., Colgan D.F., Chua N.-H.;
RT "Arabidopsis NAC1 transduces auxin signal downstream of TIR1 to
RT promote lateral root development.";
RL Genes Dev. 14:3024-3036(2000).
RN [12]
RN SEQUENCE FROM N.A.
RP STRAIN=cv. Columbia;
RX MEDLINE=21016719; PubMed=11130712; DOI=10.1038/35048500;
RA Theologis A., Ecker J.R., Palm C.J., Federspiel N.A., Kaul S.,
RA White O., Alonso J., Altafi H., Araujo R., Bowman C.L., Brooks S.Y.,
RA Buehler E., Chan A., Chao Q., Chen H., Cheuk R.F., Chin C.W.,
RA Chung M.K., Conn L., Conway A.B., Conway A.R., Creasy T.H., Dewar K.,
RA Dunn P., Btgu P., Feldblyum T.V., Feng J.-D., Fong B., Fujii C.Y.,
RA Gill J.E., Goldsmith A.D., Haas B., Hansen N.F., Hughes B., Huizar L.,
RA Hunter J.L., Jenkins J., Johnson-Hopson C., Khan S., Khaykin E.,
RA Kim C.J., Koo H.L., Kremenetskaia I., Kurtz D.B., Kwan A., Lam B.,
RA Langin-Hooper S., Lee A., Lee J.M., Lenz C.A., Li J.H., Li Y.-P.,
RA Lin X., Liu S.X., Liu Z.A., Luros J.S., Maiti R., Marziani A.,
RA Militischer J., Miranda M., Nguyen M., Nierman W.C., Osborne B.I.,
RA Pai G., Peterson J., Pham P.K., Rizzo M., Rooney T., Rowley D.,
RA Sakano H., Salzberg S.L., Schwartz J.R., Shinn P., Southwick A.M.,
RA Sun H., Tallon L.J., Tambunga G., Toriumi M.J., Town C.D.,
RA Utterback T., Van Aken S., Vaysberg M., Vysotskaia V.S., Walker M.,
RA Wu D., Yu G., Fraser C.M., Venter J.C., Davis R.W.;
RT "Sequence and analysis of chromosome 1 of the plant Arabidopsis
RT thaliana.";
RL Nature 408:816-820(2000).
RN [13]
RN SEQUENCE FROM N.A. (ISOFORM 1).
RP Brover V., Troukhan M., Alexandrov N., Lu Y.-P., Flavell R.,
RA Feldmann K.A.;
RT "Full-length cDNA from Arabidopsis thaliana.";
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
RN [14]
RN SEQUENCE FROM N.A. (ISOFORM 2).
RC STRAIN=cv. Columbia;
RX MEDLINE=22954850; PubMed=14593172; DOI=10.1126/science.1088305;
RA Yamada K., Lim J., Dale J.M., Chen H., Shinn P., Palm C.J.,
RA Southwick A.M., Wu H.C., Kim C.J., Nguyen M., Pham P.K., Cheuk R.F.,
RA Karlin-Newmann G., Liu S.X., Lam B., Sakano H., Wu T., Yu G.,
RA Miranda M., Quach H.L., Tripp M., Chang C.H., Lee J.M., Toriumi M.J.,
RA Chan M.M., Tang C.C., Onodera C.S., Deng J.M., Akiyama K., Ansari P.,
RA Arakawa T., Banh J., Banno F., Bowser L., Brooks S.Y., Carninci P.,
RA Chao Q., Choy N., Ejnu A., Goldsmith A.D., Gurjal M., Hansen N.F.,
RA Hayashizaki Y., Johnson-Hopson C., Heuan V.W., Iida K., Karnes M.,
RA Khan S., Koesema E., Ishida J., Jiang P.X., Jones T., Kawai J.,
RA Kamiya A., Meyers C., Nakajima M., Narusaka M., Seki M., Sakurai T.,
RA Satou M., Tamse R., Vaysberg M., Wallender E.K., Wong C., Yamamura Y.,
RA Yuan S., Shinozaki K., Davis R.W., Theologis A., Ecker J.R.;
RT "Empirical analysis of transcriptional activity in the Arabidopsis
RT genome.";
RL Science 302:842-846(2003).
RN [15]
RN DEGRADATION, AND INTERACTION WITH SINAT5.
RX PubMed=12226665; DOI=10.1038/nature00998;
RA Xie Q., Guo H.-S., Dallman G., Fang S., Weissman A.M., Chua N.-H.;
RT "SINAT5 promotes ubiquitin-related degradation of NAC1 to attenuate
RT auxin signals.";
RL Nature 419:167-170(2002).
RN [16]
RN NOMENCLATURE.
RX PubMed=15029955;
RA Ooka H., Satoh K., Doi K., Nagata T., Ootomi Y., Murakami K.,
RA Matubara K., Osato N., Kawai J., Carninci P., Hayashizaki Y.,
RA Suzuki K., Kojima K., Takahara Y., Yamamoto K., Kikuchi S.;
RT "Comprehensive analysis of NAC family genes in Oryza sativa and
RT Arabidopsis thaliana.";
RL DNA Res. 10:239-247(2003).
RN [1]
RN -!- FUNCTION: Transcriptional activator that mediates auxin signaling
CC

```

CC to promote lateral root development. Activates the expression of
CC two downstream auxin-responsive genes, DBP and AIR3.
CC -|- SUBUNIT: Dimer. Interacts with SINAT5.
CC -|- SUBCELLULAR LOCATION: Nuclear.
CC -|- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1; Synonyms=ANAC022;
CC IsoId=Q84TE6-1; Sequences=Displayed;
CC Name=2; Synonyms=ANAC021;
CC IsoId=Q84TE6-2; Sequences=VSP 011189;
CC Note=No experimental confirmation available;
CC -|- TISSUE SPECIFICITY: Predominantly expressed in the root tip and in
CC lateral root initiation sites. Also detected in expanding
CC cotyledon, and in leaf primordia.
CC -|- INDUCTION: Induced by auxin.
CC -|- DOMAIN: The NAC domain includes a DNA binding domain and a
CC dimerization domain.
CC -|- PTM: Ubiquitinated (Probable). The interaction with SINAT5 mediate
CC its proteasome-dependent degradation.
CC -|- SIMILARITY: Contains 1 NAC domain.
CC -|- CAUTION: Ref.2 (AA02847) sequence differs from that shown due to
CC erroneous gene model prediction.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; AF198054; AAF21437.1; --
CC EMBL; AC002304; AAF09328.1; --
CC EMBL; AC009894; AAF02847.1; ALT_SEQ.
CC EMBL; AY085996; AAM63206.1; --
CC EMBL; BT005873; AAO64808.1; --
CC FIR; C96601; C96601.
CC TRANSFAC; T05392; --
CC GeneFarm; 4063; --
CC InterPro; IPR003441; NAM.
CC DR; Pfam; PF02365; NAM; 1.
CC DR; PROSITE; PS1005; NAC; 1.
CC KW Activator; Alternative splicing; DNA-binding; Nuclear protein;
CC KW Transcription regulation; Ubl conjugation.
CC FT DOMAIN 19 171 NAC. Bipartite nuclear localization signal
CC FT DOMAIN 120 137 (Potential).
CC FT VARSPLIC 1 67 Missing (in isoform 2).
CC FT /FTId=VSP 011189.
CC SQ SEQUENCE 324 AA; 36569 MW; C70ED705D1A06957 CRC64;
NA22 ARATH Length: 324 February 4, 2005 13:17 Type: P Check: 4353 ..
Found using 'seq3' (mohamed337.key)
...
253 NPNFLFTGGSASATLTGLDFSCSDQWVLRALLSQLTKIDSLGPKESQSYGGSSBSLL
303
313 TDIGIPSTVWNC
320

1 match found in sequence:
p87592 ; p61.
(from "seq3uni.pep")
TOIG of: p87592 Check: 6620 from: 1 to: 536
ID p87592 PRELIMINARY; PRT; 536 AA.
AC p87592;
DT 01-MAY-1997 (TRENBLrel. 03, Created)

DT 01-MAY-1997 (TRENBLrel. 03, Last sequence update)
DT 01-MAR-2004 (TRENBLrel. 26, Last annotation update)
DE p61.
OS Citrus tristeza virus.
OC Viruses; ssRNA positive-strand viruses, no DNA stage; Closteroviridae;
OC Closterovirus.
OX NCBI_TaxID=12162;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=vt;
RX MEDLINE=96406950; PubMed=8811037;
RA Mawassi M., Mietkiewska E., Gofman R., Yang G., Bar-Joseph M.;
RT "Unusual sequence relationships between two isolates of citrus
RT tristeza virus";
RL J. Gen. Virol. 77:2359-2364(1996).
DR EMBL; U56902; AAB38760.1; --
DR InterPro; IPR004903; Vir_Hsp90.
DR Pfam; PF03225; Viral_Hsp90; 1.
SQ SEQUENCE 536 AA; 61296 MW; D887838B965F877 CRC64;
p87592 Length: 536 February 4, 2005 13:17 Type: P Check: 6620 ..
Found using 'seq3' (mohamed337.key)
...
75 NDFVELTGMLKSLMTGVDRKVPDELISVDHPHEVGCRFTLNDVESYLSRGEDSTDGTA
125
135 VEHTWLSNSCGKLLSSTEIDAYKTMVTKTFDSGVFGVTKLETYSLSWISLYKKHC
142

1 match found in sequence:
q08505 ; P23-like protein (Fragment).
(from "seq3uni.pep")
TOIG of: q08505 Check: 9426 from: 1 to: 145
ID Q08505 PRELIMINARY; PRT; 145 AA.
AC Q08505;
DT 01-NOV-1996 (TRENBLrel. 01, Created)
DT 01-OCT-2001 (TRENBLrel. 18, Last sequence update)
DT 01-OCT-2002 (TRENBLrel. 22, Last annotation update)
DE P23-like protein (Fragment).
OS Plasmodium berghei.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=5821;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ANKA;
RX MEDLINE=86065308;
RA Wiser M.F., Schweizer H.G.;
RT "Cytosolic protein kinase activity associated with the maturation of
RT the malaria parasite Plasmodium berghei";
RL Mol. Biochem. Parasitol. 17:179-189(1985).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=ANKA;
RX MEDLINE=88055499;
RA Wiser M.F., Plitt B.;
RT "Plasmodium berghei, P. chabaudi, and P. falciparum: similarities in
RT phosphoproteins and protein kinase activities and their stage specific
RT expression";
RL Exp. Parasitol. 64:328-335(1987).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=ANKA;
RX MEDLINE=95249497; PubMed=7731926;
RA Wiser M.F., Jennings G.J., Lockyer J.M., van Belkum A.,
RA van Doorn L.J.;

```
RT "Chaperonin-like repeats in a 34-kDa Plasmodium berghei
RL phosphoprotein.";
RL Parasitol. Res. 81:167-169(1995).
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=ANK2;
RX MEDLINE=22841434; PubMed=12756555;
RA Wiser M.F.;
RT "A Plasmodium homologue of co-chaperone p23 and its differential
RT expression during the replicative cycle of the malaria parasite.";
RL Parasitol. Res. 90:166-170(2003).
DR EMBL: L21708; AAC14463.2; -.
FT NON_TER 1
SQ SEQUENCE 145 AA; 14694 MW; 9C1B2959F72C616D CRC64;

Q08505 Length: 145 February 4, 2005 13:17 Type: P Check: 9426 ..
Found using 'seq3' (mohamed337.key)

...

45 MCGMGGMGMDIDFSKLGNGMGDMENLAGLGMQDFKNMNMNDDSSSYGDDSSDDDD
-----
105 EDDTNTKSDADSHSHACNDAKCNIDKGAHNDDAKVQEPVA
112
-----
1 match found in sequence:
q18909 ; Hypothetical protein D1005.3.
(from "seq3_uni.pep")
TOIG of: q18909 Check: 4006 from: 1 to: 358

ID Q18909 PRELIMINARY; PRT; 358 AA.
AC Q18909;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein D1005.3.
GN Name=D1005.3; ORFNames=D1005.3;
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditidae;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX MEDLINE=99069613; PubMed=9851916;
RG WormBase Consortium;
RT "Genome sequence of the nematode C. elegans: a platform for
RT investigating biology. The C. elegans Sequencing Consortium.";
RL Science 282:2012-2018(1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX Woldmann P., Hawkins J.;
RT "The sequence of C. elegans cosmid D1005.";
RL Submitted (MAY-1996) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX Waterston R.;
RL Submitted (NOV-2002) to the EMBL/GenBank/DBJ databases.
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX Wilson R.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RG WormBase Consortium;
```

```
RL Submitted (SEP-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: U58727; AAB00581.1; -.
DR PIR: T29492; T29492.
DR HSSP: P17676; I104.
DR IntAct: Q18909; -.
DR WormBase; WBGene00016997; D1005.3.
DR WormPep: D1005.3; CE06999.
KW Hypothetical protein.
SQ SEQUENCE 358 AA; 41724 MW; 927CC12C68AAD868 CRC64;

Q18909 Length: 358 February 4, 2005 13:17 Type: P Check: 4006 ..
Found using 'seq3' (mohamed337.key)

...

169 YCTGYRVPGDYDQDGYKMCVKAETPDGATKTRRAVKRPVPPDYDYQKEYSESSDMDT
-----
229 NDGSVDYSYFEPKSKTKSAGLENFKPQTRARKYKLKADEKAEPTYKLRARNNDV
236
-----
1 match found in sequence:
q66961 ; Soluble pyridine nucleotide transhydrogenase (BC 1.6.1.1).
(from "seq3_uni.pep")
TOIG of: q66961 Check: 8 from: 1 to: 466

ID Q66961 PRELIMINARY; PRT; 466 AA.
AC Q66961;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Soluble pyridine nucleotide transhydrogenase (BC 1.6.1.1).
GN Name=sthA; Synonyms=sth, udhA; ORFNames=YPT80121;
OS Versinia pseudotuberculosis IP 32953.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Versinia.
OX NCBI_TaxID=273123;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=IP 32953;
RX PubMed=15358858;
RA Chain P.S.G., Carniel E., Larimer F.W., Lamerdin J., Stoutland P.O.,
RA Regala W.M., Georgescu A.M., Vergez L.M., Land M.L., Motin L.V.,
RA Brubaker R.R., Fowler J., Hinnebusch B.J., Marceau M., Medigue C.,
RA Simonet M., Chenal-Francisque V., Souza B., Dacheux D., Elliott J.M.,
RA Derbise A., Hauser L.J., Garcia E.;
RT "Insights into the genome evolution of Versinia pseudotuberculosis.";
RT genome comparison with Versinia pseudotuberculosis.";
RL Proc. Natl. Acad. Sci. U.S.A. 101:13826-13831(2004).
CC -!- COFACTOR: FAD (By similarity).
DR EMBL: BX936398; CAH19361.1; -.
DR GO: GO:0016491; F:oxidoreductase activity; IEA.
DR InterPro: IPR000759; Adrndx reductase.
DR InterPro: IPR001327; FAD pyr redox.
DR InterPro: IPR000815; Hg reductase.
DR InterPro: IPR000205; NAD_BS.
DR InterPro: IPR001103; Pyridine_redox_2.
DR InterPro: IPR001100; Pyr redox.
DR InterPro: IPR004099; Pyr redox_dim.
DR Pfam: PF00070; Pyr_redox; 1.
DR Pfam: PF02852; Pyr_redox_dim; 1.
DR PRINTS: PR00419; ADXRDTASE.
DR PRINTS: PR00368; FADPNR.
DR PRINTS: PR00945; HGRDTASE.
DR PRINTS: PR00411; PNDRDTASEI.
DR PRINTS: PR00469; PNDRDTASEII.
DR ProDom: PD000139; FAD_pyr_redox; 1.
KW FAD; Flavoprotein; Oxidoreductase.
```

```
SQ SEQUENCE 466 AA; 51382 MW; D6CD965D6CF3E2CE CRC64;
Q66G61 Length: 466 February 4, 2005 13:17 Type: P Check: 8
Found using 'seq3' (mohamed337.key)
...
79 IKSSPADILNHADRVINQOTRMQRQGFYDRNHCHMFSGDASFIDANTVNVRYADGTSDTLQ
129
-----
139 ADMINVIATGSRPVPVNVDFNHERIYDSLTILQLSHEPQHVIYAGVIGCBYASIFR
146
...
-----
1 match found in sequence:
q69371 ; GE glycoprotein.
(from "seq3uni.pep")
TOIG of: q69371 check: 9354 from: 1 to: 540
ID Q69371 PRELIMINARY; PRT; 540 AA.
AC Q69371;
DT 01-NOV-1996 (TrEMBLrel. 01, Created)
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE GE glycoprotein.
OS Cercopithecine herpesvirus 2.
OC Viruses; dsDNA viruses, no RNA stage; Herpesviridae;
OC Alphaherpesvirinae.
OX NCBI_TaxID=10317;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=93298054; PubMed=8390827;
RA Eberle R., Zhang M., Black D.H.;
RT "Gene mapping and sequence analysis of the unique short region of the
RT simian herpesvirus SA 8 genome.";
RL Arch. Virol. 130:391-411(1993).
RN [2]
RP SEQUENCE FROM N.A.
RA Eberle R., Black D.H.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF449714; AAA46180.1; -
DR GO; GO:0016020; C:membrane; IEA.
DR InterPro; IPR003404; Herpes_glycopE.
DR Pfam; PF02480; Herpes_gE; 1.
SQ SEQUENCE 540 AA; 58049 MW; BC34E60B2F3392EE CRC64;
Q69371 Length: 540 February 4, 2005 13:17 Type: P Check: 9354
Found using 'seq3' (mohamed337.key)
...
411 VGVFGAALGLAAAGLSVWACVTCRRARAWRAVKRDPGTQTYIRLADDELADLSDGGW
461
-----
471 EDSDDDDSDRLPFGTDRPPKRGSGFQILSGTKADPWSPEARGRDLVTRVDDAARY
478
...
-----
1 match found in sequence:
q6buJ8 ; Debaryomyces hansenii chromosome C of strain CBS767 of Debaryomyces
(from "seq3uni.pep")
TOIG of: q6buJ8 check: 7607 from: 1 to: 1052
ID Q6BUJ8 PRELIMINARY; PRT; 1052 AA.
AC Q6BUJ8;
```

```
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Debaryomyces hansenii chromosome C of strain CBS767 of Debaryomyces
DE hansenii
GN ORFNames=DEHA0C11066g;
OS Debaryomyces hansenii CBS767.
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Debaryomycetes.
OX NCBI_TaxID=284592;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CBS767;
RG Genolevures;
RA Dujon B., Sherman D., Fischer G., Durrens P., Casaregola S.,
RA Lafontaine I., de Montigny J., Marck C., Neuveglise C., Tallia E.,
RA Goffard N., Frangeul L., Aigle M., Anthouard V., Babour A., Barbe V.,
RA Barnay S., Blanchin S., Beckerich J.M., Beyne E., Bleykasten C.,
RA Boissrame A., Boyer J., Catolico L., Confanioleri F., de Daruvar A.,
RA Despons L., Fabre E., Fairhead C., Ferry-Dumazet H., Groppi A.,
RA Hantraye F., Hennequin C., Jauniaux N., Joyet P., Kachouri R.,
RA Kerrest A., Koszul R., Lemaire M., Lesur I., Ma L., Muller H.,
RA Nicaud J.M., Nikolski M., Oztas S., Ozier-Kalogeropoulos A.,
RA Pellenz S., Potier S., Richard G.F., Straub M.L., Suleau A.,
RA Swenne D., Tekala F., Wesolowski-Louvel M., Westhof E., Wirth B.,
RA Zeniou-Meyer M., Zivanovic I., Bolotin-Fukuhara M., Thierry A.,
RA Bouchier C., Caudron B., Scarpelli C., Gaillardin C., Weissenbach J.,
RA Wincker P., Souciet J.L.;
RT "Genome evolution in yeasts.";
RL Nature 430:35-44(2004).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=CBS767;
RG Genoscope;
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; CR382135; CAG86192.1; -
DR GO; GO:0016491; F:oxidoreductase activity; IEA.
DR GO; GO:0006520; P:amino acid metabolism; IEA.
DR InterPro; IPR006095; GLFV dehydrog.
DR InterPro; IPR006096; GLFV dehydrog.
DR Pfam; PF00208; GLFV dehydrog; 1.
DR PROSITE; PS00074; GLFV DEHYDROGENASE; 1.
SQ SEQUENCE 1052 AA; 119267 MW; B0DBA262333B83D0 CRC64;
Q6BUJ8 Length: 1052 February 4, 2005 13:17 Type: P Check: 7607
Found using 'seq3' (mohamed337.key)
...
149 SHLGTSYRGYFSAPLNYKQDAILSGVFEKNADLSNQFVRCYFYKNNYHAEVSTDETD
199
-----
209 LEKIGDKTFLKIASAKTKELYSEIIKNVISNTGVPVKYFPIEBELEYRWVIGFRQKTS
216
...
-----
1 match found in sequence:
q6cdJ8 ; Similarity.
(from "seq3uni.pep")
TOIG of: q6cdJ8 check: 8363 from: 1 to: 176
ID Q6CDJ8 PRELIMINARY; PRT; 176 AA.
AC Q6CDJ8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DT 25-OCT-2004 (TrEMBLrel. 28, Last annotation update)
DE Similarity.
GN ORFNames=YALI0B23386g;
OS Yarrowia lipolytica CLIB99.
```

```

OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Dipodascaceae; Yarrowia.
OX NCBI_TaxID=284591;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CLIB99;
RG Genolevures;
RA Dujon B., Sherman D., Fischer G., Durrens P., Casaregola S.,
RA Lafontaine I., de Montigny J., Marck C., Neuveglise C., Talla E.,
RA Goffard N., Frangeul L., Aigle M., Anthouard V., Babour A., Barbe V.,
RA Barnay S., Blanchin S., Beckerich J.M., Beyne E., Bleykasten C.,
RA Boissane A., Boyer J., Cattolico L., Confanioleri F., de Daruvar A.,
RA Despons L., Fabre E., Fairhead C., Ferry-Dumazet H., Groppi A.,
RA Hantraye F., Hennequin C., Jauniaux N., Joyet P., Kachouri R.,
RA Kerrest A., Koszul R., Lemaire M., Lesur I., Ma L., Muller H.,
RA Nicaud J.M., Nikolski M., Oztas S., Ozier-Kalogeropoulos O.,
RA Pellenz S., Potier S., Richard G.F., Straub M.L., Suleau A.,
RA Swennene D., Tekcia F., Wesolowski-Louvel M., Westhof E., Wirth B.,
RA Zenlou-Meyer M., Zivanovic I., Bolotin-Fukuhara M., Thierry A.,
RA Bouchier C., Caudron B., Scarpelli C., Gaillardin C., Weissenbach J.,
RA Wincker P., Souciet J.L.;
RT "Genome evolution in yeasts.";
RL Nature 430:35-44(2004).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=CLIB99;
RA Genoscope;
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: CR382128; CAG83517.1; 8F12D9C224E2AE8F CRC64;
SQ SEQUENCE 176 AA; 19683 MW; 8F12D9C224E2AE8F CRC64;

Q6CJ8 Length: 176 February 4, 2005 13:17 Type: P Check: 8363
Found using 'seq3' (mohamed337.key)

...

5 ARVSHNAVQMASSRGHFHSDGFIKMKDQKHLKVMNSPENQWSTDELLSHSDSHSDEIT
55
-----|-----
65 SETLQVSKLAPFKAIPKSAALPMPDSDTEMFSLIKTLRTQNVLSHHDIDVSGVAPLT
72

...

1 match found in sequence:
q6cgw8 ; Yarrowia lipolytica chromosome A of strain CLIB99 of Yarrowia
(from "seq3uni.pep")
TOIG of: q6cgw8 Check: 9969 from: 1 to: 518

ID Q6CGV8 PRELIMINARY; PRT; 518 AA.
AC Q6CGV8;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Yarrowia lipolytica chromosome A of strain CLIB99 of Yarrowia
DE lipolytica
GN ORFNames=YALIOA15708;
OS Yarrowia lipolytica CLIB99.
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Dipodascaceae; Yarrowia.
OX NCBI_TaxID=284591;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CLIB99;
RG Genolevures;
RA Dujon B., Sherman D., Fischer G., Durrens P., Casaregola S.,
RA Lafontaine I., de Montigny J., Marck C., Neuveglise C., Talla E.,
RA Goffard N., Frangeul L., Aigle M., Anthouard V., Babour A., Barbe V.,
RA Barnay S., Blanchin S., Beckerich J.M., Beyne E., Bleykasten C.,
RA Boissane A., Boyer J., Cattolico L., Confanioleri F., de Daruvar A.,

```

```

RA Despons L., Fabre E., Fairhead C., Ferry-Dumazet H., Groppi A.,
RA Hantraye F., Hennequin C., Jauniaux N., Joyet P., Kachouri R.,
RA Kerrest A., Koszul R., Lemaire M., Lesur I., Ma L., Muller H.,
RA Nicaud J.M., Nikolski M., Oztas S., Ozier-Kalogeropoulos O.,
RA Pellenz S., Potier S., Richard G.F., Straub M.L., Suleau A.,
RA Swennene D., Tekcia F., Wesolowski-Louvel M., Westhof E., Wirth B.,
RA Zenlou-Meyer M., Zivanovic I., Bolotin-Fukuhara M., Thierry A.,
RA Bouchier C., Caudron B., Scarpelli C., Gaillardin C., Weissenbach J.,
RA Wincker P., Souciet J.L.;
RT "Genome evolution in yeasts.";
RL Nature 430:35-44(2004).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=CLIB99;
RA Genoscope;
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: CR382127; CAG84035.1; - C68FE0359CF3CCAC CRC64;
SQ SEQUENCE 518 AA; 58769 MW; C68FE0359CF3CCAC CRC64;

Q6CGV8 Length: 518 February 4, 2005 13:17 Type: P Check: 9969
Found using 'seq3' (mohamed337.key)

...

222 VSDDDIPOAERVSAAFTGNGYDEPEYKTDYVYKDFIDFDPMPDRDKRRTDMSDDDS
272
-----|-----
282 SDSSDEESDDDDKKQGGKHGKHGKNGKSGSGEKENDDDGSDSDSDGSD
289

...

1 match found in sequence:
q6df91 ; Bnlp1-prov protein.
(from "seq3uni.pep")
TOIG of: q6df91 Check: 160 from: 1 to: 308

ID Q6DF91 PRELIMINARY; PRT; 308 AA.
AC Q6DF91;
DT 25-OCT-2004 (TrEMBLrel. 28, Created)
DT 25-OCT-2004 (TrEMBLrel. 28, Last sequence update)
DE Bnlp1-prov protein.
DE Bnlp1-prov protein.
GN Name=bnlp1-prov;
OS Xenopus laevis (African clawed frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Amphibia; Batrachia; Anura; Mesobatrachia; Pipidea; Pipidae;
OC Xenopodinae; Xenopus.
OX NCBI_TaxID=83355;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Oocytes;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh P.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Brownstein M.J., Udell T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Boeak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Heltan E., Kettelman M., Madan A.C., Rodrigues S., Sanchez A.,
RA Whitling M., Madan A., Young J.W., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smallos D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;

```

RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RN Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [2]

RP SEQUENCE FROM N.A.
RC TISSUE=Oocytes;
RX MEDLINE=22341132; PubMed=12454917; DOI=10.1002/dvdy.10174;
RA Klein S.L., Strausberg R.L., Wagner L., Pontius J., Clifton S.W.,
RA Richardson P.;
RT "Genetic and genomic tools for Xenopus research: The NIH Xenopus
RT initiative";
RL Dev. Dyn. 225:384-391 (2002).
RN [3]

RP SEQUENCE FROM N.A.
RC TISSUE=Oocytes;
RA Klein S., Gerhard D.S.;
RL Submitted (JUL-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC076850; AAH76850.1; -;
DR InterPro: IPR001251; CRAL_TRIO_C.
DR SMART; SM00516; SEC14; 1;
DR PROSITE; P50191; CRAL_TRIO; 1;
SQ SEQUENCE 308 AA; 35297 MW; 74FL72191F87F0A6 CRC64;

O6DF91 Length: 308 February 4, 2005 13:17 Type: P Check: 160
Found using 'seq3' (mohamed337.key)

...
23 EEPESSECSQASPTTIIELCGNHFHFKRLSAPFISFNLENGESIASERAFQSTDDLD
73
-----|-----
83 FDIDLETNPSSELLDCPEFWDNDLPAKGTSSVCSRSVTDMDQGRKWRIFLM
90

1 match found in sequence:
q616f5 ; MKIAA0363 protein (Fragment).
(from "seq3uni.pep")
TOIG of: q616f5 check: 1672 from: 1 to: 1445

ID Q616F5 PRELIMINARY; PRT; 1445 AA.
AC Q616F5; 2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE MKIAA0363 protein (Fragment).
GN Name=MKIAA0363;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA Okazaki N., Kikuno R., Inamoto S., Koseki H., Hiraoka S.,
RA Suga Y., Hagase T., Ohara O., Koga H.;
RT "Prediction of the Coding Sequences of Mouse Homologues of KIAA Gene:
RT iii. The Complete Nucleotide Sequences of 500 Mouse KIAA-homologous
RT cDNAs Identified by Screening of Terminal Sequences of cDNA Clones
RT Randomly Sampled from Size-fractionated Libraries.";
RL DNA Res. 10:167-180 (2003).
RN [2]

RP SEQUENCE FROM N.A.
RA Okazaki N., Kikuno R., Nagase T., Ohara O., Koga H.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB182283; BAD23961.1; -;
DR InterPro: IPR002715; NAC.
DR Pfam; PF01849; NAC; 1.
FT NON_TER 1445 AA; 150775 MW; B3E8936408FAFF54 CRC64;
SQ SEQUENCE

Q616F5 Length: 1445 February 4, 2005 13:17 Type: P Check: 1672
Found using 'seq3' (mohamed337.key)

...
1207 EDSLEDAQAPGQGWESSESSSELDEYLA PPPDAQRTPGQSGSEHSSSELGE
1257
-----|-----
1267 QDLSPOKSCPAQAGPAGSNEETIAKAKQSRSEKKARKAMSKLGLRQIQGVTRITIQKS
1274

1 match found in sequence:
q6myv8 ; Surfet locus protein 4 homologue, putative.
(from "seq3uni.pep")
TOIG of: q6myv8 check: 5640 from: 1 to: 312

ID Q6MYV8 PRELIMINARY; PRT; 312 AA.
AC Q6MYV8;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Surfet locus protein 4 homologue, putative.
GN ORFNames=AFA28D10.055c;
OS Aspergillus fumigatus (Sartorya fumigata).
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiiales; Trichocomaceae; mitosporic Trichocomaceae; Aspergillus.
OX NCBI_TaxID=5085;
RN [1]
RP SEQUENCE FROM N.A.
RX PubMed=1498527; DOI=10.1016/j.fgb.2003.12.003;
RA Pain A., Woodward J., Quail M.A., Anderson M.J., Clark R., Collins M.,
RA Fosker N., Fraser A., Harris D., Larke N., Murphy L., Humphray S.,
RA O'Neil S., Perle M., Price C., Rabinowitsch E., Rajandream M.A.,
RA Salzberg S., Saunders D., Seeger K., Sharp S., Warren T.,
RA Denning D.W., Barrell B., Hall N.;
RT "Insight into the genome of Aspergillus fumigatus: analysis of a 922
RT kb region encompassing the nitrate assimilation gene cluster.";
RL Fungal Genet. Biol. 41:443-453 (2004).
DR EMBL; BX649605; CAE47901.1; -;
DR InterPro: IPR002995; Surf4.
DR InterPro: IPR011592; Surf4_rel.
DR Pfam; PF02077; SURF4; 1.
DR ProDom; PD010195; Surf4_rel; 1.
DR PROSITE; PS01339; SURF4_1.
SQ SEQUENCE 312 AA; 35126 MW; 2FA0C3B32F014746 CRC64;

Q6MYV8 Length: 312 February 4, 2005 13:17 Type: P Check: 5640
Found using 'seq3' (mohamed337.key)

1 MAQIRCTAGNLCNQHPFVGPGRADATSDPSPLDAIRBQTSKIEDWLDITSDPVKPYLPA
23
-----|-----
61 IGRFLIVVTFIEDSLRIITQWSDQLVYLRE
40

1 match found in sequence:
q6nix1 ; Dihydrolipoamide dehydrogenase.
(from "seq3uni.pep")
TOIG of: q6nix1 check: 4757 from: 1 to: 490

ID Q6NIX1 PRELIMINARY; PRT; 490 AA.
AC Q6NIX1;
DT 05-JUL-2004 (TrEMBLrel. 27, Created)
DT 05-JUL-2004 (TrEMBLrel. 27, Last sequence update)

```

DT 05-JUL-2004 (Tremblrel. 27, Last annotation update)
DE Dihydrolipoamide dehydrogenase.
GN Name=lpda; OrderedLocusNames=DP0645;
OS Corynebacterium diptheriae.
OC Bacteria; Actinobacteriia; Actinobacteridae; Actinomycetales;
OC Corynebacterineae; Corynebacteriaceae; Corynebacterium.
OX NCBI_TaxID=1717;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Biotype Gravis / NCTC 13129;
RX MEDLINE=22956443; PubMed=14602910; DOI=10.1093/nar/gkg874;
RA Cerdano-Tarraga A.-M., Efratrou A., Dover L.G., Holden M.T.G.,
RA Pallen M.J., Bentley S.D., Besra G.S., Churcher C.M., James K.D.,
RA De Zoysa A., Chillingworth T., Cronin A., Dowd L., Feltwell T.,
RA Hamlin N., Holroyd S., Jagels K., Moule S., Quail M.A.,
RA Rabinowitz E., Rutherford K.M., Thomson N.R., Unwin L.,
RA Whitehead S., Barrell B.G., Parkhill J.;
RT "The complete genome sequence and analysis of Corynebacterium
RT diptheriae NCIC13129.";
RL Nucleic Acids Res. 31:6516-6523(2003).
CC -!- COFACTOR: FAD (By similarity).
DR EMBL; BX248355; CAE49162.1; -
DR GO; GO:0005737; C:cytoplasm; IEA.
DR GO; GO:0015036; F:disulfide oxidoreductase activity; IEA.
DR GO; GO:0046872; F:metal ion binding; IEA.
DR GO; GO:0006118; P:electron transport; IEA.
DR InterPro; IPR001327; FAD pyr redox.
DR InterPro; IPR000815; Hg reductase.
DR InterPro; IPR000205; NAD BS.
DR InterPro; IPR000103; Pyridine_redux_2.
DR InterPro; IPR001100; Pyr redox.
DR InterPro; IPR004099; Pyr redox_dim.
DR Pfam; PF02852; Pyr redox; 1.
DR PRINTS; PR00368; FADPNR.
DR PRINTS; PR00945; HGRDTASE.
DR PRINTS; PR00411; PNDRDTASEI.
DR PRINTS; PR00469; PNDRDTASEII.
DR ProDom; PD000139; FAD pyr redox; 1.
KW Complete proteome; FAD; Flavoprotein; Oxidoreductase.
SQ SEQUENCE 490 AA; 52043 MW; 9651CF74EG3565B1 CRC64;

O6NIX1 Length: 490 February 4, 2005 13:17 Type: P Check: 4757
Found using 'seq3' (mohamed337.key)

...

103 ALNNRVOALAYEQSSDIRASMDAHGVVRVIDGRGSPDDYNPKOTVHYIKVDRADGTTETIE
-----
153

163 CDVLVIATGATPRILPDQPDGERILTWRIYQLTLPHELHIVGSGVTGAEFVSAPA
-----
170

...

1 match found in sequence:
q7pdc6 ; GLP_383_953_699 (GLP_383_14340_14594).
TOIG of: q7pdc6 check: 8099 from: 1 to: 84

ID Q7PD07 PRELIMINARY; PRT; 84 AA.
AC Q7PD07;
DT 01-MAR-2004 (Tremblrel. 26, Created)
DT 01-MAR-2004 (Tremblrel. 26, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE GLP_383_953_699 (GLP_383_14340_14594).
OS Giardia lamblia ATCC 50803.
OC Eukaryota; Diplomonadida; Hexamitidae; Giardia.
OX NCBI_TaxID=184922;
RN [1]

```

```

RP SEQUENCE FROM N.A.
RC STRAIN=WB C6;
RA Morrison H.G., McArthur A.G., Adam R.D., Aley S.B., Gillin F.D.,
RA Olsen G.J., Sogin M.L.;
RT "Draft sequence of the Giardia lamblia genome.";
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AACB01000141; EAA37406.1; -
SQ SEQUENCE 84 AA; 9410 MW; 8FEDA63103C8381B CRC64;

Q7PD07 Length: 84 February 4, 2005 13:17 Type: P Check: 8099
Found using 'seq3' (mohamed337.key)

1 MISCWTDHLQKPAIRQAGPLPDTTHGTFSTNAYYDSKMEAYGERTSDNRVDDP
-----
48

61 RHGETKRPNGVDTGRGVRSSS
-----
65

1 match found in sequence:
q7plc6 ; CGI2449-PD.
(from "seq3uni.pep")
TOIG of: q7plc6 check: 7105 from: 1 to: 673

ID Q7PLC6 PRELIMINARY; PRT; 673 AA.
AC Q7PLC6;
DT 01-MAR-2004 (Tremblrel. 26, Created)
DT 01-MAR-2004 (Tremblrel. 26, Last sequence update)
DT 01-MAR-2004 (Tremblrel. 26, Last annotation update)
DE CGI2449-PD.
GN Name=Gfat1; Synonyms=CGI2449;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426065; PubMed=12537568;
RA Celniker S.E., Wheeler D.A., Kronmiller B., Carlson J.W., Halpern A.,
RA Patel S., Adams M., Champagne M., Dugan S.P., Frise E., Hodgson A.,
RA George R.A., Hoskins R.A., Laverly T., Muzny D.M., Nelson C.R.,
RA Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA Svirskaas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT "Finishing a whole-genome shotgun: Release 3 of the Drosophila
RT melanogaster euchromatic genome sequence.";
RL Genome Biol. 3:0079-0079(2002).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426071;
RA Hoskins R.A., Smith C.D., Carlson J.W., Carvalho A.B., Halpern A.,
RA Kaminer J.S., Kennedy C., Mungall C.J., Sullivan B.A., Sutton G.G.,
RA Yasuhara J.C., Wakimoto B.T., Myers E.W., Celniker S.E., Rubin G.M.,
RA Karpen G.H.;
RT "Heterochromatic sequences in a Drosophila whole-genome shotgun
RT assembly.";
RL Genome Biol. 3:0085-0085(2002).
RN [3]
RP SEQUENCE FROM N.A.
RA Adams M.D., Holt R.A., Evans C.A., Gocayne J.D., Amanatides P.G.,
RA Li P.W., Henderson S.N., Sutton G.G., Wortman J.R., Yandell M.D.,
RA Zhang Q., Chen L.X., Brandon R.C., Rogers Y.H., An H.J.,
RA Andrews-Pfannkoch C., Baldwin D., Baller R.M., Basu A., Baxendale J.,
RA Beasley E.M., Besson K.Y., Bhandari D., Bolanos R.A., Buesam D.A.,
RA Center A., Chandra I., Dahlke C., Davenport L.B., Davies P.,
RA Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M., Dodson K.,
RA Doup L.E., Dunn P., Evangelista C.C., Ferriera S., Flanigan M.J.,

```

Foster C., Gabriellian A.E., Garg N.S., Glasser K., Glodek A., Gong F.,
 Gu Z., Guan P., Halpern A.L., Harris M., Heiman T.J., Houck J.,
 Hostin D., Howland T.J., Wei M.H., Ibegwam C., Jalali M., Kalush F.,
 Ke Z., Ketchum K.A., Kodira C.D., Kraft C., Kravitz S., Lai Z.,
 Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X., Liu X.,
 Mattei B., McIntosh T.C., McPherson D., Merkulov G., Miller J.R.,
 Mishina N.V., Mobarry C., Moy M., Murphy B., Nelson K.A.,
 Nusken D.R., Mobarry C., Moy M., Murphy B., Nelson K.A.,
 Remington K., Scheeler F., Shue B.C., Siden-Kiamos I., Simpson M.,
 Skupski M.P., Smith T., Spier E., Strong R., Sun E., Tector C.,
 Turner R., Venter E., Wang A.H., Wang X., Wang Z.Y., Williams S.M.,
 Woodage T., Wu D., Yao Q.A., Ye J., Zaveri J.S., Zhan M., Zhang G.,
 Zhao Q., Zheng L., Zheng X.H., Zhong F.N., Zhong W., Zhu S., Zhu X.,
 Smith H.O., Myers E.W., Venter J.C.;
 "Drosophila melanogaster Heterochromatic Scaffold.";
 Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.
 [4]
 SEQUENCE FROM N.A.
 Adams M.D., Holt R.A., Evans C.A., Gocayne J.D., Amanatides P.G.,
 Li P.W., Henderson S.N., Sutton G.G., Wortman J.R., Vandeil M.D.,
 Zhang Q., Chen L.X., Brandon R.C., Rogers V.H., An H.J.,
 Andrews-Pfankuchen C., Baldwin D., Ballew R.M., Basu A., Baxendale J.,
 Beasley E.M., Beeson K.Y., Bhandari D., Bolanos R.A., Busam D.A.,
 Center A., Chandra I., Dahlke C., Davenport L.B., Davies P.,
 Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M., Dodson K.,
 Doup L.E., Dunn P., Evangelista C.C., Ferriera S., Fianigan M.J.,
 Foster C., Gabriellian A.E., Garg N.S., Glasser K., Glodek A., Gong F.,
 Gu Z., Guan P., Halpern A.L., Harris M., Heiman T.J., Houck J.,
 Hostin D., Howland T.J., Wei M.H., Ibegwam C., Jalali M., Kalush F.,
 Ke Z., Ketchum K.A., Kodira C.D., Kraft C., Kravitz S., Lai Z.,
 Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X., Liu X.,
 Mattei B., McIntosh T.C., McPherson D., Merkulov G., Miller J.R.,
 Mishina N.V., Mobarry C., Moy M., Murphy B., Nelson K.A.,
 Nusken D.R., Mobarry C., Moy M., Murphy B., Nelson K.A.,
 Remington K., Scheeler F., Shue B.C., Siden-Kiamos I., Simpson M.,
 Skupski M.P., Smith T., Spier E., Strong R., Sun E., Tector C.,
 Turner R., Venter E., Wang A.H., Wang X., Wang Z.Y., Williams S.M.,
 Woodage T., Wu D., Yao Q.A., Ye J., Zaveri J.S., Zhan M., Zhang G.,
 Zhao Q., Zheng L., Zheng X.H., Zhong F.N., Zhong W., Zhu S., Zhu X.,
 Smith H.O., Myers E.W., Venter J.C.;
 Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.
 [5]
 SEQUENCE FROM N.A.
 Hoskins R.A., Smith C.D., Carlson J.W., Carvalho A.B., Halpern A.,
 Kaminker J.S., Kennedy C., Lewis S.E., Mungall C.J., Sullivan B.A.,
 Sutton G.G., Yasuhara J.C., Wakimoto B.T., Myers E.W., Celisner S.E.,
 Rubin G.M., Karpen G.H.;
 Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.
 -1- CAUTION: The sequence shown here is derived from an
 EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
 preliminary data.
 EMBL; AABU01002542; EAA46263.1; --
 HSP; P17169; LGDO.
 GO; GO:0005737; C:cytoplasm; IEA.
 GO; GO:0004360; F:glutamine-fructose-6-phosphate transaminase.; IEA.
 GO; GO:000529; F:sugar binding; IEA.
 GO; GO:0016051; F:carbohydrate biosynthesis; IEA.
 GO; GO:0008152; P:metabolism; IEA.
 InterPro; IPR005853; GATase_2.
 InterPro; IPR001347; SIS.
 Pfam; PF00310; GATase_2; 1.
 Pfam; PF01390; SIS; 2.
 TIGRFAMs; TIGR01135; glms; 1.
 PROSITE; PS00443; GATASE_TYP_E; UNKNOWN_1.
 SEQUENCE 673 AA; 75607 MW; BF77310B661C5E79 CRC64;
 O7PLC6 Length: 673 February 4, 2005 13:17 Type: P Check: 7105
 Found using 'seq3' (mohamed337.key)

182 KSKYPPGECVARSRRSPILGVIGIKTKTRLATDHPHILYCKDADSGKPGQVLPRSESTSEFM

-----|-----
249 LEEKEVEVFASDASAVIEHTNRVILEDDVAARDCGLTSHRLKKSLDDPHAREIT
242 Q7PLC7 : CGI2449-PA.
... TOIG of: q7plc7 check: 6056 from: 1 to: 682

1 match found in sequence:
q7plc7 : CGI2449-PA.
(from "seq3uni.pep")

ID Q7PLC7 PRELIMINARY; PRT: 682 AA.

AC Q7PLC7
DT 01-MAR-2004 (TREMBLrel. 26, Created)
DT 01-WAR-2004 (TREMBLrel. 26, Last sequence update)
DT 01-WAR-2004 (TREMBLrel. 26, Last annotation update)
DE CGI2449-PA.
GN Name=Grati.; Synonym=CGI2449;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_Taxid=7227;
[1]
RN SEQUENCE FROM N.A.
RP MEDLINE=22426065; PubMed=12537568;
RX Celniker S.E., Wheeler D.A., Krommiller B., Carlson J.W., Halpern
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.R.,
RA George R.A., Hoskins R.A., Laverty T., Muzny D.M., Nelson C.R.,
RA Paciel J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.,
RA Svirskaas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Ve
RA Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.
RA Yashuhara J.C., Wakimoto B.T., Myers E.W., Celniker S.E., Rubin
RT "Finishing a whole-genome shotgun: Release 3 of the Drosophila
RL melanogaster euchromatic genome sequence.";
RL Genome Biol. 3:0079-0079(2002).
[2]
RN SEQUENCE FROM N.A.
RP MEDLINE=22426071;
RX Hoskins R.A., Smith C.D., Carlson J.W., Carvalho A.B., Halpern
RA Kaminker J.S., Kennedy C., Mungall C.J., Sullivan B.A., Sutton
RA Yasuhara J.C., Wakimoto B.T., Myers E.W., Celniker S.E., Rubin
RA Karpen G.H.;
RT "Heterochromatic sequences in a Drosophila whole-genome shotgun
RT assembly.";
RL Genome Biol. 3:0085-0085(2002).
[3]
RN SEQUENCE FROM N.A.
RP Adams M.D., Holt R.A., Evans C.A., Gocayne J.D., Amanatides P.
RA Li P.W., Henderson S.N., Sutton G.G., Wortman J.R., Yeaman C.,
RA Zhang Q., Chen L.X., Brandon R.C., Rogers Y.H., An H.J.,
RA Andrews-Pfannkoch C., Baldwin D., Ballou R.M., Basu A., Baxendale
RA Beasley E.M., Beeson K.Y., Bhandari D., Bolanos R.A., Busam D.
RA Center A., Chandra I., Dahlke C., Davenport L.B., Davies P.,
RA Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M., Dodson K.A.,
RA Doup L.E., Dunn P., Evangelista C.C., Ferreira S., Flanagan M.,
RA Fouts L., Gabor C., Gabrielian A.E., Garg N.S., Glasser K., Glodek A.,
RA Gu Z., Guan P., Halpern A.L., Harris M., Heiman T.J., Houck J.M.,
RA Hostin D., Howland T.J., Wei M.H., Ibegwam C., Jalali M., Kalish
RA Ke Z., Ketchum K.A., Kodira C.D., Kraft C., Kravitz S., Lai Z.,
RA Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X., Liu X.,
RA Mattei B., McIntosh T.C., McPherson D., Merkulov G., Miller J.,
RA Milshina N.V., Mobarry C., Moy M., Murphy B., Nelson K.A.,
RA Nusskern D.R., Pittman G.S., Pan S., Pollard J., Puri V., Reiter
RA Nusskern D.K., Scheeler F., Shue B.C., Siden-kiamos I., Simpson
RA Renington K., Smith T., Spier E., Strong R., Sun E., Tector C.,
RA Skupski M.P., Smith T., Wang A.H., Wang X., Wang Z.Y., Williams
Turner R., Venter E., Wu D., Yao Q.A., Ye J., Zaveri J.S., Zhan M., Zhao
RA Zhao Q., Zheng L., Zheng X.H., Zhong F.N., Zhong W., Zhu S.,
RA Smith H.O., Myers E.W., Venter J.C.;

```
RT "Drosophila melanogaster Heterochromatic Scaffold.";  
RL Submitted (FEB-2003) to the EMBL/GenBank/DBJ databases.  
RN [4]  
RP SEQUENCE FROM N.A.  
RA Adams M.D., Holt R.A., Evans C.A., Gocayne J.D., Amanatides P.G.,  
RA Li P.W., Henderson S.N., Sutton G.G., Wortman J.R., Yandell M.D.,  
RA Zhang Q., Chen L.X., Brandon R.C., Rogers Y.H., An H.J.,  
RA Andrews-Pfannkoch C., Baldwin D., Ballwey R.M., Basu A., Baxendale J.,  
RA Beasley E.M., Beeson K.Y., Bhandari D., Bolanos R.A., Busam D.A.,  
RA Center A., Chandra I., Dahlke C., Davenport L.B., Davies P.,  
RA Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M., Dodson K.,  
RA Doup L.E., Dunn P., Evangelista C.C., Ferrier S., Flanigan M.J.,  
RA Fout R.C., Gabrielian A.E., Garg N.S., Glasser K., Glodek A., Gong F.,  
RA Gu Z., Guan P., Halpern A.L., Harris M., Heiman T.J., Houck J.,  
RA Hostin D., Howland T.J., Wei M.H., Ibegwam C., Jalali M., Kalush F.,  
RA Ke Z., Ketchum K.A., Kodira C.D., Kraft C., Kravitz S., Lai Z.,  
RA Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X., Liu X.,  
RA Mattei B., McIntosh T.C., McPherson D., Merkuov G., Miller J.R.,  
RA Milshina N.V., Mobarry C., Moy M., Murphy B., Nelson K.A.,  
RA Nusskern N.R., Pittman G.S., Pan S., Pollard J., Puri V., Reinert K.,  
RA Remington K., Scheeler F., Shue B.C., Siden-Kiamos I., Simpson M.,  
RA Skupski M.P., Smith T., Spier E., Strong R., Sun E., Tector C.,  
RA Turner R., Venter E., Wang A.H., Wang X., Wang Z.Y., Williams S.M.,  
RA Woodage T., Wu D., Yao Q.A., Ye J., Zaveri J.S., Zhan M., Zhang G.,  
RA Zhao Q., Zheng L., Zheng X.H., Zhong F.N., Zhong W., Zhu S., Zhu X.,  
RA Smith H.O., Myers E.W., Venter J.C.;  
RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.  
RN [5]  
RP SEQUENCE FROM N.A.  
RA Hoskins R.A., Smith C.D., Carlson J.W., Carvalho A.B., Halpern A.,  
RA Kaminker J.S., Kennedy C., Lewis S.E., Mungall C.J., Sullivan B.A.,  
RA Sutton G.G., Yasuhara J.C., Wakimoto B.T., Myers E.W., Celniker S.E.,  
RA Rubin G.M., Karpen G.H.;  
RL Submitted (MAY-2003) to the EMBL/GenBank/DBJ databases.  
CC -!- CAUTION: The sequence shown here is derived from an  
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is  
CC preliminary data.  
DR EMBL; ABAU01002542; EAA46260.1; -;  
DR HSSP; PL7169; LGDO.  
DR GO; GO:0005737; C:cytoplasm; IEA.  
DR GO; GO:0004360; F:glutamine-fructose-6-phosphate transaminase. . .; IEA.  
DR GO; GO:0005529; F:sugar binding; IEA.  
DR GO; GO:0016051; P:carbohydrate biosynthesis; IEA.  
DR GO; GO:0008152; P:metabolism; IEA.  
DR InterPro; IPR000583; GATase 2.  
DR InterPro; IPR005855; Glms_trans.  
DR InterPro; IPR001347; SIS.  
DR Pfam; PF00310; GATase_2; 1.  
DR Pfam; PF01380; SIS; 2.  
DR TIGRFAMs; TIGR01135; glms; 1.  
DR PROSITE; PS00443; GATASE TYPE II; UNKNOWN 1.  
SQ SEQUENCE 682 AA; 76654 MW; F00BDD8359566EEA CRC64;  
  
Q7PLC7 Length: 682 February 4, 2005 13:17 Type: P Check: 6056 ..  
Found using 'seq3' (mohamed337.key)  
...  
191 VASRRSPLLVGKTKYTRLATDHIPIYKDKKLCCTDQDASGKQKQVLPRESSTSEFMP  
241  
-----  
251 LEEKEVEYFPASDASAVIEHTNRVILEDDVAAVRGDTLSTHRLKKSLLDDPHAREIT  
258  
...  
-----  
1 match found in sequence:  
q7psy1; ENSANGP00000016019 (Fragment).  
(from "seq3uni.pep")  
TOIG of: q7psy1 check: 7489 from: 1 to: 715  
  
-----  
328 SLTDFQNTSICLSYEQRIGVAVFGTICTGKLAGGCKERLPATGRQRQTFSSSEKVG  
378  
-----  
388 NESKKLYDDGGKEPGDEKPPYGLELLPDGPAFAEHFKSPNASNESTEMKDFLGINS  
395  
...  
-----  
1 match found in sequence:  
q7qe24; AGCP7269 (Fragment).  
(from "seq3uni.pep")  
TOIG of: q7qe24 check: 8295 from: 1 to: 722  
  
ID Q7QE24 PRELIMINARY; PRT; 722 AA.  
AC Q7QE24;  
DT 01-MAR-2004 (TrEMBLrel. 26, Created)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE AGCP7269 (Fragment).  
GN Name=agCG51375; ORFNames=ENSANGG00000014157;  
OS Anopheles gambiae str. PEST.  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Anopheles.  
OX NCBI_TaxID=180454;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=PEST;  
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.  
CC -!- CAUTION: The sequence shown here is derived from an  
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is  
CC preliminary data.  
DR EMBL; AAB0100848; EAA07036.1; -;  
DR HSSP; P02829; IUSU.  
DR GO; GO:0005524; F:ATP binding; IEA.  
DR GO; GO:0051082; F:unfolded protein binding; IEA.  
DR GO; GO:0006457; P:protein folding; IEA.
```

```
ID Q7PSY1 PRELIMINARY; PRT; 715 AA.  
AC Q7PSY1;  
DT 01-MAR-2004 (TrEMBLrel. 26, Created)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE ENSANGP00000016019 (Fragment).  
GN Name=ENSANGG00000013530;  
OS Anopheles gambiae str. PEST.  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Anopheles.  
OX NCBI_TaxID=180454;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=PEST;  
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.  
CC -!- CAUTION: The sequence shown here is derived from an  
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is  
CC preliminary data.  
DR EMBL; AAB01008811; EAA04862.2; -;  
DR GO; GO:0005634; C:nucleus; IEA.  
DR GO; GO:0003677; F:DNA binding; IEA.  
DR InterPro; IPR009057; Homeodomain_like.  
FT NON_TER 1  
FT NON_TER 1  
FT NON_TER 1  
SQ SEQUENCE 715 AA; 80212 MW; E1EBEE20894193E CRC64;  
  
Q7PSY1 Length: 715 February 4, 2005 13:17 Type: P Check: 7489 ..  
Found using 'seq3' (mohamed337.key)  
...  
328 SLTDFQNTSICLSYEQRIGVAVFGTICTGKLAGGCKERLPATGRQRQTFSSSEKVG  
378  
-----  
388 NESKKLYDDGGKEPGDEKPPYGLELLPDGPAFAEHFKSPNASNESTEMKDFLGINS  
395  
...  
-----  
1 match found in sequence:  
q7qe24; AGCP7269 (Fragment).  
(from "seq3uni.pep")  
TOIG of: q7qe24 check: 8295 from: 1 to: 722  
  
ID Q7QE24 PRELIMINARY; PRT; 722 AA.  
AC Q7QE24;  
DT 01-MAR-2004 (TrEMBLrel. 26, Created)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)  
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)  
DE AGCP7269 (Fragment).  
GN Name=agCG51375; ORFNames=ENSANGG00000014157;  
OS Anopheles gambiae str. PEST.  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Anopheles.  
OX NCBI_TaxID=180454;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=PEST;  
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.  
CC -!- CAUTION: The sequence shown here is derived from an  
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is  
CC preliminary data.  
DR EMBL; AAB0100848; EAA07036.1; -;  
DR HSSP; P02829; IUSU.  
DR GO; GO:0005524; F:ATP binding; IEA.  
DR GO; GO:0051082; F:unfolded protein binding; IEA.  
DR GO; GO:0006457; P:protein folding; IEA.
```

DR InterPro; IPR009079; 4 helix cytokine.
DR InterPro; IPR003594; ATPbind_ATPase.
DR InterPro; IPR001404; Hsp90.
DR Pfam; PF02518; HATPase_c; 1.
DR Pfam; PF00183; HSP90; 3.
DR PRINTS; PR00775; HEATSHOCK90.
FT NON_TER 1
SQ SEQUENCE 722 AA; 81576 MW; C247E2A0F9F8E8A9 CRC64;

Q7QE24 Length: 722 February 4, 2005 13:17 Type: P Check: 8295
Found using 'seq3' (mohamed337.key)

524 TLAEASPYVESLKKRGIEVLFCYEAYDELVLQMGYLGKLVSVKEKMRGRSDASTEGKD
574

584 ADGLIEGSLKTKQIDELLPWLKDKLTGKVSNNVTKGLDTHPCVVTVEEWAARHFIX
591

1 match found in sequence:

q7qh02 : AgCP10417 (Fragment).
(from "seq3uni.pep")

TOIG of: q7qh02 check: 4946 from: 1 to: 1086

ID Q7QH02 PRELIMINARY; PRT; 1086 AA.

AC Q7QH02;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE AgCP10417 (Fragment).
GN Name=agCG54105; ORFNames=ENSANGG00000010055;
OS Anopheles gambiae str. PEST.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Anopheles.
OX NCBI_TaxID=180454;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=PEST;
RL Submitted (MAR-2002) to the EMBL/GenBank/DBJ databases.
CC -!- CAUTION: The sequence shown here is derived from an
EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
preliminary data.

DR EMBL; AAA0100823; EAA05623.1; -.

DR HSSP; Q10466; 1BPV.

DR InterPro; IPR003961; FN.III.

DR InterPro; IPR008957; FN.III-like.

DR InterPro; IPR007110; Ig-like.

DR Pfam; PF00041; fn3; 3.

DR PROSITE; PS50853; FN3; 3.

DR PROSITE; PS50835; IG.LIKE; 5.

FT NON_TER 1

FT NON_TER 1086 1086

SQ SEQUENCE 1086 AA; 118638 MW; 00B61A3A50D7C593 CRC64;

Q7QH02 Length: 1086 February 4, 2005 13:17 Type: P Check: 4946
Found using 'seq3' (mohamed337.key)

905 GGMTDFSRPMVVRDCLWIDGRWRTDTRDKDGLSEAKLLESSQNTANYADVSTDYAE
955

965 VDPRTSTFYNRSKSPDNPSFYATTVLVNCGNDCNDGKMSYQGLDGYISGASTNRSDPA
972

1 match found in sequence:

q7rrd7 : Hypothetical protein.
(from "seq3uni.pep")

TOIG of: q7rrd7 check: 3550 from: 1 to: 777

ID Q7RRD7 PRELIMINARY; PRT; 777 AA.

AC Q7RRD7;

DT 01-MAR-2004 (TrEMBLrel. 26, Created)

DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)

DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)

DE Hypothetical protein.

GN Name=PY00794;

OS Plasmodium yoelii yoelii.

OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.

OX NCBI_TaxID=73239;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=17XNL;

RX PubMed=12368865; DOI=10.1038/nature01099;

RA Carlton J.M., Angiuoli S.V., Suh B.B., Kooij T.W., Pertea M.,

RA Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L.,

RA Peterson J.D., Pop M., Kosack D.S., Shumway M.F., Bidwell S.L.,

RA Shallom S.J., van Aken S.E., Riedmuller S.B., Feldblyum T.V.,

RA Cho J.K., Quackenbush J., Sedegah M., Shoabi A., Cummings L.M.,

RA Florens L., Yates F.R. III, Raine J.D., Sinden R.E., Harris M.A.,

RA Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,

RA van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R.,

RA Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,

RA Carucci D.J.;

RT "Genome sequence and comparative analysis of the model rodent malaria

RT parasite Plasmodium yoelii yoelii.";

RL Nature 419:512-519(2002).

CC -!- CAUTION: The sequence shown here is derived from an

EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is

preliminary data.

DR EMBL; AABL01000212; EAA18518.1; -.

DR InterPro; IPR001547; GLYCO_HYDRO_5.

DR PROSITE; PS00659; GLYCOSYL_HYDROL_F5; UNKNOWN_1.

KW Hypothetical protein.

SQ SEQUENCE 777 AA; 90514 MW; 22A0B47688B83BB7 CRC64;

Q7RRD7 Length: 777 February 4, 2005 13:17 Type: P Check: 3550
Found using 'seq3' (mohamed337.key)

192 DNESLLKSPKKLNNKGIETICNDMNDKYEENAFNTSQANIDHIQKYTENSSESE
242

252 CETRTICFQNEKRIIDDDSNNSQNEVLDDSLNKCDNEEKMDKIRSNLLPHTGK
259

1 match found in sequence:

q7rrd9 : 34 kDa phosphoprotein (Fragment).
(from "seq3uni.pep")

TOIG of: q7rrd9 check: 3324 from: 1 to: 256

ID Q7RRD9 PRELIMINARY; PRT; 256 AA.

AC Q7RRD9;

DT 01-MAR-2004 (TrEMBLrel. 26, Created)

DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)

DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)

DE 34 kDa phosphoprotein (Fragment).

GN Name=PY00792;

```

OS Plasmodium yoelii yoelii.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=73239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=17XN1;
RX PubMed=12368865; DOI=10.1038/nature01099;
RA Carlton J.M., Anguolli S.V., Suh B.B., Kooij T.W., Petrea M.,
RA Silva J.C., Ermolaeva M.D., Allen J.E., Selengut J.D., Koo H.L.,
RA Peterson J.D., Pop M., Kosak D.S., Shumway M.F., Bidwell S.L.,
RA Shallow S.J., van Aken S.E., Riedmuller S.B., Feldblyum T.V.,
RA Cho J.K., Quackenbush J.J., Sedegah M., Shoabi A., Cummings L.M.,
RA Florens L., Yates F.D., Raine J.D., Sinden R.E., Harris M.A.,
RA Cunningham D.A., Preiser P.R., Bergman L.W., Vaidya A.B.,
RA van Lin L.H., Janse C.J., Waters A.P., Smith H.O., White O.R.,
RA Salzberg S.L., Venter J.C., Fraser C.M., Hoffman S.L., Gardner M.J.,
RA Carucci D.J.;
RT "Genome sequence and comparative analysis of the model rodent malaria
RT parasite Plasmodium yoelii yoelii.";
RL Nature 419:512-519(2002).
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AABL01000212; EAA18516.1; -.
DR InterPro; IPR008978; HSP20_Chap.
FT NON TER 1
SQ SEQUENCE 256 AA; 28117 MW; 113A62102D3469AD CRC64;

Q7RRD9 Length: 256 February 4, 2005 13:17 Type: P Check: 3324
Found using 'seq3' (mohamed337.key)

...

156 LGGWGGGCGMDIFSKLGNWGGMSNLACLGQWQDKNPNWDDSSSGYGGDDSSDDDD
-----|-----
223 EDDDTNKSADHSHACNDKCNIDKEGAHNDDAKQVPA
223

-----|-----
1 match found in sequence:
q7sei3 : Zgc:66137.
(from "seq3uni.pep")
TOIG of: q7sei3 Check: 173 from: 1 to: 552

ID Q7SEI3 PRELIMINARY; PRT; 552 AA.
AC Q7SEI3;
DT 01-MAR-2004 (TrEMBLrel. 26, Created)
DT 01-MAR-2004 (TrEMBLrel. 26, Last sequence update)
DE Hypothetical protein.
DE Names=NCU09742.1;
GN Neurospora crassa.
OS Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=OR74A;
RA Galagan J.E., Fitzhugh W., Ma L.-J., Smirnov S., Purcell S., Rehman B.,
RA Jaffe D., Engels R., Wang S., Nielsen C.B., Butler J., Endrizzi M.,
RA Elkins T., Ianakiev P., Pedersen D., Nelson M., Washburne M.,
RA Qui D., Ianakiev P., Kinsey J.A., Braun E.L., Zeiter A., Schulte U.,
RA Seidlrennikoff C.P., Mewes W., Staben C., Marcotte E., Greenberg D.,
RA Roy A., Foley K., Naylor J., Thomann N., Barrett R., Gnerre S.,
RA Kamal M., Kamysseilis M., Mauceli E., Bielke C., Rudd S., Frishman D.,
RA Krystofova S., Rasmussen C., Metzenberg R.L., Perkins D.D., Kroken S.,
RA Cogoni C., Macino G., Catchside D., Li W., Pratt R.J., Omani S.A.,
RA DeSouza C.C., Glaes L., Orbach M.J., Berglund J., Voelker R.,
RA Yarden O., Plamann M., Seiler S., Dunlap J., Radford A., Aramayo R.,

```

```

RA Natvig D.O., Alex L.A., Mannhaupt G., Ebole D.J., Freitag M.,
RA Paulsen I., Sachs M.S., Lander E.S., Nusbaum C., Birren B.;
RT "The Genome Sequence of the Filamentous Fungus Neurospora crassa.";
RL Nature 0:0-0(2003).
CC -!- CAUTION: The sequence shown here is derived from an
CC EMBL/GenBank/DBJ whole genome shotgun (WGS) entry which is
CC preliminary data.
DR EMBL; AABX01000032; EAA35208.1; -.
DR HSSP; Q60900; 1D9A.
DR InterPro; IPR00504; RNA_rec_mot.
DR Pfam; PF000076; RRM_1; 2.
DR PROSITE; PS50102; RRM; 2.
DR PROSITE; PS00030; RRM_RNP_1; UNKNOWN_2.
KW Hypothetical protein.
SQ SEQUENCE 552 AA; 59560 MW; CB40CE3F190C5E86 CRC64;

Q7SEI3 Length: 552 February 4, 2005 13:17 Type: P Check: 173
Found using 'seq3' (mohamed337.key)

...

93 QTYPPVMHGVFPPEAAQIQGVAGQYVPVAGYAPLPYHSHVPTPGRVASGERSSEAPG
-----|-----
143 LENRRGSYSTNESTPATPFPGTSDRGNGRIAVIRSSFTSPSPQVWASGGVWKSVP
143

-----|-----
1 match found in sequence:
q7syn3 : Zgc:66137.
(from "seq3uni.pep")
TOIG of: q7syn3 Check: 1015 from: 1 to: 420

ID Q7SYN3 PRELIMINARY; PRT; 420 AA.
AC Q7SYN3;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Zgc:66137.
GN ORFNames=zgc:66137;
OS Brachydanio rerio (Zebrafish) (Danio rerio).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Actinopterygii; Neopterygii; Teleostei; Ostariophysi; Cypriniformes;
OC Cyprinidae; Danio.
OX NCBI_TaxID=7955;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=AB; TISSUE=Whole body;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schuler G.D.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Ussdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullany S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Hellon E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).

```

```

RN
RC SEQUENCE FROM N.A.
RC STRAIN-AB; TISSUE-whole body;
RA Strausberg R.;
RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC054651; AAHS4651.1; -.
DR HSSP; Q13153; 1F3M.
DR ZFIN; ZDB-GENE-040426-2841; zgc:66137.
DR GO; GO:005524; F-ATP binding; IEA.
DR GO; GO:0004674; F-protein serine/threonine kinase activity; IEA.
DR GO; GO:0004674; P-protein amino acid phosphorylation; IEA.
DR InterPro; IPR011009; Kinase like.
DR InterPro; IPR000719; Prot kinase.
DR InterPro; IPR002290; Ser Thr_kinase.
DR Pfam; PF00069; Pkinase; 1.
DR ProDom; PD000001; Prot_kinase; 1.
DR SMART; SM00220; S_TKc; 1.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS00011; PROTEIN_KINASE_DOM; 1.
KW ATP-binding.
SQ SEQUENCE 420 AA; 46861 MW; 3DF4791331CD9E82 CRC64;

Q7SYN3 Length: 420 February 4, 2005 13:17 Type: P Check: 1015
Found using 'seq3' (mohamed337.key)

...

238 FVEACLNKEPSRPTAKELKHKLIVRPAKTSYLTDELIDKYKRWAKSRAESSDSD
      |-----
      286

298 SEPDGASGNDGNDWIFTIREKPKLQNGASLVGEEKPNRPLSQSLSTVITPV
      -----|
      305

...

1 match found in sequence:
q7z401 : C-MYC promoter-binding protein IRLB.
(from 'seq3uni.pep')
TOIG of: q7z401 check: 8069 from: 1 to: 1865

ID Q7Z401 PRELIMINARY; PRT; 1865 AA.
AC Q7Z401;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE C-MYC promoter-binding protein IRLB.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Human spinal cord;
RA Ansorge W., Krieger S., Regiert T., Rittmueller C., Schwager B.,
RA Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL832602; CAD89960.1; -.
DR InterPro; IPR005112; dDENN.
DR InterPro; IPR001194; dDENN.
DR InterPro; IPR002885; PPR.
DR InterPro; IPR005113; uDENN.
DR Pfam; PF03455; dDENN; 1.
DR Pfam; PF02141; DENN; 1.
DR Pfam; PF01535; PPR; 2.
DR Pfam; PF03456; uDENN; 1.
DR PROSITE; PS50947; dDENN; 1.
DR PROSITE; PS50211; DENN; 1.
DR PROSITE; PS50946; uDENN; 1.
KW Hypothetical protein.
KW NON_TER
FT
SQ SEQUENCE 1831 AA; 205650 MW; C9CD64C74C4A907A CRC64;

Q86T77 Length: 1831 February 4, 2005 13:17 Type: P Check: 298
Found using 'seq3' (mohamed337.key)

...

836 YFLWTKVRNVVLGVTFQKRALKKHAHLSQTTLSGGQSDLGYNLSKDEVRGDTSTEDIQ
      |-----
      886

896 EEKDKKGDCSSLSSESTKGSADCLPKLSYQNSSIVRLTGTSTNNSAGKISGESMES
      -----|
      903
```

```

DR PROSITE; PS50211; DENN; 1.
DR PROSITE; PS50946; uDENN; 1.
SQ SEQUENCE 1865 AA; 209427 MW; 475AD139CABC92B3 CRC64;

Q7Z401 Length: 1865 February 4, 2005 13:17 Type: P Check: 8069
Found using 'seq3' (mohamed337.key)

...

868 YFLWTKVRNVVLGVTFQKRALKKHAHLSQTTLSGGQSDLGYNLSKDEVRGDTSTEDIQ
      |-----
      918

928 EEKDKKGDCSSLSSESTKGSADCLPKLSYQNSSIVRLTGTSTNNSAGKISGESMGK
      -----|
      935

...

1 match found in sequence:
q86t77 : Hypothetical protein DKFPz451C1717 (Fragment).
(from 'seq3uni.pep')
TOIG of: q86t77 check: 298 from: 1 to: 1831

ID Q86T77 PRELIMINARY; PRT; 1831 AA.
AC Q86T77;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein DKFPz451C1717 (Fragment).
GN Name=DKFPz451C1717;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Human spinal cord;
RA Ansorge W., Krieger S., Regiert T., Rittmueller C., Schwager B.,
RA Mewes H.W., Weil B., Amid C., Osanger A., Fobo G., Han M., Wiemann S.;
RL Submitted (JUN-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL832602; CAD89960.1; -.
DR InterPro; IPR005112; dDENN.
DR InterPro; IPR001194; dDENN.
DR InterPro; IPR002885; PPR.
DR InterPro; IPR005113; uDENN.
DR Pfam; PF03455; dDENN; 1.
DR Pfam; PF02141; DENN; 1.
DR Pfam; PF01535; PPR; 2.
DR Pfam; PF03456; uDENN; 1.
DR PROSITE; PS50947; dDENN; 1.
DR PROSITE; PS50211; DENN; 1.
DR PROSITE; PS50946; uDENN; 1.
KW Hypothetical protein.
KW NON_TER
FT
SQ SEQUENCE 1831 AA; 205650 MW; C9CD64C74C4A907A CRC64;

Q86T77 Length: 1831 February 4, 2005 13:17 Type: P Check: 298
Found using 'seq3' (mohamed337.key)

...

836 YFLWTKVRNVVLGVTFQKRALKKHAHLSQTTLSGGQSDLGYNLSKDEVRGDTSTEDIQ
      |-----
      886

896 EEKDKKGDCSSLSSESTKGSADCLPKLSYQNSSIVRLTGTSTNNSAGKISGESMES
      -----|
      903
```

```
-----
1 match found in sequence:
q89134 ; Blr4714 protein.
  (from "seq3uni.pep")
TOIG of: q89134 check: 6303 from: 1 to: 1861

ID Q89134 PRELIMINARY; PRT; 1861 AA.
AC Q89134;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Blr4714 protein.
GN OrderedLocusNames=blr4714;
OS Bradyrhizobium japonicum.
OC Bacteria; Proteobacteria; Alphaproteobacteria; Rhizobiales;
OC Bradyrhizobiaceae; Bradyrhizobium.
OX NCBI_TaxID=375;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=USDA110;
RX MEDLINE=22484998; PubMed=12597275;
RA Kaneko T., Nakamura Y., Sato S., Minamisawa K., Uchiumi T.,
RA Sasamoto S., Watanabe A., Idesawa K., Iriguchi M., Kawashima K.,
RA Kohara M., Matsumoto M., Shimpo S., Tsuruoka H., Wada T., Yamada M.,
RA Tabata S.;
RT "Complete genomic sequence of nitrogen-fixing symbiotic bacterium
  Bradyrhizobium japonicum USDA110.";
RL DNA Res. 9:189-197(2002).
DR EMBL; AP005952; BAC49979.1; -.
DR InterPro; IPR011083; Collar.
DR InterPro; IPR011049; Serralyen_like_C.
DR Pfam; PF07484; Collar; 3.
KW Complete proteome.
SQ SEQUENCE 1861 AA; 184721 MW; EB7F4C549B8B59B5 CRC64;

Q89134 Length: 1861 February 4, 2005 13:17 Type: P Check: 6303
Found using 'seq3' (mohamed337.key)

...

273 PTCGGTHQVRDITWQVSDGTTNTITASPINNDQPSLGLTLQIPLQGTYPHSGDTSDPGT
-----
323
333 IDLGSIRTFAGSLAPNHTALASGOLLISIAQNTALFSLFGTGYGNGQTFELPNLQAK
-----
340

1 match found in sequence:
q89m11 ; Blr4382 protein.
  (from "seq3uni.pep")
TOIG of: q89m11 check: 5053 from: 1 to: 158

ID Q89M11 PRELIMINARY; PRT; 158 AA.
AC Q89M11;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Blr4382 protein.
GN OrderedLocusNames=blr4382;
OS Bradyrhizobium japonicum.
OC Bacteria; Proteobacteria; Alphaproteobacteria; Rhizobiales;
OC Bradyrhizobiaceae; Bradyrhizobium.
OX NCBI_TaxID=375;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=USDA110;
RX MEDLINE=22484998; PubMed=12597275;
RA Kaneko T., Nakamura Y., Sato S., Minamisawa K., Uchiumi T.,
RA Sasamoto S., Watanabe A., Idesawa K., Iriguchi M., Kawashima K.,
RA Kohara M., Matsumoto M., Shimpo S., Tsuruoka H., Wada T., Yamada M.,
RA Tabata S.;
RT "Complete genomic sequence of nitrogen-fixing symbiotic bacterium
  Bradyrhizobium japonicum USDA110.";
RL DNA Res. 9:189-197(2002).
DR EMBL; AP005952; BAC49979.1; -.
DR InterPro; IPR011083; Collar.
DR InterPro; IPR011049; Serralyen_like_C.
DR Pfam; PF07484; Collar; 3.
KW Complete proteome.
SQ SEQUENCE 158 AA; 17471 MW; FE53BF81378F57E4 CRC64;

Q89M11 Length: 158 February 4, 2005 13:17 Type: P Check: 5053
Found using 'seq3' (mohamed337.key)

...

61 LLSERIGVPDKLNLVAVWREAPIYSARRERAAWTEALTFPLDGVSDVYAEVTSFSE
-----
111
121 SELMYLTSAVASINVWNRFGAAYRWTPAKRPVATNAAS
-----
128

1 match found in sequence:
q8a4s4 ; Alpha-rhamnosidase.
  (from "seq3uni.pep")
TOIG of: q8a4s4 check: 3122 from: 1 to: 1152

ID Q8A4S4 PRELIMINARY; PRT; 1152 AA.
AC Q8A4S4;
DT 01-JUN-2003 (TrEMBLrel. 24, Created)
DT 01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Alpha-rhamnosidase.
GN OrderedLocusNames=Bt2523;
OS Bacteroides thetaiotaomicron.
OC Bacteria; Bacteroidetes; Bacteroides (class); Bacteroidales;
OC Bacteroidaceae; Bacteroides.
OX NCBI_TaxID=818;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=VPI-5482 / ATCC 29148;
RX MEDLINE=22550858; PubMed=12663928; DOI=10.1126/science.1080029;
RA Xu J., Bjursell M.K., Himrod J., Deng S., Carmichael L.K.,
RA Chiang H.C., Hooper L.V., Gordon J.I.;
RT "A genomic view of the human-Bacteroides thetaiotaomicron symbiosis.";
RL Science 299:2074-2076(2003).
DR EMBL; AE016936; AAC77630.1; -.
DR InterPro; IPR008902; Bac_rhamnosid.
DR Pfam; PF05592; Bac_rhamnosid; 1.
KW Complete proteome.
SQ SEQUENCE 1152 AA; 128868 MW; D0D678E79EC6C9BD CRC64;

Q8A4S4 Length: 1152 February 4, 2005 13:17 Type: P Check: 3122
Found using 'seq3' (mohamed337.key)

...

408 HYQTYDITDLRRKGENAVGAQVSSGWNDSVAHGEYGANEVGFIAKILKYTDGTSETVV
-----
458
468 TDLSLSSMDGAIRMGDYHGETYDARKESVWTKPGYNTANNKNTAVNPHFKGLIAP
-----
475
```

```
1 match found in sequence:
q8chp6 ; Polyhomeotic 3.
(from "seq3uni.pep")
TOIG of: q8chp6 check: 5433 from: 1 to: 981

ID Q8CHP6 PRELIMINARY; PRT; 981 AA.
AC Q8CHP6;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE Polyhomeotic 3.
GN Name=Phc3;
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C57BL/6J; PubMed=12384788;
RX MEDLINE=22271642;
RA Tonkin E., Hagan D.M., Li W., Strachan T.;
RT Identification and characterisation of novel mammalian homologues of
RT Drosophila polyhomeotic permits new insights into relationships between
RT members of the polyhomeotic family."
RL Hum. Genet. 111:435-442(2002).
DR EMBL; AJ414610; CAC93885.1; -.
DR HSSP; P39769; 1KW4.
DR MGD; MGI:2181434; Phc3.
DR InterPro; IPR001660; SAM.
DR InterPro; IPR011510; SAM.2.
DR Pfam; PF07647; SAM.2; 1.
DR SMART; SM00454; SAM; 1.
DR PROSITE; PS50105; SAM DOMAIN; 1.
SQ SEQUENCE 981 AA; 105438 MW; CCC3CF42C1EE06B9 CRC64;

Q8CHP6 Length: 981 February 4, 2005 13:17 Type: P Check: 5433 ..
Found using 'seq3' (mohamed337.key)

...

705 EGVFIOGLEPFPVSRSSLLIEQPKRPLLDNQVNSVCVQPELQNTYKHADNSDTEI
755
-----|-----
765 EDWMAETLEMDSELLKCFCKGKMGYPNEFLRSKRFTMCAKRYNVSCKKFKALSR
772
...

1 match found in sequence:
q8ivx2 ; C-myc promoter binding protein.
(from "seq3uni.pep")
TOIG of: q8ivx2 check: 2562 from: 1 to: 1863

ID Q8IVX2 PRELIMINARY; PRT; 1863 AA.
AC Q8IVX2;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE C-myc promoter binding protein.
GN Name=MYCPBP;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Uterus;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
```

```
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M., Butterfield Y.S.,
RA Krzywinski M.I., Skalska U., Smailus D.E., Schnerch A., Schein J.E.,
RA Jones S.J., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences."
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP SEQUENCE FROM N.A.
RC TISSUE=Uterus;
RA Strausberg R.;
RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; BC041706; AAH41706.1; -.
DR InterPro; IPR005112; dDenn.
DR InterPro; IPR001194; dDenn.
DR InterPro; IPR002885; PPR.
DR InterPro; IPR005113; uDenn.
DR Pfam; PF03455; dDenn; 1.
DR Pfam; PF02141; dDenn; 1.
DR Pfam; PF01535; PPR; 2.
DR Pfam; PF03456; uDenn; 1.
DR PROSITE; PS50947; dDenn; 1.
DR PROSITE; PS50211; dDenn; 1.
DR PROSITE; PS50946; uDenn; 1.
SQ SEQUENCE 1863 AA; 209226 MW; CE653AD6AA6749A1 CRC64;

Q8IVX2 Length: 1863 February 4, 2005 13:17 Type: P Check: 2562 ..
Found using 'seq3' (mohamed337.key)

...

868 YFLWTKVRNVLVGTQFKALKKHAHLSTTLGGQSDLGYNLSKDEVRGDTSTEDIQ
918
-----|-----
928 EKDCKGSDCSLSESTKGSADCLPKLSYQNSSSIVRLTCTSNNSAGKISGESMES
935
...

1 match found in sequence:
q8ndx5 ; Homolog of polyhomeotic 3.
(from "seq3uni.pep")
TOIG of: q8ndx5 check: 9513 from: 1 to: 983

ID Q8NDX5 PRELIMINARY; PRT; 983 AA.
AC Q8NDX5;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Homolog of polyhomeotic 3.
GN Name=PHC3;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=22271642; PubMed=12384788;
RA Tonkin E., Hagan D.M., Li W., Strachan T.;
```

RT "Identification and characterisation of novel mammalian homologues of
RT Drosophila polyhomeotic permits new insights into relationships between
RT members of the polyhomeotic family."
RL Hum. Genet. 111:435-442(2002).
DR EMBL; AJ320486; CAC86587.2; --
DR HSP; P39769; IKW4.
DR Genew; HGNC:15682; PHC3.
DR InterPro; IPR011069; Asp transf_reg_C.
DR InterPro; IPR001660; SAM.
DR InterPro; IPR011510; SAM_2.
DR Pfam; PF07647; SAM_2; 1.
DR SMART; SM00454; SAM; 1.
DR PROSITE; PS50105; SAM DOMAIN; 1.
SQ SEQUENCE 983 AA; 106161 MW; 05819632A1675049 CRC64;

Q8NDF7 Length: 983 February 4, 2005 13:17 Type: P Check: 9513 ..
Found using 'seq3' (mohamed337.key)

...
707 EGFVIOGLEPPFVSRSSLLIEQPVKKRPLLDNQVINSVCVQPELQNTKHDNSDTEM
757
767 EDMAIEETLEEMDSLLKCEFCGKMGYANFLRSKRFTCTMSCAKRYNVSCSKKFPALSR
774

...
1 match found in sequence:
q8nft7 ; Polyhomeotic 3 protein.
(from "seq3uni.pep")
TOIG of: q8nft7 check: 467 from: 1 to: 983

ID Q8NFT7 PRELIMINARY; PRT; 983 AA.
AC Q8NFT7;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Polyhomeotic 3 protein.
GN Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Levine S.S., Weiss A., Erdjument-Bromage H., Shao Z., Francis N.J.,
RA Forrester W., Tempst P., Kingston R.E.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF44193; AAM51781.1; --
DR HSP; P39769; IKW4.
DR InterPro; IPR011069; Asp transf_reg_C.
DR InterPro; IPR001660; SAM.
DR InterPro; IPR011510; SAM_2.
DR Pfam; PF07647; SAM_2; 1.
DR SMART; SM00454; SAM; 1.
DR PROSITE; PS50105; SAM DOMAIN; 1.
SQ SEQUENCE 983 AA; 106177 MW; 1FB8C95FA5C7F5B CRC64;

Q8NFT7 Length: 983 February 4, 2005 13:17 Type: P Check: 467 ..
Found using 'seq3' (mohamed337.key)

...
707 EGFVIOGLEPPFVSRSSLLIEQPVKKRPLLDNQVINSVCVQPELQNTKHDNSDTEM
757
767 EDMAIEETLEEMDSLLKCEFCGKMGYANFLRSKRFTCTMSCAKRYNVSCSKKFPALSR
774

...
1 match found in sequence:
q8nft7 ; Polyhomeotic 3 protein.
(from "seq3uni.pep")
TOIG of: q8nft7 check: 467 from: 1 to: 983

ID Q8NFT7 PRELIMINARY; PRT; 983 AA.
AC Q8NFT7;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Polyhomeotic 3 protein.
GN Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Levine S.S., Weiss A., Erdjument-Bromage H., Shao Z., Francis N.J.,
RA Forrester W., Tempst P., Kingston R.E.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF44193; AAM51781.1; --
DR HSP; P39769; IKW4.
DR InterPro; IPR011069; Asp transf_reg_C.
DR InterPro; IPR001660; SAM.
DR InterPro; IPR011510; SAM_2.
DR Pfam; PF07647; SAM_2; 1.
DR SMART; SM00454; SAM; 1.
DR PROSITE; PS50105; SAM DOMAIN; 1.
SQ SEQUENCE 983 AA; 106177 MW; 1FB8C95FA5C7F5B CRC64;

Q8NFT7 Length: 983 February 4, 2005 13:17 Type: P Check: 467 ..
Found using 'seq3' (mohamed337.key)

...
707 EGFVIOGLEPPFVSRSSLLIEQPVKKRPLLDNQVINSVCVQPELQNTKHDNSDTEM
757
767 EDMAIEETLEEMDSLLKCEFCGKMGYANFLRSKRFTCTMSCAKRYNVSCSKKFPALSR
774

...
1 match found in sequence:
q8nft7 ; Polyhomeotic 3 protein.
(from "seq3uni.pep")
TOIG of: q8nft7 check: 467 from: 1 to: 983

ID Q8NFT7 PRELIMINARY; PRT; 983 AA.
AC Q8NFT7;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Polyhomeotic 3 protein.
GN Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Levine S.S., Weiss A., Erdjument-Bromage H., Shao Z., Francis N.J.,
RA Forrester W., Tempst P., Kingston R.E.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF44193; AAM51781.1; --
DR HSP; P39769; IKW4.
DR InterPro; IPR011069; Asp transf_reg_C.
DR InterPro; IPR001660; SAM.
DR InterPro; IPR011510; SAM_2.
DR Pfam; PF07647; SAM_2; 1.
DR SMART; SM00454; SAM; 1.
DR PROSITE; PS50105; SAM DOMAIN; 1.
SQ SEQUENCE 983 AA; 106177 MW; 1FB8C95FA5C7F5B CRC64;

Q8NFT7 Length: 983 February 4, 2005 13:17 Type: P Check: 467 ..
Found using 'seq3' (mohamed337.key)

...
707 EGFVIOGLEPPFVSRSSLLIEQPVKKRPLLDNQVINSVCVQPELQNTKHDNSDTEM
757
767 EDMAIEETLEEMDSLLKCEFCGKMGYANFLRSKRFTCTMSCAKRYNVSCSKKFPALSR
774

...
1 match found in sequence:
q8nft7 ; Polyhomeotic 3 protein.
(from "seq3uni.pep")
TOIG of: q8nft7 check: 467 from: 1 to: 983

ID Q8NFT7 PRELIMINARY; PRT; 983 AA.
AC Q8NFT7;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Polyhomeotic 3 protein.
GN Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Levine S.S., Weiss A., Erdjument-Bromage H., Shao Z., Francis N.J.,
RA Forrester W., Tempst P., Kingston R.E.;
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF44193; AAM51781.1; --
DR HSP; P39769; IKW4.
DR InterPro; IPR011069; Asp transf_reg_C.
DR InterPro; IPR001660; SAM.
DR InterPro; IPR011510; SAM_2.
DR Pfam; PF07647; SAM_2; 1.
DR SMART; SM00454; SAM; 1.
DR PROSITE; PS50105; SAM DOMAIN; 1.
SQ SEQUENCE 983 AA; 106177 MW; 1FB8C95FA5C7F5B CRC64;

Q8NFT7 Length: 983 February 4, 2005 13:17 Type: P Check: 467 ..
Found using 'seq3' (mohamed337.key)

...
774
1 match found in sequence:
q8nft7 ; Early development regulator 3.
(from "seq3uni.pep")
TOIG of: q8nft7 check: 589 from: 1 to: 964

ID Q8NEZ1 PRELIMINARY; PRT; 964 AA.
AC Q8NEZ1;
DT 01-OCT-2002 (TrEMBLrel. 22, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Early development regulator 3.
GN Name=EDR3;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RA Hansen M.F., Deshpande A.M., Nellissery M.J., Reveles X., Naylor S.L.,
RA Jackson L.G., Leach R.J.;
RL Submitted (MAY-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AF380154; AAM46139.1; --
DR HSP; P39769; IKW4.
DR InterPro; IPR011069; Asp transf_reg_C.
DR InterPro; IPR001660; SAM.
DR InterPro; IPR011510; SAM_2.
DR Pfam; PF07647; SAM_2; 1.
DR SMART; SM00454; SAM; 1.
DR PROSITE; PS50105; SAM DOMAIN; 1.
SQ SEQUENCE 964 AA; 104211 MW; 79078C95F50EA206 CRC64;

Q8NEZ1 Length: 964 February 4, 2005 13:17 Type: P Check: 589 ..
Found using 'seq3' (mohamed337.key)

...
688 EGFVIOGLEPPFVSRSSLLIEQPVKKRPLLDNQVINSVCVQPELQNTKHDNSDTEM
738
748 EDMAIEETLEEMDSLLKCEFCGKMGYANFLRSKRFTCTMSCAKRYNVSCSKKFPALSR
755

...
1 match found in sequence:
q8tib4 ; Hypothetical protein MA4241.
(from "seq3uni.pep")
TOIG of: q8tib4 check: 6994 from: 1 to: 310

ID Q8TIB4 PRELIMINARY; PRT; 310 AA.
AC Q8TIB4;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein MA4241.
GN OrderedLocustNames=MA4241;
OS Methanosarcina acetivorans.
OC Archaea; Euryarchaeota; Methanomicrobia; Methanosarcinales;
OC Methanosarcinaceae; Methanosarcina.
OX NCBI_TaxID=2214;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C2A / ATCC 35395 / DSM 2834;
RX MEDLINE=21929760; PubMed=11932238; DOI=10.1101/gr.223902;
RA Galagan J.E., Nusbaum C., Roy A., Endrizzi M.G., Macdonald P.,

Q8TIB4 Length: 310 February 4, 2005 13:17 Type: P Check: 589 ..
Found using 'seq3' (mohamed337.key)

...
688 EGFVIOGLEPPFVSRSSLLIEQPVKKRPLLDNQVINSVCVQPELQNTKHDNSDTEM
738
748 EDMAIEETLEEMDSLLKCEFCGKMGYANFLRSKRFTCTMSCAKRYNVSCSKKFPALSR
755

...
1 match found in sequence:
q8tib4 ; Hypothetical protein MA4241.
(from "seq3uni.pep")
TOIG of: q8tib4 check: 6994 from: 1 to: 310

ID Q8TIB4 PRELIMINARY; PRT; 310 AA.
AC Q8TIB4;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein MA4241.
GN OrderedLocustNames=MA4241;
OS Methanosarcina acetivorans.
OC Archaea; Euryarchaeota; Methanomicrobia; Methanosarcinales;
OC Methanosarcinaceae; Methanosarcina.
OX NCBI_TaxID=2214;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C2A / ATCC 35395 / DSM 2834;
RX MEDLINE=21929760; PubMed=11932238; DOI=10.1101/gr.223902;
RA Galagan J.E., Nusbaum C., Roy A., Endrizzi M.G., Macdonald P.,

Q8TIB4 Length: 310 February 4, 2005 13:17 Type: P Check: 589 ..
Found using 'seq3' (mohamed337.key)

...
688 EGFVIOGLEPPFVSRSSLLIEQPVKKRPLLDNQVINSVCVQPELQNTKHDNSDTEM
738
748 EDMAIEETLEEMDSLLKCEFCGKMGYANFLRSKRFTCTMSCAKRYNVSCSKKFPALSR
755

...
1 match found in sequence:
q8tib4 ; Hypothetical protein MA4241.
(from "seq3uni.pep")
TOIG of: q8tib4 check: 6994 from: 1 to: 310

ID Q8TIB4 PRELIMINARY; PRT; 310 AA.
AC Q8TIB4;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein MA4241.
GN OrderedLocustNames=MA4241;
OS Methanosarcina acetivorans.
OC Archaea; Euryarchaeota; Methanomicrobia; Methanosarcinales;
OC Methanosarcinaceae; Methanosarcina.
OX NCBI_TaxID=2214;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C2A / ATCC 35395 / DSM 2834;
RX MEDLINE=21929760; PubMed=11932238; DOI=10.1101/gr.223902;
RA Galagan J.E., Nusbaum C., Roy A., Endrizzi M.G., Macdonald P.,

Q8TIB4 Length: 310 February 4, 2005 13:17 Type: P Check: 589 ..
Found using 'seq3' (mohamed337.key)

...
688 EGFVIOGLEPPFVSRSSLLIEQPVKKRPLLDNQVINSVCVQPELQNTKHDNSDTEM
738
748 EDMAIEETLEEMDSLLKCEFCGKMGYANFLRSKRFTCTMSCAKRYNVSCSKKFPALSR
755

...
1 match found in sequence:
q8tib4 ; Hypothetical protein MA4241.
(from "seq3uni.pep")
TOIG of: q8tib4 check: 6994 from: 1 to: 310

ID Q8TIB4 PRELIMINARY; PRT; 310 AA.
AC Q8TIB4;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Hypothetical protein MA4241.
GN OrderedLocustNames=MA4241;
OS Methanosarcina acetivorans.
OC Archaea; Euryarchaeota; Methanomicrobia; Methanosarcinales;
OC Methanosarcinaceae; Methanosarcina.
OX NCBI_TaxID=2214;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=C2A / ATCC 35395 / DSM 2834;
RX MEDLINE=21929760; PubMed=11932238; DOI=10.1101/gr.223902;
RA Galagan J.E., Nusbaum C., Roy A., Endrizzi M.G., Macdonald P.,

RA FitzHugh W., Calvo S., Engels R., Smirnov S., Atnoor D., Brown A.,
RA Allen N., Naylor J., Stange-Thomann N., DeArellano K., Johnson R.,
RA Linton L., McEwan P., McKernan K., Talamas J., Tirrell A., Ye W.,
RA Zimmer A., Barber R.D., Cann I., Graham D.E., Grahame D.A., Guss A.M.,
RA Hedderich R., Ingram-Smith C., Kuettnner H.C., Krzycki J.A.,
RA Leigh J.A., Li W., Liu J., Mukhopadhyay B., Reeve J.N., Smith K.,
RA Springer T.A., Umayam L.A., White O., White R.H., de Macario E.C.,
RA Perry J.G., Jarrell K.F., Jing H., Macario A.J.L., Paulsen I.T.,
RA Pritchett M., Sowers K.R., Swanson R.V., Zinder S.H., Lander E.,
RA Metcalf W.W., Birren B.;
RT "The genome of Methanococcus acetivorans reveals extensive metabolic
RT and physiological diversity.";
RL Genome Res. 12:532-542 (2002).
DR EMBL; AS011136; AM07586.1; -;
DR HSSP; Q45560; 1BWE.
DR GO; GO:0005489; F1electron transporter activity; IEA.
DR GO; GO:0005506; F1iron ion binding; IEA.
DR GO; GO:0006118; P1electron transport; IEA.
DR InterPro; IPR001450; 4Fe4S ferredoxin.
DR Pfam; PF01656; Cb1A_P.
DR Pfam; PF00037; Fer4; 2.
DR PRINTS; PRO0353; 4FE4SFERDOXIN.
DR PROSITE; PS00198; 4FE4S FERREDOXIN; UNKNOWN_1.
KW 4Fe-4S; Complete proteome; Iron; Iron-sulfur; Metal-binding.
SQ SEQUENCE 310 AA; 33172 MW; 1D0E0A5421DEBBA4 CRC64;

Q8T1B4 Length: 310 February 4, 2005 13:17 Type: P Check: 6994
Found using 'seq3' (mohamed337.key)

...
198 HDLKRAIKLTAHFRIPAVACINRYDINEKSLKLEAFRCRAGIPLRLAPYDTITTEAMM
248

258 NEETVIEYAAHSRKAQAEVFNIRKLWADIKMRLSGPCDEMCSTLPIRES
265

1 match found in sequence:
q8wzz3 ; Related to ATROPHIN-1.
(from "seq3uni.pep")
TOIG of: q8wzz3 check: 81 from: 1 to: 609

ID Q8WZZ3 PRELIMINARY; PRT; 609 AA.
AC Q8WZZ3;
DT 01-MAR-2002 (TrEMBLrel. 20, Created)
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Related to ATROPHIN-1.
GN Name=B24G3.070;
OS Neurospora crassa.
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Sordariomycetes;
OC Sordariomycetidae; Sordariales; Sordariaceae; Neurospora.
OX NCBI_TaxID=5141;
RN [1]
RP SEQUENCE FROM N.A.
RA Schulte U., Aign V., Hoheisel J., Brandt P., Fartmann B., Holland R.,
RA Nyakatura G., Mewes H.W., Mannhaupt G.;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
RN [2]
RP SEQUENCE FROM N.A.
RA German Neurospora genome project;
RL Submitted (JAN-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL670002; CAD21224.1; -;
SQ SEQUENCE 609 AA; 66237 MW; DD235095B2BE2201 CRC64;
Q8WZZ3 Length: 609 February 4, 2005 13:17 Type: P Check: 81
Found using 'seq3' (mohamed337.key)

104 EHGSPRIADVAQAQTFDDADPRDPCEADSEDSAEVSTISEDLVHYRPRAEWTSDLSD
154

164 NDEPVPSTSPFRFSDPAVPAVKSSLEAKRAKRAVRKESWNPGLACFEARRD
171

1 match found in sequence:
q96lj0 ; Hypothetical protein FLJ25442.
(from "seq3uni.pep")
TOIG of: q96lj0 check: 5066 from: 1 to: 300

ID Q96LJ0 PRELIMINARY; PRT; 300 AA.
AC Q96LJ0;
DT 01-DEC-2001 (TrEMBLrel. 19, Created)
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein FLJ25442.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Testis;
RA Kawakami B., Sugiyama A., Takemoto M., Suzuki Y., Hata H.,
RA Nakagawa K., Mizuno S., Morinaga M., Kawamura M., Sugiyama T.,
RA Irie R., Otsuki T., Sato H., Nishikawa T., Nagai K., Isogai T.,
RA Sugano S.;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AK058171; BAB71701.1; -;
DR Genew; HGNC:22957; SPATSL.
SQ SEQUENCE 300 AA; 33705 MW; 20A052131D2E4D98 CRC64;
Q96LJ0 Length: 300 February 4, 2005 13:17 Type: P Check: 5066
Found using 'seq3' (mohamed337.key)

59 CFANTTPSGKSVSSSSSVETGSPVSEPPGLPRVSAVDTADLDRKLSFSDHSSEMSL
109

119 PEVQDKYPEEPFESLLKLOPKDGHPRPWFYPRFSSNIHTYHVGCQFFNGVFLGNKRS
126

1 match found in sequence:
q9gyd3 ; Hypothetical protein L3180.04 (Hypothetical protein P265.05).
(from "seq3uni.pep")
TOIG of: q9gyd3 check: 7765 from: 1 to: 633

ID Q9GYD3 PRELIMINARY; PRT; 633 AA.
AC Q9GYD3;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 05-JUL-2004 (TrEMBLrel. 27, Last annotation update)
DE Hypothetical protein L3180.04 (Hypothetical protein P265.05).
GN Name=L3180.04; Synonyms=P265.05;
OS Leishmania major.
OC Eukaryota; Euklenozoa; Kinetoplastida; Trypanosomatidae; Leishmania.
OX NCBI_TaxID=5664;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Friedlin;

```
RX MEDLINE=98146435; PubMed=9477341;
RA Ivens A.C., Lewis S.M., Bagherzadeh A., Zhang L., Chan H.M.,
RA Smith D.F.;
RT "A physical map of the Leishmania major Friedlin genome.";
RL Genome Res. 8:135-145(1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=Friedlin;
RA Oliver K., Murphy L., Harris D., Ivens A.C., Quail M.,
RA Rajandream M.A., Barrell B.G.;
RL Submitted (AUG-2000) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=Friedlin;
RA Robben J., Grymonprez B., Weltjens I., Aert R., Volckaert G.,
RA Ivens A.C., Quail M., Rajandream M.A., Barrell B.G.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL391629; CAC05310.1; -.
DR EMBL; AL359716; CAD19414.1; -.
DR InterPro; IPR001611; LRR.
DR Pfam; PF00560; LRR 1; 1.
DR PRINTS; PR00019; LEURICHRPT.
KW Hypothetical protein.
SQ SEQUENCE 633 AA; 67461 MW; D78916F4AA74893F CRC64;

Q9GYD3 Length: 633 February 4, 2005 13:17 Type: P Check: 7765
Found using 'seq3' (mohamed337.key)

...

255 NFWRCRGVSDGDDGGRHRYVQICACPLRLDDVVDDGSEVMQHSNSTESDV
305
315 KQVAERSASAGAPSQAGGITVRRVHNSVEARAASRACVHDITHRSSLLAPGSL
322
...

1 match found in sequence:
q9lt64; Emb|CAB75482.1.
(from "seq3uni.pep")
TOIG of: q9lt64 check: 7096 from: 1 to: 677

ID Q9LT64 PRELIMINARY; PRT; 677 AA.
AC Q9LT64;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Emb|CAB75482.1.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20277480; PubMed=10819329;
RA Nakamura Y.;
RT "Structural analysis of Arabidopsis thaliana chromosome 3. I. Sequence
RT features of the regions of 4,504,864 bp covered by sixty P1 and TAC
RT clones.";
RL DNA Res. 7:131-135(2000).
RN [2]
RP SEQUENCE FROM N.A.
RA Sato S., Nakamura Y., Kaneko T., Kato T., Asamizu E., Tabata S.;
RL Submitted (APR-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL; AB025626; BAB01278.1; -.
DR GO; GO:0007242; P:intracellular signaling cascade; IEA.
DR InterPro; IPR011424; Cl.3.
DR InterPro; IPR000345; Cytc_heme_BS.
```

```
DR InterPro; IPR002219; DAG_PE-bind.
DR InterPro; IPR004146; DCI.
DR Pfam; PF03107; Cl.2; 2.
DR Pfam; PF07649; Cl.3; 5.
DR SMART; SM00109; Cl.1.
DR PROSITE; PS00190; CYTOCHROME C; UNKNOWN_1.
DR PROSITE; PS50081; DAG_PE_BIND_DOM_2; 2.
SQ SEQUENCE 677 AA; 77118 MW; 8DD02E7436D3132C CRC64;

Q9LT64 Length: 677 February 4, 2005 13:17 Type: P Check: 7096
Found using 'seq3' (mohamed337.key)

...

501 HFKTQSCGIDHTKVVIGLCKNYFLDFRCATLPLTVSLPYDDHPLTLCYGEKSSDKYW
551
561 CDICERETNTFTYTGSESGVTLHLCVLGDIRYAKPGNICEGGFVLPNNSSTRPI
568
...

1 match found in sequence:
q9n535; Hypothetical protein Y32H12A.6.
(from "seq3uni.pep")
TOIG of: q9n535 check: 9100 from: 1 to: 279

ID Q9N535 PRELIMINARY; PRT; 279 AA.
AC Q9N535;
DT 01-OCT-2000 (TrEMBLrel. 15, Created)
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein Y32H12A.6.
GN Name=Y32H12A.6; ORFNames=Y32H12A.6;
OS Caenorhabditis elegans.
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditidae; Rhabditidae;
OC Rhabditidae; Peloderinae; Caenorhabditis.
OX NCBI_TaxID=6239;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RX MEDLINE=99069613; PubMed=9851916;
RG WormBase Consortium;
RT "Genome sequence of the nematode C. elegans: a platform for
RT investigating biology. the C. elegans Sequencing Consortium.";
RL Science 282:2012-2018(1998).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Holmes A., Elliot G., Cloud J.;
RT "The sequence of C. elegans cosmid Y32H12A.";
RL Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Waterston R.H.;
RL Waterston R.H.;
RN [4]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Waterston R.;
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.
RN [5]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RA Waterston R.;
RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.
RN [6]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
```

```
RA Waterston R.;
RL Submitted (OCT-2001) to the EMBL/GenBank/DBJ databases.
RN [7]
RP SEQUENCE FROM N.A.
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA Waterston R.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
RN [8]
RP SEQUENCE FROM N.A.
RA STRAIN=Bristol N2;
RC STRAIN=Bristol N2;
RA Waterston R.;
RL Submitted (MAY-2002) to the EMBL/GenBank/DBJ databases.
RN [9]
RP SEQUENCE FROM N.A.
RA STRAIN=Bristol N2;
RC STRAIN=Bristol N2;
RA Waterston R.;
RL Submitted (NOV-2002) to the EMBL/GenBank/DBJ databases.
RN [10]
RP SEQUENCE FROM N.A.
RA STRAIN=Bristol N2;
RC STRAIN=Bristol N2;
RA Waterston R.;
RL Submitted (DEC-2002) to the EMBL/GenBank/DBJ databases.
RN [11]
RP SEQUENCE FROM N.A.
RA STRAIN=Bristol N2;
RC STRAIN=Bristol N2;
RA Wilson R.;
RL Submitted (JUL-2003) to the EMBL/GenBank/DBJ databases.
RN [12]
RP SEQUENCE FROM N.A.
RC STRAIN=Bristol N2;
RG WormBase Consortium;
RL Submitted (SEP-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL; AC006733; AAF60484.1; -
DR WormBase; WBGene00021314; Y32H12A.6.
DR WormPep; Y32H12A.6; CE21510.
DR GO; GO:0010181; F:FMN binding; IEA.
DR GO; GO:0016491; F:oxidoreductase activity; IEA.
DR InterPro; IPR008254; Flav nitox synth.
DR PROSITE; PS0902; FLAVODOXIN_Like; 1.
KW Hypothetical protein.
SQ SEQUENCE 279 AA, 31829 MW, 47286DB425912264 CRC64;

QSN535 Length: 279 February 4, 2005 13:17 Type: P Check: 9100
Found using 'seq3' (mohamed337.key)

...

211 TEVELPNTTDTKQTWERVFVFFELLQMDKHLPGMSGEDTESEVGDDRSSESSDDNE
261
-----|
271 VEEKKKSK
278

-----
1 match found in sequence:
q9vtl17 : CG3280-PA.
(from "seq3uni.pep")
TOIG of: q9vtl17 check: 9088 from: 1 to: 1937

ID Q9VT17 PRELIMINARY; PRT; 1937 AA.
AC Q9VT17;
DT 01-MAY-2000 (TrEMBLrel. 13, Created)
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE CG3280-PA.
GN ORFNames=CG3280;
OS Drosophila melanogaster (fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_taxid=7227;
```

```
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=20196006; PubMed=10731132; DOI=10.1126/science.287.5461.2185;
RA Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D.,
RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galle R.F.,
RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,
RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,
RA Brandon R.C., Rogers Y.H., Blazej R.G., Champe M., Pfeiffer B.D.,
RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Gabor G.L.,
RA Abrik J.F., Agbayani A., An H.J., Andrews-Pfannkuch C., Baldwin D.,
RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,
RA Beeson K.Y., Benos P.V., Beran B.P., Bhandari D., Bolshakov S.,
RA Borkova D., Botchan M.R., Bouck J., Brockstein P., Brothier P.,
RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,
RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,
RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,
RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferrier S., Fleischmann W.,
RA Foslter C., Gabriellian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Helman T.J., Hernandez J.R., Houck J.,
RA Hostin D., Houston K.A., Howland T.J., Wei M.H., Ibegwam C.,
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kennison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai X.,
RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacleb J.M.,
RA Palazzolo M., Pittman G.S., Pan S., Pollard J., Puri V., Reese M.G.,
RA Reinert K., Remington K., Saunders R.D., Scheeler F., Shen H.,
RA Shue B.C., Siden-Kiamos I., Simpson M., Skupski M.P., Smith T.,
RA Spier E., Spradling A.C., Stapleton M., Strong R., Sun E.,
RA Svirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.Y., Wassarman D.A., Weinstock G.M., Weissbach J.,
RA Williams S.M., Woodgett, Worley K.C., Wu D., Yang S., Yao Q.A., Ye J.,
RA Yen R.F., Zaveri J.S., Zhan M., Zhang G., Zhao Q., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster.";
Science 287:2185-2195(2000).
RN [2]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426065; PubMed=12537568;
RA Celniker S.E., Wheeler D.A., Krommiller B., Carlson J.W., Halpern A.,
RA Patel S., Adams M., Champe M., Dugan S.P., Frise E., Hodgson A.,
RA George R.A., Hoskins R.A., Lavery T., Muzny D.M., Nelson C.R.,
RA Pacleb J.M., Park S., Pfeiffer B.D., Richards S., Sodergren E.J.,
RA Svirskas R., Tabor P.E., Wan K., Stapleton M., Sutton G.G., Venter C.,
RA Weinstock G., Scherer S.E., Myers E.W., Gibbs R.A., Rubin G.M.;
RT "Finishing a whole-genome shotgun. Release 3 of the Drosophila
melanogaster euchromatic genome sequence.";
Genome Biol. 3:RESEARCH0079-RESEARCH0079(2002).
RN [3]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426070; PubMed=12537573;
RA Kaminker J.S., Bergman C.M., Krommiller B., Carlson J., Svirskas R.,
RA Patel S., Frise E., Wheeler D.A., Lewis S.E., Rubin G.M.,
RA Ashburner M., Celniker S.E.;
RT "The transposable elements of the Drosophila melanogaster euchromatin:
a genomics perspective.";
Genome Biol. 3:RESEARCH0084-RESEARCH0084(2002).
RN [4]
RP SEQUENCE FROM N.A.
RX MEDLINE=22426069; PubMed=12537572;
RA Misra S., Crosby M.A., Mungall C.J., Matthews B.B., Campbell K.S.,
RA Hradecky P., Huang Y., Kaminker J.S., Millburn G.H., Prochnik S.E.,
RA Smith C.D., Tupy J.L., Whitfield E.J., Bayraktaroglu L., Berman B.P.,
RA Bettencourt B.R., Celniker S.E., de Grey A.D., Drysdale R.A.,
RA Harris N.L., Richter J., Russo S., Schroeder A.J., Shu S.Q.,
RA Stapleton M., Yamada C., Ashburner M., Gelbart W.M., Rubin G.M.,
RA Lewis S.E.;
RT "Annotation of the Drosophila melanogaster euchromatic genome: a
```

RT systematic review. ;
RN Genome Biol. 3:RESEARCH0083-RESEARCH0083(2002).
RN [5]
RG SEQUENCE FROM N.A.
RP FlyBase;
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
RN [6]
RP SEQUENCE FROM N.A.
RG FlyBase;
RL Submitted (MAR-2004) to the EMBL/GenBank/DBJ databases.
DR EMBL: AE003551; AAF50239.2; --
DR FlyBase; Fggn0036017; CG3280.
SQ SEQUENCE 1937 AA; 217137 MW; FD2ED63CBED2FD1A CRC64;
..
Q9VT17 Length: 1937 February 4, 2005 13:17 Type: P Check: 9088 ..
Found using 'seq3' (mohamed337.key)
..
514 SLWFSPIYKINSKERPLQMLKLENETNMELKNLSSIEALRAMTPTTSLYGESTSDGLF
564
574 DDSTATWGEDGGGLFSTAAALISTTVQRLKCNMTVKSKLRNIIISGKLATT
581
..

1 match found in sequence:
q9y093 ; Glucosamine--fructose-6-phosphate aminotransferase.
(from "seq3uni.pep")
TOIG of: q9y093 Check: 7927 from: 1 to: 694
ID Q9Y093 PRELIMINARY; PRT; 694 AA.
AC Q9Y093;
DT 01-NOV-1999 (TrEMBLrel. 12, Created)
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Glucosamine--fructose-6-phosphate aminotransferase.
GN Name=Gfat1; Synonyms=gfat;
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
OX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=21573685; PubMed=11716769; DOI=10.1042/0264-6021.3600401;
RA Graack H.R., Cinque U., Kress H.;
RT "Functional regulation of glutamine:fructose-6-phosphate
aminotransferase 1 (GFAT1) of Drosophila melanogaster in a UDP-N-
acetylglucosamine and cAMP-dependent manner.";
RL Biochem. J. 360:401-412(2001).
RN [2]
RP SEQUENCE FROM N.A.
RA Graack H.;
RL Submitted (JAN-1999) to the EMBL/GenBank/DBJ databases.
DR EMBL: Y18628; CAB46365.1; --
DR HSSP; P17169; IGDO.
DR FlyBase; Fggn0027341; Gfat1.
DR GO; GO:0005737; C:cytoplasm; IEA.
DR GO; GO:0004360; F:glutamine-fructose-6-phosphate transaminase. .; IEA.
DR GO; GO:0005529; F:sugar binding; IEA.
DR GO; GO:0016740; F:transferase activity; IEA.
DR GO; GO:0016051; P:carbohydrate biosynthesis; IEA.
DR GO; GO:0008152; P:metabolism; IEA.
DR InterPro; IPR000583; GATase_2.
DR InterPro; IPR005855; Glms_trans.
DR InterPro; IPR001347; SIS.
DR Pfam; PF00310; GATase_2; 1.
DR Pfam; PF01380; SIS; 2.

DR TIGRFAMs; TIGR01135; glms; 1.
DR PROSITE; PS00443; GATASE_TYPE_II; UNKNOWN_1.
KW Aminotransferase; Transferase.
SQ SEQUENCE 694 AA; 78124 MW; 57286BA7D4F7D328 CRC64;
..
Q9Y093 Length: 694 February 4, 2005 13:17 Type: P Check: 7927 ..
Found using 'seq3' (mohamed337.key)
..
203 IKTKRLATDHPILYGKDKKLCCTQDQADSGKQDIPRHGOSREL.PVLPRSESTSEFMP
253
263 LEEKEVEFFASDASAVIEHTNRVILEDDDDVAARVDGTLSTHRLKKSLLDDPHAREIT
270
..

1 match found in sequence:
sthaverpe ; Soluble pyridine nucleotide transhydrogenase (BC 1.6.1.1) (STH)
(from "seq3uni.pep")
TOIG of: sthaverpe Check: 8 from: 1 to: 466
ID STHA YERPE STANDARD; PRT; 466 AA.
AC Q8ZA97;
DT 28-FEB-2003 (Rel. 41, Created)
DT 28-FEB-2003 (Rel. 41, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Soluble pyridine nucleotide transhydrogenase (BC 1.6.1.1) (STH)
DE (NAD(P)(+) transhydrogenase [B-specific]).
GN Name=sthA; Synonyms=sudhA; OrderedLocusNames=YPO3914, Y0321, YP3134;
OS Yersinia pestis.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;
OC Enterobacteriaceae; Yersinia.
OX NCBI_TaxID=632;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=CO-92 / Biovar Orientalis;
RX MEDLINE=21470413; PubMed=11586360; DOI=10.1038/35097083;
RA Parkhill J., Wren B.W., Thomson N.R., Titball R.W., Holden M.T.G.,
RA Prentice M.B., Sebahia M., James K.D., Churcher C.M., Mungall K.L.,
RA Baker S., Basham D., Bentley S.D., Brooks K., Cerdeno-Tarraga A.-M.,
RA Chillingworth T., Cronin A., Davies R.M., Davis P., Dougan G.,
RA Feltwell T., Hamlin N., Holroyd S., Jagels K., Karlyshev A.V.,
RA Leather S., Moule S., Oyston P.C.F., Quail M.A., Rutherford K.M.,
RA Simmonds M., Skelton J., Stevens K., Whitehead S., Barrell B.G.;
RT "Genome sequence of Yersinia pestis, the causative agent of plague.";
RL Nature 413:523-527(2001).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=KIM5 / Biovar Mediaevalis;
RX MEDLINE=22137863; PubMed=12142430;
DOI=10.1128/JB.184.16.4601-4611.2002;
RA Deng W., Burland V., Plunkett G. III, Boutin A., Mayhew G.F., Lies P.,
RA Perna N.T., Rose D.J., Mau B., Zhou S., Schwartz D.C.,
RA Fetherston J.D., Lindler L.E., Brubaker R.R., Plano G.V.,
RA Straley S.C., McDonough K.A., Nilles M.L., Matson J.S., Blattner F.R.,
RA Perry R.D.;
RT "Genome sequence of Yersinia pestis KIM.";
RL J. Bacteriol. 184:4601-4611(2002).
RN [3]
RP SEQUENCE FROM N.A.
RC STRAIN=91001 / Biovar Mediaevalis;
RA Song Y., Tong Z., Wang L., Han Y., Zhang J., Pei D., Wang J., Zhou D.,
RA Han Y., Pang X., Zhai J., Chen F., Qin H., Wang J., Li S., Guo Z.,
RA Ye C., Du Z., Lin W., Wang J., Yu J., Yang H., Wang J., Huang P.,
RA Yang R.;
RL Submitted (APR-2003) to the EMBL/GenBank/DBJ databases.
CC -!- FUNCTION: Conversion of NADPH, generated by peripheral catabolic
pathways, to NADH, which can enter the respiratory chain for

energy generation (By similarity).
 CC -|- CATALYTIC ACTIVITY: NADPH + NAD(+) = NADP(+) + NADH.
 CC -|- COFACTOR: Binds 1 FAD per subunit (By similarity).
 CC -|- SUBCELLULAR LOCATION: Cytoplasmic (By similarity).
 CC -|- SIMILARITY: Belongs to the class-I pyridine nucleotide-disulfide
 CC oxidoreductase family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----

EMBL; AJ414159; CAC93380.1; -.
 DR EMBL; AE013631; AM83912.1; ALT_INIT.
 DR EMBL; AE017139; AAS63304.1; -.
 DR PIR; AH0476; AH0476.
 DR HSP; P18925; 3LAD.
 DR HAMAP; MF 00247; -. 1.
 DR InterPro; IPR000759; Adrndx_reductase.
 DR InterPro; IPR001327; FAD_pyr_redox.
 DR InterPro; IPR000815; Hg_reductase.
 DR InterPro; IPR000205; NAD_BS.
 DR InterPro; IPR001100; Pyr_redox.
 DR InterPro; IPR004099; Pyr_redox_dim.
 DR Pfam; PF00070; Pyr_redox; 1.
 DR Pfam; PF02852; Pyr_redox_dim; 1.
 DR PRINTS; PR00419; ADXRDTASE.
 DR PRINTS; PR00368; FADPNR.
 DR PRINTS; PR00945; HGRDTASE.
 DR PRINTS; PR00411; PNDRDTASE1.
 DR ProDom; PD000139; FAD_pyr_redox; 1.
 KW Complete proteome; FAD; Flavoprotein; NAD; NADP; Oxidoreductase.
 FT NP_BIND 36 45 FAD (ADP part) (By similarity).
 SQ SEQUENCE 466 AA; 51382 MW; D6CD965D6CF3E2CE CRC64;

STHA YERPE Length: 466 February 4, 2005 13:17 Type: P Check: 8 ..
 Found using 'seq3' (mohamed337.key)

...

79 IKSPADILNHADRVINQOTRMQGFYDRNHCMSGDASFIDANTVNVRYADGTSDTLQ
 129

139 ADNVIATGSRPYRPVNVDPNHERIYVDSITLQISHEPQHVIYIGAGVIGCEYASIFR
 146

...

-- Search Statistics --

Times:	CPU	Total Elapsed
	00:00:00.01	00:00:00.00
Number of sequences searched:		42
Number of sequence hits:		42
Number of separate matches:		42
Number of sequence hits saved:		0

> O <
 O | |o IntelliGenetics
 > O <
 Quest - Quick User-directed Expression Search Tool
 Release 5.4
 -- Outline of search "seq4_ags" --
 Selected search type is key against sequence data banks or files.
 Selected scope is Sequence.
 Selected sequence key from "mohamed337.key":
 seq4 (AA) ID seq4 AA preliminary pattern
 followed by
 1 h or r or y
 2 s or g or a or t
 2 a or d or e
 2 g
 2 a or t
 2 any character
 2 t or s
 2 a or s or t
 2 d or e
 2 any character
 2 a or s
 2 a or k
 2 a or q
 2 any character
 2 a or e
 2 a or e
 2 a
 2 a or v
 2 a or r
 2 a or l
 2 any character
 2 a or e or d
 2 any character
 2 a or l
 2 a or k
 2 a or n

Selected files:
 File : seq4ags.pep

-- Output Parameters --
 File Options:
 Nucleic acid code matching Exact
 Find non-matching hits only No
 Report key used Yes
 Note position of hit Yes
 Display full annotations Yes
 Sequence context 50

-- Run Parameters --
 Run mode Batch
 Time to start comparison now
 Notify at end of run No

1 match found in sequence:
 aab07484 ; Amino acid sequence of an extendin-4 fragment.
 (from "seq4ags.pep")
 TOIG of: aab07484 check: 4889 from: 1 to: 30

ID AAB07484 standard; peptide; 30 AA.
 XX
 AC AAB07484;

XX 20-OCT-2000 (first entry)
 XX Amino acid sequence of an extendin-4 fragment.
 XX Extendin-4; Gila monster lizard; Mexican Beaded lizard; extendin;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX Heloderma suspectum.
 OS Synthetic.
 XX Key Location/Qualifiers
 FT Modified-site 30
 FT note= "optionally amidated"
 XX WO200041548-A2.
 XX 20-JUL-2000.
 XX 14-JAN-2000; 2000WO-US000942.
 XX 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Young A, Gedulin B;
 XX WPI; 2000-490999/43.
 XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX Disclosure; Page 12; 96pp; English.
 XX The present sequence represents an extendin-4 peptide. Extendins are
 CC found in the salivary glands of the Gila monster and Mexican Beaded
 CC lizard, and have sequence similarity to glucagon-like peptides. It is
 CC used in the method of the invention. The specification describes a method
 CC for lowering plasma glucagon, comprising administering an extendin, an
 CC extendin agonist, a modified extendin or a modified extendin agonist. These
 CC compounds lower plasma glucagon level. The method is useful for lowering
 CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
 CC erythema or glucagonoma. The method is also useful for treating
 CC hyperglucagonemia and other conditions that would benefit from reduced
 CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes
 XX Sequence 30 AA;
 AAB07484 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEFTFTSLSKQMBEEAVRLFIEWLKNGG
 1 28

 1 match found in sequence:
 aab07485 ; Amino acid sequence of an extendin-4 fragment.
 (from "seq4ags.pep")
 TOIG of: aab07485 check: 700 from: 1 to: 28
 ID AAB07485 standard; peptide; 28 AA.
 XX
 AC AAB07485;
 XX
 XX 20-OCT-2000 (first entry)
 DT
 XX Amino acid sequence of an extendin-4 fragment.
 DE

```

XX  Extentin-4; Gila monster lizard; Mexican Beaded lizard; exendin;
KW  glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW  hyperglucagonemia; diabetes.
XX
XX  Heloderma suspectum.
OS  Synthetic.
XX
XX  Key          Location/Qualifiers
FH  Modified-site 28
FT  /note= "optionally amidated"
XX
XX  WO200041548-A2.
XX
XX  20-JUL-2000.
XX
XX  14-JAN-2000; 2000WO-US000942.
XX
XX  14-JAN-1999; 99US-0116380P.
PR  30-APR-1999; 99US-0132017P.
PR  10-JAN-2000; 2000US-0175365P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Young A, Gedulin B;
XX
XX  WPI; 2000-490999/43.
XX
XX  Lowering plasma glucagon using exendin, an exendin agonist, a modified
PT  exendin or a modified exendin agonist, useful for treating
PT  hyperglucagonemia and diabetes.
XX
XX  Disclosure; Page 12; 96pp; English.
XX
XX  The present sequence represents an extendin-4 peptide. Extensins are
CC  found in the salivary glands of the Gila monster and Mexican Beaded
CC  lizard, and have sequence similarity to glucagon-like peptides. It is
CC  used in the method of the invention. The specification describes a method
CC  for lowering plasma glucagon, comprising administering an exendin, an
CC  exendin agonist, a modified exendin or a modified exendin agonist. These
CC  compounds lower plasma glucagon level. The method is useful for lowering
CC  plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC  erythema or glucagonoma. The method is also useful for treating
CC  hyperglucagonemia and other conditions that would benefit from reduced
CC  glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC  diabetes
XX
XX  Sequence 28 AA;
SQ
AAB07485 Length: 28 February 4, 2005 13:20 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)

1  HGGGFTSDLSKQWEREAVRLFIEWLKN
    1 28
-----
1 match found in sequence:
aab07486 ; Amino acid sequence of an extendin-4 fragment.
(from "seq4ags.pep")
TOIG of: aab07486 check: 9131 from: 1 to: 39

ID  AAB07486 standard; peptide; 39 AA.
XX
XX  AAB07486;
AC
XX
XX  20-OCT-2000 (first entry)
DT
XX
XX  Amino acid sequence of an extendin-4 fragment.
DE
XX
XX  Extentin-4; Gila monster lizard; Mexican Beaded lizard; exendin;
KW  glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW  hyperglucagonemia; diabetes.
XX

```

```

XX  Heloderma suspectum.
OS  Synthetic.
XX
XX  Key          Location/Qualifiers
FH  Modified-site 39
FT  /note= "optionally amidated"
XX
XX  WO200041548-A2.
XX
XX  20-JUL-2000.
XX
XX  14-JAN-2000; 2000WO-US000942.
XX
XX  14-JAN-1999; 99US-0116380P.
PR  30-APR-1999; 99US-0132017P.
PR  10-JAN-2000; 2000US-0175365P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Young A, Gedulin B;
XX
XX  WPI; 2000-490999/43.
XX
XX  Lowering plasma glucagon using exendin, an exendin agonist, a modified
PT  exendin or a modified exendin agonist, useful for treating
PT  hyperglucagonemia and diabetes.
XX
XX  Disclosure; Page 12; 96pp; English.
XX
XX  The present sequence represents an extendin-4 peptide. Extensins are
CC  found in the salivary glands of the Gila monster and Mexican Beaded
CC  lizard, and have sequence similarity to glucagon-like peptides. It is
CC  used in the method of the invention. The specification describes a method
CC  for lowering plasma glucagon, comprising administering an exendin, an
CC  exendin agonist, a modified exendin or a modified exendin agonist. These
CC  compounds lower plasma glucagon level. The method is useful for lowering
CC  plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC  erythema or glucagonoma. The method is also useful for treating
CC  hyperglucagonemia and other conditions that would benefit from reduced
CC  glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC  diabetes
XX
XX  Sequence 39 AA;
SQ
AAB07486 Length: 39 February 4, 2005 13:20 Type: P Check: 9131 ..
Found using 'seq4' (mohamed337.key)

1  HGGGFTSDLSKQLEEEAVRLFIEFLKNGGSSGAPPS
    1 28
-----
1 match found in sequence:
aab07487 ; Amino acid sequence of an extendin-4 fragment.
(from "seq4ags.pep")
TOIG of: aab07487 check: 261 from: 1 to: 28

ID  AAB07487 standard; peptide; 28 AA.
XX
XX  AAB07487;
AC
XX
XX  20-OCT-2000 (first entry)
DT
XX
XX  Amino acid sequence of an extendin-4 fragment.
DE
XX
XX  Extentin-4; Gila monster lizard; Mexican Beaded lizard; exendin;
KW  glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW  hyperglucagonemia; diabetes.
XX
XX  Heloderma suspectum.
OS  Synthetic.
XX

```

```

FH Key      Location/Qualifiers
FT Modified-site 28
XX      /note= "optionally amidated"
XX
XX WO200041548-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000942.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 30-APR-1999; 99US-0132017P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, Gedulin B;
XX
XX DR WPI; 2000-490999/43.
XX
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX PT extendin or a modified extendin agonist, useful for treating
XX PT hyperglucagonemia and diabetes.
XX
XX PS Disclosure; Page 12; 96pp; English.
XX
XX CC The present sequence represents an extendin-4 peptide. Extendins are
XX CC found in the salivary glands of the Gila monster and Mexican Beaded
XX CC lizard, and have sequence similarity to glucagon-like peptides. It is
XX CC used in the method of the invention. The specification describes a method
XX CC for lowering plasma glucagon, comprising administering an extendin, an
XX CC extendin agonist, a modified extendin or a modified extendin agonist. These
XX CC compounds lower plasma glucagon level. The method is useful for lowering
XX CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX CC erythema or glucagonoma. The method is also useful for treating
XX CC hyperglucagonemia and other conditions that would benefit from reduced
XX CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX CC diabetes
XX
XX SQ Sequence 28 AA;
XX
AAB07487 Length: 28 February 4, 2005 13:20 Type: P Check: 261 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEFTSLSKQLEEAVALRFLFKN 28
  |
-----
1 match found in sequence:
aab07488 ; Amino acid sequence of an extendin-4 fragment.
(from "seq4ags.pep")
TOIG of: aab07488 check: 151 from: 1 to: 28

-----
ID AAB07488 standard; peptide; 28 AA.
XX
XX AC AAB07488;
XX
XX DT 20-OCT-2000 (first entry)
XX
XX DE Amino acid sequence of an extendin-4 fragment.
XX
XX KW Extendin-4; Gila monster lizard; Mexican Beaded lizard; extendin;
XX KW Glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX KW hyperglucagonemia; diabetes.
XX
XX OS Heloderma suspectum.
XX
XX OS Synthetic.
XX
XX FH Key      Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "optionally amidated"
XX
```

```

PN WO200041548-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000942.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 30-APR-1999; 99US-0132017P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, Gedulin B;
XX
XX DR WPI; 2000-490999/43.
XX
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX PT extendin or a modified extendin agonist, useful for treating
XX PT hyperglucagonemia and diabetes.
XX
XX PS Disclosure; Page 12; 96pp; English.
XX
XX CC The present sequence represents an extendin-4 peptide. Extendins are
XX CC found in the salivary glands of the Gila monster and Mexican Beaded
XX CC lizard, and have sequence similarity to glucagon-like peptides. It is
XX CC used in the method of the invention. The specification describes a method
XX CC for lowering plasma glucagon, comprising administering an extendin, an
XX CC extendin agonist, a modified extendin or a modified extendin agonist. These
XX CC compounds lower plasma glucagon level. The method is useful for lowering
XX CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX CC erythema or glucagonoma. The method is also useful for treating
XX CC hyperglucagonemia and other conditions that would benefit from reduced
XX CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX CC diabetes
XX
XX SQ Sequence 28 AA;
XX
AAB07488 Length: 28 February 4, 2005 13:20 Type: P Check: 151 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEFTSLSKQLEEAVALRFLFKN 28
  |
-----
1 match found in sequence:
aab11126 ; extendin agonist SEQ ID NO 6.
(from "seq4ags.pep")
TOIG of: aab11126 check: 4889 from: 1 to: 30

-----
ID AAB11126 standard; peptide; 30 AA.
XX
XX AC AAB11126;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist SEQ ID NO 6.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
```

XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Disclosure; Page 25; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders
CC which would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 30 AA;
AAB11126 Length: 30 February 4, 2005 13:19 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEEEAVRLFIEWLKNGG 28

1 match found in sequence:
aab11127; exendin agonist SEQ ID NO 7.
(from "seq4ags.pep")
TOIG of: aab11127 check: 4889 from: 1 to: 30
ID AAB11127 standard; peptide; 30 AA.
XX
AC AAB11127;
XX
XX 20-FEB-2001 (first entry)
DT
DE exendin agonist SEQ ID NO 7.
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
XX WO200041546-A2.
PN
XX
PD 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
PF
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Disclosure; Page 25; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders
CC which would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake

CC which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
SQ Sequence 30 AA;
AAB11127 Length: 30 February 4, 2005 13:19 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEEEAVRLFIEWLKNGG 28

1 match found in sequence:
aab11128; exendin agonist SEQ ID NO 40.
(from "seq4ags.pep")
TOIG of: aab11128 check: 700 from: 1 to: 28
ID AAB11128 standard; peptide; 28 AA.
XX
AC AAB11128;
XX
XX 20-FEB-2001 (first entry)
DT
DE exendin agonist SEQ ID NO 40.
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
XX WO200041546-A2.
PN
XX
PD 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
PF
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Disclosure; Page 25; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders
CC which would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;
AAB11128 Length: 28 February 4, 2005 13:19 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEEEAVRLFIEWLKNGG 28

1 match found in sequence:
aab11129; exendin agonist SEQ ID NO 9.
(from "seq4ags.pep")

```

TOIG of: aab1129 check: 9131 from: 1 to: 39
ID AAB1129 standard; peptide; 39 AA.
AC AAB11129;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist SEQ ID NO 9.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Disclosure; Page 26; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB1130 Length: 28 February 4, 2005 13:19 Type: P Check: 261 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQLEEAVALFIEFLKN 28
1 -----|
1 HGEFTSLSKQLEEAVALFIEFLKN 28
1 -----|
1 match found in sequence:
1 aab1131 ; extendin agonist SEQ ID NO 8.
1 (from "seq4ags.pep")
1 TOIG of: aab1131 check: 151 from: 1 to: 28
ID AAB1131 standard; peptide; 28 AA.
XX
XX AC AAB11131;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist SEQ ID NO 8.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX OS WO200041546-A2.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX PI WPI; 2000-514584/46.
XX
XX DR DR
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 14; Page 25-26; 281pp; English.
XX
XX PS This invention describes a novel formulation (I) comprising an extendin or
XX PS extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX PS has a pH of 3-7. The products of the invention have antidiabetic
XX PS activity. The extendin or extendin agonist is used to increase the
XX PS sensitivity of a subject to insulin to treat diabetes and disorders which
XX PS would benefit from agents which lower plasma glucose levels and disorders
XX PS which would benefit from agents that delay and/or slow gastric emptying
XX PS or reducing food intake
XX
XX SQ Sequence 39 AA;
XX
AAB1129 Length: 39 February 4, 2005 13:19 Type: P Check: 9131 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQLEEAVALFIEFLKNGPSSGAPPPS 28
1 -----|
1 HGEFTSLSKQLEEAVALFIEFLKNGPSSGAPPPS 28
1 -----|
1 match found in sequence:
1 aab1130 ; extendin agonist SEQ ID NO 41.
1 (from "seq4ags.pep")
1 TOIG of: aab1130 check: 261 from: 1 to: 28
ID AAB1130 standard; peptide; 28 AA.
XX
XX AC AAB11130;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist SEQ ID NO 41.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX OS WO200041546-A2.
XX
XX PN

```

XX PS Disclosure; Page 26; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX CC
XX SQ Sequence 28 AA;

AAB11131 Length: 28 February 4, 2005 13:19 Type: P Check: 151 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIETLKN 28
1

1 match found in sequence:
aabl1134; extendin agonist peptide SEQ ID NO 42.
(from "seq4ags.pep")
TOIG of: aabl1134 check: 249 from: 1 to: 28

ID AAB11134 standard; peptide; 28 AA.
XX
XX AAB11134;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 42.
DE
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX
XX WO200041546-A2.
FN
XX
XX 20-JUL-2000.
PD
XX
XX 14-JAN-2000; 2000WO-US0000902.
PF
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, L'italien JJ, Kolterman O;
PI
XX
XX WPI; 2000-514584/46.
DR
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 49; Page 127; 281pp; English.
PS
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX CC
XX SQ Sequence 28 AA;

AAB11134 Length: 28 February 4, 2005 13:19 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIETLKN 28
1

1 match found in sequence:
aabl1135; extendin agonist peptide SEQ ID NO 43.
(from "seq4ags.pep")
TOIG of: aabl1135 check: 166 from: 1 to: 28

ID AAB11135 standard; peptide; 28 AA.
XX
XX AAB11135;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 43.
DE
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX
XX WO200041546-A2.
FN
XX
XX 20-JUL-2000.
PD
XX
XX 14-JAN-2000; 2000WO-US0000902.
PF
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, L'italien JJ, Kolterman O;
PI
XX
XX WPI; 2000-514584/46.
DR
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 50; Page 128; 281pp; English.
PS
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX CC
XX SQ Sequence 28 AA;

AAB11135 Length: 28 February 4, 2005 13:19 Type: P Check: 166 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIETLKN 28
1

1 match found in sequence:
aabl1136; extendin agonist peptide SEQ ID NO 44.
(from "seq4ags.pep")
TOIG of: aabl1136 check: 231 from: 1 to: 28

ID AAB11136 standard; peptide; 28 AA.
XX
XX AAB11136;
AC
XX
XX 20-FEB-2001 (first entry)
DT

```
XX      exendin agonist peptide SEQ ID NO 44.
DE
XX      Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW      plasma glucose; gastric emptying; food intake.
XX
XX      Synthetic.
OS
XX      WO200041546-A2.
XX
XX      20-JUL-2000.
XX
XX      14-JAN-2000; 2000WO-US000902.
PF
XX
XX      14-JAN-1999; 99US-0116380P.
PR
XX      10-JAN-2000; 2000US-0175365P.
PR
XX      (AMYL-) AMYLIN PHARM INC.
PA
XX      Young A, L'italien JJ, Kolterman O;
PI
XX      WPI; 2000-514584/46.
XX
XX      New formulations comprising an exendin or exendin agonist peptide used
PT      for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX      Example 51; Page 129; 281pp; English.
PS
XX      This invention describes a novel formulation (I) comprising an exendin or
CC      exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC      has a pH of 3-7. The products of the invention have antidiabetic
CC      activity. The exendin or exendin agonist is used to increase the
CC      sensitivity of a subject to insulin to treat diabetes and disorders which
CC      would benefit from agents which lower plasma glucose levels and disorders
CC      which would benefit from agents that delay and/or slow gastric emptying
CC      or reducing food intake
XX
XX      Sequence 28 AA;
SQ
AAB1136 Length: 28 February 4, 2005 13:19 Type: P Check: 231 ..
Found using 'seq4' (mohamed337.key)
1      HEGGTATDLSKQLEEEAVRLFIEFLKN
1      28
-----
1 match found in sequence:
aab1137; exendin agonist peptide SEQ ID NO 45.
(from "seq4ags.pep")
TOIG of: aab1137 check: 117 from: 1 to: 28
-----
ID      AAB11137 standard; peptide; 28 AA.
XX
XX      AAB11137;
AC
XX
XX      20-FEB-2001 (first entry)
DT
XX
XX      exendin agonist peptide SEQ ID NO 45.
DE
XX
XX      Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW      plasma glucose; gastric emptying; food intake.
XX
XX      Synthetic.
OS
XX      WO200041546-A2.
XX
XX      20-JUL-2000.
XX
XX      14-JAN-2000; 2000WO-US000902.
PF
XX
XX      14-JAN-1999; 99US-0116380P.
PR
XX      10-JAN-2000; 2000US-0175365P.
PR
XX      (AMYL-) AMYLIN PHARM INC.
PA
XX      Young A, L'italien JJ, Kolterman O;
PI
XX      WPI; 2000-514584/46.
XX
XX      New formulations comprising an exendin or exendin agonist peptide used
PT      for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX      Example 53; Page 130; 281pp; English.
PS
XX      This invention describes a novel formulation (I) comprising an exendin or
CC      exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC      has a pH of 3-7. The products of the invention have antidiabetic
CC      activity. The exendin or exendin agonist is used to increase the
CC      sensitivity of a subject to insulin to treat diabetes and disorders which
CC      would benefit from agents which lower plasma glucose levels and disorders
CC      which would benefit from agents that delay and/or slow gastric emptying
CC      or reducing food intake
XX
XX      Sequence 28 AA;
SQ
AAB1137 Length: 28 February 4, 2005 13:19 Type: P Check: 117 ..
Found using 'seq4' (mohamed337.key)
1      HEGGTFTADLSKQLEEEAVRLFIEFLKN
1      28
-----
1 match found in sequence:
aab1138; exendin agonist peptide SEQ ID NO 46.
(from "seq4ags.pep")
TOIG of: aab1138 check: 151 from: 1 to: 28
-----
ID      AAB11138 standard; peptide; 28 AA.
XX
XX      AAB11138;
AC
XX
XX      20-FEB-2001 (first entry)
DT
XX
XX      exendin agonist peptide SEQ ID NO 46.
DE
XX
XX      Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW      plasma glucose; gastric emptying; food intake.
XX
XX      Synthetic.
OS
XX      WO200041546-A2.
XX
XX      20-JUL-2000.
XX
XX      14-JAN-2000; 2000WO-US000902.
PF
XX
XX      14-JAN-1999; 99US-0116380P.
PR
XX      10-JAN-2000; 2000US-0175365P.
PR
XX      (AMYL-) AMYLIN PHARM INC.
PA
XX      Young A, L'italien JJ, Kolterman O;
PI
XX      WPI; 2000-514584/46.
XX
XX      New formulations comprising an exendin or exendin agonist peptide used
PT      for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX      Example 53; Page 130; 281pp; English.
PS
XX      This invention describes a novel formulation (I) comprising an exendin or
CC      exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC      has a pH of 3-7. The products of the invention have antidiabetic
CC      activity. The exendin or exendin agonist is used to increase the
CC      sensitivity of a subject to insulin to treat diabetes and disorders which
CC      would benefit from agents which lower plasma glucose levels and disorders
CC      which would benefit from agents that delay and/or slow gastric emptying
CC      or reducing food intake
XX
XX      Sequence 28 AA;
SQ
```

```
XX      (AMYL-) AMYLIN PHARM INC.
PA
XX      Young A, L'italien JJ, Kolterman O;
PI
XX      WPI; 2000-514584/46.
XX
XX      New formulations comprising an exendin or exendin agonist peptide used
PT      for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX      Example 52; Page 130; 281pp; English.
PS
XX      This invention describes a novel formulation (I) comprising an exendin or
CC      exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC      has a pH of 3-7. The products of the invention have antidiabetic
CC      activity. The exendin or exendin agonist is used to increase the
CC      sensitivity of a subject to insulin to treat diabetes and disorders which
CC      would benefit from agents which lower plasma glucose levels and disorders
CC      which would benefit from agents that delay and/or slow gastric emptying
CC      or reducing food intake
XX
XX      Sequence 28 AA;
SQ
AAB1137 Length: 28 February 4, 2005 13:19 Type: P Check: 117 ..
Found using 'seq4' (mohamed337.key)
1      HEGGTFTADLSKQLEEEAVRLFIEFLKN
1      28
-----
1 match found in sequence:
aab1138; exendin agonist peptide SEQ ID NO 46.
(from "seq4ags.pep")
TOIG of: aab1138 check: 151 from: 1 to: 28
-----
ID      AAB11138 standard; peptide; 28 AA.
XX
XX      AAB11138;
AC
XX
XX      20-FEB-2001 (first entry)
DT
XX
XX      exendin agonist peptide SEQ ID NO 46.
DE
XX
XX      Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW      plasma glucose; gastric emptying; food intake.
XX
XX      Synthetic.
OS
XX      WO200041546-A2.
XX
XX      20-JUL-2000.
XX
XX      14-JAN-2000; 2000WO-US000902.
PF
XX
XX      14-JAN-1999; 99US-0116380P.
PR
XX      10-JAN-2000; 2000US-0175365P.
PR
XX      (AMYL-) AMYLIN PHARM INC.
PA
XX      Young A, L'italien JJ, Kolterman O;
PI
XX      WPI; 2000-514584/46.
XX
XX      New formulations comprising an exendin or exendin agonist peptide used
PT      for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX      Example 53; Page 130; 281pp; English.
PS
XX      This invention describes a novel formulation (I) comprising an exendin or
CC      exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC      has a pH of 3-7. The products of the invention have antidiabetic
CC      activity. The exendin or exendin agonist is used to increase the
CC      sensitivity of a subject to insulin to treat diabetes and disorders which
CC      would benefit from agents which lower plasma glucose levels and disorders
CC      which would benefit from agents that delay and/or slow gastric emptying
CC      or reducing food intake
XX
XX      Sequence 28 AA;
SQ
```

CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 28 AA;

AAB11138 Length: 28 February 4, 2005 13:19 Type: P Check: 151 ..
 Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGEFTSDASKOLEEAVRLFIEFLKN 28

 1 match found in sequence:
 aab11139 ; extendin agonist peptide SEQ ID NO 47.
 (from "seq4ags.pep")
 TOIG of: aab11139 check: 63 from: 1 to: 28

ID AAB11139 standard; peptide; 28 AA.

AC AAB11139;

DT 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 47.

EW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

PN WO200041546-A2.

PD 20-JUL-2000.

PF 14-JAN-2000; 2000WO-US000902.

PR 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

PS Example 54; Page 131; 281pp; English.

CC This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 28 AA;

AAB11139 Length: 28 February 4, 2005 13:19 Type: P Check: 63 ..
 Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGEFTSDASKOLEEAVRLFIEFLKN 28

 1 match found in sequence:

aab11140 ; extendin agonist peptide SEQ ID NO 48.
 (from "seq4ags.pep")
 TOIG of: aab11140 check: 141 from: 1 to: 28

ID AAB11140 standard; peptide; 28 AA.

AC AAB11140;

DT 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 48.

EW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

PN WO200041546-A2.

PD 20-JUL-2000.

PF 14-JAN-2000; 2000WO-US000902.

PR 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

PS Example 55; Page 132; 281pp; English.

CC This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 28 AA;

AAB11140 Length: 28 February 4, 2005 13:19 Type: P Check: 141 ..
 Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGEFTSDLSAQLEEEAVRLFIEFLKN 28

 1 match found in sequence:
 aab11141 ; extendin agonist peptide SEQ ID NO 49.
 (from "seq4ags.pep")
 TOIG of: aab11141 check: 53 from: 1 to: 28

ID AAB11141 standard; peptide; 28 AA.

AC AAB11141;

DT 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 49.

EW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

```
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 56; Page 133; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB11141 Length: 28 February 4, 2005 13:19 Type: P Check: 53 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKALEEAVRLFIEFLKN 28
1
-----|
1 match found in sequence:
aabl1142; extendin agonist peptide SEQ ID NO 50.
(from "seq4ags.pep")
TOIG of: aabl1142 check: 107 from: 1 to: 28
ID AAB11142 standard; peptide; 28 AA.
XX
XX AAB11142;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 50.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 57; Page 133-134; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB11142 Length: 28 February 4, 2005 13:19 Type: P Check: 107 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQAEAEAVRLFIEFLKN 28
1
-----|
1 match found in sequence:
aabl1143; extendin agonist peptide SEQ ID NO 51.
(from "seq4ags.pep")
TOIG of: aabl1143 check: 201 from: 1 to: 28
ID AAB11143 standard; peptide; 28 AA.
XX
XX AAB11143;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 51.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 58; Page 134; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 28 AA;
XX
```

```
PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 57; Page 133-134; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB11142 Length: 28 February 4, 2005 13:19 Type: P Check: 107 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQAEAEAVRLFIEFLKN 28
1
-----|
1 match found in sequence:
aabl1143; extendin agonist peptide SEQ ID NO 51.
(from "seq4ags.pep")
TOIG of: aabl1143 check: 201 from: 1 to: 28
ID AAB11143 standard; peptide; 28 AA.
XX
XX AAB11143;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 51.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 58; Page 134; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 28 AA;
XX
```

```

AAB11143 Length: 28 February 4, 2005 13:19 Type: P Check: 201 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEAAVRLFIETFLKN 28
-----
1 match found in sequence:
aabil1144 ; extendin agonist peptide SEQ ID NO 52.
(from "seq4ags.pep")
TOIG of: aabil1144 check: 197 from: 1 to: 28

ID AAB11144 standard; peptide; 28 AA.
XX
AC AAB11144;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 52.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PT 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PS New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
CC Example 60; Page 136; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;

AAB11145 Length: 28 February 4, 2005 13:19 Type: P Check: 193 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEAAVRLFIETFLKN 28
-----
1 match found in sequence:
aabil1146 ; extendin agonist peptide SEQ ID NO 54.
(from "seq4ags.pep")
TOIG of: aabil1146 check: 9862 from: 1 to: 28

ID AAB11146 standard; peptide; 28 AA.
XX
AC AAB11146;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 54.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX

```



```
-----
1 match found in sequence:
aabl1149 ; extendin agonist peptide SEQ ID NO 57.
(from "seq4ags.pep")
TOIG of: aabl1149 check: 165 from: 1 to: 28

ID AAB11149 standard; peptide; 28 AA.
XX
XX AC AAB11149;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 57.
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO2000041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-017536SP.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX DR
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 64; Page 139; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;

AAB11150 Length: 28 February 4, 2005 13:19 Type: P Check: 165 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFSDLKQLBEEAVRLFIAFLKN 28
1
-----
1 match found in sequence:
aabl1150 ; extendin agonist peptide SEQ ID NO 58.
(from "seq4ags.pep")
TOIG of: aabl1150 check: 136 from: 1 to: 28

ID AAB11150 standard; peptide; 28 AA.
XX
XX AC AAB11150;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 58.
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO2000041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-017536SP.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX DR
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 64; Page 139; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;

AAB11149 Length: 28 February 4, 2005 13:19 Type: P Check: 165 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFSDLKQLBEEAVRLFIAFLKN 28
1
-----
1 match found in sequence:
aabl1150 ; extendin agonist peptide SEQ ID NO 59.
(from "seq4ags.pep")
TOIG of: aabl1150 check: 9975 from: 1 to: 28

ID AAB11151 standard; peptide; 28 AA.
XX
XX AC AAB11151;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 59.
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO2000041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-017536SP.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX DR
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 65; Page 140; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;

AAB11150 Length: 28 February 4, 2005 13:19 Type: P Check: 136 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFSDLKQLBEEAVRLFIAFLKN 28
1
-----
1 match found in sequence:
aabl1151 ; extendin agonist peptide SEQ ID NO 59.
(from "seq4ags.pep")
TOIG of: aabl1151 check: 9975 from: 1 to: 28

ID AAB11151 standard; peptide; 28 AA.
XX
XX AC AAB11151;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 59.
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO2000041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-017536SP.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX DR
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 65; Page 140; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;
```

DR WPI; 2000-514584/46.
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 XX Example 66; Page 140; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes, and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 XX Sequence 28 AA;
 AAB11151 Length: 28 February 4, 2005 13:19 Type: P Check: 9975 ..
 Found using 'seq4' (mohamed337.key)
 1 HEGGFTSDLSKQLEEEAVRLFIEFAKN 28
 |-----|
 1 match found in sequence:
 aab11152; extendin agonist peptide SEQ ID NO 60.
 (from "seq4ags.pep")
 TOIG of: aab11152 check: 9991 from: 1 to: 28

 ID AAB11152 standard; peptide; 28 AA.
 XX
 AC AAB11152;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 60.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Synthetic.
 XX
 PN WO2000041546-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US0000902.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, L'italien JJ, Kolterman O;
 XX
 DR WPI; 2000-514584/46.
 XX
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 XX Example 67; Page 141; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX

SQ Sequence 28 AA;
 AAB11152 Length: 28 February 4, 2005 13:19 Type: P Check: 9991 ..
 Found using 'seq4' (mohamed337.key)
 1 HEGGFTSDLSKQLEEEAVRLFIEFLAN 28
 |-----|
 1 match found in sequence:
 aab11153; extendin agonist peptide SEQ ID NO 61.
 (from "seq4ags.pep")
 TOIG of: aab11153 check: 9897 from: 1 to: 28

 ID AAB11153 standard; peptide; 28 AA.
 XX
 AC AAB11153;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 61.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Synthetic.
 XX
 PN WO2000041546-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US0000902.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, L'italien JJ, Kolterman O;
 XX
 DR WPI; 2000-514584/46.
 XX
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 XX Example 68; Page 142; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 XX Sequence 28 AA;
 AAB11153 Length: 28 February 4, 2005 13:19 Type: P Check: 9897 ..
 Found using 'seq4' (mohamed337.key)
 1 HEGGFTSDLSKQLEEEAVRLFIEFLKA 28
 |-----|
 1 match found in sequence:
 aab11154; extendin agonist peptide SEQ ID NO 62.
 (from "seq4ags.pep")
 TOIG of: aab11154 check: 6333 from: 1 to: 38

 ID AAB11154 standard; peptide; 38 AA.

CC This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 37 AA;

AAB11156 Length: 37 February 4, 2005 13:19 Type: P Check: 3293 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTTSLSKQMBEAVRLFIEWLKNGPSSGAPP
 1 28

1 match found in sequence:
 aab11157 ; extendin agonist peptide SEQ ID NO 65.
 (from "seq4ags.pep")
 TOIG of: aab11157 Check: 2854 from: 1 to: 37

ID AAB11157 standard; peptide; 37 AA.

XX
 AC AAB11157;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 65.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Synthetic.

XX WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX
 PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 72; Page 145; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 37 AA;

AAB11157 Length: 37 February 4, 2005 13:19 Type: P Check: 2854 ..

Found using 'seq4' (mohamed337.key)

1 HGEFTTSLSKQMBEAVRLFIEWLKNGPSSGAPP

1 28

1 match found in sequence:
 aab11158 ; extendin agonist peptide SEQ ID NO 66.
 (from "seq4ags.pep")
 TOIG of: aab11158 Check: 333 from: 1 to: 36

ID AAB11158 standard; peptide; 36 AA.

XX
 AC AAB11158;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 66.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX Example 73; Page 146; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 36 AA;

AAB11158 Length: 36 February 4, 2005 13:19 Type: P Check: 333 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTTSLSKQMBEAVRLFIEWLKNGPSSGAPP
 1 28

1 match found in sequence:
 aab11159 ; extendin agonist peptide SEQ ID NO 67.
 (from "seq4ags.pep")
 TOIG of: aab11159 Check: 9894 from: 1 to: 36

ID AAB11159 standard; peptide; 36 AA.

XX
 AC AAB11159;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 67.

XX

KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 XX plasma glucose; gastric emptying; food intake.

OS Synthetic.

PN WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an exendin or exendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 74; Page 146-147; 281pp; English.

CC This invention describes a novel formulation (I) comprising an exendin or
 CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The exendin or exendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 36 AA;

AAB11159 Length: 36 February 4, 2005 13:19 Type: P Check: 9894 ..

Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQLEEAVALRFLFKNGGPPSGAP 28

1 match found in sequence:
 aab11160 ; exendin agonist peptide SEQ ID NO 68.
 (from "seq4ags.pep")
 TOIG of: aab11160 check: 7453 from: 1 to: 35

ID AAB11160 standard; peptide; 35 AA.

XX AC AAB11160;

XX 20-FEB-2001 (first entry)

XX exendin agonist peptide SEQ ID NO 68.

XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

PN WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX

PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an exendin or exendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 75; Page 147; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
 CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The exendin or exendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 35 AA;

AAB11160 Length: 35 February 4, 2005 13:19 Type: P Check: 7453 ..

Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQMEEEAVRLFIEFLKNGGPPSSGA 28

1 match found in sequence:
 aab11161 ; exendin agonist peptide SEQ ID NO 69.
 (from "seq4ags.pep")
 TOIG of: aab11161 check: 7014 from: 1 to: 35

ID AAB11161 standard; peptide; 35 AA.

XX AC AAB11161;

XX 20-FEB-2001 (first entry)

XX exendin agonist peptide SEQ ID NO 69.

XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

PN WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an exendin or exendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 76; Page 148; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
 CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The exendin or exendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying

```

CC or reducing food intake
XX
SQ Sequence 35 AA;

AAB11161 Length: 35 February 4, 2005 13:19 Type: P Check: 7014 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEFTTSDLSKQLEEEAVRLFIEFLKNGPSSG
    28

-----
1 match found in sequence:
aabl1162; extendin agonist peptide SEQ ID NO 70.
(from "seq4ags.pep")
TOIG of: aabl1162 check: 5178 from: 1 to: 34

ID AAB11162 standard; peptide; 34 AA.
XX
AC AAB11162;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 70.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 77; Page 149; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 34 AA;

AAB11162 Length: 34 February 4, 2005 13:19 Type: P Check: 5178 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEFTTSDLSKQLEEEAVRLFIEFLKNGPSSG
    28

-----
1 match found in sequence:
aabl1163; extendin agonist peptide SEQ ID NO 71.
(from "seq4ags.pep")
TOIG of: aabl1163 check: 4739 from: 1 to: 34

ID AAB11163 standard; peptide; 34 AA.
XX
AC AAB11163;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 71.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 78; Page 149-150; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 34 AA;

AAB11163 Length: 34 February 4, 2005 13:19 Type: P Check: 4739 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEFTTSDLSKQLEEEAVRLFIEFLKNGPSSG
    28

-----
1 match found in sequence:
aabl1164; extendin agonist peptide SEQ ID NO 72.
(from "seq4ags.pep")
TOIG of: aabl1164 check: 2764 from: 1 to: 33

ID AAB11164 standard; peptide; 33 AA.
XX
AC AAB11164;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 72.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX

```

PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000902.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, L'italien JJ, Kolterman O;
 PI
 XX WPI; 2000-514584/46.
 DR
 XX
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 PT
 XX
 PS Example 79; Page 150; 281pp; English.
 XX
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 CC
 XX Sequence 33 AA;
 SQ
 AAB11164 Length: 33 February 4, 2005 13:19 Type: P Check: 2764 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEFTPTDLSKQMBEAEVRLFTIEFLKNGGPSS 28
 |-----|
 1 match found in sequence:
 aab11165; extendin agonist peptide SEQ ID NO 73.
 (from "seq4ags.pep")
 TOIG of: aab11165 check: 2325 from: 1 to: 33
 ID AAB11165 standard; peptide; 33 AA.
 XX
 AC AAB11165;
 AC
 XX 20-FEB-2001 (first entry)
 DT
 XX extendin agonist peptide SEQ ID NO 73.
 DE
 XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Synthetic.
 OS
 XX WO2000041546-A2.
 PN
 XX 20-JUL-2000.
 PD
 XX 14-JAN-2000; 2000WO-US000902.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR
 XX 10-JAN-2000; 2000US-0175365P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, L'italien JJ, Kolterman O;
 PI
 XX WPI; 2000-514584/46.
 DR
 XX
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 PT
 XX

PS Example 80; Page 151; 281pp; English.
 XX
 CC This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 CC
 XX Sequence 33 AA;
 SQ
 AAB11165 Length: 33 February 4, 2005 13:19 Type: P Check: 2325 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEFTPTDLSKQMBEAEVRLFTIEFLKNGGPSS 28
 |-----|
 1 match found in sequence:
 aab11166; extendin agonist peptide SEQ ID NO 74.
 (from "seq4ags.pep")
 TOIG of: aab11166 check: 25 from: 1 to: 32
 ID AAB11166 standard; peptide; 32 AA.
 XX
 AC AAB11166;
 AC
 XX 20-FEB-2001 (first entry)
 DT
 XX extendin agonist peptide SEQ ID NO 74.
 DE
 XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Synthetic.
 OS
 XX WO2000041546-A2.
 PN
 XX 20-JUL-2000.
 PD
 XX 14-JAN-2000; 2000WO-US000902.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR
 XX 10-JAN-2000; 2000US-0175365P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, L'italien JJ, Kolterman O;
 PI
 XX WPI; 2000-514584/46.
 DR
 XX
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 PT
 XX
 PS Example 81; Page 152; 281pp; English.
 XX
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 CC
 XX Sequence 32 AA;
 SQ
 AAB11166 Length: 32 February 4, 2005 13:19 Type: P Check: 25 ..
 Found using 'seq4' (mohamed337.key)

```

1 HEGFTSLSKQMEEEAVRLFIEWLKNGGP
  28
-----
1 match found in sequence:
aabl1167 ; extendin agonist peptide SEQ ID NO 75.
(from "seq4ags.pep")
TOIG of: aabl1167 check: 9586 from: 1 to: 32

ID AAB11167 standard; peptide; 32 AA.
XX AC AAB11167;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 75.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
    for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 82; Page 153; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
    extendin agonist peptide, a buffer and an iso-osmolality modifier which
    has a pH of 3-7. The products of the invention have antidiabetic
    activity. The extendin or extendin agonist is used to increase the
    sensitivity of a subject to insulin to treat diabetes and disorders which
    would benefit from agents which lower plasma glucose levels and disorders
    which would benefit from agents that delay and/or slow gastric emptying
    or reducing food intake
XX SQ Sequence 32 AA;

AAB1167 Length: 32 February 4, 2005 13:19 Type: P Check: 9586
Found using 'seq4' (mohamed337.key)

-----
1 HEGFTSLSKQLEEEAVRLFIEFLKNGGPS
  28
-----
1 match found in sequence:
aabl1168 ; extendin agonist peptide SEQ ID NO 76.
(from "seq4ags.pep")
TOIG of: aabl1168 check: 7369 from: 1 to: 31

ID AAB11168 standard; peptide; 31 AA.
XX AC AAB11168;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 76.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
    for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 82; Page 153; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
    extendin agonist peptide, a buffer and an iso-osmolality modifier which
    has a pH of 3-7. The products of the invention have antidiabetic
    activity. The extendin or extendin agonist is used to increase the
    sensitivity of a subject to insulin to treat diabetes and disorders which
    would benefit from agents which lower plasma glucose levels and disorders
    which would benefit from agents that delay and/or slow gastric emptying
    or reducing food intake
XX SQ Sequence 31 AA;

AAB1168 Length: 31 February 4, 2005 13:19 Type: P Check: 7369
Found using 'seq4' (mohamed337.key)

-----
1 HEGFTSLSKQMEEEAVRLFIEWLKNGGP
  28
-----
1 match found in sequence:
aabl1169 ; extendin agonist peptide SEQ ID NO 77.
(from "seq4ags.pep")
TOIG of: aabl1169 check: 6930 from: 1 to: 31

ID AAB11169 standard; peptide; 31 AA.
XX AC AAB11169;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 77.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
    for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 83; Page 153; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
    extendin agonist peptide, a buffer and an iso-osmolality modifier which
    has a pH of 3-7. The products of the invention have antidiabetic
    activity. The extendin or extendin agonist is used to increase the
    sensitivity of a subject to insulin to treat diabetes and disorders which
    would benefit from agents which lower plasma glucose levels and disorders
    which would benefit from agents that delay and/or slow gastric emptying
    or reducing food intake
XX SQ Sequence 31 AA;

AAB1169 Length: 31 February 4, 2005 13:19 Type: P Check: 7369
Found using 'seq4' (mohamed337.key)

-----
1 HEGFTSLSKQMEEEAVRLFIEWLKNGGP
  28
-----
1 match found in sequence:
aabl1169 ; extendin agonist peptide SEQ ID NO 77.
(from "seq4ags.pep")
TOIG of: aabl1169 check: 6930 from: 1 to: 31

ID AAB11169 standard; peptide; 31 AA.
XX AC AAB11169;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 77.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PS New formulations comprising an extendin or extendin agonist peptide used
    for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 83; Page 153; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
    extendin agonist peptide, a buffer and an iso-osmolality modifier which
    has a pH of 3-7. The products of the invention have antidiabetic
    activity. The extendin or extendin agonist is used to increase the
    sensitivity of a subject to insulin to treat diabetes and disorders which
    would benefit from agents which lower plasma glucose levels and disorders
    which would benefit from agents that delay and/or slow gastric emptying
    or reducing food intake
XX SQ Sequence 31 AA;

AAB1169 Length: 31 February 4, 2005 13:19 Type: P Check: 7369
Found using 'seq4' (mohamed337.key)

```

```

PA (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 84; Page 154; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 31 AA;
SQ
AAB11169 Length: 31 February 4, 2005 13:19 Type: P Check: 6930 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGFTFTDLSKQLEEEAVRLFIEFLKNGG 28
-----
1 match found in sequence:
aabl1170 ; extendin agonist peptide SEQ ID NO 78.
(from "seq4ags.pep")
TOIG of: aabl1170 check: 4450 from: 1 to: 30
ID AAB11170 standard; peptide; 30 AA.
XX
XX AC AAB11170;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 78.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US0000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PS New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 85; Page 155; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 29 AA;
SQ
AAB11171 Length: 29 February 4, 2005 13:19 Type: P Check: 2759 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGFTFTDLSKQLEEEAVRLFIEFLKNGG 28
-----
1 match found in sequence:
aabl1172 ; extendin agonist peptide SEQ ID NO 80.

```

```

CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 30 AA;
SQ
AAB11170 Length: 30 February 4, 2005 13:19 Type: P Check: 4450 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGFTFTDLSKQLEEEAVRLFIEFLKNGG 28
-----
1 match found in sequence:
aabl1171 ; extendin agonist peptide SEQ ID NO 79.
(from "seq4ags.pep")
TOIG of: aabl1171 check: 2759 from: 1 to: 29
ID AAB11171 standard; peptide; 29 AA.
XX
XX AC AAB11171;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 79.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US0000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PS New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 86; Page 156; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 29 AA;
SQ
AAB11171 Length: 29 February 4, 2005 13:19 Type: P Check: 2759 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGFTFTDLSKQLEEEAVRLFIEFLKNGG 28
-----
1 match found in sequence:
aabl1172 ; extendin agonist peptide SEQ ID NO 80.

```


PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 89; Page 158; 281pp; English.
XX

CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 38 AA;

AAB11174 Length: 38 February 4, 2005 13:19 Type: P Check: 6333 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMEEBAVRLFIEWLKNGKGGSSGAPP
28

1 match found in sequence:
aabl1175; extendin agonist peptide SEQ ID NO 83.
(from "seq4ags.pep")
TOIG of: aabl1175 check: 3541 from: 1 to: 37

ID AAB11175 standard; peptide; 37 AA.

XX AC AAB11175;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 83.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 90; Page 159; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake

XX SQ Sequence 37 AA;

AAB11175 Length: 37 February 4, 2005 13:19 Type: P Check: 3541 ..

Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMEEBAVRLFIEWLKNGKGGSSGAPP
28

1 match found in sequence:
aabl1176; extendin agonist peptide SEQ ID NO 84.
(from "seq4ags.pep")
TOIG of: aabl1176 check: 4125 from: 1 to: 37

ID AAB11176 standard; peptide; 37 AA.

XX AC AAB11176;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 84.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 91; Page 160; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake

XX SQ Sequence 37 AA;

AAB11176 Length: 37 February 4, 2005 13:19 Type: P Check: 4125 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMEEBAVRLFIEWLKNGKGGSSGAPP
28

1 match found in sequence:
aabl1177; extendin agonist peptide SEQ ID NO 85.
(from "seq4ags.pep")
TOIG of: aabl1177 check: 3293 from: 1 to: 37

ID AAB11177 standard; peptide; 37 AA.

XX AC AAB11177;

XX

DT 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 85.
DE
XX
KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 92; Page 160; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 37 AA;
AAB11177 Length: 37 February 4, 2005 13:19 Type: P Check: 3293 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMEEEAVRLFIEWLKNGPSSGAPP
1 28

1 match found in sequence:
aab11178 ; extendin agonist peptide SEQ ID NO 86.
(from "seq4ags.pep")
TOIG of: aab11178 check: 333 from: 1 to: 36
ID AAB11178 standard; peptide; 36 AA.
XX
XX AAB11178;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
DE extendin agonist peptide SEQ ID NO 86.
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 92; Page 160; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 37 AA;
AAB11177 Length: 37 February 4, 2005 13:19 Type: P Check: 3293 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMEEEAVRLFIEWLKNGPSSGAPP
1 28

1 match found in sequence:
aab11178 ; extendin agonist peptide SEQ ID NO 86.
(from "seq4ags.pep")
TOIG of: aab11178 check: 333 from: 1 to: 36
ID AAB11178 standard; peptide; 36 AA.
XX
XX AAB11178;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
DE extendin agonist peptide SEQ ID NO 86.
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 94; Page 162; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic

PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 93; Page 161; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
SQ Sequence 36 AA;
AAB11178 Length: 36 February 4, 2005 13:19 Type: P Check: 333 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMEEEAVRLFIEWLKNGPSSGAPP
1 28

1 match found in sequence:
aab11179 ; extendin agonist peptide SEQ ID NO 87.
(from "seq4ags.pep")
TOIG of: aab11179 check: 7463 from: 1 to: 35
ID AAB11179 standard; peptide; 35 AA.
XX
XX AAB11179;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
DE extendin agonist peptide SEQ ID NO 87.
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
XX WO200041546-A2.
PN
XX
XX 20-JUL-2000.
PD
XX
XX 14-JAN-2000; 2000WO-US000902.
PF
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 94; Page 162; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic

CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 35 AA;

AAB11179 Length: 35 February 4, 2005 13:19 Type: P Check: 7463 ..
Found using 'seq4' (mohamed337.key)

1 RGEFTFTDLSKQMEEEAVRLFIEWLKNGPSSGA
28

1 match found in sequence:
aabl1180 ; extendin agonist peptide SEQ ID NO 88.
(from "seq4ags.pep")
TOIG of: aabl1180 check: 4886 from: 1 to: 30

ID AAB11180 standard; peptide; 30 AA.

XX AC AAB11180;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 88.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 95; Page 163; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake

XX SQ Sequence 30 AA;

AAB11180 Length: 30 February 4, 2005 13:19 Type: P Check: 4886 ..
Found using 'seq4' (mohamed337.key)

1 HGDGFTDLSKQMEEEAVRLFIEWLKNGG
28

1 match found in sequence:
aabl1181 ; extendin agonist peptide SEQ ID NO 89.
(from "seq4ags.pep")
TOIG of: aabl1181 check: 231 from: 1 to: 28

ID AAB11181 standard; peptide; 28 AA.

XX AC AAB11181;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 89.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 96; Page 163-164; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake

XX SQ Sequence 28 AA;

AAB11181 Length: 28 February 4, 2005 13:19 Type: P Check: 231 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTATDLSKQLEEEAVRLFIEFLKN
28

1 match found in sequence:
aabl1182 ; extendin agonist peptide SEQ ID NO 90.
(from "seq4ags.pep")
TOIG of: aabl1182 check: 693 from: 1 to: 28

ID AAB11182 standard; peptide; 28 AA.

XX AC AAB11182;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 90.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

OS Synthetic.
XX WO200041546-A2.
XX
XX
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX
XX
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 97; Page 164; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;
XX
XX AAB11182 Length: 28 February 4, 2005 13:19 Type: P Check: 693 ..
XX Found using 'seq4' (mohamed337.key)
XX
XX 1 |-----|
XX 1 HGEFTFSDLSKQMEEAVALFIEWLKN 28
XX
XX -----
XX 1 match found in sequence:
XX aab11183; exendin agonist peptide SEQ ID NO 91.
XX (from "seq4ags.pep")
XX TOIG of: aab11183 check: 701 from: 1 to: 28
XX
XX ID AAB11183 standard; peptide; 28 AA.
XX
XX AC AAB11183;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE exendin agonist peptide SEQ ID NO 91.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX
XX
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 97; Page 164; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;
XX
XX AAB11182 Length: 28 February 4, 2005 13:19 Type: P Check: 693 ..
XX Found using 'seq4' (mohamed337.key)
XX
XX 1 |-----|
XX 1 HGEFTFSDLSKQMEEAVALFIEWLKN 28
XX
XX -----
XX 1 match found in sequence:
XX aab11183; exendin agonist peptide SEQ ID NO 91.
XX (from "seq4ags.pep")
XX TOIG of: aab11183 check: 701 from: 1 to: 28
XX
XX ID AAB11183 standard; peptide; 28 AA.
XX
XX AC AAB11183;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE exendin agonist peptide SEQ ID NO 91.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX
XX
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 97; Page 164; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;
XX
XX AAB11183 Length: 28 February 4, 2005 13:19 Type: P Check: 701 ..
XX Found using 'seq4' (mohamed337.key)
XX
XX 1 |-----|
XX 1 HGEFTFSDLSKQMEEAVALFIEWLKN 28
XX
XX -----
XX 1 match found in sequence:
XX aab11184; exendin agonist peptide SEQ ID NO 92.
XX (from "seq4ags.pep")
XX TOIG of: aab11184 check: 649 from: 1 to: 28
XX
XX ID AAB11184 standard; peptide; 28 AA.
XX
XX AC AAB11184;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE exendin agonist peptide SEQ ID NO 92.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX
XX
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 99; Page 166; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;
XX

XX New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 98; Page 165; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;
XX
XX AAB11183 Length: 28 February 4, 2005 13:19 Type: P Check: 701 ..
XX Found using 'seq4' (mohamed337.key)
XX
XX 1 |-----|
XX 1 HGEFTFSDLSKQMEEAVALFIEWLKN 28
XX
XX -----
XX 1 match found in sequence:
XX aab11184; exendin agonist peptide SEQ ID NO 92.
XX (from "seq4ags.pep")
XX TOIG of: aab11184 check: 649 from: 1 to: 28
XX
XX ID AAB11184 standard; peptide; 28 AA.
XX
XX AC AAB11184;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE exendin agonist peptide SEQ ID NO 92.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX
XX
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 99; Page 166; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 28 AA;
XX

```

AAB11184 Length: 28 February 4, 2005 13:19 Type: P Check: 649
Found using 'seq4' (mohamed337.key)

1 HGGGFTTSELKQWAEAEVRLFIETFLKN 28
1 -----|
1 match found in sequence:
aabl1185 ; extendin agonist peptide SEQ ID NO 93.
(from "seq4ags.pep")
TOIG of: aabl1185 check: 211 from: 1 to: 28

ID AAB11185 standard; peptide; 28 AA.
XX
AC AAB11185;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 93.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 100; Page 167; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
SQ Sequence 28 AA;

AAB11186 Length: 28 February 4, 2005 13:19 Type: P Check: 151
Found using 'seq4' (mohamed337.key)

1 HGGGFTTSDLSKQLEEEAVRLAIEFLKN 28
1 -----|
1 match found in sequence:
aabl1187 ; extendin agonist peptide SEQ ID NO 95.
(from "seq4ags.pep")
TOIG of: aabl1187 check: 654 from: 1 to: 28

ID AAB11187 standard; peptide; 28 AA.
XX
AC AAB11187;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 95.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 101; Page 167; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
SQ Sequence 28 AA;

AAB11186 Length: 28 February 4, 2005 13:19 Type: P Check: 151
Found using 'seq4' (mohamed337.key)

1 HGGGFTTSDLSKQLEEEAVRLAIEFLKN 28
1 -----|
1 match found in sequence:
aabl1187 ; extendin agonist peptide SEQ ID NO 95.
(from "seq4ags.pep")
TOIG of: aabl1187 check: 654 from: 1 to: 28

ID AAB11187 standard; peptide; 28 AA.
XX
AC AAB11187;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 95.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 100; Page 167; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
SQ Sequence 28 AA;

AAB11185 Length: 28 February 4, 2005 13:19 Type: P Check: 211
Found using 'seq4' (mohamed337.key)

1 HGGGFTTSDGSKQLEEEAVRLFIETFLKN 28
1 -----|
1 match found in sequence:
aabl1186 ; extendin agonist peptide SEQ ID NO 94.
(from "seq4ags.pep")
TOIG of: aabl1186 check: 151 from: 1 to: 28

ID AAB11186 standard; peptide; 28 AA.
XX

```

1 match found in sequence:
aabl1190 ; extendin agonist peptide SEQ ID NO 98.
(from "seq4ags.pep")
TOIG of: aabl1190 check: 2649 from: 1 to: 29

ID AAB11190 standard; peptide; 29 AA.

XX AC AAB11190;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 98.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 105; Page 170; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders
CC which would benefit from agents which lower plasma glucose levels and disorders
CC or reducing food intake

XX SQ Sequence 29 AA;

AAB11190 Length: 29 February 4, 2005 13:19 Type: P Check: 2649 ..

Found using 'seq4' (mohamed337.key)

1 HEGGFTSDASKQMBEEAVRLFIEWLKNG
1 28

1 match found in sequence:
aabl1191 ; extendin agonist peptide SEQ ID NO 99.
(from "seq4ags.pep")
TOIG of: aabl1191 check: 3183 from: 1 to: 37

ID AAB11191 standard; peptide; 37 AA.

XX AC AAB11191;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 99.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;

KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 106; Page 171; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders
CC which would benefit from agents which lower plasma glucose levels and disorders
CC or reducing food intake

XX SQ Sequence 37 AA;

AAB11191 Length: 37 February 4, 2005 13:19 Type: P Check: 3183 ..

Found using 'seq4' (mohamed337.key)

1 HEGGFTSDASKQMBEEAVRLFIEWLKNGPSSGAPP
1 28

1 match found in sequence:
aabl1193 ; extendin agonist peptide SEQ ID NO 101.
(from "seq4ags.pep")
TOIG of: aabl1193 check: 249 from: 1 to: 28

ID AAB11193 standard; peptide; 28 AA.

XX AC AAB11193;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 101.

XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 110; Page 175; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB1193 Length: 28 February 4, 2005 13:19 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGAGTFTSDLSKQMEEEAVRLFIWLN 28

1 match found in sequence:
aabl1197 ; extendin agonist peptide SEQ ID NO 105.
(from "seq4ags.pep")
TOIG of: aabl1197 check: 688 from: 1 to: 28
ID AAB11197 standard; peptide; 28 AA.
XX
XX AC AAB11197;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 105.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 114; Page 178; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake

XX Sequence 28 AA;
SQ
AAB1197 Length: 28 February 4, 2005 13:19 Type: P Check: 688 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGAGTFTSDLSKQMEEEAVRLFIWLN 28

1 match found in sequence:
aabl1200 ; extendin agonist peptide SEQ ID NO 108.
(from "seq4ags.pep")
TOIG of: aabl1200 check: 590 from: 1 to: 28
ID AAB11200 standard; peptide; 28 AA.
XX
XX AC AAB11200;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 108.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 117; Page 180; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
SQ
AAB11200 Length: 28 February 4, 2005 13:19 Type: P Check: 590 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEGTFTSDASKQMEEEAVRLFIWLN 28

1 match found in sequence:
aabl1260 ; extendin agonist peptide SEQ ID NO 168.
(from "seq4ags.pep")
TOIG of: aabl1260 check: 5882 from: 1 to: 38

ID AAB11260 standard; peptide; 38 AA.
XX AC
XX AAB11260;
XX DT
XX 20-FEB-2001 (first entry)
XX DE
XX exendin agonist peptide SEQ ID NO 168.
XX KW
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX OS
XX Synthetic.
XX PN
XX WO200041546-A2.
XX PD
XX 20-JUL-2000.
XX PF
XX 14-JAN-2000; 2000WO-US000902.
XX PR
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PA
XX (AMYL-) AMYLIN PHARM INC.
XX PI
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX DR
XX New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS
XX Example 177; Page 226-227; 281pp; English.
XX CC
XX This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX SQ
XX Sequence 38 AA;
AAB11260 Length: 38 February 4, 2005 13:19 Type: P Check: 5882 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTSDLSKQLEEEAVRLFIEFLKNGPSSGAPPP
28

1 match found in sequence:
aabl1265 ; exendin agonist peptide SEQ ID NO 173.
(from "seq4ags.pep")
TOIG of: aabl1265 check: 7002 from: 1 to: 35
ID AAB11265 standard; peptide; 35 AA.
XX AC
XX AAB11265;
XX DT
XX 20-FEB-2001 (first entry)
XX DE
XX exendin agonist peptide SEQ ID NO 173.
XX KW
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX OS
XX Synthetic.
XX PN
XX WO200041546-A2.
XX PD
XX 20-JUL-2000.
XX PF
XX 14-JAN-2000; 2000WO-US000902.
XX PR
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PA
XX (AMYL-) AMYLIN PHARM INC.
XX PI
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX DR
XX New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS
XX Example 186; Page 233; 281pp; English.

XX 14-JAN-2000; 2000WO-US000902.
XX PF
XX AAB11260;
XX PR
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PA
XX (AMYL-) AMYLIN PHARM INC.
XX PI
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX DR
XX New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS
XX Example 182; Page 230; 281pp; English.
XX CC
XX This invention describes a novel formulation (I) comprising an exendin or
XX exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The exendin or exendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX SQ
XX Sequence 35 AA;
AAB11265 Length: 35 February 4, 2005 13:19 Type: P Check: 7002 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTSDLSKQLEEEAVRLFIEFLKNGPSSGA
28

1 match found in sequence:
aabl1269 ; exendin agonist peptide SEQ ID NO 177.
(from "seq4ags.pep")
TOIG of: aabl1269 check: 9574 from: 1 to: 32
ID AAB11269 standard; peptide; 32 AA.
XX AC
XX AAB11269;
XX DT
XX 20-FEB-2001 (first entry)
XX DE
XX exendin agonist peptide SEQ ID NO 177.
XX KW
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX OS
XX Synthetic.
XX PN
XX WO200041546-A2.
XX PD
XX 20-JUL-2000.
XX PF
XX 14-JAN-2000; 2000WO-US000902.
XX PR
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PA
XX (AMYL-) AMYLIN PHARM INC.
XX PI
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX DR
XX New formulations comprising an exendin or exendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS
XX Example 186; Page 233; 281pp; English.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX Heloderma horridum.
OS WO200041546-A2.
PN 20-JUL-2000.
XX 14-JAN-2000; 2000WO-US000902.
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
PA Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
DR New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 1; Fig 1; 28lpp; English.
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX Sequence 39 AA;
SQ AAB11281 Length: 39 February 4, 2005 13:19 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)
1 HSGGTFTSLSKQMBEEAVRLFIEWLKNKGPPSGAPPPS
28

1 match found in sequence:
aabl1282; H. suspectum extendin 4 peptide SEQ ID NO 2.
(from "seq4ags.pep")
TOIG of: aabl1282 check: 9570 from: 1 to: 39
ID AAB11282 standard; peptide; 39 AA.
XX AAB11282;
AC 20-FEB-2001 (first entry)
XX H. suspectum extendin 4 peptide SEQ ID NO 2.
DE Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX Heloderma suspectum.
OS WO200041546-A2.
PN 20-JUL-2000.
XX 14-JAN-2000; 2000WO-US000902.
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
PA

XX Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
DR New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 2; Fig 2; 28lpp; English.
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX Sequence 39 AA;
SQ AAB11282 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HSGGTFTSLSKQMBEEAVRLFIEWLKNKGPPSGAPPPS
28

1 match found in sequence:
aabl1284; extendin agonist peptide SEQ ID NO 10.
(from "seq4ags.pep")
TOIG of: aabl1284 check: 9556 from: 1 to: 39
ID AAB11284 standard; peptide; 39 AA.
XX AAB11284;
AC 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 10.
DE Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX Synthetic.
OS WO200041546-A2.
PN 20-JUL-2000.
XX 14-JAN-2000; 2000WO-US000902.
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
PA Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
DR New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX Example 15; Fig 15; 28lpp; English.
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders

CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 39 AA;

AAB11284 Length: 39 February 4, 2005 13:19 Type: P Check: 9556 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTSLSKQMEEAARLFIWLNKGPPSGAPPPS
 1 28

 1 match found in sequence:
 aab11285 ; extendin agonist peptide SEQ ID NO 11.
 (from "seq4ags.pep")
 TOIG of: aab11285 Check: 9145 from: 1 to: 39

ID AAB11285 standard; peptide; 39 AA.

XX AAB11285;

AC AAB11285;

DT 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 11.

KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

XX WO200041546-A2.

XX 20-JUL-2000.

PF 14-JAN-2000; 2000WO-US000902.

PR 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 16; Fig 15; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 39 AA;

AAB11285 Length: 39 February 4, 2005 13:19 Type: P Check: 9145 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTSLSKQMEEAARLFIWLNKGPPSGAPPPS
 1 28

 1 match found in sequence:
 aab11286 ; extendin agonist peptide SEQ ID NO 12.
 (from "seq4ags.pep")

TOIG of: aab11286 . check: 9587 from: 1 to: 39

ID AAB11286 standard; peptide; 39 AA.

XX AAB11286;

DT 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 12.

KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

XX WO200041546-A2.

XX 20-JUL-2000.

PF 14-JAN-2000; 2000WO-US000902.

PR 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 17; Fig 15; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 39 AA;

AAB11286 Length: 39 February 4, 2005 13:19 Type: P Check: 9587 ..
 Found using 'seq4' (mohamed337.key)

1 YGEGFTSLSKQMEEAARLFIWLNKGPPSGAPPPS
 1 28

 1 match found in sequence:
 aab11287 ; extendin agonist peptide SEQ ID NO 13.
 (from "seq4ags.pep")
 TOIG of: aab11287 check: 9804 from: 1 to: 39

ID AAB11287 standard; peptide; 39 AA.

XX AAB11287;

DT 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 13.

KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

XX WO200041546-A2.


```

1 1 -----|
  HGEGTSDLSKQMEEEAVRLFIEWLKGPGSSGAPPPS
  28
-----
1 match found in sequence:
aabl1290 ; extendin agonist peptide SEQ ID NO 16.
(from "seq4ags.pep")
TOIG of: aabl1290 check: 9563 from: 1 to: 39

ID AAB11290 standard; peptide; 39 AA.
XX
AC AAB11290;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 16.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 21; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11291 Length: 39 February 4, 2005 13:19 Type: P Check: 9563 ..
Found using 'seq4' (mohamed337.key)

1 1 -----|
  HGEGTSDLSKQMEEEAVRLFIEWLKGPGSSGAPPPS
  28
-----
1 match found in sequence:
aabl1291 ; extendin agonist peptide SEQ ID NO 17.
(from "seq4ags.pep")
TOIG of: aabl1291 check: 9571 from: 1 to: 39

ID AAB11291 standard; peptide; 39 AA.
XX
AC AAB11291;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 17.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 21; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11290 Length: 39 February 4, 2005 13:19 Type: P Check: 9563 ..
Found using 'seq4' (mohamed337.key)

1 1 -----|
  HGEGTSDLSKQMEEEAVRLFIEWLKGPGSSGAPPPS
  28
-----
1 match found in sequence:
aabl1290 ; extendin agonist peptide SEQ ID NO 16.
(from "seq4ags.pep")
TOIG of: aabl1290 check: 9563 from: 1 to: 39

ID AAB11290 standard; peptide; 39 AA.
XX
AC AAB11290;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 16.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 21; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11291 Length: 39 February 4, 2005 13:19 Type: P Check: 9571 ..
Found using 'seq4' (mohamed337.key)

1 1 -----|
  HGEGTSDLSKQMEEEAVRLFIEWLKGPGSSGAPPPS
  28
-----
1 match found in sequence:
aabl1291 ; extendin agonist peptide SEQ ID NO 17.
(from "seq4ags.pep")
TOIG of: aabl1291 check: 9571 from: 1 to: 39

ID AAB11291 standard; peptide; 39 AA.
XX
AC AAB11291;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 17.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.

```

```

XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 23; Fig 15; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX
XX SQ Sequence 39 AA;
XX
AAB11292 Length: 39 February 4, 2005 13:19 Type: P Check: 9578 ..
Found using 'seq4' (mohamed337.key)
1 HEGTFTTDLKQMEEEAVRLFIEWLKNKGPPSGAPPPS
1 28
-----
1 match found in sequence:
aabl1293; exendin agonist peptide SEQ ID NO 19.
(from "seq4ags.pep")
TOIG of: aabl1293 check: 9579 from: 1 to: 39
ID AAB11293 standard; peptide; 39 AA.
XX AC AAB11293;
XX DT 20-FEB-2001 (first entry)
XX DE exendin agonist peptide SEQ ID NO 19.
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US0000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX PI WPI; 2000-514584/46.
XX DR New formulations comprising an exendin or exendin agonist peptide used
XX DR for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 24; Fig 15; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the

```

```

CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX SQ Sequence 39 AA;
XX
AAB11293 Length: 39 February 4, 2005 13:19 Type: P Check: 9579 ..
Found using 'seq4' (mohamed337.key)
1 HEGTFTTDLKQMEEEAVRLFIEWLKNKGPPSGAPPPS
1 28
-----
1 match found in sequence:
aabl1294; exendin agonist peptide SEQ ID NO 20.
(from "seq4ags.pep")
TOIG of: aabl1294 check: 9520 from: 1 to: 39
ID AAB11294 standard; peptide; 39 AA.
XX AC AAB11294;
XX DT 20-FEB-2001 (first entry)
XX DE exendin agonist peptide SEQ ID NO 20.
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US0000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX PI WPI; 2000-514584/46.
XX DR New formulations comprising an exendin or exendin agonist peptide used
XX DR for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 25; Fig 15; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX
XX SQ Sequence 39 AA;
XX
AAB11294 Length: 39 February 4, 2005 13:19 Type: P Check: 9520 ..
Found using 'seq4' (mohamed337.key)
1 HEGTFTTDLKQMEEEAVRLFIEWLKNKGPPSGAPPPS
1 28
-----
1 match found in sequence:

```

```

aabl1295 ; extendin agonist peptide SEQ ID NO 21.
  (from "seqtags.pep")
  TOIG of: aabl1295 check: 9081 from: 1 to: 39

ID AABL1295 standard; peptide; 39 AA.
XX
AC AABL1295;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 21.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 27; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AABL1296 Length: 39 February 4, 2005 13:19 Type: P Check: 9486 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQEEBAVRLEFLKNGGPGSGAPPPS
  1 28
  |-----|
  1 match found in sequence:
  aabl1297 ; extendin agonist peptide SEQ ID NO 23.
  (from "seqtags.pep")
  TOIG of: aabl1297 check: 9061 from: 1 to: 39

ID AABL1297 standard; peptide; 39 AA.
XX
AC AABL1297;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 23.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
WPI; 2000-514584/46.
XX

```

PT New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

PS Example 28; Fig 15; 28lpp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 39 AA;

AAB11297 Length: 39 February 4, 2005 13:19 Type: P Check: 9061 ..
 Found using 'seq4' (mohamed337.key)

```

1  |-----|
  1 HGGFTSLSKQEEAEVRLFEFLKNGGPPSSGAPPPS
    28

```

 1 match found in sequence:
 aab11299 ; extendin agonist peptide SEQ ID NO 25.
 (from "seq4ags.pep")
 TOIG of: aab11299 check: 9869 from: 1 to: 39

ID AAB11299 standard; peptide; 39 AA.

XX AC AAB11299;

XX DT 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 25.

XX Extendin, agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

PS Example 30; Fig 15; 28lpp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 39 AA;

AAB11299 Length: 39 February 4, 2005 13:19 Type: P Check: 9869 ..
 Found using 'seq4' (mohamed337.key)

```

1  |-----|
  1 HGGFTSLSKQEEAEVRLFEFLKNGGPPSSGAPPPS
    28

```

 1 match found in sequence:
 aab11300 ; extendin agonist peptide SEQ ID NO 26.
 (from "seq4ags.pep")
 TOIG of: aab11300 check: 9430 from: 1 to: 39

ID AAB11300 standard; peptide; 39 AA.

XX AC AAB11300;

XX DT 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 26.

XX Extendin, agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 31; Fig 15; 28lpp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 39 AA;

AAB11300 Length: 39 February 4, 2005 13:19 Type: P Check: 9430 ..
 Found using 'seq4' (mohamed337.key)

```

1  |-----|
  1 HGGFTSLSKQEEAEVRLFEFLKNGGPPSSGAPPPS
    28

```

 1 match found in sequence:
 aab11301 ; extendin agonist peptide SEQ ID NO 27.
 (from "seq4ags.pep")
 TOIG of: aab11301 check: 9915 from: 1 to: 39

ID AAB11301 standard; peptide; 39 AA.

XX AC AAB11301;

CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11303 Length: 39 February 4, 2005 13:19 Type: P Check: 9546 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSLSKQMEEEAVRLFIDWLKNGGPPSGAPPPS
28

1 match found in sequence:
aabl1304 ; extendin agonist peptide SEQ ID NO 30.
(from "seq4ags.pep")
TOIG of: aabl1304 check: 9145 from: 1 to: 39

ID AAB11304 standard; peptide; 39 AA.

XX AC AAB11304;
XX AC
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 30.
XX EX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.

XX PN WO200041546-A2.
XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 35; Fig 15; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake

XX SQ Sequence 39 AA;

AAB11304 Length: 39 February 4, 2005 13:19 Type: P Check: 9145 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSLSKQMEEEAVRLFIEFLKNGGPPSGAPPPS
28

1 match found in sequence:
aabl1305 ; extendin agonist peptide SEQ ID NO 31.
(from "seq4ags.pep")
TOIG of: aabl1305 check: 9570 from: 1 to: 39

1 match found in sequence:
aabl1305 ; extendin agonist peptide SEQ ID NO 31.
(from "seq4ags.pep")
TOIG of: aabl1305 check: 9570 from: 1 to: 39

ID AAB11305 standard; peptide; 39 AA.

XX AC AAB11305;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 31.

XX EX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 36; Fig 15; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake

XX SQ Sequence 39 AA;

AAB11305 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSLSKQMEEEAVRLFIEFLKNGGPPSGAPPPS
28

1 match found in sequence:
aabl1306 ; extendin agonist peptide SEQ ID NO 32.
(from "seq4ags.pep")
TOIG of: aabl1306 check: 9570 from: 1 to: 39

ID AAB11306 standard; peptide; 39 AA.

XX AC AAB11306;

XX DT 20-FEB-2001 (first entry)

XX DE extendin agonist peptide SEQ ID NO 32.

XX EX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 37; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;
AAB11306 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMEEAVALFIEWLKNGPSSGAPPPS
28

1 match found in sequence:
aabl1307; extendin agonist peptide SEQ ID NO 33.
(from "seq4ags.pep")
TOIG of: aabl1307 check: 9570 from: 1 to: 39
ID AAB11307 standard; peptide; 39 AA.
XX AC AAB11307;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 33.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 37; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;
AAB11307 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMEEAVALFIEWLKNGPSSGAPPPS
28

1 match found in sequence:
aabl1307; extendin agonist peptide SEQ ID NO 33.
(from "seq4ags.pep")
TOIG of: aabl1307 check: 9570 from: 1 to: 39
ID AAB11307 standard; peptide; 39 AA.
XX AC AAB11307;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 33.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 37; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;
AAB11307 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMEEAVALFIEWLKNGPSSGAPPPS
28

1 match found in sequence:
aabl1307; extendin agonist peptide SEQ ID NO 33.
(from "seq4ags.pep")
TOIG of: aabl1307 check: 9570 from: 1 to: 39
ID AAB11307 standard; peptide; 39 AA.
XX AC AAB11307;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 33.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 37; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;
AAB11307 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMEEAVALFIEWLKNGPSSGAPPPS
28

1 match found in sequence:
aabl1307; extendin agonist peptide SEQ ID NO 34.
(from "seq4ags.pep")
TOIG of: aabl1308 check: 9570 from: 1 to: 39
ID AAB11308 standard; peptide; 39 AA.
XX AC AAB11308;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 34.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 39; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;

DR WPI; 2000-514584/46.
XX New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 38; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;
AAB11307 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMEEAVALFIEWLKNGPSSGAPPPS
28

1 match found in sequence:
aabl1308; extendin agonist peptide SEQ ID NO 34.
(from "seq4ags.pep")
TOIG of: aabl1308 check: 9570 from: 1 to: 39
ID AAB11308 standard; peptide; 39 AA.
XX AC AAB11308;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 34.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX DR WPI; 2000-514584/46.
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 39; Fig 15; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX SQ Sequence 39 AA;


```

PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 42; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11311 Length: 39 February 4, 2005 13:19 Type: P Check: 7440 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTPTSDLSKQMBEEAVRLFIEWLKNGSGSSGAAAS
  1 28
-----
1 match found in sequence:
aabl1312 ; extendin agonist peptide SEQ ID NO 38.
(from "seq4ags.pep")
TOIG of: aabl1312 check: 7905 from: 1 to: 39

ID AAB11312 standard; peptide; 39 AA.
XX
AC AAB11312;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 38.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 43; Fig 15; 281pp; English.
XX

```

```

CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11312 Length: 39 February 4, 2005 13:19 Type: P Check: 7905 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTPTSDLSKQMBEEAVRLFIEWLKNGSGSSGAAAS
  1 28
-----
1 match found in sequence:
aabl1313 ; extendin agonist peptide SEQ ID NO 39.
(from "seq4ags.pep")
TOIG of: aabl1313 check: 7001 from: 1 to: 39

ID AAB11313 standard; peptide; 39 AA.
XX
AC AAB11313;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 39.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 44; Fig 15; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 39 AA;

AAB11313 Length: 39 February 4, 2005 13:19 Type: P Check: 7001 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTPTSDLSKQMBEEAVRLFIEWLKNGSGSSGAAAS
  1 28
-----

```

```

1
-----
1 match found in sequence:
aab36419 ; Gila monster venom extendin 3 peptide SEQ ID NO:7.
(from "seq4ags.pep")
TOIG of: aab36419 check: 9591 from: 1 to: 39

ID AAB36419 standard; peptide; 39 AA.
XX
AC AAB36419;
XX
DT 28-FEB-2001 (first entry)
XX
DE Gila monster venom extendin 3 peptide SEQ ID NO:7.
XX
KW Glucagon-like peptide-1; GLP-1; GLP-2; vasotrophic; cerebroprotective;
KW brain tissue injury; reperfusion; blood flow; ischaemia; acute stroke;
KW metabolic intervention; haemorrhage; tissue damage; medical procedure;
KW surgical; insulin; hyperglycaemia; hypoglycaemia; brain anabolism;
KW euglycaemia.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT /note= "amidated"
XX
PN WO200066142-A2.
XX
PD 09-NOV-2000.
XX
PF 01-MAY-2000; 2000WO-US011652.
XX
PR 30-APR-1999; 99US-00303016.
XX
PA (BION-) BIONEERASKA INC.
XX
PI Coolidge TR, Ehlers MRW;
XX
DR WPI; 2001-015911/02.
XX
PT A method for amelioration of brain tissue injury comprises administering
PT a composition including a compound which binds to a receptor for glucagon
PT -like peptide-1.
XX
PS Disclosure; Page 8; 19pp; English.
XX
CC The present invention describes a method for the amelioration of brain
CC tissue injury caused by reperfusion of blood flow comprising
CC administering a composition including a compound which binds to a
CC receptor for glucagon-like peptide-1 (GLP-1), in a pharmaceutical
CC carrier. The method is used for amelioration of brain tissue injury
CC caused by reperfusion of blood flow following a period of ischaemia. GLP-
CC 1 is used for metabolic intervention to improve the function of ischaemic
CC and reperused brain cells. It treats patients after an acute stroke or
CC haemorrhage and tissue damage arising from a medical procedure that is a
CC surgical event causing ischaemia of brain tissue or a medical procedure
CC involving a reperfusion event. GLP-1 is an ideal alternative to insulin
CC for the treatment of stroke as it stimulates endogenous insulin secretion
CC in the presence of normo- to hyperglycaemia but not during hypoglycaemia,
CC thus protecting against the development of severe hypoglycaemia. The
CC treatment optimises insulin secretion, increases brain anabolism,
CC enhancing insulin effectiveness by suppressing glucagon and maintains
CC euglycaemia or mild hypoglycaemia with no risk of severe hypoglycaemia.
CC The present sequence represents a Gila monster venom peptide which is
CC homologous to GLP-1, and is given in the exemplification of the present
CC invention
XX
SQ Sequence 39 AA;

1
-----
1 match found in sequence:
aab36421 ; Gila monster venom extendin 4 peptide SEQ ID NO:9.
(from "seq4ags.pep")
TOIG of: aab36421 check: 9570 from: 1 to: 39

ID AAB36421 standard; peptide; 39 AA.
XX
AC AAB36421;
XX
DT 28-FEB-2001 (first entry)
XX
DE Gila monster venom extendin 4 peptide SEQ ID NO:9.
XX
KW Glucagon-like peptide-1; GLP-1; GLP-2; vasotrophic; cerebroprotective;
KW brain tissue injury; reperfusion; blood flow; ischaemia; acute stroke;
KW metabolic intervention; haemorrhage; tissue damage; medical procedure;
KW surgical; insulin; hyperglycaemia; hypoglycaemia; brain anabolism;
KW euglycaemia.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT /note= "amidated"
XX
PN WO200066142-A2.
XX
PD 09-NOV-2000.
XX
PF 01-MAY-2000; 2000WO-US011652.
XX
PR 30-APR-1999; 99US-00303016.
XX
PA (BION-) BIONEERASKA INC.
XX
PI Coolidge TR, Ehlers MRW;
XX
DR WPI; 2001-015911/02.
XX
PT A method for amelioration of brain tissue injury comprises administering
PT a composition including a compound which binds to a receptor for glucagon
PT -like peptide-1.
XX
PS Disclosure; Page 8; 19pp; English.
XX
CC The present invention describes a method for the amelioration of brain
CC tissue injury caused by reperfusion of blood flow comprising
CC administering a composition including a compound which binds to a
CC receptor for glucagon-like peptide-1 (GLP-1), in a pharmaceutical
CC carrier. The method is used for amelioration of brain tissue injury
CC caused by reperfusion of blood flow following a period of ischaemia. GLP-
CC 1 is used for metabolic intervention to improve the function of ischaemic
CC and reperused brain cells. It treats patients after an acute stroke or
CC haemorrhage and tissue damage arising from a medical procedure that is a
CC surgical event causing ischaemia of brain tissue or a medical procedure
CC involving a reperfusion event. GLP-1 is an ideal alternative to insulin
CC for the treatment of stroke as it stimulates endogenous insulin secretion
CC in the presence of normo- to hyperglycaemia but not during hypoglycaemia,
CC thus protecting against the development of severe hypoglycaemia. The
CC treatment optimises insulin secretion, increases brain anabolism,
CC enhancing insulin effectiveness by suppressing glucagon and maintains
CC euglycaemia or mild hypoglycaemia with no risk of severe hypoglycaemia.
CC The present sequence represents a Gila monster venom peptide which is
CC homologous to GLP-1, and is given in the exemplification of the present
CC invention
XX
SQ Sequence 39 AA;

```

AAB36421 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HSGTFTSDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
1 28

1 match found in sequence:
aab36432 ; Gila monster venom exendin 3 peptide SEQ ID NO:7.
(from "seq4ags pep")
TOIG of: aab36432 check: 9591 from: 1 to: 39

ID AAB36432 standard; peptide; 39 AA.
XX
AC AAB36432;
XX
DT 28-FEB-2001 (first entry)
XX
DE Gila monster venom exendin 3 peptide SEQ ID NO:7.

XX Glucagon-like peptide-1; GLP-1; GLP-2; metabolic intervention; ischaemia;
KW reperfusion; surgical procedure; cardiac surgical procedure;
KW organ transplant; traumatic limb amputation; limb reattachment;
KW ischaemic reperfusion; gut infarct; myocardial infarct.

XX Heloderma suspectum.

OS Key Location/Qualifiers
FH Modified-site 39
FT /note= "amidated"

XX WO200066138-A2.
XX
XX 09-NOV-2000.

XX 27-APR-2000; 2000WO-US011251.
XX
XX 30-APR-1999; 99US-00302596.

XX (BION-) BIONEERASKA INC.

XX Coolidge TR, Ehlers MRW;

XX WPI; 2001-040881/05.

XX Metabolic intervention with GLP-1 improves function of ischemic and
PT reperfused tissue.

XX Disclosure; Page 13; 22pp; English.

XX The present invention describes metabolic intervention with GLP-1 which
XX improves the function of ischaemic and reperfused tissue. The method for
XX amelioration of organ tissue caused by reperfusion of blood flow
XX following a period of ischaemia comprises administering a composition
XX including a compound which binds to a receptor for glucagon-like peptide-
XX 1 (GLP-1), in a carrier. Also described are: (1) a method of metabolic
XX intervention with GLP-1 to improve the function of ischaemic and
XX reperfused tissue, the method comprising administering a composition
XX comprising GLP-1 in a carrier; and (2) a composition for use in the
XX metabolic intervention with GLP-1 as above. The method is useful after
XX surgical procedures selected from cardiac surgical procedures, organ
XX transplants, traumatic limb amputation and reattachment, a ischaemic
XX reperfusion event concurrent with gut infarct and myocardial infarct and
XX improves the function of ischaemic and reperfused tissues. The method is
XX devoid of side effects associated with current procedures. Antigenic and
XX immune stimulating properties are not adversely affected. The present
XX sequence represents a Gila monster venom peptide which is homologous to
XX GLP-1, and is given in the exemplification of the present invention

XX Sequence 39 AA;

AAB36432 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
1 28

1 match found in sequence:
aab36434 ; Gila monster venom exendin 4 peptide SEQ ID NO:9.
(from "seq4ags pep")
TOIG of: aab36434 check: 9570 from: 1 to: 39

ID AAB36434 standard; peptide; 39 AA.
XX
AC AAB36434;
XX
DT 28-FEB-2001 (first entry)
XX
DE Gila monster venom exendin 4 peptide SEQ ID NO:9.

XX Glucagon-like peptide-1; GLP-1; GLP-2; metabolic intervention; ischaemia;
KW reperfusion; surgical procedure; cardiac surgical procedure;
KW organ transplant; traumatic limb amputation; limb reattachment;
KW ischaemic reperfusion; gut infarct; myocardial infarct.

XX Heloderma suspectum.

OS Key Location/Qualifiers
FH Modified-site 39
FT /note= "amidated"

XX WO200066138-A2.

XX 09-NOV-2000.

XX 27-APR-2000; 2000WO-US011251.

XX 30-APR-1999; 99US-00302596.

XX (BION-) BIONEERASKA INC.

XX Coolidge TR, Ehlers MRW;

XX WPI; 2001-040881/05.

XX Metabolic intervention with GLP-1 improves function of ischemic and
PT reperfused tissue.

XX Disclosure; Page 13; 22pp; English.

XX The present invention describes metabolic intervention with GLP-1 which
XX improves the function of ischaemic and reperfused tissue. The method for
XX amelioration of organ tissue caused by reperfusion of blood flow
XX following a period of ischaemia comprises administering a composition
XX including a compound which binds to a receptor for glucagon-like peptide-
XX 1 (GLP-1), in a carrier. Also described are: (1) a method of metabolic
XX intervention with GLP-1 to improve the function of ischaemic and
XX reperfused tissue, the method comprising administering a composition
XX comprising GLP-1 in a carrier; and (2) a composition for use in the
XX metabolic intervention with GLP-1 as above. The method is useful after
XX surgical procedures selected from cardiac surgical procedures, organ
XX transplants, traumatic limb amputation and reattachment, a ischaemic
XX reperfusion event concurrent with gut infarct and myocardial infarct and
XX improves the function of ischaemic and reperfused tissues. The method is
XX devoid of side effects associated with current procedures. Antigenic and
XX immune stimulating properties are not adversely affected. The present
XX sequence represents a Gila monster venom peptide which is homologous to
XX GLP-1, and is given in the exemplification of the present invention

XX Sequence 39 AA;

AAB36434 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..

Found using 'seq4' (mohamed337.key)

1 HSGTFTSLSKQMEEEAVRLFIEWLKNGGSSGAPPPS
1
-----|
28

1 match found in sequence:
aab48800 ; Exendin-3, SEQ ID NO:11.
(from "seq4ags.pep")
TOIG of: aab48800 check: 9591 from: 1 to: 39

ID AAB48800 standard; peptide; 39 AA.

XX AAB48800;

DT 09-MAR-2001 (first entry)

DE Exendin-3, SEQ ID NO:11.

XX Insulinotropic peptide; insulin production; GLP-1 derivative;
KW glucagon-like peptide 1; exendin derivative; reactive group;
KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
KW insulin resistance; nervous system disorder; sedative; anxiolytic;
KW antidiabetic; neuroprotective; tranquiliser; anticonvulsant.

XX Unidentified.

XX WO200069911-A1.

XX 23-NOV-2000.

XX 17-MAY-2000; 2000WO-US013563.

XX 17-MAY-1999; 99US-0134406P.

XX 15-OCT-1999; 99US-0159783P.

XX (CONJ-) CONJUCHEM INC.

XX Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;

XX St Pierre S;

XX WPI; 2001-025008/03.

XX Novel modified insulinotropic peptides for treating diabetes, nervous

XX system disorders and for post surgery treatment, has reactive groups

XX which react with amino, hydroxy or thiol groups on blood components.

XX Claim 4; Page 88-89; 96pp; English.

XX The invention relates to modified insulinotropic peptides (ITPs), or
XX derivatives thereof which comprise a reactive group which reacts with
XX amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
XX serum albumin) to form a stable covalent bond. The insulinotropic
XX peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
XX -1) or exendin and contain a reactive group such as a maleimido group or
XX a succinimidyl group. The peptides of the invention act by stimulating
XX the synthesis or expression of insulin. A composition comprising a
XX peptide of the invention is useful for treating diabetes, particularly
XX type II (maturity onset) diabetes. It is also useful as a sedative; for
XX the treatment of nervous system disorders including anxiety, psychosis,
XX seizures, panic attacks, hysteria and sleep disorders; to induce an
XX anxiolytic effect on the central nervous system (CNS); to activate the
XX CNS for the treatment of disorders such as depression, memory loss and
XX narcolepsy; and as a treatment for insulin resistance, particularly that
XX which occurs after certain types of surgery. The conjugation of a peptide
XX of the invention to a blood component via the reactive group provides
XX increased stability in the presence of peptidases. The peptides of the
XX invention therefore have a longer in vivo half-life as they are less
XX susceptible to proteolytic degradation. The present sequence represents
XX an insulinotropic peptide of the invention

XX Sequence 39 AA;

AAB48800 Length: 39 February 4, 2005 13:19 Type: P Check: 9591

Found using 'seq4' (mohamed337.key)

1 HSDGFTSLSKQMEEEAVRLFIEWLKNGGSSGAPPPS
1
-----|
28

1 match found in sequence:
aab48801 ; Exendin-4, SEQ ID NO:12.
(from "seq4ags.pep")
TOIG of: aab48801 check: 9570 from: 1 to: 39

ID AAB48801 standard; peptide; 39 AA.

XX AAB48801;

DT 09-MAR-2001 (first entry)

DE Exendin-4, SEQ ID NO:12.

XX Insulinotropic peptide; insulin production; GLP-1 derivative;
KW glucagon-like peptide 1; exendin derivative; reactive group;
KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
KW insulin resistance; nervous system disorder; sedative; anxiolytic;
KW antidiabetic; neuroprotective; tranquiliser; anticonvulsant.

XX Unidentified.

XX WO200069911-A1.

XX 23-NOV-2000.

XX 17-MAY-2000; 2000WO-US013563.

XX 17-MAY-1999; 99US-0134406P.

XX 15-OCT-1999; 99US-0159783P.

XX (CONJ-) CONJUCHEM INC.

XX Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;

XX St Pierre S;

XX WPI; 2001-025008/03.

XX Novel modified insulinotropic peptides for treating diabetes, nervous

XX system disorders and for post surgery treatment, has reactive groups

XX which react with amino, hydroxy or thiol groups on blood components.

XX Claim 4; Page 89; 96pp; English.

XX The invention relates to modified insulinotropic peptides (ITPs), or
XX derivatives thereof which comprise a reactive group which reacts with
XX amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
XX serum albumin) to form a stable covalent bond. The insulinotropic
XX peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
XX -1) or exendin and contain a reactive group such as a maleimido group or
XX a succinimidyl group. The peptides of the invention act by stimulating
XX the synthesis or expression of insulin. A composition comprising a
XX peptide of the invention is useful for treating diabetes, particularly
XX type II (maturity onset) diabetes. It is also useful as a sedative; for
XX the treatment of nervous system disorders including anxiety, psychosis,
XX seizures, panic attacks, hysteria and sleep disorders; to induce an
XX anxiolytic effect on the central nervous system (CNS); to activate the
XX CNS for the treatment of disorders such as depression, memory loss and
XX narcolepsy; and as a treatment for insulin resistance, particularly that
XX which occurs after certain types of surgery. The conjugation of a peptide
XX of the invention to a blood component via the reactive group provides
XX increased stability in the presence of peptidases. The peptides of the
XX invention therefore have a longer in vivo half-life as they are less
XX susceptible to proteolytic degradation. The present sequence represents
XX an insulinotropic peptide referred to in the disclosure of the invention

XX Sequence 39 AA;
 AAB48801 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)

1 HEGTFTDLSKQMBEEAVRLFIEWLKNGPSSGAPPPS
 1 28

 1 match found in sequence:
 aab48803 ; Exendin-4(1-30)Tyr31, SEQ ID NO:14.
 (from "seq4ags.pep")
 TOIG of: aab48803 check: 7648 from: 1 to: 31

ID AAB48803 standard; peptide; 31 AA.
 XX AAB48803;
 AC AAB48807;
 XX 09-MAR-2001 (first entry)
 DT 09-MAR-2001 (first entry)
 DE Exendin-4(1-30)Tyr31, SEQ ID NO:14.
 XX Insulinotropic peptide; insulin production; GLP-1 derivative;
 KW glucagon-like peptide 1; exendin derivative; reactive group;
 KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
 KW insulin resistance; nervous system disorder; sedative; anxiolytic;
 KW antidiabetic; neuroprotective; tranquilliser; anticonvulsant.
 XX Synthetic.
 OS WO200069911-A1.
 XX 23-NOV-2000.
 PD 17-MAY-2000; 2000WO-US013563.
 PF 17-MAY-1999; 99US-0134406P.
 PR 15-OCT-1999; 99US-0159783P.
 XX (CONJ-) CONJUCHEM INC.
 PA Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
 PI St Pierre S;
 PI WPI; 2001-025008/03.
 DR Novel modified insulinotropic peptides for treating diabetes, nervous
 PT system disorders and for post surgery treatment, has reactive groups
 PT which react with amino, hydroxy or thiol groups on blood components.
 XX Claim 4; Page 90; 96pp; English.

The invention relates to modified insulinotropic peptides (ITPs), or
 CC derivatives thereof which comprise a reactive group which reacts with
 CC amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
 CC serum albumin) to form a stable covalent bond. The insulinotropic
 CC peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
 CC -1) or exendin and contain a reactive group such as a maleimido group or
 CC a succinimidyl group. The peptides of the invention act by stimulating
 CC the synthesis or expression of insulin. A composition comprising a
 CC peptide of the invention is useful for treating diabetes, particularly
 CC type II (maturity onset) diabetes. It is also useful as a sedative; for
 CC the treatment of nervous system disorders including anxiety, psychosis,
 CC seizures, panic attacks, hysteria and sleep disorders; to induce an
 CC anxiolytic effect on the central nervous system (CNS); to activate the
 CC CNS for the treatment of disorders such as depression, memory loss and
 CC narcolepsy; and as a treatment for insulin resistance, particularly that
 CC which occurs after certain types of surgery. The conjugation of a peptide
 CC of the invention to a blood component via the reactive group provides
 CC increased stability in the presence of peptidases. The peptides of the
 CC invention therefore have a longer in vivo half-life as they are less

CC susceptible to proteolytic degradation. The present sequence represents
 CC an insulinotropic peptide of the invention

XX Sequence 31 AA;
 AAB48803 Length: 31 February 4, 2005 13:19 Type: P Check: 7648 ..
 Found using 'seq4' (mohamed337.key)

1 HEGTFTDLSKQMBEEAVRLFIEWLKNGG
 1 28

 1 match found in sequence:
 aab48807 ; Exendin-derived insulinotropic peptide, SEQ ID NO:18.
 (from "seq4ags.pep")
 TOIG of: aab48807 check: 2570 from: 1 to: 40

ID AAB48807 standard; peptide; 40 AA.
 XX AAB48807;
 AC AAB48807;
 XX 09-MAR-2001 (first entry)
 DT 09-MAR-2001 (first entry)
 DE Exendin-derived insulinotropic peptide, SEQ ID NO:18.
 XX Insulinotropic peptide; insulin production; GLP-1 derivative;
 KW glucagon-like peptide 1; exendin derivative; reactive group;
 KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
 KW insulin resistance; nervous system disorder; sedative; anxiolytic;
 KW antidiabetic; neuroprotective; tranquilliser; anticonvulsant.
 XX Synthetic.
 OS WO200069911-A1.
 XX 23-NOV-2000.
 PD 17-MAY-2000; 2000WO-US013563.
 PF 17-MAY-1999; 99US-0134406P.
 PR 15-OCT-1999; 99US-0159783P.
 XX (CONJ-) CONJUCHEM INC.
 PA Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
 PI St Pierre S;
 PI WPI; 2001-025008/03.
 DR Novel modified insulinotropic peptides for treating diabetes, nervous
 PT system disorders and for post surgery treatment, has reactive groups
 PT which react with amino, hydroxy or thiol groups on blood components.
 XX Claim 5; Page 91; 96pp; English.

The invention relates to modified insulinotropic peptides (ITPs), or
 CC derivatives thereof which comprise a reactive group which reacts with
 CC amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
 CC serum albumin) to form a stable covalent bond. The insulinotropic
 CC peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
 CC -1) or exendin and contain a reactive group such as a maleimido group or
 CC a succinimidyl group. The peptides of the invention act by stimulating
 CC the synthesis or expression of insulin. A composition comprising a
 CC peptide of the invention is useful for treating diabetes, particularly
 CC type II (maturity onset) diabetes. It is also useful as a sedative; for
 CC the treatment of nervous system disorders including anxiety, psychosis,
 CC seizures, panic attacks, hysteria and sleep disorders; to induce an
 CC anxiolytic effect on the central nervous system (CNS); to activate the
 CC CNS for the treatment of disorders such as depression, memory loss and
 CC narcolepsy; and as a treatment for insulin resistance, particularly that
 CC which occurs after certain types of surgery. The conjugation of a peptide
 CC of the invention to a blood component via the reactive group provides
 CC increased stability in the presence of peptidases. The peptides of the
 CC invention therefore have a longer in vivo half-life as they are less

CC increased stability in the presence of peptidases. The peptides of the
 CC invention therefore have a longer in vivo half-life as they are less
 CC susceptible to proteolytic degradation. The present sequence represents
 CC an insulinotropic peptide of the invention

XX Sequence 40 AA;

AA48807 Length: 40 February 4, 2005 13:19 Type: P Check: 2570 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQMEAEAVRLFIEWLKNGPSSGAPPSK
 28

 1 match found in sequence:
 aab48822 ; Exendin-4(1-39)Lys40.
 (from "seq4ags.pep")
 TOIG of: aab48822 check: 2570 from: 1 to: 40

ID AAB48822 standard; peptide; 40 AA.

XX AAB48822;

AC 09-MAR-2001 (first entry)

DT Exendin-4(1-39)Lys40.

XX Insulinotropic peptide; insulin production; GLP-1 derivative;
 KW glucagon-like peptide 1; exendin derivative; reactive group;
 KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
 KW insulin resistance; nervous system disorder; sedative; anxiolytic;
 KW antidiabetic; neuroprotective; tranquiliser; anticonvulsant.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 40
 FT /note= "side chain is linked to a maleimidopropionic acid
 FT (MPA) moiety, optionally via two AEEA (2-(2-
 FT amino)ethoxy]ethoxy acetic acid) linking groups"

XX WO200069911-A1.

XX 23-NOV-2000.

XX 17-MAY-2000; 2000WO-US013563.

XX 17-MAY-1999; 99US-0134406P.

XX 15-OCT-1999; 99US-0159783P.

XX (CONJ-) CONJUCHEM INC.

XX Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
 PI St Pierre S;

XX WPI; 2001-025008/03.

XX Novel modified insulinotropic peptides for treating diabetes, nervous
 PT system disorders and for post surgery treatment, has reactive groups
 PT which react with amino, hydroxy or thiol groups on blood components.

XX Claim 19; Page 62; 96pp; English.

XX The invention relates to modified insulinotropic peptides (ITPs), or
 CC derivatives thereof which comprise a reactive group which reacts with
 CC amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
 CC serum albumin) to form a stable covalent bond. The insulinotropic
 CC peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
 CC -1) or exendin and contain a reactive group such as a maleimido group or
 CC a succinimidyl group. The peptides of the invention act by stimulating
 CC the synthesis or expression of insulin. A composition comprising a
 CC peptide of the invention is useful for treating diabetes, particularly

CC type II (maturity onset) diabetes. It is also useful as a sedative; for
 CC the treatment of nervous system disorders including anxiety, psychosis,
 CC seizures, panic attacks, hysteria and sleep disorders; to induce an
 CC anxiolytic effect on the central nervous system (CNS); to activate the
 CC CNS for the treatment of disorders such as depression, memory loss and
 CC narcolepsy; and as a treatment for insulin resistance, particularly that
 CC which occurs after certain types of surgery. The conjugation of a peptide
 CC of the invention to a blood component via the reactive group provides
 CC increased stability in the presence of peptidases. The peptides of the
 CC invention therefore have a longer in vivo half-life as they are less
 CC susceptible to proteolytic degradation. The present sequence represents
 CC an insulinotropic peptide of the invention

XX Sequence 40 AA;

AA48822 Length: 40 February 4, 2005 13:19 Type: P Check: 2570 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQMEAEAVRLFIEWLKNGPSSGAPPSK
 28

 1 match found in sequence:
 aab48823 ; Exendin-3(1-39)Lys40.
 (from "seq4ags.pep")
 TOIG of: aab48823 check: 2591 from: 1 to: 40

ID AAB48823 standard; peptide; 40 AA.

XX AAB48823;

AC 09-MAR-2001 (first entry)

DT Exendin-3(1-39)Lys40.

XX Insulinotropic peptide; insulin production; GLP-1 derivative;
 KW glucagon-like peptide 1; exendin derivative; reactive group;
 KW peptidase stabilisation; blood protein; conjugation; type II diabetes;
 KW insulin resistance; nervous system disorder; sedative; anxiolytic;
 KW antidiabetic; neuroprotective; tranquiliser; anticonvulsant.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 40
 FT /note= "Side chain is linked to a maleimidopropionic acid
 FT (MPA) moiety, optionally via two AEEA (2-(2-
 FT amino)ethoxy]ethoxy acetic acid) linking groups"

XX WO200069911-A1.

XX 23-NOV-2000.

XX 17-MAY-2000; 2000WO-US013563.

XX 17-MAY-1999; 99US-0134406P.

XX 15-OCT-1999; 99US-0159783P.

XX (CONJ-) CONJUCHEM INC.

XX Bridon DP, L'archeveque B, Ezrin AM, Holmes DL, Leblanc A;
 PI St Pierre S;

XX WPI; 2001-025008/03.

XX Novel modified insulinotropic peptides for treating diabetes, nervous
 PT system disorders and for post surgery treatment, has reactive groups
 PT which react with amino, hydroxy or thiol groups on blood components.
 XX Claim 19; Page 69; 96pp; English.

XX The invention relates to modified insulinotropic peptides (ITPs), or

CC derivatives thereof which comprise a reactive group which reacts with
 CC amino groups, hydroxyl groups or thiol groups on blood components (e.g.,
 CC serum albumin) to form a stable covalent bond. The insulinotropic
 CC peptides of the invention are derivatives of glucagon-like peptide 1 (GLP
 CC -1) or exendin and contain a reactive group such as a maleimido group or
 CC a succinimidyl group. The peptides of the invention act by stimulating
 CC the synthesis or expression of insulin. A composition comprising a
 CC peptide of the invention is useful for treating diabetes, particularly
 CC type II (maturity onset) diabetes. It is also useful as a sedative; for
 CC the treatment of nervous system disorders including anxiety, psychosis,
 CC seizures, panic attacks, hysteria and sleep disorders; to induce an
 CC anxiolytic effect on the central nervous system (CNS); to activate the
 CC CNS for the treatment of disorders such as depression, memory loss and
 CC narcolepsy; and as a treatment for insulin resistance, particularly that
 CC which occurs after certain types of surgery. The conjugation of a peptide
 CC of the invention to a blood component via the reactive group provides
 CC increased stability in the presence of peptidases. The peptides of the
 CC invention therefore have a longer in vivo half-life as they are less
 CC susceptible to proteolytic degradation. The present sequence represents
 CC an insulinotropic peptide of the invention
 XX
 SQ Sequence 40 AA;

AAB49823 Length: 40 February 4, 2005 13:19 Type: P Check: 2591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGTFSTDLKQMBEEAVRLFIEWLKNGG 28
 |-----|
 1

1 match found in sequence:
 aab52825 ; Extendin-4 peptide #1.
 (from "seq4ags.pep")
 TOIG of: aab52825 check: 4889 from: 1 to: 30

ID AAB52825 standard; peptide; 30 AA.

XX AAB52825;
 AC
 XX 28-FEB-2001 (first entry)
 DT
 XX Extendin-4 peptide #1.
 DE
 XX
 XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 KW
 XX Heloderma sp.

XX WO200066629-A1.
 PN
 XX 09-NOV-2000.
 PD
 XX 28-APR-2000; 2000WO-US011814.
 PF
 XX 30-APR-1999; 99US-0132018P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA

XX Young A, Prickett K;
 PI
 XX WPI; 2000-672834/65.
 DR

PT Modified exendin or an exendin agonist linked to one or more polyethylene
 PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
 PT treating disorders such as diabetes and obesity.
 PT
 XX

PS Disclosure; Page 15; 119pp; English.

XX The present invention relates to extendins and their agonists which have
 XX been modified with molecular weight increasing agents such as
 CC polyethylene glycol (PEG). These can be used in the treatment of
 CC diabetes, obesity, impaired glucose tolerance, postprandial dumping

CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX
 SQ Sequence 30 AA;

AAB52825 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTSLSKQMBEEAVRLFIEWLKNGG 28
 |-----|
 1

1 match found in sequence:
 aab52826 ; Extendin-4 peptide #2.
 (from "seq4ags.pep")
 TOIG of: aab52826 check: 4889 from: 1 to: 30

ID AAB52826 standard; peptide; 30 AA.

XX AAB52826;
 AC
 XX 28-FEB-2001 (first entry)
 DT
 XX Extendin-4 peptide #2.
 DE
 XX
 XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 KW
 XX Heloderma sp.

XX WO200066629-A1.
 PN
 XX 09-NOV-2000.
 PD
 XX 28-APR-2000; 2000WO-US011814.
 PF
 XX 30-APR-1999; 99US-0132018P.
 PR

XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, Prickett K;
 PI
 XX WPI; 2000-672834/65.

XX Modified exendin or an exendin agonist linked to one or more polyethylene
 PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
 PT treating disorders such as diabetes and obesity.
 PT
 XX Disclosure; Page 15; 119pp; English.
 PS
 XX The present invention relates to extendins and their agonists which have
 CC been modified with molecular weight increasing agents such as
 CC polyethylene glycol (PEG). These can be used in the treatment of
 CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
 CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX

SQ Sequence 30 AA;

AAB52826 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTSLSKQMBEEAVRLFIEWLKNGG 28
 |-----|
 1

1 match found in sequence:
 aab52827 ; Extendin-4 peptide #3.
 (from "seq4ags.pep")
 TOIG of: aab52827 check: 700 from: 1 to: 28

```

ID AAB52827 standard; peptide; 28 AA.
XX
AC AAB52827;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin-4 peptide #3.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
PT Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
PS Disclosure; Page 15; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 28 AA;
XX
AAB52827 Length: 28 February 4, 2005 13:20 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSDLSKQWEEAVRLFIEWLKN
1 28
-----
1 match found in sequence:
aab52828 ; Extendin-4 peptide #4.
(from "seq4ags.pep")
TOIG of: aab52828 check: 9131 from: 1 to: 39
ID AAB52828 standard; peptide; 39 AA.
XX
AC AAB52828;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin-4 peptide #4.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
PT Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
PS Disclosure; Page 15; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 28 AA;
XX
AAB52827 Length: 28 February 4, 2005 13:20 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSDLSKQWEEAVRLFIEWLKN
1 28
-----
1 match found in sequence:
aab52828 ; Extendin-4 peptide #4.
(from "seq4ags.pep")
TOIG of: aab52828 check: 9131 from: 1 to: 39
ID AAB52828 standard; peptide; 39 AA.
XX
AC AAB52828;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin-4 peptide #4.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.

```

```

XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
DR Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX treating disorders such as diabetes and obesity.
XX
PS Disclosure; Page 15; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 39 AA;
XX
AAB52828 Length: 39 February 4, 2005 13:20 Type: P Check: 9131 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSDLSKQWEEAVRLFIEWLKN
1 28
-----
1 match found in sequence:
aab52829 ; Extendin-4 peptide #5.
(from "seq4ags.pep")
TOIG of: aab52829 check: 261 from: 1 to: 28
ID AAB52829 standard; peptide; 28 AA.
XX
AC AAB52829;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin-4 peptide #5.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
PT Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
PS Disclosure; Page 15; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 39 AA;
XX
AAB52828 Length: 39 February 4, 2005 13:20 Type: P Check: 9131 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSDLSKQWEEAVRLFIEWLKN
1 28
-----
1 match found in sequence:
aab52829 ; Extendin-4 peptide #5.
(from "seq4ags.pep")
TOIG of: aab52829 check: 261 from: 1 to: 28
ID AAB52829 standard; peptide; 28 AA.
XX
AC AAB52829;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin-4 peptide #5.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
PT Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
PS Disclosure; Page 15; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of

```

```

CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 28 AA;

AAB52829 Length: 28 February 4, 2005 13:20 Type: P Check: 261 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGGFTFTDLSKQLEEEAVRLFIETFLKN 28
  |-----|
  1 match found in sequence:
  aab52830 ; Extending-4 peptide #6.
  (from "seq4ags.pep")
  TOIG of: aab52830 check: 151 from: 1 to: 28

ID AAB52830 standard; peptide; 28 AA.
XX
AC
AC AAB52830;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending-4 peptide #6.
XX
KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX
PS WPI; 2000-672834/65.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 28 AA;

AAB52830 Length: 28 February 4, 2005 13:20 Type: P Check: 151 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGGFTFTDLSKQLEEEAVRLFIETFLKN 28
  |-----|
  1 match found in sequence:
  aab52840 ; Extending-4 peptide #7.
  (from "seq4ags.pep")
  TOIG of: aab52840 check: 9570 from: 1 to: 39

```

```

ID AAB52840 standard; peptide; 39 AA.
XX
AC
AC AAB52840;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending-4 peptide #7.
XX
KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 2000WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX
PS WPI; 2000-672834/65.
XX
CC Modified extendin or an extendin agonist linked to one or more polyethylene
CC glycol (PEG) polymers, modulate plasma glucose levels, useful for
CC treating disorders such as diabetes and obesity.
XX
CC Example 4; Page 71; 119pp; English.
XX
CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 39 AA;

AAB52840 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGGFTFTDLSKQLEEEAVRLFIETFLKN 28
  |-----|
  1 match found in sequence:
  aab52841 ; Extending-4 peptide #8.
  (from "seq4ags.pep")
  TOIG of: aab52841 check: 9570 from: 1 to: 39

ID AAB52841 standard; peptide; 39 AA.
XX
AC
AC AAB52841;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending-4 peptide #8.
XX
KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX

```

```

PF 28-APR-2000; 2000WO-US011814.
XX
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PR 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Example 4; Page 71; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 39 AA;
AC
XX
XX AAB52845 Length: 39 February 4, 2005 13:20 Type: P Check: 9570
Found using 'seq4' (mohamed337.key)
1
1 HEGGFTSLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
28
-----
1 match found in sequence:
aab52845; Extendin-4 peptide #12.
(from "seq4ags.pep")
TOIG of: aab52845 check: 9560 from: 1 to: 39
ID AAB52845 standard; peptide; 39 AA.
XX
XX AAB52845;
AC
XX
XX 28-FEB-2001 (first entry)
DT
XX
XX Extendin-4 peptide #12.
DE
XX
XX Extendin, agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
OS
XX
XX WO200066629-A1.
PN
XX
XX 09-NOV-2000.
PD
XX
XX 28-APR-2000; 2000WO-US011814.
PF
XX
XX 30-APR-1999; 99US-0132018P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, Prickett K;
PI
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Example 4; Page 72; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 39 AA;
AC
XX
XX AAB52845 Length: 39 February 4, 2005 13:20 Type: P Check: 9570
Found using 'seq4' (mohamed337.key)
1
1 HEGGFTSLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
28
-----
1 match found in sequence:
aab52845; Extendin-4 peptide #12.
(from "seq4ags.pep")
TOIG of: aab52845 check: 9560 from: 1 to: 39
ID AAB52845 standard; peptide; 39 AA.
XX
XX AAB52845;
AC
XX
XX 28-FEB-2001 (first entry)
DT
XX
XX Extendin-4 peptide #12.
DE
XX
XX Extendin, agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
OS
XX
XX WO200066629-A1.
PN
XX
XX 09-NOV-2000.
PD
XX
XX 28-APR-2000; 2000WO-US011814.
PF
XX
XX 30-APR-1999; 99US-0132018P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, Prickett K;
PI
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Example 4; Page 72; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as

```

```

CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 39 AA;
AC
XX
XX AAB52845 Length: 39 February 4, 2005 13:20 Type: P Check: 9560
Found using 'seq4' (mohamed337.key)
1
1 HEGGFTSLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
28
-----
1 match found in sequence:
aab52852; Extendin-4 peptide #19.
(from "seq4ags.pep")
TOIG of: aab52852 check: 9270 from: 1 to: 39
ID AAB52852 standard; peptide; 39 AA.
XX
XX AAB52852;
AC
XX
XX 28-FEB-2001 (first entry)
DT
XX
XX Extendin-4 peptide #19.
DE
XX
XX Extendin, agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
OS
XX
XX WO200066629-A1.
PN
XX
XX 09-NOV-2000.
PD
XX
XX 28-APR-2000; 2000WO-US011814.
PF
XX
XX 30-APR-1999; 99US-0132018P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, Prickett K;
PI
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Example 4; Page 72; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 39 AA;
AC
XX
XX AAB52852 Length: 39 February 4, 2005 13:20 Type: P Check: 9270
Found using 'seq4' (mohamed337.key)
1
1 HEGGFTSLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
28
-----
1 match found in sequence:
aab52853; Extendin-4 peptide #20.
(from "seq4ags.pep")

```

```

TOIG of: aab52853 check: 9270 from: 1 to: 39
ID AAB52853 standard; peptide; 39 AA.
AC AAB52853;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin-4 peptide #20.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Example 4; Page 72; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX CC Sequence 39 AA;
XX SQ

AAB52853 Length: 39 February 4, 2005 13:20 Type: P Check: 9270 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEGFTSLSKQMEEEAVRLFIEKLKNGPSSGAPPPS
    28

-----
1 match found in sequence:
aab52855 ; Extendin-4 peptide #22.
(from "seq4ags.pep")
TOIG of: aab52855 check: 9686 from: 1 to: 39

ID AAB52855 standard; peptide; 39 AA.
XX AC AAB52855;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin-4 peptide #22.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Example 4; Page 72; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX CC Sequence 39 AA;
XX SQ

AAB52853 Length: 39 February 4, 2005 13:20 Type: P Check: 9270 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEGFTSLSKQMEEEAVRLFIEKLKNGPSSGAPPPS
    28

-----
1 match found in sequence:
aab52855 ; Extendin-4 peptide #22.
(from "seq4ags.pep")
TOIG of: aab52855 check: 9686 from: 1 to: 39

ID AAB52855 standard; peptide; 39 AA.
XX AC AAB52855;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin-4 peptide #22.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Example 4; Page 72; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX CC Sequence 39 AA;
XX SQ

AAB52855 Length: 39 February 4, 2005 13:20 Type: P Check: 9686 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEGFTSLSKQMEEEAVRLFIEKLKNGPSSGAPPPS
    28

-----
1 match found in sequence:
aab52856 ; Extendin-4 peptide #23.
(from "seq4ags.pep")
TOIG of: aab52856 check: 9690 from: 1 to: 39

ID AAB52856 standard; peptide; 39 AA.
XX AC AAB52856;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin-4 peptide #23.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Example 4; Page 72; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX CC Sequence 39 AA;
XX SQ

```

CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 39 AA;

AAB52856 Length: 39 February 4, 2005 13:20 Type: P Check: 9690 ..
Found using 'seq4' (mohamed337.key)

1 HGGFTFTSLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
28

1 match found in sequence:
aab52857 ; Extending-4 peptide #24.
(from "seq4tags.pep")

TOIG of: aab52857 check: 9570 from: 1 to: 39

ID AAB52857 standard; peptide; 39 AA.

XX AC AAB52857;

XX DT 28-FEB-2001 (first entry)

XX DE Extending-4 peptide #24.

XX KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.

XX OS Heloderma sp.

XX PN WO200066629-A1.

XX PD 09-NOV-2000.

XX PF 28-APR-2000; 2000WO-US011814.

XX PR 30-APR-1999; 99US-0132018P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, Prickett K;

XX WPI; 2000-672834/65.

XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
glycol (PEG) polymers, modulate plasma glucose levels, useful for
treating disorders such as diabetes and obesity.

PS Example 4; Page 73; 119pp; English.

XX CC The present invention relates to extendins and their agonists which have
been modified with molecular weight increasing agents such as
polyethylene glycol (PEG). These can be used in the treatment of
diabetes, obesity, impaired glucose tolerance, postprandial dumping
syndrome, postprandial hyperglycaemia, eating disorders, insulin
resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 39 AA;

AAB52857 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HGGFTFTSLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
28

1 match found in sequence:
aab52858 ; Extending-4 peptide #25.

(from "seq4tags.pep")
TOIG of: aab52858 check: 9570 from: 1 to: 39

ID AAB52858 standard; peptide; 39 AA.

XX AC AAB52858;

XX DT 28-FEB-2001 (first entry)

XX DE Extending-4 peptide #25.

XX KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.

XX OS Heloderma sp.

XX PN WO200066629-A1.

XX PD 09-NOV-2000.

XX PF 28-APR-2000; 2000WO-US011814.

XX PR 30-APR-1999; 99US-0132018P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, Prickett K;

XX WPI; 2000-672834/65.

XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
glycol (PEG) polymers, modulate plasma glucose levels, useful for
treating disorders such as diabetes and obesity.

PS Example 4; Page 73; 119pp; English.

XX CC The present invention relates to extendins and their agonists which have
been modified with molecular weight increasing agents such as
polyethylene glycol (PEG). These can be used in the treatment of
diabetes, obesity, impaired glucose tolerance, postprandial dumping
syndrome, postprandial hyperglycaemia, eating disorders, insulin
resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 39 AA;

AAB52858 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HGGFTFTSLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
28

1 match found in sequence:

aab52859 ; Extending-4 peptide #26.

(from "seq4tags.pep")

TOIG of: aab52859 check: 8907 from: 1 to: 42

ID AAB52859 standard; peptide; 42 AA.

XX AC AAB52859;

XX DT 28-FEB-2001 (first entry)

XX DE Extending-4 peptide #26.

XX KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.

XX OS Heloderma sp.

XX PN WO200066629-A1.

XX

```

PD 09-NOV-2000.
XX
XX 28-APR-2000; 2000WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX treating disorders such as diabetes and obesity.
XX
XX Example 4; Page 73; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
XX polyethylene glycol (PEG). These can be used in the treatment of
XX diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 42 AA;
XX
AAB52859 Length: 42 February 4, 2005 13:20 Type: P Check: 8907 ..
Found using 'seq4' (mohamed337.key)
1 CHWGGTFTSDLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
4 31
-----
1 match found in sequence:
aab52871; Mexican beaded lizard extendin-3 protein.
(from "seq4ags.pep")
TOIG of: aab52871 check: 9591 from: 1 to: 39

ID AAB52871 standard; peptide; 39 AA.
XX
XX AC AAB52871;
XX
XX DT 28-FEB-2001 (first entry)
XX
XX DE Mexican beaded lizard extendin-3 protein.
XX
XX Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX
XX OS Heloderma horridum.
XX
XX PN WO200066629-A1.
XX
XX PD 09-NOV-2000.
XX
XX PF 28-APR-2000; 2000WO-US011814.
XX
XX PR 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX treating disorders such as diabetes and obesity.
XX
XX Example 1; Fig 1; 119pp; English.

```

```

CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 39 AA;
XX
AAB52871 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)
1 HSDGTFTSDLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
1 28
-----
1 match found in sequence:
aab52872; Gila monster extendin-4 protein.
(from "seq4ags.pep")
TOIG of: aab52872 check: 9570 from: 1 to: 39

ID AAB52872 standard; peptide; 39 AA.
XX
XX AC AAB52872;
XX
XX DT 28-FEB-2001 (first entry)
XX
XX DE Gila monster extendin-4 protein.
XX
XX Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX
XX OS Heloderma suspectum.
XX
XX PN WO200066629-A1.
XX
XX PD 09-NOV-2000.
XX
XX PF 28-APR-2000; 2000WO-US011814.
XX
XX PR 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX treating disorders such as diabetes and obesity.
XX
XX Example 2; Fig 2; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
XX polyethylene glycol (PEG). These can be used in the treatment of
XX diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 39 AA;
XX
AAB52872 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HCEGTFTSDLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
1 28
-----
1 match found in sequence:

```

```
aab52890 ; Extendin agonist compound #18.
(from "seq4ags.pep")
TOIG of: aab52890 Check: 4889 from: 1 to: 30

ID AAB52890 standard; peptide; 30 AA.
XX
XX AC AAB52890;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #18.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX CC Sequence 30 AA;
XX SQ

AAB52890 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFSDLSKQMEEEAVRLFIEWLKNGG
1 28
-----|
1 match found in sequence:
aab52891 ; Extendin agonist compound #19.
(from "seq4ags.pep")
TOIG of: aab52891 Check: 700 from: 1 to: 28

ID AAB52891 standard; peptide; 28 AA.
XX
XX AC AAB52891;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #19.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX CC Sequence 28 AA;
XX SQ

AAB52891 Length: 28 February 4, 2005 13:20 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFSDLSKQMEEEAVRLFIEWLKKN
1 28
-----|
1 match found in sequence:
aab52892 ; Extendin agonist compound #20.
(from "seq4ags.pep")
TOIG of: aab52892 Check: 261 from: 1 to: 28

ID AAB52892 standard; peptide; 28 AA.
XX
XX AC AAB52892;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #20.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
```

```
XX CC The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX SQ Sequence 28 AA;

AAB52892 Length: 28 February 4, 2005 13:20 Type: P Check: 261 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIEFLKN 28
1 -----
1 match found in sequence:
aab52893 ; Extendin agonist compound #21.
(from "seq4ags.pep")
TOIG of: aab52893 check: 249 from: 1 to: 28

ID AAB52893 standard; peptide; 28 AA.
XX AC AAB52893;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #21.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX SQ Sequence 28 AA;

AAB52893 Length: 28 February 4, 2005 13:20 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIEFLKN 28
1 -----
1 match found in sequence:
aab52893 ; Extendin agonist compound #23.
(from "seq4ags.pep")
TOIG of: aab52893 check: 231 from: 1 to: 28

ID AAB52893 standard; peptide; 28 AA.
XX AC AAB52893;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #23.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX SQ Sequence 28 AA;
```

```
1 match found in sequence:
aab52894 ; Extendin agonist compound #22.
(from "seq4ags.pep")
TOIG of: aab52894 check: 166 from: 1 to: 28

ID AAB52894 standard; peptide; 28 AA.
XX AC AAB52894;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #22.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX SQ Sequence 28 AA;

AAB52894 Length: 28 February 4, 2005 13:20 Type: P Check: 166 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIEFLKN 28
1 -----
1 match found in sequence:
aab52895 ; Extendin agonist compound #23.
(from "seq4ags.pep")
TOIG of: aab52895 check: 231 from: 1 to: 28

ID AAB52895 standard; peptide; 28 AA.
XX AC AAB52895;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #23.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX SQ Sequence 28 AA;
```



```
-----
1 match found in sequence:
aab52898 ; Extending agonist compound #26.
(from "seq4ags.pep")
TOIG of: aab52898 check: 63 from: 1 to: 28

ID AAB52898 standard; peptide; 28 AA.
XX
XX
AC AAB52898;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #26.
XX
KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
XX
XX WO200066629-A1.
XX
XX 09-NOV-2000.
XX
XX 28-APR-2000; 2000WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 28 AA;
XX
AAB52898 Length: 28 February 4, 2005 13:20 Type: P Check: 63 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  HGEFTFTSLAKLEEEAVRLFIEFLKN 28
  |-----|

-----
1 match found in sequence:
aab52899 ; Extending agonist compound #27.
(from "seq4ags.pep")
TOIG of: aab52899 check: 141 from: 1 to: 28

ID AAB52899 standard; peptide; 28 AA.
XX
XX
AC AAB52899;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #27.
XX
KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
XX

-----
1 match found in sequence:
aab52899 ; Extending agonist compound #28.
(from "seq4ags.pep")
TOIG of: aab52900 check: 53 from: 1 to: 28

ID AAB52900 standard; peptide; 28 AA.
XX
XX
AC AAB52900;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #28.
XX
KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
XX
XX WO200066629-A1.
XX
XX 09-NOV-2000.
XX
XX 28-APR-2000; 2000WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 28 AA;
XX
AAB52899 Length: 28 February 4, 2005 13:20 Type: P Check: 141 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  HGEFTFTSLAKLEEEAVRLFIEFLKN 28
  |-----|

-----
1 match found in sequence:
aab52900 ; Extending agonist compound #28.
(from "seq4ags.pep")
TOIG of: aab52900 check: 53 from: 1 to: 28

ID AAB52900 standard; peptide; 28 AA.
XX
XX
AC AAB52900;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #28.
XX
KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
XX
XX WO200066629-A1.
XX
XX 09-NOV-2000.
XX
XX 28-APR-2000; 2000WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 28 AA;
XX
AAB52899 Length: 28 February 4, 2005 13:20 Type: P Check: 141 ..
Found using 'seq4' (mohamed337.key)
```

```
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX SQ Sequence 28 AA;

AAB52900 Length: 28 February 4, 2005 13:20 Type: P Check: 53 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HEGTFTSDLSKALBEEAVRLFIEFLKN 28

-----
1 match found in sequence:
aab52901 ; Extendin agonist compound #29.
  (from "seq4ags.pep")
TOIG of: aab52901 check: 107 from: 1 to: 28

ID AAB52901 standard; peptide; 28 AA.
XX AC AAB52901;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #29.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX SQ Sequence 28 AA;

AAB52901 Length: 28 February 4, 2005 13:20 Type: P Check: 107 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HEGTFTSDLSKALBEEAVRLFIEFLKN 28

-----
1 match found in sequence:
aab52901 ; Extendin agonist compound #31.
  (from "seq4ags.pep")
TOIG of: aab52901 check: 197 from: 1 to: 28

ID AAB52901 standard; peptide; 28 AA.
XX AC AAB52901;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #31.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX SQ Sequence 28 AA;
```

```
-----
1 match found in sequence:
aab52902 ; Extendin agonist compound #30.
  (from "seq4ags.pep")
TOIG of: aab52902 check: 201 from: 1 to: 28

ID AAB52902 standard; peptide; 28 AA.
XX AC AAB52902;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #30.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX SQ Sequence 28 AA;

AAB52902 Length: 28 February 4, 2005 13:20 Type: P Check: 201 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HEGTFTSDLSKALBEEAVRLFIEFLKN 28

-----
1 match found in sequence:
aab52903 ; Extendin agonist compound #31.
  (from "seq4ags.pep")
TOIG of: aab52903 check: 197 from: 1 to: 28

ID AAB52903 standard; peptide; 28 AA.
XX AC AAB52903;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #31.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX SQ Sequence 28 AA;
```


PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
 XX treating disorders such as diabetes and obesity.
 PS Disclosure; Fig 4; 119pp; English.
 XX
 CC The present invention relates to extendins and their agonists which have
 CC been modified with molecular weight increasing agents such as
 CC polyethylene glycol (PEG). These can be used in the treatment of
 CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
 CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX
 XX Sequence 28 AA;
 SQ
 AAB52908 Length: 28 February 4, 2005 13:20 Type: P Check: 165 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIAFKN 28
 1

 1 match found in sequence:
 aab52909; Extendin agonist compound #37.
 (from "seq4ags.pep")
 TOIG of: aab52909 check: 136 from: 1 to: 28

ID AAB52909 standard; peptide; 28 AA.
 AC AAB52909;
 XX
 XX Sequence 28 AA;
 DT 28-FEB-2001 (first entry)
 DE Extendin agonist compound #37.
 XX
 XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 XX
 OS Heloderma sp.
 XX
 XX WO200066629-A1.
 PN
 XX
 XX 09-NOV-2000.
 PD
 XX
 XX 28-APR-2000; 2000WO-US011814.
 PF
 XX
 XX 30-APR-1999; 99US-0132018P.
 PR
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX
 XX Young A, Prickett K;
 PI
 XX
 XX WPI; 2000-672834/65.
 PN
 XX
 XX 09-NOV-2000.
 PD
 XX
 XX 28-APR-2000; 2000WO-US011814.
 PF
 XX
 XX 30-APR-1999; 99US-0132018P.
 PR
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX
 XX Young A, Prickett K;
 PI
 XX
 XX WPI; 2000-672834/65.
 DR
 XX
 XX Modified extendin or an extendin agonist linked to one or more polyethylene
 PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
 PT treating disorders such as diabetes and obesity.
 XX
 XX Disclosure; Fig 4; 119pp; English.
 PS
 XX The present invention relates to extendins and their agonists which have
 CC been modified with molecular weight increasing agents such as
 CC polyethylene glycol (PEG). These can be used in the treatment of
 CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
 CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX
 XX Sequence 28 AA;
 SQ
 AAB52909 Length: 28 February 4, 2005 13:20 Type: P Check: 136 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIAFKN 28
 1

 1 match found in sequence:
 aab52911; Extendin agonist compound #39.
 (from "seq4ags.pep")
 TOIG of: aab52911 check: 9991 from: 1 to: 28

ID AAB52911 standard; peptide; 28 AA.
 AC AAB52911;
 XX
 XX Sequence 28 AA;
 DT 28-FEB-2001 (first entry)
 DE Extendin agonist compound #39.
 XX
 XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;

1 HEGGFTSDLSKQLEEEAVRLFIAFKN 28
 1

 1 match found in sequence:
 aab52910; Extendin agonist compound #38.
 (from "seq4ags.pep")
 TOIG of: aab52910 check: 9975 from: 1 to: 28

ID AAB52910 standard; peptide; 28 AA.
 AC AAB52910;
 XX
 XX Sequence 28 AA;
 DT 28-FEB-2001 (first entry)
 DE Extendin agonist compound #38.
 XX
 XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 XX
 OS Heloderma sp.
 XX
 XX WO200066629-A1.
 PN
 XX
 XX 09-NOV-2000.
 PD
 XX
 XX 28-APR-2000; 2000WO-US011814.
 PF
 XX
 XX 30-APR-1999; 99US-0132018P.
 PR
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX
 XX Young A, Prickett K;
 PI
 XX
 XX WPI; 2000-672834/65.
 DR
 XX
 XX Modified extendin or an extendin agonist linked to one or more polyethylene
 PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
 PT treating disorders such as diabetes and obesity.
 XX
 XX Disclosure; Fig 4; 119pp; English.
 PS
 XX The present invention relates to extendins and their agonists which have
 CC been modified with molecular weight increasing agents such as
 CC polyethylene glycol (PEG). These can be used in the treatment of
 CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
 CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX
 XX Sequence 28 AA;
 SQ
 AAB52910 Length: 28 February 4, 2005 13:20 Type: P Check: 9975 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIAFKN 28
 1

 1 match found in sequence:
 aab52911; Extendin agonist compound #39.
 (from "seq4ags.pep")
 TOIG of: aab52911 check: 9991 from: 1 to: 28

ID AAB52911 standard; peptide; 28 AA.
 AC AAB52911;
 XX
 XX Sequence 28 AA;
 DT 28-FEB-2001 (first entry)
 DE Extendin agonist compound #39.
 XX
 XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;

KW insulin-resistance syndrome; food intake.

XX Heloderma sp.

XX WO200066629-A1.

XX 09-NOV-2000.

XX 28-APR-2000; 2000WO-US011814.

XX 30-APR-1999; 99US-0132018P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, Prickett K;

XX WPI; 2000-672834/65.

XX Modified extendin or an extendin agonist linked to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.

XX Disclosure; Fig 4; 119pp; English.

XX The present invention relates to extendins and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion

XX Sequence 28 AA;

XX AAB52911 Length: 28 February 4, 2005 13:20 Type: P Check: 9991 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTTSDLSKQLEEAVALFIEFLAN 28

1 match found in sequence:
aab52912 ; Extendin agonist compound #40.
(from "seq4ags.pep")
TOIG of: aab52912 Check: 9897 from: 1 to: 28

ID AAB52912 standard; peptide; 28 AA.

XX AAB52912;

XX 28-FEB-2001 (first entry)

XX Extendin agonist compound #40.

XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.

XX Heloderma sp.

XX WO200066629-A1.

XX 09-NOV-2000.

XX 28-APR-2000; 2000WO-US011814.

XX 30-APR-1999; 99US-0132018P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, Prickett K;

XX WPI; 2000-672834/65.

XX

PT Modified extendin or an extendin agonist linked to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.

XX Disclosure; Fig 4; 119pp; English.

XX The present invention relates to extendins and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion

XX Sequence 28 AA;

XX AAB52912 Length: 28 February 4, 2005 13:20 Type: P Check: 9897 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTTSDLSKQLEEAVALFIEFLKA 28

1 match found in sequence:
aab52913 ; Extendin agonist compound #41.
(from "seq4ags.pep")
TOIG of: aab52913 Check: 6333 from: 1 to: 38

ID AAB52913 standard; peptide; 38 AA.

XX AAB52913;

XX 28-FEB-2001 (first entry)

XX Extendin agonist compound #41.

XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.

XX Heloderma sp.

XX WO200066629-A1.

XX 09-NOV-2000.

XX 28-APR-2000; 2000WO-US011814.

XX 30-APR-1999; 99US-0132018P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, Prickett K;

XX WPI; 2000-672834/65.

XX Modified extendin or an extendin agonist linked to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.

XX Disclosure; Fig 4; 119pp; English.

XX The present invention relates to extendins and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion

XX Sequence 38 AA;

XX AAB52913 Length: 38 February 4, 2005 13:20 Type: P Check: 6333 ..
Found using 'seq4' (mohamed337.key)


```
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
PS Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 37 AA;
SQ
AAB52916 Length: 37 February 4, 2005 13:20 Type: P Check: 2854 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQLEEEAVRLFIEFLKNGPSSGAPP
  1
-----
1 match found in sequence:
aab52917 ; Extendin agonist compound #45.
(from "seq4ags.pep")
TOIG of: aab52917 check: 333 from: 1 to: 36
ID AAB52917 standard; peptide; 36 AA.
XX
XX AAB52917;
AC
XX 28-FEB-2001 (first entry)
DT
XX Extendin agonist compound #45.
DE
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
KW
XX Heloderma sp.
OS
XX WO200066629-A1.
PN
XX 09-NOV-2000.
PD
XX 28-APR-2000; 2000WO-US011814.
PF
XX 30-APR-1999; 99US-0132018P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, Prickett K;
PI
XX WPI; 2000-672834/65.
DR
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 36 AA;
SQ
AAB52917 Length: 36 February 4, 2005 13:20 Type: P Check: 333 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQLEEEAVRLFIEFLKNGPSSGAPP
  1
-----
1 match found in sequence:
aab52917 ; Extendin agonist compound #45.
(from "seq4ags.pep")
TOIG of: aab52917 check: 333 from: 1 to: 36
ID AAB52917 standard; peptide; 36 AA.
XX
XX AAB52917;
AC
XX 28-FEB-2001 (first entry)
DT
XX Extendin agonist compound #45.
DE
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
KW
XX Heloderma sp.
OS
XX WO200066629-A1.
PN
XX 09-NOV-2000.
PD
XX 28-APR-2000; 2000WO-US011814.
PF
XX 30-APR-1999; 99US-0132018P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, Prickett K;
PI
XX WPI; 2000-672834/65.
DR
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 36 AA;
SQ
AAB52917 Length: 36 February 4, 2005 13:20 Type: P Check: 333 ..
Found using 'seq4' (mohamed337.key)
```

```
1 HGEFTSLSKQLEEEAVRLFIEFLKNGPSSGAPP
  1
-----
1 match found in sequence:
aab52918 ; Extendin agonist compound #46.
(from "seq4ags.pep")
TOIG of: aab52918 check: 9894 from: 1 to: 36
ID AAB52918 standard; peptide; 36 AA.
XX
XX AAB52918;
AC
XX 28-FEB-2001 (first entry)
DT
XX Extendin agonist compound #46.
DE
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
KW
XX Heloderma sp.
OS
XX WO200066629-A1.
PN
XX 09-NOV-2000.
PD
XX 28-APR-2000; 2000WO-US011814.
PF
XX 30-APR-1999; 99US-0132018P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, Prickett K;
PI
XX WPI; 2000-672834/65.
DR
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 36 AA;
SQ
AAB52918 Length: 36 February 4, 2005 13:20 Type: P Check: 9894 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQLEEEAVRLFIEFLKNGPSSGAPP
  1
-----
1 match found in sequence:
aab52919 ; Extendin agonist compound #47.
(from "seq4ags.pep")
TOIG of: aab52919 check: 7453 from: 1 to: 35
ID AAB52919 standard; peptide; 35 AA.
XX
XX AAB52919;
AC
XX 28-FEB-2001 (first entry)
DT
XX Extendin agonist compound #47.
DE
```

```
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX WO200066629-A1.
XX
XX 09-NOV-2000.
XX
XX 28-APR-2000; 2000WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 35 AA;
XX
AAB52919 Length: 35 February 4, 2005 13:20 Type: P Check: 7453 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMEEEAVRLFIEFLKNGGPSSGA 28
-----
1 match found in sequence:
aab52920 ; Extendin agonist compound #48.
(from "seq4ags.pep")
TOIG of: aab52920 check: 7014 from: 1 to: 35
ID AAB52920 standard; peptide; 35 AA.
XX
XX AAB52920;
XX
XX 28-FEB-2001 (first entry)
XX
XX Extendin agonist compound #48.
XX
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX
XX WO200066629-A1.
XX
XX 09-NOV-2000.
XX
XX 28-APR-2000; 2000WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 35 AA;
XX
AAB52920 Length: 35 February 4, 2005 13:20 Type: P Check: 7014 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQLEEEAVRLFIEFLKNGGPSSGA 28
-----
1 match found in sequence:
aab52921 ; Extendin agonist compound #49.
(from "seq4ags.pep")
TOIG of: aab52921 check: 5178 from: 1 to: 34
ID AAB52921 standard; peptide; 34 AA.
XX
XX AAB52921;
XX
XX 28-FEB-2001 (first entry)
XX
XX Extendin agonist compound #49.
XX
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX
XX WO200066629-A1.
XX
XX 09-NOV-2000.
XX
XX 28-APR-2000; 2000WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 34 AA;
XX
AAB52921 Length: 34 February 4, 2005 13:20 Type: P Check: 5178 ..
```

Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEEAVRLFIEFLKNGGPSSG
28

1 match found in sequence:
aab52922 ; Extendin agonist compound #50.
(from "seq4ags.pap")
TOIG of: aab52922 check: 4739 from: 1 to: 34

ID AAB52922 standard; peptide; 34 AA.

XX AC AAB52922;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #50.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.

XX WO200066629-A1.
XX PN 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.

XX PT Modified extendin or an extendin agonist linked to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendins and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion

XX Sequence 34 AA;

AAB52922 Length: 34 February 4, 2005 13:20 Type: P Check: 4739 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEEAVRLFIEFLKNGGPSSG
28

1 match found in sequence:
aab52923 ; Extendin agonist compound #51.
(from "seq4ags.pap")
TOIG of: aab52923 check: 2764 from: 1 to: 33

ID AAB52923 standard; peptide; 33 AA.

XX AC AAB52923;
XX DT 28-FEB-2001 (first entry)
XX

DE Extendin agonist compound #51.

XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.

XX OS Heloderma sp.

XX WO200066629-A1.
XX PN 09-NOV-2000.

XX PF 28-APR-2000; 2000WO-US011814.

XX PR 30-APR-1999; 99US-0132018P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.

XX PT Modified extendin or an extendin agonist linked to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.

XX CC The present invention relates to extendins and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion

XX Sequence 33 AA;

AAB52923 Length: 33 February 4, 2005 13:20 Type: P Check: 2764 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEEAVRLFIEFLKNGGPSS
28

1 match found in sequence:
aab52924 ; Extendin agonist compound #52.
(from "seq4ags.pap")
TOIG of: aab52924 check: 2325 from: 1 to: 33

ID AAB52924 standard; peptide; 33 AA.

XX AC AAB52924;
XX DT 28-FEB-2001 (first entry)

XX DE Extendin agonist compound #52.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.

XX OS Heloderma sp.

XX WO200066629-A1.
XX PN 09-NOV-2000.

XX PF 28-APR-2000; 2000WO-US011814.

XX PR 30-APR-1999; 99US-0132018P.

XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;


```
XX Extendin agonist compound #55.
DE Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX WO200066629-A1.
XX 09-NOV-2000.
XX 28-APR-2000; 2000WO-US011814.
XX 30-APR-1999; 99US-0132018P.
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 31 AA;
XX
AAB52927 Length: 31 February 4, 2005 13:20 Type: P Check: 7369 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEAEAVRLFIEFLKNGGP
1 28
-----
1 match found in sequence:
aab52928 ; Extendin agonist compound #56.
(from "seq4ags.pep")
TOIG of: aab52928 check: 6930 from: 1 to: 31
ID AAB52928 standard; peptide; 31 AA.
XX AC AAB52928;
XX 28-FEB-2001 (first entry)
DE Extendin agonist compound #56.
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX WO200066629-A1.
XX 09-NOV-2000.
XX 28-APR-2000; 2000WO-US011814.
XX 30-APR-1999; 99US-0132018P.
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 31 AA;
XX
AAB52928 Length: 31 February 4, 2005 13:20 Type: P Check: 6930 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEAEAVRLFIEFLKNGGP
1 28
-----
1 match found in sequence:
aab52929 ; Extendin agonist compound #57.
(from "seq4ags.pep")
TOIG of: aab52929 check: 4450 from: 1 to: 30
ID AAB52929 standard; peptide; 30 AA.
XX AC AAB52929;
XX 28-FEB-2001 (first entry)
DE Extendin agonist compound #57.
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX WO200066629-A1.
XX 09-NOV-2000.
XX 28-APR-2000; 2000WO-US011814.
XX 30-APR-1999; 99US-0132018P.
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 30 AA;
XX
```

```
PI Young A, Prickett K;
XX WPI; 2000-672834/65.
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 31 AA;
XX
AAB52928 Length: 31 February 4, 2005 13:20 Type: P Check: 6930 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEAEAVRLFIEFLKNGGP
1 28
-----
1 match found in sequence:
aab52929 ; Extendin agonist compound #57.
(from "seq4ags.pep")
TOIG of: aab52929 check: 4450 from: 1 to: 30
ID AAB52929 standard; peptide; 30 AA.
XX AC AAB52929;
XX 28-FEB-2001 (first entry)
DE Extendin agonist compound #57.
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX WO200066629-A1.
XX 09-NOV-2000.
XX 28-APR-2000; 2000WO-US011814.
XX 30-APR-1999; 99US-0132018P.
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 30 AA;
XX
```

AAB52929 Length: 30 February 4, 2005 13:20 Type: P Check: 4450 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
HGEFTFTDLSKQLEEEAVRLFIEFLKNGG
28

1 match found in sequence:
aab52930 : Extending agonist compound #58.
(from "seq4ags.pep")
TOIG of: aab52930 check: 2759 from: 1 to: 29

ID AAB52930 standard; peptide; 29 AA.
XX AC AAB52930;
XX DT 28-FEB-2001 (first entry)
XX DE Extending agonist compound #58.
XX KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.
XX CC The present invention relates to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendings and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion

Sequence 29 AA;
AAB52930 Length: 29 February 4, 2005 13:20 Type: P Check: 2759 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
HGEFTFTDLSKQLEEEAVRLFIEFLKNGG
28

1 match found in sequence:
aab52931 : Extending agonist compound #59.
(from "seq4ags.pep")
TOIG of: aab52931 check: 2320 from: 1 to: 29

ID AAB52931 standard; peptide; 29 AA.
XX AC AAB52931;
XX

DT 28-FEB-2001 (first entry)
XX Extending agonist compound #59.
XX KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Prickett K;
XX DR WPI; 2000-672834/65.
XX CC Modified extendin or an extendin agonist linked to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.
XX PS Disclosure; Fig 4; 119pp; English.
XX CC The present invention relates to extendings and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion

Sequence 29 AA;
AAB52931 Length: 29 February 4, 2005 13:20 Type: P Check: 2320 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
HGEFTFTDLSKQLEEEAVRLFIEFLKNGG
28

1 match found in sequence:
aab52932 : Extending agonist compound #60.
(from "seq4ags.pep")
TOIG of: aab52932 check: 6333 from: 1 to: 38

ID AAB52932 standard; peptide; 38 AA.
XX AC AAB52932;
XX DT 28-FEB-2001 (first entry)
XX DE Extending agonist compound #60.
XX KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PA (AMYL-) AMYLIN PHARM INC.

XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
XX polyethylene glycol (PEG). These can be used in the treatment of
XX diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 38 AA;
XX
AAB52932 Length: 38 February 4, 2005 13:20 Type: P Check: 6333 ..
Found using 'seq4' (mohamed337.key)
1 HGGTFTSDLSKQMEEEAVRLFIEWLKNKGSPSSGAPPP
1 28

1 match found in sequence:
aab52933 ; Extendin agonist compound #61.
(from "seq4ags.pep")
TOIG of: aab52933 check: 6333 from: 1 to: 38
ID AAB52933 standard; peptide; 38 AA.
XX
XX AC AAB52933;
XX
XX 28-FEB-2001 (first entry)
XX
XX Extendin agonist compound #61.
XX
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
XX
XX WO200066629-A1.
XX
XX 09-NOV-2000.
XX
XX 28-APR-2000; 2000WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
XX polyethylene glycol (PEG). These can be used in the treatment of
XX diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX

SQ Sequence 38 AA;
AAB52933 Length: 38 February 4, 2005 13:20 Type: P Check: 6333 ..
Found using 'seq4' (mohamed337.key)
1 HGGTFTSDLSKQMEEEAVRLFIEWLKNKGSPSSGAPPP
1 28

1 match found in sequence:
aab52934 ; Extendin agonist compound #62.
(from "seq4ags.pep")
TOIG of: aab52934 check: 3541 from: 1 to: 37
ID AAB52934 standard; peptide; 37 AA.
XX
XX AC AAB52934;
XX
XX 28-FEB-2001 (first entry)
XX
XX Extendin agonist compound #62.
XX
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
XX
XX WO200066629-A1.
XX
XX 09-NOV-2000.
XX
XX 28-APR-2000; 2000WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
XX polyethylene glycol (PEG). These can be used in the treatment of
XX diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 37 AA;
XX
AAB52934 Length: 37 February 4, 2005 13:20 Type: P Check: 3541 ..
Found using 'seq4' (mohamed337.key)
1 HGGTFTSDLSKQMEEEAVRLFIEWLKNKGXSSGAPP
1 28

1 match found in sequence:
aab52935 ; Extendin agonist compound #63.
(from "seq4ags.pep")
TOIG of: aab52935 check: 4125 from: 1 to: 37
ID AAB52935 standard; peptide; 37 AA.
XX
XX AC AAB52935;


```
XX SQ Sequence 36 AA;
AAB52937 Length: 36 February 4, 2005 13:20 Type: P Check: 333
Found using 'seq4' (mohamed337.key)
1 HGGTFTSDLSKQMEEEAVRLFIEWLKNKGPSGAP
1
-----
1 match found in sequence:
aab52938 ; Extending agonist compound #66.
(from "seq4ags.pep")
TOIG of: aab52938 check: 7463 from: 1 to: 35
ID AAB52938 standard; peptide; 35 AA.
XX AC
XX AC AAB52938;
XX DT
XX DT 28-FEB-2001 (first entry)
XX DE
XX DE Extending agonist compound #66.
XX KW
XX KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS
XX OS Heloderma sp.
XX PN
XX PN WO200066629-A1.
XX PD
XX PD 09-NOV-2000.
XX PF
XX PF 28-APR-2000; 2000WO-US011814.
XX PR
XX PR 30-APR-1999; 99US-0132018P.
XX PA
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI
XX PI Young A, Prickett K;
XX XX
XX XX WPI; 2000-672834/65.
XX PT
XX PT Modified extendin or an extendin agonist linked to one or more polyethylene
XX PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX PT treating disorders such as diabetes and obesity.
XX PS
XX PS Disclosure; Fig 4; 119pp; English.
XX CC
XX CC The present invention relates to extendins and their agonists which have
XX CC been modified with molecular weight increasing agents such as
XX CC polyethylene glycol (PEG). These can be used in the treatment of
XX CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX SQ
XX SQ Sequence 30 AA;
AAB52939 Length: 30 February 4, 2005 13:20 Type: P Check: 4886
Found using 'seq4' (mohamed337.key)
1 HGGTFTSDLSKQMEEEAVRLFIEWLKNKG
1 28
-----
1 match found in sequence:
aab52940 ; Extending agonist compound #68.
(from "seq4ags.pep")
TOIG of: aab52940 check: 369 from: 1 to: 28
ID AAB52940 standard; peptide; 28 AA.
XX AC
XX AC AAB52940;
XX DT
XX DT 28-FEB-2001 (first entry)
XX DE
XX DE Extending agonist compound #68.
XX KW
XX KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS
XX OS Heloderma sp.
XX PN
XX PN WO200066629-A1.
XX PD
XX PD 09-NOV-2000.
XX PF
XX PF 28-APR-2000; 2000WO-US011814.
XX PR
XX PR 30-APR-1999; 99US-0132018P.
XX SQ
XX SQ Sequence 30 AA;
AAB52939 Length: 30 February 4, 2005 13:20 Type: P Check: 4886
Found using 'seq4' (mohamed337.key)
1 HGGTFTSDLSKQMEEEAVRLFIEWLKNKG
1 28
-----
1 match found in sequence:
aab52940 ; Extending agonist compound #68.
(from "seq4ags.pep")
TOIG of: aab52940 check: 369 from: 1 to: 28
ID AAB52940 standard; peptide; 28 AA.
XX AC
XX AC AAB52940;
XX DT
XX DT 28-FEB-2001 (first entry)
XX DE
XX DE Extending agonist compound #68.
XX KW
XX KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX KW insulin-resistance syndrome; food intake.
XX OS
XX OS Heloderma sp.
XX PN
XX PN WO200066629-A1.
XX PD
XX PD 09-NOV-2000.
XX PF
XX PF 28-APR-2000; 2000WO-US011814.
XX PR
XX PR 30-APR-1999; 99US-0132018P.
```

XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX Modified extendin or an extendin agonist linked to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.
XX Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 28 AA;
AAB52940 Length: 28 February 4, 2005 13:20 Type: P Check: 369 ..
Found using 'seq4' (mohamed337.key)
1 HEGGTXSDLSKQLEEEAVRLFIEFLKN 28

1 match found in sequence:
aab52941 ; Extendin agonist compound #69.
(from "seq4ags.pep")
TOIG of: aab52941 check: 693 from: 1 to: 28
ID AAB52941 standard; peptide; 28 AA.
XX AC AAB52941;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #69.
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX WO200066629-A1.
XX AC AAB52941;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #69.
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
(AMYL-) AMYLIN PHARM INC.
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX Modified extendin or an extendin agonist linked to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.
XX Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 28 AA;
AAB52942 Length: 28 February 4, 2005 13:20 Type: P Check: 701 ..
Found using 'seq4' (mohamed337.key)
1 HEGGTFSSDLSKQMEEEAVRLFIEWLKN 28

1 match found in sequence:
aab52943 ; Extendin agonist compound #71.
(from "seq4ags.pep")
TOIG of: aab52943 check: 649 from: 1 to: 28
ID AAB52943 standard; peptide; 28 AA.

CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 28 AA;
AAB52941 Length: 28 February 4, 2005 13:20 Type: P Check: 693 ..
Found using 'seq4' (mohamed337.key)
1 HEGGTFSSDLSKQMEEEAVRLFIEWLKN 28

1 match found in sequence:
aab52942 ; Extendin agonist compound #70.
(from "seq4ags.pep")
TOIG of: aab52942 check: 701 from: 1 to: 28
ID AAB52942 standard; peptide; 28 AA.
XX AC AAB52942;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #70.
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX WO200066629-A1.
XX AC AAB52942;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #70.
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX Heloderma sp.
XX WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
(AMYL-) AMYLIN PHARM INC.
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX Modified extendin or an extendin agonist linked to one or more polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for treating disorders such as diabetes and obesity.
XX Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have been modified with molecular weight increasing agents such as polyethylene glycol (PEG). These can be used in the treatment of diabetes, obesity, impaired glucose tolerance, postprandial dumping syndrome, postprandial hyperglycaemia, eating disorders, insulin resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 28 AA;
AAB52942 Length: 28 February 4, 2005 13:20 Type: P Check: 701 ..
Found using 'seq4' (mohamed337.key)
1 HEGGTFSSDLSKQMEEEAVRLFIEWLKN 28

1 match found in sequence:
aab52943 ; Extendin agonist compound #71.
(from "seq4ags.pep")
TOIG of: aab52943 check: 649 from: 1 to: 28
ID AAB52943 standard; peptide; 28 AA.

CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX Sequence 28 AA;
 SQ
 AAB52946 Length: 28 February 4, 2005 13:20 Type: P Check: 1045 ..
 Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGEFTSDLSKQMBEEAVRLFEXWLKN 28

 1 match found in sequence:
 aab52947 ; Extending agonist compound #75.
 (from "seq4ags.pep")
 TOIG of: aab52947 check: 237 from: 1 to: 28

ID AAB52947 standard; peptide; 28 AA.
 XX
 AC AAB52947;
 XX
 DT 28-FEB-2001 (first entry)
 XX
 DE Extending agonist compound #75.
 XX
 KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 XX
 OS Heloderma sp.
 XX
 PN WO200066629-A1.
 XX
 PD 09-NOV-2000.
 XX
 PF 28-APR-2000; 2000WO-US011814.
 XX
 PR 30-APR-1999; 99US-0132018P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Prickett K;
 XX
 WPI; 2000-672834/65.
 XX
 DR Modified extendin or an extendin agonist linked to one or more polyethylene
 PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
 PT treating disorders such as diabetes and obesity.
 XX
 PS Disclosure; Fig 4; 119pp; English.
 XX
 CC The present invention relates to extendins and their agonists which have
 CC been modified with molecular weight increasing agents such as
 CC polyethylene glycol (PEG). These can be used in the treatment of
 CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
 CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX
 SQ Sequence 28 AA;
 XX
 PI Young A, Prickett K;
 XX
 WPI; 2000-672834/65.
 XX
 DR Modified extendin or an extendin agonist linked to one or more polyethylene
 PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
 PT treating disorders such as diabetes and obesity.
 XX
 PS Disclosure; Fig 4; 119pp; English.
 XX
 CC The present invention relates to extendins and their agonists which have
 CC been modified with molecular weight increasing agents such as
 CC polyethylene glycol (PEG). These can be used in the treatment of
 CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
 CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX
 SQ Sequence 28 AA;
 XX
 DT 28-FEB-2001 (first entry)
 XX
 DE Extending agonist compound #75.
 XX
 KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 XX
 OS Heloderma sp.
 XX
 PN WO200066629-A1.
 XX
 PD 09-NOV-2000.
 XX
 PF 28-APR-2000; 2000WO-US011814.
 XX
 PR 30-APR-1999; 99US-0132018P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Prickett K;
 XX
 WPI; 2000-672834/65.
 XX
 DR Modified extendin or an extendin agonist linked to one or more polyethylene
 PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
 PT treating disorders such as diabetes and obesity.
 XX
 PS Disclosure; Fig 4; 119pp; English.
 XX
 CC The present invention relates to extendins and their agonists which have
 CC been modified with molecular weight increasing agents such as
 CC polyethylene glycol (PEG). These can be used in the treatment of
 CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
 CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX
 SQ Sequence 28 AA;
 XX
 DT 28-FEB-2001 (first entry)
 XX
 DE Extending agonist compound #75.
 XX
 KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 XX
 OS Heloderma sp.
 XX
 PN WO200066629-A1.
 XX
 PD 09-NOV-2000.
 XX
 PF 28-APR-2000; 2000WO-US011814.
 XX

ID AAB52948 standard; peptide; 33 AA.
 XX
 AC AAB52948;
 XX
 DT 28-FEB-2001 (first entry)
 XX
 DE Extending agonist compound #76.
 XX
 KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 XX
 OS Heloderma sp.
 XX
 PN WO200066629-A1.
 XX
 PD 09-NOV-2000.
 XX
 PF 28-APR-2000; 2000WO-US011814.
 XX
 PR 30-APR-1999; 99US-0132018P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Prickett K;
 XX
 WPI; 2000-672834/65.
 XX
 DR Modified extendin or an extendin agonist linked to one or more polyethylene
 PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
 PT treating disorders such as diabetes and obesity.
 XX
 PS Disclosure; Fig 4; 119pp; English.
 XX
 CC The present invention relates to extendins and their agonists which have
 CC been modified with molecular weight increasing agents such as
 CC polyethylene glycol (PEG). These can be used in the treatment of
 CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
 CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
 CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
 XX
 SQ Sequence 33 AA;
 XX
 DT 28-FEB-2001 (first entry)
 XX
 DE Extending agonist compound #77.
 XX
 KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 XX
 OS Heloderma sp.
 XX
 PN WO200066629-A1.
 XX
 PD 09-NOV-2000.
 XX
 PF 28-APR-2000; 2000WO-US011814.
 XX

1 match found in sequence:
 aab52949 ; Extending agonist compound #77.
 (from "seq4ags.pep")
 TOIG of: aab52949 check: 2649 from: 1 to: 29

1 |-----|
 1 HGEFTSDASKQLEEEAVRLFIEFLKNGPSS 28

 1 match found in sequence:
 aab52949 ; Extending agonist compound #77.
 (from "seq4ags.pep")
 TOIG of: aab52949 check: 2649 from: 1 to: 29

ID AAB52949 standard; peptide; 29 AA.
 XX
 AC AAB52949;
 XX
 DT 28-FEB-2001 (first entry)
 XX
 DE Extending agonist compound #77.
 XX
 KW Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
 KW insulin-resistance syndrome; food intake.
 XX
 OS Heloderma sp.
 XX
 PN WO200066629-A1.
 XX
 PD 09-NOV-2000.
 XX
 PF 28-APR-2000; 2000WO-US011814.
 XX

```
XX 30-APR-1999; 99US-0132018P.
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Prickett K;
XX WPI; 2000-672834/65.
XX Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
XX treating disorders such as diabetes and obesity.
XX Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
XX polyethylene glycol (PEG). These can be used in the treatment of
XX diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 29 AA;
AAB52949 Length: 29 February 4, 2005 13:20 Type: P Check: 2649 ..
Found using 'seq4' (mohamed337.key)
1 HGGFTTSDASKQMEEEAVRLFIEWLKNG
1 28
-----
1 match found in sequence:
aab52950; Extendin agonist compound #78.
(from "seq4ags.pep")
TOIG of: aab52950 check: 3183 from: 1 to: 37
ID AAB52950 standard; peptide; 37 AA.
XX AC AAB52950;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #78.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PS Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
XX polyethylene glycol (PEG). These can be used in the treatment of
XX diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 28 AA;
AAB52960 Length: 28 February 4, 2005 13:20 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)
1 HGGFTTSDASKQMEEEAVRLFIEWLKNG
1 28
-----
1 match found in sequence:
aab52964; Extendin agonist compound #92.
(from "seq4ags.pep")
TOIG of: aab52964 check: 688 from: 1 to: 28
```

```
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 37 AA;
AAB52950 Length: 37 February 4, 2005 13:20 Type: P Check: 3183 ..
Found using 'seq4' (mohamed337.key)
1 HGGFTTSDASKQMEEEAVRLFIEWLKNGGPPSSGAPP
1 28
-----
1 match found in sequence:
aab52960; Extendin agonist compound #88.
(from "seq4ags.pep")
TOIG of: aab52960 check: 249 from: 1 to: 28
ID AAB52960 standard; peptide; 28 AA.
XX AC AAB52960;
XX DT 28-FEB-2001 (first entry)
XX DE Extendin agonist compound #88.
XX KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
XX insulin-resistance syndrome; food intake.
XX OS Heloderma sp.
XX PN WO200066629-A1.
XX PD 09-NOV-2000.
XX PF 28-APR-2000; 2000WO-US011814.
XX PR 30-APR-1999; 99US-0132018P.
XX PS Disclosure; Fig 4; 119pp; English.
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
XX polyethylene glycol (PEG). These can be used in the treatment of
XX diabetes, obesity, impaired glucose tolerance, postprandial dumping
XX syndrome, postprandial hyperglycaemia, eating disorders, insulin
XX resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX Sequence 28 AA;
AAB52960 Length: 28 February 4, 2005 13:20 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)
1 HGGFTTSDASKQMEEEAVRLFIEWLKNG
1 28
-----
1 match found in sequence:
aab52964; Extendin agonist compound #92.
(from "seq4ags.pep")
TOIG of: aab52964 check: 688 from: 1 to: 28
```

```

PF 28-APR-2000; 200WO-US011814.
XX
XX 30-APR-1999; 99US-0132018P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 28 AA;
XX
AAB52967 Length: 28 February 4, 2005 13:20 Type: P Check: 590 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  | HEGTFTSDASKQMEEEAVRLFIEWLKN      28
  |
  |-----|
1 1 match found in sequence:
   aab53026 ; Extendin agonist compound #154.
   (from "seq4ags.pep")
TOIG or: aab53026 check: 5882 from: 1 to: 38

ID AAB53026 standard; peptide; 38 AA.
XX
AC AAB53026;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extendin agonist compound #154.
XX
KW Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
OS Heloderma sp.
XX
PN WO200066629-A1.
XX
PD 09-NOV-2000.
XX
PF 28-APR-2000; 200WO-US011814.
XX
PR 30-APR-1999; 99US-0132018P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Prickett K;
XX
XX WPI; 2000-672834/65.
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
XX
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG) polymers, modulate plasma glucose levels, useful for
CC treating disorders such as diabetes and obesity.

```

CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 38 AA;

AAB53026 Length: 38 February 4, 2005 13:20 Type: P Check: 5882 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGAGTFTDLSKQLEEEAVRLFIEFLKNGPSSGADPP 28

1 match found in sequence:
aab53031; Extending agonist compound #159.
(from "seq4ags.pep")
TOIG of: aab53031 check: 7002 from: 1 to: 35

ID AAB53031 standard; peptide; 35 AA.
XX
AC AAB53031;
XX
AC AAB53031;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #159.
XX
DE Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
KW
XX Heloderma sp.
OS
XX WO200066629-A1.
PN
XX 09-NOV-2000.
PD
XX 28-APR-2000; 2000WO-US011814.
PF
XX 30-APR-1999; 99US-0132018P.
PR
XX (AMYL-) AMYLIN PHARM INC.
XX
PA Young A, Prickett K;
XX
PI WPI; 2000-672834/65.
XX
DR Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
PT
XX Heloderma sp.
OS
XX WO200066629-A1.
PN
XX 09-NOV-2000.
PD
XX 28-APR-2000; 2000WO-US011814.
PF
XX 30-APR-1999; 99US-0132018P.
PR
XX (AMYL-) AMYLIN PHARM INC.
XX
PA Young A, Prickett K;
XX
PI WPI; 2000-672834/65.
XX
DR Disclosure; Fig 4; 119pp; English.
PS
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 35 AA;

AAB53031 Length: 35 February 4, 2005 13:20 Type: P Check: 7002 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGAGTFTDLSKQLEEEAVRLFIEFLKNGPSSGA 28

1 match found in sequence:
aab53035; Extending agonist compound #163.
(from "seq4ags.pep")
TOIG of: aab53035 check: 6321 from: 1 to: 38

ID AAB53035 standard; peptide; 32 AA.
XX
AC AAB53035;
XX
AC AAB53035;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #163.
XX
DE Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
KW
XX Heloderma sp.
OS
XX WO200066629-A1.
PN
XX 09-NOV-2000.
PD

TOIG of: aab53035 check: 9574 from: 1 to: 32

ID AAB53035 standard; peptide; 32 AA.
XX
AC AAB53035;
XX
AC AAB53035;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #163.
XX
DE Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
KW
XX Heloderma sp.
OS
XX WO200066629-A1.
PN
XX 09-NOV-2000.
PD
XX 28-APR-2000; 2000WO-US011814.
PF
XX 30-APR-1999; 99US-0132018P.
PR
XX (AMYL-) AMYLIN PHARM INC.
XX
PA Young A, Prickett K;
XX
PI WPI; 2000-672834/65.
XX
DR Modified extendin or an extendin agonist linked to one or more polyethylene
XX glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
PT
XX Disclosure; Fig 4; 119pp; English.
PS
XX The present invention relates to extendins and their agonists which have
XX been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
SQ Sequence 32 AA;

AAB53035 Length: 32 February 4, 2005 13:20 Type: P Check: 9574 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGAGTFTDLSKQLEEEAVRLFIEFLKNGGPS 28

1 match found in sequence:
aab53039; Extending agonist compound #167.
(from "seq4ags.pep")
TOIG of: aab53039 check: 6321 from: 1 to: 38

ID AAB53039 standard; peptide; 38 AA.
XX
AC AAB53039;
XX
AC AAB53039;
XX
DT 28-FEB-2001 (first entry)
XX
DE Extending agonist compound #167.
XX
DE Extending; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
KW
XX Heloderma sp.
OS
XX WO200066629-A1.
PN
XX 09-NOV-2000.
PD

```

XX 28-APR-2000; 2000WO-US011814.
PF
XX
XX 30-APR-1999; 99US-0132018P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, Prickett K;
PI
XX
XX WPI; 2000-672834/65.
DR
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
PS
XX The present invention relates to extendins and their agonists which have
CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 38 AA;
XX
AAB53039 Length: 38 February 4, 2005 13:20 Type: P Check: 6321 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGAGTFTSLSKQMBEEAVRLFIEWLKNKGPSGAPPP 28
1
-----
1 match found in sequence:
aab53043; Extendin agonist compound #171.
(from "seq4ags.pep")
TOIG of: aab53043 check: 7441 from: 1 to: 35
ID AAB53043 standard; peptide; 35 AA.
XX
AC AAB53043;
XX
XX 28-FEB-2001 (first entry)
DT
XX
XX Extendin agonist compound #171.
DE
XX
XX Extendin; agonist; diabetes; obesity; eating disorder; dyslipidaemia;
KW insulin-resistance syndrome; food intake.
XX
XX Heloderma sp.
OS
XX
XX WO200066629-A1.
PN
XX
XX 09-NOV-2000.
PD
XX
XX 28-APR-2000; 2000WO-US011814.
PF
XX
XX 30-APR-1999; 99US-0132018P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young A, Prickett K;
PI
XX
XX WPI; 2000-672834/65.
DR
XX
XX Modified extendin or an extendin agonist linked to one or more polyethylene
PT glycol (PEG) polymers, modulate plasma glucose levels, useful for
PT treating disorders such as diabetes and obesity.
XX
XX Disclosure; Fig 4; 119pp; English.
PS
XX The present invention relates to extendins and their agonists which have

```

```

CC been modified with molecular weight increasing agents such as
CC polyethylene glycol (PEG). These can be used in the treatment of
CC diabetes, obesity, impaired glucose tolerance, postprandial dumping
CC syndrome, postprandial hyperglycaemia, eating disorders, insulin
CC resistance syndrome, dyslipidaemia and to suppress glucagon secretion
XX
XX Sequence 35 AA;
XX
AAB53043 Length: 35 February 4, 2005 13:20 Type: P Check: 7441 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGAGTFTSLSKQMBEEAVRLFIEWLKNKGPSGSA 28
1
-----
1 match found in sequence:
aab60252; Gila monster venom GLP-1 analogue, extendin 3.
(from "seq4ags.pep")
TOIG of: aab60252 check: 9591 from: 1 to: 39
ID AAB60252 standard; peptide; 39 AA.
XX
AC AAB60252;
XX
XX 28-MAR-2001 (first entry)
DT
XX
XX Gila monster venom GLP-1 analogue, extendin 3.
DE
XX
XX Extendin 3; Gila monster venom; GLP-1 analogue; glucagon-like peptide-1;
KW type II diabetes; non-insulin dependent diabetes mellitus; NIDDM;
KW beta-cell function; secretory capacity; impaired glucose tolerance; IGT;
KW beta-cell stimulatory test; diagnostic test; insulinotropic.
XX
XX Heloderma suspectum.
OS
XX
XX WO200077039-A2.
PN
XX
XX 21-DEC-2000.
PD
XX
XX 14-JUN-2000; 2000WO-US016428.
PF
XX
XX 15-JUN-1999; 99US-00333415.
PR
XX
XX (BION-) BIONEBRASKA INC.
PA
XX
XX Holst JJ, Vilseboll T;
PI
XX
XX WPI; 2001-102518/11.
DR
XX
XX Evaluating beta-cell secretory capacity and responsiveness to glucose,
PT useful for diagnosing impaired glucose tolerance and diabetes, comprises
PT employing glucagon-like-peptide-1 as a diagnostic test to determine beta-
PT cell function.
XX
XX Disclosure; Page 13; 42pp; English.
PS
XX
XX The invention relates to a new method for evaluating beta-cell secretory
CC capacity in an individual, or responsiveness of a beta-cell to glucose,
CC comprising the administration of glucose and glucagon-like peptide-1 (GLP
CC -1) or its biologically active analogues. The response in the individual
CC is then measured against the standard response of a healthy individual to
CC determine if the individual has impaired beta-cell function. The method
CC is useful for detecting impaired beta-cell function in an individual, and
CC is particularly useful for diagnosing impaired glucose tolerance (IGT)
CC and non-insulin-dependent (type II) diabetes. The method is a rapid test
CC of beta-cell function, which is a marker for impaired glucose tolerance.
CC Unlike prior methods, the method is reliable and without significant
CC adverse side effects and/or patient pain and discomfort. The method also
CC provides information about insulin secretory capacity, and is easy and
CC reproducible. The present sequence represents a Gila monster venom GLP-1
CC analogue peptide referred to in the disclosure of the invention
XX

```

SQL Sequence 39 AA;

AAB60252 Length: 39 February 4, 2005 13:19 Type: P Check: 9591
Found using 'seq4' (mohamed337.key)

1 HSDGTTSDLSKQMBEEAVRLFIEWLKNKGPPSSGAPPPS
28
TOIG of: aab60254 check: 9570 from: 1 to: 39

1 match found in sequence:
aab60254 ; Gila monster venom GLP-1 analogue, extendin 4.
(from "seq4ags.pep")
TOIG of: aab60254 check: 9570 from: 1 to: 39

ID AAB60254 standard; peptide; 39 AA.

XX AC AAB60254;

XX DT 28-MAR-2001 (first entry)

XX DE Gila monster venom GLP-1 analogue, extendin 4.

XX KW Extendin 4; Gila monster venom; GLP-1 analogue; glucagon-like peptide-1;
type II diabetes; non-insulin dependent diabetes mellitus; NIDDM;
beta-cell function; secretory capacity; impaired glucose tolerance; IGT;
beta-cell stimulatory test; diagnostic test; insulinotropic.

XX OS Heloderma suspectum.

XX PN WO200077039-A2.

XX PD 21-DEC-2000.

XX PF 14-JUN-2000; 2000WO-US016428.

XX PR 15-JUN-1999; 99US-00333415.

XX PA (BION-) BIONEBRASKA INC.

XX PI Holst JJ, Vilsbøll T;

XX PS WPI; 2001-102518/11.

XX CC Evaluating beta-cell secretory capacity and responsiveness to glucose,
PT useful for diagnosing impaired glucose tolerance and diabetes, comprises
PT employing glucagon-like-peptide-1 as a diagnostic test to determine beta-
cell function.

XX PS Disclosure; Page 13; 42pp; English.

XX CC The invention relates to a new method for evaluating beta-cell secretory
CC capacity in an individual, or responsiveness of a beta-cell to glucose,
CC comprising the administration of glucose and glucagon-like peptide-1 (GLP
CC -1) or its biologically active analogues. The response in the individual
CC is then measured against the standard response of a healthy individual to
CC determine if the individual has impaired beta-cell function. The method
CC is useful for detecting impaired beta-cell function in an individual, and
CC is particularly useful for diagnosing impaired glucose tolerance (IGT)
CC and non-insulin-dependent (type II) diabetes. The method is a rapid test
CC of beta-cell function, which is a marker for impaired glucose tolerance.
CC Unlike prior methods, the method is reliable and without significant
CC adverse side effects and/or patient pain and discomfort. The method also
CC provides information about insulin secretory capacity, and is easy and
CC reproducible. The present sequence represents a Gila monster venom GLP-1
CC analogue peptide referred to in the disclosure of the invention

XX SQL Sequence 39 AA;

AAB60254 Length: 39 February 4, 2005 13:19 Type: P Check: 9570
Found using 'seq4' (mohamed337.key)

1 HSGGTTSDLSKQMBEEAVRLFIEWLKNKGPPSSGAPPPS
28

1 match found in sequence:
aab64181 ; Mexican beaded lizard extendin-3, SEQ ID NO:1.
(from "seq4ags.pep")
TOIG of: aab64181 check: 9591 from: 1 to: 39

ID AAB64181 standard; peptide; 39 AA.

XX AC AAB64181;

XX DT 27-MAR-2001 (first entry)

XX DE Mexican beaded lizard extendin-3, SEQ ID NO:1.

XX KW Extendin-3; gestational diabetes mellitus; GDM; insulin resistance;
pregnancy complication; neonatal abnormality; blood glucose modulator;
insulinotropic; anorectic; Mexican beaded lizard.

XX OS Heloderma horridum.

XX PN WO200073331-A2.

XX PD 07-DEC-2000.

XX PF 23-MAY-2000; 2000WO-US014231.

XX PR 01-JUN-1999; 99US-00323867.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Hiles R, Prickett KS;

XX DR WPI; 2001-137634/14.

XX CC Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

XX PS Claim 11; Page 10-11; 133pp; English.

XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of fetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents extendin-3
CC from the Mexican beaded lizard which is specifically claimed for use in
CC the invention

XX SQL Sequence 39 AA;

AAB64181 Length: 39 February 4, 2005 13:19 Type: P Check: 9591
Found using 'seq4' (mohamed337.key)

```

1 1 HSDGFTSLSKQMEEEAVRLFIWLKNGSPSSGAPPPS
    1 1 HSDGFTSLSKQMEEEAVRLFIWLKNGSPSSGAPPPS
    28 28
-----
1 match found in sequence:
aab64182 ; Gila monster extendin-4, SEQ ID NO:2.
(from "seq4ags.pep")
TOIG of: aab64182 check: 9570 from: 1 to: 39
ID AAB64182 standard; peptide; 39 AA.
XX AC AAB64182;
XX DT 27-MAR-2001 (first entry)
XX DE Gila monster extendin-4, SEQ ID NO:2.
XX KW Extendin-4; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; Gila monster.
XX OS Heloderma suspectum.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Claim 12; Page 11; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents extendin-4
XX CC from the Gila monster, which is specifically claimed for use in the
XX CC invention
XX SQ Sequence 39 AA;

```

```

AAB64182 Length: 39 February 4, 2005 13:19 Type: P Check: 9570
Found using 'seq4' (mohamed337.key)
1 HCEGFTSLSKQMEEEAVRLFIWLKNGSPSSGAPPPS
  1 1 HCEGFTSLSKQMEEEAVRLFIWLKNGSPSSGAPPPS
  28 28
-----
1 match found in sequence:
aab64185 ; Extendin-4 (1-30), SEQ ID NO:6.
(from "seq4ags.pep")
TOIG of: aab64185 check: 4889 from: 1 to: 30
ID AAB64185 standard; peptide; 30 AA.
XX AC AAB64185;
XX DT 27-MAR-2001 (first entry)
XX DE Extendin-4 (1-30), SEQ ID NO:6.
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Claim 13; Page 13; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a
XX CC specifically claimed extendin agonist, which is based upon the sequence of
XX CC extendin-4

```

SQ Sequence 30 AA;

AAB64185 Length: 30 February 4, 2005 13:19 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
HGGTFTSDLSKQMEEEAVRLFIEWLKNGG 28
1

1 match found in sequence:
aab64186 ; Exendin-4 (1-30)-amide, SEQ ID NO:7.
(from "seq4ags.pep")
TOIG of: aab64186 check: 4889 from: 1 to: 30

ID AAB64186 standard; peptide; 30 AA.

XX AAB64186;

XX 27-MAR-2001 (first entry)

XX Exendin-4 (1-30)-amide, SEQ ID NO:7.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.

OS Heloderma suspectum.

OS Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

XX Claim 13; Page 13; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a

CC specifically claimed exendin agonist, which is based upon the sequence of
CC exendin-4

SQ Sequence 30 AA;

AAB64186 Length: 30 February 4, 2005 13:19 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
HGGTFTSDLSKQMEEEAVRLFIEWLKNGG 28
1

1 match found in sequence:

aab64187 ; [Leu 14, Ala 22, Phe 25]- exendin-4 (1-28) amide, SEQ ID NO:8.
(from "seq4ags.pep")

TOIG of: aab64187 check: 151 from: 1 to: 28

ID AAB64187 standard; peptide; 28 AA.

XX AAB64187;

XX 27-MAR-2001 (first entry)

XX [Leu 14, Ala 22, Phe 25]- exendin-4 (1-28) amide, SEQ ID NO:8.

XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.

OS Heloderma suspectum.

OS Synthetic.

XX WO200073331-A2.

XX 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

XX Disclosure; Page 13; 133pp; English.

XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a

CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 28 AA;
 AAB64187 Length: 28 February 4, 2005 13:19 Type: P Check: 151 ..
 Found using 'seq4' (mohamed337.key)
 1 |-----|
 1 HGEFTFTDLSKQLEEEAVRLAIEFLKN 28

 1 match found in sequence:
 aab64188 ; [Leu 14, Phe 25]- extendin-4 amide, SEQ ID NO:9.
 (from "seq4ags.pep")
 TOIG of: aab64188 check: 9131 from: 1 to: 39
 ID AAB64188 standard; peptide; 39 AA.
 XX
 AC AAB64188;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE [Leu 14, Phe 25]- extendin-4 amide, SEQ ID NO:9.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 XX insulinotropic; anorectic; extendin-4.
 KW Heloderma suspectum.
 OS Synthetic.
 OS
 XX WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Claim 13; Page 13; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for

CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a
 CC specifically claimed extendin agonist, which is based upon the sequence of
 CC extendin-4
 XX
 SQ Sequence 39 AA;
 AAB64188 Length: 39 February 4, 2005 13:19 Type: P Check: 9131 ..
 Found using 'seq4' (mohamed337.key)
 1 |-----|
 1 HGEFTFTDLSKQLEEEAVRLFIEFLKNGPSSGAPPS 28

 1 match found in sequence:
 aab64189 ; Extendin agonist, SEQ ID NO:9.
 (from "seq4ags.pep")
 TOIG of: aab64189 check: 9351 from: 1 to: 39
 ID AAB64189 standard; peptide; 39 AA.
 XX
 AC AAB64189;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:9.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 XX insulinotropic; anorectic; extendin-4.
 OS Heloderma suspectum.
 OS Synthetic.
 OS
 XX WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 1; Fig 1A; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for

CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 39 AA;

AAB64189 Length: 39 February 4, 2005 13:19 Type: P Check: 9351 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTTSLSKQLEEEAVRLPIELFKNGPSSGAPPPS
 1 28
 -----|-----
 1 match found in sequence:
 aab64190 ; Extendin agonist, SEQ ID NO:10.
 (from "seq4ags.pep")
 TOIG of: aab64190 check: 9776 from: 1 to: 39

ID AAB64190 standard; peptide; 39 AA.
 AC AAB64190;
 XX
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:10.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 XX WO200073331-A2.
 PN
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 2; Fig 1A; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.

CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 39 AA;

AAB64190 Length: 39 February 4, 2005 13:19 Type: P Check: 9776 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTTSLSKQLEEEAVRLPIELFKNGPSSGAPPPS
 1 28
 -----|-----
 1 match found in sequence:
 aab64191 ; Extendin agonist, SEQ ID NO:11.
 (from "seq4ags.pep")
 TOIG of: aab64191 check: 9365 from: 1 to: 39

ID AAB64191 standard; peptide; 39 AA.
 XX
 AC AAB64191;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extendin agonist, SEQ ID NO:11.
 XX
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 XX WO200073331-A2.
 PN
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 3; Fig 1A; 133pp; English.
 XX
 CC The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities

CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. CC Extensins are peptides from the salivary secretions of the Gila monster CC (extensin-4) and the Mexican bearded lizard (extensin-3) which exhibit CC homology with several members of the glucagon-like peptide family. CC particularly GLP-1, and have similar insulinotropic effects. Unlike the CC compounds used to treat type 2 diabetes, which are contraindicated for CC GDM, extensins and extensin agonists do not cross the placenta and thus do CC not cause severe prolonged hypoglycaemia in the newborn. They have a CC potent and prolonged effect on blood glucose, and, unlike conventional CC insulin therapy, should not cause weight gain, as they inhibit gastric CC emptying and reduce appetite. The present sequence represents a extensin CC agonist of the invention which is based upon the sequence of extensin-4 XX Sequence 39 AA;

AAB64191 Length: 39 February 4, 2005 13:19 Type: P Check: 9365 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSLSKQMEEAARLPFLKNGSPSGAPPPS 28
1 -----
1 match found in sequence:
aab64192 ; Extensin agonist, SEQ ID NO:12.
(from "seq4ags.pep")
TOIG of: aab64192 check: 9807 from: 1 to: 39

ID AAB64192 standard; peptide; 39 AA.
XX AAB64192;
AC
XX 27-MAR-2001 (first entry)
DT
XX Extensin agonist, SEQ ID NO:12.
DE
XX Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extensin-4.
XX Heloderma suspectum.
OS Synthetic.
OS WO200073331-A2.
PN
XX 07-DEC-2000.
PD
XX 23-MAY-2000; 2000WO-US014231.
PF
XX 01-JUN-1999; 99US-00323867.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Hiles R, Prickett KS;
PI
XX WPI; 2001-137634/14.
DR
XX Use of extensins or extensin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
PS Example 3; Fig 1A; 133pp; English.
XX

The invention relates to the use of an extensin (AAB64181-B64182) or an CC extensin agonist (AAB64185-B64368) for treating gestational diabetes CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a CC combination of increased insulin resistance and a diminished ability to CC increase insulin secretion. In contrast, in a normal pregnancy, both CC insulin resistance and insulin secretion increase. GDM pregnancies are CC associated with complications in both the mother and the foetus. Women CC with GDM have increased rates of Caesarian delivery, hypertensive CC disorders such as pre-eclampsia, and urinary tract infections. GDM CC

CC results in an elevated rate of foetal abnormalities such as neural tube CC defects, and is associated with an increased risk of neonatal morbidities CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. CC Extensins are peptides from the salivary secretions of the Gila monster CC (extensin-4) and the Mexican bearded lizard (extensin-3) which exhibit CC homology with several members of the glucagon-like peptide family, CC particularly GLP-1, and have similar insulinotropic effects. Unlike the CC compounds used to treat type 2 diabetes, which are contraindicated for CC GDM, extensins and extensin agonists do not cross the placenta and thus do CC not cause severe prolonged hypoglycaemia in the newborn. They have a CC potent and prolonged effect on blood glucose, and, unlike conventional CC insulin therapy, should not cause weight gain, as they inhibit gastric CC emptying and reduce appetite. The present sequence represents a extensin CC agonist of the invention which is based upon the sequence of extensin-4 XX Sequence 39 AA;

AAB64192 Length: 39 February 4, 2005 13:19 Type: P Check: 9807 ..
Found using 'seq4' (mohamed337.key)

1 YGEGTFTSLSKQMEEAARLPFLKNGSPSGAPPPS 28
1 -----
1 match found in sequence:
aab64193 ; Extensin agonist, SEQ ID NO:13.
(from "seq4ags.pep")
TOIG of: aab64193 check: 24 from: 1 to: 39

ID AAB64193 standard; peptide; 39 AA.
XX AAB64193;
AC
XX 27-MAR-2001 (first entry)
DT
XX Extensin agonist, SEQ ID NO:13.
DE
XX Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extensin-4.
XX Heloderma suspectum.
OS Synthetic.
OS WO200073331-A2.
PN
XX 07-DEC-2000.
PD
XX 23-MAY-2000; 2000WO-US014231.
PF
XX 01-JUN-1999; 99US-00323867.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Hiles R, Prickett KS;
PI
XX WPI; 2001-137634/14.
DR
XX Use of extensins or extensin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
PS Example 4; Fig 1A; 133pp; English.
XX

The invention relates to the use of an extensin (AAB64181-B64182) or an CC extensin agonist (AAB64185-B64368) for treating gestational diabetes CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a CC combination of increased insulin resistance and a diminished ability to CC increase insulin secretion. In contrast, in a normal pregnancy, both CC insulin resistance and insulin secretion increase. GDM pregnancies are CC associated with complications in both the mother and the foetus. Women CC

CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and extensin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extensin
 CC agonist of the invention which is based upon the sequence of extensin-4
 XX
 SQ Sequence 39 AA;

AAB64193 Length: 39 February 4, 2005 13:19 Type: P Check: 24 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTSLSKQMBEEAVRLPIEWLKNKGPPSGAPPY
 1
 28

1 match found in sequence:
 aab64194 ; Extensin agonist, SEQ ID NO:14.
 (from "seq4ags.pep")
 TOIG of: aab64194 check: 9787 from: 1 to: 39

ID AAB64194 standard; peptide; 39 AA.

XX
 AC AAB64194;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extensin agonist, SEQ ID NO:14.
 XX
 KW Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extensin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extensins or extensin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 5; Fig 1A; 133pp; English.
 XX
 CC The invention relates to the use of an extensin (AAB64181-B64182) or an
 CC extensin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both

CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extensins and extensin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extensin
 CC agonist of the invention which is based upon the sequence of extensin-4
 XX
 SQ Sequence 39 AA;

AAB64194 Length: 39 February 4, 2005 13:19 Type: P Check: 9787 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTSLSKQMBEEAVRLPIEWLKNKGPPSGAPPY
 1
 28

1 match found in sequence:
 aab64195 ; Extensin agonist, SEQ ID NO:15.
 (from "seq4ags.pep")
 TOIG of: aab64195 check: 9898 from: 1 to: 39

ID AAB64195 standard; peptide; 39 AA.

XX
 AC AAB64195;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Extensin agonist, SEQ ID NO:15.
 XX
 KW Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extensin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of extensins or extensin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 6; Fig 1A; 133pp; English.
 XX
 CC The invention relates to the use of an extensin (AAB64181-B64182) or an
 CC extensin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a

CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC SQ Sequence 39 AA;

AAB64195 Length: 39 February 4, 2005 13:19 Type: P Check: 9898 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTSLSKQMBEEAVRLPIELWLNKGSPSSGAPPPS
 28

 1 match found in sequence:
 aab64196 ; Exendin agonist, SEQ ID NO:16.
 (from "seq4ags.pep")
 TOIG of: aab64196 Check: 9783 from: 1 to: 39

ID AAB64196 standard; peptide; 39 AA.

XX
 XX AAB64196;
 AC
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:16.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 7; Fig 1A; 133pp; English.
 PS
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an

CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC SQ Sequence 39 AA;

AAB64196 Length: 39 February 4, 2005 13:19 Type: P Check: 9783 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTSLSKQMBEEAVRLPIELWLNKGSPSSGAPPPS
 28

 1 match found in sequence:
 aab64197 ; Exendin agonist, SEQ ID NO:17.
 (from "seq4ags.pep")
 TOIG of: aab64197 Check: 9791 from: 1 to: 39

ID AAB64197 standard; peptide; 39 AA.

XX
 AC AAB64197;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:17.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 8; Fig 1A; 133pp; English.
 PS

```

XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX CC
XX CC Sequence 39 AA;
XX CC
XX CC AAB64197 Length: 39 February 4, 2005 13:19 Type: P Check: 9791
XX CC Found using 'seq4' (mohamed337.key)
XX CC
1 HCGEGFTDLSKQMEEEAVRLPIEWLKNKGSPSGAPPPS
1 28
-----
1 match found in sequence:
aab64198 ; Extendin agonist, SEQ ID NO:18.
(from "seq4ags.pep")
TOIG of: aab64198 check: 9798 from: 1 to: 39

ID AAB64198 standard; peptide; 39 AA.
XX AC AAB64198;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:18.
XX DE
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX OS
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PD
XX PF 23-MAY-2000; 2000WO-US014231.
XX PF
XX PR 01-JUN-1999; 99US-00323867.
XX PR
XX PA (AMYL-) AMYLIN PHARM INC.
XX PA
XX PI Hiles R, Prickett KS;
XX PI
XX DR WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.

```

```

XX CC Example 9; Fig 1A; 133pp; English.
XX CC
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX CC
XX CC Sequence 39 AA;
XX CC
XX CC AAB64198 Length: 39 February 4, 2005 13:19 Type: P Check: 9798
XX CC Found using 'seq4' (mohamed337.key)
XX CC
1 HCGEGFTDLSKQMEEEAVRLPIEWLKNKGSPSGAPPPS
1 28
-----
1 match found in sequence:
aab64199 ; Extendin agonist, SEQ ID NO:19.
(from "seq4ags.pep")
TOIG of: aab64199 check: 9799 from: 1 to: 39

ID AAB64199 standard; peptide; 39 AA.
XX AC AAB64199;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:19.
XX DE
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX OS
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PD
XX PF 23-MAY-2000; 2000WO-US014231.
XX PF
XX PR 01-JUN-1999; 99US-00323867.
XX PR
XX PA (AMYL-) AMYLIN PHARM INC.
XX PA
XX PI Hiles R, Prickett KS;
XX PI
XX DR WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT

```

```

PT Glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
PS Example 10; Fig 1A; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 39 AA;
AAB64199 Length: 39 February 4, 2005 13:19 Type: P Check: 9799 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSELSKQMBEEAVRLPIEWLNKGSPSSGAPPPS
1
-----|-----|
1 match found in sequence:
aab64200 ; Extendin agonist, SEQ ID NO:20.
(from "seq4ags.pep")
TOIG of: aab64200 check: 9910 from: 1 to: 39

ID AAB64200 standard; peptide; 39 AA.
XX
AC AAB64200;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:20.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.

```

```

XX Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 11; Fig 1A; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 39 AA;
AAB64200 Length: 39 February 4, 2005 13:19 Type: P Check: 9910 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSDXSKQMBEEAVRLPIEWLNKGSPSSGAPPPS
1
-----|-----|
1 match found in sequence:
aab64201 ; Extendin agonist, SEQ ID NO:21.
(from "seq4ags.pep")
TOIG of: aab64201 check: 9471 from: 1 to: 39

ID AAB64201 standard; peptide; 39 AA.
XX
AC AAB64201;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:21.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;

```



```

XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 14; Fig 1B; 133pp; English.
XX PS
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 39 AA;
XX
AAB64203 Length: 39 February 4, 2005 13:19 Type: P Check: 9519
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQXEEAVRLPIEFLKNGPSSGAPPPS
1 28
-----
1 match found in sequence:
aab64204 ; Extendin agonist, SEQ ID NO:24.
(from "seq4ags.pep")
TOIG of: aab64204 check: 9966 from: 1 to: 39
ID AAB64204 standard; peptide; 39 AA.
XX AC AAB64204;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:24.
XX DE
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX OS
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PD
XX PF 23-MAY-2000; 2000WO-US014231.

```

```

XX PR 01-JUN-1999; 99US-00323867.
XX PR (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 15; Fig 1B; 133pp; English.
XX PS
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 39 AA;
XX
AAB64204 Length: 39 February 4, 2005 13:19 Type: P Check: 9966
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQXEEAVRLKIEWLKNKGPPSSGAPPPS
1 28
-----
1 match found in sequence:
aab64205 ; Extendin agonist, SEQ ID NO:25.
(from "seq4ags.pep")
TOIG of: aab64205 check: 9790 from: 1 to: 39
ID AAB64205 standard; peptide; 39 AA.
XX AC AAB64205;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:25.
XX DE
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX OS
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PD

```

```

XX 23-MAY-2000; 2000WO-US014231.
XX PF
XX 01-JUN-1999; 99US-00323867.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Hiles R, Prickett KS;
XX PI
XX WPI; 2001-137634/14.
XX DR
XX Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS
XX Example 16; Fig 1B; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 39 AA;
AAB64205 Length: 39 February 4, 2005 13:19 Type: P Check: 9790
Found using 'seq4' (mohamed337.key)
1 HGEFTTSLSKQMEEEAVRLPIELKNGSPSSGAPPPS
1
-----
1 match found in sequence:
aab64206 ; Extendin agonist, SEQ ID NO:26.
(from "seq4ags.pep")
TOIG of: aab64206 check: 9351 from: 1 to: 39

ID AAB64206 standard; peptide; 39 AA.
XX
XX AAB64206;
XX AC
XX 27-MAR-2001 (first entry)
XX DT
XX Extendin agonist, SEQ ID NO:26.
XX DE
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX KW
XX Heloderma suspectum.
XX OS
XX Synthetic.
XX OS
XX WO200073331-A2.

```

```

XX 07-DEC-2000.
XX PD
XX 23-MAY-2000; 2000WO-US014231.
XX PF
XX 01-JUN-1999; 99US-00323867.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Hiles R, Prickett KS;
XX PI
XX WPI; 2001-137634/14.
XX DR
XX Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS
XX Example 17; Fig 1B; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 39 AA;
AAB64206 Length: 39 February 4, 2005 13:19 Type: P Check: 9351
Found using 'seq4' (mohamed337.key)
1 HGEFTTSLSKQLEEEAVRLPIELKNGSPSSGAPPPS
1
-----
1 match found in sequence:
aab64207 ; Extendin agonist, SEQ ID NO:27.
(from "seq4ags.pep")
TOIG of: aab64207 check: 135 from: 1 to: 39

ID AAB64207 standard; peptide; 39 AA.
XX
XX AAB64207;
XX AC
XX 27-MAR-2001 (first entry)
XX DT
XX Extendin agonist, SEQ ID NO:27.
XX DE
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX KW
XX Heloderma suspectum.
XX OS
XX Synthetic.
XX OS

```



```
KW insulintropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX
XX 07-DEC-2000.
PD
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 20; Fig 1B; 133pp; English.
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 39 AA;
SQ
AAB64209 Length: 39 February 4, 2005 13:19 Type: P Check: 9766 ..
Found using 'seq4' (mohamed337.key)
1 HGGGTFTSDLSKQWEEAEVRLPIDLWLNKGPPSSGAPPPS
1 28
-----
1 match found in sequence:
aab64210 ; Exendin agonist, SEQ ID NO:30.
(from "seq4ags.pep")
TOIG of: aab64210 check: 9365 from: 1 to: 39
ID AAB64210 standard; peptide; 39 AA.
XX
XX AAB64210;
AC
XX 27-MAR-2001 (first entry)
XX
XX Exendin agonist, SEQ ID NO:30.
XX
```

```
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulintropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX
XX 07-DEC-2000.
PD
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 21; Fig 1B; 133pp; English.
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 39 AA;
SQ
AAB64210 Length: 39 February 4, 2005 13:19 Type: P Check: 9365 ..
Found using 'seq4' (mohamed337.key)
1 HGGGTFTSDLSKQWEEAEVRLPIDLWLNKGPPSSGAPPPS
1 28
-----
1 match found in sequence:
aab64211 ; Exendin agonist, SEQ ID NO:31.
(from "seq4ags.pep")
TOIG of: aab64211 check: 926 from: 1 to: 39
ID AAB64211 standard; peptide; 39 AA.
XX
XX AAB64211;
AC
XX 27-MAR-2001 (first entry)
XX
XX
```

```

DE  Exendin agonist, SEQ ID NO:31.
XX
KW  Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW  pregnancy complication; neonatal abnormality; blood glucose modulator;
XX  insulinotropic; anorectic; exendin-4.
OS  Heloderma suspectum.
XX  Synthetic.
XX  WO200073331-A2.
XX  PD 07-DEC-2000.
XX  PF 23-MAY-2000; 2000WO-US014231.
XX  PR 01-JUN-1999; 99US-00323867.
XX  PA (AMYL-) AMYLIN PHARM INC.
XX  PI Hiles R, Prickett KS;
XX  WPI; 2001-137634/14.
XX  DR
XX  Use of exendins or exendin agonists for lowering or reducing blood
PT  glucose levels and treating gestational diabetes mellitus in a subject,
PT  especially in a human.
XX  Example 22; Fig 1B; 133pp; English.
XX
CC  The invention relates to the use of an exendin (AAB64181-B64182) or an
CC  exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC  mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC  combination of increased insulin resistance and a diminished ability to
CC  increase insulin secretion. In contrast, in a normal pregnancy, both
CC  insulin resistance and insulin secretion increase. GDM pregnancies are
CC  associated with complications in both the mother and the foetus. Women
CC  with GDM have increased rates of Caesarian delivery, hypertensive
CC  disorders such as pre-eclampsia, and urinary tract infections. GDM
CC  results in an elevated rate of foetal abnormalities such as neural tube
CC  defects, and is associated with an increased risk of neonatal morbidities
CC  such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC  hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC  Exendins are peptides from the salivary secretions of the Gila monster
CC  (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC  homology with several members of the glucagon-like peptide family,
CC  particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC  compounds used to treat type 2 diabetes, which are contraindicated for
CC  GDM, exendins and exendin agonists do not cross the placenta and thus do
CC  not cause severe prolonged hypoglycaemia in the newborn. They have a
CC  potent and prolonged effect on blood glucose, and, unlike conventional
CC  insulin therapy, should not cause weight gain, as they inhibit gastric
CC  emptying and reduce appetite. The present sequence represents a exendin
CC  agonist of the invention which is based upon the sequence of exendin-4
XX  SQ
Sequence 39 AA;
AAB64211 Length: 39 February 4, 2005 13:19 Type: P Check: 926
Found using 'seq4' (mohamed337.key)
1 HEGFTTSDLKQMEEEAVRLPIEWLKNKGXSSGAXXXS
1 -----|-----|
1 1 HEGFTTSDLKQMEEEAVRLPIEWLKNKGXSSGAXXXS
1 28
-----
1 match found in sequence:
aab64212 ; Exendin agonist, SEQ ID NO:32.
(from "seq4ags.pep")
TOIG of: aab64212 check: 678 from: 1 to: 39
ID AAB64212 standard; peptide; 39 AA.
XX AAB64212;
XX

```

```

DT  27-MAR-2001 (first entry)
XX
DE  Exendin agonist, SEQ ID NO:32.
XX
KW  Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW  pregnancy complication; neonatal abnormality; blood glucose modulator;
XX  insulinotropic; anorectic; exendin-4.
OS  Heloderma suspectum.
XX  Synthetic.
XX  WO200073331-A2.
XX  PD 07-DEC-2000.
XX  PF 23-MAY-2000; 2000WO-US014231.
XX  PR 01-JUN-1999; 99US-00323867.
XX  PA (AMYL-) AMYLIN PHARM INC.
XX  PI Hiles R, Prickett KS;
XX  WPI; 2001-137634/14.
XX  DR
XX  Use of exendins or exendin agonists for lowering or reducing blood
PT  glucose levels and treating gestational diabetes mellitus in a subject,
PT  especially in a human.
XX  Example 23; Fig 1B; 133pp; English.
XX
CC  The invention relates to the use of an exendin (AAB64181-B64182) or an
CC  exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC  mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC  combination of increased insulin resistance and a diminished ability to
CC  increase insulin secretion. In contrast, in a normal pregnancy, both
CC  insulin resistance and insulin secretion increase. GDM pregnancies are
CC  associated with complications in both the mother and the foetus. Women
CC  with GDM have increased rates of Caesarian delivery, hypertensive
CC  disorders such as pre-eclampsia, and urinary tract infections. GDM
CC  results in an elevated rate of foetal abnormalities such as neural tube
CC  defects, and is associated with an increased risk of neonatal morbidities
CC  such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC  hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC  Exendins are peptides from the salivary secretions of the Gila monster
CC  (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC  homology with several members of the glucagon-like peptide family,
CC  particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC  compounds used to treat type 2 diabetes, which are contraindicated for
CC  GDM, exendins and exendin agonists do not cross the placenta and thus do
CC  not cause severe prolonged hypoglycaemia in the newborn. They have a
CC  potent and prolonged effect on blood glucose, and, unlike conventional
CC  insulin therapy, should not cause weight gain, as they inhibit gastric
CC  emptying and reduce appetite. The present sequence represents a exendin
CC  agonist of the invention which is based upon the sequence of exendin-4
XX  SQ
Sequence 39 AA;
AAB64212 Length: 39 February 4, 2005 13:19 Type: P Check: 678
Found using 'seq4' (mohamed337.key)
1 HEGFTTSDLKQMEEEAVRLPIEWLKNKGXSSGAXXXS
1 -----|-----|
1 1 HEGFTTSDLKQMEEEAVRLPIEWLKNKGXSSGAXXXS
1 28
-----
1 match found in sequence:
aab64213 ; Exendin agonist, SEQ ID NO:33.
(from "seq4ags.pep")
TOIG of: aab64213 check: 926 from: 1 to: 39
ID AAB64213 standard; peptide; 39 AA.
XX AAB64213
XX

```

```

AC AAB64213;
XX
XX 27-MAR-2001 (first entry)
XX
XX Exendin agonist, SEQ ID NO:33.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
OS
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 24; Fig 1B; 133pp; English.
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the fetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 39 AA;

```

```

AAB64213 Length: 39 February 4, 2005 13:19 Type: P Check: 926 ..
Found using 'seq4' (mohamed337.key)

```

```

1 HGGTFTSDLSKQMBEEAVRLPIEWLKNKGXSGAXXXS
|-----|
28

```

```

1 match found in sequence:
aab64214; Exendin agonist, SEQ ID NO:34.
(from "seq4ags.pep")
TOIG of: aab64214 check: 678 from: 1 to: 39

```

```

ID AAB64214 standard; peptide; 39 AA.
XX
XX AAB64214;
XX
XX 27-MAR-2001 (first entry)
XX
XX Exendin agonist, SEQ ID NO:34.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
OS
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 25; Fig 1B; 133pp; English.
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
XX exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the fetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Exendins are peptides from the salivary secretions of the Gila monster
XX (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, exendins and exendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a exendin
XX agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 39 AA;

```

```

AAB64214 Length: 39 February 4, 2005 13:19 Type: P Check: 678 ..
Found using 'seq4' (mohamed337.key)

```

```

1 HGGTFTSDLSKQMBEEAVRLPIEWLKNKGXSGAXXXS
|-----|
28

```

```

1 match found in sequence:
aab64215; Exendin agonist, SEQ ID NO:35.
(from "seq4ags.pep")

```

```
TOIG of: aab64215 check: 487 from: 1 to: 39
ID AAB64215 standard; peptide; 39 AA.
XX AC AAB64215;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:35.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of exendins or exendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 26; Fig 1B; 133pp; English.
XX CC The invention relates to the use of an exendin (AAB64181-B64182) or an
XX CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Exendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family.
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, exendins and exendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a exendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX SQ Sequence 39 AA;
AAB64215 Length: 39 February 4, 2005 13:19 Type: P Check: 487 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQLEEEAVRLPIEFKNGKSGXGXKX
1
-----
1 match found in sequence:
```

```
aab64216 ; Exendin agonist, SEQ ID NO:36.
(from "seqtags.pep")
TOIG of: aab64216 check: 487 from: 1 to: 39
ID AAB64216 standard; peptide; 39 AA.
XX AC AAB64216;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:36.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of exendins or exendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 27; Fig 1B; 133pp; English.
XX CC The invention relates to the use of an exendin (AAB64181-B64182) or an
XX CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Exendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family.
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, exendins and exendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a exendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX SQ Sequence 39 AA;
AAB64216 Length: 39 February 4, 2005 13:19 Type: P Check: 487 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQLEEEAVRLPIEFKNGKSGXGXKX
1
-----
1 match found in sequence:
```

```

-----
1 match found in sequence:
aab64217 ; Exendin agonist, SEQ ID NO:37.
(from "seq4ags.pep")
TOIG of: aab64217 check: 7660 from: 1 to: 39

ID AAB64217 standard; peptide; 39 AA.
XX
AC AAB64217;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:37.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 28; Fig 1B; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 39 AA;

AAB64217 Length: 39 February 4, 2005 13:19 Type: P Check: 7660 ..
Found using 'seq4' (mohamed337.key)

-----
1 match found in sequence:
aab64218 ; Exendin agonist, SEQ ID NO:38.
(from "seq4ags.pep")
TOIG of: aab64218 check: 8125 from: 1 to: 39

ID AAB64218 standard; peptide; 39 AA.
XX
AC AAB64218;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:38.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 29; Fig 1B; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 39 AA;

AAB64218 Length: 39 February 4, 2005 13:19 Type: P Check: 8125 ..
Found using 'seq4' (mohamed337.key)

```

```

1 1 HEGGTFDLSKQMEEEAVRLPIEWLKNQGPSSGAAAS
    |-----|
    28
1 match found in sequence:
aab64219 ; Exendin agonist, SEQ ID NO:39.
(from "seq4ags.pep")
TOIG of: aab64219 check: 7221 from: 1 to: 39

ID AAB64219 standard; peptide; 39 AA.
XX
AC AAB64219;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:39.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 30; Fig 1B; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 39 AA;

```

```

SQ Sequence 28 AA;
AAB64220 Length: 28 February 4, 2005 13:19 Type: P Check: 700
Found using 'seq4' (mohamed337.key)

-----|-----|
1 HEGTFTSLSKQMEEEAVRLFIEFLKN 28
1 match found in sequence:
aab64221 ; [Leu 14, Phe 25]- extendin-4 (1-28) amide, SEQ ID NO:41.
(from "seq4ags.pep")
TOIG of: aab64221 check: 261 from: 1 to: 28

ID AAB64221 standard; peptide; 28 AA.
XX AC AAB64221;
XX DT 27-MAR-2001 (first entry)
XX DE [Leu 14, Phe 25]- extendin-4 (1-28) amide, SEQ ID NO:41.
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Claim 13; Page 13; 133pp; English.

The invention relates to the use of an extendin (AAB64181-B64182) or an
extendin agonist (AAB64185-B64368) for treating gestational diabetes
mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
combination of increased insulin resistance and a diminished ability to
increase insulin secretion. In contrast, in a normal pregnancy, both
insulin resistance and insulin secretion increase. GDM pregnancies are
associated with complications in both the mother and the foetus. Women
with GDM have increased rates of Caesarian delivery, hypertensive
disorders such as pre-eclampsia, and urinary tract infections. GDM
results in an elevated rate of foetal abnormalities such as neural tube
defects, and is associated with an increased risk of neonatal morbidities
such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
Extendins are peptides from the salivary secretions of the Gila monster
(exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
homology with several members of the glucagon-like peptide family,
particularly GLP-1, and have similar insulinotropic effects. Unlike the
compounds used to treat type 2 diabetes, which are contraindicated for
GDM, extendins and extendin agonists do not cross the placenta and thus do
not cause severe prolonged hypoglycaemia in the newborn. They have a
potent and prolonged effect on blood glucose, and, unlike conventional
insulin therapy, should not cause weight gain, as they inhibit gastric
emptying and reduce appetite. The present sequence represents a

```

```

CC specifically claimed extendin agonist, which is based upon the sequence of
CC extendin-4
XX
SQ Sequence 28 AA;
AAB64221 Length: 28 February 4, 2005 13:19 Type: P Check: 261
Found using 'seq4' (mohamed337.key)

-----|-----|
1 HEGTFTSLSKQLEEEAVRLFIEFLKN 28
1 match found in sequence:
aab64222 ; Extendin agonist, SEQ ID NO:42.
(from "seq4ags.pep")
TOIG of: aab64222 check: 249 from: 1 to: 28

ID AAB64222 standard; peptide; 28 AA.
XX AC AAB64222;
XX DT 27-MAR-2001 (first entry)
XX DE Extendin agonist, SEQ ID NO:42.
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 35; Page 47; 133pp; English.

The invention relates to the use of an extendin (AAB64181-B64182) or an
extendin agonist (AAB64185-B64368) for treating gestational diabetes
mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
combination of increased insulin resistance and a diminished ability to
increase insulin secretion. In contrast, in a normal pregnancy, both
insulin resistance and insulin secretion increase. GDM pregnancies are
associated with complications in both the mother and the foetus. Women
with GDM have increased rates of Caesarian delivery, hypertensive
disorders such as pre-eclampsia, and urinary tract infections. GDM
results in an elevated rate of foetal abnormalities such as neural tube
defects, and is associated with an increased risk of neonatal morbidities
such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
Extendins are peptides from the salivary secretions of the Gila monster
(exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
homology with several members of the glucagon-like peptide family,
particularly GLP-1, and have similar insulinotropic effects. Unlike the
compounds used to treat type 2 diabetes, which are contraindicated for
GDM, extendins and extendin agonists do not cross the placenta and thus do
not cause severe prolonged hypoglycaemia in the newborn. They have a

```

CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 28 AA;

AAB64222 Length: 28 February 4, 2005 13:19 Type: P Check: 249 ..
 Found using 'seq4' (mohamed337.key)

```

1  |-----|
  1  HEGAGFTSDLSKQLEEEAVRLFIEFLKN      28
-----
1 match found in sequence:
aab64223 ; Extendin agonist, SEQ ID NO:43.
(from "seq4ags.pep")
TOIG of: aab64223 check: 166 from: 1 to: 28

ID AAB64223 standard; peptide; 28 AA.
XX
AC AAB64223;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:43.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PW WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 36; Page 48; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for

```

CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 28 AA;

AAB64223 Length: 28 February 4, 2005 13:19 Type: P Check: 166 ..
 Found using 'seq4' (mohamed337.key)

```

1  |-----|
  1  HEGAGFTSDLSKQLEEEAVRLFIEFLKN      28
-----
1 match found in sequence:
aab64224 ; Extendin agonist, SEQ ID NO:44.
(from "seq4ags.pep")
TOIG of: aab64224 check: 231 from: 1 to: 28

ID AAB64224 standard; peptide; 28 AA.
XX
AC AAB64224;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:44.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PW WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PI WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 37; Page 48; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for

```


CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 28 AA;

AAB64230 Length: 28 February 4, 2005 13:19 Type: P Check: 107 ..
 Found using 'seq4' (mohamed337.key)

```

1  |-----|
  1  HCGGFTSDLSKQAEAEVRLFIETPLKN 28

```

 1 match found in sequence:
 aab64231; Exendin agonist, SEQ ID NO:51.
 (from "seq4ags.pep")
 TOIG of: aab64231 check: 201 from: 1 to: 28

ID AAB64231 standard; peptide; 28 AA.

```

XX AAB64231;
AC
XX
XX 27-MAR-2001 (first entry)
DT
XX
XX Exendin agonist, SEQ ID NO:51.
DE
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
PN
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Hiles R, Prickett KS;
PI
XX
XX WPI; 2001-137634/14.
DR
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 44; Page 52; 133pp; English.
PS
XX
XX The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes

```

CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 28 AA;

AAB64231 Length: 28 February 4, 2005 13:19 Type: P Check: 201 ..
 Found using 'seq4' (mohamed337.key)

```

1  |-----|
  1  HCGGFTSDLSKQAEAEVRLFIETPLKN 28

```

 1 match found in sequence:
 aab64232; Exendin agonist, SEQ ID NO:52.
 (from "seq4ags.pep")
 TOIG of: aab64232 check: 197 from: 1 to: 28

ID AAB64232 standard; peptide; 28 AA.

```

XX AAB64232;
AC
XX
XX 27-MAR-2001 (first entry)
DT
XX
XX Exendin agonist, SEQ ID NO:52.
DE
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
PN
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Hiles R, Prickett KS;
PI
XX
XX WPI; 2001-137634/14.
DR
XX
XX Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 45; Page 52; 133pp; English.
PS
XX

```

```

CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 28 AA;
AAB64232 Length: 28 February 4, 2005 13:19 Type: P Check: 197 ..
Found using 'seq4' (mohamed337.key)
1 HGEGTFSDLSKQLEAEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aab64233 ; Extendin agonist, SEQ ID NO:53.
(from "seq4ags.pep")
TOIG of: aab64233 check: 193 from: 1 to: 28

ID AAB64233 standard; peptide; 28 AA.
XX
XX AAB64233;
AC
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:53.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX

```

```

PS Example 46; Page 53; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 28 AA;
AAB64233 Length: 28 February 4, 2005 13:19 Type: P Check: 193 ..
Found using 'seq4' (mohamed337.key)
1 HGEGTFSDLSKQLEAEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aab64234 ; Extendin agonist, SEQ ID NO:54.
(from "seq4ags.pep")
TOIG of: aab64234 check: 9862 from: 1 to: 28

ID AAB64234 standard; peptide; 28 AA.
XX
XX AAB64234;
AC
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:54.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX

```

```

PT especially in a human.
XX Example 47; Page 53; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
XX
AAB64234 Length: 28 February 4, 2005 13:19 Type: P Check: 9862
Found using 'seq4' (mohamed337.key)
1 HGEGFTSDLSKQLEEAARLFIEFLKN 28
1 |-----|
1 HGEGFTSDLSKQLEEAARLFIEFLKN 28
-----
1 match found in sequence:
aab64235 : Extendin agonist, SEQ ID NO:55.
(from "seq4ags.pep")
TOIG of: aab64235 check: 9921 from: 1 to: 28
ID AAB64235 standard; peptide; 28 AA.
XX
XX AAB64235;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:55.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX
Use of extendins or extendin agonists for lowering or reducing blood
glucose levels and treating gestational diabetes mellitus in a subject,
especially in a human.
Example 48; Page 54; 133pp; English.
The invention relates to the use of an extendin (AAB64181-B64182) or an
extendin agonist (AAB64185-B64368) for treating gestational diabetes
mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
combination of increased insulin resistance and a diminished ability to
increase insulin secretion. In contrast, in a normal pregnancy, both
insulin resistance and insulin secretion increase. GDM pregnancies are
associated with complications in both the mother and the fetus. Women
with GDM have increased rates of Caesarian delivery, hypertensive
disorders such as pre-eclampsia, and urinary tract infections. GDM
results in an elevated rate of foetal abnormalities such as neural tube
defects, and is associated with an increased risk of neonatal morbidities
such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
Extendins are peptides from the salivary secretions of the Gila monster
(extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
homology with several members of the glucagon-like peptide family,
particularly GLP-1, and have similar insulinotropic effects. Unlike the
compounds used to treat type 2 diabetes, which are contraindicated for
GDM, extendins and extendin agonists do not cross the placenta and thus do
not cause severe prolonged hypoglycaemia in the newborn. They have a
potent and prolonged effect on blood glucose, and, unlike conventional
insulin therapy, should not cause weight gain, as they inhibit gastric
emptying and reduce appetite. The present sequence represents a extendin
agonist of the invention which is based upon the sequence of extendin-4
Sequence 28 AA;
AAB64235 Length: 28 February 4, 2005 13:19 Type: P Check: 9921
Found using 'seq4' (mohamed337.key)
1 HGEGFTSDLSKQLEEAVALFIEFLKN 28
1 |-----|
1 HGEGFTSDLSKQLEEAVALFIEFLKN 28
-----
1 match found in sequence:
aab64236 : Extendin agonist, SEQ ID NO:56.
(from "seq4ags.pep")
TOIG of: aab64236 check: 30 from: 1 to: 28
ID AAB64236 standard; peptide; 28 AA.
XX
XX AAB64236;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:56.
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Hiles R, Prickett KS;
XX
XX PI
XX

```

```

DR WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 49; Page 54; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
SQ
AAB64236 Length: 28 February 4, 2005 13:19 Type: P Check: 30 ..
Found using 'seq4' (mohamed337.key)
1 HCEGFTSDLSKQLEEEAVRLFIEFLKN 28
1 -----|
1 HCEGFTSDLSKQLEEEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aab64237 ; Extendin agonist, SEQ ID NO:57.
(from "seq4ags.pep")
TOIG of: aab64237 check: 165 from: 1 to: 28
ID AAB64237 standard; peptide; 28 AA.
XX
XX AAB64237;
AC
XX
XX 27-MAR-2001 (first entry)
DT
XX
XX Extendin agonist, SEQ ID NO:57.
DE
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS
OS Synthetic.
XX
XX WO200073331-A2.
PN
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX

```

```

PI Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX Example 50; Page 55; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
SQ
AAB64237 Length: 28 February 4, 2005 13:19 Type: P Check: 165 ..
Found using 'seq4' (mohamed337.key)
1 HCEGFTSDLSKQLEEEAVRLFIEFLKN 28
1 -----|
1 HCEGFTSDLSKQLEEEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aab64238 ; Extendin agonist, SEQ ID NO:58.
(from "seq4ags.pep")
TOIG of: aab64238 check: 136 from: 1 to: 28
ID AAB64238 standard; peptide; 28 AA.
XX
XX AAB64238;
AC
XX
XX 27-MAR-2001 (first entry)
DT
XX
XX Extendin agonist, SEQ ID NO:58.
DE
XX
XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX Heloderma suspectum.
OS
OS Synthetic.
XX
XX WO200073331-A2.
PN
XX
XX 07-DEC-2000.
PD
XX
XX 23-MAY-2000; 2000WO-US014231.
PF
XX
XX 01-JUN-1999; 99US-00323867.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX

```

```

PA (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 51; Page 55; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 28 AA;
AAB64238 Length: 28 February 4, 2005 13:19 Type: P Check: 136 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQLEEEAVRLFIEAKN
1 |-----|
1 HGEFTSDLSKQLEEEAVRLFIEAKN 28
-----
1 match found in sequence:
aab64239 ; Extendin agonist, SEQ ID NO:59.
(from "seq4ags.pep")
TOIG of: aab64239 check: 9975 from: 1 to: 28

ID AAB64239 standard; peptide; 28 AA.
XX
AC AAB64239;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:59.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX

```

```

PR 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 52; Page 56; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the fetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 28 AA;
AAB64239 Length: 28 February 4, 2005 13:19 Type: P Check: 9975 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQLEEEAVRLFIEAKN
1 |-----|
1 HGEFTSDLSKQLEEEAVRLFIEAKN 28
-----
1 match found in sequence:
aab64240 ; Extendin agonist, SEQ ID NO:60.
(from "seq4ags.pep")
TOIG of: aab64240 check: 9991 from: 1 to: 28

ID AAB64240 standard; peptide; 28 AA.
XX
AC AAB64240;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:60.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX

```

```

PF 23-MAY-2000; 2000WO-US014231.
XX
XX
PR 01-JUN-1999; 99US-00323867.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Hiles R, Prickett KS;
XX
XX
DR WPI; 2001-137634/14.
XX
XX
DR Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX
PS Example 53; Page 56; 133pp; English.
XX
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX
SQ Sequence 28 AA;
XX
AAB64240 Length: 28 February 4, 2005 13:19 Type: P Check: 9991
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTFTSDLSKQLEEEAVRLFIETFLAN 28
-----|
1 match found in sequence:
aab64241; Extendin agonist, SEQ ID NO:61.
(from "seq4ags.pep")
TOIG of: aab64241 check: 9897 from: 1 to: 28
ID AAB64241 standard; peptide; 28 AA.
XX
AC AAB64241;
XX
XX
DT 27-MAR-2001 (first entry)
XX
XX
DE Extendin agonist, SEQ ID NO:61.
XX
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX
OS Heloderma suspectum.
OS Synthetic.
XX
XX
PN WO200073331-A2.
XX

```

```

PD 07-DEC-2000.
XX
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
XX
PR 01-JUN-1999; 99US-00323867.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Hiles R, Prickett KS;
XX
XX
DR WPI; 2001-137634/14.
XX
XX
DR Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
XX
PS Example 54; Page 57; 133pp; English.
XX
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
XX
SQ Sequence 28 AA;
XX
AAB64241 Length: 28 February 4, 2005 13:19 Type: P Check: 9897
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTFTSDLSKQLEEEAVRLFIETFLKA 28
-----|
1 match found in sequence:
aab64242; Extendin agonist, SEQ ID NO:62.
(from "seq4ags.pep")
TOIG of: aab64242 check: 6333 from: 1 to: 38
ID AAB64242 standard; peptide; 38 AA.
XX
AC AAB64242;
XX
XX
DT 27-MAR-2001 (first entry)
XX
XX
DE Extendin agonist, SEQ ID NO:62.
XX
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
XX
OS Heloderma suspectum.
OS Synthetic.
XX
XX

```

```

PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 55; Page 57; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 38 AA;

AAB64242 Length: 38 February 4, 2005 13:19 Type: P Check: 6333
Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQMBEEAVRLFIEFLKNGSPSSGAPPP
1
-----|-----|
1 match found in sequence:
aab64243 ; Extendin agonist, SEQ ID NO:63.
(from "seq4ags.pep")
TOIG of: aab64243 check: 5894 from: 1 to: 38

ID AAB64243 standard; peptide; 38 AA.
XX
AC AAB64243;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:63.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.

OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 56; Page 58; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 38 AA;

AAB64243 Length: 38 February 4, 2005 13:19 Type: P Check: 5894
Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQMBEEAVRLFIEFLKNGSPSSGAPPP
1
-----|-----|
1 match found in sequence:
aab64244 ; Extendin agonist, SEQ ID NO:64.
(from "seq4ags.pep")
TOIG of: aab64244 check: 3293 from: 1 to: 37

ID AAB64244 standard; peptide; 37 AA.
XX
AC AAB64244;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:64.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.

```

```

XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 57; Page 58; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 37 AA;
AAB64244 Length: 37 February 4, 2005 13:19 Type: P Check: 3293 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTTSDLSKQMEEAVALRFLFIEWLNKGPFSSGAPP
28
-----
1 match found in sequence:
aab64245; Extendin agonist, SEQ ID NO:65.
(from "seq4ags.pep")
TOIG of: aab64245 check: 2854 from: 1 to: 37
ID AAB64245 standard; peptide; 37 AA.
XX AC AAB64245;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:65.
XX DE
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;

```

```

KW KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW KW insulinotropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 58; Page 59; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican bearded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 37 AA;
AAB64245 Length: 37 February 4, 2005 13:19 Type: P Check: 2854 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTTSDLSKQMEEAVALRFLFIEWLNKGPFSSGAPP
28
-----
1 match found in sequence:
aab64246; Extendin agonist, SEQ ID NO:66.
(from "seq4ags.pep")
TOIG of: aab64246 check: 333 from: 1 to: 36
ID AAB64246 standard; peptide; 36 AA.
XX AC AAB64246;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DT
XX DE Extendin agonist, SEQ ID NO:66.

```

```

XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulintropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX PS Example 59; Page 59; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulintropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin-4
XX agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 36 AA;

```

```

AAB64246 Length: 36 February 4, 2005 13:19 Type: P Check: 333
Found using 'seq4' (mohamed337.key)

```

```

1 HGEFTFTDLSKQMBEEAVRLFIEFLKNGPSSGAP
28

```

```

-----
1 match found in sequence:
aab64247; Extendin agonist, SEQ ID NO:67.
(from "seq4ags.pep")
TOIG of: aab64247 check: 9894 from: 1 to: 36

```

```

ID AAB64247 standard; peptide; 36 AA.
XX AC AAB64247;
XX DT 27-MAR-2001 (first entry)

```

```

XX DE Extendin agonist, SEQ ID NO:67.
XX KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX pregnancy complication; neonatal abnormality; blood glucose modulator;
XX insulintropic; anorectic; extendin-4.
XX OS Heloderma suspectum.
XX Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX PS Example 60; Page 60; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulintropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin-4
XX agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 36 AA;

```

```

AAB64247 Length: 36 February 4, 2005 13:19 Type: P Check: 9894
Found using 'seq4' (mohamed337.key)

```

```

1 HGEFTFTDLSKQMBEEAVRLFIEFLKNGPSSGAP
28

```

```

-----
1 match found in sequence:
aab64248; Extendin agonist, SEQ ID NO:68.
(from "seq4ags.pep")
TOIG of: aab64248 check: 7453 from: 1 to: 35

```

```

ID AAB64248 standard; peptide; 35 AA.
XX AC AAB64248;

```

	XX AC	AAB64249;		XX DT	27-MAR-2001 (first entry)		XX DE	Exendin agonist, SEQ ID NO:68.		XX KW	Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance; pregnancy complication; neonatal abnormality; blood glucose modulator; insulinotropic; anorectic; exendin-4. Heloderma suspectum. Synthetic. WO200073331-A2. 07-DEC-2000. 23-MAY-2000; 2000MO-USO14231. 01-JUN-1999; 99US-00323867. (AMYL-) AMYLIN PHARM INC. Hiles R, Prickett KS; WPI; 2001-137634/14. Use of extendins or exendin agonists for lowering or reducing blood glucose levels and treating gestational diabetes mellitus in a subject, especially in a human. Example 61; Page 60; 133pp; English. The invention relates to the use of an exendin (AAB64181-B64182) or an exendin agonist (AAB64185-B64388) for treating gestational diabetes mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a combination of increased insulin resistance and a diminished ability to increase insulin secretion. In contrast, in a normal pregnancy, both insulin resistance and insulin secretion increase. GDM pregnancies are associated with complications in both the mother and the foetus. Women with GDM have increased rates of Caesarian delivery, hypertensive disorders such as pre-eclampsia, and urinary tract infections. GDM results in an elevated rate of foetal abnormalities such as neural tube defects, and is associated with an increased risk of neonatal morbidities such as hypoglycaemia, hyposcalcaemia, hypomagnesaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. Exendins are peptides from the salivary secretions of the Gila monster (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit homology with several members of the glucagon-like peptide family, particularly GLP-1, and have similar insulintropic effects. Unlike the compounds used to treat type 2 diabetes, which are contraindicated for GDM, exendins and exendin agonists do not cross the placenta and thus do not cause severe prolonged hypoglycaemia in the newborn. They have a potent and prolonged effect on blood glucose, and, unlike conventional insulin therapy, should not cause weight gain, as they inhibit gastric emptying and reduce appetite. The present sequence represents a exendin agonist of the invention which is based upon the sequence of exendin-4	Sequence 35 AA; AAB64249 Length: 35 February 4, 2005 13:19 Type: P Check: 7453 .. Found using 'seq4' (mohamed337.key) ----- ----- HGEGTFTSDLSKQLEEAVERLFIIEFLNKGPFSSGA 1 28 ----- ----- 1 HGEGTFTSDLSKQLEEAVERLFIIEFLNKGPFSSGA 28 ----- ----- 1 match found in sequence: aab64249 ; Exendin agonist, SEQ ID NO:69. (from "seq4ags.pep") TOIG of: aab64249 check: 7014 from: 1 to: 35 DD AAB64249 standard; peptide: 35 AA.
	XX AC	AAB64249;		XX DT	27-MAR-2001 (first entry)		XX DE	Exendin agonist, SEQ ID NO:69.		XX KW	Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance; pregnancy complication; neonatal abnormality; blood glucose modulator; insulinotropic; anorectic; exendin-4. Heloderma suspectum. Synthetic. WO200073331-A2. 07-DEC-2000. 23-MAY-2000; 2000MO-USO14231. 01-JUN-1999; 99US-00323867. (AMYL-) AMYLIN PHARM INC. Hiles R, Prickett KS; WPI; 2001-137634/14. Use of extendins or exendin agonists for lowering or reducing blood glucose levels and treating gestational diabetes mellitus in a subject, especially in a human. Example 62; Page 61; 133pp; English. The invention relates to the use of an exendin (AAB64181-B64182) or an exendin agonist (AAB64185-B64388) for treating gestational diabetes mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a combination of increased insulin resistance and a diminished ability to increase insulin secretion. In contrast, in a normal pregnancy, both insulin resistance and insulin secretion increase. GDM pregnancies are associated with complications in both the mother and the foetus. Women with GDM have increased rates of Caesarian delivery, hypertensive disorders such as pre-eclampsia, and urinary tract infections. GDM results in an elevated rate of foetal abnormalities such as neural tube defects, and is associated with an increased risk of neonatal morbidities such as hypoglycaemia, hypocalaemia, hypomagnesaemia, polycythemia, hyperbilirubinemia, and subsequent childhood and adolescent obesity. Exendins are peptides from the salivary secretions of the Gila monster (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit homology with several members of the glucagon-like peptide family, particularly GLP-1, and have similar insulintropic effects. Unlike the compounds used to treat type 2 diabetes, which are contraindicated for GDM, exendins and exendin agonists do not cross the placenta and thus do not cause severe prolonged hypoglycemia in the newborn. They have a potent and prolonged effect on blood glucose, and, unlike conventional insulin therapy, should not cause weight gain, as they inhibit gastric emptying and reduce appetite. The present sequence represents a exendin agonist of the invention which is based upon the sequence of exendin-4	Sequence 35 AA; AAB64249 Length: 35 February 4, 2005 13:19 Type: P Check: 7014 .. Found using 'seq4' (mohamed337.key) ----- ----- HGEGTFTSDLSKQLEEAVERLFIIEFLNKGPFSSGA 1 28 ----- ----- 1 HGEGTFTSDLSKQLEEAVERLFIIEFLNKGPFSSGA 28 ----- ----- 1 match found in sequence: aab64250 ; Exendin agonist, SEQ ID NO:70. (from "seq4ags.pap") TOIG of: aab64250 check: 5178 from: 1 to: 34

	XX	AAB64249;	
	AC		
	DT	27-MAR-2001 (first entry)	
	DE	Exendin agonist, SEQ ID NO:69.	
	KW	Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance; pregnancy complication; neonatal abnormality; blood glucose modulator; insulinotropic; anorectic; exendin-4. Heloderma suspectum. Synthetic. WO200073331-A2. 07-DEC-2000. 23-MAY-2000; 2000WO-USO14231. 01-JUN-1999; 99US-00323867. (AMYL-) AMYLIN PHARM INC. Hiles R, Prickett KS; WPI; 2001-137634/14. Use of extendins or exendin agonists for lowering or reducing blood glucose levels and treating gestational diabetes mellitus in a subject, especially in a human. Example 62; Page 61; 133pp; English.	
	PS	The invention relates to the use of an exendin (AAB64181-B64182) or an exendin agonist (AAB64185-B64368) for treating gestational diabetes mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a combination of increased insulin resistance and a diminished ability to increase insulin secretion. In contrast, in a normal pregnancy, both insulin resistance and insulin secretion increase. GDM pregnancies are associated with complications in both the mother and the foetus. Women with GDM have increased rates of Caesarian delivery, hypertensive disorders such as pre-eclampsia, and urinary tract infections. GDM results in an elevated rate of foetal abnormalities such as neural tube defects, and is associated with an increased risk of neonatal morbidities such as hypoglycaemia, hypocalaemia, hypomagnesaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. Exendins are peptides from the salivary secretions of the Gila monster (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit homology with several members of the glucagon-like peptide family, particularly GLP-1, and have similar insulintropic effects. Unlike the compounds used to treat type 2 diabetes, which are contraindicated for GDM, exendins and exendin agonists do not cross the placenta and thus do not cause severe prolonged hypoglycaemia in the newborn. They have a potent and prolonged effect on blood glucose, and, unlike conventional insulin therapy, should not cause weight gain, as they inhibit gastric emptying and reduce appetite. The present sequence represents a exendin agonist of the invention which is based upon the sequence of exendin-4	
	SQ	Sequence 35 AA;	
		AAB64249 Length: 35 February 4, 2005 13:19 Type: P Check: 7014 .. Found using 'seq4' (mohamed337.key) ----- ----- 1 HGEFTTSDLSKMLEEAVRLFIETLKNIGPFSSGA 28	
		1 match found in sequence: aab64250 ; Exendin agonist, SEQ ID NO:70. (from "seq4ags.pep") TOIG of: aab64250 check: 5178 from: 1 to: 34	

	XX	27-MAR-2001 (first entry)	
	DE	Exendin agonist, SEQ ID NO:68.	
	KW	Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance; pregnancy complication; neonatal abnormality; blood glucose modulator; insulinotropic; anorectic; exendin-4. Heloderma suspectum. Synthetic. WO200073331-A2. 07-DEC-2000. 23-MAY-2000; 2000WO-USO14231. 01-JUN-1999; 99US-00323867. (AMYL-) AMYLIN PHARM INC. Hiles R, Prickett KS; WPI; 2001-137634/14. Use of extendins or exendin agonists for lowering or reducing blood glucose levels and treating gestational diabetes mellitus in a subject, especially in a human. Example 61; Page 60; 133pp; English.	
	PS	The invention relates to the use of an exendin (AAB64181-B64182) or an exendin agonist (AAB64185-B64368) for treating gestational diabetes mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a combination of increased insulin resistance and a diminished ability to increase insulin secretion. In contrast, in a normal pregnancy, both insulin resistance and insulin secretion increase. GDM pregnancies are associated with complications in both the mother and the foetus. Women with GDM have increased rates of Caesarian delivery, hypertensive disorders such as pre-eclampsia, and urinary tract infections. GDM results in an elevated rate of foetal abnormalities such as neural tube defects, and is associated with an increased risk of neonatal morbidities such as hypoglycaemia, hypocalaemia, hypomagnesaemia, polycythaemia, hyperbilirubinaemia, and subsequent childhood and adolescent obesity. Exendins are peptides from the salivary secretions of the Gila monster (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit homology with several members of the glucagon-like peptide family, particularly GLP-1, and have similar insulintropic effects. Unlike the compounds used to treat type 2 diabetes, which are contraindicated for GDM, exendins and exendin agonists do not cross the placenta and thus do not cause severe prolonged hypoglycaemia in the newborn. They have a potent and prolonged effect on blood glucose, and, unlike conventional insulin therapy, should not cause weight gain, as they inhibit gastric emptying and reduce appetite. The present sequence represents a exendin agonist of the invention which is based upon the sequence of exendin-4	
	SQ	Sequence 35 AA;	
		AAB64249 Length: 35 February 4, 2005 13:19 Type: P Check: 7453 .. Found using 'seq4' (mohamed337.key) ----- ----- 1 HGEFTTSDLSKMQEEAEVRLFIETLNKGPPSSGA 28	
		1 match found in sequence: aab64249 ; Exendin agonist, SEQ ID NO:69. (from "seq4ags.pep") TOIG of: aab64249 check: 7014 from: 1 to: 35	

```

ID AAB64250 standard; peptide; 34 AA.
XX
AC AAB64250;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:70.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 63; Page 61; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 34 AA;
AAB64250 Length: 34 February 4, 2005 13:19 Type: P Check: 5178
Found using 'seq4' (mohamed337.key)
1 HGEFTFTDLSKQMBEEAVRLFIEFLKNGPSSG
1
-----
1 match found in sequence:
aab64251 ; Exendin agonist, SEQ ID NO:71.

```

1 match found in sequence:
aab64252 ; Exendin agonist, SEQ ID NO:72.
(from "seq4ags.pep")
TOIG of: aab64252 check: 2764 from: 1 to: 33

ID AAB64252 standard; peptide; 33 AA.
XX AAB64252;
AC
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:72.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 65; Page 62; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 33 AA;

AAB64252 Length: 33 February 4, 2005 13:19 Type: P Check: 2764 ..
Found using 'seq4' (mohamed337.key)

1 match found in sequence:
aab64253 ; Exendin agonist, SEQ ID NO:73.
(from "seq4ags.pep")
TOIG of: aab64253 check: 2325 from: 1 to: 33

ID AAB64253 standard; peptide; 33 AA.
XX AAB64253;
AC
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:73.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 66; Page 63; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 33 AA;

AAB64253 Length: 33 February 4, 2005 13:19 Type: P Check: 2325 ..
Found using 'seq4' (mohamed337.key)

1 match found in sequence:
aab64252 ; Exendin agonist, SEQ ID NO:72.
(from "seq4ags.pep")
TOIG of: aab64252 check: 2764 from: 1 to: 33

ID AAB64252 standard; peptide; 33 AA.
XX AAB64252;
AC
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:72.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 65; Page 62; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 33 AA;

AAB64252 Length: 33 February 4, 2005 13:19 Type: P Check: 2764 ..
Found using 'seq4' (mohamed337.key)

1 match found in sequence:
aab64253 ; Exendin agonist, SEQ ID NO:73.
(from "seq4ags.pep")
TOIG of: aab64253 check: 2325 from: 1 to: 33

ID AAB64253 standard; peptide; 33 AA.
XX AAB64253;
AC
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:73.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 66; Page 63; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 33 AA;

AAB64253 Length: 33 February 4, 2005 13:19 Type: P Check: 2325 ..
Found using 'seq4' (mohamed337.key)

```

1 HEGTFTSDLSKQLEBEAVRLFIEFLKNGGPSS
1
-----
1 match found in sequence:
aab64254 ; Exendin agonist, SEQ ID NO:74.
(from "seq4ags.pep")
TOIG of: aab64254 check: 25 from: 1 to: 32

ID AAB64254 standard; peptide; 32 AA.
XX
AC AAB64254;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:74.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 67; Page 63; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 32 AA;

AAB64254 Length: 32 February 4, 2005 13:19 Type: P Check: 25
Found using 'seq4' (mohamed337.key)

```

Sequence 32 AA;

AAB64255 Length: 32 February 4, 2005 13:19 Type: P Check: 9586 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQLEEEAVRLFIEFLKNGGSPS 28
 1 -----|
 1 match found in sequence:
 aab64256 ; Exendin agonist, SEQ ID NO:76.
 (from "seq4ags.pep")
 TOIG of: aab64256 check: 7369 from: 1 to: 31

ID AAB64256 standard; peptide; 31 AA.
 XX
 AC AAB64256;
 XX
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:76.
 XX
 XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 PI Hiles R, Prickett KS;
 XX
 XX WPI; 2001-137634/14.
 XX
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 69; Page 64; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin-4
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX

SQ Sequence 31 AA;
 AAB64256 Length: 31 February 4, 2005 13:19 Type: P Check: 7369 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQMEEEAVRLFIEWLKNKGPP 28
 1 -----|
 1 match found in sequence:
 aab64257 ; Exendin agonist, SEQ ID NO:77.
 (from "seq4ags.pep")
 TOIG of: aab64257 check: 6930 from: 1 to: 31

ID AAB64257 standard; peptide; 31 AA.
 XX
 AC AAB64257;
 XX
 AC
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:77.
 XX
 XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 PI Hiles R, Prickett KS;
 XX
 XX WPI; 2001-137634/14.
 XX
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 70; Page 64; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GIP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC emptying and reduce appetite. The present sequence represents a exendin

CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 29 AA;

AAB64259 Length: 29 February 4, 2005 13:19 Type: P Check: 2759 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQMEEEAVRLFIEFLKNG
 1 |-----|
 28

 1 match found in sequence:
 aab64260 ; Extendin agonist, SEQ ID NO:80.
 (from "seq4ags.pep")
 TOIG of: aab64260 check: 2320 from: 1 to: 29
 ID AAB64260 standard; peptide; 29 AA.

XX AC AAB64260;
 XX AC AAB64261;
 XX DT 27-MAR-2001 (first entry)
 XX DE Extendin agonist, SEQ ID NO:80.
 XX DE Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX OS Heloderma suspectum.
 OS Synthetic.
 XX WO200073331-A2.
 XX 07-DEC-2000.
 XX 23-MAY-2000; 2000WO-US014231.
 XX 01-JUN-1999; 99US-00323867.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Hiles R, Prickett KS;
 XX WPI; 2001-137634/14.
 XX
 XX Use of extendins or extendin agonists for lowering or reducing blood
 XX glucose levels and treating gestational diabetes mellitus in a subject,
 XX especially in a human.
 XX
 XX Example 73; Page 66; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the

CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin-4
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX
 SQ Sequence 29 AA;

AAB64260 Length: 29 February 4, 2005 13:19 Type: P Check: 2320 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQLEEEAVRLFIEFLKNG
 1 |-----|
 28

 1 match found in sequence:
 aab64261 ; Extendin agonist, SEQ ID NO:81.
 (from "seq4ags.pep")
 TOIG of: aab64261 check: 7221 from: 1 to: 38
 ID AAB64261 standard; peptide; 38 AA.

XX AC AAB64261;
 XX AC AAB64261;
 XX DT 27-MAR-2001 (first entry)
 XX DE Extendin agonist, SEQ ID NO:81.
 XX DE Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX OS Heloderma suspectum.
 OS Synthetic.
 XX WO200073331-A2.
 XX 07-DEC-2000.
 XX 23-MAY-2000; 2000WO-US014231.
 XX 01-JUN-1999; 99US-00323867.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Hiles R, Prickett KS;
 XX WPI; 2001-137634/14.
 XX
 XX Use of extendins or extendin agonists for lowering or reducing blood
 XX glucose levels and treating gestational diabetes mellitus in a subject,
 XX especially in a human.
 XX
 XX Example 74; Page 66; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit

CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 38 AA;
 SQ Sequence 38 AA;
 AAB64261 Length: 38 February 4, 2005 13:19 Type: P Check: 7221 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEFTFTDLSKQMEEEAVRLFIEWLKNKGPPSSGAXXX
 28

 1 match found in sequence:
 aab64262 ; Extendin agonist, SEQ ID NO:82.
 (from "seq4ags.pep")
 TOIG of: aab64262 check: 7221 from: 1 to: 38
 ID AAB64262 standard; peptide; 38 AA.
 XX AAB64262;
 AC AAB64262;
 DT 27-MAR-2001 (first entry)
 XX Extendin agonist, SEQ ID NO:82.
 DE Extendin agonist, SEQ ID NO:82.
 KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX Heloderma suspectum.
 OS Synthetic.
 XX WO200073331-A2.
 PN 07-DEC-2000.
 PD 23-MAY-2000; 2000WO-US014231.
 XX 01-JUN-1999; 99US-00323867.
 PR (AMYL-) AMYLIN PHARM INC.
 XX Hiles R, Prickett KS;
 PA WPI; 2001-137634/14.
 DR Use of extendins or extendin agonists for lowering or reducing blood
 XX glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 PT Example 75; Page 67; 133pp; English.
 PS The invention relates to the use of an extendin (AAB64181-B64182) or an
 XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.

CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX Sequence 38 AA;
 SQ Sequence 38 AA;
 AAB64262 Length: 38 February 4, 2005 13:19 Type: P Check: 7221 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEFTFTDLSKQMEEEAVRLFIEWLKNKGPPSSGAXXX
 28

 1 match found in sequence:
 aab64263 ; Extendin agonist, SEQ ID NO:83.
 (from "seq4ags.pep")
 TOIG of: aab64263 check: 2828 from: 1 to: 37
 ID AAB64263 standard; peptide; 37 AA.
 XX AAB64263;
 AC AAB64263;
 DT 27-MAR-2001 (first entry)
 XX Extendin agonist, SEQ ID NO:83.
 DE Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.
 XX Heloderma suspectum.
 OS Synthetic.
 XX WO200073331-A2.
 PN 07-DEC-2000.
 PD 23-MAY-2000; 2000WO-US014231.
 XX 01-JUN-1999; 99US-00323867.
 PR (AMYL-) AMYLIN PHARM INC.
 XX Hiles R, Prickett KS;
 PA WPI; 2001-137634/14.
 DR Use of extendins or extendin agonists for lowering or reducing blood
 XX glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 PT Example 76; Page 67; 133pp; English.
 PS The invention relates to the use of an extendin (AAB64181-B64182) or an
 XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities

CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC Sequence 37 AA;
 SQ

AAB64263 Length: 37 February 4, 2005 13:19 Type: P Check: 2828 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTDLSKQMBEEAVRLFIEWLKNGGSSGAPP 28
 |-----|
 1 HGGTFTDLSKQMBEEAVRLFIEWLKNGGSSGAAA 28

 1 match found in sequence:
 aab64264 ; Exendin agonist, SEQ ID NO:84.
 (from "seq4ags.pep")
 TOIG of: aab64264 check: 1733 from: 1 to: 37

ID AAB64264 standard; peptide; 37 AA.
 XX
 AC AAB64264;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:84.
 XX
 EX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 PX WPI; 2001-137634/14.
 XX
 DR Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 77; Page 68; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM

CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Exendins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 CC
 CC Sequence 37 AA;
 SQ

AAB64264 Length: 37 February 4, 2005 13:19 Type: P Check: 1733 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTDLSKQMBEEAVRLFIEWLKNGGSSGAAA 28
 |-----|
 1 HGGTFTDLSKQMBEEAVRLFIEWLKNGGSSGAAA 28

 1 match found in sequence:
 aab64265 ; Exendin agonist, SEQ ID NO:85.
 (from "seq4ags.pep")
 TOIG of: aab64265 check: 4125 from: 1 to: 37

ID AAB64265 standard; peptide; 37 AA.
 XX
 AC AAB64265;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:85.
 XX
 EX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 PX WPI; 2001-137634/14.
 XX
 DR Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 78; Page 68; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM

CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of fetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extending are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 37 AA;
 AAB64265 Length: 37 February 4, 2005 13:19 Type: P Check: 4125 ..
 Found using 'seq4' (mohamed337.key)
 1 HEGTFTSLSKQMEEEAVRLFIEWLKNGXSGSXX
 1
 -----|-----
 28
 1 match found in sequence:
 aab64266 ; Exendin agonist, SEQ ID NO:86.
 (from "seq4ags.pep")
 TOIG of: aab64266 check: 869 from: 1 to: 36
 ID AAB64266 standard; peptide; 36 AA.
 XX
 AC AAB64266;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:86.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 79; Page 69; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both

CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of fetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extending are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX
 SQ Sequence 36 AA;
 AAB64266 Length: 36 February 4, 2005 13:19 Type: P Check: 869 ..
 Found using 'seq4' (mohamed337.key)
 1 HEGTFTSLSKQMEEEAVRLFIEWLKNGXSGSXX
 1
 -----|-----
 28
 1 match found in sequence:
 aab64267 ; Exendin agonist, SEQ ID NO:87.
 (from "seq4ags.pep")
 TOIG of: aab64267 check: 7463 from: 1 to: 35
 ID AAB64267 standard; peptide; 35 AA.
 XX
 AC AAB64267;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:87.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 PT Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 PS Example 80; Page 69; 133pp; English.
 XX
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an
 CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a

CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX Sequence 35 AA;

AAB64267 Length: 35 February 4, 2005 13:19 Type: P Check: 7463 ..
 Found using 'seq4' (mohamed337.key)

1 RRGFTTSLSKQMEEEAVRLFIEWLKNQGPSSGA
 1
 |-----|
 28

1 match found in sequence:
 aab64268 ; Exendin agonist, SEQ ID NO:88.
 (from "seq4ags.pep")
 TOIG of: aab64268 check: 4886 from: 1 to: 30

ID AAB64268 standard; peptide; 30 AA.
 XX
 AC AAB64268;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:88.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 81; Page 70; 133pp; English.
 PS
 CC The invention relates to the use of an exendin (AAB64181-B64182) or an

CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the foetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extensins are peptides from the salivary secretions of the Gila monster
 CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, exendins and exendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a exendin
 CC agonist of the invention which is based upon the sequence of exendin-4
 XX

SQ Sequence 30 AA;

AAB64268 Length: 30 February 4, 2005 13:19 Type: P Check: 4886 ..
 Found using 'seq4' (mohamed337.key)

1 HGDGTTSLSKQMEEEAVRLFIEWLKNKG
 1
 |-----|
 28

1 match found in sequence:
 aab64269 ; Exendin agonist, SEQ ID NO:89.
 (from "seq4ags.pep")
 TOIG of: aab64269 check: 369 from: 1 to: 28

ID AAB64269 standard; peptide; 28 AA.
 XX
 AC AAB64269;
 XX
 DT 27-MAR-2001 (first entry)
 XX
 DE Exendin agonist, SEQ ID NO:89.
 XX
 KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; exendin-4.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX
 PN WO200073331-A2.
 XX
 PD 07-DEC-2000.
 XX
 PF 23-MAY-2000; 2000WO-US014231.
 XX
 PR 01-JUN-1999; 99US-00323867.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Hiles R, Prickett KS;
 XX
 DR WPI; 2001-137634/14.
 XX
 XX Use of exendins or exendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.
 XX
 XX Example 82; Page 70; 133pp; English.
 PS

```

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 28 AA;
AAB64269 Length: 28 February 4, 2005 13:19 Type: P Check: 369 ..
Found using 'seq4' (mohamed337.key)
1 HEGGTXSDLSKQLEEEAVRLFIEFLKN 28
|-----|
1 HEGGTXSDLSKQLEEEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
aab64270 ; Extendin agonist, SEQ ID NO:90.
(from "seq4ags.pep")
TOIG of: aab64270 check: 693 from: 1 to: 28

ID AAB64270 standard; peptide; 28 AA.
XX
AC AAB64270;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:90.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PT WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

```

```

XX Example 83; Page 71; 133pp; English.
XX
CC The invention relates to the use of an extendin (AAB64181-B64182) or an
CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Extendins are peptides from the salivary secretions of the Gila monster
CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, extendins and extendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a extendin
CC agonist of the invention which is based upon the sequence of extendin-4
XX
SQ Sequence 28 AA;
AAB64270 Length: 28 February 4, 2005 13:19 Type: P Check: 693 ..
Found using 'seq4' (mohamed337.key)
1 HEGTFSDDLKQMEEEAVRLFIEFLKN 28
|-----|
1 HEGTFSDDLKQMEEEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
aab64271 ; Extendin agonist, SEQ ID NO:91.
(from "seq4ags.pep")
TOIG of: aab64271 check: 701 from: 1 to: 28

ID AAB64271 standard; peptide; 28 AA.
XX
AC AAB64271;
XX
DT 27-MAR-2001 (first entry)
XX
DE Extendin agonist, SEQ ID NO:91.
XX
KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; extendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
PT WPI; 2001-137634/14.
XX
PT Use of extendins or extendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.

```

PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 84; Page 71; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the fetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX

SQ Sequence 28 AA;

AAB64271 Length: 28 February 4, 2005 13:19 Type: P Check: 701 ..

Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGEFTFSTDLKQMEAEVRLFIWLKN 28

 1 match found in sequence:
 aab64272 ; Extendin agonist, SEQ ID NO:92.
 (from "seq4ags.pep")

TOIG of: aab64272 check: 649 from: 1 to: 28

ID AAB64272 standard; peptide; 28 AA.

XX AAB64272;

AC AAB64273;

DT 27-MAR-2001 (first entry)

DE Extendin agonist, SEQ ID NO:92.

XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

XX Heloderma suspectum.

OS Synthetic.

XX WO200073331-A2.

PN 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

PF 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

PI WPI; 2001-137634/14.

XX

XX Use of extendins or extendin agonists for lowering or reducing blood
 PT glucose levels and treating gestational diabetes mellitus in a subject,
 PT especially in a human.

XX Example 85; Page 72; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an
 CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
 CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
 CC combination of increased insulin resistance and a diminished ability to
 CC increase insulin secretion. In contrast, in a normal pregnancy, both
 CC insulin resistance and insulin secretion increase. GDM pregnancies are
 CC associated with complications in both the mother and the fetus. Women
 CC with GDM have increased rates of Caesarian delivery, hypertensive
 CC disorders such as pre-eclampsia, and urinary tract infections. GDM
 CC results in an elevated rate of foetal abnormalities such as neural tube
 CC defects, and is associated with an increased risk of neonatal morbidities
 CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
 CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
 CC Extendins are peptides from the salivary secretions of the Gila monster
 CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
 CC homology with several members of the glucagon-like peptide family,
 CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
 CC compounds used to treat type 2 diabetes, which are contraindicated for
 CC GDM, extendins and extendin agonists do not cross the placenta and thus do
 CC not cause severe prolonged hypoglycaemia in the newborn. They have a
 CC potent and prolonged effect on blood glucose, and, unlike conventional
 CC insulin therapy, should not cause weight gain, as they inhibit gastric
 CC emptying and reduce appetite. The present sequence represents a extendin
 CC agonist of the invention which is based upon the sequence of extendin-4
 XX

SQ Sequence 28 AA;

AAB64272 Length: 28 February 4, 2005 13:19 Type: P Check: 649 ..

Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGEFTFSTDLKQMEAEVRLFIWLKN 28

 1 match found in sequence:
 aab64273 ; Extendin agonist, SEQ ID NO:93.
 (from "seq4ags.pep")

TOIG of: aab64273 check: 381 from: 1 to: 28

ID AAB64273 standard; peptide; 28 AA.

XX AAB64273;

AC AAB64273;

DT 27-MAR-2001 (first entry)

DE Extendin agonist, SEQ ID NO:93.

XX Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
 KW pregnancy complication; neonatal abnormality; blood glucose modulator;
 KW insulinotropic; anorectic; extendin-4.

XX Heloderma suspectum.

OS Synthetic.

XX WO200073331-A2.

PN 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

PF 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

PI

```

XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX
XX Example 86; Page 72; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
SQ
AAB64273 Length: 28 February 4, 2005 13:19 Type: P Check: 381
Found using 'seq4' (mohamed337.key)
1 HGEFTTSDXSKQLEEAVALRLEFLKN 28
1 -----|-----|
1 match found in sequence:
aab64274 : Exendin agonist, SEQ ID NO:94.
(from "seq4ags.pep")
TOIG of: aab64274 check: 657 from: 1 to: 28
ID AAB64274 standard; peptide; 28 AA.
XX
XX AAB64274;
XX
XX 27-MAR-2001 (first entry)
XX
XX Exendin agonist, SEQ ID NO:94.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
XX OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX PA

```

```

XX Hiles R, Prickett KS;
XX
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX
XX Example 87; Page 73; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX
XX Sequence 28 AA;
SQ
AAB64274 Length: 28 February 4, 2005 13:19 Type: P Check: 657
Found using 'seq4' (mohamed337.key)
1 HGEFTTSDLSKQLEEAVALRLEFLKN 28
1 -----|-----|
1 match found in sequence:
aab64275 : Exendin agonist, SEQ ID NO:95.
(from "seq4ags.pep")
TOIG of: aab64275 check: 1045 from: 1 to: 28
ID AAB64275 standard; peptide; 28 AA.
XX
XX AAB64275;
XX
XX 27-MAR-2001 (first entry)
XX
XX Exendin agonist, SEQ ID NO:95.
XX
XX Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX
XX Heloderma suspectum.
XX OS Synthetic.
XX
XX WO200073331-A2.
XX
XX 07-DEC-2000.
XX
XX 23-MAY-2000; 2000WO-US014231.
XX
XX 01-JUN-1999; 99US-00323867.
XX
XX

```

```

XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 88; Page 73; 133pp; English.
XX PS The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 28 AA;
AAB64275 Length: 28 February 4, 2005 13:19 Type: P Check: 1045 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTFTDLSKQMBEEAVRLFPELKN 28
-----|
1 match found in sequence:
aab64276 ; Extendin agonist, SEQ ID NO:96.
(from "seq4ags.pep")
TOIG of: aab64276 check: 237 from: 1 to: 28
ID AAB64276 standard; peptide; 28 AA.
XX AC
XX AC AAB64276;
XX DT
XX DT 27-MAR-2001 (first entry)
XX DE Extendin agonist, SEQ ID NO:96.
XX DE
XX DE Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX KW
XX OS Heloderma suspectum.
XX OS Synthetic.
XX OS
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PD
XX PF 23-MAY-2000; 2000WO-US014231.
XX PF

```

```

XX PR 01-JUN-1999; 99US-0023867.
XX PR (AMYL-) AMYLIN PHARM INC.
XX PA
XX PA Hiles R, Prickett KS;
XX PI
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 89; Page 74; 133pp; English.
XX PS The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of extendin-4
XX SQ Sequence 28 AA;
AAB64276 Length: 28 February 4, 2005 13:19 Type: P Check: 237 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTFTDLSKQMBEEAVRLFPELKN 28
-----|
1 match found in sequence:
aab64277 ; Extendin agonist, SEQ ID NO:97.
(from "seq4ags.pep")
TOIG of: aab64277 check: 2215 from: 1 to: 33
ID AAB64277 standard; peptide; 33 AA.
XX AC
XX AC AAB64277;
XX DT
XX DT 27-MAR-2001 (first entry)
XX DE
XX DE Extendin agonist, SEQ ID NO:97.
XX DE
XX DE Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; extendin-4.
XX KW
XX OS Heloderma suspectum.
XX OS Synthetic.
XX OS
XX PN WO200073331-A2.
XX PN
XX PD 07-DEC-2000.
XX PD

```

```

XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX DR WPI; 2001-137634/14.
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 90; Page 74; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX SQ Sequence 33 AA;
AAB64277 Length: 33 February 4, 2005 13:19 Type: P Check: 2215
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEGFTSDASKQLEEEAVRLFIEFLKNGPPSS
28
-----
1 match found in sequence:
aab64278 ; Exendin agonist, SEQ ID NO:98.
(from "seq4ags.pep")
TOIG of: aab64278 check: 2649 from: 1 to: 29
ID AAB64278 standard; peptide; 29 AA.
XX AC AAB64278;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:98.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.

```

```

XX PD 07-DEC-2000.
XX XX 23-MAY-2000; 2000WO-US014231.
XX PF 01-JUN-1999; 99US-00323867.
XX PR (AMYL-) AMYLIN PHARM INC.
XX PA Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR Use of extendins or extendin agonists for lowering or reducing blood
XX DR glucose levels and treating gestational diabetes mellitus in a subject,
XX DR especially in a human.
XX PS Example 91; Page 75; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX SQ Sequence 29 AA;
AAB64278 Length: 29 February 4, 2005 13:19 Type: P Check: 2649
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEGFTSDASKQMEEEAVRLFIEFLKNG
28
-----
1 match found in sequence:
aab64279 ; Exendin agonist, SEQ ID NO:99.
(from "seq4ags.pep")
TOIG of: aab64279 check: 4015 from: 1 to: 37
ID AAB64279 standard; peptide; 37 AA.
XX AC AAB64279;
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:99.
XX KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX OS Heloderma suspectum.
XX OS Synthetic.

```

```

XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 92; Page 75; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX CC
XX SQ Sequence 37 AA;
AAB64279 Length: 37 February 4, 2005 13:19 Type: P Check: 4015
Found using 'seq4' (mohamed337.key)
1 HGEGFTSDASKQMEAEVRLFIWLNKGXSGXGX
1 |-----|
1 HGEGFTSDASKQMEAEVRLFIWLNKGXSGXGX
1 |-----|
1 match found in sequence:
aab64281: Exendin agonist, SEQ ID NO:101.
(from "seq4ags.pep")
TOIG of: aab64281 check: 249 from: 1 to: 28
ID AAB64281 standard; peptide; 28 AA.
XX AC AAB64281;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:101.
XX DE
XX DE Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW insulinotropic; anorectic; exendin-4.
XX KW

```

```

OS OS Heloderma suspectum.
XX OS Synthetic.
XX PN WO200073331-A2.
XX PD 07-DEC-2000.
XX PF 23-MAY-2000; 2000WO-US014231.
XX PR 01-JUN-1999; 99US-00323867.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Hiles R, Prickett KS;
XX PI WPI; 2001-137634/14.
XX DR
XX PT Use of extendins or extendin agonists for lowering or reducing blood
XX PT glucose levels and treating gestational diabetes mellitus in a subject,
XX PT especially in a human.
XX PS Example 96; Page 78; 133pp; English.
XX CC The invention relates to the use of an extendin (AAB64181-B64182) or an
XX CC extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX CC combination of increased insulin resistance and a diminished ability to
XX CC increase insulin secretion. In contrast, in a normal pregnancy, both
XX CC insulin resistance and insulin secretion increase. GDM pregnancies are
XX CC associated with complications in both the mother and the foetus. Women
XX CC with GDM have increased rates of Caesarian delivery, hypertensive
XX CC disorders such as pre-eclampsia, and urinary tract infections. GDM
XX CC results in an elevated rate of foetal abnormalities such as neural tube
XX CC defects, and is associated with an increased risk of neonatal morbidities
XX CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX CC Extendins are peptides from the salivary secretions of the Gila monster
XX CC (exendin-4) and the Mexican bearded lizard (exendin-3) which exhibit
XX CC homology with several members of the glucagon-like peptide family,
XX CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX CC compounds used to treat type 2 diabetes, which are contraindicated for
XX CC GDM, extendins and extendin agonists do not cross the placenta and thus do
XX CC not cause severe prolonged hypoglycaemia in the newborn. They have a
XX CC potent and prolonged effect on blood glucose, and, unlike conventional
XX CC insulin therapy, should not cause weight gain, as they inhibit gastric
XX CC emptying and reduce appetite. The present sequence represents a extendin
XX CC agonist of the invention which is based upon the sequence of exendin-4
XX CC
XX SQ Sequence 28 AA;
AAB64281 Length: 28 February 4, 2005 13:19 Type: P Check: 249
Found using 'seq4' (mohamed337.key)
1 HGAGFTSDLSKQLEAEVRLFIPLKN
1 |-----|
1 HGAGFTSDLSKQLEAEVRLFIPLKN
1 |-----|
1 match found in sequence:
aab64285: Exendin agonist, SEQ ID NO:105.
(from "seq4ags.pep")
TOIG of: aab64285 check: 688 from: 1 to: 28
ID AAB64285 standard; peptide; 28 AA.
XX AC AAB64285;
XX AC
XX DT 27-MAR-2001 (first entry)
XX DE Exendin agonist, SEQ ID NO:105.
XX DE
XX DE Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
XX KW pregnancy complication; neonatal abnormality; blood glucose modulator;
XX KW

```

```

KW insulintropic; anorectic; extendin-4.
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX 07-DEC-2000.
XX 23-MAY-2000; 2000WO-US014231.
XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 100; Page 80; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
AAB64285 Length: 28 February 4, 2005 13:19 Type: P Check: 688
Found using 'seq4' (mohamed337.key)

1 HCGGTFTSDLSKQMEEEAVRLFIWLNK 28
|-----|
1 match found in sequence:
aab64288 ; Extendin agonist, SEQ ID NO:108.
(from "seq4ags.pep")
TOIG of: aab64288 check: 590 from: 1 to: 28

ID AAB64288 standard; peptide; 28 AA.
XX
XX AAB64288;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:108.
XX

```

```

KW insulintropic; anorectic; extendin-4.
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX 07-DEC-2000.
XX 23-MAY-2000; 2000WO-US014231.
XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 100; Page 80; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
AAB64285 Length: 28 February 4, 2005 13:19 Type: P Check: 688
Found using 'seq4' (mohamed337.key)

1 HCGGTFTSDLSKQMEEEAVRLFIWLNK 28
|-----|
1 match found in sequence:
aab64288 ; Extendin agonist, SEQ ID NO:108.
(from "seq4ags.pep")
TOIG of: aab64288 check: 590 from: 1 to: 28

ID AAB64288 standard; peptide; 28 AA.
XX
XX AAB64288;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:108.
XX

```

```

KW Extendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulintropic; anorectic; extendin-4.
XX Heloderma suspectum.
OS Synthetic.
XX WO200073331-A2.
XX 07-DEC-2000.
XX 23-MAY-2000; 2000WO-US014231.
XX 01-JUN-1999; 99US-00323867.
XX (AMYL-) AMYLIN PHARM INC.
XX Hiles R, Prickett KS;
XX WPI; 2001-137634/14.
XX
XX Use of extendins or extendin agonists for lowering or reducing blood
XX glucose levels and treating gestational diabetes mellitus in a subject,
XX especially in a human.
XX
XX Example 103; Page 81; 133pp; English.
XX
XX The invention relates to the use of an extendin (AAB64181-B64182) or an
XX extendin agonist (AAB64185-B64368) for treating gestational diabetes
XX mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
XX combination of increased insulin resistance and a diminished ability to
XX increase insulin secretion. In contrast, in a normal pregnancy, both
XX insulin resistance and insulin secretion increase. GDM pregnancies are
XX associated with complications in both the mother and the foetus. Women
XX with GDM have increased rates of Caesarian delivery, hypertensive
XX disorders such as pre-eclampsia, and urinary tract infections. GDM
XX results in an elevated rate of foetal abnormalities such as neural tube
XX defects, and is associated with an increased risk of neonatal morbidities
XX such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
XX hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
XX Extendins are peptides from the salivary secretions of the Gila monster
XX (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
XX homology with several members of the glucagon-like peptide family,
XX particularly GLP-1, and have similar insulinotropic effects. Unlike the
XX compounds used to treat type 2 diabetes, which are contraindicated for
XX GDM, extendins and extendin agonists do not cross the placenta and thus do
XX not cause severe prolonged hypoglycaemia in the newborn. They have a
XX potent and prolonged effect on blood glucose, and, unlike conventional
XX insulin therapy, should not cause weight gain, as they inhibit gastric
XX emptying and reduce appetite. The present sequence represents a extendin
XX agonist of the invention which is based upon the sequence of extendin-4
XX
XX Sequence 28 AA;
AAB64288 Length: 28 February 4, 2005 13:19 Type: P Check: 590
Found using 'seq4' (mohamed337.key)

1 HCGGTFTSDLSKQMEEEAVRLFIWLNK 28
|-----|
1 match found in sequence:
aab64348 ; Extendin agonist, SEQ ID NO:168.
(from "seq4ags.pep")
TOIG of: aab64348 check: 5882 from: 1 to: 38

ID AAB64348 standard; peptide; 38 AA.
XX
XX AAB64348;
XX
XX 27-MAR-2001 (first entry)
XX
XX Extendin agonist, SEQ ID NO:168.
XX

```

```

DE  Extentin agonist, SEQ ID NO:168.
XX
XX  Extentin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW  pregnancy complication; neonatal abnormality; blood glucose modulator;
KW  insulinotropic; anorectic; extendin-4.
XX
OS  Heloderma suspectum.
OS  Synthetic.
XX
PN  WO200073331-A2.
XX
XX  07-DEC-2000.
XX
XX  23-MAY-2000; 2000WO-US014231.
XX
XX  01-JUN-1999; 99US-00323867.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Hiles R, Prickett KS;
XX
XX  WPI; 2001-137634/14.
XX
XX  Use of extendins or extendin agonists for lowering or reducing blood
PT  glucose levels and treating gestational diabetes mellitus in a subject,
PT  especially in a human.
XX
PS  Example 163; Page 111; 133pp; English.
XX
CC  The invention relates to the use of an extendin (AAB64181-B64182) or an
CC  extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC  mellitus (GDM) in a patient. GDM arises during pregnancy and is due to a
CC  combination of increased insulin resistance and a diminished ability to
CC  increase insulin secretion. In contrast, in a normal pregnancy, both
CC  insulin resistance and insulin secretion increase. GDM pregnancies are
CC  associated with complications in both the mother and the foetus. Women
CC  with GDM have increased rates of Caesarian delivery, hypertensive
CC  disorders such as pre-eclampsia, and urinary tract infections. GDM
CC  results in an elevated rate of foetal abnormalities such as neural tube
CC  defects, and is associated with an increased risk of neonatal morbidities
CC  such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC  hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC  Extendins are peptides from the salivary secretions of the Gila monster
CC  (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC  homology with several members of the glucagon-like peptide family,
CC  particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC  compounds used to treat type 2 diabetes, which are contraindicated for
CC  GDM, extendins and extendin agonists do not cross the placenta and thus do
CC  not cause severe prolonged hypoglycaemia in the newborn. They have a
CC  potent and prolonged effect on blood glucose, and, unlike conventional
CC  insulin therapy, should not cause weight gain, as they inhibit gastric
CC  emptying and reduce appetite. The present sequence represents a extendin
CC  agonist of the invention which is based upon the sequence of extendin-4
XX
SQ  Sequence 38 AA;
AAB64348 Length: 38 February 4, 2005 13:19 Type: P Check: 5882
Found using 'seq4' (mohamed337.key)
1  HGAGTFTSDLSKQLEEAIVRLFIETFLKNGPSSGAPP
1
-----
1 match found in sequence:
aab64353 ; Extentin agonist, SEQ ID NO:173.
(from "seq4ags.pep")
TOIG of: aab64353 check: 7002 from: 1 to: 35
ID  AAB64353 standard; peptide; 35 AA.
XX
AC  AAB64353;
XX

```

```

DT  27-MAR-2001 (first entry)
XX
XX  Extentin agonist, SEQ ID NO:173.
XX
XX  Extentin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW  pregnancy complication; neonatal abnormality; blood glucose modulator;
KW  insulinotropic; anorectic; extendin-4.
XX
OS  Heloderma suspectum.
OS  Synthetic.
XX
XX  WO200073331-A2.
XX
XX  07-DEC-2000.
XX
XX  23-MAY-2000; 2000WO-US014231.
XX
XX  01-JUN-1999; 99US-00323867.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Hiles R, Prickett KS;
XX
XX  WPI; 2001-137634/14.
XX
XX  Use of extendins or extendin agonists for lowering or reducing blood
PT  glucose levels and treating gestational diabetes mellitus in a subject,
PT  especially in a human.
XX
PS  Example 168; Page 114; 133pp; English.
XX
CC  The invention relates to the use of an extendin (AAB64181-B64182) or an
CC  extendin agonist (AAB64185-B64368) for treating gestational diabetes
CC  mellitus (GDM) in a patient. GDM arises during pregnancy and is due to a
CC  combination of increased insulin resistance and a diminished ability to
CC  increase insulin secretion. In contrast, in a normal pregnancy, both
CC  insulin resistance and insulin secretion increase. GDM pregnancies are
CC  associated with complications in both the mother and the foetus. Women
CC  with GDM have increased rates of Caesarian delivery, hypertensive
CC  disorders such as pre-eclampsia, and urinary tract infections. GDM
CC  results in an elevated rate of foetal abnormalities such as neural tube
CC  defects, and is associated with an increased risk of neonatal morbidities
CC  such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC  hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC  Extendins are peptides from the salivary secretions of the Gila monster
CC  (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit
CC  homology with several members of the glucagon-like peptide family,
CC  particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC  compounds used to treat type 2 diabetes, which are contraindicated for
CC  GDM, extendins and extendin agonists do not cross the placenta and thus do
CC  not cause severe prolonged hypoglycaemia in the newborn. They have a
CC  potent and prolonged effect on blood glucose, and, unlike conventional
CC  insulin therapy, should not cause weight gain, as they inhibit gastric
CC  emptying and reduce appetite. The present sequence represents a extendin
CC  agonist of the invention which is based upon the sequence of extendin-4
XX
SQ  Sequence 35 AA;
AAB64353 Length: 35 February 4, 2005 13:19 Type: P Check: 7002
Found using 'seq4' (mohamed337.key)
1  HGAGTFTSDLSKQLEEAIVRLFIETFLKNGPSSGA
1
-----
1 match found in sequence:
aab64357 ; Extentin agonist, SEQ ID NO:177.
(from "seq4ags.pep")
TOIG of: aab64357 check: 9574 from: 1 to: 32
ID  AAB64357 standard; peptide; 32 AA.
XX

```

```

AC AAB64357;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:177.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 172; Page 116; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64358) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 32 AA;

AAB64357 Length: 32 February 4, 2005 13:19 Type: P Check: 9574 ..
Found using 'seq4' (mohamed337.key)

1 HGAGTFTSLSKQLEEAARLFLFIEFLKNGGPS
28
1
-----
1 match found in sequence:
aab64361; Exendin agonist, SEQ ID NO:181.
TOIG of: aab64361 check: 7457 from: 1 to: 38

```

```

ID AAB64361 standard; peptide; 38 AA.
XX
AC AAB64361;
XX
DT 27-MAR-2001 (first entry)
XX
DE Exendin agonist, SEQ ID NO:181.
XX
KW Exendin agonist; gestational diabetes mellitus; GDM; insulin resistance;
KW pregnancy complication; neonatal abnormality; blood glucose modulator;
KW insulinotropic; anorectic; exendin-4.
XX
OS Heloderma suspectum.
OS Synthetic.
XX
PN WO200073331-A2.
XX
PD 07-DEC-2000.
XX
PF 23-MAY-2000; 2000WO-US014231.
XX
PR 01-JUN-1999; 99US-00323867.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Hiles R, Prickett KS;
XX
DR WPI; 2001-137634/14.
XX
PT Use of exendins or exendin agonists for lowering or reducing blood
PT glucose levels and treating gestational diabetes mellitus in a subject,
PT especially in a human.
XX
PS Example 176; Page 118; 133pp; English.
XX
CC The invention relates to the use of an exendin (AAB64181-B64182) or an
CC exendin agonist (AAB64185-B64368) for treating gestational diabetes
CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a
CC combination of increased insulin resistance and a diminished ability to
CC increase insulin secretion. In contrast, in a normal pregnancy, both
CC insulin resistance and insulin secretion increase. GDM pregnancies are
CC associated with complications in both the mother and the foetus. Women
CC with GDM have increased rates of Caesarian delivery, hypertensive
CC disorders such as pre-eclampsia, and urinary tract infections. GDM
CC results in an elevated rate of foetal abnormalities such as neural tube
CC defects, and is associated with an increased risk of neonatal morbidities
CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,
CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.
CC Exendins are peptides from the salivary secretions of the Gila monster
CC (exendin-4) and the Mexican beaded lizard (exendin-3) which exhibit
CC homology with several members of the glucagon-like peptide family,
CC particularly GLP-1, and have similar insulinotropic effects. Unlike the
CC compounds used to treat type 2 diabetes, which are contraindicated for
CC GDM, exendins and exendin agonists do not cross the placenta and thus do
CC not cause severe prolonged hypoglycaemia in the newborn. They have a
CC potent and prolonged effect on blood glucose, and, unlike conventional
CC insulin therapy, should not cause weight gain, as they inhibit gastric
CC emptying and reduce appetite. The present sequence represents a exendin
CC agonist of the invention which is based upon the sequence of exendin-4
XX
SQ Sequence 38 AA;

AAB64361 Length: 38 February 4, 2005 13:19 Type: P Check: 7457 ..
Found using 'seq4' (mohamed337.key)

1 HGAGTFTSLSKQLEEAARLFLFIEFLKNGKSSGAXXX
28
1
-----
1 match found in sequence:
aab64365; Exendin agonist, SEQ ID NO:185.
(from "seq4ags.pep")

```

TOIG of: aab64365 check: 7441 from: 1 to: 35

ID AAB64365 standard; peptide; 35 AA.

XX AAB64365;

AC AAB64365;

XX 27-MAR-2001 (first entry)

XX Extensin agonist, SEQ ID NO:185.

XX Extensin agonist; gestational diabetes mellitus; GDM; insulin resistance;

KW pregnancy complication; neonatal abnormality; blood glucose modulator;

KW insulinotropic; anorectic; extendin-4.

XX Heloderma suspectum.

OS Synthetic.

XX WO200073331-A2.

PN 07-DEC-2000.

XX 23-MAY-2000; 2000WO-US014231.

XX 01-JUN-1999; 99US-00323867.

XX (AMYL-) AMYLIN PHARM INC.

XX Hiles R, Prickett KS;

XX WPI; 2001-137634/14.

XX Use of extendins or extendin agonists for lowering or reducing blood

PT glucose levels and treating gestational diabetes mellitus in a subject,

PT especially in a human.

XX Example 180; Page 120; 133pp; English.

XX The invention relates to the use of an extendin (AAB64181-B64182) or an

CC extendin agonist (AAB64185-B64368) for treating gestational diabetes

CC mellitus (GDM) in a patient. GDM arises during pregnancy, and is due to a

CC combination of increased insulin resistance and a diminished ability to

CC increase insulin secretion. In contrast, in a normal pregnancy, both

CC insulin resistance and insulin secretion increase. GDM pregnancies are

CC associated with complications in both the mother and the foetus. Women

CC with GDM have increased rates of Caesarian delivery, hypertensive

CC disorders such as pre-eclampsia, and urinary tract infections. GDM

CC results in an elevated rate of foetal abnormalities such as neural tube

CC defects, and is associated with an increased risk of neonatal morbidities

CC such as hypoglycaemia, hypocalcaemia, hypomagnesaemia, polycythaemia,

CC hyperbilirubinaemia, and subsequent childhood and adolescent obesity.

CC Extendins are peptides from the salivary secretions of the Gila monster

CC (extendin-4) and the Mexican beaded lizard (extendin-3) which exhibit

CC homology with several members of the glucagon-like peptide family,

CC particularly GLP-1, and have similar insulinotropic effects. Unlike the

CC compounds used to treat type 2 diabetes, which are contraindicated for

CC GDM, extendins and extendin agonists do not cross the placenta and thus do

CC not cause severe prolonged hypoglycaemia in the newborn. They have a

CC potent and prolonged effect on blood glucose, and, unlike conventional

CC insulin therapy, should not cause weight gain, as they inhibit gastric

CC emptying and reduce appetite. The present sequence represents a extendin

CC agonist of the invention which is based upon the sequence of extendin-4

XX Sequence 35 AA;

SQ

AAB64365 Length: 35 February 4, 2005 13:19 Type: P Check: 7441 ..

Found using 'seq4' (mohamed337.key)

1 HGAGTFTSDLSKQMEEEAVRLFIETLKNKGPPSSGA

28

1 match found in sequence:

aab69951 ; des Ser39-exendin-4(1-39) - (Lys)6-NH2.

(from "seq4ags.pep")

TOIG of: aab69951 check: 5008 from: 1 to: 44

ID AAB69951 standard; peptide; 44 AA.

XX AAB69951;

AC AAB69951;

XX 02-MAY-2001 (first entry)

XX des Ser39-exendin-4(1-39) - (Lys)6-NH2.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;

KW antiinflammatory; peptide conjugate; diabetes; obesity;

KW insulin resistance syndrome; eating disorder; hyperglycaemia;

KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

OS WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

XX 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the

PT level of blood glucose and for treating diseases like diabetes, obesity

PT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)

CC which is an extendin at least 90 % homologous to extendin-4, a variant of

CC extendin comprising 1-5 deletions at positions 34-39 or a lys at position

CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-

CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino

CC isobutyric acid for Ala at position 8 and/or having a lipophilic

CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently

CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,

CC Y, N, Q, D, G, K, R, H, W, Orn, and amino acid units of formula -NH-

CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and

CC phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3

CC substituents selected from halogen, hydroxy, amino, cyano, nitro,

CC sulfono, and carboxy, and phenyl and phenylmethyl are optionally

CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,

CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and

CC R2, together with the carbon atom to which they are bound, form a

CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic

CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide

CC of the peptide conjugate with the proviso that X is not extendin-4 or

CC extendin-3. The peptide conjugate is useful in the manufacture of a

CC pharmaceutical composition for use in treatment of type 1 or type 2

CC diabetes, insulin resistance syndrome, obesity, eating disorder,

CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for

CC treating disease states associated with elevated blood glucose levels

CC elicited by hormones known to increase blood glucose levels, such as

CC catechol amines including adrenalin, glucocorticoids, growth hormone and

CC glucagon. It is useful in regulation of gastric emptying, for stimulating

CC insulin release, for lowering plasma lipid level, and for reducing

CC mortality and morbidity after myocardial infarction

XX Sequence 44 AA;

SQ

AAB69951 Length: 44 February 4, 2005 13:19 Type: P Check: 5008 ..

Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTTDLKQMEAEAVRLFIEWLKNGGPPSGAPPKKKKK
28

1 match found in sequence:
aab69952 ; des Ala35-exendin-4 (1-39) - (Lys) 6-NH2.
(from "seq4ags.pap")
TOIG of: aab69952 check: 5122 from: 1 to: 44

ID AAB69952 standard; peptide; 44 AA.
XX AC AAB69952;
XX DT 02-MAY-2001 (first entry)
XX DE des Pro36-exendin-4 (1-39) - (Lys) 6-NH2.
XX KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX OS Synthetic.
XX PN WO200104156-A1.
XX PD 18-JAN-2001.
XX PF 12-JUL-2000; 2000WO-DK000393.
XX PR 12-JUL-1999; 99US-0143591P.
XX PR 09-AUG-1999; 99EP-00610043.
XX PA (ZEAL-) ZEALAND PHARM AS.
XX Larsen BD, Mikkelsen JD, Neve S;
XX WPI; 2001-159381/16.

Novel peptide agonist of Glucagon-like peptide, useful for decreasing the level of blood glucose and for treating diseases like diabetes, obesity and eating disorders.

Claim 22; Page 66; 83pp; English.

The present sequence is a peptide conjugate comprising a peptide (X) which is an extendin at least 90 % homologous to extendin-4, a variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys at position 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino isobutyric acid for Ala at position 8 and/or having a lipophilic substituent, and Z, a peptide sequence of 4-20 amino acids covalently bound to the variant. Each amino acid in Z is selected from A, L, S, T, Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-C(=O)-, R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3 sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from halogen, hydroxy, amino, cyano, nitro, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide of the peptide conjugate with the proviso that X is not extendin-4 or extendin-3. The peptide conjugate is useful in the manufacture of a pharmaceutical composition for use in treatment of type 1 or type 2 diabetes, insulin resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic disorders and gastric disease. It is useful for treating disease states associated with elevated blood glucose levels elicited by hormones known to increase blood glucose levels, such as catechol amines including adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in regulation of gastric emptying, for stimulating insulin release, for lowering plasma lipid level, and for reducing mortality and morbidity after myocardial infarction

Sequence 44 AA;

AAB69952 Length: 44 February 4, 2005 13:19 Type: P Check: 5122 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTTDLKQMEAEAVRLFIEWLKNGGPPSGAPPKKKKK
28

1 match found in sequence:
aab69953 ; des Ala35-exendin-4 (1-39) - (Lys) 6-NH2.
(from "seq4ags.pap")
TOIG of: aab69953 check: 5647 from: 1 to: 44

ID AAB69953 standard; peptide; 44 AA.
XX AC AAB69953;
XX DT 02-MAY-2001 (first entry)
XX DE des Ala35-exendin-4 (1-39) - (Lys) 6-NH2.
XX KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX OS Synthetic.
XX PN WO200104156-A1.
XX PD 18-JAN-2001.
XX PF 12-JUL-2000; 2000WO-DK000393.
XX PR 12-JUL-1999; 99US-0143591P.
XX PR 09-AUG-1999; 99EP-00610043.
XX PA (ZEAL-) ZEALAND PHARM AS.
XX Larsen BD, Mikkelsen JD, Neve S;
XX WPI; 2001-159381/16.

Novel peptide agonist of Glucagon-like peptide, useful for decreasing the level of blood glucose and for treating diseases like diabetes, obesity and eating disorders.

Claim 22; Page 66; 83pp; English.

The present sequence is a peptide conjugate comprising a peptide (X) which is an extendin at least 90 % homologous to extendin-4, a variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys at position 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino isobutyric acid for Ala at position 8 and/or having a lipophilic substituent, and Z, a peptide sequence of 4-20 amino acids covalently bound to the variant. Each amino acid in Z is selected from A, L, S, T, Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-C(=O)-, R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3 sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from halogen, hydroxy, amino, cyano, nitro, halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide of the peptide conjugate with the proviso that X is not extendin-4 or extendin-3. The peptide conjugate is useful in the manufacture of a pharmaceutical composition for use in treatment of type 1 or type 2 diabetes, insulin resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic disorders and gastric disease. It is useful for treating disease states associated with elevated blood glucose levels elicited by hormones known to increase blood glucose levels, such as

CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 XX
 SQ Sequence 44 AA;

AAB69953 Length: 44 February 4, 2005 13:19 Type: P Check: 5647 ..

Found using 'seq4' (mohamed337.key)

```

1 HGEFTTSDLSKQMEAEVRLFIWLKNGGSPSSGPPPSKKKKK
  28
  |-----|
  1

```

1 match found in sequence:

aab69954 ; des Gly34-extendin-4(1-39) - (Lys)6-NH2.
 (from "seq4ags.pep")
 TOIG of: aab69954 check: 5443 from: 1 to: 44

ID AAB69954 standard; peptide; 44 AA.

XX AAB69954;

AC 02-MAY-2001 (first entry)

DT des Gly34-extendin-4(1-39) - (Lys)6-NH2.

DE
 XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 FT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)
 CC which is an extendin at least 90 % homologous to extendin-4, a variant of
 CC extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-

CC C(R1) (R2) -C(=O) -. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
 CC phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfono, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 XX
 SQ Sequence 44 AA;

AAB69954 Length: 44 February 4, 2005 13:19 Type: P Check: 5443 ..

Found using 'seq4' (mohamed337.key)

```

1 HGEFTTSDLSKQMEAEVRLFIWLKNGGSPSSGPPPSKKKKK
  28
  |-----|
  1

```

1 match found in sequence:

aab69955 ; des Ser39-(Lys)40 (palmitoyl)extendin-4(1-39) - (Lys)7-NH2.
 (from "seq4ags.pep")
 TOIG of: aab69955 check: 1833 from: 1 to: 46

ID AAB69955 standard; peptide; 46 AA.

XX AAB69955;

XX 02-MAY-2001 (first entry)

XX des Ser39-(Lys)40 (palmitoyl)extendin-4(1-39) - (Lys)7-NH2.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 FT and eating disorders.

XX Claim 22; Page 66; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X)

CC which is an extendin at least 90 & homologous to extendin-4, a variant of
 CC extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 CC isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
 CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
 CC phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction

XX Sequence 46 AA;

AAB69955 Length: 46 February 4, 2005 13:19 Type: P Check: 1833 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTSLSKQMEEEAVRLFIEWLKNGSPSSGAPPKPKKKKKKKK
 28

1 match found in sequence:
 aab69956 ; des Gly34-(Lys40(palmitoyl))extendin-4(1-39)-(Lys)7-NH2.
 (from "seq4ags.pep")
 TOIG of: aab69956 check: 2268 from: 1 to: 46

ID AAB69956 standard; peptide; 46 AA.
 AC AAB69956;
 XX
 XX
 DT 02-MAY-2001 (first entry)
 XX
 XX des Gly34-(Lys40(palmitoyl))extendin-4(1-39)-(Lys)7-NH2.
 XX
 XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX
 PT
 PT
 XX
 PS

Claim 22; Page 66; 83pp; English.

The present sequence is a peptide conjugate comprising a peptide (X) which is an extendin at least 90 & homologous to extendin-4, a variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys at position 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino isobutyric acid for Ala at position 8 and/or having a lipophilic substituent, and Z, a peptide sequence of 4-20 amino acids covalently bound to the variant. Each amino acid in Z is selected from A, L, S, T, Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents selected from halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl, R2, together with the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide of the peptide conjugate with the proviso that X is not extendin-4 or extendin-3. The peptide conjugate is useful in the manufacture of a pharmaceutical composition for use in treatment of type 1 or type 2 diabetes, insulin resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic disorders and gastric disease. It is useful for treating disease states associated with elevated blood glucose levels elicited by hormones known to increase blood glucose levels, such as catechol amines including adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in regulation of gastric emptying, for stimulating insulin release, for lowering plasma lipid level, and for reducing mortality and morbidity after myocardial infarction

SQ Sequence 46 AA;

AAB69956 Length: 46 February 4, 2005 13:19 Type: P Check: 2268 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTSLSKQMEEEAVRLFIEWLKNGSPSSAPPKPKKKKKKKK
 28

1 match found in sequence:
 aab69957 ; des Ala35-(Lys40(palmitoyl))extendin-4(1-39)-(Lys)7-NH2.
 (from "seq4ags.pep")
 TOIG of: aab69957 check: 2472 from: 1 to: 46

ID AAB69957 standard; peptide; 46 AA.

XX AAB69957;

XX 02-MAY-2001 (first entry)

XX des Ala35-(Lys40(palmitoyl))extendin-4(1-39)-(Lys)7-NH2.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX Lys40(palmitoyl)exendin-4(1-39) - (Lys)7-NH2.
DE
XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX Synthetic.
OS
XX WO200104156-A1.
PN
XX 18-JAN-2001.
PD
XX 12-JUL-2000; 2000WO-DK000393.
PF
XX 12-JUL-1999; 99US-0143591P.
PR
XX 09-AUG-1999; 99EP-00610043.
PR
XX (ZEAL-) ZEALAND PHARM AS.
PA
XX Larsen BD, Mikkelsen JD, Neve S;
PI
XX WPI; 2001-159381/16.
DR
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
PS Claim 22; Page 66; 83pp; English.
XX
CC The present sequence is a peptide conjugate comprising a peptide (X)
CC which is an exendin at least 90 % homologous to exendin-4, a variant of
CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
CC isobutyric acid for Ala at position 8 and/or having a lipophilic
CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
CC C(R1)(R2)-C(=O)-, R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
CC phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
CC sulfono, and carboxy, and phenyl and phenylmethyl are optionally
CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and
CC R2, together with the carbon atom to which they are bound, form a
CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
CC of the peptide conjugate with the proviso that X is not exendin-4 or
CC exendin-3. The peptide conjugate is useful in the manufacture of a
CC pharmaceutical composition for use in treatment of type 1 or type 2
CC diabetes, insulin resistance syndrome, obesity, eating disorder,
CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
CC treating disease states associated with elevated blood glucose levels
CC elicited by hormones known to increase blood glucose levels, such as
CC catechol amines including adrenalin, glucocorticoids, growth hormone and
CC glucagon. It is useful in regulation of gastric emptying, for stimulating
CC insulin release, for lowering plasma lipid level, and for reducing
CC mortality and morbidity after myocardial infarction
XX
SQ Sequence 47 AA;
AAB69959 Length: 47 February 4, 2005 13:19 Type: P Check: 5670 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQMBEAVRLFIEMLNKGGPSSGAPPPSKKKKKKK
28
1

1 match found in sequence:
aab69962 ; des Pro36-exendin-4(1-39)-NH2.

(from "seqtags.pep")
TOIG of: aab69962 check: 6447 from: 1 to: 38
ID AAB69962 standard; peptide; 38 AA.
XX
AC AAB69962;
XX
DT 02-MAY-2001 (first entry)
XX
DE des Pro36-exendin-4(1-39)-NH2.
XX
KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX Synthetic.
OS
XX WO200104156-A1.
PN
XX 18-JAN-2001.
PD
XX 12-JUL-2000; 2000WO-DK000393.
PF
XX 12-JUL-1999; 99US-0143591P.
PR
XX 09-AUG-1999; 99EP-00610043.
PR
XX (ZEAL-) ZEALAND PHARM AS.
PA
XX Larsen BD, Mikkelsen JD, Neve S;
PI
XX WPI; 2001-159381/16.
DR
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
PS Claim 23; Page 67; 83pp; English.
XX
CC The present sequence is peptide X, a component of a novel peptide
CC conjugate. X is an exendin at least 90 % homologous to exendin-4, a
CC variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys
CC at position 40 having a lipophilic substituent, a glucagon-like peptide
CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
CC C(=O)-, R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-
CC methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents
CC selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and
CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
CC substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
CC amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with
CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
CC conjugate with the proviso that X is not exendin-4 or exendin-3. The
CC peptide conjugate is useful in the manufacture of a pharmaceutical
CC composition for use in treatment of type 1 or type 2 diabetes, insulin
CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
CC disorders and gastric disease. It is useful for treating disease states
CC associated with elevated blood glucose levels elicited by hormones known
CC to increase blood glucose levels, such as catechol amines including
CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
CC regulation of gastric emptying, for stimulating insulin release, for
CC lowering plasma lipid level, and for reducing mortality and morbidity
CC after myocardial infarction
XX
SQ Sequence 38 AA;
AAB69962 Length: 38 February 4, 2005 13:19 Type: P Check: 6447 ..
Found using 'seq4' (mohamed337.key)

Fri Feb 4 14:12:16 2005

```
1 HEGGFTSDLSKQMEEAARLFIWLKNGSPSSGAPPS
1 -----
1 match found in sequence:
aab69963 ; des Ala35-exendin-4(1-39)-NH2.
(from "seq4ags.pep")
TOIG of: aab69963 check: 6972 from: 1 to: 38

ID AAB69963 standard; peptide; 38 AA.
XX
AC AAB69963;
XX
DT 02-MAY-2001 (first entry)
XX
DE des Ala35-exendin-4(1-39)-NH2.
XX
KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX
OS Synthetic.
XX
PN WO200104156-A1.
XX
PD 18-JAN-2001.
XX
PF 12-JUL-2000; 2000WO-DK000393.
XX
PR 12-JUL-1999; 99US-0143591P.
XX
PR 09-AUG-1999; 99EP-00610043.
XX
PA (ZEAL-) ZEALAND PHARM AS.
XX
PI Larsen BD, Mikkelsen JD, Neve S;
XX
PS WPI; 2001-159381/16.
XX
CC The present sequence is peptide X, a component of a novel peptide
CC conjugate. X is an exendin at least 90 % homologous to exendin-4, a
CC variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys
CC at position 40 having a lipophilic substituent, a glucagon-like peptide
CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
CC C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and phenyl-
CC methyl, where C1-6-alkyl is optionally substituted with 1-3 substituents
CC selected from halogen, hydroxy, amino, cyano, nitro, sulfonyl, and
CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
CC substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
CC amino, cyano, nitro, sulfonyl, and carboxy; or R1 and R2, together with
CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
CC conjugate with the proviso that X is not exendin-4 or exendin-3. The
CC peptide conjugate is useful in the manufacture of a pharmaceutical
CC composition for use in treatment of type 1 or type 2 diabetes, insulin
CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
CC disorders and gastric disease. It is useful for treating disease states
CC associated with elevated blood glucose levels elicited by hormones known
CC to increase blood glucose levels, such as catechol amines including
CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
```

```
CC regulation of gastric emptying, for stimulating insulin release, for
CC lowering plasma lipid level, and for reducing mortality and morbidity
CC after myocardial infarction
XX
SQ Sequence 38 AA;
AAB69963 Length: 38 February 4, 2005 13:19 Type: P Check: 6972 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEEAARLFIWLKNGSPSSGPPPS
1 -----
1 match found in sequence:
aab69964 ; des Gly34-exendin-4(1-39)-NH2.
(from "seq4ags.pep")
TOIG of: aab69964 check: 6768 from: 1 to: 38

ID AAB69964 standard; peptide; 38 AA.
XX
AC AAB69964;
XX
DT 02-MAY-2001 (first entry)
XX
DE des Gly34-exendin-4(1-39)-NH2.
XX
KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX
OS Synthetic.
XX
PN WO200104156-A1.
XX
PD 18-JAN-2001.
XX
PF 12-JUL-2000; 2000WO-DK000393.
XX
PR 12-JUL-1999; 99US-0143591P.
XX
PR 09-AUG-1999; 99EP-00610043.
XX
PA (ZEAL-) ZEALAND PHARM AS.
XX
PI Larsen BD, Mikkelsen JD, Neve S;
XX
PS WPI; 2001-159381/16.
XX
CC Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
CC level of blood glucose and for treating diseases like diabetes, obesity
CC and eating disorders.
XX
CC Claim 23; Page 67; 83pp; English.
XX
CC The present sequence is peptide X, a component of a novel peptide
CC conjugate. X is an exendin at least 90 % homologous to exendin-4, a
CC variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys
CC at position 40 having a lipophilic substituent, a glucagon-like peptide
CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
CC C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and phenyl-
CC methyl, where C1-6-alkyl is optionally substituted with 1-3 substituents
CC selected from halogen, hydroxy, amino, cyano, nitro, sulfonyl, and
CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
CC substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
CC amino, cyano, nitro, sulfonyl, and carboxy; or R1 and R2, together with
CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
```

CC conjugate with the proviso that X is not extendin-4 or extendin-3. The
 CC peptide conjugate is useful in the manufacture of a pharmaceutical
 CC composition for use in treatment of type 1 or type 2 diabetes, insulin
 CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
 CC disorders and gastric disease. It is useful for treating disease states
 CC associated with elevated blood glucose levels elicited by hormones known
 CC to increase blood glucose levels, such as catechol amines including
 CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
 CC regulation of gastric emptying, for stimulating insulin release, for
 CC lowering plasma lipid level, and for reducing mortality and morbidity
 CC after myocardial infarction
 XX
 XX Sequence 38 AA;

AAB69964 Length: 38 February 4, 2005 13:19 Type: P Check: 6768 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQMEEAVALFIEWLKNGGPPSSAPPPS
 1 28

 1 match found in sequence:
 aab69965 ; des Gly34-(Lys40(palmitoyl)extendin-4(1-39)-NH2.
 (from "seq4ags.pep")
 TOIG of: aab69965 check: 9693 from: 1 to: 39

ID AAB69965 standard; peptide; 39 AA.
 XX
 AC AAB69965;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 DE des Gly34-(Lys40(palmitoyl)extendin-4(1-39)-NH2.
 XX
 KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.
 XX
 PN WO200104156-A1.
 XX
 PD 18-JAN-2001.
 XX
 PF 12-JUL-2000; 2000WO-DK000393.
 XX
 PR 12-JUL-1999; 99US-0143591P.
 PR 09-AUG-1999; 99EP-00610043.
 XX
 PA (ZEAL-) ZEALAND PHARM AS.
 XX
 PI Larsen BD, Mikkelsen JD, Neve S;
 XX
 DR WPI; 2001-159381/16.
 XX
 PT Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.
 XX
 PS Claim 23; Page 67; 83pp; English.

CC The present sequence is peptide X, a component of a novel peptide
 CC conjugate. X is an extendin at least 90 % homologous to extendin-4, a
 CC variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys
 CC at position 40 having a lipophilic substituent, a glucagon-like peptide
 CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
 CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
 CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
 CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
 CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
 CC C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and phenyl-

CC methyl, where C1-6-alkyl is optionally substituted with 1-3 substituents
 CC selected from halogen, hydroxy, amino, cyano, nitro, sulfonyl, and
 CC carboxyl, and phenyl and phenylmethyl are optionally substituted with 1-3
 CC substituents selected from C1-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
 CC amino, cyano, nitro, sulfonyl, and carboxyl; or R1 and R2, together with
 CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
 CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropionic acid or its salt, or the C-terminal amide of the peptide
 CC conjugate with the proviso that X is not extendin-4 or extendin-3. The
 CC peptide conjugate is useful in the manufacture of a pharmaceutical
 CC composition for use in treatment of type 1 or type 2 diabetes, insulin
 CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
 CC disorders and gastric disease. It is useful for treating disease states
 CC associated with elevated blood glucose levels elicited by hormones known
 CC to increase blood glucose levels, such as catechol amines including
 CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
 CC regulation of gastric emptying, for stimulating insulin release, for
 CC lowering plasma lipid level, and for reducing mortality and morbidity
 CC after myocardial infarction
 XX
 XX Sequence 39 AA;

AAB69965 Length: 39 February 4, 2005 13:19 Type: P Check: 9693 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQMEEAVALFIEWLKNGGPPSSAPPPSK
 1 28

 1 match found in sequence:
 aab69966 ; des Ala35-(Lys40(palmitoyl)extendin-4(1-39)-NH2.
 (from "seq4ags.pep")
 TOIG of: aab69966 check: 9897 from: 1 to: 39

ID AAB69966 standard; peptide; 39 AA.
 XX
 AC AAB69966;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 DE des Ala35-(Lys40(palmitoyl)extendin-4(1-39)-NH2.
 XX
 KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.
 XX
 PN WO200104156-A1.
 XX
 PD 18-JAN-2001.
 XX
 PF 12-JUL-2000; 2000WO-DK000393.
 XX
 PR 12-JUL-1999; 99US-0143591P.
 PR 09-AUG-1999; 99EP-00610043.
 XX
 PA (ZEAL-) ZEALAND PHARM AS.
 XX
 PI Larsen BD, Mikkelsen JD, Neve S;
 XX
 DR WPI; 2001-159381/16.
 XX
 PT Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.
 XX
 PS Claim 23; Page 67; 83pp; English.

CC The present sequence is peptide X, a component of a novel peptide
 CC conjugate. X is an extendin at least 90 % homologous to extendin-4, a

CC variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys
 CC at position 40 having a lipophilic substituent, a glucagon-like peptide
 CC (GUP-1) (7-36) or GUP-1 (7-37) having a substitution of D-Ala, Gly or
 CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
 CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
 CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
 CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
 CC C(=O)-, R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-
 CC methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents
 CC selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and
 CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
 CC substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
 CC amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with
 CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
 CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
 CC conjugate with the proviso that X is not exendin-4 or exendin-3. The
 CC peptide conjugate is useful in the manufacture of a pharmaceutical
 CC composition for use in treatment of type 1 or type 2 diabetes, insulin
 CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
 CC disorders and gastric disease. It is useful for treating disease states
 CC associated with elevated blood glucose levels elicited by hormones known
 CC to increase blood glucose levels, such as catechol amines including
 CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
 CC regulation of gastric emptying, for stimulating insulin release, for
 CC lowering plasma lipid level, and for reducing mortality and morbidity
 CC after myocardial infarction

XX Sequence 39 AA;

AAAB69967 Length: 39 February 4, 2005 13:19 Type: P Check: 9897 ..

Found using 'seq4' (mohamed337.key)

1 HGEFTTSLSKQMEEEAVRLFIEWLKNGSPSSGPPPSK
 28

1 match found in sequence:

aab69967 ; des Pro36-(Lys40 (palmitoyl)exendin-4(1-39)-NH2.

(from "seqtags.pep")

TOIG of: aab69967 check: 9372 from: 1 to: 39

ID AAB69967 standard; peptide; 39 AA.

XX AAB69967;

XX 02-MAY-2001 (first entry)

DE des Pro36-(Lys40 (palmitoyl)exendin-4(1-39)-NH2.

XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

XX 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

XX

PT Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 PT level of blood glucose and for treating diseases like diabetes, obesity
 PT and eating disorders.

XX Claim 23; Page 67; 83pp; English.

XX The present sequence is peptide X, a component of a novel peptide
 CC conjugate. X is an exendin at least 90 % homologous to exendin-4, a
 CC variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys
 CC at position 40 having a lipophilic substituent, a glucagon-like peptide
 CC (GUP-1) (7-36) or GUP-1 (7-37) having a substitution of D-Ala, Gly or
 CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
 CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
 CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
 CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
 CC C(=O)-, R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-
 CC methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents
 CC selected from halogen, hydroxy, amino, cyano, nitro, sulfono, and
 CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
 CC substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
 CC amino, cyano, nitro, sulfono, and carboxy; or R1 and R2, together with
 CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
 CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
 CC conjugate with the proviso that X is not exendin-4 or exendin-3. The
 CC peptide conjugate is useful in the manufacture of a pharmaceutical
 CC composition for use in treatment of type 1 or type 2 diabetes, insulin
 CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
 CC disorders and gastric disease. It is useful for treating disease states
 CC associated with elevated blood glucose levels elicited by hormones known
 CC to increase blood glucose levels, such as catechol amines including
 CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
 CC regulation of gastric emptying, for stimulating insulin release, for
 CC lowering plasma lipid level, and for reducing mortality and morbidity
 CC after myocardial infarction

XX Sequence 39 AA;

AAAB69967 Length: 39 February 4, 2005 13:19 Type: P Check: 9372 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTTSLSKQMEEEAVRLFIEWLKNGSPSSGPPPSK
 28

1 match found in sequence:

aab69968 ; Exendin-4(1-39) - (Lys)6-NH2.

(from "seqtags.pep")

TOIG of: aab69968 check: 8695 from: 1 to: 45

ID AAB69968 standard; peptide; 45 AA.

XX AAB69968;

XX 02-MAY-2001 (first entry)

XX Exendin-4(1-39) - (Lys)6-NH2.

XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
 KW antinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.

XX Synthetic.

XX WO200104156-A1.

XX 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

XX 12-JUL-1999; 99US-0143591P.

XX

```

PR 09-AUG-1999; 99EP-00610043.
XX (ZEAL-) ZEALAND PHARM AS.
XX
XX Larsen BD, Mikkelsen JD, Neve S;
XX
XX WPI; 2001-159381/16.
XX
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
XX level of blood glucose and for treating diseases like diabetes, obesity
XX and eating disorders.
XX
XX Claim 24; Page 67; 83pp; English.
XX
XX The present sequence is a peptide conjugate comprising a peptide (X)
XX which is an extendin at least 90 % homologous to extendin-4, a variant of
XX extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
XX 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
XX 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
XX isobutyric acid for Ala at position 8 and/or having a lipophilic
XX substituent, and Z, a peptide sequence of 4-20 amino acids covalently
XX bound to the variant. Each amino acid in Z is selected from A, L, S, T,
XX Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
XX C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
XX phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
XX substituents selected from halogen, hydroxy, amino, cyano, nitro,
XX substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
XX halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and
XX R2, together with the carbon atom to which they are bound, form a
XX cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
XX acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
XX of the peptide conjugate with the proviso that X is not extendin-4 or
XX extendin-3. The peptide conjugate is useful in the manufacture of a
XX pharmaceutical composition for use in treatment of type 1 or type 2
XX diabetes, insulin resistance syndrome, obesity, eating disorder,
XX hyperglycaemia, metabolic disorders and gastric disease. It is useful for
XX treating disease states associated with elevated blood glucose levels
XX elicited by hormones known to increase blood glucose levels, such as
XX catechol amines including adrenalin, glucocorticoids, growth hormone and
XX glucagon. It is useful in regulation of gastric emptying, for stimulating
XX insulin release, for lowering plasma lipid level, and for reducing
XX mortality and morbidity after myocardial infarction
XX
XX Sequence 45 AA;
XX
AAB69968 Length: 45 February 4, 2005 13:19 Type: P Check: 8695 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMBEAVRLFIEWLKNGPSSGAPPSPKSKKKK
1
-----
1 match found in sequence:
aab69969 ; des Pro36-extendin-4(1-39) - (Lys)6-NH2.
(from "seq4ags.pep")
TOIG of: aab69969 check: 5122 from: 1 to: 44
ID AAB69969 standard; peptide; 44 AA.
XX
XX AAB69969;
XX
XX 02-MAY-2001 (first entry)
XX
XX des Pro36-extendin-4(1-39) - (Lys)6-NH2.
XX
XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
XX antiinflammatory; peptide conjugate; diabetes; obesity;
XX insulin resistance syndrome; eating disorder; hyperglycaemia;
XX metabolic disorder; gastric disease; myocardial infarction.
XX
XX Synthetic.
XX

```

```

XX WO200104156-A1.
XX
XX 18-JAN-2001.
XX
XX 12-JUL-2000; 200WO-DK000393.
XX
XX 12-JUL-1999; 99US-0143591P.
XX
XX 09-AUG-1999; 99EP-00610043.
XX
XX (ZEAL-) ZEALAND PHARM AS.
XX
XX Larsen BD, Mikkelsen JD, Neve S;
XX
XX WPI; 2001-159381/16.
XX
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
XX level of blood glucose and for treating diseases like diabetes, obesity
XX and eating disorders.
XX
XX Claim 27; Page 68; 83pp; English.
XX
XX The present sequence is a peptide conjugate comprising a peptide (X)
XX which is an extendin at least 90 % homologous to extendin-4, a variant of
XX extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
XX 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
XX 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
XX isobutyric acid for Ala at position 8 and/or having a lipophilic
XX substituent, and Z, a peptide sequence of 4-20 amino acids covalently
XX bound to the variant. Each amino acid in Z is selected from A, L, S, T,
XX Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
XX C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
XX phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
XX substituents selected from halogen, hydroxy, amino, cyano, nitro,
XX sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
XX substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
XX halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and
XX R2, together with the carbon atom to which they are bound, form a
XX cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
XX acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
XX of the peptide conjugate with the proviso that X is not extendin-4 or
XX extendin-3. The peptide conjugate is useful in the manufacture of a
XX pharmaceutical composition for use in treatment of type 1 or type 2
XX diabetes, insulin resistance syndrome, obesity, eating disorder,
XX hyperglycaemia, metabolic disorders and gastric disease. It is useful for
XX treating disease states associated with elevated blood glucose levels
XX elicited by hormones known to increase blood glucose levels, such as
XX catechol amines including adrenalin, glucocorticoids, growth hormone and
XX glucagon. It is useful in regulation of gastric emptying, for stimulating
XX insulin release, for lowering plasma lipid level, and for reducing
XX mortality and morbidity after myocardial infarction
XX
XX Sequence 44 AA;
XX
AAB69969 Length: 44 February 4, 2005 13:19 Type: P Check: 5122 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMBEAVRLFIEWLKNGPSSGAPPSPKSKKKK
1
-----
1 match found in sequence:
aab69971 ; Extendin-4(1-39).
(from "seq4ags.pep")
TOIG of: aab69971 check: 9570 from: 1 to: 39
ID AAB69971 standard; peptide; 39 AA.
XX
XX AAB69971;
XX
XX 02-MAY-2001 (first entry)
XX
XX

```

DE Exendin-4(1-39).
XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
XX antinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX Unidentified.
OS
XX WO200104156-A1.
XX 18-JAN-2001.
XX
XX 12-JUL-2000; 2000WO-DK000393.
PR 12-JUL-1999; 99US-0143591P.
PR 09-AUG-1999; 99EP-00610043.
XX (ZEAL-) ZEALAND PHARM AS.
XX Larsen BD, Mikkelsen JD, Neve S;
XX WPI; 2001-159381/16.
XX
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
XX Claim 6; Page 62; 83pp; English.
XX
XX The present sequence is peptide X, a component of a novel peptide
CC conjugate. X is an exendin at least 90 % homologous to exendin-4, a
CC variant of exendin comprising 1-5 deletions at positions 34-39 or a Lys
CC at position 40 having a lipophilic substituent, a glucagon-like peptide
CC (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
CC alpha-amino isobutyric acid for Ala at position 8 and/or having a
CC lipophilic substituent. X is covalently bound to Z, a peptide sequence of
CC 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
CC Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
CC C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-
CC methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents
CC selected from halogen, hydroxy, amino, cyano, nitro, sulfonyl, and
CC carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
CC substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
CC amino, cyano, nitro, sulfonyl, and carboxy; or R1 and R2, together with
CC the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
CC or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
CC diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
CC conjugate with the proviso that X is not exendin-4 or exendin-3. The
CC peptide conjugate is useful in the manufacture of a pharmaceutical
CC composition for use in treatment of type 1 or type 2 diabetes, insulin
CC resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
CC disorders and gastric disease. It is useful for treating disease states
CC associated with elevated blood glucose levels elicited by hormones known
CC to increase blood glucose levels, such as catechol amines including
CC adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
CC regulation of gastric emptying, for stimulating insulin release, for
CC lowering plasma lipid level, and for reducing mortality and morbidity
CC after myocardial infarction
XX
XX Sequence 39 AA;
SQ
AAB69979 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGFTSLSKQMEEEAVRLFIEWLKNKGSPSGAPPPS
28
1 match found in sequence:
aab69979 ; des Pro36, Pro37-exendin-4(1-39)-(Lys)6-NH2.
(from "seq4ags.pep")

TOIG of: aab69979 check: 441 from: 1 to: 36
ID AAB69979 standard; peptide; 36 AA.
XX
AC AAB69979;
XX
DT 02-MAY-2001 (first entry)
XX
XX des Pro36, Pro37-exendin-4(1-39)-(Lys)6-NH2.
XX
XX Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX
OS Synthetic.
XX WO200104156-A1.
XX
XX 18-JAN-2001.
XX
XX 12-JUL-2000; 2000WO-DK000393.
XX
XX 12-JUL-1999; 99US-0143591P.
PR 09-AUG-1999; 99EP-00610043.
XX
XX (ZEAL-) ZEALAND PHARM AS.
XX
XX Larsen BD, Mikkelsen JD, Neve S;
XX WPI; 2001-159381/16.
XX
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
XX Claim 22; Page 66; 83pp; English.
XX
XX The present sequence is a peptide conjugate comprising a peptide (X)
CC which is an exendin at least 90 % homologous to exendin-4, a variant of
CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
CC isobutyric acid for Ala at position 8 and/or having a lipophilic
CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
CC phenylmethyl, where Cl-6-alkyl is optionally substituted with 1-3
CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
CC halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and
CC R2, together with the carbon atom to which they are bound, form a
CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
CC of the peptide conjugate with the proviso that X is not exendin-4 or
CC exendin-3. The peptide conjugate is useful in the manufacture of a
CC pharmaceutical composition for use in treatment of type 1 or type 2
CC diabetes, insulin resistance syndrome, obesity, eating disorder,
CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
CC treating disease states associated with elevated blood glucose levels
CC elicited by hormones known to increase blood glucose levels, such as
CC catechol amines including adrenalin, glucocorticoids, growth hormone and
CC glucagon. It is useful in regulation of gastric emptying, for stimulating
CC insulin release, for lowering plasma lipid level, and for reducing
CC mortality and morbidity after myocardial infarction
XX
XX Sequence 36 AA;
SQ
AAB69979 Length: 36 February 4, 2005 13:19 Type: P Check: 441 ..
Found using 'seq4' (mohamed337.key)

```

1 HGGFTSLSKQMBEEAVRLFIEWLKNGPSSGAS
  28
-----
1 match found in sequence:
aab69980 ; (Lys)6-des Pro36, Pro37, Pro38-exendin-4(1-39)-NH2.
      (from "seq4ags.pep")
TOIG of: aab69980 check: 8306 from: 1 to: 42

ID AAB69980 standard; peptide; 42 AA.
XX
AC AAB69980;
XX
DT 02-MAY-2001 (first entry)
XX
DE (Lys)6-des Pro36, Pro37, Pro38-exendin-4(1-39)-NH2.
XX
KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX
OS Synthetic.
XX
PN WO200104156-A1.
XX
PD 18-JAN-2001.
XX
PF 12-JUL-2000; 2000WO-DK000393.
XX
PR 12-JUL-1999; 99US-0143591P.
PR 09-AUG-1999; 99EP-00610043.
XX
PA (ZEAL-) ZEALAND PHARM AS.
XX
PI Larsen BD, Mikkelsen JD, Neve S;
XX
DR WPI; 2001-159381/16.
XX
PT Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
PS Claim 22; Page 66; 83pp; English.
XX
CC The present sequence is a peptide conjugate comprising a peptide (X)
CC which is an exendin at least 90 % homologous to exendin-4, a variant of
CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
CC isobutyric acid for Ala at position 8 and/or having a lipophilic
CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
CC C(R1)(R2)-C(=O)-, R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
CC phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
CC sulfono, and carboxy, and phenyl and phenylmethyl are optionally
CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and
CC R2, together with the carbon atom to which they are bound, form a
CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
CC of the peptide conjugate with the proviso that X is not exendin-4 or
CC exendin-3. The peptide conjugate is useful in the manufacture of a
CC pharmaceutical composition for use in treatment of type 1 or type 2
CC diabetes, insulin resistance syndrome, obesity, eating disorder,
CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
CC treating disease states associated with elevated blood glucose levels
CC elicited by hormones known to increase blood glucose levels, such as
CC catechol amines including adrenalin, glucocorticoids, growth hormone and
CC glucagon. It is useful in regulation of gastric emptying, for stimulating

```

```

CC insulin release, for lowering plasma lipid level, and for reducing
CC mortality and morbidity after myocardial infarction
XX
SQ Sequence 42 AA;
AA69980 Length: 42 February 4, 2005 13:19 Type: P Check: 8306
Found using 'seq4' (mohamed337.key)
1 KKKKKKGEGFTSLSKQMBEEAVRLFIEWLKNGPSSGAS
  34
-----
1 match found in sequence:
aab69981 ; Asn(Glu)5-des Pro36, Pro37, Pro38-exendin-4(1-39)-NH2.
      (from "seq4ags.pep")
TOIG of: aab69981 check: 8189 from: 1 to: 42

```

```

ID AAB69981 standard; peptide; 42 AA.
XX
AC AAB69981;
XX
DT 02-MAY-2001 (first entry)
XX
DE Asn(Glu)5-des Pro36, Pro37, Pro38-exendin-4(1-39)-NH2.
XX
KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; anorectic;
KW antiinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.
XX
OS Synthetic.
XX
PN WO200104156-A1.
XX
PD 18-JAN-2001.
XX
PF 12-JUL-2000; 2000WO-DK000393.
XX
PR 12-JUL-1999; 99US-0143591P.
PR 09-AUG-1999; 99EP-00610043.
XX
PA (ZEAL-) ZEALAND PHARM AS.
XX
PI Larsen BD, Mikkelsen JD, Neve S;
XX
DR WPI; 2001-159381/16.
XX
PT Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
PT level of blood glucose and for treating diseases like diabetes, obesity
PT and eating disorders.
XX
PS Claim 22; Page 66; 83pp; English.
XX
CC The present sequence is a peptide conjugate comprising a peptide (X)
CC which is an exendin at least 90 % homologous to exendin-4, a variant of
CC exendin comprising 1-5 deletions at positions 34-39 or a Lys at position
CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
CC 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
CC isobutyric acid for Ala at position 8 and/or having a lipophilic
CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
CC C(R1)(R2)-C(=O)-, R1 and R2 are selected from H, Cl-6-alkyl, phenyl and
CC phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3
CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
CC sulfono, and carboxy, and phenyl and phenylmethyl are optionally
CC substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl,
CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy; or R1 and
CC R2, together with the carbon atom to which they are bound, form a
CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
CC of the peptide conjugate with the proviso that X is not exendin-4 or

```

CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 XX
 SQ Sequence 42 AA;

AAB69981 Length: 42 February 4, 2005 13:19 Type: P Check: 8189 ..
 Found using 'seq4' (mohamed337.key)

1 NEEEEHGEFTTDLKQMEEEAVRLFIEWLKNGPSSGAS
 34

 1 match found in sequence:
 aab69982 ; (Lys)6-des Pro36, Pro37, Pro38-exendin-4(1-39) - (Lys)6-NH2.
 (from "seq4ags.pep")
 TOIG of: aab69982 check: 8781 from: 1 to: 48

ID AAB69982 standard; peptide; 48 AA.
 XX
 AC AAB69982;
 DT 02-MAY-2001 (first entry)
 XX (Lys)6-des Pro36, Pro37, Pro38-exendin-4(1-39) - (Lys)6-NH2.
 DE
 XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.
 XX WO200104156-A1.
 XX 18-JAN-2001.
 XX 12-JUL-2000; 2000WO-DK000393.
 XX 12-JUL-1999; 99US-0143591P.
 PR 09-AUG-1999; 99EP-00610043.
 XX (ZEAL-) ZEALAND PHARM AS.
 PA
 XX Larsen BD, Mikkelsen JD, Neve S;
 PI WPI; 2001-159381/16.
 XX

Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 level of blood glucose and for treating diseases like diabetes, obesity
 and eating disorders.

Claim 22; Page 66; 83pp; English.

The present sequence is a peptide conjugate comprising a peptide (X)
 which is an extendin at least 90 % homologous to extendin-4, a variant of
 extendin comprising 1-5 deletions at positions 34-39 or a Lys at position
 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-
 36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino
 isobutyric acid for Ala at position 8 and/or having a lipophilic
 CC substituent, and Z, a peptide sequence of 4-20 amino acids covalently
 CC bound to the variant. Each amino acid in Z is selected from A, L, S, T,
 CC Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-
 CC C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, C1-6-alkyl, phenyl and
 CC phenyl-methyl, where C1-6-alkyl is optionally substituted with 1-3

CC substituents selected from halogen, hydrogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally
 CC substituted with 1-3 substituents selected from C1-6-alkyl, C2-6-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and
 CC R2, together with the carbon atom to which they are bound, form a
 CC cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic
 CC acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide
 CC of the peptide conjugate with the proviso that X is not extendin-4 or
 CC extendin-3. The peptide conjugate is useful in the manufacture of a
 CC pharmaceutical composition for use in treatment of type 1 or type 2
 CC diabetes, insulin resistance syndrome, obesity, eating disorder,
 CC hyperglycaemia, metabolic disorders and gastric disease. It is useful for
 CC treating disease states associated with elevated blood glucose levels
 CC elicited by hormones known to increase blood glucose levels, such as
 CC catechol amines including adrenalin, glucocorticoids, growth hormone and
 CC glucagon. It is useful in regulation of gastric emptying, for stimulating
 CC insulin release, for lowering plasma lipid level, and for reducing
 CC mortality and morbidity after myocardial infarction
 XX
 SQ Sequence 48 AA;

AAB69982 Length: 48 February 4, 2005 13:19 Type: P Check: 8781 ..
 Found using 'seq4' (mohamed337.key)

1 KKKKKKHGEFTTDLKQMEEEAVRLFIEWLKNGPSSGASKKKKKX
 34

 1 match found in sequence:
 aab69983 ; Asn(Glu)5-des Pro36, Pro37, Pro38-exendin-4(1-39) - (Lys)6-NH2.
 (from "seq4ags.pep")
 TOIG of: aab69983 check: 8664 from: 1 to: 48

ID AAB69983 standard; peptide; 48 AA.
 XX
 AC AAB69983;
 XX 02-MAY-2001 (first entry)
 XX Asn(Glu)5-des Pro36, Pro37, Pro38-exendin-4(1-39) - (Lys)6-NH2.
 DE
 XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
 KW antiinflammatory; peptide conjugate; diabetes; obesity;
 KW insulin resistance syndrome; eating disorder; hyperglycaemia;
 KW metabolic disorder; gastric disease; myocardial infarction.
 XX
 OS Synthetic.
 XX WO200104156-A1.
 XX 18-JAN-2001.
 XX 12-JUL-2000; 2000WO-DK000393.
 XX 12-JUL-1999; 99US-0143591P.
 PR 09-AUG-1999; 99EP-00610043.
 XX (ZEAL-) ZEALAND PHARM AS.
 PA
 XX Larsen BD, Mikkelsen JD, Neve S;
 PI WPI; 2001-159381/16.
 XX

Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
 level of blood glucose and for treating diseases like diabetes, obesity
 and eating disorders.

Claim 22; Page 66; 83pp; English.

The present sequence is a peptide conjugate comprising a peptide (X)
 which is an extendin at least 90 % homologous to extendin-4, a variant of
 extendin comprising 1-5 deletions at positions 34-39 or a Lys at position

CC 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino isobutyric acid for Ala at position 8 and/or having a lipophilic substituent, and Z, a peptide sequence of 4-20 amino acids covalently bound to the variant. Each amino acid in Z is selected from A, L, S, T, Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3 sulfono, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and R2, together with the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide of the peptide conjugate with the proviso that X is not extendin-4 or extendin-3. The peptide conjugate is useful in the manufacture of a pharmaceutical composition for use in treatment of type 1 or type 2 diabetes, insulin resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic disorders and gastric disease. It is useful for treating disease states associated with elevated blood glucose levels elicited by hormones known to increase blood glucose levels, such as catechol amines including adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in regulation of gastric emptying, for stimulating insulin release, for lowering plasma lipid level, and for reducing mortality and morbidity after myocardial infarction

XX Sequence 48 AA;

AAB69983 Length: 48 February 4, 2005 13:19 Type: P Check: 8664 ..
Found using 'seq4' (mohamed337.key)

1 NEEBEEHGBTFTSDLSKQWEEAVRLFIEWLKNQGPSSGASKKKKK
7

34

1 match found in sequence:
aab69984 ; des Pro36, Pro37, Pro38-extendin-4(1-39)-(Lys)6-NH2.
(from "seq4ags.pep")
TOIG of: aab69984 check: 8216 from: 1 to: 42

ID AAB69984 standard; peptide; 42 AA.

XX AAB69984;

AC AAB69989;

DT 02-MAY-2001 (first entry)

DE des Pro36, Pro37, Pro38-extendin-4(1-39)-(Lys)6-NH2.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
KW antinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.

OS Synthetic.

XX WO200104156-A1.

PN 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

PR 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.

XX Larsen BD, Mikkelsen JD, Neve S;

XX WPI; 2001-159381/16.

PT Novel peptide agonist of Glucagon-like peptide, useful for decreasing the

level of blood glucose and for treating diseases like diabetes, obesity and eating disorders.

Claim 22; Page 67; 83pp; English.

XX The present sequence is a peptide conjugate comprising a peptide (X) which is an extendin at least 90 % homologous to extendin-4, a variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys at position 40 having a lipophilic substituent, a glucagon-like peptide (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or alpha-amino isobutyric acid for Ala at position 8 and/or having a lipophilic substituent, and Z, a peptide sequence of 4-20 amino acids covalently bound to the variant. Each amino acid in Z is selected from A, L, S, T, Y, N, Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-methyl, where Cl-6-alkyl is optionally substituted with 1-3 sulfono, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3 substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy, amino, cyano, nitro, sulfonyl, and carboxy; or R1 and R2, together with the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl, or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-diaminopropanoic acid or its salt, or the C-terminal amide of the peptide conjugate with the proviso that X is not extendin-4 or extendin-3. The peptide conjugate is useful in the manufacture of a pharmaceutical composition for use in treatment of type 1 or type 2 diabetes, insulin resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic disorders and gastric disease. It is useful for treating disease states associated with elevated blood glucose levels elicited by hormones known to increase blood glucose levels, such as catechol amines including adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in regulation of gastric emptying, for stimulating insulin release, for lowering plasma lipid level, and for reducing mortality and morbidity after myocardial infarction

XX Sequence 42 AA;

AAB69984 Length: 42 February 4, 2005 13:19 Type: P Check: 8216 ..
Found using 'seq4' (mohamed337.key)

1 HEGTFTSDLSKQWEEAVRLFIEWLKNQGPSSGASKKKKK
1
28

1 match found in sequence:

aab69989 ; des Pro36-des Pro37-extendin-4(1-39)-NH2.
(from "seq4ags.pep")
TOIG of: aab69989 check: 3404 from: 1 to: 37

ID AAB69989 standard; peptide; 37 AA.

XX AAB69989;

XX 02-MAY-2001 (first entry)

DT des Pro36-des Pro37-extendin-4(1-39)-NH2.

XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
KW antinflammatory; peptide conjugate; diabetes; obesity;
KW insulin resistance syndrome; eating disorder; hyperglycaemia;
KW metabolic disorder; gastric disease; myocardial infarction.

OS Synthetic.

XX WO200104156-A1.

PN 18-JAN-2001.

XX 12-JUL-2000; 2000WO-DK000393.

PR 12-JUL-1999; 99US-0143591P.

PR 09-AUG-1999; 99EP-00610043.

XX (ZEAL-) ZEALAND PHARM AS.
XX Larsen BD, Mikkelsen JD, Neve S;
XX WPI; 2001-159381/16.
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
XX level of blood glucose and for treating diseases like diabetes, obesity
XX and eating disorders.
XX Claim 23; Page 67; 83pp; English.
XX The present sequence is peptide X, a component of a novel peptide
XX conjugate. X is an extendin at least 90 % homologous to extendin-4, a
XX variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys
XX at position 40 having a lipophilic substituent, a glucagon-like peptide
XX (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
XX alpha-amino isobutyric acid for Ala at position 8 and/or having a
XX lipophilic substituent. X is covalently bound to Z, a peptide sequence of
XX 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
XX Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
XX C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-
XX methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents
XX selected from halogen, hydroxy, amino, cyano, nitro, sulfonyl, and
XX carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
XX substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
XX amino, cyano, nitro, sulfonyl, and carboxy; or R1 and R2, together with
XX the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
XX or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
XX diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
XX conjugate with the proviso that X is not extendin-4 or extendin-3. The
XX peptide conjugate is useful in the manufacture of a pharmaceutical
XX composition for use in treatment of type 1 or type 2 diabetes, insulin
XX resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
XX disorders and gastric disease. It is useful for treating disease states
XX associated with elevated blood glucose levels elicited by hormones known
XX to increase blood glucose levels, such as catechol amines including
XX adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
XX regulation of gastric emptying, for stimulating insulin release, for
XX lowering plasma lipid level, and for reducing mortality and morbidity
XX after myocardial infarction
XX Sequence 37 AA;
SQ
AAB69989 Length: 37 February 4, 2005 13:19 Type: P Check: 3404 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTDLSKQMEAEAVRLFIEWLKNGPSSGAPS
28
1 match found in sequence:
aab69990 ; des Pro37-des Pro 38-extendin-4(1-39)-NH2.
(from "seq4ags.pep")
TOIG of: aab69990 check: 441 from: 1 to: 36
ID AAB69990 standard; peptide; 36 AA.
XX AAB69990;
XX 02-MAY-2001 (first entry)
XX des Pro36-des Pro37-des Pro 38-extendin-4(1-39)-NH2.
XX Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; anorectic;
XX antiinflammatory; peptide conjugate; diabetes; obesity;
XX insulin resistance syndrome; eating disorder; hyperglycaemia;
XX metabolic disorder; gastric disease; myocardial infarction.
XX Synthetic.
XX OS
XX

PN WO200104156-A1.
XX 18-JAN-2001.
XX 12-JUL-2000; 2000WO-DK000393.
XX 12-JUL-1999; 99US-0143591P.
XX 09-AUG-1999; 99EP-00610043.
XX (ZEAL-) ZEALAND PHARM AS.
XX Larsen BD, Mikkelsen JD, Neve S;
XX WPI; 2001-159381/16.
XX Novel peptide agonist of Glucagon-like peptide, useful for decreasing the
XX level of blood glucose and for treating diseases like diabetes, obesity
XX and eating disorders.
XX Claim 23; Page 67; 83pp; English.
XX The present sequence is peptide X, a component of a novel peptide
XX conjugate. X is an extendin at least 90 % homologous to extendin-4, a
XX variant of extendin comprising 1-5 deletions at positions 34-39 or a Lys
XX at position 40 having a lipophilic substituent, a glucagon-like peptide
XX (GLP-1) (7-36) or GLP-1 (7-37) having a substitution of D-Ala, Gly or
XX alpha-amino isobutyric acid for Ala at position 8 and/or having a
XX lipophilic substituent. X is covalently bound to Z, a peptide sequence of
XX 4-20 amino acids. Each amino acid in Z is selected from A, L, S, T, Y, N,
XX Q, D, G, K, R, H, M, Orn, and amino acid units of formula -NH-C(R1)(R2)-
XX C(=O)-. R1 and R2 are selected from H, Cl-6-alkyl, phenyl and phenyl-
XX methyl, where Cl-6-alkyl is optionally substituted with 1-3 substituents
XX selected from halogen, hydroxy, amino, cyano, nitro, sulfonyl, and
XX carboxy, and phenyl and phenylmethyl are optionally substituted with 1-3
XX substituents selected from Cl-6-alkyl, C2-6-alkenyl, halogen, hydroxy,
XX amino, cyano, nitro, sulfonyl, and carboxy; or R1 and R2, together with
XX the carbon atom to which they are bound, form a cyclopentyl, cyclohexyl,
XX or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
XX diaminopropanoic acid or its salt, or the C-terminal amide of the peptide
XX conjugate with the proviso that X is not extendin-4 or extendin-3. The
XX peptide conjugate is useful in the manufacture of a pharmaceutical
XX composition for use in treatment of type 1 or type 2 diabetes, insulin
XX resistance syndrome, obesity, eating disorder, hyperglycaemia, metabolic
XX disorders and gastric disease. It is useful for treating disease states
XX associated with elevated blood glucose levels, such as catechol amines including
XX adrenalin, glucocorticoids, growth hormone and glucagon. It is useful in
XX regulation of gastric emptying, for stimulating insulin release, for
XX lowering plasma lipid level, and for reducing mortality and morbidity
XX after myocardial infarction
XX Sequence 36 AA;
SQ
AAB69990 Length: 36 February 4, 2005 13:19 Type: P Check: 441 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTDLSKQMEAEAVRLFIEWLKNGPSSGAS
28
1 match found in sequence:
aab85925 ; Gila monster venom extendin 3 peptide fragment.
(from "seq4ags.pep")
TOIG of: aab85925 check: 9591 from: 1 to: 39
ID AAB85925 standard; peptide; 39 AA.
XX AAB85925;
XX 30-NOV-2001 (first entry)
XX Gila monster venom extendin 3 peptide fragment.
XX DE

```

XX KW GLP-1; organ tissue; injury; reperfusion; ischemia; glucose; exendin;
XX KW glucagon-like peptide-1; vasotropic; antiarrhythmic; antidiabetic;
XX KW gila monster; venom.
OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT /note= "C-terminal amide"
XX PN US6284725-B1.
XX PD 04-SEP-2001.
XX PF 30-APR-1999; 99US-00302596.
XX PR 08-OCT-1998; 98US-0103498P.
XX PA (BION-) BIONEERASKA INC.
XX PI Coolidge TR, Ehlers MRW;
XX PI WPI; 2001-040881/05.
XX PS Disclosure; Col 7-10; 10pp; English.
XX CC The invention is directed towards the amelioration of organ tissue injury
XX CC caused by reperfusion of blood flow after ischemia. The method involves
XX CC administering a composition containing a compound which binds to a
XX CC receptor for glucagon-like peptide-1 (GLP-1) in a carrier. GLP-1
XX CC effectively enhances peripheral glucose uptake without inducing dangerous
XX CC hypoglycemia. GLP-1 strongly suppresses glucagon secretion, independent
XX CC of its insulinotropic action and powerfully reduces plasma free fatty
XX CC acid (FFA) level having major toxic mechanism during myocardial ischemia,
XX CC substantially more than can be accomplished with insulin. The method is
XX CC without side effects normally attendant with therapies presently
XX CC available. GLP-1 suppresses paracrine by intra-islet release of insulin
XX CC or somatostatin. GLP-1 is unique in its capacity to simultaneously
XX CC stimulate insulin secretion and inhibit glucagon release. The present
XX CC sequence represents a gila monster venom exendin 3 peptide fragment,
XX CC homologous to a mammalian GLP-1 peptide fragment
XX SQ Sequence 39 AA;

AAB85925 Length: 39 February 4, 2005 13:19 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNKGPSGAPPSPS
1 28
-----
1 match found in sequence:
aab85927 : Gila monster venom exendin 4 peptide fragment.
(from "seq4ags.pep")
TOIG of: aab85927 check: 9570 from: 1 to: 39

ID AAB85927 standard; peptide; 39 AA.
XX AC AAB85927;
XX DT 30-NOV-2001 (first entry)
XX DE Gila monster venom exendin 4 peptide fragment.
XX KW GLP-1; organ tissue; injury; reperfusion; ischemia; glucose; exendin;
XX KW glucagon-like peptide-1; vasotropic; antiarrhythmic; antidiabetic;
XX KW gila monster; venom.

```

```

OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT /note= "C-terminal amide"
XX PN US6284725-B1.
XX PD 04-SEP-2001.
XX PF 30-APR-1999; 99US-00302596.
XX PR 08-OCT-1998; 98US-0103498P.
XX PA (BION-) BIONEERASKA INC.
XX PI Coolidge TR, Ehlers MRW;
XX PI WPI; 2001-040881/05.
XX PS Disclosure; Col 7-10; 10pp; English.
XX CC The invention is directed towards the amelioration of organ tissue injury
XX CC caused by reperfusion of blood flow after ischemia. The method involves
XX CC administering a composition containing a compound which binds to a
XX CC receptor for glucagon-like peptide-1 (GLP-1) in a carrier. GLP-1
XX CC effectively enhances peripheral glucose uptake without inducing dangerous
XX CC hypoglycemia. GLP-1 strongly suppresses glucagon secretion, independent
XX CC of its insulinotropic action and powerfully reduces plasma free fatty
XX CC acid (FFA) level having major toxic mechanism during myocardial ischemia,
XX CC substantially more than can be accomplished with insulin. The method is
XX CC without side effects normally attendant with therapies presently
XX CC available. GLP-1 suppresses paracrine by intra-islet release of insulin
XX CC or somatostatin. GLP-1 is unique in its capacity to simultaneously
XX CC stimulate insulin secretion and inhibit glucagon release. The present
XX CC sequence represents a gila monster venom exendin 4 peptide fragment,
XX CC homologous to a mammalian GLP-1 peptide fragment
XX SQ Sequence 39 AA;

AAB85927 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQMEEEAVRLFIEWLKNKGPSGAPPSPS
1 28
-----
1 match found in sequence:
aae08345 ; Heloderma horridum exendin-3 peptide.
(from "seq4ags.pep")
TOIG of: aae08345 check: 9591 from: 1 to: 39

ID AAE08345 standard; peptide; 39 AA.
XX AC AAE08345;
XX DT 01-NOV-2001 (first entry)
XX DE Heloderma horridum exendin-3 peptide.
XX KW Exendin-3; antilipemic; cardiant; triglyceride; inotropic; diuretic;
XX KW coronary heart disease; dyslipidaemia.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT /note= "C-terminal amide"
XX

```

PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Disclosure; Page 10; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is extendin-3 peptide from Heloderma horridum
XX
XX Sequence 39 AA;
SQ
AAE08345 Length: 39 February 4, 2005 13:19 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)
1 HSDGFTSLSKQMEEEAVRLFIEWLKNKGPPSGAPPPS
28

1 match found in sequence:
aae08346 ; Heloderma suspectrum extendin-4 peptide.
(from "seq4ags.pep")
TOIG of: aae08346 check: 9570 from: 1 to: 39
ID AAE08346 standard; peptide; 39 AA.
XX
AC AAE08346;
XX
DT 01-NOV-2001 (first entry)
XX
DE Heloderma suspectrum extendin-4 peptide.
XX
KW Extendin-4; antilipemic; cardiant; triglyceride; inotropic; diuretic;
KW coronary heart disease; dyslipidaemia.
XX
OS Heloderma suspectrum.
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Disclosure; Page 10; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is extendin-3 peptide from Heloderma horridum
XX
XX Sequence 39 AA;
SQ
AAE08346 Length: 39 February 4, 2005 13:19 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)
1 HSDGFTSLSKQMEEEAVRLFIEWLKNKGPPSGAPPPS
28

1 match found in sequence:
aae08346 ; Heloderma suspectrum extendin-4 peptide.
(from "seq4ags.pep")
TOIG of: aae08346 check: 9570 from: 1 to: 39
ID AAE08346 standard; peptide; 39 AA.
XX
AC AAE08346;
XX
DT 01-NOV-2001 (first entry)
XX
DE Heloderma suspectrum extendin-4 peptide.
XX
KW Extendin-4; antilipemic; cardiant; triglyceride; inotropic; diuretic;
KW coronary heart disease; dyslipidaemia.
XX
OS Heloderma suspectrum.
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX

XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Disclosure; Page 10; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is extendin-4 peptide from Heloderma suspectrum
XX
XX Sequence 39 AA;
SQ
AAE08346 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HSDGFTSLSKQMEEEAVRLFIEWLKNKGPPSGAPPPS
28

1 match found in sequence:
aae08350 ; Heloderma suspectrum extendin-4 peptide (residues 1-30).
(from "seq4ags.pep")
TOIG of: aae08350 check: 4889 from: 1 to: 30
ID AAE08350 standard; peptide; 30 AA.
XX
AC AAE08350;
XX
DT 01-NOV-2001 (first entry)
XX
DE Heloderma suspectrum extendin-4 peptide (residues 1-30).
XX
KW Extendin-4; antilipemic; cardiant; triglyceride; inotropic; diuretic;
KW coronary heart disease; dyslipidaemia.
XX
OS Heloderma suspectrum.
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Claim 13; Page 14; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present sequence is an agonist of extendin, extendin-4 (residues 1-30) from
CC Heloderma suspectrum
XX
XX Sequence 30 AA;
SQ

AAE08350 Length: 30 February 4, 2005 13:19 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTFTSDLSKQMEEEAVRLFIEWLKGG
28

1 match found in sequence:

aae08351 : Heloderma suspectrum extendin-4 peptide (residues 1-30) amide.
(from "seq4ags.pep")

TOIG of: aae08351 check: 4889 from: 1 to: 30

ID AAE08351 standard; peptide; 30 AA.

XX

AC AAE08351;

XX 01-NOV-2001 (first entry)

XX Heloderma suspectrum extendin-4 peptide (residues 1-30) amide.

XX Extendin-4; antilipemic; cardiant; triglyceride; inotropic; diuretic;

XX coronary heart disease; dyslipidaemia.

XX Heloderma suspectrum.

XX Key Location/Qualifiers

XX Modified-site 30

XX /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.

XX Claim 13; Page 56; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present sequence is an agonist of extendin, extendin-4 amide (residues 1-
XX 30) from Heloderma suspectrum

XX Sequence 30 AA;

AAE08351 Length: 30 February 4, 2005 13:19 Type: P Check: 4889 ..

Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTFTSDLSKQMEEEAVRLFIEWLKGG
28

1 match found in sequence:

aae08352 : Heloderma suspectrum modified extendin-4 amide peptide (residues 1-28
(from "seq4ags.pep")

TOIG of: aae08352 check: 151 from: 1 to: 28

ID AAE08352 standard; peptide; 28 AA.

XX

AC AAE08352;

XX 01-NOV-2001 (first entry)

XX Heloderma suspectrum modified extendin-4 amide peptide (residues 1-28)#1.

XX Extendin-4; antilipemic; cardiant; triglyceride; inotropic; diuretic;

XX coronary heart disease; dyslipidaemia.

XX Heloderma suspectrum.

XX Key Location/Qualifiers

XX Modified-site 28

XX /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.

XX Disclosure; Page 14; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering extendin or an
XX extendin agonist. Extendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Extendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present sequence is Heloderma suspectrum modified extendin-4 amide
XX (residues 1-28) which is an agonist of extendin

XX Sequence 28 AA;

AAE08352 Length: 28 February 4, 2005 13:19 Type: P Check: 151 ..

Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTFTSDLSKQLEEEAVRLAIFLKN
28

1 match found in sequence:

aae08353 : Heloderma suspectrum modified extendin-4 peptide.
(from "seq4ags.pep")

TOIG of: aae08353 check: 9131 from: 1 to: 39

ID AAE08353 standard; peptide; 39 AA.

XX

AC AAE08353;

XX 01-NOV-2001 (first entry)

XX Heloderma suspectrum modified extendin-4 peptide.

XX Extendin-4; antilipemic; cardiant; triglyceride; inotropic; diuretic;

XX coronary heart disease; dyslipidaemia.

```

XX OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT Note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI WPI; 2001-514422/56.
XX DR Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidaemia.
XX PS Claim 13; Page 14; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present sequence is Heloderma suspectum modified extendin-4 peptide which
XX CC is an agonist of extendin
XX SQ Sequence 39 AA;
XX AA08353 Length: 39 February 4, 2005 13:19 Type: P Check: 9131 ..
XX Found using 'seq4' (mohamed337.key)
1 HGGFTSDLSKQLEEEAVRLFIEFLKNGSPSGAPPPS
1 28
-----
1 match found in sequence:
aae08354 ; Extendin agonist peptide #1.
(from "seq4ags.pep")
TOIG of: aae08354 check: 9556 from: 1 to: 39
ID AAE08354 standard; peptide; 39 AA.
XX AC AAE08354;
XX DT 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #1.
XX EX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT Note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI WPI; 2001-514422/56.
XX DR Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidaemia.
XX PS Claim 13; Page 14; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present sequence is Heloderma suspectum modified extendin-4 peptide which
XX CC is an agonist of extendin
XX SQ Sequence 39 AA;
XX AA08355 Length: 39 February 4, 2005 13:19 Type: P Check: 9556 ..
XX Found using 'seq4' (mohamed337.key)
1 HGGFTSDLSKQLEEEAVRLFIEFLKNGSPSGAPPPS
1 28
-----
1 match found in sequence:
aae08355 ; Extendin agonist peptide #2.
(from "seq4ags.pep")
TOIG of: aae08355 check: 9145 from: 1 to: 39
ID AAE08355 standard; peptide; 39 AA.
XX AC AAE08355;
XX DT 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #2.
XX EX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT Note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI WPI; 2001-514422/56.
XX DR Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidaemia.
XX PS Example 2; Page; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin. Note: The present
XX CC sequence is not shown in the specification but is derived from SEQ ID
XX CC NO:3 shown in page 17 of the specification
XX SQ Sequence 39 AA;
XX AA08354 Length: 39 February 4, 2005 13:19 Type: P Check: 9556 ..
XX Found using 'seq4' (mohamed337.key)
1 HGGFTSDLSKQLEEEAVRLFIEFLKNGSPSGAPPPS
1 28
-----
1 match found in sequence:
aae08355 ; Extendin agonist peptide #2.
(from "seq4ags.pep")
TOIG of: aae08355 check: 9145 from: 1 to: 39
ID AAE08355 standard; peptide; 39 AA.
XX AC AAE08355;
XX DT 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #2.
XX EX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT Note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI WPI; 2001-514422/56.
XX DR Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidaemia.

```

XX PS Example 3a; Page; 161pp; English.

XX CC The patent discloses a method for modulating plasma or postprandial

CC triglyceride and other lipid levels by administering exendin or an

CC exendin agonist. Exendins have inotropic and diuretic effects. They

CC suppress the secretion of glucagon. Exendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride

CC concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia. and for modifying postprandial triglyceride levels. The

CC present peptide sequence is an agonist of exendin. Note: The present

CC sequence is not shown in the specification but is derived from SEQ ID

CC NO:3 shown in page 17 of the specification

XX SQ Sequence 39 AA;

AAE08355 Length: 39 February 4, 2005 13:19 Type: P Check: 9145 ..

Found using 'seq4' (mohamed337.key)

1 |-----|

1 HGEFTTSDLSKQMBEEAVRLFIEFLKNGGPGSSGAPPPS 28

1 match found in sequence:

aae08356 ; Exendin agonist peptide #3.

(from "seq4ags.pep")

TOIG of: aae08356 check: 9587 from: 1 to: 39

ID AAE08356 standard; peptide; 39 AA.

XX AC AAE08356;

XX DT 01-NOV-2001 (first entry)

XX DE Exendin agonist peptide #3.

XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;

XX KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 39

FT /note= "C-terminal amide"

XX WO200151078-A1.

XX PD 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride

PT levels, and treating heart disease and dyslipidemia.

XX Example 3b; Page; 161pp; English.

XX CC The patent discloses a method for modulating plasma or postprandial

CC triglyceride and other lipid levels by administering exendin or an

CC exendin agonist. Exendins have inotropic and diuretic effects. They

CC suppress the secretion of glucagon. Exendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride

CC concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia, and for modifying postprandial triglyceride levels. The

CC present peptide sequence is an agonist of exendin. Note: The present

CC sequence is not shown in the specification but is derived from SEQ ID

CC NO:3 shown in page 17 of the specification

XX SQ Sequence 39 AA;

AAE08356 Length: 39 February 4, 2005 13:19 Type: P Check: 9587 ..

Found using 'seq4' (mohamed337.key)

1 |-----|

1 YGEGFTTSDLSKQMBEEAVRLFIEFLKNGGPGSSGAPPPS 28

1 match found in sequence:

aae08357 ; Exendin agonist peptide #4.

(from "seq4ags.pep")

TOIG of: aae08357 check: 9804 from: 1 to: 39

ID AAE08357 standard; peptide; 39 AA.

XX AC AAE08357;

XX DT 01-NOV-2001 (first entry)

XX DE Exendin agonist peptide #4.

XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;

XX KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 39

FT /note= "C-terminal amide"

XX WO200151078-A1.

XX PD 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride

PT levels, and treating heart disease and dyslipidemia.

XX Example 4; Page; 161pp; English.

XX CC The patent discloses a method for modulating plasma or postprandial

CC triglyceride and other lipid levels by administering exendin or an

CC exendin agonist. Exendins have inotropic and diuretic effects. They

CC suppress the secretion of glucagon. Exendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride

CC concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia, and for modifying postprandial triglyceride levels. The

CC present peptide sequence is an agonist of exendin. Note: The present

CC sequence is not shown in the specification but is derived from SEQ ID

CC NO:3 shown in page 17 of the specification

XX SQ Sequence 39 AA;

AAE08357 Length: 39 February 4, 2005 13:19 Type: P Check: 9804 ..

Found using 'seq4' (mohamed337.key)

1 |-----|

1 HGEFTTSDLSKQMBEEAVRLFIEFLKNGGPGSSGAPPPY 28

```

-----
1 match found in sequence:
aae08358 ; Exendin agonist peptide #5.
(from "seq4ags.pep")
TOIG of: aae08358 check: 9567 from: 1 to: 39

ID AAE08358 standard; peptide; 39 AA.
XX
AC AAE08358;
XX
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #5.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT Modified-site 39 /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 5; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;

AAE08358 Length: 39 February 4, 2005 13:19 Type: P Check: 9567 ..
Found using 'seq4' (mohamed337.key)

1 HGEGTFTSLSKQMEEEAVRLFIEWLKNKGFPSSGAPPPS
28

-----
1 match found in sequence:
aae08359 ; Exendin agonist peptide #6.
(from "seq4ags.pep")
TOIG of: aae08359 check: 9678 from: 1 to: 39

ID AAE08359 standard; peptide; 39 AA.
XX
AC AAE08359;
XX
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #6.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX

```

```

DT 01-NOV-2001 (first entry)
XX
XX Exendin agonist peptide #6.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 6 /note= "Naphthylalanine"
FT Modified-site 39
FT Modified-site 39 /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 6; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;

AAE08359 Length: 39 February 4, 2005 13:19 Type: P Check: 9678 ..
Found using 'seq4' (mohamed337.key)

1 HGEGTFTSLSKQMEEEAVRLFIEWLKNKGFPSSGAPPPS
28

-----
1 match found in sequence:
aae08360 ; Exendin agonist peptide #7.
(from "seq4ags.pep")
TOIG of: aae08360 check: 9563 from: 1 to: 39

ID AAE08360 standard; peptide; 39 AA.
XX
AC AAE08360;
XX
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #7.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX

```

1 match found in sequence:

aae08365 ; Exendin agonist peptide #12.

(from "seq4ags.pep")

TOIG of: aae08365 Check: 9251 from: 1 to: 39

ID AAE08365 standard; peptide; 39 AA.

XX

XX

AC AAE08365;

XX

DT 01-NOV-2001 (first entry)

XX

DE Exendin agonist peptide #12.

XX

KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT

Modified-site 10

FT

/note= "Pentylglycine"

FT

Modified-site 39

FT

/note= "C-terminal amide"

XX

PN WO200151078-A1.

XX

PD 19-JUL-2001.

XX

PF 09-JAN-2001; 2001WO-US000719.

XX

PR 10-JAN-2000; 2000US-0175365P.

XX

PA (AMYL-) AMYLIN PHARM INC.

XX

PI Kolterman OG, Young AA;

XX

DR WPI; 2001-514422/56.

XX

PT Use of exendin and exendin agonist compounds for modulating triglyceride

XX

PS Example 12; Page; 161pp; English.

XX

CC The patent discloses a method for modulating plasma or postprandial

CC triglyceride and other lipid levels by administering exendin or an

CC exendin agonist. Exendins have inotropic and diuretic effects. They

CC suppress the secretion of glucagon. Exendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride

CC concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia, and for modifying postprandial triglyceride levels. The

CC present peptide sequence is an agonist of exendin. Note: The present

CC sequence is not shown in the specification but is derived from SEQ ID

CC NO:3 shown in page 17 of the specification

XX

SQ Sequence 39 AA;

XX

AAE08365 Length: 39 February 4, 2005 13:19 Type: P Check: 9251 ..

Found using 'seq4' (mohamed337.key)

1

HCGEFTSDLSKQLEEAVALFIEWLKNGPSSGAPPPS

1

1 match found in sequence:

aae08366 ; Exendin agonist peptide #13.

(from "seq4ags.pep")

TOIG of: aae08366 Check: 9724 from: 1 to: 39

ID AAE08366 standard; peptide; 39 AA.

XX

AC AAE08366;

XX

DT 01-NOV-2001 (first entry)

XX

DE Exendin agonist peptide #13.

XX

KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT

Modified-site 14

FT

/note= "Pentylglycine"

FT

Modified-site 39

FT

/note= "C-terminal amide"

XX

PN WO200151078-A1.

XX

PD 19-JUL-2001.

XX

PF 09-JAN-2001; 2001WO-US000719.

XX

PR 10-JAN-2000; 2000US-0175365P.

XX

PA (AMYL-) AMYLIN PHARM INC.

XX

PI Kolterman OG, Young AA;

XX

DR WPI; 2001-514422/56.

XX

PT Use of exendin and exendin agonist compounds for modulating triglyceride

XX

PS levels, and treating heart disease and dyslipidemia.

XX

Example 13; Page; 161pp; English.

XX

CC The patent discloses a method for modulating plasma or postprandial

CC triglyceride and other lipid levels by administering exendin or an

CC exendin agonist. Exendins have inotropic and diuretic effects. They

CC suppress the secretion of glucagon. Exendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride

CC concentrations. They are used to treat coronary heart disease and

CC dyslipidaemia, and for modifying postprandial triglyceride levels. The

CC present peptide sequence is an agonist of exendin. Note: The present

CC sequence is not shown in the specification but is derived from SEQ ID

CC NO:3 shown in page 17 of the specification

XX

SQ Sequence 39 AA;

XX

AAE08366 Length: 39 February 4, 2005 13:19 Type: P Check: 9724 ..

Found using 'seq4' (mohamed337.key)

1

HCGEFTSDLSKQLEEAVALFIEWLKNGPSSGAPPPS

1

1 match found in sequence:

aae08367 ; Exendin agonist peptide #14.

(from "seq4ags.pep")

TOIG of: aae08367 check: 9299 from: 1 to: 39

ID AAE08367 standard; peptide; 39 AA.

XX

AC AAE08367;

XX

DT 01-NOV-2001 (first entry)

XX

DE Exendin agonist peptide #14.

XX

KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX

```
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 14
FT Modified-site /note= "Pentyglycine"
FT Modified-site 39
FT Modified-site /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 14; Page; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin. Note: The present
XX sequence is not shown in the specification but is derived from SEQ ID
XX NO:3 shown in page 17 of the specification
XX
XX Sequence 39 AA;
XX
AAE08367 Length: 39 February 4, 2005 13:19 Type: P Check: 9299 ..
Found using 'seq4' (mohamed337.key)
1 HGGFTFTDLSKQXEEAVRLFTIEFLKNGPSSGAPPPS
1 28
-----
1 match found in sequence:
aae08368 ; Exendin agonist peptide #15.
(from "seq4ags.pep")
TOIG of: aae08368 check: 9966 from: 1 to: 39
ID AAE08368 standard; peptide; 39 AA.
XX
XX AAE08368;
XX
XX AC
XX
XX 01-NOV-2001 (first entry)
XX
XX Exendin agonist peptide #15.
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT Modified-site 22
FT Modified-site /note= "Naphthylalanine"
FT Modified-site 39
FT Modified-site /note= "C-terminal amide"
XX
PN WO200151078-A1.
```

```
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 15; Page; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin. Note: The present
XX sequence is not shown in the specification but is derived from SEQ ID
XX NO:3 shown in page 17 of the specification
XX
XX Sequence 39 AA;
XX
AAE08368 Length: 39 February 4, 2005 13:19 Type: P Check: 9966 ..
Found using 'seq4' (mohamed337.key)
1 HGGFTFTDLSKQXEEAVRLXIEWLXNGPSSGAPPPS
1 28
-----
1 match found in sequence:
aae08369 ; Exendin agonist peptide #16.
(from "seq4ags.pep")
TOIG of: aae08369 check: 9869 from: 1 to: 39
ID AAE08369 standard; peptide; 39 AA.
XX
XX AAE08369;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX Exendin agonist peptide #16.
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT Modified-site 39
FT Modified-site /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
```

DR WPI; 2001-514422/56.
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX Example 16; Page; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX Sequence 39 AA;
SQ

AAE08369 Length: 39 February 4, 2005 13:19 Type: P Check: 9869 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSLSKQMEEEAVRLFVFLKNGGPGSSGAPPPS
28

1 match found in sequence:
aae08370 ; Extendin agonist peptide #17.
(from "seq4ags.pep")
TOIG of: aae08370 check: 9430 from: 1 to: 39

ID AAE08370 standard; peptide; 39 AA.
XX
AC AAE08370;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #17.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 39
FT Modified-site 39 /note= "C-terminal amide"
FT
XX WO200151078-A1.
PN
XX 19-JUL-2001.
PD
XX 09-JAN-2001; 2001WO-US000719.
PF
XX 10-JAN-2000; 2000US-0175365P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX Example 17; Page; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX Sequence 39 AA;
SQ

AAE08370 Length: 39 February 4, 2005 13:19 Type: P Check: 9430 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSLSKQMEEEAVRLFVFLKNGGPGSSGAPPPS
28

1 match found in sequence:
aae08371 ; Extendin agonist peptide #18.
(from "seq4ags.pep")
TOIG of: aae08371 check: 9915 from: 1 to: 39

ID AAE08371 standard; peptide; 39 AA.
XX
AC AAE08371;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #18.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 23
FT Modified-site 39 /note= "Tertiary-butylglycine"
FT Modified-site 39 /note= "C-terminal amide"
FT
XX WO200151078-A1.
PN
XX 19-JUL-2001.
PD
XX 09-JAN-2001; 2001WO-US000719.
PF
XX 10-JAN-2000; 2000US-0175365P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX Example 18; Page; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX Sequence 39 AA;
SQ

AAE08371 Length: 39 February 4, 2005 13:19 Type: P Check: 9915 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEEAVRLFKEWLKNGGSPSGAPPPS

1

1 match found in sequence:
aae08372 ; Exendin agonist peptide #19.
(from "seq4ags.pep")

TOIG of: aae08372 check: 9476 from: 1 to: 39

ID AAE08372 standard; peptide; 39 AA.

XX AC AAE08372;

XX DT 01-NOV-2001 (first entry)

XX DE Exendin agonist peptide #19.

XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 23

XX FT Modified-site 39 /note= "Tertiary-butylglycine"

XX FT Modified-site /note= "C-terminal amide"

XX PN WO200151078-A1.

XX PD 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.

XX PS Example 19; Page; 161pp; English.

XX CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification

XX SQ Sequence 39 AA;

AAE08372 Length: 39 February 4, 2005 13:19 Type: P Check: 9476 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEEAVRLFKEWLKNGGSPSGAPPPS

1

1 match found in sequence:

aae08373 ; Exendin agonist peptide #20.
(from "seq4ags.pep")
TOIG of: aae08373 check: 9546 from: 1 to: 39

ID AAE08373 standard; peptide; 39 AA.

XX AC AAE08373;

XX DT 01-NOV-2001 (first entry)

XX DE Exendin agonist peptide #20.

XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 39

XX FT Modified-site /note= "C-terminal amide"

XX PN WO200151078-A1.

XX PD 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.

XX PS Example 20; Page; 161pp; English.

XX CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification

XX SQ Sequence 39 AA;

AAE08373 Length: 39 February 4, 2005 13:19 Type: P Check: 9546 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEEAVRLFIDWLKNGGSPSGAPPPS

1

1 match found in sequence:
aae08374 ; Exendin agonist peptide #21.
(from "seq4ags.pep")

TOIG of: aae08374 check: 9145 from: 1 to: 39

ID AAE08374 standard; peptide; 39 AA.

XX AC AAE08374;

XX DT 01-NOV-2001 (first entry)

XX DE Exendin agonist peptide #21.

```

XX  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
OS  Synthetic.
XX  Key Location/Qualifiers
FH  Modified-site 39
FT  /note= "C-terminal amide"
XX  WO200151078-A1.
XX  19-JUL-2001.
XX  09-JAN-2001; 2001WO-US000719.
XX  10-JAN-2000; 2000US-0175365P.
XX  (AMYL-) AMYLIN PHARM INC.
XX  Kolterman OG, Young AA;
XX  WPI; 2001-514422/56.
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
PT  levels, and treating heart disease and dyslipidaemia.
PS  Example 21; Page; 161pp; English.
XX  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin. Note: The present
CC  sequence is not shown in the specification but is derived from SEQ ID
CC  NO:3 shown in page 17 of the specification
XX  Sequence 39 AA;
SQ  AAE08374 Length: 39 February 4, 2005 13:19 Type: P Check: 9145 ..
Found using 'seq4' (mohamed337.key)
1  HCGEGTSDLSKQMEEEAVRLFIEFLKNGCPSSGAPPPS
    |-----|
    28
-----
1 match found in sequence:
aae08375 ; Exendin agonist peptide #22.
(from "seq4ags.pep")
TOIG of: aae08375 check: 706 from: 1 to: 39
ID  AAE08375 standard; peptide; 39 AA.
XX  AC
XX  AAE08375;
XX  01-NOV-2001 (first entry)
XX  Exendin agonist peptide #22.
XX  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX  Synthetic.
XX  Key Location/Qualifiers
FH  Modified-site 31
FT  /note= "Thioprolin"
FT  Modified-site 36
FT  /note= "Thioprolin"
FT  Modified-site 36
FT  /note= "Thioprolin"

```

```

FT  Modified-site 37
FT  /note= "Thioprolin"
FT  Modified-site 38
FT  /note= "Thioprolin"
FT  Modified-site 39
FT  /note= "C-terminal amide"
XX  WO200151078-A1.
XX  19-JUL-2001.
XX  09-JAN-2001; 2001WO-US000719.
XX  10-JAN-2000; 2000US-0175365P.
XX  (AMYL-) AMYLIN PHARM INC.
XX  Kolterman OG, Young AA;
XX  WPI; 2001-514422/56.
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
PT  levels, and treating heart disease and dyslipidaemia.
PS  Example 22; Page; 161pp; English.
XX  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin. Note: The present
CC  sequence is not shown in the specification but is derived from SEQ ID
CC  NO:3 shown in page 17 of the specification
XX  Sequence 39 AA;
SQ  AAE08375 Length: 39 February 4, 2005 13:19 Type: P Check: 706 ..
Found using 'seq4' (mohamed337.key)
1  HCGEGTSDLSKQMEEEAVRLFIEFLKNGXSGAXXS
    |-----|
    28
-----
1 match found in sequence:
aae08376 ; Exendin agonist peptide #23.
(from "seq4ags.pep")
TOIG of: aae08376 check: 458 from: 1 to: 39
ID  AAE08376 standard; peptide; 39 AA.
XX  AC
XX  AAE08376;
XX  01-NOV-2001 (first entry)
XX  Exendin agonist peptide #23.
XX  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX  Synthetic.
XX  Key Location/Qualifiers
FH  Modified-site 36
FT  /note= "Thioprolin"
FT  Modified-site 37
FT  /note= "Thioprolin"
FT  Modified-site 38
FT  /note= "Thioprolin"
FT  Modified-site 39

```



```
PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 25; Page; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
XX Sequence 39 AA;
SQ
AAE08378 Length: 39 February 4, 2005 13:19 Type: P Check: 458 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTSLSKQMBEEAVRLFIEFLKNGPSSGAXXXS
28
-----
1 match found in sequence:
aae08379 ; Exendin agonist peptide #26.
(from "seq4ags.pep")
TOIG of: aae08379 check: 267 from: 1 to: 39
ID AAE08379 standard; peptide; 39 AA.
XX
XX AC AAE08379;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Exendin agonist peptide #26.
XX
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 31 /note= "Thiopropoline"
FT Modified-site 36 /note= "Thiopropoline"
FT Modified-site 37 /note= "Thiopropoline"
FT Modified-site 38 /note= "Thiopropoline"
FT Modified-site 39 /note= "Thiopropoline"
FT Modified-site 39 /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
```

```
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 26; Page; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
XX Sequence 39 AA;
SQ
AAE08379 Length: 39 February 4, 2005 13:19 Type: P Check: 267 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTSLSKQMBEEAVRLFIEFLKNGXSSGAXXXS
28
-----
1 match found in sequence:
aae08380 ; Exendin agonist peptide #27.
(from "seq4ags.pep")
TOIG of: aae08380 check: 267 from: 1 to: 39
ID AAE08380 standard; peptide; 39 AA.
XX
XX AC AAE08380;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Exendin agonist peptide #27.
XX
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 31 /note= "Homopropoline"
FT Modified-site 36 /note= "Homopropoline"
FT Modified-site 37 /note= "Homopropoline"
FT Modified-site 38 /note= "Homopropoline"
FT Modified-site 39 /note= "Homopropoline"
FT Modified-site 39 /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
```

DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 27; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;
AAE08380 Length: 39 February 4, 2005 13:19 Type: P Check: 267 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQLEEEAVRLFIEFLKNGXSGAXXS
28

1 match found in sequence:
aae08381; Exendin agonist peptide #28.
(from "seq4ags.pep")
TOIG of: aae08381 check: 7440 from: 1 to: 39
ID AAE08381 standard; peptide; 39 AA.
XX
AC AAE08381;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #28.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "N-Methyl-alanine"
FT Modified-site 36 /note= "N-Methyl-alanine"
FT Modified-site 37 /note= "N-Methyl-alanine"
FT Modified-site 38 /note= "N-Methyl-alanine"
FT Modified-site 39 /note= "N-Methyl-alanine"
FT Modified-site /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride

PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 28; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;
AAE08381 Length: 39 February 4, 2005 13:19 Type: P Check: 7440 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQLEEEAVRLFIEFLKNGXSGAXXS
28

1 match found in sequence:
aae08382; Exendin agonist peptide #29.
(from "seq4ags.pep")
TOIG of: aae08382 check: 7905 from: 1 to: 39
ID AAE08382 standard; peptide; 39 AA.
XX
AC AAE08382;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #29.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 36 /note= "N-Methyl-alanine"
FT Modified-site 37 /note= "N-Methyl-alanine"
FT Modified-site 38 /note= "N-Methyl-alanine"
FT Modified-site 39 /note= "N-Methyl-alanine"
FT Modified-site /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 29; Page; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial

CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;

AAE08382 Length: 39 February 4, 2005 13:19 Type: P Check: 7905 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQMEEEAVRLFIEFLKNGGSPSSGAAAS
28

1 match found in sequence:
aae08383 ; Exendin agonist peptide #30.
(from "seq4ags.pep")
TOIG of: aae08383 check: 7001 from: 1 to: 39

ID AAE08383 standard; peptide; 39 AA.

XX AC AAE08383;

XX DT 01-NOV-2001 (first entry)

XX DE Exendin agonist peptide #30.

XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 31 /note= "N-Methyl-alanine"
XX FT Modified-site 36 /note= "N-Methyl-alanine"
XX FT Modified-site 37 /note= "N-Methyl-alanine"
XX FT Modified-site 38 /note= "N-Methyl-alanine"
XX FT Modified-site 39 /note= "N-Methyl-alanine"
XX FT Modified-site /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719.

XX PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.

XX PS Example 30; Page; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin. Note: The present
CC sequence is not shown in the specification but is derived from SEQ ID
CC NO:3 shown in page 17 of the specification
XX
SQ Sequence 39 AA;

AAE08383 Length: 39 February 4, 2005 13:19 Type: P Check: 7001 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQLEEEAVRLFIEFLKNGGSSGAAAS
28

1 match found in sequence:
aae08384 ; Heloderma suspectum exendin-4 amide peptide (residues 1-28).
(from "seq4ags.pep")
TOIG of: aae08384 check: 700 from: 1 to: 28

ID AAE08384 standard; peptide; 28 AA.

XX AC AAE08384;

XX DT 01-NOV-2001 (first entry)

XX DE Heloderma suspectum exendin-4 amide peptide (residues 1-28).

XX Exendin-4; antilipemic; cardiant; triglyceride; inotropic; diuretic;
XX coronary heart disease; dyslipidaemia.

XX OS Heloderma suspectum.

XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719.

XX PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.

XX Claim 13; Page 57; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present sequence is an agonist of exendin, exendin-4 amide (residues 1-
XX 28) from Heloderma suspectum

XX Sequence 28 AA;

AAE08384 Length: 28 February 4, 2005 13:19 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)

```

1 1-----|
  HGGFTFTSLSKQMBEEAVRLFIEFLKN 28
  1
-----
1 match found in sequence:
aae08385 ; Heloderma suspectum modified extendin-4 amide peptide (residues 1-28)
(from "seq4ags.pep")
TOIG of: aae08385 check: 261 from: 1 to: 28

ID AAE08385 standard; peptide; 28 AA.
XX AC AAE08385;
XX AC AAE08385;
XX DT 01-NOV-2001 (first entry)
XX DE Heloderma suspectum modified extendin-4 amide peptide (residues 1-28) #2.
XX KW Extendin-4; antilipemic; cardiatic; triglyceride; inotropic; diuretic;
XX KW coronary heart disease; dyslipidaemia.
XX OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
XX 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT Claim 13; Page 58; 161pp; English.
XX PS
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia. and for modifying postprandial triglyceride levels. The
XX CC present sequence is Heloderma suspectum modified extendin-4 amide
XX CC (residues 1-28) which is an agonist of extendin
XX SQ Sequence 28 AA;

AAE08385 Length: 28 February 4, 2005 13:19 Type: P Check: 261 ..
Found using 'seq4' (mohamed337.key)

1 1-----|
  HGGFTFTSLSKQMBEEAVRLFIEFLKN 28
  1
-----
1 match found in sequence:
aae08386 ; Heloderma suspectum modified extendin-4 amide peptide (residues 1-28)
(from "seq4ags.pep")
TOIG of: aae08386 check: 249 from: 1 to: 28

ID AAE08386 standard; peptide; 28 AA.
XX AC AAE08386;
XX AC AAE08386;
XX DT 01-NOV-2001 (first entry)
XX DE Heloderma suspectum modified extendin-4 amide peptide (residues 1-28) #31.
XX KW Extendin-4; antilipemic; cardiatic; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
XX 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT Claim 13; Page 58; 161pp; English.
XX PS
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia. and for modifying postprandial triglyceride levels. The
XX CC present sequence is Heloderma suspectum modified extendin-4 amide
XX CC (residues 1-28) which is an agonist of extendin
XX SQ Sequence 28 AA;

AAE08386 Length: 28 February 4, 2005 13:19 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)

1 1-----|
  HGGFTFTSLSKQMBEEAVRLFIEFLKN 28
  1
-----
1 match found in sequence:
aae08387 ; Heloderma suspectum modified extendin-4 amide peptide (residues 1-28)
(from "seq4ags.pep")
TOIG of: aae08387 check: 166 from: 1 to: 28

ID AAE08387 standard; peptide; 28 AA.
XX AC AAE08387;
XX AC AAE08387;
XX DT 01-NOV-2001 (first entry)
XX DE Heloderma suspectum modified extendin-4 amide peptide (residues 1-28) #32.
XX KW Extendin-4; antilipemic; cardiatic; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
XX 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT Example 35; Page 58; 161pp; English.
XX PS
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia. and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 28 AA;

AAE08386 Length: 28 February 4, 2005 13:19 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)

1 1-----|
  HGGFTFTSLSKQMBEEAVRLFIEFLKN 28
  1
-----
1 match found in sequence:
aae08387 ; Heloderma suspectum modified extendin-4 amide peptide (residues 1-28)
(from "seq4ags.pep")
TOIG of: aae08387 check: 166 from: 1 to: 28

ID AAE08387 standard; peptide; 28 AA.
XX AC AAE08387;
XX AC AAE08387;
XX DT 01-NOV-2001 (first entry)
XX DE Heloderma suspectum modified extendin-4 amide peptide (residues 1-28) #32.
XX KW Extendin-4; antilipemic; cardiatic; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
XX 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT Example 35; Page 58; 161pp; English.
XX PS
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia. and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 28 AA;

AAE08386 Length: 28 February 4, 2005 13:19 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)

```

```

AC AAE08386;
XX 01-NOV-2001 (first entry)
XX Extendin agonist peptide #31.
XX Extendin agonist; antilipemic; cardiatic; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
XX 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT Example 35; Page 58; 161pp; English.
XX PS
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia. and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 28 AA;

AAE08386 Length: 28 February 4, 2005 13:19 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)

1 1-----|
  HGGFTFTSLSKQMBEEAVRLFIEFLKN 28
  1
-----
1 match found in sequence:
aae08387 ; Heloderma suspectum modified extendin-4 amide peptide (residues 1-28)
(from "seq4ags.pep")
TOIG of: aae08387 check: 166 from: 1 to: 28

ID AAE08387 standard; peptide; 28 AA.
XX AC AAE08387;
XX AC AAE08387;
XX DT 01-NOV-2001 (first entry)
XX DE Heloderma suspectum modified extendin-4 amide peptide (residues 1-28) #32.
XX KW Extendin-4; antilipemic; cardiatic; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
XX 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX XX
XX XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PT Example 35; Page 58; 161pp; English.
XX PS
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia. and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 28 AA;

AAE08386 Length: 28 February 4, 2005 13:19 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)

```


CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;

AAE08389 Length: 28 February 4, 2005 13:19 Type: P Check: 117 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTADLSKQLEEEAVRLFIEFLKN
28

1 match found in sequence:
aae08390 ; Extendin agonist peptide #35.
(from "seq4ags.pep")
TOIG of: aae08390 check: 151 from: 1 to: 28

ID AAE08390 standard; peptide; 28 AA.

XX AAE08390;

AC AAE08390;

DT 01-NOV-2001 (first entry)

DE Extendin agonist peptide #35.

KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 28

FT /note= "C-terminal amide"

PN WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-017536SP.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG; Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride

XX levels, and treating heart disease and dyslipidemia.

XX Example 39; Page 61; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin

XX Sequence 28 AA;

AAE08390 Length: 28 February 4, 2005 13:19 Type: P Check: 151 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTDASKQLEEEAVRLFIEFLKN
28

1 match found in sequence:
aae08391 ; Extendin agonist peptide #36.
(from "seq4ags.pep")
TOIG of: aae08391 check: 63 from: 1 to: 28

ID AAE08391 standard; peptide; 28 AA.

XX AAE08391;

DT 01-NOV-2001 (first entry)

DE Extendin agonist peptide #36.

KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 28

FT /note= "C-terminal amide"

PN WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-017536SP.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG; Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride

XX levels, and treating heart disease and dyslipidemia.

XX Example 40; Page 61; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin

XX Sequence 28 AA;

AAE08391 Length: 28 February 4, 2005 13:19 Type: P Check: 63 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDAKQLEEEAVRLFIEFLKN
28

1 match found in sequence:
aae08392 ; Extendin agonist peptide #37.
(from "seq4ags.pep")
TOIG of: aae08392 check: 141 from: 1 to: 28

ID AAE08392 standard; peptide; 28 AA.

XX AAE08392;

DT 01-NOV-2001 (first entry)

DE Extendin agonist peptide #37.

```

XX  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX  Synthetic.
XX  Key Location/Qualifiers
FH  Modified-site 28
FT  /note= "C-terminal amide"
XX  WO200151078-A1.
XX  19-JUL-2001.
XX  09-JAN-2001; 2001WO-US000719.
XX  10-JAN-2000; 2000US-0175365P.
XX  (AMYL-) AMYLIN PHARM INC.
XX  Kolterman OG, Young AA;
XX  WPI; 2001-514422/56.
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
PT  levels, and treating heart disease and dyslipidemia.
XX  Example 41; Page 62; 161pp; English.
XX  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin
XX  Sequence 28 AA;
XX  AAE08392 Length: 28 February 4, 2005 13:19 Type: P Check: 141 ..
XX  Found using 'seq4' (mohamed337.key)
1  HGEFTFTDLSAQLEEEAVRLFIEFLKN
1  28
-----
1 match found in sequence:
aae08393 ; Exendin agonist peptide #38.
(from "seq4ags.pep")
TOIG of: aae08393 check: 53 from: 1 to: 28
ID  AAE08393 standard; peptide; 28 AA.
XX  AAE08393;
XX  AC
XX  DT 01-NOV-2001 (first entry)
XX  DE Exendin agonist peptide #38.
XX  KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX  OS Synthetic.
XX  FH Key Location/Qualifiers
FT  Modified-site 28
FT  /note= "C-terminal amide"
XX  PN WO200151078-A1.
XX  PD 19-JUL-2001.
XX  09-JAN-2001; 2001WO-US000719.
XX  10-JAN-2000; 2000US-0175365P.
XX  (AMYL-) AMYLIN PHARM INC.
XX  Kolterman OG, Young AA;
XX  WPI; 2001-514422/56.
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
PT  levels, and treating heart disease and dyslipidemia.
XX  Example 41; Page 62; 161pp; English.
XX  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin
XX  Sequence 28 AA;
XX  AAE08393 Length: 28 February 4, 2005 13:19 Type: P Check: 141 ..
XX  Found using 'seq4' (mohamed337.key)
1  HGEFTFTDLSAQLEEEAVRLFIEFLKN
1  28
-----
1 match found in sequence:
aae08393 ; Exendin agonist peptide #38.
(from "seq4ags.pep")
TOIG of: aae08393 check: 53 from: 1 to: 28
ID  AAE08393 standard; peptide; 28 AA.
XX  AAE08393;
XX  AC
XX  DT 01-NOV-2001 (first entry)
XX  DE Exendin agonist peptide #38.
XX  KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX  OS Synthetic.
XX  FH Key Location/Qualifiers
FT  Modified-site 28
FT  /note= "C-terminal amide"
XX  PN WO200151078-A1.
XX  PD 19-JUL-2001.

```

```

XX  09-JAN-2001; 2001WO-US000719.
XX  10-JAN-2000; 2000US-0175365P.
XX  (AMYL-) AMYLIN PHARM INC.
XX  Kolterman OG, Young AA;
XX  WPI; 2001-514422/56.
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
PT  levels, and treating heart disease and dyslipidemia.
XX  Example 42; Page 62; 161pp; English.
XX  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin
XX  Sequence 28 AA;
XX  AAE08393 Length: 28 February 4, 2005 13:19 Type: P Check: 53 ..
XX  Found using 'seq4' (mohamed337.key)
1  HGEFTFTDLSKALBEEAVRLFIEFLKN
1  28
-----
1 match found in sequence:
aae08394 ; Exendin agonist peptide #39.
(from "seq4ags.pep")
TOIG of: aae08394 check: 107 from: 1 to: 28
ID  AAE08394 standard; peptide; 28 AA.
XX  AAE08394;
XX  AC
XX  DT 01-NOV-2001 (first entry)
XX  DE Exendin agonist peptide #39.
XX  KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX  OS Synthetic.
XX  FH Key Location/Qualifiers
FT  Modified-site 28
FT  /note= "C-terminal amide"
XX  PN WO200151078-A1.
XX  PD 19-JUL-2001.
XX  09-JAN-2001; 2001WO-US000719.
XX  10-JAN-2000; 2000US-0175365P.
XX  (AMYL-) AMYLIN PHARM INC.
XX  Kolterman OG, Young AA;
XX  WPI; 2001-514422/56.
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
PT  levels, and treating heart disease and dyslipidemia.

```

```
XX Example 43; Page 63; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;

AAE08394 Length: 28 February 4, 2005 13:19 Type: P Check: 107 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQAEAEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aae08395 ; Extendin agonist peptide #40.
(from "seq4ags.pep")
TOIG of: aae08395 check: 201 from: 1 to: 28

ID AAE08395 standard; peptide; 28 AA.
XX
AC AAE08395;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #40.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
PD 19-JUL-2001.
XX
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 44; Page 64; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;

AAE08396 Length: 28 February 4, 2005 13:19 Type: P Check: 197 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQAEAEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aae08397 ; Extendin agonist peptide #42.
(from "seq4ags.pep")
TOIG of: aae08397 check: 193 from: 1 to: 28

ID AAE08396 standard; peptide; 28 AA.
XX
AC AAE08396;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #41.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
PD 19-JUL-2001.
XX
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidaemia.
XX
XX Example 45; Page 64; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;

AAE08396 Length: 28 February 4, 2005 13:19 Type: P Check: 197 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQAEAEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aae08397 ; Extendin agonist peptide #42.
(from "seq4ags.pep")
TOIG of: aae08397 check: 193 from: 1 to: 28
```

```

ID  AAE08397 standard; peptide; 28 AA.
XX
AC  AAE08397;
XX
DT  01-NOV-2001 (first entry)
XX
DE  Exendin agonist peptide #42.
XX
KW  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX
OS  Synthetic.
XX
FH  Key Location/Qualifiers
FT  Modified-site 28
FT  /note= "C-terminal amide"
XX
PN  WO200151078-A1.
XX
PD  19-JUL-2001.
XX
PF  09-JAN-2001; 2001WO-US000719.
XX
PR  10-JAN-2000; 2000US-0175365P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Kolterman OG, Young AA;
XX
XX  WPI; 2001-514422/56.
XX
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
XX  levels, and treating heart disease and dyslipidemia.
XX
XX  Example 46; Page 65; 161pp; English.
XX
CC  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin
XX
SQ  Sequence 28 AA;

AAE08397 Length: 28 February 4, 2005 13:19 Type: P Check: 193 ..
Found using 'seq4' (mohamed337.key)

1  |-----|
   | HGEFTFTSLSKQLSEEAVALFLFIEFLKN 28
   |
-----
1 match found in sequence:
aae08398 ; Exendin agonist peptide #43.
(from "seq4ags.pep")
TOIG of: aae08398 check: 9862 from: 1 to: 28

ID  AAE08398 standard; peptide; 28 AA.
XX
AC  AAE08398;
XX
DT  01-NOV-2001 (first entry)
XX
DE  Exendin agonist peptide #43.
XX
KW  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX
OS  Synthetic.
XX
FH  Key Location/Qualifiers
FT  Modified-site 28
FT  /note= "C-terminal amide"
XX
PN  WO200151078-A1.
XX
PD  19-JUL-2001.
XX
PF  09-JAN-2001; 2001WO-US000719.
XX
PR  10-JAN-2000; 2000US-0175365P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Kolterman OG, Young AA;
XX
XX  WPI; 2001-514422/56.
XX
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
XX  levels, and treating heart disease and dyslipidemia.
XX
XX  Example 46; Page 65; 161pp; English.
XX
CC  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin
XX
SQ  Sequence 28 AA;

AAE08397 Length: 28 February 4, 2005 13:19 Type: P Check: 193 ..
Found using 'seq4' (mohamed337.key)

1  |-----|
   | HGEFTFTSLSKQLSEEAVALFLFIEFLKN 28
   |
-----
1 match found in sequence:
aae08398 ; Exendin agonist peptide #43.
(from "seq4ags.pep")
TOIG of: aae08398 check: 9862 from: 1 to: 28

ID  AAE08398 standard; peptide; 28 AA.
XX
AC  AAE08398;
XX
DT  01-NOV-2001 (first entry)
XX
DE  Exendin agonist peptide #43.
XX
KW  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX
OS  Synthetic.
XX
FH  Key Location/Qualifiers
FT  Modified-site 28
FT  /note= "C-terminal amide"
XX
PN  WO200151078-A1.
XX
PD  19-JUL-2001.
XX
PF  09-JAN-2001; 2001WO-US000719.
XX
PR  10-JAN-2000; 2000US-0175365P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Kolterman OG, Young AA;
XX
XX  WPI; 2001-514422/56.
XX
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
XX  levels, and treating heart disease and dyslipidemia.
XX
XX  Example 47; Page 65; 161pp; English.
XX
CC  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin
XX
SQ  Sequence 28 AA;

AAE08398 Length: 28 February 4, 2005 13:19 Type: P Check: 9862 ..
Found using 'seq4' (mohamed337.key)

1  |-----|
   | HGEFTFTSLSKQLSEEAARLFIEFLKN 28
   |
-----
1 match found in sequence:
aae08399 ; Exendin agonist peptide #44.
(from "seq4ags.pep")
TOIG of: aae08399 check: 9921 from: 1 to: 28

ID  AAE08399 standard; peptide; 28 AA.
XX
AC  AAE08399;
XX
DT  01-NOV-2001 (first entry)
XX
DE  Exendin agonist peptide #44.
XX
KW  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX
OS  Synthetic.
XX
FH  Key Location/Qualifiers
FT  Modified-site 28
FT  /note= "C-terminal amide"
XX
PN  WO200151078-A1.
XX
PD  19-JUL-2001.
XX
PF  09-JAN-2001; 2001WO-US000719.
XX
PR  10-JAN-2000; 2000US-0175365P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Kolterman OG, Young AA;
XX
XX  WPI; 2001-514422/56.
XX
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
XX  levels, and treating heart disease and dyslipidemia.
XX
XX  Example 47; Page 65; 161pp; English.
XX
CC  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin
XX
SQ  Sequence 28 AA;

AAE08398 Length: 28 February 4, 2005 13:19 Type: P Check: 9862 ..
Found using 'seq4' (mohamed337.key)

1  |-----|
   | HGEFTFTSLSKQLSEEAARLFIEFLKN 28
   |
-----
1 match found in sequence:
aae08399 ; Exendin agonist peptide #44.
(from "seq4ags.pep")
TOIG of: aae08399 check: 9921 from: 1 to: 28

ID  AAE08399 standard; peptide; 28 AA.
XX
AC  AAE08399;
XX
DT  01-NOV-2001 (first entry)
XX
DE  Exendin agonist peptide #44.
XX
KW  Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW  diuretic; coronary heart disease; dyslipidaemia.
XX
OS  Synthetic.
XX
FH  Key Location/Qualifiers
FT  Modified-site 28
FT  /note= "C-terminal amide"
XX
PN  WO200151078-A1.
XX
PD  19-JUL-2001.
XX
PF  09-JAN-2001; 2001WO-US000719.
XX
PR  10-JAN-2000; 2000US-0175365P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Kolterman OG, Young AA;
XX
XX  WPI; 2001-514422/56.
XX
XX  Use of exendin and exendin agonist compounds for modulating triglyceride
XX  levels, and treating heart disease and dyslipidemia.
XX
XX  Example 47; Page 65; 161pp; English.
XX
CC  The patent discloses a method for modulating plasma or postprandial
CC  triglyceride and other lipid levels by administering exendin or an
CC  exendin agonist. Exendins have inotropic and diuretic effects. They
CC  suppress the secretion of glucagon. Exendin and its agonists have a
CC  significant effect on the reduction of blood serum triglyceride
CC  concentrations. They are used to treat coronary heart disease and
CC  dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC  present peptide sequence is an agonist of exendin
XX
SQ  Sequence 28 AA;

```

PA (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidemia.

PS Example 48; Page 66; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial triglyceride and other lipid levels by administering extendin or an extendin agonist. Extendins have inotropic and diuretic effects. They suppress the secretion of glucagon. Extendin and its agonists have a significant effect on the reduction of blood serum triglyceride concentrations. They are used to treat coronary heart disease and dyslipidaemia, and for modifying postprandial triglyceride levels. The present peptide sequence is an agonist of extendin

XX Sequence 28 AA;

AAE08399 Length: 28 February 4, 2005 13:19 Type: P Check: 9921 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTSLSKQLEBEAVALFTIEFLKN 28
|-----|

1 match found in sequence:
aae08400 ; Extendin agonist peptide #45.
(from "seq4ags.pep")
TOIG of: aae08400 check: 30 from: 1 to: 28

ID AAE08400 standard; peptide; 28 AA.

XX AAE08400;

XX 01-NOV-2001 (first entry)

DE Extendin agonist peptide #45.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
diuretic; coronary heart disease; dyslipidaemia.

OS Synthetic.

XX Key Location/Qualifiers
FH Modified-site 28

FT /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US0000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidemia.

PS Example 49; Page 66; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial triglyceride and other lipid levels by administering extendin or an

CC extendin agonist. Extendins have inotropic and diuretic effects. They suppress the secretion of glucagon. Extendin and its agonists have a significant effect on the reduction of blood serum triglyceride concentrations. They are used to treat coronary heart disease and dyslipidaemia, and for modifying postprandial triglyceride levels. The present peptide sequence is an agonist of extendin

XX Sequence 28 AA;

AAE08400 Length: 28 February 4, 2005 13:19 Type: P Check: 30 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTSLSKQLEBEAVALFTIEFLKN 28
|-----|

1 match found in sequence:
aae08401 ; Extendin agonist peptide #46.
(from "seq4ags.pep")
TOIG of: aae08401 check: 165 from: 1 to: 28

ID AAE08401 standard; peptide; 28 AA.

XX AAE08401;

XX 01-NOV-2001 (first entry)

DE Extendin agonist peptide #46.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
diuretic; coronary heart disease; dyslipidaemia.

OS Synthetic.

XX Key Location/Qualifiers
FH Modified-site 28

FT /note= "C-terminal amide"

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US0000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride levels, and treating heart disease and dyslipidemia.

XX Example 50; Page 67; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial triglyceride and other lipid levels by administering extendin or an extendin agonist. Extendins have inotropic and diuretic effects. They suppress the secretion of glucagon. Extendin and its agonists have a significant effect on the reduction of blood serum triglyceride concentrations. They are used to treat coronary heart disease and dyslipidaemia, and for modifying postprandial triglyceride levels. The present peptide sequence is an agonist of extendin

XX Sequence 28 AA;

AAE08401 Length: 28 February 4, 2005 13:19 Type: P Check: 165 ..
Found using 'seq4' (mohamed337.key)

-----|

```
1 HEGGFTTSLSKQLEEEAVRLFIAFLKN 28
1
-----
1 match found in sequence:
aae08402 ; Exendin agonist peptide #47.
(from "seq4ags.pep")
TOIG of: aae08402 check: 136 from: 1 to: 28

ID AAE08402 standard; peptide; 28 AA.
XX
AC AAE08402;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #47.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 51; Page 68; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08402 Length: 28 February 4, 2005 13:19 Type: P Check: 136 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTTSLSKQLEEEAVRLFIEALKN 28
1
-----
1 match found in sequence:
aae08403 ; Exendin agonist peptide #48.
(from "seq4ags.pep")
TOIG of: aae08403 check: 9975 from: 1 to: 28

ID AAE08403 standard; peptide; 28 AA.
XX
AC AAE08403;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #48.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 51; Page 68; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08402 Length: 28 February 4, 2005 13:19 Type: P Check: 136 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTTSLSKQLEEEAVRLFIEALKN 28
1
-----
1 match found in sequence:
aae08403 ; Exendin agonist peptide #48.
(from "seq4ags.pep")
TOIG of: aae08403 check: 9975 from: 1 to: 28

ID AAE08403 standard; peptide; 28 AA.
XX
AC AAE08403;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #49.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 52; Page 68; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08403 Length: 28 February 4, 2005 13:19 Type: P Check: 9975 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTTSLSKQLEEEAVRLFIEFAKN 28
1
-----
1 match found in sequence:
aae08404 ; Exendin agonist peptide #49.
(from "seq4ags.pep")
TOIG of: aae08404 check: 9991 from: 1 to: 28

ID AAE08404 standard; peptide; 28 AA.
XX
AC AAE08404;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #49.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 52; Page 68; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;
```

```
PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX PS Example 53; Page 69; 161pp; English.
XX
XX CC The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
XX SQ Sequence 28 AA;

AAE08404 Length: 28 February 4, 2005 13:19 Type: P Check: 9991 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQLBEEAVRLFIEFLAN 28
1 -----|
1 match found in sequence:
aao08405 ; Exendin agonist peptide #50.
(from "seq4ags.pep")
TOIG of: aae08405 check: 9897 from: 1 to: 28

ID AAE08405 standard; peptide; 28 AA.
XX
XX AC AAE08405;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Exendin agonist peptide #50.
XX
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX PS Example 53; Page 69; 161pp; English.
XX
XX CC The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
XX SQ Sequence 28 AA;

AAE08405 Length: 28 February 4, 2005 13:19 Type: P Check: 9897 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQLBEEAVRLFIEFLKA 28
1 -----|
1 match found in sequence:
aao08405 ; Exendin agonist peptide #51.
(from "seq4ags.pep")
TOIG of: aae08406 check: 6333 from: 1 to: 38

ID AAE08406 standard; peptide; 38 AA.
XX
XX AC AAE08406;
XX
XX DT 01-NOV-2001 (first entry)
XX
XX DE Exendin agonist peptide #51.
XX
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 38
XX PN WO200151078-A1.
XX
XX PD 19-JUL-2001.
XX
XX PF 09-JAN-2001; 2001WO-US000719.
XX
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Kolterman OG, Young AA;
XX
XX DR WPI; 2001-514422/56.
XX
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX PS Example 55; Page 70; 161pp; English.
XX
XX CC The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
```

```
CC present peptide sequence is an agonist of exendin
XX Sequence 38 AA;
SQ

AAE08406 Length: 38 February 4, 2005 13:19 Type: P Check: 6333 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  | HGGTFTSLSKQMBEAEVRLFIWLKNGGPGSSGAPP
  | 28
  | 1

-----
1 match found in sequence:
aee08407 ; Exendin agonist peptide #52.
(from "seq4ags.pep")
TOIG of: aae08407 check: 5894 from: 1 to: 38

ID AAE08407 standard; peptide; 38 AA.
XX
AC AAE08407;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #52.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 38 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 56; Page 71; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 38 AA;

AAE08407 Length: 38 February 4, 2005 13:19 Type: P Check: 5894 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  | HGGTFTSLSKQMBEAEVRLFIWLKNGGPGSSGAPP
  | 28
  | 1

-----
1 match found in sequence:
aee08407 ; Exendin agonist peptide #52.
(from "seq4ags.pep")
TOIG of: aae08407 check: 5894 from: 1 to: 38

ID AAE08407 standard; peptide; 38 AA.
XX
AC AAE08407;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #52.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 38 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 56; Page 71; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 38 AA;

AAE08407 Length: 38 February 4, 2005 13:19 Type: P Check: 5894 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  | HGGTFTSLSKQMBEAEVRLFIWLKNGGPGSSGAPP
  | 28
  | 1

-----
1 match found in sequence:
aee08407 ; Exendin agonist peptide #52.
(from "seq4ags.pep")
TOIG of: aae08407 check: 5894 from: 1 to: 38

ID AAE08407 standard; peptide; 38 AA.
XX
AC AAE08407;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #52.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 38 /note= "C-terminal amide"
FT
XX WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 56; Page 71; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 38 AA;

AAE08408 Length: 37 February 4, 2005 13:19 Type: P Check: 3293 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  | HGGTFTSLSKQMBEAEVRLFIWLKNGGPGSSGAPP
  | 28
  | 1

-----
1 match found in sequence:
aee08409 ; Exendin agonist peptide #54.
(from "seq4ags.pep")
TOIG of: aae08409 check: 2854 from: 1 to: 37

ID AAE08409 standard; peptide; 37 AA.
XX
AC AAE08409;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #54.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
```

KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
PA Location/Qualifiers
FH Key
FT Modified-site 37
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-017536SP.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
XX Example 58; Page 72; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 37 AA;
SQ
AAE08409 Length: 37 February 4, 2005 13:19 Type: P Check: 2854 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQLEAEAVRLFIEFLKNGPSSGAPP
28

1 match found in sequence:
aae08410; Extendin agonist peptide #55.
(from "seq4ags.pep")
TOIG of: aae08410 check: 333 from: 1 to: 36
ID AAE08410 standard; peptide; 36 AA.
XX
AC AAE08410;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #55.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 36
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 36
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX

XX
XX 10-JAN-2000; 2000US-017536SP.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
XX Example 59; Page 72; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 36 AA;
SQ
AAE08410 Length: 36 February 4, 2005 13:19 Type: P Check: 333 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEAEAVRLFIEFLKNGPSSGAP
28

1 match found in sequence:
aae08411; Extendin agonist peptide #56.
(from "seq4ags.pep")
TOIG of: aae08411 check: 9894 from: 1 to: 36
ID AAE08411 standard; peptide; 36 AA.
XX
AC AAE08411;
XX
XX 01-NOV-2001 (first entry)
XX
XX Extendin agonist peptide #56.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 36
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
XX
XX 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-017536SP.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.
XX
XX Example 60; Page 73; 161pp; English.
XX
XX

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 36 AA;

AAE08411 Length: 36 February 4, 2005 13:19 Type: P Check: 9894 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIEFLKNGPSSGAP
28

1 match found in sequence:
aae08412 ; Extendin agonist peptide #57.
(from "seq4ags.pep")
TOIG of: aae08412 check: 7453 from: 1 to: 35

ID AAE08412 standard; peptide; 35 AA.

XX AAE08412;
AC
XX
DT 01-NOV-2001 (first entry)
DE
XX
DE Extendin agonist peptide #57.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 35
FT /note= "C-terminal amide"
FT

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.

XX Example 61; Page 73; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX

XX Sequence 35 AA;

AAE08412 Length: 35 February 4, 2005 13:19 Type: P Check: 7453 ..

Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIEFLKNGPSSGA
28

1 match found in sequence:
aae08413 ; Extendin agonist peptide #58.
(from "seq4ags.pep")
TOIG of: aae08413 check: 7014 from: 1 to: 35

ID AAE08413 standard; peptide; 35 AA.

XX AAE08413;

DT 01-NOV-2001 (first entry)

DE Extendin agonist peptide #58.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 35
FT /note= "C-terminal amide"
FT

XX WO200151078-A1.

XX 19-JUL-2001.

XX 09-JAN-2001; 2001WO-US000719.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Kolterman OG, Young AA;

XX WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidaemia.

XX Example 62; Page 74; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX

SQ Sequence 35 AA;

AAE08413 Length: 35 February 4, 2005 13:19 Type: P Check: 7014 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAVRLFIEFLKNGPSSGA
28

1 match found in sequence:
aae08414 ; Extendin agonist peptide #59.
(from "seq4ags.pep")
TOIG of: aae08414 check: 5178 from: 1 to: 34

ID AAE08414 standard; peptide; 34 AA.

```
XX AAE08414;
AC
XX 01-NOV-2001 (first entry)
DT
XX
XX Extendin agonist peptide #59.
DE
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 34
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 63; Page 75; 161pp; English.
PS
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 34 AA;
SQ
AAE08414 Length: 34 February 4, 2005 13:19 Type: P Check: 5178 ..
Found using 'seq4' (mohamed337.key)
1 HGGGTFTSDLSKQLEEEAVRLFIETLKNKGPPSSG
28
-----
1 match found in sequence:
aae08415; Extendin agonist peptide #60.
(from "seq4ags.pep")
TOIG of: aae08415 check: 4739 from: 1 to: 34
ID AAE08415 standard; peptide; 34 AA.
XX
XX AAE08415;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Extendin agonist peptide #60.
DE
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 34
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 63; Page 75; 161pp; English.
PS
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 34 AA;
SQ
AAE08414 Length: 34 February 4, 2005 13:19 Type: P Check: 5178 ..
Found using 'seq4' (mohamed337.key)
1 HGGGTFTSDLSKQLEEEAVRLFIETLKNKGPPSSG
28
-----
1 match found in sequence:
aae08415; Extendin agonist peptide #60.
(from "seq4ags.pep")
TOIG of: aae08415 check: 4739 from: 1 to: 34
ID AAE08415 standard; peptide; 34 AA.
XX
XX AAE08415;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Extendin agonist peptide #60.
DE
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 34
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 63; Page 75; 161pp; English.
PS
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 34 AA;
SQ
```

```
FT Modified-site 34
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 64; Page 75; 161pp; English.
PS
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 34 AA;
SQ
AAE08415 Length: 34 February 4, 2005 13:19 Type: P Check: 4739 ..
Found using 'seq4' (mohamed337.key)
1 HGGGTFTSDLSKQLEEEAVRLFIETLKNKGPPSSG
28
-----
1 match found in sequence:
aae08416; Extendin agonist peptide #61.
(from "seq4ags.pep")
TOIG of: aae08416 check: 2764 from: 1 to: 33
ID AAE08416 standard; peptide; 33 AA.
XX
XX AAE08416;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Extendin agonist peptide #61.
DE
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 33
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
```

PI Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX Example 65; Page 76; 161pp; English.
PS
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 33 AA;
SQ
AAE08416 Length: 33 February 4, 2005 13:19 Type: P Check: 2764 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMEEEAVRLFIEWLKNGGPS 28

1 match found in sequence:
aae08417; Extendin agonist peptide #62.
(from "seq4ags.pep")
TOIG of: aae08417 check: 2325 from: 1 to: 33
ID AAE08417 standard; peptide; 33 AA.
XX
AC AAE08417;
XX
XX 01-NOV-2001 (first entry)
DT
DE Extendin agonist peptide #62.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 33
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US0000719.
PF
XX 10-JAN-2000; 2000US-0175365P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX Example 66; Page 76; 161pp; English.
PS
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a

CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 33 AA;
SQ
AAE08417 Length: 33 February 4, 2005 13:19 Type: P Check: 2325 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMEEEAVRLFIEWLKNGGPS 28

1 match found in sequence:
aae08418; Extendin agonist peptide #63.
(from "seq4ags.pep")
TOIG of: aae08418 check: 25 from: 1 to: 32
ID AAE08418 standard; peptide; 32 AA.
XX
AC AAE08418;
XX
XX 01-NOV-2001 (first entry)
DT
DE Extendin agonist peptide #63.
XX
XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 32
FT /note= "C-terminal amide"
XX
XX WO200151078-A1.
PN
PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US0000719.
PF
XX 10-JAN-2000; 2000US-0175365P.
PR
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Kolterman OG, Young AA;
PI
XX WPI; 2001-514422/56.
DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX Example 67; Page 77; 161pp; English.
PS
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX Sequence 32 AA;
SQ
AAE08418 Length: 32 February 4, 2005 13:19 Type: P Check: 25 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMEEEAVRLFIEWLKNGGPS 28

1 match found in sequence:
aae08417; Extendin agonist peptide #62.
(from "seq4ags.pep")
TOIG of: aae08417 check: 2325 from: 1 to: 33

PD 19-JUL-2001.
XX
XX 09-JAN-2001; 2001WO-US000719.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 70; Page 79; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
XX Sequence 31 AA;
AAE08421 Length: 31 February 4, 2005 13:19 Type: P Check: 6930 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQLEEEAVRLFIEFLKNGGP 28

1 match found in sequence:
aae08422 ; Exendin agonist peptide #67.
(from "seq4ags.pep")
TOIG of: aae08422 check: 4450 from: 1 to: 30
ID AAE08422 standard; peptide; 30 AA.
XX
XX AAE08422;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Exendin agonist peptide #67.
DE
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
PT
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 70; Page 79; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
XX Sequence 31 AA;
AAE08421 Length: 31 February 4, 2005 13:19 Type: P Check: 6930 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQLEEEAVRLFIEFLKNGGP 28

1 match found in sequence:
aae08422 ; Exendin agonist peptide #67.
(from "seq4ags.pep")
TOIG of: aae08422 check: 4450 from: 1 to: 30
ID AAE08422 standard; peptide; 30 AA.
XX
XX AAE08422;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Exendin agonist peptide #67.
DE
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
PT
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 72; Page 80; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX

PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 71; Page 79; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX
XX Sequence 30 AA;
AAE08422 Length: 30 February 4, 2005 13:19 Type: P Check: 4450 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQLEEEAVRLFIEFLKNGG 28

1 match found in sequence:
aae08423 ; Exendin agonist peptide #68.
(from "seq4ags.pep")
TOIG of: aae08423 check: 2759 from: 1 to: 29
ID AAE08423 standard; peptide; 29 AA.
XX
XX AAE08423;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Exendin agonist peptide #68.
DE
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 29
FT /note= "C-terminal amide"
PT
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 72; Page 80; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
XX triglyceride and other lipid levels by administering exendin or an
XX exendin agonist. Exendins have inotropic and diuretic effects. They
XX suppress the secretion of glucagon. Exendin and its agonists have a
XX significant effect on the reduction of blood serum triglyceride
XX concentrations. They are used to treat coronary heart disease and
XX dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX present peptide sequence is an agonist of exendin
XX

```
SQ Sequence 29 AA;
AAE08423 Length: 29 February 4, 2005 13:19 Type: P Check: 2759 ..
Found using 'seq4' (mohamed337.key)
1
1 HGGFTFTSLSKQMEEEAVRLFIEWLKNG
28
-----
1 match found in sequence:
aae08424 ; Exendin agonist peptide #69.
(from "seq4ags.pep")
TOIG of: aae08424 check: 2320 from: 1 to: 29
ID AAE08424 standard; peptide; 29 AA.
XX AC AAE08424;
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #69.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 29
XX FT Modified-site /note= "C-terminal amide"
XX FT
XX FT
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PS WPI; 2001-514422/56.
XX DR Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 73; Page 80; 16ipp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin
XX SQ Sequence 29 AA;
AAE08424 Length: 29 February 4, 2005 13:19 Type: P Check: 2320 ...
Found using 'seq4' (mohamed337.key)
1
1 HGGFTFTSLSKQMEEEAVRLFIEWLKNG
28
-----
1 match found in sequence:
aae08425 ; Exendin agonist peptide #70.
(from "seq4ags.pep")
TOIG of: aae08425 check: 7221 from: 1 to: 38
ID AAE08425 standard; peptide; 38 AA.
XX AC AAE08425;
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #70.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 31
XX FT Modified-site /note= "Thioprolin"
XX FT Modified-site 36
XX FT Modified-site /note= "Thioprolin"
XX FT Modified-site 37
XX FT Modified-site /note= "Thioprolin"
XX FT Modified-site 38
XX FT Modified-site /note= "Thioprolin; C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX PS WPI; 2001-514422/56.
XX DR Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 74; Page 81; 16ipp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin
XX SQ Sequence 38 AA;
AAE08425 Length: 38 February 4, 2005 13:19 Type: P Check: 7469 ..
Found using 'seq4' (mohamed337.key)
1
1 HGGFTFTSLSKQMEEEAVRLFIEWLKNGXSSGAXXX
28
-----
1 match found in sequence:
aae08426 ; Exendin agonist peptide #70.
(from "seq4ags.pep")
TOIG of: aae08426 check: 7221 from: 1 to: 38
ID AAE08426 standard; peptide; 38 AA.
XX AC AAE08426;
XX DT 01-NOV-2001 (first entry)
```

```
XX DE Extendin agonist peptide #70.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 36 Location/Qualifiers
XX FT /note= "Thioprolin"
XX FT Modified-site 37 /note= "Thioprolin"
XX FT Modified-site 38 /note= "Thioprolin; C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX PT Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 75; Page 82; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 38 AA;
AAE08426 Length: 38 February 4, 2005 13:19 Type: P Check: 7221 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMBEEAVRLFIEWLKGSGAXX
1 28
-----
1 match found in sequence:
aae08427 ; Extendin agonist peptide #72.
(from "seq4ags.pep")
TOIG of: aae08427 check: 2828 from: 1 to: 37
ID AAE08427 standard; peptide; 37 AA.
XX AC AAE08427;
XX DT 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #72.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 36 Location/Qualifiers
XX FT /note= "Thioprolin"
XX FT Modified-site 37 /note= "Thioprolin; C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX PT Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 75; Page 82; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 38 AA;
AAE08426 Length: 38 February 4, 2005 13:19 Type: P Check: 7221 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMBEEAVRLFIEWLKGSGAXX
1 28
-----
1 match found in sequence:
aae08427 ; Extendin agonist peptide #72.
(from "seq4ags.pep")
TOIG of: aae08427 check: 2828 from: 1 to: 37
ID AAE08427 standard; peptide; 37 AA.
XX AC AAE08427;
XX DT 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #72.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 36 Location/Qualifiers
XX FT /note= "Thioprolin"
XX FT Modified-site 37 /note= "Thioprolin; C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX PT Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 75; Page 82; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 37 AA;
AAE08427 Length: 37 February 4, 2005 13:19 Type: P Check: 2828 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMBEEAVRLFIEWLKGSGAGAPP
1 28
-----
1 match found in sequence:
aae08428 ; Extendin agonist peptide #73.
(from "seq4ags.pep")
TOIG of: aae08428 check: 1733 from: 1 to: 37
ID AAE08428 standard; peptide; 37 AA.
XX AC AAE08428;
XX DT 01-NOV-2001 (first entry)
XX DE Extendin agonist peptide #73.
XX KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 31 Location/Qualifiers
XX FT /note= "N-Methyl-alanine"
XX FT Modified-site 36 /note= "N-Methyl-alanine"
XX FT Modified-site 37 /note= "N-Methyl-alanine"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX DR WPI; 2001-514422/56.
XX PT Use of extendin and extendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 76; Page 82; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering extendin or an
XX CC extendin agonist. Extendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Extendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of extendin
XX SQ Sequence 37 AA;
```

```
PF 09-JAN-2001; 2001WO-US000719.
XX
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 77; Page 83; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 37 AA;
SQ
AAE08428 Length: 37 February 4, 2005 13:19 Type: P Check: 1733 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEGFTSLSQMEEEAVRLFIEWLNKGSSGAAA
28
-----
1 match found in sequence:
aae08429; Exendin agonist peptide #74.
(from "seq4ags.pep")
TOIG of: aae08429 check: 4125 from: 1 to: 37
ID AAE08429 standard; peptide; 37 AA.
XX
XX AAE08429;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Exendin agonist peptide #74.
DE
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 31
FT Modified-site /note= "Homoproline"
DE Modified-site 36
FT Modified-site /note= "Homoproline"
FT Modified-site 37
XX /note= "Homoproline; C-terminal amide"
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX Modified-site 31 /note= "Homoproline"
FT Modified-site 36
FT Modified-site /note= "Homoproline"
FT Modified-site 37
XX /note= "Homoproline; C-terminal amide"
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
```

```
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 78; Page 84; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 37 AA;
SQ
AAE08429 Length: 37 February 4, 2005 13:19 Type: P Check: 4125 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEGFTSLSQMEEEAVRLFIEWLNKGSSGAXX
28
-----
1 match found in sequence:
aae08430; Exendin agonist peptide #75.
(from "seq4ags.pep")
TOIG of: aae08430 check: 869 from: 1 to: 36
ID AAE08430 standard; peptide; 36 AA.
XX
XX AAE08430;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Exendin agonist peptide #75.
DE
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 31
FT Modified-site /note= "Homoproline"
DE Modified-site 36
FT Modified-site /note= "Homoproline; C-terminal amide"
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX Example 79; Page 84; 161pp; English.
XX
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
```

CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin

SQ Sequence 36 AA;

AAE08430 Length: 36 February 4, 2005 13:19 Type: P Check: 869 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSLSKQMEEEAVRLFIEWLKNGXSSGAX
28

1 match found in sequence:

aae08431 ; Extendin agonist peptide #76.

(from "seq4ags.pep")

TOIG of: aae08431 check: 7463 from: 1 to: 35

ID AAE08431 standard; peptide; 35 AA.

XX AC AAE08431;

DT 01-NOV-2001 (first entry)

XX DE Extendin agonist peptide #76.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 35

FT /note= "C-terminal amide"

XX PN WO200151078-A1.

XX PD 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.

XX Example 80; Page 85; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin

SQ Sequence 35 AA;

AAE08431 Length: 35 February 4, 2005 13:19 Type: P Check: 7463 ..
Found using 'seq4' (mohamed337.key)

1 RGGTFTSLSKQMEEEAVRLFIEWLKNGGPSSGA
28

1 match found in sequence:

aae08432 ; Extendin agonist peptide #77.

(from "seq4ags.pep")

TOIG of: aae08432 check: 4886 from: 1 to: 30

ID AAE08432 standard; peptide; 30 AA.

XX AC AAE08432;

DT 01-NOV-2001 (first entry)

XX DE Extendin agonist peptide #77.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX PN WO200151078-A1.

XX PD 19-JUL-2001.

XX PF 09-JAN-2001; 2001WO-US000719..

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Kolterman OG, Young AA;

XX DR WPI; 2001-514422/56.

XX Use of extendin and extendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.

XX Example 81; Page 86; 161pp; English.

XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin

SQ Sequence 30 AA;

AAE08432 Length: 30 February 4, 2005 13:19 Type: P Check: 4886 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSLSKQMEEEAVRLFIEWLKNGG
28

1 match found in sequence:

aae08433 ; Extendin agonist peptide #78.

(from "seq4ags.pep")

TOIG of: aae08433 check: 369 from: 1 to: 28

ID AAE08433 standard; peptide; 28 AA.

XX AC AAE08433;

DT 01-NOV-2001 (first entry)

XX DE Extendin agonist peptide #78.

```
XX Extentin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
OS
XX Key Location/Qualifiers
FH Modified-site 6
FT Modified-site /note= "Naphthylalanine"
FT Modified-site 28
FT Modified-site /note= "C-terminal amide"
XX WO200151078-A1.
XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX Use of extentin and extentin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX Example 82; Page 86; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extentin or an
CC extentin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extentin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extentin
XX Sequence 28 AA;
SQ
AAE08433 Length: 28 February 4, 2005 13:19 Type: P Check: 369 ..
Found using 'seq4' (mohamed337.key)
1 HEGTYSLSKQLBEEAVRLPIEFLKN 28
-----
1 match found in sequence:
aae08434 ; Extentin agonist peptide #79.
(from "seq4ags.pep")
TOIG of: aae08434 check: 693 from: 1 to: 28
ID AAE08434 standard; peptide; 28 AA.
XX AC
XX AC AAE08435;
XX DT 01-NOV-2001 (first entry)
XX DE Extentin agonist peptide #79.
XX KW Extentin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 28
FT Modified-site /note= "C-terminal amide"
XX WO200151078-A1.
XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX Use of extentin and extentin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX Example 82; Page 86; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extentin or an
CC extentin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extentin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extentin
XX Sequence 28 AA;
SQ
AAE08433 Length: 28 February 4, 2005 13:19 Type: P Check: 369 ..
Found using 'seq4' (mohamed337.key)
1 HEGTYSLSKQLBEEAVRLPIEFLKN 28
-----
1 match found in sequence:
aae08434 ; Extentin agonist peptide #79.
(from "seq4ags.pep")
TOIG of: aae08434 check: 693 from: 1 to: 28
ID AAE08434 standard; peptide; 28 AA.
XX AC
XX AC AAE08435;
XX DT 01-NOV-2001 (first entry)
XX DE Extentin agonist peptide #79.
XX KW Extentin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 28
FT Modified-site /note= "C-terminal amide"
XX WO200151078-A1.
```

```
XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
XX Use of extentin and extentin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX Example 83; Page 87; 161pp; English.
XX The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extentin or an
CC extentin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extentin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extentin
XX Sequence 28 AA;
SQ
AAE08434 Length: 28 February 4, 2005 13:19 Type: P Check: 693 ..
Found using 'seq4' (mohamed337.key)
1 HEGTFSSDLSKQMBEEAVRLFIEWLKN 28
-----
1 match found in sequence:
aae08435 ; Extentin agonist peptide #80.
(from "seq4ags.pep")
TOIG of: aae08435 check: 701 from: 1 to: 28
ID AAE08435 standard; peptide; 28 AA.
XX AC
XX AC AAE08435;
XX DT 01-NOV-2001 (first entry)
XX DE Extentin agonist peptide #80.
XX KW Extentin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 28
FT Modified-site /note= "C-terminal amide"
XX WO200151078-A1.
XX 19-JUL-2001.
XX 09-JAN-2001; 2001WO-US000719.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Kolterman OG, Young AA;
XX WPI; 2001-514422/56.
```

PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 84; Page 87; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 28 AA;
XX
AAE08435 Length: 28 February 4, 2005 13:19 Type: P Check: 701 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HEGFTSTLSKQMEAEAVRLFIEFLKN 28

1 match found in sequence:
aae08436 ; Exendin agonist peptide #81.
(from "seq4ags.pep")
TOIG of: aae08436 check: 649 from: 1 to: 28

ID AAE08436 standard; peptide; 28 AA.
XX
AC AAE08436;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #81.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "C-terminal amide"
FT Modified-site 28 /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 85; Page 88; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX
SQ Sequence 28 AA;
AAE08436 Length: 28 February 4, 2005 13:19 Type: P Check: 649 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HEGFTSTLSKQMAEAEAVRLFIEFLKN 28

1 match found in sequence:
aae08437 ; Exendin agonist peptide #82.
(from "seq4ags.pep")
TOIG of: aae08437 check: 381 from: 1 to: 28

ID AAE08437 standard; peptide; 28 AA.
XX
AC AAE08437;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #82.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX diuretic; coronary heart disease; dyslipidaemia.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 10 /note= "Pentylglycine"
FT Modified-site 28 /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 86; Page 89; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;
AAE08437 Length: 28 February 4, 2005 13:19 Type: P Check: 381 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HEGFTSTLSKQLEAEAVRLFIEFLKN 28

```
1 match found in sequence:
aee08438 ; Exendin agonist peptide #83.
(from "seq4ags.pep")
TOIG of: aae08438 check: 657 from: 1 to: 28

ID AAE08438 standard; peptide; 28 AA.
XX
AC AAE08438;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #83.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 22
FT Modified-site /note= "Naphthylalanine"
FT Modified-site 28
FT Modified-site /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-017536SP.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 87; Page 89; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08438 Length: 28 February 4, 2005 13:19 Type: P Check: 657 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSLSKQLEEEAVRLXIEFLKN 28
|-----|
1 match found in sequence:
aee08438 ; Exendin agonist peptide #84.
(from "seq4ags.pep")
TOIG of: aae08439 check: 1045 from: 1 to: 28

ID AAE08439 standard; peptide; 28 AA.
XX
AC AAE08439;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #84.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT Modified-site /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-017536SP.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
DR WPI; 2001-514422/56.
XX
PT Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 88; Page 90; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
SQ Sequence 28 AA;

AAE08439 Length: 28 February 4, 2005 13:19 Type: P Check: 1045 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSLSKQMBEEAVRLFPEWLKN 28
|-----|
1 match found in sequence:
aee08440 ; Exendin agonist peptide #85.
(from "seq4ags.pep")
TOIG of: aae08440 check: 237 from: 1 to: 28

ID AAE08440 standard; peptide; 28 AA.
XX
AC AAE08440;
XX
DT 01-NOV-2001 (first entry)
XX
DE Exendin agonist peptide #85.
XX
KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT Modified-site /note= "C-terminal amide"
XX
```

PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
PS Example 89; Page 90; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;
AAE08440 Length: 28 February 4, 2005 13:19 Type: P Check: 237 ..
Found using 'seq4' (mohamed337.key)
1 HEGCTFTSLSKQLEEEAVRLFIDFLKN 28

1 match found in sequence:
aee08441; Extendin agonist peptide #86.
(from "seq4ags.pep")
TOIG of: aae08441 check: 2215 from: 1 to: 33
ID AAE08441 standard; peptide; 33 AA.
XX
AC AAE08441;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #86.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 33
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
PS Example 91; Page 91; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 28 AA;
AAE08441 Length: 28 February 4, 2005 13:19 Type: P Check: 237 ..
Found using 'seq4' (mohamed337.key)
1 HEGCTFTSLSKQLEEEAVRLFIDFLKN 28

1 match found in sequence:
aee08441; Extendin agonist peptide #86.
(from "seq4ags.pep")
TOIG of: aae08441 check: 2215 from: 1 to: 33
ID AAE08441 standard; peptide; 33 AA.
XX
AC AAE08441;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #86.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 33
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
DR

XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
PS Example 90; Page 91; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 33 AA;
AAE08441 Length: 33 February 4, 2005 13:19 Type: P Check: 2215 ..
Found using 'seq4' (mohamed337.key)
1 HEGCTFTSDASKQLEEEAVRLFIEFLKNGGPSS 28

1 match found in sequence:
aee08442; Extendin agonist peptide #87.
(from "seq4ags.pep")
TOIG of: aae08442 check: 2649 from: 1 to: 29
ID AAE08442 standard; peptide; 29 AA.
XX
AC AAE08442;
XX
DT 01-NOV-2001 (first entry)
XX
DE Extendin agonist peptide #87.
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 29
FT /note= "C-terminal amide"
XX
PN WO200151078-A1.
XX
PD 19-JUL-2001.
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Kolterman OG, Young AA;
XX
XX WPI; 2001-514422/56.
DR
XX Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
PS Example 91; Page 91; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
SQ Sequence 33 AA;

CC present peptide sequence is an agonist of extendin

XX Sequence 29 AA;

SQ

AAE08442 Length: 29 February 4, 2005 13:19 Type: P Check: 2649 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDASKQMEEEAVRLFIEWLKNG 28
|-----|
1

1 match found in sequence:
aae08443 ; Extendin agonist peptide #88.
(from "seq4ags.pep")
TOIG of: aae08443 check: 4015 from: 1 to: 37

ID AAE08443 standard; peptide; 37 AA.

XX AAE08443;

AC AC AAE08443;

XX 01-NOV-2001 (first entry)

XX Extendin agonist peptide #88.

DE XX Extendin agonist peptide #88.

XX Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;

KW diuretic; coronary heart disease; dyslipidaemia.

XX Synthetic.

OS

XX Key

FT Modified-site 31

FT Modified-site 36

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

FT Modified-site 37

```
XX DE Exendin agonist peptide #94.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX XX
XX DR WPI; 2001-514422/56.
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 100; Page 97; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin
XX SQ Sequence 28 AA;
AAE08452 Length: 28 February 4, 2005 13:19 Type: P Check: 688 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTSLSKQMEEEAVRLPIEWLKN 28
|-----|
1 match found in sequence:
aae08452 ; Exendin agonist peptide #97.
(from "seq4ags.pep")
TOIG of: aae08452 check: 590 from: 1 to: 28
ID AAE08452 standard; peptide; 28 AA.
XX AC AAE08452;
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #97.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX XX
XX DR WPI; 2001-514422/56.
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 100; Page 97; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin
XX SQ Sequence 28 AA;
AAE08452 Length: 28 February 4, 2005 13:19 Type: P Check: 688 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTSLSKQMEEEAVRLPIEWLKN 28
|-----|
1 match found in sequence:
aae08452 ; Exendin agonist peptide #97.
(from "seq4ags.pep")
TOIG of: aae08452 check: 590 from: 1 to: 28
ID AAE08452 standard; peptide; 28 AA.
XX AC AAE08452;
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #97.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
```

```
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX XX
XX DR WPI; 2001-514422/56.
XX PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX PT levels, and treating heart disease and dyslipidemia.
XX PS Example 103; Page 99; 161pp; English.
XX CC The patent discloses a method for modulating plasma or postprandial
XX CC triglyceride and other lipid levels by administering exendin or an
XX CC exendin agonist. Exendins have inotropic and diuretic effects. They
XX CC suppress the secretion of glucagon. Exendin and its agonists have a
XX CC significant effect on the reduction of blood serum triglyceride
XX CC concentrations. They are used to treat coronary heart disease and
XX CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
XX CC present peptide sequence is an agonist of exendin
XX SQ Sequence 28 AA;
AAE08452 Length: 28 February 4, 2005 13:19 Type: P Check: 590 ..
Found using 'seq4' (mohamed337.key)
1 HGEGETFTSDASKQMEEEAVRLPIEWLKN 28
|-----|
1 match found in sequence:
aae08512 ; Exendin agonist peptide #157.
(from "seq4ags.pep")
TOIG of: aae08512 check: 5882 from: 1 to: 38
ID AAE08512 standard; peptide; 38 AA.
XX AC AAE08512;
XX DT 01-NOV-2001 (first entry)
XX DE Exendin agonist peptide #157.
XX KW Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
XX KW diuretic; coronary heart disease; dyslipidaemia.
XX OS Synthetic.
XX FH Key
XX FT Modified-site 28
XX FT /note= "C-terminal amide"
XX PN WO200151078-A1.
XX PD 19-JUL-2001.
XX PF 09-JAN-2001; 2001WO-US000719.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Kolterman OG, Young AA;
XX XX
XX DR WPI; 2001-514422/56.
```

PT Use of exendin and exendin agonist compounds for modulating triglyceride
XX levels, and treating heart disease and dyslipidemia.
XX
XX Example 163; Page 134; 161pp; English.
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 38 AA;
SQ
AAE08512 Length: 38 February 4, 2005 13:19 Type: P Check: 5882 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGAGTFTDLSKQLEEAVALRFLFIEFLKNGPSSGAPP 28

1 match found in sequence:
aae08517; Exendin agonist peptide #162.
(from "seq4ags.pep")
TOIG of: aae08517 check: 7002 from: 1 to: 35

ID AAE08517 standard; peptide; 35 AA.
XX
XX AAE08517;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Exendin agonist peptide #162.
DE
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 35
FT /note= "C-terminal amide"
FT
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US0000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 168; Page 137; 161pp; English.
PS
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin

XX Sequence 35 AA;
SQ
AAE08517 Length: 35 February 4, 2005 13:19 Type: P Check: 7002 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGAGTFTDLSKQLEEAVALRFLFIEFLKNGPSSGA 28

1 match found in sequence:
aae08521; Exendin agonist peptide #166.
(from "seq4ags.pep")
TOIG of: aae08521 check: 9574 from: 1 to: 32

ID AAE08521 standard; peptide; 32 AA.
XX
XX AAE08521;
AC
XX
XX 01-NOV-2001 (first entry)
DT
XX
XX Exendin agonist peptide #166.
DE
XX
XX Exendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 32
FT /note= "C-terminal amide"
FT
XX
XX WO200151078-A1.
PN
XX
XX 19-JUL-2001.
PD
XX
XX 09-JAN-2001; 2001WO-US0000719.
PF
XX
XX 10-JAN-2000; 2000US-0175365P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Kolterman OG, Young AA;
PI
XX
XX WPI; 2001-514422/56.
DR
XX
XX Use of exendin and exendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
PT
XX
XX Example 172; Page 140; 161pp; English.
PS
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering exendin or an
CC exendin agonist. Exendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Exendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of exendin
XX
XX Sequence 32 AA;
SQ
AAE08521 Length: 32 February 4, 2005 13:19 Type: P Check: 9574 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGAGTFTDLSKQLEEAVALRFLFIEFLKNGGPS 28

1 match found in sequence:
aae08525; Exendin agonist peptide #170.

```
(from "seq4ags.pep")
TOIG of: aae08525 check: 7457 from: 1 to: 38
ID AAE08525 standard; peptide; 38 AA.
AC AAE08525;
XX
XX
DT 01-NOV-2001 (first entry)
XX
XX
DE Extendin agonist peptide #170.
XX
XX
KW Extendin agonist; antilipemic; cardiant; triglyceride; inotropic;
KW diuretic; coronary heart disease; dyslipidaemia.
XX
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT Modified-site 31
FT Modified-site 36 /note= "Thioprolin"
FT Modified-site 37 /note= "Thioprolin"
FT Modified-site 37 /note= "Thioprolin"
FT Modified-site 38 /note= "Thioprolin; C-terminal amide"
FT
FT
XX WO200151078-A1.
XX
XX
XX
XX
FH Key Location/Qualifiers
FT Modified-site 35
FT Modified-site 35 /note= "C-terminal amide"
FT
FT
XX WO200151078-A1.
XX
XX
XX
XX
PD 19-JUL-2001.
XX
XX
XX
XX
PF 09-JAN-2001; 2001WO-US000719.
XX
XX
XX
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
XX
XX
PI Kolterman OG, Young AA;
XX
XX
XX
XX
DR WPI; 2001-514422/56.
XX
XX
XX
XX
PT Use of extendin and extendin agonist compounds for modulating triglyceride
PT levels, and treating heart disease and dyslipidemia.
XX
XX
XX
XX
PS Example 180; Page 145; 161pp; English.
XX
XX
XX
XX
CC The patent discloses a method for modulating plasma or postprandial
CC triglyceride and other lipid levels by administering extendin or an
CC extendin agonist. Extendins have inotropic and diuretic effects. They
CC suppress the secretion of glucagon. Extendin and its agonists have a
CC significant effect on the reduction of blood serum triglyceride
CC concentrations. They are used to treat coronary heart disease and
CC dyslipidaemia, and for modifying postprandial triglyceride levels. The
CC present peptide sequence is an agonist of extendin
XX
XX
XX
XX
SQ Sequence 35 AA;
AAE08529 Length: 35 February 4, 2005 13:19 Type: P Check: 7441 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTSLSKQMBEEAVRLFIEWLKNGKGPSSGA
1
-----
1 match found in sequence:
aael4425 : Gila monster extendin 3 peptide.
(from "seq4ags.pep")
TOIG of: aael4425 check: 9591 from: 1 to: 39
ID AAE14425 standard; peptide; 39 AA.
XX
XX
AC AAE14425;
XX
XX
XX
XX
DT 26-MAR-2002 (first entry)
XX
XX
XX
XX
DE Gila monster extendin 3 peptide.
XX
XX
XX
XX
KW Acute coronary syndrome; ACS; Q-wave myocardial infarction; Q-wave MI;
KW angina; non-Q-wave cardiac necrosis; ischaemic heart disease;
KW congestive heart failure; heart murmur; troponin I; troponin T;
KW creatine kinase myocardial isoenzyme; CK-MB; ST-segment; chest pain;
KW nausea; palpitation; dizziness; angioplasty; pulmonary oedema;
KW peripheral oedema; extrasystole; arterial fibrillation; arrhythmia;
KW diabetes; hypertension; hypercholesterolaemia; hyperlipidaemia; obesity;
KW smoking; impaired glucose tolerance; blood glucose; thrombolytic therapy;
KW cardiac distress; glucagon-like peptide-1; GLP-1 homologue; Gila monster;
```

KW exendin 3.
 XX Heloderma suspectum.
 XX
 XX Key Location/Qualifiers
 XX Modified-site 39 /note= "C-terminal amide"
 XX
 XX WO200189554-A2.
 XX
 XX 29-NOV-2001.
 XX
 XX 18-MAY-2001; 2001WO-US015996.
 XX
 XX 19-MAY-2000; 2000US-0205239P.
 XX
 XX (BION-) BIONEERASKA INC.
 XX
 XX Coolidge TR, Ehlers M;
 XX
 XX WPI; 2002-089892/12.
 XX
 XX New method of treating patients suffering from acute coronary syndrome,
 XX but not suffering from Q-wave myocardial infarction involves the use of
 XX glucagon-like peptide-1 derivatives.
 XX
 XX Disclosure; Page 15; 38pp; English.
 XX
 XX The invention relates to a novel method of treating patients suffering
 XX from acute coronary syndrome (ACS) and not from Q-wave myocardial
 XX infarction (Q-wave MI) that involves administering a glucagon-like
 XX peptide-1 (GLP-1) molecule to the patients. The method is also useful for
 XX treating patients suffering from stable/unstable angina, non-Q-wave
 XX cardiac necrosis, ischaemic heart disease or at a risk of developing
 XX ischaemic heart disease, cardiac abnormalities including congestive heart
 XX failure, worsening heart murmur (due to mitral regurgitation and cardiac
 XX conduction disturbances); for treating patients who have a blood troponin
 XX I level of less than 0.4 ng/ml and blood troponin T level of no more than
 XX 0.1 ng/ml; do not have elevated blood creatine kinase myocardial enzyme
 XX and ST-segment elevation, do not exhibit a pathological Q-wave, exhibit
 XX chest pain at rest or chest pain following minimal exertion (that is
 XX poorly responsive to sublingual nitrates), nausea, shortness of breath,
 XX palpitation and dizziness and have not suffered from a Q-wave myocardial
 XX infarction prior to the onset of the symptoms, and having normal ECG. The
 XX GLP-1 compound is further useful in angioplasty, for treating patients
 XX showing symptoms of pulmonary and peripheral oedema, atrial or
 XX ventricular extrasystoles, arterial fibrillation and other arrhythmias;
 XX and those suffering from diabetes, hypertension, hypercholesterolaemia,
 XX hyperlipidaemia, obesity and smoking. The administration of GLP-1
 XX following a Q-myocardial infarction (QMI) ameliorates the tissue damage
 XX that results from the QMI and subsequent reperfusion-induced injury. An
 XX advantage of using GLP-1 molecules is that high doses can be used without
 XX consequent hypoglycaemia and hyperglycaemia. Thus doses up to 10 nmol/kg
 XX can be used without adverse effects, as the action of the molecules are
 XX ideal for optimising glucose metabolism in individuals including those
 XX with impaired glucose tolerance and elevated or aberrant blood glucose
 XX levels. The molecule increases the time during which thrombolytic therapy
 XX becomes effective following the first symptom of cardiac distress. The
 XX present sequence is Gila monster exendin 3 peptide which is homologous to
 XX mammalian GLP-1 peptide.
 XX
 XX Sequence 39 AA;
 XX
 XX AAE14425 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
 XX Found using 'seq4' (mohamed337.key)
 XX
 XX -----
 XX 1 HSDGTFSDLSKQMEAEAVRLFIEWLKNGGPGSGAPPPS
 XX 1 28
 XX -----
 XX 1 match found in sequence:

aae14427 ; Gila monster exendin 4 peptide.
 (from "seq4agr.pap")
 TOIG of: aae14427 check: 9570 from: 1 to: 39
 ID AAE14427 standard; peptide; 39 AA.
 XX
 XX AAE14427;
 XX
 XX 26-MAR-2002 (first entry)
 XX
 XX Gila monster exendin 4 peptide.
 XX
 XX Acute coronary syndrome; ACS; Q-wave myocardial infarction; Q-wave MI;
 XX angina; non-Q-wave cardiac necrosis; ischaemic heart disease;
 XX congestive heart failure; heart murmur; troponin I; troponin T;
 XX creatine kinase myocardial isoenzyme; CK-MB; ST-segment; chest pain;
 XX nausea; palpitation; dizziness; angiotensin; angiotensinase;
 XX peripheral oedema; extrasystole; arterial fibrillation; arrhythmia;
 XX diabetes; hypertension; hypercholesterolaemia; hyperlipidaemia; obesity;
 XX smoking; impaired glucose tolerance; blood glucose; thrombolytic therapy;
 XX cardiac distress; glucagon-like peptide-1; GLP-1 homolog; Gila monster;
 XX exendin 4.
 XX
 XX Heloderma suspectum.
 XX
 XX Key Location/Qualifiers
 XX Modified-site 39 /note= "C-terminal amide"
 XX
 XX WO200189554-A2.
 XX
 XX 29-NOV-2001.
 XX
 XX 18-MAY-2001; 2001WO-US015996.
 XX
 XX 19-MAY-2000; 2000US-0205239P.
 XX
 XX (BION-) BIONEERASKA INC.
 XX
 XX Coolidge TR, Ehlers M;
 XX
 XX WPI; 2002-089892/12.
 XX
 XX New method of treating patients suffering from acute coronary syndrome,
 XX but not suffering from Q-wave myocardial infarction involves the use of
 XX glucagon-like peptide-1 derivatives.
 XX
 XX Disclosure; Page 15; 38pp; English.
 XX
 XX The invention relates to a novel method of treating patients suffering
 XX from acute coronary syndrome (ACS) and not from Q-wave myocardial
 XX infarction (Q-wave MI) that involves administering a glucagon-like
 XX peptide-1 (GLP-1) molecule to the patients. The method is also useful for
 XX treating patients suffering from stable/unstable angina, non-Q-wave
 XX cardiac necrosis, ischaemic heart disease or at a risk of developing
 XX ischaemic heart disease, cardiac abnormalities including congestive heart
 XX failure, worsening heart murmur (due to mitral regurgitation and cardiac
 XX conduction disturbances); for treating patients who have a blood troponin
 XX I level of less than 0.4 ng/ml and blood troponin T level of no more than
 XX 0.1 ng/ml; do not have elevated blood creatine kinase myocardial enzyme
 XX and ST-segment elevation, do not exhibit a pathological Q-wave, exhibit
 XX chest pain at rest or chest pain following minimal exertion (that is
 XX poorly responsive to sublingual nitrates), nausea, shortness of breath,
 XX palpitation and dizziness and have not suffered from a Q-wave myocardial
 XX infarction prior to the onset of the symptoms, and having normal ECG. The
 XX GLP-1 compound is further useful in angioplasty, for treating patients
 XX showing symptoms of pulmonary and peripheral oedema, atrial or
 XX ventricular extrasystoles, arterial fibrillation and other arrhythmias;
 XX and those suffering from diabetes, hypertension, hypercholesterolaemia,
 XX hyperlipidaemia, obesity and smoking. The administration of GLP-1
 XX following a Q-myocardial infarction (QMI) ameliorates the tissue damage
 XX that results from the QMI and subsequent reperfusion-induced injury. An
 XX advantage of using GLP-1 molecules is that high doses can be used without
 XX consequent hypoglycaemia and hyperglycaemia. Thus doses up to 10 nmol/kg
 XX can be used without adverse effects, as the action of the molecules are
 XX ideal for optimising glucose metabolism in individuals including those
 XX with impaired glucose tolerance and elevated or aberrant blood glucose
 XX levels. The molecule increases the time during which thrombolytic therapy
 XX becomes effective following the first symptom of cardiac distress. The
 XX present sequence is Gila monster exendin 3 peptide which is homologous to
 XX mammalian GLP-1 peptide.

CC advantage of using GLP-1 molecules is that high doses can be used without
CC consequent hypoglycaemia and hyperglycaemia. Thus doses up to 10 nmol/kg
CC can be used without adverse effects, as the action of the molecules are
CC ideal for optimising glucose metabolism in individuals including those
CC with impaired glucose tolerance and elevated or aberrant blood glucose
CC levels. The molecule increases the time during which thrombolytic therapy
CC becomes effective following the first symptom of cardiac distress. The
CC present sequence is Gila monster extendin 4 peptide which is homologous to
CC mammalian GLP-1 peptide
XX
XX
SQ Sequence 39 AA;

AAE30912 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
1
-----|-----|
28

1 match found in sequence:
aee30912 ; Extendin-3 peptide (7-45).
(from "seq4ags.pep")
TOIG of: aae30912 check: 9591 from: 1 to: 39

ID AAE30912 standard; peptide; 39 AA.
XX
XX AC AAE30912;
XX
XX DT 24-FEB-2003 (first entry)
XX
XX DE Extendin-3 peptide (7-45).
XX
XX KW Glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig; therapy;
KW non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
KW extendin-3.
XX
XX OS Unidentified.
XX
XX PN WO200246227-A2.
XX
XX PD 13-JUN-2002.
XX
XX PF 29-NOV-2001; 2001WO-US043165.
XX
XX PR 07-DEC-2000; 2000US-0251954P.
XX
XX PA (ELIL) LILLY & CO ELI.

XX Glaesner W, Micanovic R, Tschang SR;
XX WPI; 2003-018534/01.
XX
XX Novel heterologous fusion protein, useful for treating non-insulin
PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
PT 1 compound fused to human albumin or to the Fc portion of an
PT immunoglobulin.
XX
XX PS Disclosure; Page 31; 200pp; English.
XX
XX The invention relates to a heterologous fusion protein comprising a first
CC polypeptide fused to a second polypeptide, where the polypeptides has a N
CC -terminus and a C-terminus and the first polypeptide is a glucagon-like
CC peptide 1 (GLP-1) compound and the second is a human albumin or its
CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
CC analogue or fragment, where the C-terminus of first polypeptide is fused
CC to the N-terminus of the second polypeptide. The invention is useful for
CC normalising blood glucose levels in mammal, for treating a patient with
CC non-insulin diabetes mellitus or obesity, or for the manufacture of
CC medicament for treating the above mentioned diseases. The present
CC sequence is extendin-3 peptide used in the invention
XX
SQ Sequence 39 AA;

AAE30912 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
1
-----|-----|
28

1 match found in sequence:
aee30920 ; Extendin-4-linker-human serum albumin (HSA) fusion protein.
XX
XX
SQ Sequence 39 AA;

AAE30912 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
1
-----|-----|
28

1 match found in sequence:
aee30913 ; Extendin-4 peptide (7-45).
(from "seq4ags.pep")
TOIG of: aae30913 check: 9570 from: 1 to: 39

ID AAE30913 standard; peptide; 39 AA.
XX
XX AC AAE30913;
XX
XX DT 24-FEB-2003 (first entry)
XX
XX DE Extendin-4 peptide (7-45).
XX
XX KW Glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig; therapy;
KW non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
KW extendin-4.
XX
XX OS Unidentified.
XX
XX PN WO200246227-A2.
XX
XX PD 13-JUN-2002.
XX
XX PF 29-NOV-2001; 2001WO-US043165.
XX
XX PR 07-DEC-2000; 2000US-0251954P.
XX
XX PA (ELIL) LILLY & CO ELI.
XX
XX Glaesner W, Micanovic R, Tschang SR;
XX WPI; 2003-018534/01.

XX Novel heterologous fusion protein, useful for treating non-insulin
PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
PT 1 compound fused to human albumin or to the Fc portion of an
PT immunoglobulin.
XX
XX PS Disclosure; Page 32; 200pp; English.

XX The invention relates to a heterologous fusion protein comprising a first
CC polypeptide fused to a second polypeptide, where the polypeptides has a N
CC -terminus and a C-terminus and the first polypeptide is a glucagon-like
CC peptide 1 (GLP-1) compound and the second is a human albumin or its
CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
CC analogue or fragment, where the C-terminus of first polypeptide is fused
CC to the N-terminus of the second polypeptide. The invention is useful for
CC normalising blood glucose levels in mammal, for treating a patient with
CC non-insulin diabetes mellitus or obesity, or for the manufacture of
CC medicament for treating the above mentioned diseases. The present
CC sequence is extendin-4 peptide used in the invention
XX
XX SQ Sequence 39 AA;

AAE30913 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
1
-----|-----|
28

1 match found in sequence:
aee30920 ; Extendin-4-linker-human serum albumin (HSA) fusion protein.
XX
XX
SQ Sequence 39 AA;

```

(from "seq4ags.pep")
TOIG of: aae30920 check: 3586 from: 1 to: 640
ID AAE30920 standard; protein; 640 AA.
XX AC AAE30920;
XX DT 24-FEB-2003 (first entry)
XX DE Extendin-4-linker-human serum albumin (HSA) fusion protein.
XX KW Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
XX KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
XX KW fusion protein.
XX OS Homo sapiens.
XX OS Unidentified.
XX OS Chimeric.
XX PN WO200246227-A2.
XX PD 13-JUN-2002.
XX PF 29-NOV-2001; 2001WO-US043165.
XX PR 07-DEC-2000; 2000US-0251954P.
XX PA (ELIL ) LILLY & CO ELI.
XX PI Glaesner W, Micanovic R, Tschang SR;
XX DR WPI; 2003-018534/01.
XX PT Novel heterologous fusion protein, useful for treating non-insulin
XX PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
XX PT 1 compound fused to human albumin or to the Fc portion of an
XX PT immunoglobulin.
XX PS Example 6; Page 81-82; 200pp; English.
XX CC The invention relates to a heterologous fusion protein comprising a first
XX CC polypeptide fused to a second polypeptide, where the polypeptides has a N
XX CC terminus and a C-terminus and the first polypeptide is a glucagon-like
XX CC peptide 1 (GLP-1) compound and the second is a human albumin or its
XX CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
XX CC analogue or fragment, where the C-terminus of first polypeptide is fused
XX CC to the N-terminus of the second polypeptide. The invention is useful for
XX CC normalising blood glucose levels in mammal, for treating a patient with
XX CC non-insulin diabetes mellitus or obesity, or for the manufacture of
XX CC medicament for treating the above mentioned diseases. The present
XX CC sequence is a fusion protein of the invention
XX SQ Sequence 640 AA;
AAE30920 Length: 640 February 4, 2005 13:20 Type: P Check: 3586 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTTSLSKQMBEEAVRLFIEWLKNGSPSGAPPSPSGGGGGGGGGGGGSDAHKS
28
61 EVAHFKDLGEENFKALV
...
1 match found in sequence:
aae30932 ; Extendin-4-Immunoglobulin G1 (IgG1) fusion protein.
(from "seq4ags.pep")
TOIG of: aae30932 check: 5210 from: 1 to: 272
ID AAE30932 standard; protein; 272 AA.
XX AC AAE30932;
XX DT 24-FEB-2003 (first entry)
XX DE Extendin-4-Immunoglobulin G1 (IgG1) fusion protein.
XX KW Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
XX KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
XX KW fusion protein.
XX OS Homo sapiens.
XX OS Unidentified.
XX OS Chimeric.
XX PN WO200246227-A2.
XX PD 13-JUN-2002.
XX PF 29-NOV-2001; 2001WO-US043165.
XX PR 07-DEC-2000; 2000US-0251954P.
XX PA (ELIL ) LILLY & CO ELI.
XX PI Glaesner W, Micanovic R, Tschang SR;
XX DR WPI; 2003-018534/01.
XX PT Novel heterologous fusion protein, useful for treating non-insulin
XX PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
XX PT 1 compound fused to human albumin or to the Fc portion of an
XX PT immunoglobulin.
XX PS Example 6; Page 84; 200pp; English.
XX CC The invention relates to a heterologous fusion protein comprising a first
XX CC polypeptide fused to a second polypeptide, where the polypeptides has a N
XX CC terminus and a C-terminus and the first polypeptide is a glucagon-like
XX CC peptide 1 (GLP-1) compound and the second is a human albumin or its
XX CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
XX CC analogue or fragment, where the C-terminus of first polypeptide is fused
XX CC to the N-terminus of the second polypeptide. The invention is useful for
XX CC normalising blood glucose levels in mammal, for treating a patient with
XX CC non-insulin diabetes mellitus or obesity, or for the manufacture of
XX CC medicament for treating the above mentioned diseases. The present
XX CC sequence is a fusion protein of the invention
XX SQ Sequence 272 AA;
AAE30932 Length: 272 February 4, 2005 13:20 Type: P Check: 5210 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTTSLSKQMBEEAVRLFIEWLKNGSPSGAPPSPSGGGGGGGGGGGGSDAHKS
28
61 GGPSVFLFPFKDTLMI
...
1 match found in sequence:
aae30933 ; Extendin-4-C2-Immunoglobulin G1 (IgG1) fusion protein.
(from "seq4ags.pep")
TOIG of: aae30933 check: 4385 from: 1 to: 272
ID AAE30933 standard; protein; 272 AA.
XX AC AAE30933;
XX DT 24-FEB-2003 (first entry)
XX DE Extendin-4-C2-Immunoglobulin G1 (IgG1) fusion protein.

```

```

XX Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
KW fusion protein.
XX
OS Homo sapiens.
OS Unidentified.
OS Chimeric.
XX
XX WO200246227-A2.
XX
XX 13-JUN-2002.
XX
XX 29-NOV-2001; 2001WO-US043165.
XX
XX 07-DEC-2000; 2000US-0251954P.
XX
XX (ELIL ) LILLY & CO ELI.
XX
XX Glaesner W, Micanovic R, Tschang SR;
XX
XX WPI; 2003-018534/01.
XX
XX Novel heterologous fusion protein, useful for treating non-insulin
PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
PT 1 compound fused to human albumin or to the Fc portion of an
PT immunoglobulin.
XX
XX Example 6; Page 85; 200pp; English.
XX
XX The invention relates to a heterologous fusion protein comprising a first
CC polypeptide fused to a second polypeptide, where the polypeptides has a N
CC -terminus and a C-terminus and the first polypeptide is a glucagon -like
CC peptide 1 (GLP-1) compound and the second is a human albumin or its
CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
CC analogue or fragment, where the C-terminus of first polypeptide is fused
CC to the N-terminus of the second polypeptide. The invention is useful for
CC normalising blood glucose levels in mammal, for treating a patient with
CC non-insulin diabetes mellitus or obesity, or for the manufacture of
CC medicament for treating the above mentioned diseases. The present
CC sequence is a fusion protein of the invention
XX
SQ Sequence 272 AA;
AAE30933 Length: 272 February 4, 2005 13:20 Type: P Check: 4385 ..
Found using 'Seq4' (mohamed337.key)
1 |-----|
1 HGEGTFTDLSKQMEEEAVRLFIEWLKNGSPSSGASSGAEPKSCDKTHTCPPCPAPELL
28
61 GGPSVFLPPPKDTLMI
...
-----
1 match found in sequence:
aee30934 ; Exendin-4-linker-Immunoglobulin G1 (IgG1) fusion protein.
(from "seq4ags.pep")
TOIG of: aae30934 check: 7029 from: 1 to: 287
ID AAE30934 standard; protein; 287 AA.
XX
AC AAE30934;
XX
XX 24-FEB-2003 (first entry)
XX
XX Exendin-4-linker-Immunoglobulin G1 (IgG1) fusion protein.
XX
XX Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic;
KW fusion protein.
XX
XX

```

```

OS Homo sapiens.
OS Unidentified.
OS Chimeric.
XX
XX WO200246227-A2.
XX
XX 13-JUN-2002.
XX
XX 29-NOV-2001; 2001WO-US043165.
XX
XX 07-DEC-2000; 2000US-0251954P.
XX
XX (ELIL ) LILLY & CO ELI.
XX
XX Glaesner W, Micanovic R, Tschang SR;
XX
XX WPI; 2003-018534/01.
XX
XX Novel heterologous fusion protein, useful for treating non-insulin
PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
PT 1 compound fused to human albumin or to the Fc portion of an
PT immunoglobulin.
XX
XX Example 6; Page 85; 200pp; English.
XX
XX The invention relates to a heterologous fusion protein comprising a first
CC polypeptide fused to a second polypeptide, where the polypeptides has a N
CC -terminus and a C-terminus and the first polypeptide is a glucagon -like
CC peptide 1 (GLP-1) compound and the second is a human albumin or its
CC analogue or fragment, or the Fc portion of an immunoglobulin (Ig) or its
CC analogue or fragment, where the C-terminus of first polypeptide is fused
CC to the N-terminus of the second polypeptide. The invention is useful for
CC normalising blood glucose levels in mammal, for treating a patient with
CC non-insulin diabetes mellitus or obesity, or for the manufacture of
CC medicament for treating the above mentioned diseases. The present
CC sequence is a fusion protein of the invention
XX
SQ Sequence 287 AA;
AAE30934 Length: 287 February 4, 2005 13:20 Type: P Check: 7029 ..
Found using 'Seq4' (mohamed337.key)
1 |-----|
1 HGEGTFTDLSKQMEEEAVRLFIEWLKNGSPSSGAPPSPSSGGGGGGGGGSAEPKSC
28
61 DKHTCPPCPAPELLGGP
...
-----
1 match found in sequence:
aee30937 ; Human GLP/exendin peptide analogue #1.
(from "seq4ags.pep")
TOIG of: aae30937 check: 7369 from: 1 to: 31
ID AAE30937 standard; peptide; 31 AA.
XX
AC AAE30937;
XX
XX 24-FEB-2003 (first entry)
XX
XX Human GLP/exendin peptide analogue #1.
XX
XX Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Modified-site 31
XX FT /note= "C-terminal amide"
XX

```

```

PN WO200246227-A2.
XX
XX
PD 13-JUN-2002.
XX
XX
PF 29-NOV-2001; 2001WO-US043165.
XX
XX
PR 07-DEC-2000; 2000US-0251954P.
XX
XX
PA (ELIL ) LILLY & CO ELI.
XX
XX
PI Glaesner W, Micanovic R, Tschang SR;
XX
XX
DR WPI; 2003-018534/01.
XX
XX
XX Novel heterologous fusion protein, useful for treating non-insulin
PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
PT 1 compound fused to human albumin or to the Fc portion of an
XX immunoglobulin.
XX
XX Example 6; Page 90; 200pp; English.
XX
XX The invention relates to a heterologous fusion protein comprising a first
CC polypeptide fused to a second polypeptide, where the polypeptides has a N
CC terminus and a C-terminus and the first polypeptide is a glucagon-like
CC peptide 1 (GLP-1) compound and the second is a human albumin or its
CC analogue or fragment, where the Fc portion of an immunoglobulin (Ig) or its
CC analogue or fragment, where the C-terminus of first polypeptide is fused
CC to the N-terminus of the second polypeptide. The invention is useful for
CC normalising blood glucose levels in mammal, for treating a patient with
CC non-insulin diabetes mellitus or obesity, or for the manufacture of
CC medicament for treating the above mentioned diseases. The present
CC sequence is human GLP/exendin peptide analogue
XX
XX Sequence 31 AA;
SQ
AAE30937 Length: 31 February 4, 2005 13:20 Type: P Check: 7369 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGPF
1 28
-----
1 match found in sequence:
aae30938 ; Human GLP/exendin peptide analogue #2.
(from "seq4ags.pep")
TOIG of: aae30938 check: 9570 from: 1 to: 39
ID AAE30938 standard; peptide; 39 AA.
XX
XX AAE30938;
AC
XX
XX 24-FEB-2003 (first entry)
DT
XX
XX Human GLP/exendin peptide analogue #2.
DE
XX
XX Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
FT
XX
XX WO200246227-A2.
PN
XX
XX 13-JUN-2002.
PD
XX
XX 29-NOV-2001; 2001WO-US043165.
PF
XX
XX
PR 07-DEC-2000; 2000US-0251954P.
XX
XX
PA (ELIL ) LILLY & CO ELI.
XX
XX
PI Glaesner W, Micanovic R, Tschang SR;
XX
XX
DR WPI; 2003-018534/01.
XX
XX
XX Novel heterologous fusion protein, useful for treating non-insulin
PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
PT 1 compound fused to human albumin or to the Fc portion of an
XX immunoglobulin.
XX
XX Example 6; Page 90; 200pp; English.
XX
XX The invention relates to a heterologous fusion protein comprising a first
CC polypeptide fused to a second polypeptide, where the polypeptides has a N
CC terminus and a C-terminus and the first polypeptide is a glucagon-like
CC peptide 1 (GLP-1) compound and the second is a human albumin or its
CC analogue or fragment, where the Fc portion of an immunoglobulin (Ig) or its
CC analogue or fragment, where the C-terminus of first polypeptide is fused
CC to the N-terminus of the second polypeptide. The invention is useful for
CC normalising blood glucose levels in mammal, for treating a patient with
CC non-insulin diabetes mellitus or obesity, or for the manufacture of
CC medicament for treating the above mentioned diseases. The present
CC sequence is human GLP/exendin peptide analogue
XX
XX Sequence 31 AA;
SQ
AAE30937 Length: 31 February 4, 2005 13:20 Type: P Check: 7369 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGPF
1 28
-----
1 match found in sequence:
aae30938 ; Human GLP/exendin peptide analogue #2.
(from "seq4ags.pep")
TOIG of: aae30938 check: 9570 from: 1 to: 39
ID AAE30938 standard; peptide; 39 AA.
XX
XX AAE30938;
AC
XX
XX 24-FEB-2003 (first entry)
DT
XX
XX Human GLP/exendin peptide analogue #2.
DE
XX
XX Human; glucagon-like peptide 1; GLP-1; albumin; immunoglobulin; Ig;
KW therapy; non-insulin diabetes mellitus; obesity; antidiabetic; anorectic.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
FT
XX
XX WO200246227-A2.
PN
XX
XX 13-JUN-2002.
PD
XX
XX 29-NOV-2001; 2001WO-US043165.
PF
XX
XX
PR 07-DEC-2000; 2000US-0251954P.
XX
XX
PA (ELIL ) LILLY & CO ELI.
XX
XX
PI Glaesner W, Micanovic R, Tschang SR;
XX
XX
DR WPI; 2003-018534/01.
XX
XX
XX Novel heterologous fusion protein, useful for treating non-insulin
PT dependent diabetes mellitus or obesity, comprises a glucagon-like peptide
PT 1 compound fused to human albumin or to the Fc portion of an
XX immunoglobulin.
XX
XX Example 6; Page 90; 200pp; English.
XX
XX The invention relates to a heterologous fusion protein comprising a first
CC polypeptide fused to a second polypeptide, where the polypeptides has a N
CC terminus and a C-terminus and the first polypeptide is a glucagon-like
CC peptide 1 (GLP-1) compound and the second is a human albumin or its
CC analogue or fragment, where the Fc portion of an immunoglobulin (Ig) or its
CC analogue or fragment, where the C-terminus of first polypeptide is fused
CC to the N-terminus of the second polypeptide. The invention is useful for
CC normalising blood glucose levels in mammal, for treating a patient with
CC non-insulin diabetes mellitus or obesity, or for the manufacture of
CC medicament for treating the above mentioned diseases. The present
CC sequence is human GLP/exendin peptide analogue
XX
XX Sequence 39 AA;
SQ
AAE30938 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQMEEEAVRLFIEWLKNKGPPPS
1 28
-----
1 match found in sequence:
aag62439 ; Exendin polypeptide #1.
(from "seq4ags.pep")
TOIG of: aag62439 check: 7617 from: 1 to: 31
ID AAG62439 standard; peptide; 31 AA.
XX
XX AAG62439;
AC
XX
XX 04-SEP-2001 (first entry)
DT
XX
XX Exendin polypeptide #1.
DE
XX
XX Beta cell degeneration; GLP-1; glucagon-like peptide-1; agonist;
KW antiapoptotic; cytostatic; immunosuppressive; neuroprotective; nootropic;
KW anti-HIV; antiparkinsonian; cerebroprotective; antidiabetic; stroke;
KW type 2 diabetes; cancer; immunological disorder; multiple sclerosis;
KW acquired immunodeficiency syndrome; AIDS; neurodegenerative disorder;
KW Alzheimer's disease; Parkinson's disease; exendin.
XX
XX Unidentified.
OS
XX
XX Key Location/Qualifiers
FH Misc-difference 31
FT /label= Pro, Tyr
FT
XX
XX WO200135988-A1.
PN
XX
XX 25-MAY-2001.
PD
XX
XX 10-NOV-2000; 2000WO-DK000625.
PF
XX
XX 12-NOV-1999; 99DK-00001628.
PR
XX
XX 22-FEB-2000; 2000DK-00000270.
PR
XX
XX (NOVO ) NOVO NORDISK AS.
PA
XX
XX Knudsen LB, Godfredsen CF, Petersen JS, Carr RD;
PI

```

```

XX WPI; 2001-329208/34.
XX Treating beta cell degeneration in subjects, particularly humans,
XX involves administering GLP-1 agonists.
XX Disclosure; Page 41; 59pp; English.
XX This invention relates to a method of treating beta cell degeneration
XX through the administration of a GLP-1 (glucagon-like peptide-1) agonist.
XX Use of the method results in antiapoptotic; cytostatic; immunosuppressive
XX ; neuroprotective; neurotropic; anti-HIV (human immunodeficiency virus);
XX antiParkinsonian; cerebroprotective; and antidiabetic activity. The
XX claims refer to the use of a specific GLP-1 analogue Arg34, Lys26(N-
XX epsilon)-Glu(N-alpha-hexadecanoyl))-GLP-1 (7-37). The method is
XX used for the treatment of beta cell degeneration, particularly apoptosis
XX of beta cells. The GLP-1 agonist is used to modulate, inhibit, decrease
XX or prevent beta cell degeneration, loss of beta cell function, beta cell
XX dysfunction and/or death of beta cells, such as necrosis or apoptosis of
XX beta cells, in subjects, preferably mammals, especially humans. The
XX apoptosis is associated with type 2 diabetes, cancer, immunological
XX disorders, multiple sclerosis, acquired immunodeficiency syndrome (AIDS),
XX and neurodegenerative disorders such as Alzheimer's disease, stroke and
XX Parkinson's disease. The present sequence represents an extendin
XX polypeptide, an GLP-1 agonist which can be used in the method of the
XX invention
XX Sequence 31 AA;
AAG62439 Length: 31 February 4, 2005 13:20 Type: P Check: 7617 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMBEEAVRLFIEWLKNGGX
1 28
-----
1 match found in sequence:
aag70462 ; Exendin-4.
(from "seq4ags.pep")
TOIG of: aag70462 check: 9570 from: 1 to: 39
ID AAG70462 standard; peptide; 39 AA.
XX AC AAG70462;
XX DT 13-JUL-2001 (first entry)
XX DE Exendin-4.
XX KW Exendin-1; pituitary adenylate cyclase activating peptide; PACAP;
XX KW antidiabetic; antiasthmatic; hypotensive; cardiant; antiulcer;
XX KW respiratory disease; diabetes; glucose intolerance; asthma;
XX KW male fertility; cardiovascular disease; ulcer; gene therapy;
XX KW PACAP receptor 3; R3; agonist.
XX OS Unidentified.
XX PN WO200123420-A2.
XX PD 05-APR-2001.
XX PF 27-SEP-2000; 2000WO-US026638.
XX PR 28-SEP-1999; 99US-00407832.
XX PR 15-JUN-2000; 2000US-00595280.
XX PA (FARB ) BAYER CORP.
XX PI Pan C, Teutsumi M, Shanafelt AB;
XX DR WPI; 2001-367200/38.
XX

```

```

PT Novel pituitary adenylate cyclase activating peptide receptor 3 agonist
PT useful for treating type 2 diabetes, asthma, hypertension, ulcers and
PT cardiovascular diseases.
XX PS Disclosure; Page 6; 62pp; English.
XX The present sequence is provided in a specification relating to pituitary
XX CC adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonist
XX CC polypeptides. The polypeptides stimulate insulin release from pancreatic
XX CC beta cells. They are useful for treating metabolic disorders such as type
XX CC 2 diabetes and the pre-diabetic state of impaired glucose tolerance. They
XX CC are useful for treating respiratory diseases and for stimulating insulin
XX CC release in a glucose-dependent manner. The R3 agonists are useful for
XX CC treating and/or preventing diseases and conditions such as diabetes,
XX CC asthma, hypertension, male reproduction problems including human sperm
XX CC motility, cardiovascular diseases and ulcers. They are useful in gene
XX CC therapy
XX SQ Sequence 39 AA;
AAG70462 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMBEEAVRLFIEWLKNGGSPSSGAPPS
1 28
-----
1 match found in sequence:
aao19591 ; Gila monster exendin 3.
(from "seq4ags.pep")
TOIG of: aao19591 check: 9591 from: 1 to: 39
ID AAO19591 standard; peptide; 39 AA.
XX AC AAO19591;
XX DT 23-OCT-2003 (revised)
XX DT 13-FEB-2003 (first entry)
XX DE Gila monster exendin 3.
XX KW Gila monster; glucagon-like peptide-1; insulin resistance; diabetes;
XX KW atherosclerotic cardiovascular disease; congestive heart failure; GLP-1;
XX KW antidiabetic; antiarteriosclerotic; cardiant.
XX OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 39 /note= "C-terminal amide"
XX PN WO200285406-A1.
XX PD 31-OCT-2002.
XX PF 24-APR-2002; 2002WO-US013088.
XX PR 24-APR-2001; 2001US-0285699P.
XX PA (REST-) RESTORAGEN INC.
XX PI Holst JJ, Olsen MZ, Hathaway DR;
XX DR WPI; 2003-046959/04.
XX PT Treatment of insulin resistance-associated conditions, e.g. type-2 pre-
XX PT diabetes, ASCD, drug-induced insulin resistance, congestive heart failure
XX PT or diminished exercise capacity, comprises administration of GLP-1.
XX PS Disclosure; Page 15; 60pp; English.
XX CC The present invention relates to a method of treating insulin resistance-

```

CC associated conditions comprising administration of glucagon-like peptide-1 (GLP-1). The method is useful for treating insulin resistance-
 CC associated conditions, especially type-2 pre-diabetes, atherosclerotic
 CC cardiovascular diseases (ASCD), drug-induced insulin resistance
 CC (especially glucocorticoid- or growth hormone-induced), congestive heart
 CC failure (not associated with toxic hypervolemia), diminished exercise
 CC capacity of skeletal muscle and left ventricular dysfunction with cardiac
 CC metabolic myopathy or diminished exercise capacity of skeletal muscle.
 CC The present sequence is an extendin protein from the Gila monster.
 CC (Updated on 23-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 39 AA;

AAO19591 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGTFSDLKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
 1
 28

1 match found in sequence:

aaol19593 ; Gila monster extendin 4.
 (from "seq4ags.pep")
 TOIG of: aaol19593 check: 9570 from: 1 to: 39

ID AAO19593 standard; peptide; 39 AA.

XX AC AAO19593;

DT 23-OCT-2003 (revised)
 DT 13-FEB-2003 (first entry)

DE Gila monster extendin 4.

XX Gila monster; glucagon-like peptide-1; insulin resistance; diabetes;
 KW atherosclerotic cardiovascular disease; congestive heart failure; GLP-1;
 KW antidiabetic; antiarteriosclerotic; cardiant.

OS Heloderma suspectum.

FH Key Location/Qualifiers
 FT Modified-site 39

FT /note= "C-terminal amide"

PN WO200285406-A1.

XX PD 31-OCT-2002.

XX PF 24-APR-2002; 2002WO-US013088.

XX PR 24-APR-2001; 2001US-0285699P.

XX PA (REST-) RESTORAGEN INC.

XX PI Holst JJ, Olsen MZ, Hathaway DR;

XX DR WPI; 2003-046959/04.

XX Treatment of insulin resistance-associated conditions, e.g. type-2 pre-
 PT diabetes, ASCD, drug-induced insulin resistance, congestive heart failure
 PT or diminished exercise capacity, comprises administration of GLP-1.

XX PS Disclosure; Page 15; 60pp; English.

XX The present invention relates to a method of treating insulin resistance-
 CC associated conditions comprising administration of glucagon-like peptide-
 CC 1 (GLP-1). The method is useful for treating insulin resistance-
 CC associated conditions, especially type-2 pre-diabetes, atherosclerotic
 CC cardiovascular diseases (ASCD), drug-induced insulin resistance
 CC (especially glucocorticoid- or growth hormone-induced), congestive heart
 CC failure (not associated with toxic hypervolemia), diminished exercise
 CC capacity of skeletal muscle and left ventricular dysfunction with cardiac

CC metabolic myopathy or diminished exercise capacity of skeletal muscle.
 CC The present sequence is an extendin protein from the Gila monster.
 CC (Updated on 23-OCT-2003 to standardise OS field)
 XX
 SQ Sequence 39 AA;

AAO19593 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGTFSDLKQMEEEAVRLFIEWLKNGGPGSSGAPPPS
 1
 28

1 match found in sequence:

aaR80543 ; Heloderma suspectum extendin-4 residues 1-31 (Extendin-4(1-31)).
 (from "seq4ags.pep")
 TOIG of: aaR80543 check: 7369 from: 1 to: 31

ID AAR80543 standard; peptide; 31 AA.

XX AC AAR80543;

XX DT 27-FEB-1996 (first entry)

XX DE Heloderma suspectum extendin-4 residues 1-31 (Extendin-4(1-31)).
 XX Extendin-4; residues 1-31; Extendin-4(1-31); diabetes mellitus;
 KW hyperglycaemia; insulinotropic peptide.

XX OS Heloderma suspectum.

XX PN US5424286-A.

XX PD 13-JUN-1995.

XX PF 24-MAY-1993; 93US-00066480.

XX PR 24-MAY-1993; 93US-00066480.

XX PA (ENGJ/) ENG J.

XX PI Eng J;

XX WPI; 1995-262627/34.

XX Stimulating/inhibiting insulin release with extendin polypeptide(s) - for
 PT treating diabetes mellitus and preventing hyperglycaemia.

XX PS Claim 1; Col 13-14; 17pp; English.

XX AAR80543 is the Heloderma suspectum extendin-4 residues 1-31. It is an
 CC insulinotropic peptide, and can therefore be used in the treatment of
 CC diabetes mellitus (types I or II), and for the prevention of
 CC hyperglycaemia. It normalises hyperglycaemia through glucose-dependent
 CC and insulin-(in)dependent mechanisms

XX SQ Sequence 31 AA;

AAR80543 Length: 31 February 4, 2005 13:19 Type: P Check: 7369 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGTFSDLKQMEEEAVRLFIEWLKNGGP
 1
 28

1 match found in sequence:

aaR80544 ; Heloderma suspectum extendin-4 residues 1-31-Tyr31.
 (from "seq4ags.pep")
 TOIG of: aaR80544 check: 7648 from: 1 to: 31

ID AAR80544 standard; peptide; 31 AA.


```
1 HGGFTFTDLSKQMEEEAVRLFIEWLKNGSPSGAPPPS
1 -----|-----|
1 HGGFTFTDLSKQMEEEAVRLFIEWLKNGSPSGAPPPS
28
-----
1 match found in sequence:
au05785 ; Insulin release stimulating polypeptide, extendin.
(from "seq4ags.pep")
TOIG of: au05785 Check: 7617 from: 1 to: 31

ID AU05785 standard; peptide; 31 AA.
XX
XX AC AU05785;
XX
XX DT 24-OCT-2001 (first entry)
XX
XX DE Insulin release stimulating polypeptide, extendin.
XX
XX KW Insulin release; extendin; GLP-1; diabetes type I; diabetes type II;
XX obesity; gastric ulcers; gastric acid secretion; apoptosis; antidiabetic;
XX anorectic; antiulcer.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Misc-difference 31
XX FT /label= Pro, Tyr
XX
XX PN WO200151071-A2.
XX
XX PD 19-JUL-2001.
XX
XX PF 11-JAN-2001; 2001WO-DK000015.
XX
XX PR 11-JAN-2000; 2000DK-00000030.
XX
XX PA (NOVO ) NOVO NORDISK AS.
XX
XX PI Anderson K, Agerso H;
XX
XX DR WPI; 2001-502577/55.
XX
XX PT New pulmonary liquid or dry formulation comprises a GLP-1 compound to
XX which a lipophilic substituent is attached, optionally via a spacer,
XX useful in a pulmonary delivery device.
XX
XX PS Disclosure; Page 6; 30pp; English.
XX
XX CC The invention relates to a new pulmonary liquid or dry formulation
XX comprises a GLP-1 compound to which a lipophilic substituent is attached,
XX optionally via a spacer. The formulation is useful in a pulmonary
XX delivery device. The formulation is useful for reducing blood glucose
XX levels, treating diabetes type I, diabetes type II, obesity and gastric
XX ulcers, and inhibiting gastric acid secretion and apoptosis of beta-
XX cells. The present sequence is an extendin peptide, derivatives of which
XX can be used as a spacer peptide with GLP-1
XX
XX SQ Sequence 31 AA;
XX
XX AU05785 Length: 31 February 4, 2005 13:20 Type: P Check: 7617 ..
XX Found using 'seq4' (mohamed337.key)
XX
1 HGGFTFTDLSKQMEEEAVRLFIEWLKNGGX
1 -----|-----|
1 HGGFTFTDLSKQMEEEAVRLFIEWLKNGGX
28
-----
1 match found in sequence:
au07291 ; Extendin polypeptide fragment #1.
(from "seq4ags.pep")
TOIG of: au07291 Check: 7617 from: 1 to: 31

ID AU07291 standard; peptide; 31 AA.
XX
XX AC AU07291;
XX
XX DT 24-OCT-2001 (first entry)
XX
XX DE Extendin polypeptide fragment #1.
XX
XX KW Extendin; glucagon-like peptide-1; GLP-1; crystallisation;
XX diabetes mellitus; hyperglycaemia; therapeutic.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Misc-difference 31
XX FT /label= Pro, Tyr
XX
XX PN WO200157084-A1.
XX
XX PD 09-AUG-2001.
XX
XX PF 31-JAN-2001; 2001WO-DK000067.
XX
XX PR 31-JAN-2000; 2000DK-00000156.
XX
XX PA (NOVO ) NOVO NORDISK AS.
XX
XX PI Arentsen AC;
XX
XX DR WPI; 2001-514598/56.
XX
XX PT Producing crystals of glucagon-like peptide-1 analog for preparing the
XX pharmaceutical composition, by preparing aqueous solution comprising the
XX analog, salt and organic solvent, and isolating crystals after formation.
XX
XX PS Disclosure; Page 18; 33pp; English.
XX
XX CC The invention relates to a method of producing crystals of a glucagon-
XX like peptide-1 (GLP-1) analogue or producing a GLP-1 analogue or a GLP-1
XX analogue attached to a lipophilic substituent, which involves preparing
XX an aqueous solution comprising a GLP-1 analogue, a salt, and an organic
XX solvent, and isolating the crystals after formation. The method is useful
XX for producing crystals of a GLP-1 or for producing a GLP-1 analogue
XX attached to a lipophilic substituent. These are useful for preparing a
XX pharmaceutical composition such as an injectable drug, and as an
XX intermediate product in the manufacturing process for preparing GLP-1
XX analogue, and for preparing a mono-acylated GLP-1 analogue. The
XX implementation of a crystallisation step in the manufacturing process for
XX the preparation of a GLP-1 analogue results in removal of coloured
XX compounds from the fermentation broth, reduction of yeast host cell
XX proteins, such as Saccharomyces cerevisiae proteins as well as removal of
XX water, and low loss of the GLP-1 analogue from the mother liquor. The
XX present sequence represents the amino acid sequence of extendin
XX polypeptide fragment #1. a GLP-1 analogue used to treat diabetes mellitus
XX types I or II and prevention of hyperglycaemia
XX
XX SQ Sequence 31 AA;
XX
XX AU07291 Length: 31 February 4, 2005 13:19 Type: P Check: 7617 ..
XX Found using 'seq4' (mohamed337.key)
XX
1 HGGFTFTDLSKQMEEEAVRLFIEWLKNGGX
1 -----|-----|
1 HGGFTFTDLSKQMEEEAVRLFIEWLKNGGX
28
-----
1 match found in sequence:
au07378 ; Glucagon-like peptide-1 (GLP-1) homologue, extendin 3.
(from "seq4ags.pep")
TOIG of: au07378 Check: 9591 from: 1 to: 39

ID AU07378 standard; peptide; 39 AA.
XX
```

```

AC AAU07378;
XX
XX 18-DEC-2001 (first entry)
XX
XX Glucagon-like peptide-1 (GLP-1) homologue, extendin 3.
XX
XX Antidiarrhoeic; antiinflammatory; antiaddictive; premedication;
KW antro-duodenal motility; glucagon-like peptide-1; GLP-1; endoscopy;
KW diarrhoea; post-operative dumping syndrome; irritable bowel syndrome;
KW narcotics withdrawal; extendin 3.
XX
XX Homo sapiens.
XX
XX WO2000168112-A2.
XX
XX 20-SEP-2001.
XX
XX 14-MAR-2001; 2001WO-EP002882.
XX
XX 14-MAR-2000; 2000US-0189091P.
XX
XX (GOEK/) GOEKE B.
XX (SCHI/) SCHIRRA J.
XX
XX Goeke B, Schirra J;
XX
XX WPI; 2001-596887/67.
XX
XX Inhibiting antro-duodenal motility, useful to prevent or treat
XX gastrointestinal disorders such as irritable bowel syndrome and non-
XX infectious diarrhea, comprises administering glucagon-like peptide.
XX
XX Disclosure; Page 13; 43pp; English.
XX
XX The invention relates to a method of inhibiting antro-duodenal motility
XX in a patient, comprising administering a glucagon-like peptide (GLP-1)
XX molecule. The method is used to premedicate or in endoscopic procedures
XX or to treat or prevent non-infectious acute and chronic diarrhoea, post-
XX operative dumping syndrome, irritable bowel syndrome or symptoms
XX associated with narcotics withdrawal. Unlike prior art treatment with
XX glucagon, the invention is not contraindicated in persons with diabetes,
XX does not incur the risks of side effects such as nausea, and is not
XX expensive. The present sequence represents mammalian glucagon-like
XX peptide-1, (GLP-1) homologue, extendin 3 as described in the method of the
XX invention
XX
XX Sequence 39 AA;
XX
AAU07378 Length: 39 February 4, 2005 13:19 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  |HSDGFTSDLSKQMEAEAVRLFIEWLKNKGPPSSGAPPPS
  1 28

-----
1 match found in sequence:
aau07378 : Glucagon-like peptide-1 (GLP-1) homologue, extendin 4.
(from "seq4ags.pep")
TOIG of: aau07380 check: 9570 from: 1 to: 39

ID AAU07380 standard; peptide; 39 AA.
XX
XX AAU07380;
XX
XX 18-DEC-2001 (first entry)
XX
XX Glucagon-like peptide-1 (GLP-1) homologue, extendin 4.
XX
XX Antidiarrhoeic; antiinflammatory; antiaddictive; premedication;
KW antro-duodenal motility; glucagon-like peptide-1; GLP-1; endoscopy;
KW diarrhoea; post-operative dumping syndrome; irritable bowel syndrome;
KW narcotics withdrawal; extendin 4.
XX

```

```

XX Homo sapiens.
XX
XX WO2000168112-A2.
XX
XX 20-SEP-2001.
XX
XX 14-MAR-2001; 2001WO-EP002882.
XX
XX 14-MAR-2000; 2000US-0189091P.
XX
XX (GOEK/) GOEKE B.
XX (SCHI/) SCHIRRA J.
XX
XX Goeke B, Schirra J;
XX
XX WPI; 2001-596887/67.
XX
XX Inhibiting antro-duodenal motility, useful to prevent or treat
XX gastrointestinal disorders such as irritable bowel syndrome and non-
XX infectious diarrhea, comprises administering glucagon-like peptide.
XX
XX Disclosure; Page 13; 43pp; English.
XX
XX The invention relates to a method of inhibiting antro-duodenal motility
XX in a patient, comprising administering a glucagon-like peptide (GLP-1)
XX molecule. The method is used to premedicate or in endoscopic procedures
XX or to treat or prevent non-infectious acute and chronic diarrhoea, post-
XX operative dumping syndrome, irritable bowel syndrome or symptoms
XX associated with narcotics withdrawal. Unlike prior art treatment with
XX glucagon, the invention is not contraindicated in persons with diabetes,
XX does not incur the risks of side effects such as nausea, and is not
XX expensive. The present sequence represents mammalian glucagon-like
XX peptide-1, (GLP-1) homologue, extendin 4 as described in the method of the
XX invention
XX
XX Sequence 39 AA;
XX
AAU07380 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  |HSGFTSDLSKQMEAEAVRLFIEWLKNKGPPSSGAPPPS
  1 28

-----
1 match found in sequence:
aau08763 : Human extendin degenerate peptide fragment.
(from "seq4ags.pep")
TOIG of: aau08763 check: 7617 from: 1 to: 31

ID AAU08763 standard; peptide; 31 AA.
XX
XX AAU08763;
XX
XX 16-JAN-2002 (first entry)
XX
XX Human extendin degenerate peptide fragment.
XX
XX Human; glucagon-like peptide 1; GLP-1; serum lipid; triglyceride; plasma;
KW low density lipoprotein; high density lipoprotein; cholesterol; stroke;
KW fatty acid; plasma; apolipoprotein; dyslipidaemia; fatty acid; artery;
KW cerebrovascular disease; cardiovascular disease; aneurysm; surgery;
KW bypass graft stenosis; diabetes mellitus; anticoagulative treatment;
KW coronary thrombosis; antilipaseic; cardiant; cerebroprotective; extendin;
KW antidiabetic; antiarteriosclerotic; vasotropic; nootropic; antianginal.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX Misc-difference 31 /label= Pro, Tyr
XX

```

PN WO200166135-A1.
 XX 13-SEP-2001.
 PD
 XX
 XX 08-MAR-2001; 2001WO-DK000150.
 PF
 XX 08-MAR-2000; 2000DK-00000375.
 PR
 XX (NOVO) NOVO NORDISK AS.
 PA
 XX Knudsen LB, Selmer J, Sturis J, Larsen PJ;
 PI WPI; 2001-602602/68.
 DR
 XX
 XX Use of glucagon-like peptide-1 agonist for manufacturing a medicament for
 PT lowering total serum lipids e.g. low density lipoproteins and
 PT cholesterol.
 XX
 XX Disclosure; Page 40; 52pp; English.
 PS
 XX The invention relates to a medicament for lowering serum lipids,
 CC comprising a glucagon-like peptide 1 (GLP-1) agonist. The GLP-1 agonist
 CC is used for lowering total serum lipids such as low density lipoproteins
 CC particularly small, dense lipoproteins, triglycerides, cholesterol and
 CC non-esterified fatty acids, for increasing high density lipoproteins, for
 CC lowering plasma levels of lipoprotein, for inhibiting generation of
 CC apolipoprotein, for treating dyslipidaemia in humans and also for
 CC lowering fatty acids, such as free fatty acids and non-esterified fatty
 CC acids. The medicament is also useful for treating cerebrovascular
 CC diseases and cardiovascular diseases such as stroke, cerebral
 CC haemorrhage, coronary heart disease, coronary artery disease, diabetic
 CC vasculopathy, atherosclerosis, peripheral atherosclerosis,
 CC arteriosclerosis, myocardial infarction, ischaemic heart disease,
 CC restenosis, peripheral artery disease, angina pectoris, intermittent
 CC claudication, aneurysms of aorta and other large arteries, bypass graft
 CC stenosis and diabetes mellitus. The peptides may also be used in
 CC anticoagulative treatment e.g. following a coronary thrombosis or after
 CC surgery. This sequence represents a fragment of a degenerate extendin
 CC polypeptide, a GLP-1 agonist
 XX
 XX Sequence 31 AA;
 SQ
 AAU08763 Length: 31 February 4, 2005 13:19 Type: P Check: 7617 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGCTFTSLSKQMEEEAVRLFIWLNKXG 28
 1

 1 match found in sequence:
 aaw39301; H. horridum extendin-3 peptide.
 (from "seq4ags.pep")
 TOIG of: aaw39301 Check: 5420 from: 1 to: 30
 ID AAW39301 standard; peptide; 30 AA.
 XX
 AC AAW39301;
 AC
 XX 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 DT
 XX H. horridum extendin-3 peptide.
 DE
 XX
 XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 KW
 XX Heloderma horridum.
 OS
 XX Key Location/Qualifiers
 FH Modified-site 30
 FT /note= "This residue can be any amino acid except Gly"
 FT
 XX WO9746584-A1.
 PN
 XX 11-DEC-1997.
 PD
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 PF
 XX 05-JUN-1996; 96DE-01022502.
 PR
 XX 13-SEP-1996; 96DE-01037230.
 PR
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 PA
 XX Hoffmann E, Goeke R, Goeke B;
 PI WPI; 1998-042119/04.
 DR
 XX Truncated versions of extendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 PT
 XX Claim 1; Page 3; 150pp; English.
 PS
 XX This peptide is a fragment of extendin-3 isolated from Heloderma horridum.
 CC This peptide and its salts, esters and derivatives can be used to treat
 CC diabetes mellitus. They stimulate biosynthesis and secretion of insulin,
 CC but have the opposite effect on glucagon, and independent of this
 CC activity can increase peripheral glucose utilisation. Extendin-3 and
 CC extendin-4 are only active when blood sugar levels are high, so they will
 CC not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1)
 CC and the known extendins, they are more active (effective at lower doses),
 CC more stable to degradation and metabolism and have a longer lasting
 CC effect. Truncated forms of this peptide can be made more economically
 CC than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
 CC
 XX Sequence 30 AA;
 SQ
 AAW39301 Length: 30 February 4, 2005 13:19 Type: P Check: 5420 ..
 Found using 'seq4' (mohamed337.key)
 1 HSDGTFTSLSKQMEEEAVRLFIWLNKXG 28
 1

 1 match found in sequence:
 aaw39302; H. horridum extendin-4 peptide.
 (from "seq4ags.pep")
 TOIG of: aaw39302 Check: 5399 from: 1 to: 30
 ID AAW39302 standard; peptide; 30 AA.
 XX
 AC AAW39302;
 AC
 XX 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 DT
 XX H. horridum extendin-4 peptide.
 DE
 XX
 XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 KW
 XX Heloderma horridum.
 OS
 XX Key Location/Qualifiers
 FH Modified-site 30
 FT /note= "This residue can be any amino acid except Gly"
 FT
 XX WO9746584-A1.
 PN
 XX 11-DEC-1997.
 PD
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 PF
 XX 05-JUN-1996; 96DE-01022502.
 PR
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 PA
 XX Hoffmann E, Goeke R, Goeke B;
 PI WPI; 1998-042119/04.
 DR
 XX Truncated versions of extendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 PT
 XX Claim 1; Page 3; 150pp; English.
 PS
 XX This peptide is a fragment of extendin-3 isolated from Heloderma horridum.
 CC This peptide and its salts, esters and derivatives can be used to treat
 CC diabetes mellitus. They stimulate biosynthesis and secretion of insulin,
 CC but have the opposite effect on glucagon, and independent of this
 CC activity can increase peripheral glucose utilisation. Extendin-3 and
 CC extendin-4 are only active when blood sugar levels are high, so they will
 CC not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1)
 CC and the known extendins, they are more active (effective at lower doses),
 CC more stable to degradation and metabolism and have a longer lasting
 CC effect. Truncated forms of this peptide can be made more economically
 CC than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
 CC
 XX Sequence 30 AA;
 SQ

```

PR 13-SEP-1996; 96DE-01037230.
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 1; Page 4; 150pp; English.
XX
XX This peptide is a fragment of exendin-4 isolated from Heloderma horridum.
XX This peptide and its salts, esters and derivatives can be used to treat
XX diabetes mellitus. They stimulate biosynthesis and secretion of insulin,
XX but have the opposite effect on glucagon, and independent of this
XX activity can increase peripheral glucose utilisation. Exendin-3 and
XX exendin-4 are only active when blood sugar levels are high, so they will
XX not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1)
XX and the known exendins, they are more active (effective at lower doses),
XX more stable to degradation and metabolism and have a longer lasting
XX effect. Truncated forms of this peptide can be made more economically
XX than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39302 Length: 30 February 4, 2005 13:19 Type: P Check: 5399
Found using 'seq4' (mohamed337.key)
1
1 HGEFTFSDLSKQXEEAVRLFIEWLKNGX
28
-----
1 match found in sequence:
aaw39303 ; H. horridum exendin-4 peptide derivative #1.
(from "seq4ags.pep")
TOIG of: aaw39303 check: 5373 from: 1 to: 30
ID AAW39303 standard; peptide; 30 AA.
XX
XX AAW39303;
AC
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #1.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 14 /label= Nle
FT Modified-site 30 /note= "Norleucine"
FT Modified-site 30 /note= "C-terminal amide"
XX
XX WO9746584-A1.
PN
XX
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 1; Page 4; 150pp; English.
XX
XX This peptide is a fragment of exendin-4 isolated from Heloderma horridum.
XX This peptide and its salts, esters and derivatives can be used to treat
XX diabetes mellitus. They stimulate biosynthesis and secretion of insulin,
XX but have the opposite effect on glucagon, and independent of this
XX activity can increase peripheral glucose utilisation. Exendin-3 and
XX exendin-4 are only active when blood sugar levels are high, so they will
XX not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1)
XX and the known exendins, they are more active (effective at lower doses),
XX more stable to degradation and metabolism and have a longer lasting
XX effect. Truncated forms of this peptide can be made more economically
XX than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39303 Length: 30 February 4, 2005 13:19 Type: P Check: 5373
Found using 'seq4' (mohamed337.key)
1
1 HGEFTFSDLSKQXEEAVRLFIEWLKNGR
28
-----
1 match found in sequence:
aaw39304 ; H. horridum exendin-4 peptide derivative #2.
(from "seq4ags.pep")
TOIG of: aaw39304 check: 5583 from: 1 to: 30
ID AAW39304 standard; peptide; 30 AA.
XX
XX AAW39304;
AC
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #2.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 14 /label= Nle
FT Modified-site 30 /note= "Norleucine"
FT Modified-site 30 /note= "C-terminal amide"
XX
XX WO9746584-A1.
PN
XX
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX

```

```

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX Claim 2; Page 20; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX Sequence 30 AA;
SQ

AAW39304 Length: 30 February 4, 2005 13:19 Type: P Check: 5583 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQXEEAVRLFIWLNKG 28
-----
1 match found in sequence:
aaw39305 ; H. horridum exendin-3 peptide derivative #1.
(from "seq4ags.pep")
TOIG of: aaw39305 Check: 5394 from: 1 to: 30

ID AAW39305 standard; peptide; 30 AA.
XX
XX AAW39305;
AC
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-3 peptide derivative #1.
DE
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
OS
XX Key Location/Qualifiers
PH Modified-site 14 /label= Nle
FT /note= "Norleucine"
FT Modified-site 30 /note= "C-terminal amide"
FT
XX WO9746584-A1.
XX
XX 11-DEC-1997.
PD
XX 05-JUN-1997; 97WO-EP002930.
PF
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
PA
XX Hoffmann E, Goeke R, Goeke B;
PI
XX WPI; 1998-042119/04.
DR
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and

```

```

PT do not induce hypoglycaemia.
XX Claim 2; Page 20; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX Sequence 30 AA;
SQ

AAW39305 Length: 30 February 4, 2005 13:19 Type: P Check: 5394 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQXEEAVRLFIWLNKGR 28
-----
1 match found in sequence:
aaw39306 ; H. horridum exendin-4 peptide derivative #3.
(from "seq4ags.pep")
TOIG of: aaw39306 Check: 5373 from: 1 to: 30

ID AAW39306 standard; peptide; 30 AA.
XX
XX AAW39306;
AC
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #3.
DE
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
OS
XX Key Location/Qualifiers
PH Modified-site 30 /note= "C-terminal amide"
FT
XX WO9746584-A1.
XX
XX 11-DEC-1997.
PD
XX 05-JUN-1997; 97WO-EP002930.
PF
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
PA
XX Hoffmann E, Goeke R, Goeke B;
PI
XX WPI; 1998-042119/04.
DR
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX Claim 2; Page 21; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the

```

CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39306 Length: 30 February 4, 2005 13:19 Type: P Check: 5373 ..
 Found using 'seq4' (mohamed337.key)

1 HGGCTFTSDLSKQEEAEVRLFIWLKNGR
 28

 1 match found in sequence:
 aaw39308 ; H. horridum exendin-4 peptide derivative #5.
 (from "seq4ags.pep")

TOIG of: aaw39308 check: 4988 from: 1 to: 30

ID AAW39308 standard; peptide; 30 AA.

XX AAW39308;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum exendin-4 peptide derivative #5.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

FT WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-BP002930.

XX 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 22; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective

CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39308 Length: 30 February 4, 2005 13:19 Type: P Check: 4988 ..
 Found using 'seq4' (mohamed337.key)

1 HGGCTFTSDLSKQEEAEVRLFIWLKNGR
 28

 1 match found in sequence:
 aaw39309 ; H. horridum exendin-4 peptide derivative #6.
 (from "seq4ags.pep")

TOIG of: aaw39309 check: 4855 from: 1 to: 30

ID AAW39309 standard; peptide; 30 AA.

XX AAW39309;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum exendin-4 peptide derivative #6.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

FT WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-BP002930.

PR 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 22; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX

SQ Sequence 30 AA;

```
AAW39309 Length: 30 February 4, 2005 13:19 Type: P Check: 4855
Found using 'seq4' (mohamed337.key)
-----
1 HEGTFTSDLSKQMEEEAVRLFIEWLKAGR
1
-----
1 match found in sequence:
aaw39310 ; H. horridum exendin-4 peptide derivative #7.
(from "seq4ags.pep")
TOIG of: aaw39310 check: 4624 from: 1 to: 30

ID AAW39310 standard; peptide; 30 AA.
XX
AC AAW39310;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #7.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT
XX
XX WO9746584-A1.
PN
XX
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EP002930.
PF
XX
XX 05-JUN-1996; 96DE-01022502.
PR
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF) BOEHRINGER MANNHEIM GMBH.
PA
XX
XX Hoffmann E, Goeke R, Goeke B;
PI
XX
XX WPI; 1998-042119/04.
PS
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 23; 150pp; English.
PS
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ

AAW39310 Length: 30 February 4, 2005 13:19 Type: P Check: 4624
Found using 'seq4' (mohamed337.key)
-----
1 HEGTFTSDLSKQMEEEAVRLFIEWLKAGR
1
-----
1 match found in sequence:
aaw39312 ; H. horridum exendin-4 peptide derivative #9.
(from "seq4ags.pep")
```

28

1

```
-----
1 match found in sequence:
aaw39311 ; H. horridum exendin-4 peptide derivative #8.
(from "seq4ags.pep")
TOIG of: aaw39311 check: 5051 from: 1 to: 30

ID AAW39311 standard; peptide; 30 AA.
XX
AC AAW39311;
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #8.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal OH group"
FT
XX
XX WO9746584-A1.
PN
XX
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EP002930.
PF
XX
XX 05-JUN-1996; 96DE-01022502.
PR
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF) BOEHRINGER MANNHEIM GMBH.
PA
XX
XX Hoffmann E, Goeke R, Goeke B;
PI
XX
XX WPI; 1998-042119/04.
PS
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 24; 150pp; English.
PS
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
XX Sequence 30 AA;
SQ

AAW39311 Length: 30 February 4, 2005 13:19 Type: P Check: 5051
Found using 'seq4' (mohamed337.key)
-----
1 HEGTFTSDLSKQMEEEAVRLFIEWLKAGR
1
-----
1 match found in sequence:
aaw39312 ; H. horridum exendin-4 peptide derivative #9.
(from "seq4ags.pep")
```

```
TOIG of: aaw39312  check: 5163  from: 1  to: 30
ID AAW39312 standard; peptide; 30 AA.
XX AC AAW39312;
XX AC
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX H. horridum exendin-4 peptide derivative #9.
XX DE
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX XX
XX FH Key Location/Qualifiers
FT Modified-site 1
FT Modified-site 1 /note= "N-terminal acetylated"
FT Modified-site 30
FT Modified-site 30 /note= "C-terminal OH group"
XX XX
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PF 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX XX
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 24; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
XX
AAW39312 Length: 30 February 4, 2005 13:19 Type: P Check: 5163
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQIEEAVRLFIWLNKGR
1 28
-----
1 match found in sequence:
aaw39314 ; H. horridum exendin-3 peptide derivative #2.
(from "seq4ags.pep")
TOIG of: aaw39314  check: 4898  from: 1  to: 30
ID AAW39314 standard; peptide; 30 AA.
XX AC AAW39314;
XX AC
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX H. horridum exendin-3 peptide derivative #2.
XX DE
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX XX
XX FH Key Location/Qualifiers
FT Modified-site 30
FT Modified-site 30 /note= "C-terminal amide"
XX XX
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PF 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX XX
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 24; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
XX
AAW39314 Length: 30 February 4, 2005 13:19 Type: P Check: 4898
Found using 'seq4' (mohamed337.key)
1 HSDGFTFTSLSKQIEEAVRLFIWLNKGR
1 28
-----
1 match found in sequence:
aaw39315 ; H. horridum exendin-3 peptide derivative #3.
(from "seq4ags.pep")
TOIG of: aaw39315  check: 4802  from: 1  to: 30
ID AAW39315 standard; peptide; 30 AA.
XX AC AAW39315;
XX AC
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX H. horridum exendin-3 peptide derivative #3.
```

```

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX WO9746584-A1.
XX 11-DEC-1997.
XX 05-JUN-1997; 97WO-EP002930.
XX 05-JUN-1996; 96DE-01022502.
XX 13-SEP-1996; 96DE-01037230.
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX Claim 2; Page 24; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX Sequence 30 AA;
AAW39315 Length: 30 February 4, 2005 13:19 Type: P Check: 4802
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HSDGFTSLSKQAEAEAVRLFIEWLANGR 28
-----
1 match found in sequence:
aaw39316 ; H. horridum exendin-3 peptide derivative #4.
(from "seq4ags.pep")
TOIG of: aaw39316 check: 4786 from: 1 to: 30
ID AAW39316 standard; peptide; 30 AA.
XX AC AAW39316;
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX H. horridum exendin-3 peptide derivative #4.
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX Key Location/Qualifiers
FT Modified-site 14
FT /label= Nle
FT /note= "norleucine"
FT Modified-site 30
FT /note= "C-terminal amide"

```

```

PH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX WO9746584-A1.
XX 11-DEC-1997.
XX 05-JUN-1997; 97WO-EP002930.
XX 05-JUN-1996; 96DE-01022502.
XX 13-SEP-1996; 96DE-01037230.
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX Claim 2; Page 24; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX Sequence 30 AA;
AAW39316 Length: 30 February 4, 2005 13:19 Type: P Check: 4786
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HSDGFTSLSKQAEAEAVRLFIEWKNGR 28
-----
1 match found in sequence:
aaw39317 ; H. horridum exendin-4 peptide derivative #11.
(from "seq4ags.pep")
TOIG of: aaw39317 check: 5361 from: 1 to: 30
ID AAW39317 standard; peptide; 30 AA.
XX AC AAW39317;
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX H. horridum exendin-4 peptide derivative #11.
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX Key Location/Qualifiers
FT Modified-site 14
FT /label= Nle
FT /note= "norleucine"
FT Modified-site 30
FT /note= "C-terminal amide"

```

```

XX PN WO9746584-A1.
XX XX
XX PD 11-DEC-1997.
XX XX
XX PF 05-JUN-1997; 97WO-EP002930.
XX XX
XX PR 05-JUN-1996; 96DE-01022502.
XX XX
XX PR 13-SEP-1996; 96DE-01037230.
XX XX
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX XX
XX PI Hoffmann E, Goeke R, Goeke B;
XX XX
XX DR WPI; 1998-042119/04.
XX XX
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS Claim 2; Page 24; 150pp; English.
XX XX
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39317 Length: 30 February 4, 2005 13:19 Type: P Check: 5361 ..
Found using 'seq4' (mohamed337.key)

1 HAEFTTSDLSKQXEEBAVRLFIWLNKGR
1 |-----|
1 HAEFTTSDLSKQXEEBAVRLFIWLNKGR
28

-----
1 match found in sequence:
aaw39331 ; H. horridum exendin-4 peptide derivative #25.
(from "seq4ags.pep")
TOIG of: aaw39331 check: 5397 from: 1 to: 30

ID AAW39331 standard; peptide; 30 AA.
XX XX
XX AC AAW39331;
XX XX
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX XX
XX DE H. horridum exendin-4 peptide derivative #25.
XX XX
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 14 /label= Nle
XX FT /note= "norleucine"
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN WO9746584-A1.
XX XX
XX PD 11-DEC-1997.
XX XX
XX PF 05-JUN-1997; 97WO-EP002930.
XX XX
XX PR 05-JUN-1996; 96DE-01022502.
XX XX
XX PR 13-SEP-1996; 96DE-01037230.
XX XX
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX XX
XX PI Hoffmann E, Goeke R, Goeke B;
XX XX
XX DR WPI; 1998-042119/04.
XX XX
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS Claim 2; Page 24; 150pp; English.
XX XX
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39331 Length: 30 February 4, 2005 13:19 Type: P Check: 5397 ..
Found using 'seq4' (mohamed337.key)

1 HSEGFTTSDLSKQXEEBAVRLFIWLNKGR
1 |-----|
1 HSEGFTTSDLSKQXEEBAVRLFIWLNKGR
28

-----
1 match found in sequence:
aaw39332 ; H. horridum exendin-4 peptide derivative #26.
(from "seq4ags.pep")
TOIG of: aaw39332 check: 5399 from: 1 to: 30

ID AAW39332 standard; peptide; 30 AA.
XX XX
XX AC AAW39332;
XX XX
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX XX
XX DE H. horridum exendin-4 peptide derivative #26.
XX XX
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX XX
XX FH Key Location/Qualifiers
XX FT Modified-site 14 /label= Nle
XX FT /note= "norleucine"
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN WO9746584-A1.
XX XX
XX PD 11-DEC-1997.
XX XX
XX PF 05-JUN-1997; 97WO-EP002930.
XX XX
XX PR 05-JUN-1996; 96DE-01022502.
XX XX
XX PR 13-SEP-1996; 96DE-01037230.
XX XX
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX XX
XX PI Hoffmann E, Goeke R, Goeke B;
XX XX
XX DR WPI; 1998-042119/04.
XX XX
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS Claim 2; Page 25; 150pp; English.
XX XX
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39331 Length: 30 February 4, 2005 13:19 Type: P Check: 5397 ..
Found using 'seq4' (mohamed337.key)

```

```
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 25; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GluPI) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX Sequence 30 AA;
SQ
AAW39332 Length: 30 February 4, 2005 13:19 Type: P Check: 5399 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HTEGFTSDLSKQXEEAVRLFIWLKNGR
28
-----
1 match found in sequence:
aaw39337 ; H. horridum exendin-3 peptide derivative #6.
(from "seq4ags.pep")
TOIG of: aaw39337 check: 4522 from: 1 to: 30
ID AAW39337 standard; peptide; 30 AA.
XX
XX AAW39337;
AC
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-3 peptide derivative #6.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
PN
XX
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EF002930.
PF
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
PI
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
```

```
PI Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
XX Claim 2; Page 25; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GluPI) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX Sequence 30 AA;
SQ
AAW39337 Length: 30 February 4, 2005 13:19 Type: P Check: 4522 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HSDGFTSDLSKQAEAEAVRLFIEALKNGR
28
-----
1 match found in sequence:
aaw39338 ; H. horridum exendin-3 peptide derivative #7.
(from "seq4ags.pep")
TOIG of: aaw39338 check: 5075 from: 1 to: 30
ID AAW39338 standard; peptide; 30 AA.
XX
XX AAW39338;
AC
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-3 peptide derivative #7.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
PN
XX
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EF002930.
PF
XX
XX 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goeke R, Goeke B;
PI
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
```

```

PT do not induce hypoglycaemia.
PS Claim 2; Page 26; 150pp; English.
XX
CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 30 AA;

AAW39338 Length: 30 February 4, 2005 13:19 Type: P Check: 5075 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HSGTFTSDLSKQAEERAVRLFIEWLKNGR
    28

-----
1 match found in sequence:
aaw39340 ; H. horridum exendin-4 peptide derivative #30.
(from "seq4ags.pep")
TOIG of: aaw39340 check: 5039 from: 1 to: 30

ID AAW39340 standard; peptide; 30 AA.
XX
AC AAW39340;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
DE H. horridum exendin-4 peptide derivative #30.
XX
KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
OS Heloderma horridum.
XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
PN W09746584-A1.
XX
PD 11-DEC-1997.
XX
PF 05-JUN-1997; 97WO-EP002930.
XX
PR 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
PI Hoffmann E, Goeke R, Goeke B;
XX
PT WPI; 1998-042119/04.
XX
PS Truncated versions of exendin peptide(s) for treating diabetes - increase
PS secretion and biosynthesis of insulin, but reduce those of glucagon, and
PS do not induce hypoglycaemia.
XX
DR Claim 2; Page 26; 150pp; English.
XX
CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 30 AA;

AAW39340 Length: 30 February 4, 2005 13:19 Type: P Check: 5039 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGAGTFTSDLSKQAEERAVRLFIEWLKNGR
    28

-----
1 match found in sequence:
aaw39341 ; H. horridum exendin-4 peptide derivative #31.
(from "seq4ags.pep")
TOIG of: aaw39341 check: 4956 from: 1 to: 30

ID AAW39341 standard; peptide; 30 AA.
XX
AC AAW39341;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
DE H. horridum exendin-4 peptide derivative #31.
XX
KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
OS Heloderma horridum.
XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
PN W09746584-A1.
XX
PD 11-DEC-1997.
XX
PF 05-JUN-1997; 97WO-EP002930.
XX
PR 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
PI Hoffmann E, Goeke R, Goeke B;
XX
PT WPI; 1998-042119/04.
XX
PS Truncated versions of exendin peptide(s) for treating diabetes - increase
PS secretion and biosynthesis of insulin, but reduce those of glucagon, and
PS do not induce hypoglycaemia.
XX
DR Claim 2; Page 26; 150pp; English.
XX
CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective

```

CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

AAW39341 Length: 30 February 4, 2005 13:19 Type: P Check: 4956 ..
 Found using 'seq4' (mohamed337.key)

1 HEGFTYSDLSKQAEBAVRLFIWLKNGR
 1 28

 1 match found in sequence:
 aaw39343 ; H. horridum exendin-4 peptide derivative #33.
 (from "seq4ags.pep")
 TOIG of: aaw39343 check: 5165 from: 1 to: 30

ID AAW39343 standard; peptide; 30 AA.

XX AAW39343;

AC AAW39343;

DT 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

DE H. horridum exendin-4 peptide derivative #33.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

OS Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

FT WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

XX 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 26; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

AAW39343 Length: 30 February 4, 2005 13:19 Type: P Check: 5165 ..
 Found using 'seq4' (mohamed337.key)

1 HEGFTYSDLSKQAEBAVRLFIWLKNGR
 1 28

 1 match found in sequence:
 aaw39344 ; H. horridum exendin-4 peptide derivative #34.
 (from "seq4ags.pep")
 TOIG of: aaw39344 check: 5069 from: 1 to: 30

ID AAW39344 standard; peptide; 30 AA.

XX AAW39344;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

DE H. horridum exendin-4 peptide derivative #34.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;

KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

OS Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

FT WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

XX 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 26; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

XX Sequence 30 AA;

AAW39344 Length: 30 February 4, 2005 13:19 Type: P Check: 5069 ..
 Found using 'seq4' (mohamed337.key)

1 HEGFTYSDLSKQAEBAVRLFIWLKNGR
 1 28

```
1
-----
1 match found in sequence:
aaw39345 ; H. horridum exendin-4 peptide derivative #35.
(from "seq4ags.pep")
TOIG of: aaw39345 check: 5044 from: 1 to: 30

ID AAW39345 standard; peptide; 30 AA.
XX
AC AAW39345;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
DE H. horridum exendin-4 peptide derivative #35.
XX
KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
OS Heloderma horridum.
XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
PN WO9746584-A1.
XX
PD 11-DEC-1997.
XX
PF 05-JUN-1997; 97WO-EP002930.
XX
PR 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
PA (BOEP ) BOEHRINGER MANNHEIM GMBH.
XX
PI Hoffmann E, Goeke R, Goeke B;
XX
DR WPI; 1998-042119/04.
XX
PT Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
PS Claim 2; Page 26; 150pp; English.
XX
CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 30 AA;

AAW39345 Length: 30 February 4, 2005 13:19 Type: P Check: 5044 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGGTFTTDLKQAEERAVRLFIEWLNKGR
28

-----
1 match found in sequence:
aaw39349 ; H. horridum exendin-4 peptide derivative #39.
(from "seq4ags.pep")
TOIG of: aaw39349 check: 5060 from: 1 to: 30

ID AAW39349 standard; peptide; 30 AA.
XX
AC AAW39349;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
DE H. horridum exendin-4 peptide derivative #37.
XX
KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
OS Heloderma horridum.
XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
PN WO9746584-A1.
XX
PD 11-DEC-1997.
XX
PF 05-JUN-1997; 97WO-EP002930.
XX
PR 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
PA (BOEP ) BOEHRINGER MANNHEIM GMBH.
XX
PI Hoffmann E, Goeke R, Goeke B;
XX
DR WPI; 1998-042119/04.
XX
PT Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
PS Claim 2; Page 26; 150pp; English.
XX
CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 30 AA;

AAW39345 Length: 30 February 4, 2005 13:19 Type: P Check: 5044 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGGTFTTDLKQAEERAVRLFIEWLNKGR
28

-----
1 match found in sequence:
aaw39347 ; H. horridum exendin-4 peptide derivative #37.
(from "seq4ags.pep")
TOIG of: aaw39347 check: 5059 from: 1 to: 30

ID AAW39347 standard; peptide; 30 AA.
XX
AC AAW39347;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
DE H. horridum exendin-4 peptide derivative #37.
XX
KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
OS Heloderma horridum.
XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
PN WO9746584-A1.
XX
PD 11-DEC-1997.
XX
PF 05-JUN-1997; 97WO-EP002930.
XX
PR 05-JUN-1996; 96DE-01022502.
PR 13-SEP-1996; 96DE-01037230.
XX
PA (BOEP ) BOEHRINGER MANNHEIM GMBH.
XX
PI Hoffmann E, Goeke R, Goeke B;
XX
DR WPI; 1998-042119/04.
XX
PT Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX
PS Claim 2; Page 26; 150pp; English.
XX
CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 30 AA;

AAW39347 Length: 30 February 4, 2005 13:19 Type: P Check: 5059 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGGTFTTDLKQAEERAVRLFIEWLNKGR
28

-----
1 match found in sequence:
aaw39349 ; H. horridum exendin-4 peptide derivative #39.
(from "seq4ags.pep")
TOIG of: aaw39349 check: 5060 from: 1 to: 30

ID AAW39349 standard; peptide; 30 AA.
XX
AC AAW39349;
XX
```

```

DT 25-MAR-2003 (revised)
XX 05-JUN-1998 (first entry)
XX H. horridum extendin-4 peptide derivative #39.
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX Key Location/Qualifiers
XX Modified-site 30
XX /note= "C-terminal amide"
XX WO9746584-A1.
XX 11-DEC-1997.
XX 05-JUN-1997; 97WO-EP002930.
XX 05-JUN-1996; 96DE-01022502.
XX 13-SEP-1996; 96DE-01037230.
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX Claim 2; Page 26; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Extendin-3 and extendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known extendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX Sequence 30 AA;
AAW39349 Length: 30 February 4, 2005 13:19 Type: P Check: 5060 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTTSELSKQAEAEAVRLFIEWLKNGR
1 28
-----
1 match found in sequence:
aaw39350 ; H. horridum extendin-4 peptide derivative #40.
(from "seq4ags.pep")
TOIG of: aaw39350 check: 4941 from: 1 to: 30
ID AAW39350 standard; peptide; 30 AA.
XX AC AAW39350;
XX 25-MAR-2003 (revised)
XX 05-JUN-1998 (first entry)
XX H. horridum extendin-4 peptide derivative #40.
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX Key Location/Qualifiers
XX Modified-site 30

```

```

KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX Key Location/Qualifiers
XX Modified-site 30
XX /note= "C-terminal amide"
XX WO9746584-A1.
XX 11-DEC-1997.
XX 05-JUN-1997; 97WO-EP002930.
XX 05-JUN-1996; 96DE-01022502.
XX 13-SEP-1996; 96DE-01037230.
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX Hoffmann E, Goeke R, Goeke B;
XX WPI; 1998-042119/04.
XX Truncated versions of extendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX Claim 2; Page 26; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Extendin-3 and extendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known extendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX Sequence 30 AA;
AAW39350 Length: 30 February 4, 2005 13:19 Type: P Check: 4941 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTTSDASKQAEAEAVRLFIEWLKNGR
1 28
-----
1 match found in sequence:
aaw39351 ; H. horridum extendin-4 peptide derivative #41.
(from "seq4ags.pep")
TOIG of: aaw39351 check: 4853 from: 1 to: 30
ID AAW39351 standard; peptide; 30 AA.
XX AC AAW39351;
XX 25-MAR-2003 (revised)
XX 05-JUN-1998 (first entry)
XX H. horridum extendin-4 peptide derivative #41.
XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX glucagon reduction; hypoglycaemia; glucose; treatment.
XX Heloderma horridum.
XX Key Location/Qualifiers
XX Modified-site 30

```

```

FT XX /note= "C-terminal amide"
PN PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX DR WPI; 1998-042119/04.
XX CC Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX FT do not induce hypoglycaemia.
XX PS Claim 2; Page 26; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;
AAW39351 Length: 30 February 4, 2005 13:19 Type: P Check: 4853 ..
Found using 'seq4' (mohamed337.key)
1 HGCGTFTSDLSAQAEERAVRLFIEWLNKGR
1 28
-----|
1 match found in sequence:
aaw39352 ; H. horridum exendin-4 peptide derivative #42.
(from "seq4ags.pep")
TOIG of: aaw39352 check: 4931 from: 1 to: 30
ID AAW39352 standard; peptide; 30 AA.
XX AC AAW39352;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide derivative #42.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX DR WPI; 1998-042119/04.
XX CC Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX FT do not induce hypoglycaemia.
XX PS Claim 2; Page 26; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;
AAW39351 Length: 30 February 4, 2005 13:19 Type: P Check: 4853 ..
Found using 'seq4' (mohamed337.key)
1 HGCGTFTSDLSAQAEERAVRLFIEWLNKGR
1 28
-----|
1 match found in sequence:
aaw39352 ; H. horridum exendin-4 peptide derivative #43.
(from "seq4ags.pep")
TOIG of: aaw39353 check: 4843 from: 1 to: 30
ID AAW39353 standard; peptide; 30 AA.
XX AC AAW39353;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide derivative #43.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.

```

```

XX Hoffmann E, Goetze R, Goetze B;
XX WPI; 1998-042119/04.
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX Claim 2; Page 26; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX Sequence 30 AA;
AAW39353 Length: 30 February 4, 2005 13:19 Type: P Check: 4843 ..
Found using 'seq4' (mohamed337.key)
1 HEGFTFTSLSKAABEAVRLFIEWLKNGR
1 28
-----
1 match found in sequence:
aaw39354 ; H. horridum exendin-4 peptide derivative #44.
(from "seq4ags.pep")
TOIG of: aaw39354 check: 4991 from: 1 to: 30

ID AAW39354 standard; peptide; 30 AA.
XX AC AAW39354;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide derivative #44.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goetze R, Goetze B;
XX WPI; 1998-042119/04.
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX Claim 2; Page 26; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX Sequence 30 AA;
AAW39354 Length: 30 February 4, 2005 13:19 Type: P Check: 4991 ..
Found using 'seq4' (mohamed337.key)
1 HEGFTFTSLSKAABEAVRLFIEWLKNGR
1 28
-----
1 match found in sequence:
aaw39354 ; H. horridum exendin-4 peptide derivative #48.
(from "seq4ags.pep")
TOIG of: aaw39359 check: 4711 from: 1 to: 30

ID AAW39359 standard; peptide; 30 AA.
XX AC AAW39359;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide derivative #48.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goetze R, Goetze B;
XX WPI; 1998-042119/04.
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX Claim 2; Page 27; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

```

```

PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX Claim 2; Page 27; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX Sequence 30 AA;
AAW39354 Length: 30 February 4, 2005 13:19 Type: P Check: 4991 ..
Found using 'seq4' (mohamed337.key)
1 HEGFTFTSLSKAABEAVRLFIEWLKNGR
1 28
-----
1 match found in sequence:
aaw39359 ; H. horridum exendin-4 peptide derivative #48.
(from "seq4ags.pep")
TOIG of: aaw39359 check: 4711 from: 1 to: 30

ID AAW39359 standard; peptide; 30 AA.
XX AC AAW39359;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide derivative #48.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goetze R, Goetze B;
XX WPI; 1998-042119/04.
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX Claim 2; Page 27; 150pp; English.
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4

```

CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39359 Length: 30 February 4, 2005 13:19 Type: P Check: 4711 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTSDLSKQAEBAVALFIEWLKNGR
 28

 1 match found in sequence:
 aaw39360 ; H. horridum exendin-3 peptide derivative #10.
 (from "seq4ags.pep")
 TOIG of: aaw39360 check: 5490 from: 1 to: 30

ID AAW39360 standard; peptide; 30 AA.
 XX
 AC AAW39360;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 DE H. horridum exendin-3 peptide derivative #10.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 XX
 OS Heloderma horridum.

Key Location/Qualifiers
 FT Modified-site 30 /note= "C-terminal amide"
 FT

XX WO9746584-A1.
 XX 11-DEC-1997.
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 XX
 XX 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 XX
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 PA
 XX Hoffmann E, Goetze R, Goetze B;
 PI
 XX WPI; 1998-042119/04.
 DR

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 XX

PS Claim 2; Page 27; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like

CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX

SQ Sequence 30 AA;

AAW39360 Length: 30 February 4, 2005 13:19 Type: P Check: 5490 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGTFSTSDLSKQAEBAVALFIEWLKNGR
 28

 1 match found in sequence:
 aaw39361 ; H. horridum exendin-4 peptide derivative #49.
 (from "seq4ags.pep")
 TOIG of: aaw39361 check: 5350 from: 1 to: 30

ID AAW39361 standard; peptide; 30 AA.
 XX
 AC AAW39361;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 DE H. horridum exendin-4 peptide derivative #49.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 XX
 OS Heloderma horridum.

Key Location/Qualifiers
 FT Modified-site 30 /note= "C-terminal amide"
 FT

XX WO9746584-A1.
 XX 11-DEC-1997.
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 XX
 XX 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 XX
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 PA
 XX Hoffmann E, Goetze R, Goetze B;
 PI
 XX WPI; 1998-042119/04.
 DR

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 XX

PS Claim 2; Page 27; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX

SQ Sequence 30 AA;
AAW39361 Length: 30 February 4, 2005 13:19 Type: P Check: 5350 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFTSDLSKQABEEAVRLFVLEWLNKGR 28
-----|-----
1 match found in sequence:
aaw39363 ; H. horridum exendin-4 peptide derivative #51.
(from "seq4ags.pep")
TOIG of: aaw39363 check: 4501 from: 1 to: 30

ID AAW39363 standard; peptide; 30 AA.
XX AC AAW39363;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide derivative #51.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX PI WPI; 1998-042119/04.
XX PS Claim 2; Page 27; 150pp; English.
XX CC Truncated versions of exendin peptide(s) for treating diabetes - increase secretion and biosynthesis of insulin, but reduce those of glucagon, and do not induce hypoglycaemia.
XX CC Claim 2; Page 27; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4 isolated from Heloderma horridum which are used in a novel method for the treatment of diabetes mellitus. These peptides can stimulate biosynthesis and secretion of insulin, but have the opposite effect on glucagon, and independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high, so they will not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1) and the known exendins, they are more active (effective at lower doses), more stable to degradation and metabolism and have a longer lasting effect. Truncated forms of this peptide can be made more economically than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX SQ Sequence 30 AA;
AAW39363 Length: 30 February 4, 2005 13:19 Type: P Check: 4501 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFTSDLSKQABEEAVRLFVLEWLNKGR 28
-----|-----
1 match found in sequence:
aaw39365 ; H. horridum exendin-4 peptide derivative #53.

1 HEGGTFTSDLSKQABEEAVRLFIEALKNGR 28
-----|-----
1 match found in sequence:
aaw39364 ; H. horridum exendin-4 peptide derivative #52.
(from "seq4ags.pep")
TOIG of: aaw39364 check: 4765 from: 1 to: 30

ID AAW39364 standard; peptide; 30 AA.
XX AC AAW39364;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum exendin-4 peptide derivative #52.
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX PI WPI; 1998-042119/04.
XX PS Truncated versions of exendin peptide(s) for treating diabetes - increase secretion and biosynthesis of insulin, but reduce those of glucagon, and do not induce hypoglycaemia.
XX PS Claim 2; Page 27; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4 isolated from Heloderma horridum which are used in a novel method for the treatment of diabetes mellitus. These peptides can stimulate biosynthesis and secretion of insulin, but have the opposite effect on glucagon, and independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high, so they will not induce hypoglycaemia. Compared with glucagon-like peptide 1 (GLP1) and the known exendins, they are more active (effective at lower doses), more stable to degradation and metabolism and have a longer lasting effect. Truncated forms of this peptide can be made more economically than full length versions. (Updated on 25-MAR-2003 to correct PR field.)
XX SQ Sequence 30 AA;
AAW39364 Length: 30 February 4, 2005 13:19 Type: P Check: 4765 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFTSDLSKQABEEAVRLFIEWAKNGR 28
-----|-----
1 match found in sequence:
aaw39365 ; H. horridum exendin-4 peptide derivative #53.

```

(from "seq4ags.pep")
TOIG of: aaw39365 check: 4781 from: 1 to: 30
ID AAW39365 standard; peptide; 30 AA.
XX
AC AAW39365;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #53.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
OS Heloderma horridum.
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
PN
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EP002930.
PF
XX
XX 05-JUN-1996; 96DE-01022502.
PR
XX 13-SEP-1996; 96DE-01037230.
PR
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
PA
XX
XX Hoffmann E, Goeke R, Goeke B;
PI
XX
XX WPI; 1998-042119/04.
DR
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
PT
XX
XX Claim 2; Page 27; 150pp; English.
PS
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 30 AA;
AAW39365 Length: 30 February 4, 2005 13:19 Type: P Check: 4781
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEFTFTDLSKQAEAEVRLFIEMLANGR
    28

-----
1 match found in sequence:
aaw39366 ; H. horridum exendin-4 peptide derivative #54.
(from "seq4ags.pep")
TOIG of: aaw39366 check: 4877 from: 1 to: 30
ID AAW39366 standard; peptide; 30 AA.
XX
AC AAW39366;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #55.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
OS Heloderma horridum.
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
XX
XX WO9746584-A1.
PN
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EP002930.
PF
XX
XX 05-JUN-1996; 96DE-01022502.
PR
XX 13-SEP-1996; 96DE-01037230.
PR
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
PA
XX
XX Hoffmann E, Goeke R, Goeke B;
PI
XX
XX WPI; 1998-042119/04.
DR
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
PT
XX
XX Claim 2; Page 27; 150pp; English.
PS
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC
CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known exendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX
SQ Sequence 30 AA;
AAW39366 Length: 30 February 4, 2005 13:19 Type: P Check: 4877
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGEFTFTDLSKQAEAEVRLFIEMLANGR
    28

-----
1 match found in sequence:
aaw39367 ; H. horridum exendin-4 peptide derivative #55.
(from "seq4ags.pep")
TOIG of: aaw39367 check: 5051 from: 1 to: 30
ID AAW39367 standard; peptide; 30 AA.
XX
AC AAW39367;
XX
DT 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-4 peptide derivative #55.
DE
XX
XX

```

KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 OS Heloderma horridum.
 XX
 XX Key Location/Qualifiers
 FH Modified-site 30
 FT /note= "C-terminal amide"
 FT
 XX
 XX WO9746584-A1.
 PN 11-DEC-1997.
 PD
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 PF
 XX
 XX 05-JUN-1996; 96DE-01022502.
 PR
 XX 13-SEP-1996; 96DE-01037230.
 PR
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 PA
 XX Hoffmann E, Goeke R, Goeke B;
 PI WPI; 1998-042119/04.
 XX
 XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 PT
 XX Claim 2; Page 27; 150pp; English.
 PS
 XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;
 AAW39367 Length: 30 February 4, 2005 13:19 Type: P Check: 5051
 Found using 'seq4' (mohamed337.key)
 1 HSGTFTSLSKQAEAEAVRLFIEWLKNGR 28
 |-----|
 1 match found in sequence:
 aaw39368 ; H. horridum exendin-3 peptide derivative #11.
 (from "seq4ags.pep")
 TOIG of: aaw39368 check: 5240 from: 1 to: 30
 ID AAW39368 standard; peptide; 30 AA.
 XX
 AC AAW39368;
 XX
 XX 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 XX H. horridum exendin-3 peptide derivative #11.
 DE
 XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 KW Heloderma horridum.
 OS
 XX Key Location/Qualifiers
 FH Modified-site 30
 FT /note= "C-terminal amide"
 FT
 XX

FT Modified-site 30
 FT /note= "C-terminal amide"
 XX
 PN WO9746584-A1.
 XX
 XX 11-DEC-1997.
 PD
 XX
 XX 05-JUN-1997; 97WO-EP002930.
 PF
 XX
 XX 05-JUN-1996; 96DE-01022502.
 PR
 XX 13-SEP-1996; 96DE-01037230.
 PR
 XX (BOEF) BOEHRINGER MANNHEIM GMBH.
 PA
 XX Hoffmann E, Goeke R, Goeke B;
 PI WPI; 1998-042119/04.
 XX
 XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 PT
 XX Claim 2; Page 27; 150pp; English.
 PS
 XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;
 AAW39368 Length: 30 February 4, 2005 13:19 Type: P Check: 5240
 Found using 'seq4' (mohamed337.key)
 1 HSDGFTSLSKQMBEAEAVRLFIEWLKNGR 28
 |-----|
 1 match found in sequence:
 aaw39369 ; H. horridum exendin-3 peptide derivative #12.
 (from "seq4ags.pep")
 TOIG of: aaw39369 check: 5604 from: 1 to: 30
 ID AAW39369 standard; peptide; 30 AA.
 XX
 AC AAW39369;
 XX
 XX 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 XX H. horridum exendin-3 peptide derivative #12.
 DE
 XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 KW Heloderma horridum.
 OS
 XX Key Location/Qualifiers
 FH Modified-site 14
 FT /label= Nle
 FT /note= "Norleucine"
 FT Modified-site 30
 FT /note= "C-terminal amide"
 XX

```

PN WO9746584-A1.
XX
PD 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goetze R, Goetze B;
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 27; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
SQ

AAW39369 Length: 30 February 4, 2005 13:19 Type: P Check: 5604 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HSDGFTSLSKQXEEAEVRLFIWLKNGY
28

-----
1 match found in sequence:
aaw39370 : H. horridum exendin-3 peptide derivative #13.
(from "seq4ags.pep")
TOIG of: aaw39370 check: 5394 from: 1 to: 30

ID AAW39370 standard; peptide; 30 AA.
XX
XX AC AAW39370;
XX
XX DT 25-MAR-2003 (revised)
XX
XX DT 05-JUN-1998 (first entry)
XX
XX DE H. horridum exendin-3 peptide derivative #13.
XX
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX OS Heloderma horridum.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 14 /label= Nle
XX FT /note= "Norleucine"
XX FT Modified-site 30 /note= "C-terminal OH group"
XX
XX PN WO9746584-A1.
XX
XX PD 11-DEC-1997.
XX
XX

```

```

XX
XX 05-JUN-1997; 97WO-EP002930.
XX
XX 05-JUN-1996; 96DE-01022502.
XX
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
XX
XX Hoffmann E, Goetze R, Goetze B;
XX
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 28; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
SQ

AAW39370 Length: 30 February 4, 2005 13:19 Type: P Check: 5394 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HSDGFTSLSKQXEEAEVRLFIWLKNGR
28

-----
1 match found in sequence:
aaw39371 : H. horridum exendin-3 peptide derivative #14.
(from "seq4ags.pep")
TOIG of: aaw39371 check: 5072 from: 1 to: 30

ID AAW39371 standard; peptide; 30 AA.
XX
XX AC AAW39371;
XX
XX DT 25-MAR-2003 (revised)
XX
XX DT 05-JUN-1998 (first entry)
XX
XX DE H. horridum exendin-3 peptide derivative #14.
XX
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX
XX OS Heloderma horridum.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 14 /label= Nle
XX FT /note= "Norleucine"
XX FT Modified-site 30 /note= "C-terminal amide"
XX
XX PN WO9746584-A1.
XX
XX PD 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
XX

```

PR 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 XX
 PA (BOEF) BOEHRINGER MANNHEIM GMBH.
 XX Hoffmann E, Goeke R, Goeke B;
 XX WPI; 1998-042119/04.
 XX
 PR Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 XX
 PS Claim 2; Page 28; 150pp; English.
 XX
 CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39371 Length: 30 February 4, 2005 13:19 Type: P Check: 5072 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSLSKQAEAEAVRLFIEWLKNGR
 28

 1 match found in sequence:
 aaw39378 ; H. horridum exendin-3 peptide derivative #21.
 (from "seq4ags.pep")
 TOIG of: aaw39378 check: 5358 from: 1 to: 30

ID AAW39378 standard; peptide; 30 AA.
 XX
 AC AAW39378;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 DE H. horridum exendin-3 peptide derivative #21.
 XX
 KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 XX
 OS Heloderma horridum.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 14
 FT /label= Nle
 FT /note= "Norleucine"
 FT Modified-site 30
 FT /note= "C-terminal amide"
 XX
 PN WO9746584-A1.
 XX
 PD 11-DEC-1997.
 XX
 PF 05-JUN-1997; 97WO-EP002930.
 XX
 PR 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 XX

PA (BOEF) BOEHRINGER MANNHEIM GMBH.
 XX Hoffmann E, Goeke R, Goeke B;
 XX WPI; 1998-042119/04.
 XX
 PR Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.
 XX
 PS Claim 2; Page 28; 150pp; English.
 XX
 CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39378 Length: 30 February 4, 2005 13:19 Type: P Check: 5358 ..
 Found using 'seq4' (mohamed337.key)

1 HADGFTSLSKQAEAEAVRLFIEWLKNGR
 28

 1 match found in sequence:
 aaw39383 ; H. horridum exendin-3 peptide derivative #26.
 (from "seq4ags.pep")
 TOIG of: aaw39383 check: 5370 from: 1 to: 30

ID AAW39383 standard; peptide; 30 AA.
 XX
 AC AAW39383;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1998 (first entry)
 XX
 DE H. horridum exendin-3 peptide derivative #26.
 XX
 KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 XX
 OS Heloderma horridum.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 14
 FT /label= Nle
 FT /note= "Norleucine"
 FT Modified-site 30
 FT /note= "C-terminal amide"
 XX
 PN WO9746584-A1.
 XX
 PD 11-DEC-1997.
 XX
 PF 05-JUN-1997; 97WO-EP002930.
 XX
 PR 05-JUN-1996; 96DE-01022502.
 PR 13-SEP-1996; 96DE-01037230.
 XX
 PA (BOEF) BOEHRINGER MANNHEIM GMBH.
 XX Hoffmann E, Goeke R, Goeke B;

```

XX DR WPI; 1998-042119/04.
XX PT
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS
XX PS Claim 2; Page 28; 150pp; English.
XX CC
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39383 Length: 30 February 4, 2005 13:19 Type: P Check: 5370 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGDTFTSLSKQXEEAVRLFIEWLKNGR
28

-----
1 match found in sequence:
aaw39393 ; H. horridum exendin-3 peptide derivative #36.
(from "seq4ags.pep")
TOIG of: aaw39393 check: 5396 from: 1 to: 30

ID AAW39393 standard; peptide; 30 AA.
XX AC
XX AC AAW39393;
XX DT
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE
XX DE H. horridum exendin-3 peptide derivative #36.
XX KW
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS
XX OS Heloderma horridum.
XX FH
XX FH Key Location/Qualifiers
XX FT
XX FT Modified-site 14 /label= Nle
XX FT /note= "Norleucine"
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX FT
XX PN
XX PN WO9746584-A1.
XX PD
XX PD 11-DEC-1997.
XX PF
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA
XX PA (BOE ) BOEHRINGER MANNHEIM GMBH.
XX PI
XX PI Hoffmann E, Goeke R, Goeke B;
XX DR
XX DR WPI; 1998-042119/04.
XX PT
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS
XX PS Claim 2; Page 28; 150pp; English.
XX CC
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39393 Length: 30 February 4, 2005 13:19 Type: P Check: 5396 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGDTFTSLSKQXEEAVRLFIEWLKNGR
28

-----
1 match found in sequence:
aaw39397 ; H. horridum exendin-3 peptide derivative #40.
(from "seq4ags.pep")
TOIG of: aaw39397 check: 5063 from: 1 to: 30

ID AAW39397 standard; peptide; 30 AA.
XX AC
XX AC AAW39397;
XX DT
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE
XX DE H. horridum exendin-3 peptide derivative #40.
XX KW
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS
XX OS Heloderma horridum.
XX FH
XX FH Key Location/Qualifiers
XX FT
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN
XX PN WO9746584-A1.
XX PD
XX PD 11-DEC-1997.
XX PF
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA
XX PA (BOE ) BOEHRINGER MANNHEIM GMBH.
XX PI
XX PI Hoffmann E, Goeke R, Goeke B;
XX DR
XX DR WPI; 1998-042119/04.
XX PT
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS
XX PS Claim 2; Page 29; 150pp; English.
XX SQ

```

```

XX PT
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS
XX PS Claim 2; Page 29; 150pp; English.
XX CC
XX CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX CC isolated from Heloderma horridum which are used in a novel method for the
XX CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX CC and secretion of insulin, but have the opposite effect on glucagon, and
XX CC independent of this activity can increase peripheral glucose utilisation.
XX CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX CC so they will not induce hypoglycaemia. Compared with glucagon-like
XX CC peptide 1 (GLP1) and the known exendins, they are more active (effective
XX CC at lower doses), more stable to degradation and metabolism and have a
XX CC longer lasting effect. Truncated forms of this peptide can be made more
XX CC economically than full length versions. (Updated on 25-MAR-2003 to
XX CC correct PR field.)
XX SQ Sequence 30 AA;

AAW39393 Length: 30 February 4, 2005 13:19 Type: P Check: 5396 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGDTFTSLSKQXEEAVRLFIEWLKNGR
28

-----
1 match found in sequence:
aaw39397 ; H. horridum exendin-3 peptide derivative #40.
(from "seq4ags.pep")
TOIG of: aaw39397 check: 5063 from: 1 to: 30

ID AAW39397 standard; peptide; 30 AA.
XX AC
XX AC AAW39397;
XX DT
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE
XX DE H. horridum exendin-3 peptide derivative #40.
XX KW
XX KW Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS
XX OS Heloderma horridum.
XX FH
XX FH Key Location/Qualifiers
XX FT
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN
XX PN WO9746584-A1.
XX PD
XX PD 11-DEC-1997.
XX PF
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA
XX PA (BOE ) BOEHRINGER MANNHEIM GMBH.
XX PI
XX PI Hoffmann E, Goeke R, Goeke B;
XX DR
XX DR WPI; 1998-042119/04.
XX PT
XX PT Truncated versions of exendin peptide(s) for treating diabetes - increase
XX PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX PT do not induce hypoglycaemia.
XX PS
XX PS Claim 2; Page 29; 150pp; English.
XX SQ

```

CC Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX
 SQ Sequence 30 AA;

AAW39397 Length: 30 February 4, 2005 13:19 Type: P Check: 5063 ..

Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQAEAEAVRLFIEWLKNGR
 28

1 match found in sequence:
 aaw39398 ; H. horridum exendin-3 peptide derivative #41.
 (from "seq4ags.pep")

TOIG of: aaw39398 check: 4977 from: 1 to: 30

ID AAW39398 standard; peptide; 30 AA.

XX AC AAW39398;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

DE H. horridum exendin-3 peptide derivative #41.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 XX Heloderma horridum.

OS

XX Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 29; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,

CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 XX

SQ Sequence 30 AA;

AAW39398 Length: 30 February 4, 2005 13:19 Type: P Check: 4977 ..

Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQAEAEAVRLFIEWLKNGR
 28

1 match found in sequence:

aaw39400 ; H. horridum exendin-3 peptide derivative #43.
 (from "seq4ags.pep")

TOIG of: aaw39400 check: 5186 from: 1 to: 30

ID AAW39400 standard; peptide; 30 AA.

XX AC AAW39400;

XX 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

DE H. horridum exendin-3 peptide derivative #43.

XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.
 XX Heloderma horridum.

OS

XX Key Location/Qualifiers

FT Modified-site 30

FT /note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

PR 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goeke R, Goeke B;

XX WPI; 1998-042119/04.

XX Truncated versions of exendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 29; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Exendin-3 and exendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known exendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)

```

XX      Sequence 30 AA;
SQ
AAW39400 Length: 30 February 4, 2005 13:19 Type: P Check: 5186
Found using 'seq4' (mohamed337.key)
1      |-----|
      HSDGTYTSDLSKQAEBAVRLFIWLNKGR
      1
      1 match found in sequence:
      aaw39401; H. horridum extendin-3 peptide derivative #44.
      (from "seq4ags.pep")
      TOIG of: aaw39401 check: 5090 from: 1 to: 30
      ID AAW39401 standard; peptide; 30 AA.
      XX
      AC AAW39401;
      XX
      DT 25-MAR-2003 (revised)
      DT 05-JUN-1998 (first entry)
      XX
      DE H. horridum extendin-3 peptide derivative #44.
      XX
      KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
      KW glucagon reduction; hypoglycaemia; glucose; treatment.
      XX
      OS Heloderma horridum.
      XX
      FH Key Location/Qualifiers
      FT Modified-site 30 /note= "C-terminal amide"
      FT
      XX
      PN WO9746584-A1.
      XX
      PD 11-DEC-1997.
      XX
      PF 05-JUN-1997; 97WO-EP002930.
      XX
      PR 05-JUN-1996; 96DE-01022502.
      PR 13-SEP-1996; 96DE-01037230.
      XX
      PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
      XX
      PI Hoffmann E, Goetze R, Goetze B;
      XX
      WPI; 1998-042119/04.
      XX
      PT Truncated versions of extendin peptide(s) for treating diabetes - increase
      PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
      PT do not induce hypoglycaemia.
      XX
      PS Claim 2; Page 29; 150pp; English.
      XX
      CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
      CC isolated from Heloderma horridum which are used in a novel method for the
      CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
      CC and secretion of insulin, but have the opposite effect on glucagon, and
      CC independent of this activity can increase peripheral glucose utilisation.
      CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
      CC so they will not induce hypoglycaemia. Compared with glucagon-like
      CC peptide 1 (GLP1) and the known extendins, they are more active (effective
      CC at lower doses), more stable to degradation and metabolism and have a
      CC longer lasting effect. Truncated forms of this peptide can be made more
      CC economically than full length versions. (Updated on 25-MAR-2003 to
      CC correct PR field.)
      XX
      SQ Sequence 30 AA;
      AAW39401 Length: 30 February 4, 2005 13:19 Type: P Check: 5090
      Found using 'seq4' (mohamed337.key)
1      |-----|
      HSDGTYTSDLSKQAEBAVRLFIWLNKGR
      1
      1 match found in sequence:
      aaw39402 standard; peptide; 30 AA.
      XX
      AC AAW39402;
      XX
      DT 25-MAR-2003 (revised)
      DT 05-JUN-1998 (first entry)
      XX
      DE H. horridum extendin-3 peptide derivative #45.
      XX
      KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
      KW glucagon reduction; hypoglycaemia; glucose; treatment.
      XX
      OS Heloderma horridum.
      XX
      FH Key Location/Qualifiers
      FT Modified-site 30 /note= "C-terminal amide"
      FT
      XX
      PN WO9746584-A1.
      XX
      PD 11-DEC-1997.
      XX
      PF 05-JUN-1997; 97WO-EP002930.
      XX
      PR 05-JUN-1996; 96DE-01022502.
      PR 13-SEP-1996; 96DE-01037230.
      XX
      PA (BOEF ) BOEHRINGER MANNHEIM GMBH.
      XX
      PI Hoffmann E, Goetze R, Goetze B;
      XX
      WPI; 1998-042119/04.
      XX
      PT Truncated versions of extendin peptide(s) for treating diabetes - increase
      PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
      PT do not induce hypoglycaemia.
      XX
      PS Claim 2; Page 30; 150pp; English.
      XX
      CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
      CC isolated from Heloderma horridum which are used in a novel method for the
      CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
      CC and secretion of insulin, but have the opposite effect on glucagon, and
      CC independent of this activity can increase peripheral glucose utilisation.
      CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
      CC so they will not induce hypoglycaemia. Compared with glucagon-like
      CC peptide 1 (GLP1) and the known extendins, they are more active (effective
      CC at lower doses), more stable to degradation and metabolism and have a
      CC longer lasting effect. Truncated forms of this peptide can be made more
      CC economically than full length versions. (Updated on 25-MAR-2003 to
      CC correct PR field.)
      XX
      SQ Sequence 30 AA;
      AAW39402 Length: 30 February 4, 2005 13:19 Type: P Check: 5065
      Found using 'seq4' (mohamed337.key)
1      |-----|
      HSDGTYTSDLSKQAEBAVRLFIWLNKGR
      1
      1 match found in sequence:

```

aaw39404 ; H. horridum extendin-3 peptide derivative #47.
(from "seq4ags.pep")
TOIG of: aaw39404 check: 5080 from: 1 to: 30

ID AAW39404 standard; peptide; 30 AA.

XX AC AAW39404;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum extendin-3 peptide derivative #47.
XX KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.

XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-AL.

XX PD 11-DEC-1997.

XX PF 05-JUN-1997; 97WO-EP002930.

XX PR 05-JUN-1996; 96DE-01022502.

XX PR 13-SEP-1996; 96DE-01037230.

XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.

XX PI Hoffmann E, Goetze R, Goetze B;

XX PR WPI; 1998-042119/04.

XX PT Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX PS Claim 2; Page 30; 150pp; English.

XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)

XX SQ Sequence 30 AA;

AAW39404 Length: 30 February 4, 2005 13:19 Type: P Check: 5080 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTTDLKSQAEEAVRLFIEWLKNGR
28

1 match found in sequence:
aaw39406 ; H. horridum extendin-3 peptide derivative #49.
(from "seq4ags.pep")

TOIG of: aaw39406 check: 5081 from: 1 to: 30

ID AAW39406 standard; peptide; 30 AA.

XX

AC AAW39406;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)

XX DE H. horridum extendin-3 peptide derivative #49.

XX KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX OS Heloderma horridum.

XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-AL.

XX PD 11-DEC-1997.

XX PF 05-JUN-1997; 97WO-EP002930.

XX PR 05-JUN-1996; 96DE-01022502.

XX PR 13-SEP-1996; 96DE-01037230.

XX PA (BOEF) BOEHRINGER MANNHEIM GMBH.

XX PI Hoffmann E, Goetze R, Goetze B;

XX PR WPI; 1998-042119/04.

XX PT Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX PS Claim 2; Page 30; 150pp; English.

XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)

XX SQ Sequence 30 AA;

AAW39406 Length: 30 February 4, 2005 13:19 Type: P Check: 5081 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTTDLKSQAEEAVRLFIEWLKNGR
28

1 match found in sequence:
aaw39407 ; H. horridum extendin-3 peptide derivative #50.
(from "seq4ags.pep")

TOIG of: aaw39407 check: 4962 from: 1 to: 30

ID AAW39407 standard; peptide; 30 AA.

XX AC AAW39407;

XX DT 25-MAR-2003 (revised)

XX DT 05-JUN-1998 (first entry)

XX DE H. horridum extendin-3 peptide derivative #50.


```

PD 11-DEC-1997.
XX
XX 05-JUN-1997; 97WO-EP002930.
PF
XX 05-JUN-1996; 96DE-01022502.
PR
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
PA
XX Hoffmann E, Goeke R, Goeke B;
PI
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 30; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39409 Length: 30 February 4, 2005 13:19 Type: P Check: 4931 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HSGGTFTSDLSAQABEEAVRLFIEWLKNGR 28
-----
1 match found in sequence:
aaw39410 ; H. horridum exendin-3 peptide derivative #53.
(from "seq4ags.pep")
TOIG of: aaw39410 check: 4864 from: 1 to: 30
-----
ID AAW39410 standard; peptide; 30 AA.
XX
XX AAW39410;
AC
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-3 peptide derivative #53.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
KW
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT
XX
XX WO9746584-A1.
PN
XX
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EP002930.
PF
XX
XX 05-JUN-1996; 96DE-01022502.
PR
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
PA
XX Hoffmann E, Goeke R, Goeke B;
PI
XX WPI; 1998-042119/04.
XX
XX

```

```

XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
PA
XX Hoffmann E, Goeke R, Goeke B;
PI
XX WPI; 1998-042119/04.
XX
XX Truncated versions of exendin peptide(s) for treating diabetes - increase
XX secretion and biosynthesis of insulin, but reduce those of glucagon, and
XX do not induce hypoglycaemia.
XX
XX Claim 2; Page 30; 150pp; English.
XX
XX Peptides AAW39303-W39420 are fragments of exendin-3 and exendin-4
XX isolated from Heloderma horridum which are used in a novel method for the
XX treatment of diabetes mellitus. These peptides can stimulate biosynthesis
XX and secretion of insulin, but have the opposite effect on glucagon, and
XX independent of this activity can increase peripheral glucose utilisation.
XX Exendin-3 and exendin-4 are only active when blood sugar levels are high,
XX so they will not induce hypoglycaemia. Compared with glucagon-like
XX peptide 1 (GLP1) and the known exendins, they are more active (effective
XX at lower doses), more stable to degradation and metabolism and have a
XX longer lasting effect. Truncated forms of this peptide can be made more
XX economically than full length versions. (Updated on 25-MAR-2003 to
XX correct PR field.)
XX
XX Sequence 30 AA;
SQ
AAW39410 Length: 30 February 4, 2005 13:19 Type: P Check: 4864 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HSDGTFTSDLSKAABEEAVRLFIEWLKNGR 28
-----
1 match found in sequence:
aaw39411 ; H. horridum exendin-3 peptide derivative #54.
(from "seq4ags.pep")
TOIG of: aaw39411 check: 5012 from: 1 to: 30
-----
ID AAW39411 standard; peptide; 30 AA.
XX
XX AAW39411;
AC
XX
XX 25-MAR-2003 (revised)
DT 05-JUN-1998 (first entry)
XX
XX H. horridum exendin-3 peptide derivative #54.
DE
XX
XX Exendin-3; exendin 4; diabetes; insulin; secretion; biosynthesis;
KW glucagon reduction; hypoglycaemia; glucose; treatment.
KW
XX
XX Heloderma horridum.
OS
XX
XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT
XX
XX WO9746584-A1.
PN
XX
XX 11-DEC-1997.
PD
XX
XX 05-JUN-1997; 97WO-EP002930.
PF
XX
XX 05-JUN-1996; 96DE-01022502.
PR
XX 13-SEP-1996; 96DE-01037230.
XX
XX (BOEF ) BOEHRINGER MANNHEIM GMBH.
PA
XX Hoffmann E, Goeke R, Goeke B;
PI
XX WPI; 1998-042119/04.
XX
XX

```

```

XX PT Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX PS Claim 2; Page 30; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX SQ Sequence 30 AA;
AAW39411 Length: 30 February 4, 2005 13:19 Type: P Check: 5012 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HSDGTFSTLSKQAEAEVRLFIWLKNGR 28
-----
1 match found in sequence:
aaw39415 ; H. horridum extendin-3 peptide derivative #58.
(from "seq4aggs.pep")
TOIG of: aaw39415 check: 4732 from: 1 to: 30
ID AAW39415 standard; peptide; 30 AA.
XX AC AAW39415;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum extendin-3 peptide derivative #58.
XX KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOE ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX DR WPI; 1998-042119/04.
XX PT Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX PS Claim 2; Page 30; 150pp; English.

```

```

XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.
CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
CC so they will not induce hypoglycaemia. Compared with glucagon-like
CC peptide 1 (GLP1) and the known extendins, they are more active (effective
CC at lower doses), more stable to degradation and metabolism and have a
CC longer lasting effect. Truncated forms of this peptide can be made more
CC economically than full length versions. (Updated on 25-MAR-2003 to
CC correct PR field.)
XX SQ Sequence 30 AA;
AAW39415 Length: 30 February 4, 2005 13:19 Type: P Check: 4732 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HSDGTFSTLSKQAEAEVRLFIWLKNGR 28
-----
1 match found in sequence:
aaw39416 ; H. horridum extendin-3 peptide derivative #59.
(from "seq4aggs.pep")
TOIG of: aaw39416 check: 5490 from: 1 to: 30
ID AAW39416 standard; peptide; 30 AA.
XX AC AAW39416;
XX DT 25-MAR-2003 (revised)
XX DT 05-JUN-1998 (first entry)
XX DE H. horridum extendin-3 peptide derivative #59.
XX KW Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
XX KW glucagon reduction; hypoglycaemia; glucose; treatment.
XX OS Heloderma horridum.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "C-terminal amide"
XX PN WO9746584-A1.
XX PD 11-DEC-1997.
XX PF 05-JUN-1997; 97WO-EP002930.
XX PR 05-JUN-1996; 96DE-01022502.
XX PR 13-SEP-1996; 96DE-01037230.
XX PA (BOE ) BOEHRINGER MANNHEIM GMBH.
XX PI Hoffmann E, Goeke R, Goeke B;
XX DR WPI; 1998-042119/04.
XX PT Truncated versions of extendin peptide(s) for treating diabetes - increase
PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
PT do not induce hypoglycaemia.
XX PS Claim 2; Page 30; 150pp; English.
XX CC Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
CC isolated from Heloderma horridum which are used in a novel method for the
CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
CC and secretion of insulin, but have the opposite effect on glucagon, and
CC independent of this activity can increase peripheral glucose utilisation.

```

CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to
 CC correct PR field.)
 CC
 SQ Sequence 30 AA;

AAW39416 Length: 30 February 4, 2005 13:19 Type: P Check: 5490 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGTFSTLSKQAEAEAVRLVFWLKNGR
 28

 1 match found in sequence:
 aaw39417 ; H. horridum extendin-3 peptide derivative #60.
 (from "seq4ags.pep")
 TOIG of: aaw39417 check: 5371 from: 1 to: 30

ID AAW39417 standard; peptide; 30 AA.

XX AC AAW39417;

XX DT 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum extendin-3 peptide derivative #60.

XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 30 /note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

XX 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goetze R, Goetze B;

XX WPI; 1998-042119/04.

XX Truncated versions of extendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 30; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to

CC correct PR field.)
 XX
 SQ Sequence 30 AA;
 AAW39417 Length: 30 February 4, 2005 13:19 Type: P Check: 5371 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGTFSTLSKQAEAEAVRLVFWLKNGR
 28

 1 match found in sequence:
 aaw39420 ; H. horridum extendin-3 peptide derivative #63.
 (from "seq4ags.pep")
 TOIG of: aaw39420 check: 5394 from: 1 to: 30

ID AAW39420 standard; peptide; 30 AA.

XX AC AAW39420;

XX DT 25-MAR-2003 (revised)

DT 05-JUN-1998 (first entry)

XX H. horridum extendin-3 peptide derivative #63.

XX Extendin-3; extendin 4; diabetes; insulin; secretion; biosynthesis;
 KW glucagon reduction; hypoglycaemia; glucose; treatment.

XX Heloderma horridum.

XX Key Location/Qualifiers

FT Modified-site 14 /label= Nle

FT /note= "Norleucine"

FT Modified-site 30 /note= "C-terminal amide"

XX WO9746584-A1.

XX 11-DEC-1997.

XX 05-JUN-1997; 97WO-EP002930.

XX 05-JUN-1996; 96DE-01022502.

XX 13-SEP-1996; 96DE-01037230.

XX (BOEF) BOEHRINGER MANNHEIM GMBH.

XX Hoffmann E, Goetze R, Goetze B;

XX WPI; 1998-042119/04.

XX Truncated versions of extendin peptide(s) for treating diabetes - increase
 PT secretion and biosynthesis of insulin, but reduce those of glucagon, and
 PT do not induce hypoglycaemia.

XX Claim 2; Page 31; 150pp; English.

XX Peptides AAW39303-W39420 are fragments of extendin-3 and extendin-4
 CC isolated from Heloderma horridum which are used in a novel method for the
 CC treatment of diabetes mellitus. These peptides can stimulate biosynthesis
 CC and secretion of insulin, but have the opposite effect on glucagon, and
 CC independent of this activity can increase peripheral glucose utilisation.
 CC Extendin-3 and extendin-4 are only active when blood sugar levels are high,
 CC so they will not induce hypoglycaemia. Compared with glucagon-like
 CC peptide 1 (GLP1) and the known extendins, they are more active (effective
 CC at lower doses), more stable to degradation and metabolism and have a
 CC longer lasting effect. Truncated forms of this peptide can be made more
 CC economically than full length versions. (Updated on 25-MAR-2003 to

XX correct PR field.)
 XX Sequence 30 AA;

AAW39420 Length: 30 February 4, 2005 13:19 Type: P Check: 5394 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTSLSKQEEAEVRLFIWLKNGR
28

1 match found in sequence:
aaw47608 ; Gila monster extendin-3.
(from "seq4ags.pep")
TOIG of: aaw47608 Check: 9591 from: 1 to: 39

ID AAW47608 standard; peptide; 39 AA.

XX AC AAW47608;

XX DT 03-JUL-1998 (first entry)

XX DE Gila monster extendin-3.

XX KW Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX KW postprandial dumping syndrome; postprandial hyperglycaemia;
XX KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX KW Gila monster venom; extendin-3.

XX OS Heloderma horridum.

XX FH Key Location/Qualifiers
XX FT Modified-site 39 /note= "amidated"

XX PN WO9805351-A1.
XX PD 12-FEB-1998.

XX PF 08-AUG-1997; 97WO-US014199.

XX PR 08-AUG-1996; 96US-00694954.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Gedulin B, Beeley NRA, Prickett KS;

XX DR WPI; 1998-145351/13.

XX PT Regulating gastrointestinal motility using extendins or their agonists -
XX PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX PT glucose tolerance etc., also in diagnostic investigations.

XX PS Claim 20 and 21; Fig 1; 70pp; English.

XX CC AAW47549 describes a generic extendin agonist, provided that it does have
XX CC the formula of either extendin-3 (AAW47608) or extendin-4 (AAW47609).
XX CC Extendin agonists, which reduce gastric motility and delay gastric
XX CC emptying, can be used to treat spasm (where associated with acute
XX CC diverticulitis or disorders of the biliary tract or sphincter of Oddi),
XX CC postprandial dumping syndrome and hyperglycaemia (particularly associated
XX CC with type 2 diabetes), type 1 diabetes, impaired glucose tolerance, toxin
XX CC ingestion (an extendin agonist is administered to prevent stomach contents
XX CC passing into the intestines, then the stomach pumped) and obesity. They
XX CC can also be administered to subjects undergoing gastrointestinal
XX CC diagnostic investigation, particularly radiological or by magnetic
XX CC resonance imaging. Extendins, components of Gila monster venom, have some
XX CC sequence similarity to glucagon-like peptides (GLP). They are GLP
XX CC agonists and have been suggested (US5424286) for treatment of diabetes
XX CC and prevention of hyperglycaemia

XX SQ Sequence 39 AA;

AAW47608 Length: 39 February 4, 2005 13:19 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTSLSKQEEAEVRLFIWLKNGR
28

1 match found in sequence:
aaw47609 ; Gila monster extendin-4.
(from "seq4ags.pep")
TOIG of: aaw47609 Check: 9570 from: 1 to: 39

ID AAW47609 standard; peptide; 39 AA.

XX AC AAW47609;

XX DT 03-JUL-1998 (first entry)

XX DE Gila monster extendin-4.

XX KW Extendin agonist; gastric motility; gastric emptying; treatment; spasm;
XX KW postprandial dumping syndrome; postprandial hyperglycaemia;
XX KW type 1 diabetes; impaired glucose tolerance; toxin ingestion; obesity;
XX KW Gila monster venom; extendin-4.

XX OS Heloderma suspectum.

XX FH Key Location/Qualifiers
XX FT Modified-site 39 /note= "amidated"

XX PN WO9805351-A1.
XX PD 12-FEB-1998.

XX PF 08-AUG-1997; 97WO-US014199.

XX PR 08-AUG-1996; 96US-00694954.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Gedulin B, Beeley NRA, Prickett KS;

XX DR WPI; 1998-145351/13.

XX PT Regulating gastrointestinal motility using extendins or their agonists -
XX PT for treating spasm, diabetic postprandial hyperglycaemia, impaired
XX PT glucose tolerance etc., also in diagnostic investigations.

XX PS Claim 20 and 21; Fig 1; 70pp; English.

XX CC AAW47549 describes a generic extendin agonist, provided that it does have
XX CC the formula of either extendin-3 (AAW47608) or extendin-4 (AAW47609).
XX CC Extendin agonists, which reduce gastric motility and delay gastric
XX CC emptying, can be used to treat spasm (where associated with acute
XX CC diverticulitis or disorders of the biliary tract or sphincter of Oddi),
XX CC postprandial dumping syndrome and hyperglycaemia (particularly associated
XX CC with type 2 diabetes), type 1 diabetes, impaired glucose tolerance, toxin
XX CC ingestion (an extendin agonist is administered to prevent stomach contents
XX CC passing into the intestines, then the stomach pumped) and obesity. They
XX CC can also be administered to subjects undergoing gastrointestinal
XX CC diagnostic investigation, particularly radiological or by magnetic
XX CC resonance imaging. Extendins, components of Gila monster venom, have some
XX CC sequence similarity to glucagon-like peptides (GLP). They are GLP
XX CC agonists and have been suggested (US5424286) for treatment of diabetes
XX CC and prevention of hyperglycaemia

XX SQ Sequence 39 AA;

AAW47609 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HSDGFTSLSKQEEAEVRLFIWLKNGR
28


```

PF 07-JAN-1998; 98WO-US000449.
XX
PR 07-JAN-1997; 97US-003490SP.
PR 08-AUG-1997; 97US-0055404P.
PR 14-NOV-1997; 97US-0065442P.
PR 14-NOV-1997; 97US-0066029P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beesley NRA, Prickett KS, Bhavsar S;
XX
XX WPI; 1998-398796/34.
XX
XX Reducing food intake by administering exendin(s) or their analogue(s) -
PT for treatment of e.g. obesity, type II diabetes, eating disorders and
PT insulin resistance.
XX
XX Claim 18, 26; Page 12; 214pp; English.
XX
XX The invention relates to a new method for treating disorders that are
CC alleviated by reducing food intake, in particular obesity, type II
CC diabetes, eating disorders, insulin resistance syndrome, elevated plasma
CC glucose levels or the risk of cardiac disease. The method comprises
CC administering an exendin or an exendin agonist. The treatment reduces
CC appetite and lowers plasma lipid levels. It inhibits food consumption as
CC effectively as amylin or cholecystokinin but has a much longer-lasting
CC action (still effective after 6 hours in a mouse model). The present
CC sequence is that of exendin-4 (1-28) amide which is one of the preferred
CC compounds for use in the method
XX
XX Sequence 28 AA;
SQ
AAW61772 Length: 28 February 4, 2005 13:19 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTFTSDLSKQMEEAFLFIWLKN 28

-----
1 match found in sequence:
aaw61773 ; Leu(14), Phe(25)-exendin-4 amide, for reducing food intake.
(from "seq4ags.pep")
TOIG of: aaw61773 check: 9131 from: 1 to: 39

ID AAW61773 standard; peptide; 39 AA.
XX
AC AAW61773;
XX
XX
DT 29-MAR-1999 (first entry)
XX
XX Leu(14), Phe(25)-exendin-4 amide, for reducing food intake.
XX
XX Exendin; obesity; type II diabetes; eating disorders; cardiac disease;
KW insulin resistance syndrome; elevated plasma glucose level; agonist.
XX
XX Heloderma:suspectum.
OS
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal is in amide form"
XX
XX WO9830231-A1.
XX
XX 16-JUL-1998.
XX
XX 07-JAN-1998; 98WO-US000449.
XX
XX 07-JAN-1997; 97US-003490SP.
XX 08-AUG-1997; 97US-0055404P.
XX 14-NOV-1997; 97US-0065442P.
XX 14-NOV-1997; 97US-0066029P.

```

```

XX (AMYL-) AMYLIN PHARM INC.
PA
PI Beoley NRA, Prickett KS, Bhavsar S;
XX
XX WPI; 1998-398796/34.
DR
XX
XX Reducing food intake by administering exendin(s) or their analogue(s) -
PT for treatment of e.g. obesity, type II diabetes, eating disorders and
PT insulin resistance.
XX
XX Claim 18, 26; Page 12; 214pp; English.
PS
XX
XX The invention relates to a new method for treating disorders that are
CC alleviated by reducing food intake, in particular obesity, type II
CC diabetes, eating disorders, insulin resistance syndrome, elevated plasma
CC glucose levels, or the risk of cardiac disease. The method comprises
CC administering an exendin or an exendin agonist. The treatment reduces
CC appetite and lowers plasma lipid levels. It inhibits food consumption as
CC effectively as amylin or cholecystokinin but has a much longer-lasting
CC action (still effective after 6 hours in a mouse model). The present
CC sequence is that of an exendin-4 variant which is one of the preferred
CC compounds for use in the method
XX
XX Sequence 39 AA;
SQ
AAW61773 Length: 39 February 4, 2005 13:19 Type: P Check: 9131 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGGFTSDLSKQLBEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aaw61774; Leu(14), Phe(25)-exendin-4 (1-28) amide, for reducing food intake.
(from "seq4ags.pep")
TOIG of: aaw61774 check: 261 from: 1 to: 28
-----
ID AAW61774 standard; peptide; 28 AA.
XX
XX AC AAW61774;
XX
XX DT 29-MAR-1999 (first entry)
XX
XX DE Leu(14), Phe(25)-exendin-4 (1-28) amide, for reducing food intake.
XX
XX KW Exendin; obesity; type II diabetes; eating disorders; cardiac disease;
KW insulin resistance syndrome; elevated plasma glucose level; agonist.
XX
XX OS Heloderma suspectum.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 28 /note= "the C-terminal is in amide form"
FT
XX WO9830231-A1.
XX
XX PD 16-JUL-1998.
XX
XX PF 07-JAN-1998; 98WO-US000449.
XX
XX PR 07-JAN-1997; 97US-0034905P.
XX
XX PR 08-AUG-1997; 97US-0055404P.
XX
XX PR 14-NOV-1997; 97US-0065442P.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beoley NRA, Prickett KS, Bhavsar S;
XX
XX WPI; 1998-398796/34.
XX

```

```

XX Reducing food intake by administering exendin(s) or their analogue(s) -
PT for treatment of e.g. obesity, type II diabetes, eating disorders and
PT insulin resistance.
XX
XX Claim 18, 26; Page 12; 214pp; English.
PS
XX
XX The invention relates to a new method for treating disorders that are
CC alleviated by reducing food intake, in particular obesity, type II
CC diabetes, eating disorders, insulin resistance syndrome, elevated plasma
CC glucose levels, or the risk of cardiac disease. The method comprises
CC administering an exendin or an exendin agonist. The treatment reduces
CC appetite and lowers plasma lipid levels. It inhibits food consumption as
CC effectively as amylin or cholecystokinin but has a much longer-lasting
CC action (still effective after 6 hours in a mouse model). The present
CC sequence is that of an exendin-4 variant which is one of the preferred
CC compounds for use in the method
XX
XX Sequence 28 AA;
SQ
AAW61774 Length: 28 February 4, 2005 13:19 Type: P Check: 261 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGGFTSDLSKQLBEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aaw61775; Leu(14), Ala(22), Phe(25)-exendin-4 (1-28) amide.
(from "seq4ags.pep")
TOIG of: aaw61775 check: 151 from: 1 to: 28
-----
ID AAW61775 standard; peptide; 28 AA.
XX
XX AC AAW61775;
XX
XX DT 29-MAR-1999 (first entry)
XX
XX DE Leu(14), Ala(22), Phe(25)-exendin-4 (1-28) amide.
XX
XX KW Exendin; obesity; type II diabetes; eating disorders; cardiac disease;
KW insulin resistance syndrome; elevated plasma glucose level; agonist.
XX
XX OS Heloderma suspectum.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 28 /note= "the C-terminal is in amide form"
FT
XX WO9830231-A1.
XX
XX PD 16-JUL-1998.
XX
XX PF 07-JAN-1998; 98WO-US000449.
XX
XX PR 07-JAN-1997; 97US-0034905P.
XX
XX PR 08-AUG-1997; 97US-0055404P.
XX
XX PR 14-NOV-1997; 97US-0065442P.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beoley NRA, Prickett KS, Bhavsar S;
XX
XX WPI; 1998-398796/34.
XX
XX Reducing food intake by administering exendin(s) or their analogue(s) -
PT for treatment of e.g. obesity, type II diabetes, eating disorders and
PT insulin resistance.
XX
XX Claim 18, 26; Page 12; 214pp; English.
PS

```

XX The invention relates to a new method for treating disorders that are
 CC alleviated by reducing food intake, in particular obesity, type II
 CC diabetes, eating disorders, insulin resistance syndrome, elevated plasma
 CC glucose levels, or the risk of cardiac disease. The method comprises
 CC administering an extendin or an extendin agonist. The treatment reduces
 CC appetite and lowers plasma lipid levels. It inhibits food consumption as
 CC effectively as amylin or cholecystokinin but has a much longer-lasting
 CC action (still effective after 6 hours in a mouse model). The present
 CC sequence is that of an extendin-4 variant which is one of the preferred
 CC compounds for use in the method
 XX
 XX Sequence '28 AA';
 SQ
 AAW61775 Length: 28 February 4, 2005 13:19 Type: P Check: 151 ..
 Found using 'seq4' (mohamed337.key)

1 HEGTFTSDLSKQLEBEAVRLAIEFLKN 28
 1

 1 match found in sequence:
 aaw70288 ; Heloderma suspectum proextendin peptide.
 (from "seq4ags.pep")
 TOIG of: aaw70288 check: 973 from: 1 to: 87

ID AAW70288 standard; protein; 87 AA.
 AC
 AC AAW70288;
 XX
 DT 06-NOV-1998 (first entry)
 XX
 DE Heloderma suspectum proextendin peptide.
 XX
 XX Heloderma suspectum proextendin; extendin N-terminal peptide; ENTP;
 KW extendin 4 peptide; extendin 3 gene; Heloderma horridum; metabolic disease;
 KW drug screening; endocrine tumour; organ failure; cell metabolism;
 KW diabetes; reptilian venom peptide.
 XX
 OS Heloderma suspectum.
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..47
 FT /note= "ENTP"
 FT Peptide 1..23
 FT /note= "Signal peptide"
 FT Cleavage-site 46..47
 FT /note= "Dipeptidyl peptidase cleavage site"
 FT Peptide 48..87
 FT /note= "Extendin 4"
 XX
 XX WO9835033-A1.
 PN
 XX
 XX 13-AUG-1998.
 PD
 XX
 XX 04-FEB-1998; 98WO-CA000071.
 PF
 XX
 XX 05-FEB-1997; 97US-0037412P.
 PR
 XX 07-FEB-1997; 97GB-00002582.
 PR
 XX
 XX (ONEO-) 1149336 ONTARIO INC.
 PA
 XX
 XX Drucker DJ;
 PI
 XX
 XX WPI; 1998-447230/38.
 DR
 XX N-PSDB; AAV33163.
 DR
 XX
 XX New nucleic acid encoding proextendin - used to diagnose and treat, e.g.
 PT endocrine tumours, also to treat poisoning by reptile venom.
 PT
 XX
 XX Claim 3; Fig 2; 26pp; English.
 PS
 XX

CC The Heloderma suspectum proextendin peptide is encoded by its cDNA which
 CC was isolated from a H. suspectum salivary gland cDNA library. The
 CC proextendin protein comprises of a novel extendin N-terminal peptide (ENTP)
 CC linked to the N-terminus of the extendin 4 peptide by a consensus
 CC dipeptidyl peptidase cleavage site. The proextendin cDNA can be used to
 CC clone or identify related sequences (e.g. the extendin 3 gene of Heloderma
 CC horridum, mutant alleles and proextendin gene regulatory defects
 CC associated with metabolic disease) and species homologues (e.g. for
 CC developing animal models for drug screening). The proextendin peptide can
 CC be used to raise antibodies. Anti-proextendin antibodies are claimed to be
 CC useful for diagnosing conditions associated with altered levels of
 CC proextendin (e.g. endocrine tumours and organ failure), for identifying
 CC other regulators of cell metabolism, in drug screens and for treating
 CC metabolic diseases (e.g. diabetes) and for neutralising, or detecting,
 CC reptilian venom peptides
 XX
 XX Sequence 87 AA;
 SQ
 AAW70288 Length: 87 February 4, 2005 13:19 Type: P Check: 973 ..
 Found using 'seq4' (mohamed337.key)

1 MKILWLCVFGFLFLATLFPISMQMPVESGLSSSDSASSSPASKIKRHGEGTFTSDLSKQ 48
 1

 61 MEEAVRLFIWLKNGGPPSSGAPPFSG 75
 75

 1 match found in sequence:
 aay03717 ; Amino acid sequence of extendin-3.
 (from "seq4ags.pep")
 TOIG of: aay03717 check: 9591 from: 1 to: 39

ID AAY03717 standard; peptide; 39 AA.
 XX
 AC AAY03717;
 XX
 DT 08-JUN-1999 (first entry)
 XX
 DE Amino acid sequence of extendin-3.
 XX
 XX
 KW Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
 KW diagnostic; gastro-intestinal; radiological; generic.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 FT
 XX
 XX WO9907404-A1.
 PN
 XX
 XX 18-FEB-1999.
 PD
 XX
 XX 06-AUG-1998; 98WO-US016387.
 PF
 XX
 XX 08-AUG-1997; 97US-0055404P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX
 XX Beeley NRA, Prickett KS;
 PI
 XX WPI; 1999-180403/15.
 DR
 XX
 XX New extendin agonists - useful in the treatment of Type I and II diabetes.
 PS
 XX Disclosure; Fig 2; 70pp; English.
 XX
 XX The invention relates to extendin agonists which slow gastric emptying and
 CC lower plasma glucose levels. The peptides are of the formula Xaa1-Xaa2-
 CC Xaa3-Gly-Thr-Xaa4-Xaa5-Xaa6-Xaa7-Lys-Gln-Xaa9-Glu-Glu-- Glu-Ala-

CC Val-Arg-Leu-Xaa10- Xaa11- Xaa12- Xaa13-Leu-Lys-Asn-Gly-Gly Xaa14-Ser-Ser-
 CC Gly-Ala- Xaa15-Xaa16- Xaa17- Xaa18-2; wherein: Xaa1 is His, Arg or Tyr;
 CC Xaa2 is Ser, Gly, Ala, or Thr; Xaa3 is Asp or Glu; Xaa4 is Phe, Tyr, or
 CC naphthylalanine; Xaa5 is Thr or Ser; Xaa6 is Ser or Thr; Xaa7 is Asp or
 CC Glu; Xaa8 is Leu, Ile, Val, pentylglycine, or Met; Xaa9 is Leu, Ile,
 CC pentylglycine, Val, or Met; Xaa10 is Phe, Tyr, or naphthylalanine; Xaa11
 CC is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met; Xaa12 is Glu
 CC or Asp; Xaa13 is Trp, Phe, Tyr, or naphthylalanine; Xaa14, Xaa15, Xaa16,
 CC and Xaa17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-
 CC alkylglycine, N-alkylpentylglycine, or N-alkylalanine; Xaa18 is Ser, Thr,
 CC or Tyr; and Z is -OH or -NH2 with the proviso that the sequence is not
 CC the amino acid sequences shown in the present sequence and AAY03718. The
 CC specification claims for a second peptide of the above formula where Xaa1
 CC is His, Arg, Tyr or 4-imidazopropionyl. The extendin agonists are used to
 CC treat Type I and II diabetes, disorders which would be benefited by
 CC agents which lower plasma glucose levels, and disorders which would be
 CC benefited by agents useful in delaying and/or slowing gastric emptying.
 CC Delayed gastric emptying is a useful diagnostic aid in gastro-intestinal
 CC radiological examinations. The present sequence represents the amino acid
 CC sequence of extendin-3
 XX
 SQ Sequence 39 AA;

AAY03717 Length: 39 February 4, 2005 13:19 Type: P Check: 9591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEAEAVRLFIEWLKNKGPPSGAPPPS
 1
 28

1 match found in sequence:

ay03718 ; Amino acid sequence of extendin-4.

(from "seq4ags.pep")
 TOIG of: ay03718 check: 9570 from: 1 to: 39

ID AAY03718 standard; peptide; 39 AA.

XX AC AAY03718;

XX DT 08-JUN-1999 (first entry)

XX DE Amino acid sequence of extendin-4.

XX KW Extendin; agonist; diabetes; disorder; plasma glucose; gastric;
 XX KW diagnostic; gastro-intestinal; radiological; generic.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 39 /note= "C-terminal amide"

XX FT WO9097404-A1.

XX PD 18-FEB-1999.

XX PF 06-AUG-1998; 98WO-US016387.

XX PR 08-AUG-1997; 97US-0055404P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett KS;

XX DR WPI; 1999-180403/15.

XX PT New extendin agonists - useful in the treatment of Type I and II diabetes.

XX PS Disclosure; Fig 3; 70pp; English.

XX CC The invention relates to extendin agonists which slow gastric emptying and
 CC lower plasma glucose levels. The peptides are of the formula Xaa1-Xaa2-

CC Xaa3-Gly-Thr-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Ser-Lys-Gln-Xaa9-Glu-Glu-- Glu-Ala-
 CC Val-Arg-Leu-Xaa10- Xaa11- Xaa12- Xaa13-Leu-Lys-Asn-Gly-Gly Xaa14-Ser-Ser-
 CC Gly-Ala- Xaa15-Xaa16- Xaa17- Xaa18-2; wherein: Xaa1 is His, Arg or Tyr;
 CC Xaa2 is Ser, Gly, Ala, or Thr; Xaa3 is Asp or Glu; Xaa4 is Phe, Tyr, or
 CC naphthylalanine; Xaa5 is Thr or Ser; Xaa6 is Ser or Thr; Xaa7 is Asp or
 CC Glu; Xaa8 is Leu, Ile, Val, pentylglycine, or Met; Xaa9 is Leu, Ile,
 CC pentylglycine, Val, or Met; Xaa10 is Phe, Tyr, or naphthylalanine; Xaa11
 CC is Ile, Val, Leu, pentylglycine, tert-butylglycine, or Met; Xaa12 is Glu
 CC or Asp; Xaa13 is Trp, Phe, Tyr, or naphthylalanine; Xaa14, Xaa15, Xaa16,
 CC and Xaa17 are independently Pro, homoproline, 3Hyp, 4Hyp, thioproline, N-
 CC alkylglycine, N-alkylpentylglycine, or N-alkylalanine; Xaa18 is Ser, Thr,
 CC or Tyr; and Z is -OH or -NH2 with the proviso that the sequence is not
 CC the amino acid sequences shown in the present sequence and AAY03717. The
 CC specification claims for a second peptide of the above formula where Xaa1
 CC is His, Arg, Tyr or 4-imidazopropionyl. The extendin agonists are used to
 CC treat Type I and II diabetes, disorders which would be benefited by
 CC agents which lower plasma glucose levels, and disorders which would be
 CC benefited by agents useful in delaying and/or slowing gastric emptying.
 CC Delayed gastric emptying is a useful diagnostic aid in gastro-intestinal
 CC radiological examinations. The present sequence represents the amino acid
 CC sequence of extendin-4
 XX
 SQ Sequence 39 AA;

AAY03718 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEAEAVRLFIEWLKNKGPPSGAPPPS
 1
 28

1 match found in sequence:

ay17536 ; Extendin agonist peptide #2.

(from "seq4ags.pep")
 TOIG of: ay17536 check: 249 from: 1 to: 28

ID AAY17536 standard; peptide; 28 AA.

XX AC AAY17536;

XX DT 09-AUG-1999 (first entry)

XX DE Extendin agonist peptide #2.

XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX OS Synthetic.

XX OS Heloderma sp.

XX FN WO925728-A1.

XX PD 27-MAY-1999.

XX PF 13-NOV-1998; 98WO-US024273.

XX PR 14-NOV-1997; 97US-0066029P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett KS;

XX DR WPI; 1999-347456/29.

XX PT Peptide agonists of extendin - delay stomach emptying, for treating
 XX PT diabetes and hypo- or hyper-glycemia.

XX PS Claim 28; Fig 4; 144pp; English.

XX CC AAY17535 to AAY17624 represent extendin peptide agonists. Extendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard

CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 28 AA;
 SQ

AA17536 Length: 28 February 4, 2005 13:19 Type: P Check: 249 ..
 Found using 'seq4' (mohamed337.key)

1 HGAGTFTSDLSKQMBEEAVRLFIEWLKN 28
 1

1 match found in sequence:
 aay17540; Exendin agonist peptide #6.
 (from "seq4ags.pep")
 TOIG of: aay17540 check: 688 from: 1 to: 28

ID AAY17540 standard; peptide; 28 AA.
 XX
 AC AAY17540;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #6.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925728-A1.
 PD 27-MAY-1999.
 PF 13-NOV-1998; 98WO-US024273.
 PR 14-NOV-1997; 97US-0066029P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-347456/29.
 PT Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.
 XX
 PS Claim 28; Fig 4; 144pp; English.

CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
 CC peptides that are found in the venom of the Gila-monster, a lizard
 CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
 CC to treat diabetes mellitus (types I or II), hyperglycaemia or
 CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
 CC extendins and their agonists. They regulate gastric motility and slow
 CC gastric emptying (resulting in lower post-prandial glucose levels)
 XX Sequence 28 AA;
 SQ

AA17540 Length: 28 February 4, 2005 13:19 Type: P Check: 688 ..
 Found using 'seq4' (mohamed337.key)

1 HGAGTFTSDLSKQMBEEAVRLFIEWLKN 28
 1

1 match found in sequence:
 aay17540; Exendin agonist peptide #6.
 (from "seq4ags.pep")
 TOIG of: aay17540 check: 688 from: 1 to: 28

1 match found in sequence:
 aay17543; Exendin agonist peptide #9.
 (from "seq4ags.pep")
 TOIG of: aay17543 check: 590 from: 1 to: 28

ID AAY17543 standard; peptide; 28 AA.
 XX
 AC AAY17543;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #9.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925728-A1.
 PD 27-MAY-1999.
 PF 13-NOV-1998; 98WO-US024273.
 PR 14-NOV-1997; 97US-0066029P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-347456/29.
 PT Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.
 XX
 PS Claim 28; Fig 4; 144pp; English.

AA17543 Length: 28 February 4, 2005 13:19 Type: P Check: 590 ..
 Found using 'seq4' (mohamed337.key)

1 HGEGTFTSDASKQMBEEAVRLFIEWLKN 28
 1

1 match found in sequence:
 aay17603; Exendin agonist peptide #69.
 (from "seq4ags.pep")
 TOIG of: aay17603 check: 5882 from: 1 to: 38

ID AAY17603 standard; peptide; 38 AA.
 XX
 AC AAY17603;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #69.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925728-A1.
 PD 27-MAY-1999.
 PF 13-NOV-1998; 98WO-US024273.
 PR 14-NOV-1997; 97US-0066029P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-347456/29.
 PT Peptide agonists of exendin - delay stomach emptying, for treating
 PT diabetes and hypo- or hyper-glycemia.
 XX
 PS Claim 28; Fig 4; 144pp; English.

AA17543 Length: 28 February 4, 2005 13:19 Type: P Check: 590 ..
 Found using 'seq4' (mohamed337.key)

1 HGEGTFTSDASKQMBEEAVRLFIEWLKN 28
 1

1 match found in sequence:
 aay17603; Exendin agonist peptide #69.
 (from "seq4ags.pep")
 TOIG of: aay17603 check: 5882 from: 1 to: 38

ID AAY17603 standard; peptide; 38 AA.
 XX
 AC AAY17603;
 XX
 DT 09-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #69.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

```
XX Synthetic.
OS Heloderma sp.
XX WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX SQ Sequence 38 AA;

AAY17603 Length: 38 February 4, 2005 13:19 Type: P Check: 5882 ..
Found using 'seq4' (mohamed337.key)

1 HGAGTFTSDLSKQLEEEAVRLFIEFLKNGGPGSGAPP
1
-----|-----|
1 match found in sequence:
aay17608 ; Exendin agonist peptide #74.
(from "seq4ags pep")
TOIG of: aay17608 check: 7002 from: 1 to: 35

ID AAY17608 standard; peptide; 35 AA.
XX
XX AC AAY17608;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #74.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX SQ Sequence 38 AA;

AAY17603 Length: 38 February 4, 2005 13:19 Type: P Check: 5882 ..
Found using 'seq4' (mohamed337.key)

1 HGAGTFTSDLSKQLEEEAVRLFIEFLKNGGPGSGAPP
1
-----|-----|
1 match found in sequence:
aay17608 ; Exendin agonist peptide #74.
(from "seq4ags pep")
TOIG of: aay17608 check: 7002 from: 1 to: 35

ID AAY17608 standard; peptide; 35 AA.
XX
XX AC AAY17608;
XX
XX DT 09-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #74.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925728-A1.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024273.
XX
XX PR 14-NOV-1997; 97US-0066029P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX WPI; 1999-347456/29.
XX
XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX diabetes and hypo- or hyper-glycemia.
XX
XX PS Claim 28; Fig 4; 144pp; English.
XX
XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX peptides that are found in the venom of the Gila-monster, a lizard
XX endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX to treat diabetes mellitus (types I or II), hyperglycaemia or
XX hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX exendins and their agonists. They regulate gastric motility and slow
XX gastric emptying (resulting in lower post-prandial glucose levels)
XX
XX SQ Sequence 32 AA;
```

AAV17612 Length: 32 February 4, 2005 13:19 Type: P Check: 9574 ..
Found using 'seq4' (mohamed337.key)

1 HGAGTFTDLSKQMBEEAVRLFIEFLKNGGPS
28

1 match found in sequence:

aay17616 ; Exendin agonist peptide #82.
(from "seq4ags.pep")
TOIG of: aay17616 check: 7457 from: 1 to: 38

ID AAY17616 standard; peptide; 38 AA.

XX AC
XX AAY17616;

DT 09-AUG-1999 (first entry)

XX DE Exendin agonist peptide #82.

XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX OS Synthetic.

XX OS Heloderma sp.

XX PN WO9925728-A1.

XX PD 27-MAY-1999.

XX PF 13-NOV-1998; 98WO-US024273.

XX PR 14-NOV-1997; 97US-0066029P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett KS;

XX DR WPI; 1999-347456/29.

XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.

XX PS Claim 28; Fig 4; 144pp; English.

XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC exendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)

XX SQ Sequence 38 AA;

AAV17616 Length: 38 February 4, 2005 13:19 Type: P Check: 7457 ..
Found using 'seq4' (mohamed337.key)

1 HGAGTFTDLSKQMBEEAVRLFIEFLKNGCXSGAXXX
28

1 match found in sequence:

aay17620 ; Exendin agonist peptide #86.
(from "seq4ags.pep")
TOIG of: aay17620 check: 7441 from: 1 to: 35

ID AAY17620 standard; peptide; 35 AA.

XX

AC AAY17620;

XX DT 09-AUG-1999 (first entry)

XX DE Exendin agonist peptide #86.

XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX OS Synthetic.

XX OS Heloderma sp.

XX PN WO9925728-A1.

XX PD 27-MAY-1999.

XX PF 13-NOV-1998; 98WO-US024273.

XX PR 14-NOV-1997; 97US-0066029P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Beeley NRA, Prickett KS;

XX DR WPI; 1999-347456/29.

XX PT Peptide agonists of exendin - delay stomach emptying, for treating
XX PT diabetes and hypo- or hyper-glycemia.

XX PS Claim 28; Fig 4; 144pp; English.

XX CC AAY17535 to AAY17624 represent exendin peptide agonists. Exendins are
XX CC peptides that are found in the venom of the Gila-monster, a lizard
XX CC endogenous to Arizona and Northern Mexico. The peptide agonists are used
XX CC to treat diabetes mellitus (types I or II), hyperglycaemia or
XX CC hypoglycaemia. They can also be used for in vitro and in vivo studies on
XX CC exendins and their agonists. They regulate gastric motility and slow
XX CC gastric emptying (resulting in lower post-prandial glucose levels)

XX SQ Sequence 35 AA;

AAV17620 Length: 35 February 4, 2005 13:19 Type: P Check: 7441 ..
Found using 'seq4' (mohamed337.key)

1 HGAGTFTDLSKQMBEEAVRLFIEFLKNGGPSSGA
28

1 match found in sequence:

aay24809 ; Exendin agonist peptide #1.
(from "seq4ags.pep")
TOIG of: aay24809 check: 4889 from: 1 to: 30

ID AAY24809 standard; peptide; 30 AA.

XX AC

XX AC AAY24809;

DT 24-AUG-1999 (first entry)

XX DE Exendin agonist peptide #1.

XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX OS Synthetic.

XX OS Heloderma sp.

XX PN WO9925727-A2.

XX PD 27-MAY-1999.

CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 28 AA;

AAAY24811 Length: 28 February 4, 2005 13:19 Type: P Check: 275 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGGTFTSLSKQMEEEAVRLFIEFLKN 28

1 match found in sequence:
aay24812 ; Exendin agonist peptide #4.
(from "seq4ags.pep")
TOIG of: aay24812 check: 263 from: 1 to: 28

ID AAY24812 standard; peptide; 28 AA.
XX
AC AAY24812;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #4.
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX
OS Synthetic.
OS Heloderma sp.
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.

CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying

XX Sequence 28 AA;
AAAY24812 Length: 28 February 4, 2005 13:19 Type: P Check: 263 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGGTFTSLSKQMEEEAVRLFIEFLKN 28

1 match found in sequence:
aay24813 ; Exendin agonist peptide #5.
(from "seq4ags.pep")
TOIG of: aay24813 check: 166 from: 1 to: 28

ID AAY24813 standard; peptide; 28 AA.
XX
AC AAY24813;
XX
DT 24-AUG-1999 (first entry)
XX
DE Exendin agonist peptide #5.

XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX
OS Synthetic.
OS Heloderma sp.
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.

XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.

XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.

XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.

CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying

XX Sequence 28 AA;

AAAY24813 Length: 28 February 4, 2005 13:19 Type: P Check: 166 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGGTFTSLSKQMEEEAVRLFIEFLKN 28

1 match found in sequence:
aay24814 ; Exendin agonist peptide #6.
(from "seq4ags.pep")
TOIG of: aay24814 check: 231 from: 1 to: 28

ID AAY24814 standard; peptide; 28 AA.
XX
AC AAY24814;
XX
DT 24-AUG-1999 (first entry)

```

XX DE      Exendin agonist peptide #6.
XX KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS      Synthetic.
XX OS      Heloderma sp.
XX PN      WO9925727-A2.
XX PD      27-MAY-1999.
XX PF      13-NOV-1998; 98WO-US024210.
XX PR      14-NOV-1997; 97US-0065442P.
XX PA      (AMYL-) AMYLIN PHARM INC.
XX PI      Beeley NRA, Prickett KS;
XX DR      WPI; 1999-394773/33.
XX XX      New exendin agonist peptides - can regulate gastric motility and slow
XX PT      gastric emptying, used for treating, e.g. diabetes.
XX PS      Claim 18; Fig 4; 108pp; English.
XX CC      AAY24809 to AAY24877 represent exendin agonist peptides which can
XX CC      regulate gastric motility and slow gastric emptying. The peptides can be
XX CC      used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC      conditions. The peptides are exendin agonists which have activity as
XX CC      agents to regulate gastric motility and to slow gastric emptying, as
XX CC      evidenced by the ability to reduce post-prandial glucose levels in
XX CC      mammals. They can be used for the treatment of Type I and II diabetes and
XX CC      hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC      treatment of disorders which would be benefited by agents which lower
XX CC      plasma glucose levels and in treatment of disorders which would be
XX CC      benefited with agents useful in delaying and/or slowing gastric emptying
XX XX      Sequence 28 AA;
XX PD      AAY24814 Length: 28 February 4, 2005 13:19 Type: P Check: 231 ..
XX PF      Found using 'seq4' (mohamed337.key)
1 1  |-----|
    HGEGTATSDLSKQLBEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay24815 ; Exendin agonist peptide #7.
(from "seq4ags.pep")
TOIG of: aay24815 check: 117 from: 1 to: 28

ID AAY24815 standard; peptide; 28 AA.
XX AC      AAY24815;
XX DT      24-AUG-1999 (first entry)
XX DE      Exendin agonist peptide #7.
XX KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS      Synthetic.
XX OS      Heloderma sp.
XX PN      WO9925727-A2.
XX PD      27-MAY-1999.
XX PF      13-NOV-1998; 98WO-US024210.
XX PR      14-NOV-1997; 97US-0065442P.
XX PA      (AMYL-) AMYLIN PHARM INC.
XX PI      Beeley NRA, Prickett KS;
XX DR      WPI; 1999-394773/33.
XX XX      New exendin agonist peptides - can regulate gastric motility and slow
XX PT      gastric emptying, used for treating, e.g. diabetes.
XX PS      Claim 18; Fig 4; 108pp; English.
XX CC      AAY24809 to AAY24877 represent exendin agonist peptides which can
XX CC      regulate gastric motility and slow gastric emptying. The peptides can be
XX CC      used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC      conditions. The peptides are exendin agonists which have activity as
XX CC      agents to regulate gastric motility and to slow gastric emptying, as
XX CC      evidenced by the ability to reduce post-prandial glucose levels in
XX CC      mammals. They can be used for the treatment of Type I and II diabetes and
XX CC      hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC      treatment of disorders which would be benefited by agents which lower
XX CC      plasma glucose levels and in treatment of disorders which would be
XX CC      benefited with agents useful in delaying and/or slowing gastric emptying
XX XX      Sequence 28 AA;
XX PD      AAY24814 Length: 28 February 4, 2005 13:19 Type: P Check: 231 ..
XX PF      Found using 'seq4' (mohamed337.key)
1 1  |-----|
    HGEGTATSDLSKQLBEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay24815 ; Exendin agonist peptide #7.
(from "seq4ags.pep")
TOIG of: aay24815 check: 117 from: 1 to: 28

ID AAY24815 standard; peptide; 28 AA.
XX AC      AAY24815;
XX DT      24-AUG-1999 (first entry)
XX DE      Exendin agonist peptide #7.
XX KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS      Synthetic.
XX OS      Heloderma sp.
XX PN      WO9925727-A2.
XX PD      27-MAY-1999.
XX PF      13-NOV-1998; 98WO-US024210.
XX PR      14-NOV-1997; 97US-0065442P.
XX PA      (AMYL-) AMYLIN PHARM INC.
XX PI      Beeley NRA, Prickett KS;
XX DR      WPI; 1999-394773/33.

```

```

PD 27-MAY-1999.
XX 13-NOV-1998; 98WO-US024210.
XX 14-NOV-1997; 97US-0065442P.
XX (AMYL-) AMYLIN PHARM INC.
XX Beeley NRA, Prickett KS;
XX WPI; 1999-394773/33.
XX XX      New exendin agonist peptides - can regulate gastric motility and slow
XX PT      gastric emptying, used for treating, e.g. diabetes.
XX PS      Claim 18; Fig 4; 108pp; English.
XX CC      AAY24809 to AAY24877 represent exendin agonist peptides which can
XX CC      regulate gastric motility and slow gastric emptying. The peptides can be
XX CC      used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC      conditions. The peptides are exendin agonists which have activity as
XX CC      agents to regulate gastric motility and to slow gastric emptying, as
XX CC      evidenced by the ability to reduce post-prandial glucose levels in
XX CC      mammals. They can be used for the treatment of Type I and II diabetes and
XX CC      hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC      treatment of disorders which would be benefited by agents which lower
XX CC      plasma glucose levels and in treatment of disorders which would be
XX CC      benefited with agents useful in delaying and/or slowing gastric emptying
XX XX      Sequence 28 AA;
XX PD      AAY24815 Length: 28 February 4, 2005 13:19 Type: P Check: 117 ..
XX PF      Found using 'seq4' (mohamed337.key)
1 1  |-----|
    HGEGTFTADLSKQLBEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay24816 ; Exendin agonist peptide #8.
(from "seq4ags.pep")
TOIG of: aay24816 check: 151 from: 1 to: 28

ID AAY24816 standard; peptide; 28 AA.
XX AC      AAY24816;
XX DT      24-AUG-1999 (first entry)
XX DE      Exendin agonist peptide #8.
XX KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS      Synthetic.
XX OS      Heloderma sp.
XX PN      WO9925727-A2.
XX PD      27-MAY-1999.
XX PF      13-NOV-1998; 98WO-US024210.
XX PR      14-NOV-1997; 97US-0065442P.
XX PA      (AMYL-) AMYLIN PHARM INC.
XX PI      Beeley NRA, Prickett KS;
XX DR      WPI; 1999-394773/33.

```

```

PT New extendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 28 AA;
SQ
AAY24816 Length: 28 February 4, 2005 13:19 Type: P Check: 151 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDASKQLEEEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aay24817; Extendin agonist peptide #9.
(from "seq4ags.pep")
TOIG of: aay24817 check: 63 from: 1 to: 28
ID AAY24817 standard; peptide; 28 AA.
XX
XX AAY24817;
AC
XX
XX 24-AUG-1999 (first entry)
DT
XX
XX Extendin agonist peptide #9.
DE
XX
XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO9925727-A2.
PN
XX
XX 27-MAY-1999.
PD
XX
XX 13-NOV-1998; 98WO-US024210.
PF
XX
XX 14-NOV-1997; 97US-0065442P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
PI
XX
XX WPI; 1999-394773/33.
DR
XX
XX New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
PS Claim 18; Fig 4; 108pp; English.
XX
XX AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and

```

```

CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 28 AA;
SQ
AAY24817 Length: 28 February 4, 2005 13:19 Type: P Check: 63 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDAKQLEEEAVRLFIEFLKN 28
1 -----|
1 match found in sequence:
aay24818; Extendin agonist peptide #10.
(from "seq4ags.pep")
TOIG of: aay24818 check: 141 from: 1 to: 28
ID AAY24818 standard; peptide; 28 AA.
XX
XX AAY24818;
AC
XX
XX 24-AUG-1999 (first entry)
DT
XX
XX Extendin agonist peptide #10.
DE
XX
XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO9925727-A2.
PN
XX
XX 27-MAY-1999.
PD
XX
XX 13-NOV-1998; 98WO-US024210.
PF
XX
XX 14-NOV-1997; 97US-0065442P.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Beeley NRA, Prickett KS;
PI
XX
XX WPI; 1999-394773/33.
DR
XX
XX New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
PS Claim 18; Fig 4; 108pp; English.
XX
XX AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 28 AA;
SQ
AAY24818 Length: 28 February 4, 2005 13:19 Type: P Check: 141 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSAQLEEEAVRLFIEFLKN
1 -----|

```



```

XX PD 27-MAY-1999.
XX XX
XX PF 13-NOV-1998; 98WO-US024210.
XX XX
XX PR 14-NOV-1997; 97US-0065442P.
XX XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX XX
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX XX
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying
XX XX
XX SQ Sequence 28 AA;
XX
XX AAY24821 Length: 28 February 4, 2005 13:19 Type: P Check: 201 ..
XX Found using 'seq4' (mohamed337.key)
XX
1 |-----|
1 HEGFTTSDLSKQLAEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay24822 ; Extendin agonist peptide #14.
(from "seq4ags.pep")
TOIG of: aay24822 check: 197 from: 1 to: 28

ID AAY24822 standard; peptide; 28 AA.
XX
XX AC AAY24822;
XX XX
XX DT 24-AUG-1999 (first entry)
XX XX
XX DE Extendin agonist peptide #14.
XX XX
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX XX
XX OS Synthetic.
XX OS Heloderma sp.
XX XX
XX PN WO9925727-A2.
XX XX
XX PD 24-AUG-1999 (first entry)
XX XX
XX DE Extendin agonist peptide #14.
XX XX
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX XX
XX OS Synthetic.
XX OS Heloderma sp.
XX XX
XX PN WO9925727-A2.
XX XX
XX PD 27-MAY-1999.
XX XX
XX PF 13-NOV-1998; 98WO-US024210.
XX XX
XX PR 14-NOV-1997; 97US-0065442P.
XX XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX XX
XX DR WPI; 1999-394773/33.
XX XX

```

```

XX XX
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX XX
XX PS Claim 18; Fig 4; 108pp; English.
XX XX
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying
XX XX
XX SQ Sequence 28 AA;
XX
XX AAY24822 Length: 28 February 4, 2005 13:19 Type: P Check: 197 ..
XX Found using 'seq4' (mohamed337.key)
XX
1 |-----|
1 HEGFTTSDLSKQLAEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay24823 ; Extendin agonist peptide #15.
(from "seq4ags.pep")
TOIG of: aay24823 check: 193 from: 1 to: 28

ID AAY24823 standard; peptide; 28 AA.
XX
XX AC AAY24823;
XX XX
XX DT 24-AUG-1999 (first entry)
XX XX
XX DE Extendin agonist peptide #15.
XX XX
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX XX
XX OS Synthetic.
XX OS Heloderma sp.
XX XX
XX PN WO9925727-A2.
XX XX
XX PD 27-MAY-1999.
XX XX
XX PF 13-NOV-1998; 98WO-US024210.
XX XX
XX PR 14-NOV-1997; 97US-0065442P.
XX XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX XX
XX PI Beeley NRA, Prickett KS;
XX XX
XX DR WPI; 1999-394773/33.
XX XX
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX XX
XX PS Claim 18; Fig 4; 108pp; English.
XX XX
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying
XX XX

```

CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;

AAAY24823 Length: 28 February 4, 2005 13:19 Type: P Check: 193 ..
 Found using 'seq4' (mohamed337.key)

1 HCGGTFSTDLKQLEEAVALRIFIEFLKN 28
 1

 1 match found in sequence:
 aay24824 ; Exendin agonist peptide #16.
 (from "seq4ags.pep")
 TOIG of: aay24824 check: 9862 from: 1 to: 28

ID AAY24824 standard; peptide; 28 AA.
 XX
 AC AAY24824;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #16.
 XX
 KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 WPI; 1999-394773/33.
 XX
 New exendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 Claim 18; Fig 4; 108pp; English.

AAAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;

AAAY24824 Length: 28 February 4, 2005 13:19 Type: P Check: 9862 ..
 Found using 'seq4' (mohamed337.key)

1 HCGGTFSTDLKQLEEAVALRIFIEFLKN 28
 1

 1 match found in sequence:
 aay24824 ; Exendin agonist peptide #16.
 (from "seq4ags.pep")
 TOIG of: aay24824 check: 9862 from: 1 to: 28

1 HCGGTFSTDLKQLEEAVALRIFIEFLKN 28
 1

 1 match found in sequence:
 aay24825 ; Exendin agonist peptide #17.
 (from "seq4ags.pep")
 TOIG of: aay24825 check: 9921 from: 1 to: 28

ID AAY24825 standard; peptide; 28 AA.
 XX
 AC AAY24825;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Exendin agonist peptide #17.

XX Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 WPI; 1999-394773/33.
 XX
 New exendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 Claim 18; Fig 4; 108pp; English.

AAAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;

AAAY24825 Length: 28 February 4, 2005 13:19 Type: P Check: 9921 ..
 Found using 'seq4' (mohamed337.key)

1 HCGGTFSTDLKQLEEAVALRIFIEFLKN 28
 1

 1 match found in sequence:
 aay24826 ; Exendin agonist peptide #18.
 (from "seq4ags.pep")
 TOIG of: aay24826 check: 30 from: 1 to: 28

ID AAY24826 standard; peptide; 28 AA.
 XX
 AC AAY24826;


```

DR WPI; 1999-394773/33.
XX
PT New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
XX Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 28 AA;
XX
AAY24828 Length: 28 February 4, 2005 13:19 Type: P Check: 136 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTFTDLSKQLEEEAVRLFIEALKN 28
-----
1 match found in sequence:
aay24829; Extendin agonist peptide #21.
(from "seq4ags.pep")
TOIG of: aay24829 check: 9975 from: 1 to: 28

ID AAY24829 standard; peptide; 28 AA.
XX
AC AAY24829;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #21.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-394773/33.
XX
New extendin agonist peptides - can regulate gastric motility and slow
gastric emptying, used for treating, e.g. diabetes.
XX
Claim 18; Fig 4; 108pp; English.
XX
AAY24809 to AAY24877 represent extendin agonist peptides which can
regulate gastric motility and slow gastric emptying. The peptides can be
used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
conditions. The peptides are extendin agonists which have activity as
agents to regulate gastric motility and to slow gastric emptying, as
evidenced by the ability to reduce post-prandial glucose levels in
mammals. They can be used for the treatment of Type I and II diabetes and
hyperglycaemic or hypoglycaemic conditions. They can also be used for the
treatment of disorders which would be benefited by agents which lower
plasma glucose levels and in treatment of disorders which would be
benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 28 AA;
XX
AAY24828 Length: 28 February 4, 2005 13:19 Type: P Check: 136 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTFTDLSKQLEEEAVRLFIEALKN 28
-----
1 match found in sequence:
aay24829; Extendin agonist peptide #21.
(from "seq4ags.pep")
TOIG of: aay24829 check: 9975 from: 1 to: 28

ID AAY24829 standard; peptide; 28 AA.
XX
AC AAY24829;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #21.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-394773/33.
XX
New extendin agonist peptides - can regulate gastric motility and slow
gastric emptying, used for treating, e.g. diabetes.
XX
Claim 18; Fig 4; 108pp; English.
XX
AAY24809 to AAY24877 represent extendin agonist peptides which can
regulate gastric motility and slow gastric emptying. The peptides can be
used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
conditions. The peptides are extendin agonists which have activity as
agents to regulate gastric motility and to slow gastric emptying, as
evidenced by the ability to reduce post-prandial glucose levels in
mammals. They can be used for the treatment of Type I and II diabetes and
hyperglycaemic or hypoglycaemic conditions. They can also be used for the
treatment of disorders which would be benefited by agents which lower
plasma glucose levels and in treatment of disorders which would be
benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 28 AA;
XX
AAY24829 Length: 28 February 4, 2005 13:19 Type: P Check: 9975 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTFTDLSKQLEEEAVRLFIEAFKN 28
-----
1 match found in sequence:
aay24830; Extendin agonist peptide #22.
(from "seq4ags.pep")
TOIG of: aay24830 check: 9991 from: 1 to: 28

ID AAY24830 standard; peptide; 28 AA.
XX
AC AAY24830;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #22.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
WPI; 1999-394773/33.
XX
New extendin agonist peptides - can regulate gastric motility and slow
gastric emptying, used for treating, e.g. diabetes.
XX
Claim 18; Fig 4; 108pp; English.
XX
AAY24809 to AAY24877 represent extendin agonist peptides which can
regulate gastric motility and slow gastric emptying. The peptides can be
used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
conditions. The peptides are extendin agonists which have activity as
agents to regulate gastric motility and to slow gastric emptying, as
evidenced by the ability to reduce post-prandial glucose levels in
mammals. They can be used for the treatment of Type I and II diabetes and
hyperglycaemic or hypoglycaemic conditions. They can also be used for the
treatment of disorders which would be benefited by agents which lower
plasma glucose levels and in treatment of disorders which would be
benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 28 AA;
XX
AAY24830 Length: 28 February 4, 2005 13:19 Type: P Check: 9991 ..
Found using 'seq4' (mohamed337.key)

```



```

XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX XX 13-NOV-1998; 98WO-US024210.
XX PF 14-NOV-1997; 97US-0065442P.
XX PR (AMYL-) AMYLIN PHARM INC.
XX PA Beoley NRA, Prickett KS;
XX PI WPI; 1999-394773/33.
XX DR New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of Type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying
XX CC
XX SQ Sequence 38 AA;
XX AAY24833 Length: 38 February 4, 2005 13:19 Type: P Check: 5894
XX Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQLEEEAVRLFIEFLKNGGPFSSGAPPP
28
-----
1 match found in sequence:
aay24834; Extendin agonist peptide #26.
(from "seq4ags.pep")
TOIG of: aay24834 check: 6333 from: 1 to: 38
-----
ID AAY24834 standard; peptide; 38 AA.
XX AC AAY24834;
XX DT 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #26.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beoley NRA, Prickett KS;
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beoley NRA, Prickett KS;

```

```

XX DR WPI; 1999-394773/33.
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PS gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of Type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying
XX CC
XX SQ Sequence 38 AA;
XX AAY24834 Length: 38 February 4, 2005 13:19 Type: P Check: 6333
XX Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQLEEEAVRLFIEFLKNGGPFSSGAPPP
28
-----
1 match found in sequence:
aay24835; Extendin agonist peptide #27.
(from "seq4ags.pep")
TOIG of: aay24835 check: 2854 from: 1 to: 37
-----
ID AAY24835 standard; peptide; 37 AA.
XX AC AAY24835;
XX DT 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #27.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beoley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PS gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of Type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying
XX CC
XX SQ Sequence 38 AA;

```

CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 37 AA;

AAAY24835 Length: 37 February 4, 2005 13:19 Type: P Check: 2854 ..
 Found using 'seq4' (mohamed337.key)

1 HGGGTFTSDLSKQLEEAARLFIETLKNKGPPSSGAPP
 1 28

 1 match found in sequence:
 aay24836 ; Exendin agonist peptide #28.
 (from "seq4ags.pep")
 TOIG of: aay24836 check: 333 from: 1 to: 36

ID AAY24836 standard; peptide; 36 AA.

XX AAY24836;

AC AAY24836;

XX 24-AUG-1999 (first entry)

DT Exendin agonist peptide #28.

DE Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.

OS Heloderma sp.

XX WO9925727-A2.

XX 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024210.

XX 14-NOV-1997; 97US-0065442P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett KS;

XX WPI; 1999-394773/33.

XX New exendin agonist peptides - can regulate gastric motility and slow

XX gastric emptying, used for treating, e.g. diabetes.

XX Claim 18; Fig 4; 108pp; English.

XX AAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 36 AA;

AAAY24836 Length: 36 February 4, 2005 13:19 Type: P Check: 333 ..
 Found using 'seq4' (mohamed337.key)

1 HGGGTFTSDLSKQLEEAARLFIETLKNKGPPSSGAP
 1 28

 1 match found in sequence:
 aay24837 ; Exendin agonist peptide #29.
 (from "seq4ags.pep")
 TOIG of: aay24837 check: 9894 from: 1 to: 36

ID AAY24837 standard; peptide; 36 AA.

XX AAY24837;

XX 24-AUG-1999 (first entry)

DT Exendin agonist peptide #29.

DE Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;

XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.

XX Synthetic.

OS Heloderma sp.

XX WO9925727-A2.

XX 27-MAY-1999.

XX 13-NOV-1998; 98WO-US024210.

XX 14-NOV-1997; 97US-0065442P.

XX (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett KS;

XX WPI; 1999-394773/33.

XX New exendin agonist peptides - can regulate gastric motility and slow

XX gastric emptying, used for treating, e.g. diabetes.

XX Claim 18; Fig 4; 108pp; English.

XX AAY24809 to AAY24877 represent exendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are exendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 36 AA;

AAAY24837 Length: 36 February 4, 2005 13:19 Type: P Check: 9894 ..
 Found using 'seq4' (mohamed337.key)

1 HGGGTFTSDLSKQLEEAARLFIETLKNKGPPSSGAP
 1 28

 1 match found in sequence:
 aay24838 ; Exendin agonist peptide #30.
 (from "seq4ags.pep")
 TOIG of: aay24838 check: 7453 from: 1 to: 35

ID AAY24838 standard; peptide; 35 AA.

PI Beeley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX
 PT New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 PS Claim 18; Fig 4; 108pp; English.
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 34 AA;
 AAY24840 Length: 34 February 4, 2005 13:19 Type: P Check: 5178 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGFTFTDLSKQMBEEAVRLFIEFLKNGPSSG 28
 |-----|
 1 match found in sequence:
 aay24841; Extendin agonist peptide #33.
 (from "seq4ags.pep")
 TOIG of: aay24841 Check: 4739 from: 1 to: 34
 ID AAY24841 standard; peptide; 34 AA.
 XX
 AC AAY24841;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #33.
 XX
 XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 CC New extendin agonist peptides - can regulate gastric motility and slow
 CC gastric emptying, used for treating, e.g. diabetes.
 XX
 PS Claim 18; Fig 4; 108pp; English.
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 34 AA;
 AAY24840 Length: 34 February 4, 2005 13:19 Type: P Check: 5178 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGFTFTDLSKQMBEEAVRLFIEFLKNGPSSG 28
 |-----|
 1 match found in sequence:
 aay24841; Extendin agonist peptide #33.
 (from "seq4ags.pep")
 TOIG of: aay24841 Check: 4739 from: 1 to: 34
 ID AAY24841 standard; peptide; 34 AA.
 XX
 AC AAY24841;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #33.
 XX
 XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 CC New extendin agonist peptides - can regulate gastric motility and slow
 CC gastric emptying, used for treating, e.g. diabetes.
 XX
 PS Claim 18; Fig 4; 108pp; English.
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic

CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 34 AA;
 AAY24841 Length: 34 February 4, 2005 13:19 Type: P Check: 4739 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGFTFTDLSKQMBEEAVRLFIEFLKNGPSSG 28
 |-----|
 1 match found in sequence:
 aay24842; Extendin agonist peptide #34.
 (from "seq4ags.pep")
 TOIG of: aay24842 Check: 2764 from: 1 to: 33
 ID AAY24842 standard; peptide; 33 AA.
 XX
 AC AAY24842;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #34.
 XX
 XX Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 CC New extendin agonist peptides - can regulate gastric motility and slow
 CC gastric emptying, used for treating, e.g. diabetes.
 XX
 PS Claim 18; Fig 4; 108pp; English.
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 33 AA;
 AAY24842 Length: 33 February 4, 2005 13:19 Type: P Check: 2764 ..

```

Found using 'seq4' (mohamed337.key)
1  HEGGFTSLSKQMEEEAVRLFIEWLKNGGPSS
   1 28
-----
1 match found in sequence:
aay24843 ; Exendin agonist peptide #35.
  (from "seq4ags.pep")
TOIG of: aay24843 check: 2325 from: 1 to: 33

ID AAY24843 standard; peptide; 33 AA.
XX
XX
AC AAY24843;
XX
XX
DT 24-AUG-1999 (first entry)
XX
XX
DE Exendin agonist peptide #35.
XX
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FN WO9925727-A2.
XX
XX
PD 27-MAY-1999.
XX
XX
PF 13-NOV-1998; 98WO-US024210.
XX
XX
PR 14-NOV-1997; 97US-0065442P.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Beeley NRA, Prickett KS;
XX
XX
PS WPI; 1999-394773/33.
XX
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
XX
PS Claim 18; Fig 4; 108pp; English.
XX
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX
SQ Sequence 33 AA;

AAY24843 Length: 33 February 4, 2005 13:19 Type: P Check: 2325 ..
Found using 'seq4' (mohamed337.key)

1  HEGGFTSLSKQMEEEAVRLFIEWLKNGGPSS
   1 28
-----
1 match found in sequence:
aay24844 ; Exendin agonist peptide #36.
  (from "seq4ags.pep")
TOIG of: aay24844 check: 25 from: 1 to: 32

ID AAY24844 standard; peptide; 32 AA.
XX
XX
AC AAY24844;
XX
XX
DT 24-AUG-1999 (first entry)
XX
XX
DE Exendin agonist peptide #36.
XX
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX
OS Synthetic.
OS Heloderma sp.
XX
XX
FN WO9925727-A2.
XX
XX
PD 27-MAY-1999.
XX
XX
PF 13-NOV-1998; 98WO-US024210.
XX
XX
PR 14-NOV-1997; 97US-0065442P.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Beeley NRA, Prickett KS;
XX
XX
PS WPI; 1999-394773/33.
XX
XX
PT New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
XX
PS Claim 18; Fig 4; 108pp; English.
XX
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX
SQ Sequence 32 AA;

AAY24844 Length: 32 February 4, 2005 13:19 Type: P Check: 25 ..
Found using 'seq4' (mohamed337.key)

1  HEGGFTSLSKQMEEEAVRLFIEWLKNGGPSS
   1 28
-----
1 match found in sequence:
aay24845 ; Exendin agonist peptide #37.
  (from "seq4ags.pep")
TOIG of: aay24845 check: 9586 from: 1 to: 32

ID AAY24845 standard; peptide; 32 AA.
XX
XX
AC AAY24845;
XX
XX
DT 24-AUG-1999 (first entry)
XX
XX
DE Exendin agonist peptide #37.
XX
XX
KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX

```

```

OS Synthetic.
OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of Type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying
XX CC Sequence 32 AA;
XX SQ
AAY24845 Length: 32 February 4, 2005 13:19 Type: P Check: 9586 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQBEEAVRLFIETLKNKGPS
1 -----|-----|
1 match found in sequence:
aay24846; Extendin agonist peptide #38.
(from "seq4ags.pep")
TOIG of: aay24846 check: 7369 from: 1 to: 31
-----
ID AAY24846 standard; peptide; 31 AA.
XX AC AAY24846;
XX DT 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #38.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.

```

```

XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of Type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying
XX CC Sequence 31 AA;
XX SQ
AAY24846 Length: 31 February 4, 2005 13:19 Type: P Check: 7369 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQBEEAVRLFIETLKNKGPS
1 -----|-----|
1 match found in sequence:
aay24847; Extendin agonist peptide #39.
(from "seq4ags.pep")
TOIG of: aay24847 check: 6930 from: 1 to: 31
-----
ID AAY24847 standard; peptide; 31 AA.
XX AC AAY24847;
XX DT 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #39.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are extendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of Type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying
XX CC Sequence 31 AA;
XX SQ
AAY24846 Length: 31 February 4, 2005 13:19 Type: P Check: 7369 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQBEEAVRLFIETLKNKGPS
1 -----|-----|
1 match found in sequence:
aay24847; Extendin agonist peptide #39.
(from "seq4ags.pep")
TOIG of: aay24847 check: 6930 from: 1 to: 31
-----
ID AAY24847 standard; peptide; 31 AA.
XX AC AAY24847;
XX DT 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #39.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX PT New extendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent extendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be

```

CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX Sequence 31 AA;

AAAY24847 Length: 31 February 4, 2005 13:19 Type: P Check: 6930 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLEEAVALRFLFIEFLKNGP
1 28

1 match found in sequence:
aay24848 ; Extendin agonist peptide #40.
(from "seq4ags.pep")
TOIG of: aay24848 check: 4450 from: 1 to: 30

ID AAY24848 standard; peptide; 30 AA.
XX AC AAY24848;
XX DT 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #40.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX PS WPI; 1999-394773/33.
XX DR New extendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX PT Claim 18; Fig 4; 108pp; English.
XX SQ Sequence 30 AA;

AAAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX Sequence 30 AA;

AAAY24848 Length: 30 February 4, 2005 13:19 Type: P Check: 4450 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLEEAVALRFLFIEFLKNGG
1 28

1 match found in sequence:
aay24849 ; Extendin agonist peptide #41.
(from "seq4ags.pep")
TOIG of: aay24849 check: 2759 from: 1 to: 29

ID AAY24849 standard; peptide; 29 AA.
XX AC AAY24849;
XX DT 24-AUG-1999 (first entry)
XX DE Extendin agonist peptide #41.
XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX PS WPI; 1999-394773/33.
XX DR New extendin agonist peptides - can regulate gastric motility and slow
XX gastric emptying, used for treating, e.g. diabetes.
XX PT Claim 18; Fig 4; 108pp; English.
XX SQ Sequence 29 AA;

AAAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX Sequence 29 AA;

AAAY24849 Length: 29 February 4, 2005 13:19 Type: P Check: 2759 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQMEEAVALRFLFIEFLKNG
1 28

1 match found in sequence:
aay24850 ; Extendin agonist peptide #42.
(from "seq4ags.pep")
TOIG of: aay24850 check: 2320 from: 1 to: 29

```

ID AAY24850 standard; peptide; 29 AA.
XX
AC AAY24850;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #42.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
XX
New extendin agonist peptides - can regulate gastric motility and slow
gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 29 AA;
XX
AAY24850 Length: 29 February 4, 2005 13:19 Type: P Check: 2320 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQLEBEAVRLFIEFLKNG
1 28
-----
1 match found in sequence:
aay24851; Extendin agonist peptide #43.
(from "seq4ags.pep")
TOIG of: aay24851 check: 7469 from: 1 to: 38

ID AAY24851 standard; peptide; 38 AA.
XX
AC AAY24851;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #43.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX

```

```

XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
XX
New extendin agonist peptides - can regulate gastric motility and slow
gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 38 AA;
XX
AAY24851 Length: 38 February 4, 2005 13:19 Type: P Check: 7469 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQLEBEAVRLFIEFLKNGXSGAXXX
1 28
-----
1 match found in sequence:
aay24852; Extendin agonist peptide #44.
(from "seq4ags.pep")
TOIG of: aay24852 check: 7221 from: 1 to: 38

ID AAY24852 standard; peptide; 38 AA.
XX
AC AAY24852;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #44.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX

```

```

PA (AMYL-) AMYLIN PHARM INC.
XX Beeley NRA, Prickett KS;
XX WPI; 1999-394773/33.
XX
XX New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
XX Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent exendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are exendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 38 AA;
SQ
AAY24852 Length: 38 February 4, 2005 13:19 Type: P Check: 7221 ..
Found using 'seq4' (mohamed337.key)
1 HGGFTTSDLSKQMBEEAVRLFIWLKNGGPGSSGAXXX
  1 |-----|
  28
-----
1 match found in sequence:
aay24853 ; Exendin agonist peptide #45.
(from "seq4ags.pep")
TOIG of: aay24853 check: 2828 from: 1 to: 37

ID AAY24853 standard; peptide; 37 AA.
XX
XX AC AAY24853;
XX
XX DT 24-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #45.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925727-A2.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024210.
XX
XX PR 14-NOV-1997; 97US-0065442P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX PS WPI; 1999-394773/33.
XX
XX New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
XX Claim 18; Fig 4; 108pp; English.
XX
XX AAY24809 to AAY24877 represent exendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be
XX used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX conditions. The peptides are exendin agonists which have activity as
XX agents to regulate gastric motility and to slow gastric emptying, as
XX evidenced by the ability to reduce post-prandial glucose levels in
XX mammals. They can be used for the treatment of Type I and II diabetes and
XX hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX treatment of disorders which would be benefited by agents which lower
XX plasma glucose levels and in treatment of disorders which would be
XX benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 37 AA;
SQ
AAY24853 Length: 37 February 4, 2005 13:19 Type: P Check: 2828 ..
Found using 'seq4' (mohamed337.key)
1 HGGFTTSDLSKQMBEEAVRLFIWLKNGGSSGAPP
  1 |-----|
  28
-----
1 match found in sequence:
aay24854 ; Exendin agonist peptide #46.
(from "seq4ags.pep")
TOIG of: aay24854 check: 1733 from: 1 to: 37

ID AAY24854 standard; peptide; 37 AA.
XX
XX AC AAY24854;
XX
XX DT 24-AUG-1999 (first entry)
XX
XX DE Exendin agonist peptide #46.
XX
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO9925727-A2.
XX
XX PD 27-MAY-1999.
XX
XX PF 13-NOV-1998; 98WO-US024210.
XX
XX PR 14-NOV-1997; 97US-0065442P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Beeley NRA, Prickett KS;
XX
XX PS WPI; 1999-394773/33.
XX
XX New exendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
XX Claim 18; Fig 4; 108pp; English.
XX
XX AAY24809 to AAY24877 represent exendin agonist peptides which can
XX regulate gastric motility and slow gastric emptying. The peptides can be
XX used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX conditions. The peptides are exendin agonists which have activity as
XX agents to regulate gastric motility and to slow gastric emptying, as
XX evidenced by the ability to reduce post-prandial glucose levels in
XX mammals. They can be used for the treatment of Type I and II diabetes and
XX hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX treatment of disorders which would be benefited by agents which lower
XX plasma glucose levels and in treatment of disorders which would be
XX benefited with agents useful in delaying and/or slowing gastric emptying
XX
XX Sequence 37 AA;
SQ

```

AAy24854 Length: 37 February 4, 2005 13:19 Type: P Check: 1733 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQMEEEAVRLFIEWLKNGGASSGAAA
28

1 match found in sequence:
aay24855 ; Exendin agonist peptide #47.
(from "seq4ags.pep")
TOIG of: aay24855 check: 4125 from: 1 to: 37

ID AAY24855 standard; peptide; 37 AA.
XX AC AAY24855;
XX DT 24-AUG-1999 (first entry)
XX DE Exendin agonist peptide #47.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX PT New exendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent exendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are exendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of Type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying

SQ Sequence 37 AA;
AAy24855 Length: 37 February 4, 2005 13:19 Type: P Check: 4125 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQMEEEAVRLFIEWLKNGGASSGAXX
28

1 match found in sequence:
aay24856 ; Exendin agonist peptide #48.
(from "seq4ags.pep")

TOIG of: aay24856 check: 869 from: 1 to: 36

ID AAY24856 standard; peptide; 36 AA.
XX AC AAY24856;
XX DT 24-AUG-1999 (first entry)
XX DE Exendin agonist peptide #48.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
XX KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO9925727-A2.
XX PD 27-MAY-1999.
XX PF 13-NOV-1998; 98WO-US024210.
XX PR 14-NOV-1997; 97US-0065442P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Beeley NRA, Prickett KS;
XX DR WPI; 1999-394773/33.
XX PT New exendin agonist peptides - can regulate gastric motility and slow
XX PT gastric emptying, used for treating, e.g. diabetes.
XX PS Claim 18; Fig 4; 108pp; English.
XX CC AAY24809 to AAY24877 represent exendin agonist peptides which can
XX CC regulate gastric motility and slow gastric emptying. The peptides can be
XX CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
XX CC conditions. The peptides are exendin agonists which have activity as
XX CC agents to regulate gastric motility and to slow gastric emptying, as
XX CC evidenced by the ability to reduce post-prandial glucose levels in
XX CC mammals. They can be used for the treatment of Type I and II diabetes and
XX CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
XX CC treatment of disorders which would be benefited by agents which lower
XX CC plasma glucose levels and in treatment of disorders which would be
XX CC benefited with agents useful in delaying and/or slowing gastric emptying

SQ Sequence 36 AA;
AAy24856 Length: 36 February 4, 2005 13:19 Type: P Check: 869 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQMEEEAVRLFIEWLKNGGSSGAX
28

1 match found in sequence:
aay24857 ; Exendin agonist peptide #49.
(from "seq4ags.pep")
TOIG of: aay24857 check: 7463 from: 1 to: 35

ID AAY24857 standard; peptide; 35 AA.
XX AC AAY24857;
XX DT 24-AUG-1999 (first entry)
XX DE Exendin agonist peptide #49.
XX KW Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
XX KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;

KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX Synthetic.
 OS Heloderma sp.
 XX WO9925727-A2.
 PN 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024210.
 XX 14-NOV-1997; 97US-0065442P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT Claim 18; Fig 4; 108pp; English.
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 35 AA;
 SQ AAY24857 Length: 35 February 4, 2005 13:19 Type: P Check: 7463 ..
 Found using 'seq4' (mohamed337.key)
 1 RGEFTSLSKQMBEEAVRLFIEWLKNGPSSGA
 1

 1 match found in sequence:
 aay24858 ; Extendin agonist peptide #50.
 (from "seq4ags.pep")
 TOIG of: aay24858 check: 4886 from: 1 to: 30
 ID AAY24858 standard; peptide; 30 AA.
 XX AC AAY24858;
 XX DT 24-AUG-1999 (first entry)
 XX DE Extendin agonist peptide #50.
 XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX OS Synthetic.
 OS Heloderma sp.
 XX PN WO9925727-A2.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024210.
 XX 14-NOV-1997; 97US-0065442P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT Claim 18; Fig 4; 108pp; English.
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 35 AA;
 SQ AAY24857 Length: 35 February 4, 2005 13:19 Type: P Check: 7463 ..
 Found using 'seq4' (mohamed337.key)
 1 RGEFTSLSKQMBEEAVRLFIEWLKNGPSSGA
 1

 1 match found in sequence:
 aay24858 ; Extendin agonist peptide #50.
 (from "seq4ags.pep")
 TOIG of: aay24858 check: 4886 from: 1 to: 30
 ID AAY24858 standard; peptide; 30 AA.
 XX AC AAY24858;
 XX DT 24-AUG-1999 (first entry)
 XX DE Extendin agonist peptide #50.
 XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX OS Synthetic.
 OS Heloderma sp.
 XX PN WO9925727-A2.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024210.
 XX 14-NOV-1997; 97US-0065442P.

XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT Claim 18; Fig 4; 108pp; English.
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 30 AA;
 SQ AAY24858 Length: 30 February 4, 2005 13:19 Type: P Check: 4886 ..
 Found using 'seq4' (mohamed337.key)
 1 HGDGFTSLSKQMBEEAVRLFIEWLKNGG
 1

 1 match found in sequence:
 aay24859 ; Extendin agonist peptide #51.
 (from "seq4ags.pep")
 TOIG of: aay24859 check: 383 from: 1 to: 28
 ID AAY24859 standard; peptide; 28 AA.
 XX AC AAY24859;
 XX DT 24-AUG-1999 (first entry)
 XX DE Extendin agonist peptide #51.
 XX KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX OS Synthetic.
 OS Heloderma sp.
 XX PN WO9925727-A2.
 XX 27-MAY-1999.
 XX 13-NOV-1998; 98WO-US024210.
 XX 14-NOV-1997; 97US-0065442P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Beeley NRA, Prickett KS;
 XX WPI; 1999-394773/33.
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT Claim 18; Fig 4; 108pp; English.
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX Sequence 30 AA;
 SQ AAY24858 Length: 30 February 4, 2005 13:19 Type: P Check: 4886 ..
 Found using 'seq4' (mohamed337.key)

CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;
 AAY24859 Length: 28 February 4, 2005 13:19 Type: P Check: 383 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEQTYTSDLSKQMBEEAVRLFIEFLKN 28
 |-----|
 1 match found in sequence:
 aay24860 ; Extendin agonist peptide #52.
 (from "seq4ags.pep")
 TOIG of: aay24860 check: 693 from: 1 to: 28
 ID AAY24860 standard; peptide; 28 AA.
 AC AAY24860;
 XX
 DT 24-AUG-1999 (first entry)
 DE Extendin agonist peptide #52.
 XX
 KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 PT New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 PS Claim 18; Fig 4; 108pp; English.
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX

SQ Sequence 28 AA;
 AAY24860 Length: 28 February 4, 2005 13:19 Type: P Check: 693 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEQTFSSDLSKQMBEEAVRLFIEFLKN 28
 |-----|
 1 match found in sequence:
 aay24861 ; Extendin agonist peptide #53.
 (from "seq4ags.pep")
 TOIG of: aay24861 check: 701 from: 1 to: 28
 ID AAY24861 standard; peptide; 28 AA.
 AC AAY24861;
 XX
 DT 24-AUG-1999 (first entry)
 DE Extendin agonist peptide #53.
 XX
 KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PF 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Beeley NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 PT New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 XX
 PS Claim 18; Fig 4; 108pp; English.
 XX
 CC AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;
 AAY24861 Length: 28 February 4, 2005 13:19 Type: P Check: 701 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEQTFSTDLSKQMBEEAVRLFIEFLKN 28
 |-----|
 1 match found in sequence:
 aay24862 ; Extendin agonist peptide #54.
 (from "seq4ags.pep")

(from "seq4ags.pep")
TOIG of: aay24862 check: 649 from: 1 to: 28

```

ID AAY24862 standard; peptide; 28 AA.
XX
AC AAY24862;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #54.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 28 AA;
XX
AAY24862 Length: 28 February 4, 2005 13:19 Type: P Check: 649 ..
Found using 'seq4' (mohamed337.key)

1 HGGFTFTSELSQMAEEAVRLFIEWLKN 28
-----
1 match found in sequence:
aay24863 ; Extendin agonist peptide #55.
(from "seq4ags.pep")
TOIG of: aay24863 check: 381 from: 1 to: 28

ID AAY24863 standard; peptide; 28 AA.
XX
AC AAY24863;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #55.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;

```

```

KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX
PR 14-NOV-1997; 97US-0065442P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett KS;
XX
DR WPI; 1999-394773/33.
XX
PT New extendin agonist peptides - can regulate gastric motility and slow
PT gastric emptying, used for treating, e.g. diabetes.
XX
PS Claim 18; Fig 4; 108pp; English.
XX
CC AAY24809 to AAY24877 represent extendin agonist peptides which can
CC regulate gastric motility and slow gastric emptying. The peptides can be
CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC conditions. The peptides are extendin agonists which have activity as
CC agents to regulate gastric motility and to slow gastric emptying, as
CC evidenced by the ability to reduce post-prandial glucose levels in
CC mammals. They can be used for the treatment of Type I and II diabetes and
CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC treatment of disorders which would be benefited by agents which lower
CC plasma glucose levels and in treatment of disorders which would be
CC benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ Sequence 28 AA;
XX
AAY24863 Length: 28 February 4, 2005 13:19 Type: P Check: 381 ..
Found using 'seq4' (mohamed337.key)

1 HGGFTFTSDXSQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay24864 ; Extendin agonist peptide #56.
(from "seq4ags.pep")
TOIG of: aay24864 check: 657 from: 1 to: 28

ID AAY24864 standard; peptide; 28 AA.
XX
AC AAY24864;
XX
DT 24-AUG-1999 (first entry)
XX
DE Extendin agonist peptide #56.
XX
KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS Synthetic.
OS Heloderma sp.
XX
FN WO9925727-A2.
XX
PD 27-MAY-1999.
XX
PF 13-NOV-1998; 98WO-US024210.
XX

```

PR 14-NOV-1997; 97US-0065442P.
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Bealey NRA, Prickett KS;
 PI
 XX WPI; 1999-394773/33.
 DR
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT
 XX Claim 18; Fig 4; 108pp; English.
 PS
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;
 AAY24864 Length: 28 February 4, 2005 13:19 Type: P Check: 657 ..
 Found using 'seq4' (mohamed337.key)
 1 |-----|
 1 HGEFTSLSKQLEEEAVRLXIEFLKN 28

 1 match found in sequence:
 aay24865; Extendin agonist peptide #57.
 (from "seq4ags.pep")
 TOIG of: aay24865 check: 1045 from: 1 to: 28
 ID AAY24865 standard; peptide; 28 AA.
 XX
 AC AAY24865;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #57.
 XX
 KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PP 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Bealey NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT
 XX Claim 18; Fig 4; 108pp; English.

XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX
 SQ Sequence 28 AA;
 AAY24865 Length: 28 February 4, 2005 13:19 Type: P Check: 1045 ..
 Found using 'seq4' (mohamed337.key)
 1 |-----|
 1 HGEFTSLSKQLEEEAVRLFXEFLKN 28

 1 match found in sequence:
 aay24867; Extendin agonist peptide #59.
 (from "seq4ags.pep")
 TOIG of: aay24867 check: 2215 from: 1 to: 33
 ID AAY24867 standard; peptide; 33 AA.
 XX
 AC AAY24867;
 XX
 DT 24-AUG-1999 (first entry)
 XX
 DE Extendin agonist peptide #59.
 XX
 KW Extendin; agonist; Heloderma sp; Gila monster; venom; lizard;
 XX diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
 KW hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO9925727-A2.
 XX
 PD 27-MAY-1999.
 XX
 PP 13-NOV-1998; 98WO-US024210.
 XX
 PR 14-NOV-1997; 97US-0065442P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Bealey NRA, Prickett KS;
 XX
 DR WPI; 1999-394773/33.
 XX
 XX New extendin agonist peptides - can regulate gastric motility and slow
 PT gastric emptying, used for treating, e.g. diabetes.
 PT
 XX Claim 18; Fig 4; 108pp; English.
 PS
 XX AAY24809 to AAY24877 represent extendin agonist peptides which can
 CC regulate gastric motility and slow gastric emptying. The peptides can be
 CC used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
 CC conditions. The peptides are extendin agonists which have activity as
 CC agents to regulate gastric motility and to slow gastric emptying, as
 CC evidenced by the ability to reduce post-prandial glucose levels in
 CC mammals. They can be used for the treatment of Type I and II diabetes and
 CC hyperglycaemic or hypoglycaemic conditions. They can also be used for the
 CC treatment of disorders which would be benefited by agents which lower
 CC plasma glucose levels and in treatment of disorders which would be
 CC benefited with agents useful in delaying and/or slowing gastric emptying
 XX

```

XX      SQ      Sequence 33 AA;
AAAY24867 Length: 33 February 4, 2005 13:19 Type: P Check: 2215
Found using 'seq4' (mohamed337.key)

1      |-----|
      1 HGEFTSDASKQLEEEAVRLFIEFLKNGGPSS
      28

-----
1 match found in sequence:
aay24868 ; Exendin agonist peptide #60.
(from "seq4ags.pep")
TOIG of: aay24868 check: 2649 from: 1 to: 29

ID      AAY24868 standard; peptide; 29 AA.
XX
AC      AAY24868;
XX
DT      24-AUG-1999 (first entry)
XX
DE      Exendin agonist peptide #60.
XX
KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
PN      WO9925727-A2.
XX
PD      27-MAY-1999.
XX
PF      13-NOV-1998; 98WO-US024210.
XX
PR      14-NOV-1997; 97US-0065442P.
XX
PA      (AMYL-) AMYLIN PHARM INC.
XX
PI      Beeley NRA, Prickett KS;
XX
PS      WPI; 1999-394773/33.
XX
PT      New exendin agonist peptides - can regulate gastric motility and slow
PT      gastric emptying, used for treating, e.g. diabetes.
XX
PS      Claim 18; Fig 4; 108pp; English.
XX
CC      AAY24809 to AAY24877 represent exendin agonist peptides which can
CC      regulate gastric motility and slow gastric emptying. The peptides can be
CC      used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC      conditions. The peptides are exendin agonists which have activity as
CC      agents to regulate gastric motility and to slow gastric emptying, as
CC      evidenced by the ability to reduce post-prandial glucose levels in
CC      mammals. They can be used for the treatment of Type I and II diabetes and
CC      hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC      treatment of disorders which would be benefited by agents which lower
CC      plasma glucose levels and in treatment of disorders which would be
CC      benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ      Sequence 29 AA;
AAAY24868 Length: 29 February 4, 2005 13:19 Type: P Check: 2649
Found using 'seq4' (mohamed337.key)

1      |-----|
      1 HGEFTSDASKQLEEEAVRLFIEFLKNG
      28

-----
1 match found in sequence:
aay24868 ; Exendin agonist peptide #60.
(from "seq4ags.pep")
TOIG of: aay24868 check: 2649 from: 1 to: 29

```

```

aay24869 ; Exendin agonist peptide #61.
(from "seq4ags.pep")
TOIG of: aay24869 check: 4015 from: 1 to: 37

ID      AAY24869 standard; peptide; 37 AA.
XX
AC      AAY24869;
XX
DT      24-AUG-1999 (first entry)
XX
DE      Exendin agonist peptide #61.
XX
KW      Exendin; agonist; Heloderma sp; Gila monster; venom; lizard;
KW      diabetes mellitus type I; diabetes mellitus type II; hyperglycaemia;
KW      hypoglycaemia; plasma glucose; gastric emptying; stomach emptying.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
PN      WO9925727-A2.
XX
PD      27-MAY-1999.
XX
PF      13-NOV-1998; 98WO-US024210.
XX
PR      14-NOV-1997; 97US-0065442P.
XX
PA      (AMYL-) AMYLIN PHARM INC.
XX
PI      Beeley NRA, Prickett KS;
XX
PS      WPI; 1999-394773/33.
XX
PT      New exendin agonist peptides - can regulate gastric motility and slow
PT      gastric emptying, used for treating, e.g. diabetes.
XX
PS      Claim 18; Fig 4; 108pp; English.
XX
CC      AAY24809 to AAY24877 represent exendin agonist peptides which can
CC      regulate gastric motility and slow gastric emptying. The peptides can be
CC      used for treating e.g. diabetes or hyperglycaemic or hypoglycaemic
CC      conditions. The peptides are exendin agonists which have activity as
CC      agents to regulate gastric motility and to slow gastric emptying, as
CC      evidenced by the ability to reduce post-prandial glucose levels in
CC      mammals. They can be used for the treatment of Type I and II diabetes and
CC      hyperglycaemic or hypoglycaemic conditions. They can also be used for the
CC      treatment of disorders which would be benefited by agents which lower
CC      plasma glucose levels and in treatment of disorders which would be
CC      benefited with agents useful in delaying and/or slowing gastric emptying
XX
SQ      Sequence 37 AA;
AAAY24869 Length: 37 February 4, 2005 13:19 Type: P Check: 4015
Found using 'seq4' (mohamed337.key)

1      |-----|
      1 HGEFTSDASKQLEEEAVRLFIEFLKNGXSGXAX
      28

-----
1 match found in sequence:
aay31501 ; Exendin-3 peptide sequence.
(from "seq4ags.pep")
TOIG of: aay31501 check: 9591 from: 1 to: 39

ID      AAY31501 standard; peptide; 39 AA.
XX
AC      AAY31501;
XX
DT      08-NOV-1999 (first entry)
XX
DE      Exendin-3 peptide sequence.
XX

```

KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma horridum.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 PN WO9940788-A1.
 XX
 XX 19-AUG-1999.
 PD
 XX
 XX 05-FEB-1999; 99WO-US002554.
 PF
 XX 13-FEB-1998; 98US-0075122P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young AA, Vine W, Beeley NRA, Prickett K;
 PI WPI; 1999-527332/44.
 DR
 XX Increasing urine flow by administering peptides or peptide agonists.
 PT
 XX
 XX Claim 14; Page 7; 94pp; English.
 PS
 XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. The
 CC present sequence represents an exendin-3 peptide which can be used in the
 CC methods of the invention
 XX
 SQ Sequence 39 AA;
 AAY31501 Length: 39 February 4, 2005 13:19 Type: P Check: 9591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSLSKQMBEEAVRLFIEWLKNKGPSGAPPPS
 28

1 match found in sequence:
 aay31502; Exendin-4 peptide sequence.
 (from "seq4ags.pep")
 TOIG of: aay31502 check: 9570 from: 1 to: 39

ID AAY31502 standard; peptide; 39 AA.
 XX
 AC AAY31502;
 XX
 DT 08-NOV-1999 (first entry)
 XX
 DE Exendin-4 peptide sequence.

XX
 KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma suspectum.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 PN WO9940788-A1.
 XX
 XX 19-AUG-1999.
 PD
 XX
 XX 05-FEB-1999; 99WO-US002554.
 PF
 XX 13-FEB-1998; 98US-0075122P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young AA, Vine W, Beeley NRA, Prickett K;
 PI WPI; 1999-527332/44.
 DR
 XX Increasing urine flow by administering peptides or peptide agonists.
 PT
 XX
 XX Claim 15; Page 7; 94pp; English.
 PS
 XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. The
 CC present sequence represents an exendin-4 peptide which can be used in the
 CC methods of the invention
 XX
 SQ Sequence 39 AA;
 AAY31502 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)

1 HCEGFTSLSKQMBEEAVRLFIEWLKNKGPSGAPPPS
 28

1 match found in sequence:
 aay31505; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31505 check: 4889 from: 1 to: 30

ID AAY31505 standard; peptide; 30 AA.
 XX
 AC AAY31505;
 XX
 DT 08-NOV-1999 (first entry)
 XX

```

DE  XX  Extending agonist peptide.
KW  XX  Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  XX  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  XX  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  XX  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  XX  hypertension; urine flow.
OS  XX  Synthetic.
OS  XX  Heloderma sp.
XX  XX
FH  XX  Key  Location/Qualifiers
FT  XX  Modified-site 30
FT  XX  /note= "C-terminal amide"
XX  XX
PN  XX  WO9940788-A1.
XX  XX
PD  XX  19-AUG-1999.
XX  XX
PF  XX  05-FEB-1999; 99WO-US002554.
XX  XX
PR  XX  13-FEB-1998; 98US-0075122P.
XX  XX
PA  XX  (AMYL-) AMYLIN PHARM INC.
XX  XX
PI  XX  Young AA, Vine W, Beeley NRA, Prickett K;
XX  XX  WPI; 1999-527332/44.
XX  XX
PT  Increasing urine flow by administering peptides or peptide agonists.
XX  XX
PS  Example 4; Page 32; 9app; English.
XX  XX
CC  The invention relates to new methods of increasing urine flow that
CC  comprises administering an extendin or extendin agonist, or a GLP-1
CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
CC  increasing urine flow, decreasing potassium concentration in urine,
CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  rapid diuresis, preparing an individual for surgical procedure,
CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  disorder that can be alleviated by increasing cardiac contractility
CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  excretion and sodium excretion without increasing potassium loss, and are
CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  AAY31505-560 represent examples of extendin agonists compounds
XX  XX
SQ  Sequence 30 AA;

AAY31505 Length: 30 February 4, 2005 13:19 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1  |-----|
  1  HGGGFTSLSKQMEEEAVRLFIEWLKNG 28
  |-----|

-----
1 match found in sequence:
aay31506 ; Extending agonist peptide.
  (from "seq4ags.pep")
TOIG of: aay31506 check: 700 from: 1 to: 28

ID  AAY31506 standard; peptide; 28 AA.
XX
AC  AAY31506;
XX
DT  08-NOV-1999 (first entry)
XX

```

```

DE  XX  Extending agonist peptide.
KW  XX  Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  XX  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  XX  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  XX  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  XX  hypertension; urine flow.
OS  XX  Synthetic.
OS  XX  Heloderma sp.
XX  XX
FH  XX  Key  Location/Qualifiers
FT  XX  Modified-site 28
FT  XX  /note= "C-terminal amide"
XX  XX
PN  XX  WO9940788-A1.
XX  XX
PD  XX  19-AUG-1999.
XX  XX
PF  XX  05-FEB-1999; 99WO-US002554.
XX  XX
PR  XX  13-FEB-1998; 98US-0075122P.
XX  XX
PA  XX  (AMYL-) AMYLIN PHARM INC.
XX  XX
PI  XX  Young AA, Vine W, Beeley NRA, Prickett K;
XX  XX  WPI; 1999-527332/44.
XX  XX
PT  Increasing urine flow by administering peptides or peptide agonists.
XX  XX
PS  Example 5; Page 33; 9app; English.
XX  XX
CC  The invention relates to new methods of increasing urine flow that
CC  comprises administering an extendin or extendin agonist, or a GLP-1
CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
CC  increasing urine flow, decreasing potassium concentration in urine,
CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  rapid diuresis, preparing an individual for surgical procedure,
CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  disorder that can be alleviated by increasing cardiac contractility
CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  excretion and sodium excretion without increasing potassium loss, and are
CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  AAY31505-560 represent examples of extendin agonists compounds
XX  XX
SQ  Sequence 28 AA;

AAY31506 Length: 28 February 4, 2005 13:19 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)

1  |-----|
  1  HGGGFTSLSKQMEEEAVRLFIEWLKN 28
  |-----|

-----
1 match found in sequence:
aay31507 ; Extending agonist peptide.
  (from "seq4ags.pep")
TOIG of: aay31507 check: 261 from: 1 to: 28

ID  AAY31507 standard; peptide; 28 AA.
XX
AC  AAY31507;
XX
DT  08-NOV-1999 (first entry)
XX

```

```

DE      Extandin agonist peptide.
XX
KW      Extandin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
FH      Key      Location/Qualifiers
FT      Modified-site 28
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 6; Page 33; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an extandin or extandin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      extandin, extandin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of extandin agonists compounds
XX
XX      Sequence 28 AA;
XX
XX      AAY31507 Length: 28 February 4, 2005 13:19 Type: P Check: 261
XX      Found using 'seq4' (mohamed337.key)
XX
1      1      HGEGFTSDLSKQLEEEAVRLFIEFLKN      28
      |-----|
      1 match found in sequence:
      aay31508 ; Extandin agonist peptide.
      (from "seq4ags.pep")
      TOIG of: aay31508 check: 249 from: 1 to: 28

ID      AAY31508 standard; peptide; 28 AA.
XX
AC      AAY31508;
XX
XX      08-NOV-1999 (first entry)
XX

```

```

DE      Extandin agonist peptide.
XX
KW      Extandin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
FH      Key      Location/Qualifiers
FT      Modified-site 28
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 7; Page 34; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an extandin or extandin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      extandin, extandin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of extandin agonists compounds
XX
XX      Sequence 28 AA;
XX
XX      AAY31508 Length: 28 February 4, 2005 13:19 Type: P Check: 249
XX      Found using 'seq4' (mohamed337.key)
XX
1      1      HGEGFTSDLSKQLEEEAVRLFIEFLKN      28
      |-----|
      1 match found in sequence:
      aay31509 ; Extandin agonist peptide.
      (from "seq4ags.pep")
      TOIG of: aay31509 check: 166 from: 1 to: 28

ID      AAY31509 standard; peptide; 28 AA.
XX
AC      AAY31509;
XX
XX      08-NOV-1999 (first entry)
XX

```

```

DE  Exendin agonist peptide.
XX
KW  Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  hypertension; urine flow.
XX
OS  Synthetic.
OS  Heloderma sp.
XX
FH  Key                               Location/Qualifiers
FT  Modified-site                     28
FT  /note= "C-terminal amide"
XX
PN  WO9940788-A1.
XX
PD  19-AUG-1999.
XX
PF  05-FEB-1999; 99WO-US002554.
XX
PR  13-FEB-1998; 98US-0075122P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Young AA, Vine W, Beeley NRA, Prickett K;
XX  WPI; 1999-527332/44.
XX
PT  Increasing urine flow by administering peptides or peptide agonists.
XX
PS  Example 8; Page 34; 94pp; English.
XX
CC  The invention relates to new methods of increasing urine flow that
CC  comprises administering an exendin or exendin agonist, or a GLP-1
CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC  increasing urine flow, decreasing potassium concentration in urine,
CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  rapid diuresis, preparing an individual for surgical procedure,
CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  disorder that can be alleviated by increasing cardiac contractility
CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  excretion and sodium excretion without increasing potassium loss, and are
CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  AAY31505-560 represent examples of exendin agonists compounds
XX
SQ  Sequence 28 AA;

AAY31509 Length: 28 February 4, 2005 13:19 Type: P Check: 166
Found using 'seq4' (mohamed337.key)

1  HGEAFTSDLSKQLEEEAVRLFIEFLKN 28
1  HGEAFTSDLSKQLEEEAVRLFIEFLKN 28

-----
1 match found in sequence:
aay31510 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31510 check: 231 from: 1 to: 28

ID  AAY31510 standard; peptide; 28 AA.
XX
AC  AAY31510;
XX
DT  08-NOV-1999 (first entry)
XX

DE  Exendin agonist peptide.
XX
KW  Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  hypertension; urine flow.
XX
OS  Synthetic.
OS  Heloderma sp.
XX
FH  Key                               Location/Qualifiers
FT  Modified-site                     28
FT  /note= "C-terminal amide"
XX
PN  WO9940788-A1.
XX
PD  19-AUG-1999.
XX
PF  05-FEB-1999; 99WO-US002554.
XX
PR  13-FEB-1998; 98US-0075122P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Young AA, Vine W, Beeley NRA, Prickett K;
XX  WPI; 1999-527332/44.
XX
PT  Increasing urine flow by administering peptides or peptide agonists.
XX
PS  Example 9; Page 35; 94pp; English.
XX
CC  The invention relates to new methods of increasing urine flow that
CC  comprises administering an exendin or exendin agonist, or a GLP-1
CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC  increasing urine flow, decreasing potassium concentration in urine,
CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  rapid diuresis, preparing an individual for surgical procedure,
CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  disorder that can be alleviated by increasing cardiac contractility
CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  excretion and sodium excretion without increasing potassium loss, and are
CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  AAY31505-560 represent examples of exendin agonists compounds
XX
SQ  Sequence 28 AA;

AAY31510 Length: 28 February 4, 2005 13:19 Type: P Check: 231
Found using 'seq4' (mohamed337.key)

1  HGEATATSDLSKQLEEEAVRLFIEFLKN 28
1  HGEATATSDLSKQLEEEAVRLFIEFLKN 28

-----
1 match found in sequence:
aay31511 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31511 check: 117 from: 1 to: 28

ID  AAY31511 standard; peptide; 28 AA.
XX
AC  AAY31511;
XX
DT  08-NOV-1999 (first entry)
XX

```

```
DE      Extendin agonist peptide.
XX
KW      Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
FH      Key      Location/Qualifiers
FT      Modified-site      28
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 10; Page 35; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an extendin or extendin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of extendin agonists compounds
XX
XX      Sequence 28 AA;
XX
XX      AAY31511 Length: 28 February 4, 2005 13:19 Type: P Check: 117 ..
XX      Found using 'seq4' (mohamed337.key)
XX
1      |-----|
1      HGEGETFADLSKQLEEEAVRLFIPLKN      28
XX
-----
1 match found in sequence:
aay31512 ; Extendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31512 check: 151 from: 1 to: 28
XX
ID      AAY31512 standard; peptide; 28 AA.
XX
AC      AAY31512;
XX
XX      08-NOV-1999 (first entry)
XX
XX
```

```
DE      Extendin agonist peptide.
XX
KW      Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
FH      Key      Location/Qualifiers
FT      Modified-site      28
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 11; Page 36; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an extendin or extendin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of extendin agonists compounds
XX
XX      Sequence 28 AA;
XX
XX      AAY31512 Length: 28 February 4, 2005 13:19 Type: P Check: 151 ..
XX      Found using 'seq4' (mohamed337.key)
XX
1      |-----|
1      HGEGETFTSDASKQLEEEAVRLFIPLKN      28
XX
-----
1 match found in sequence:
aay31513 ; Extendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31513 check: 63 from: 1 to: 28
XX
ID      AAY31513 standard; peptide; 28 AA.
XX
AC      AAY31513;
XX
XX      08-NOV-1999 (first entry)
XX
XX
```

```
DE  XX  Extensin agonist peptide.
KW  XX  Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  XX  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  XX  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  XX  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  XX  hypertension; urine flow.
OS  OS  Synthetic.
OS  OS  Heloderma sp.
XX  XX
XX  FH  Key  Location/Qualifiers
XX  FT  Modified-site 28
XX  FT  /note= "C-terminal amide"
XX  XX
XX  PN  WO9940788-A1.
XX  PD  19-AUG-1999.
XX  XX
XX  PF  05-FEB-1999; 99WO-US002554.
XX  PF
XX  PR  13-FEB-1998; 98US-0075122P.
XX  PR
XX  PA  (AMYL-) AMYLIN PHARM INC.
XX  PA
XX  PI  Young AA, Vine W, Beeley NRA, Prickett K;
XX  PI  WPI; 1999-527332/44.
XX  DR
XX  PT  Increasing urine flow by administering peptides or peptide agonists.
XX  PT
XX  PS  Example 12; Page 36; 94pp; English.
XX  PS
XX  CC  The invention relates to new methods of increasing urine flow that
XX  CC  comprises administering an extensin or extensin agonist, or a GLP-1
XX  CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX  CC  extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX  CC  increasing urine flow, decreasing potassium concentration in urine,
XX  CC  preventing or alleviating a disorder associated with toxic hypervolemia
XX  CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX  CC  edema, cirrhosis, or hypertension). They can also be used for inducing
XX  CC  rapid diuresis, preparing an individual for surgical procedure,
XX  CC  increasing renal plasma flow and glomerular filtration rate, treating pre
XX  CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX  CC  disorder that can be alleviated by increasing cardiac contractility
XX  CC  (congestive heart failure, pulmonary edema, systemic edema or renal
XX  CC  failure). Unlike prior art diuretics, the new methods increase urine
XX  CC  excretion and sodium excretion without increasing potassium loss, and are
XX  CC  fast acting. They have a prolonged duration of action, are inotropic,
XX  CC  have a low toxicity, and are easily administered intravenously. Sequences
XX  CC  AAY31505-560 represent examples of extensin agonists compounds
XX  XX
XX  SQ  Sequence 28 AA;
XX  SQ
AAY31513 Length: 28 February 4, 2005 13:19 Type: P Check: 63 ..
Found using 'seq4' (mohamed337.key)
1 1 HGEFTTSDLAQLEBEEAVRLFIEFLKN 28
1 1 HGEFTTSDLAQLEBEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay31514; Extensin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31514 check: 141 from: 1 to: 28
ID AAY31514 standard; peptide; 28 AA.
XX
XX AC AAY31514;
XX XX
XX DT 08-NOV-1999 (first entry)
XX XX
```

```
DE  XX  Extensin agonist peptide.
KW  XX  Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  XX  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  XX  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  XX  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  XX  hypertension; urine flow.
OS  OS  Synthetic.
OS  OS  Heloderma sp.
XX  XX
XX  FH  Key  Location/Qualifiers
XX  FT  Modified-site 28
XX  FT  /note= "C-terminal amide"
XX  XX
XX  PN  WO9940788-A1.
XX  PD  19-AUG-1999.
XX  XX
XX  PF  05-FEB-1999; 99WO-US002554.
XX  PF
XX  PR  13-FEB-1998; 98US-0075122P.
XX  PR
XX  PA  (AMYL-) AMYLIN PHARM INC.
XX  PA
XX  PI  Young AA, Vine W, Beeley NRA, Prickett K;
XX  PI  WPI; 1999-527332/44.
XX  DR
XX  PT  Increasing urine flow by administering peptides or peptide agonists.
XX  PT
XX  PS  Example 12; Page 36; 94pp; English.
XX  PS
XX  CC  The invention relates to new methods of increasing urine flow that
XX  CC  comprises administering an extensin or extensin agonist, or a GLP-1
XX  CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX  CC  extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX  CC  increasing urine flow, decreasing potassium concentration in urine,
XX  CC  preventing or alleviating a disorder associated with toxic hypervolemia
XX  CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX  CC  edema, cirrhosis, or hypertension). They can also be used for inducing
XX  CC  rapid diuresis, preparing an individual for surgical procedure,
XX  CC  increasing renal plasma flow and glomerular filtration rate, treating pre
XX  CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX  CC  disorder that can be alleviated by increasing cardiac contractility
XX  CC  (congestive heart failure, pulmonary edema, systemic edema or renal
XX  CC  failure). Unlike prior art diuretics, the new methods increase urine
XX  CC  excretion and sodium excretion without increasing potassium loss, and are
XX  CC  fast acting. They have a prolonged duration of action, are inotropic,
XX  CC  have a low toxicity, and are easily administered intravenously. Sequences
XX  CC  AAY31505-560 represent examples of extensin agonists compounds
XX  XX
XX  SQ  Sequence 28 AA;
XX  SQ
AAY31513 Length: 28 February 4, 2005 13:19 Type: P Check: 63 ..
Found using 'seq4' (mohamed337.key)
1 1 HGEFTTSDLAQLEBEEAVRLFIEFLKN 28
1 1 HGEFTTSDLAQLEBEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay31514; Extensin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31514 check: 141 from: 1 to: 28
ID AAY31514 standard; peptide; 28 AA.
XX
XX AC AAY31514;
XX XX
XX DT 08-NOV-1999 (first entry)
XX XX
```

```

DE      Exendin agonist peptide.
XX
XX      Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
XX      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site 28
FT      /note= "C-terminal amide"
FT
XX      WO9940788-A1.
XX      PN
XX      PD 19-AUG-1999.
XX      PF 05-FEB-1999; 99WO-US002554.
XX      PR 13-FEB-1998; 98US-0075122P.
XX      PA (AMYL-) AMYLIN PHARM INC.
XX      PI Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX      PT Increasing urine flow by administering peptides or peptide agonists.
XX      PS      Example 14; Page 37; 94pp; English.
XX      CC      The invention relates to new methods of increasing urine flow that
CC      comprises administering an exendin or exendin agonist, or a GLP-1
CC      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC      exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC      increasing urine flow, decreasing potassium concentration in urine,
CC      preventing or alleviating a disorder associated with toxic hypervolemia
CC      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC      edema, cirrhosis, or hypertension). They can also be used for inducing
CC      rapid diuresis, preparing an individual for surgical procedure,
CC      increasing renal plasma flow and glomerular filtration rate, treating pre
CC      -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC      disorder that can be alleviated by increasing cardiac contractility
CC      (congestive heart failure, pulmonary edema, systemic edema or renal
CC      failure). Unlike prior art diuretics, the new methods increase urine
CC      excretion and sodium excretion without increasing potassium loss, and are
CC      fast acting. They have a prolonged duration of action, are inotropic,
CC      have a low toxicity, and are easily administered intravenously. Sequences
CC      AAY31505-560 represent examples of exendin agonists compounds
XX      SQ      Sequence 28 AA;
XX
XX      AAY31515 Length: 28 February 4, 2005 13:19 Type: P Check: 53
XX      Found using 'seq4' (mohamed337.key)
XX
1      |-----|
1      HEGFTSDLSKALEEAVRLPIEFLKN 28
XX
-----
1 match found in sequence:
aay31516 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31516 check: 107 from: 1 to: 28
XX
ID AAY31516 standard; peptide; 28 AA.
XX
AC AAY31516;
XX
XX 08-NOV-1999 (first entry)
XX
XX

```

```

DE      Exendin agonist peptide.
XX
XX      Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
XX      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site 28
FT      /note= "C-terminal amide"
FT
XX      WO9940788-A1.
XX      PN
XX      PD 19-AUG-1999.
XX      PF 05-FEB-1999; 99WO-US002554.
XX      PR 13-FEB-1998; 98US-0075122P.
XX      PA (AMYL-) AMYLIN PHARM INC.
XX      PI Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX      PT Increasing urine flow by administering peptides or peptide agonists.
XX      PS      Example 15; Page 38; 94pp; English.
XX      CC      The invention relates to new methods of increasing urine flow that
CC      comprises administering an exendin or exendin agonist, or a GLP-1
CC      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC      exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC      increasing urine flow, decreasing potassium concentration in urine,
CC      preventing or alleviating a disorder associated with toxic hypervolemia
CC      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC      edema, cirrhosis, or hypertension). They can also be used for inducing
CC      rapid diuresis, preparing an individual for surgical procedure,
CC      increasing renal plasma flow and glomerular filtration rate, treating pre
CC      -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC      disorder that can be alleviated by increasing cardiac contractility
CC      (congestive heart failure, pulmonary edema, systemic edema or renal
CC      failure). Unlike prior art diuretics, the new methods increase urine
CC      excretion and sodium excretion without increasing potassium loss, and are
CC      fast acting. They have a prolonged duration of action, are inotropic,
CC      have a low toxicity, and are easily administered intravenously. Sequences
CC      AAY31505-560 represent examples of exendin agonists compounds
XX      SQ      Sequence 28 AA;
XX
XX      AAY31516 Length: 28 February 4, 2005 13:19 Type: P Check: 107
XX      Found using 'seq4' (mohamed337.key)
XX
1      |-----|
1      HEGFTSDLSKQAEAEAVRLPIEFLKN 28
XX
-----
1 match found in sequence:
aay31517 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31517 check: 201 from: 1 to: 28
XX
ID AAY31517 standard; peptide; 28 AA.
XX
AC AAY31517;
XX
XX 08-NOV-1999 (first entry)
XX
XX

```

```

DE  XX  Exendin agonist peptide.
KW  XX  Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  KW  hypertension; urine flow.
OS  OS  Synthetic.
OS  OS  Heloderma sp.
XX  XX
FH  XX  Key      Location/Qualifiers
FT  XX  Modified-site 28
FT  XX  /note= "C-terminal amide"
XX  XX
PN  XX  WO9940788-A1.
XX  XX
PD  XX  19-AUG-1999.
XX  XX
PF  XX  05-FEB-1999; 99WO-US002554.
XX  XX
PR  XX  13-FEB-1998; 98US-0075122P.
XX  XX
PA  XX  (AMYL-) AMYLIN PHARM INC.
XX  XX
PI  XX  Young AA, Vine W, Beeley NRA, Prickett K;
XX  XX  WPI; 1999-527332/44.
XX  XX
PT  XX  Increasing urine flow by administering peptides or peptide agonists.
XX  XX
PS  XX  Example 16; Page 38; 94pp; English.
XX  XX
CC  XX  The invention relates to new methods of increasing urine flow that
CC  CC  comprises administering an exendin or exendin agonist, or a GLP-1
CC  CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  CC  exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC  CC  increasing urine flow, decreasing potassium concentration in urine,
CC  CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  CC  rapid diuresis, preparing an individual for surgical procedure,
CC  CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  CC  disorder that can be alleviated by increasing cardiac contractility
CC  CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  CC  excretion and sodium excretion without increasing potassium loss, and are
CC  CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  CC  AAY31505-560 represent examples of exendin agonists compounds
XX  XX
SQ  XX  Sequence 28 AA;

AAY31517 Length: 28 February 4, 2005 13:19 Type: P Check: 201 ..
Found using 'seq4' (mohamed337.key)

1 1 HGEFTTSDLSKQLAEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
aay31518 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31518 check: 197 from: 1 to: 28

ID AAY31518 standard; peptide; 28 AA.
XX
AC AAY31518;
XX
DT 08-NOV-1999 (first entry)
XX

DE  XX  Exendin agonist peptide.
KW  XX  Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  KW  hypertension; urine flow.
OS  OS  Synthetic.
OS  OS  Heloderma sp.
XX  XX
FH  XX  Key      Location/Qualifiers
FT  XX  Modified-site 28
FT  XX  /note= "C-terminal amide"
XX  XX
PN  XX  WO9940788-A1.
XX  XX
PD  XX  19-AUG-1999.
XX  XX
PF  XX  05-FEB-1999; 99WO-US002554.
XX  XX
PR  XX  13-FEB-1998; 98US-0075122P.
XX  XX
PA  XX  (AMYL-) AMYLIN PHARM INC.
XX  XX
PI  XX  Young AA, Vine W, Beeley NRA, Prickett K;
XX  XX  WPI; 1999-527332/44.
XX  XX
PT  XX  Increasing urine flow by administering peptides or peptide agonists.
XX  XX
PS  XX  Example 16; Page 38; 94pp; English.
XX  XX
CC  XX  The invention relates to new methods of increasing urine flow that
CC  CC  comprises administering an exendin or exendin agonist, or a GLP-1
CC  CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  CC  exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC  CC  increasing urine flow, decreasing potassium concentration in urine,
CC  CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  CC  rapid diuresis, preparing an individual for surgical procedure,
CC  CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  CC  disorder that can be alleviated by increasing cardiac contractility
CC  CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  CC  excretion and sodium excretion without increasing potassium loss, and are
CC  CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  CC  AAY31505-560 represent examples of exendin agonists compounds
XX  XX
SQ  XX  Sequence 28 AA;

AAY31518 Length: 28 February 4, 2005 13:19 Type: P Check: 197 ..
Found using 'seq4' (mohamed337.key)

1 1 HGEFTTSDLSKQLAEAVRLFIEFLKN 28
|-----|
1 match found in sequence:
aay31519 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31519 check: 193 from: 1 to: 28

ID AAY31519 standard; peptide; 28 AA.
XX
AC AAY31519;
XX
DT 08-NOV-1999 (first entry)
XX

```

```

DE      Exendin agonist peptide.
XX
KW      Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
FH      Key      Location/Qualifiers
FT      Modified-site 28      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1999; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 18; Page 39; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an exendin or exendin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of exendin agonists compounds
XX
XX      Sequence 28 AA;
XX
XX      AAY31519 Length: 28 February 4, 2005 13:19 Type: P Check: 193
XX      Found using 'seq4' (mohamed337.key)
XX
1      |-----|
1      HGEFTSLSKQLEAAVRLFIEFLKN 28
XX
-----
1 match found in sequence:
aay31520 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31520 check: 9862 from: 1 to: 28
XX
ID      AAY31520 standard; peptide; 28 AA.
XX
XX      AAY31520;
XX
XX      08-NOV-1999 (first entry)
XX
XX

```

```

DE      Exendin agonist peptide.
XX
KW      Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
FH      Key      Location/Qualifiers
FT      Modified-site 28      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1999; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 19; Page 40; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an exendin or exendin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of exendin agonists compounds
XX
XX      Sequence 28 AA;
XX
XX      AAY31520 Length: 28 February 4, 2005 13:19 Type: P Check: 9862
XX      Found using 'seq4' (mohamed337.key)
XX
1      |-----|
1      HGEFTSLSKQLEAAARLFIEFLKN 28
XX
-----
1 match found in sequence:
aay31521 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31521 check: 9921 from: 1 to: 28
XX
ID      AAY31521 standard; peptide; 28 AA.
XX
XX      AAY31521;
XX
XX      08-NOV-1999 (first entry)
XX
XX

```

```

DE  Extentin agonist peptide.
XX
XX  Extentin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX  hypertension; urine flow.
XX
XX  Synthetic.
OS  Heloderma sp.
XX
XX  Key      Location/Qualifiers
FH  Modified-site 28
FT  /note= "C-terminal amide"
XX
XX  WO9940788-A1.
PN
XX  19-AUG-1999.
PD
XX
XX  05-FEB-1999; 99WO-US002554.
PF
XX  13-FEB-1998; 98US-0075122P.
PR
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Young AA, Vine W, Beeley NRA, Prickett K;
PI  WPI; 1999-527332/44.
XX
XX  Increasing urine flow by administering peptides or peptide agonists.
PT
XX
XX  Example 20; Page 40; 94pp; English.
XX
XX  The invention relates to new methods of increasing urine flow that
CC  comprises administering an extentin or extentin agonist, or a GLP-1
CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  extentin, extentin agonist, GLP-1 or GLP-1 agonist are useful for
CC  increasing urine flow, decreasing potassium concentration in urine,
CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  rapid diuresis, preparing an individual for surgical procedure,
CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  disorder that can be alleviated by increasing cardiac contractility
CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  excretion and sodium excretion without increasing potassium loss, and are
CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  AAY31505-560 represent examples of extentin agonists compounds
XX
XX  Sequence 28 AA;
SQ
AAY31521 Length: 28 February 4, 2005 13:19 Type: P Check: 9921 ..
Found using 'seq4' (mohamed337.key)

1  HGEFTSDLSKQLEEEAVALFIEFLKN 28
|-----|
1 match found in sequence:
aay31522 ; Extentin agonist peptide.
(from "seq4ags pep")
TOIG of: aay31522 check: 30 from: 1 to: 28

ID AAY31522 standard; peptide; 28 AA.
XX
XX  AAY31522;
AC
XX  08-NOV-1999 (first entry)
DT
XX

```

```

DE  Extentin agonist peptide.
XX
XX  Extentin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX  hypertension; urine flow.
XX
XX  Synthetic.
OS  Heloderma sp.
XX
XX  Key      Location/Qualifiers
FH  Modified-site 28
FT  /note= "C-terminal amide"
XX
XX  WO9940788-A1.
PN
XX  19-AUG-1999.
PD
XX
XX  05-FEB-1999; 99WO-US002554.
PF
XX  13-FEB-1998; 98US-0075122P.
PR
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Young AA, Vine W, Beeley NRA, Prickett K;
PI  WPI; 1999-527332/44.
XX
XX  Increasing urine flow by administering peptides or peptide agonists.
PT
XX
XX  Example 21; Page 41; 94pp; English.
XX
XX  The invention relates to new methods of increasing urine flow that
CC  comprises administering an extentin or extentin agonist, or a GLP-1
CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  extentin, extentin agonist, GLP-1 or GLP-1 agonist are useful for
CC  increasing urine flow, decreasing potassium concentration in urine,
CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  rapid diuresis, preparing an individual for surgical procedure,
CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  disorder that can be alleviated by increasing cardiac contractility
CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  excretion and sodium excretion without increasing potassium loss, and are
CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  AAY31505-560 represent examples of extentin agonists compounds
XX
XX  Sequence 28 AA;
SQ
AAY31522 Length: 28 February 4, 2005 13:19 Type: P Check: 30 ..
Found using 'seq4' (mohamed337.key)

1  HGEFTSDLSKQLEEEAVRAFIEFLKN 28
|-----|
1 match found in sequence:
aay31523 ; Extentin agonist peptide.
(from "seq4ags pep")
TOIG of: aay31523 check: 165 from: 1 to: 28

ID AAY31523 standard; peptide; 28 AA.
XX
XX  AAY31523;
AC
XX  08-NOV-1999 (first entry)
DT
XX

```

```

DE      Exendin agonist peptide.
XX
KW      Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
XX      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site      28
FT      /note= "C-terminal amide"
FT
XX      WO9940788-A1.
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 22; Page 41; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an exendin or exendin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of exendin agonists compounds
XX
XX      Sequence 28 AA;
SQ
AAY31523 Length: 28 February 4, 2005 13:19 Type: P Check: 165
Found using 'seq4' (mohamed337.key)

1      |-----|
      1      HGGGTTSDLSKQLEEEAVRLFTAFLEKN      28

-----
1 match found in sequence:
aay31524; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31524 check: 136 from: 1 to: 28

ID      AAY31524 standard; peptide; 28 AA.
XX
XX      AAY31524;
AC
XX
XX      08-NOV-1999 (first entry)
DT
XX

```

```

DE      Exendin agonist peptide.
XX
KW      Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
XX      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site      28
FT      /note= "C-terminal amide"
FT
XX      WO9940788-A1.
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 23; Page 42; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an exendin or exendin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of exendin agonists compounds
XX
XX      Sequence 28 AA;
SQ
AAY31524 Length: 28 February 4, 2005 13:19 Type: P Check: 136
Found using 'seq4' (mohamed337.key)

1      |-----|
      1      HGGGTTSDLSKQLEEEAVRLFTAFLEKN      28

-----
1 match found in sequence:
aay31525; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31525 check: 9975 from: 1 to: 28

ID      AAY31525 standard; peptide; 28 AA.
XX
XX      AAY31525;
AC
XX
XX      08-NOV-1999 (first entry)
DT
XX

```

DE	XX	Exendin agonist peptide.	DE	XX	Exendin agonist peptide.
KW	XX	Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;	KW	XX	Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW	XX	diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;	KW	XX	diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW	XX	eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;	KW	XX	eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW	XX	congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;	KW	XX	congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW	XX	hypertension; urine flow.	KW	XX	hypertension; urine flow.
OS	OS	Synthetic.	OS	OS	Synthetic.
OS	OS	Heloderma sp.	OS	OS	Heloderma sp.
XX	XX		XX	XX	
PH	XX	Key	PH	XX	Key
FT	XX	Location/Qualifiers	FT	XX	Location/Qualifiers
FT	XX	28	FT	XX	28
FT	XX	/note= "C-terminal amide"	FT	XX	/note= "C-terminal amide"
XX	XX		XX	XX	
PN	XX	WO9940788-A1.	PN	XX	WO9940788-A1.
XX	XX		XX	XX	
PD	XX	19-AUG-1999.	PD	XX	19-AUG-1999.
XX	XX		XX	XX	
XX	XX	05-FEB-1999; 99WO-US002554.	XX	XX	05-FEB-1999; 99WO-US002554.
PF	XX		PF	XX	
XX	XX		XX	XX	
PR	XX	13-FEB-1998; 98US-0075122P.	PR	XX	13-FEB-1998; 98US-0075122P.
XX	XX		XX	XX	
XX	XX	(AMYL-) AMYLIN PHARM INC.	XX	XX	(AMYL-) AMYLIN PHARM INC.
PA	XX		PA	XX	
XX	XX		XX	XX	
PI	XX	Young AA, Vine W, Beeley NRA, Prickett K;	PI	XX	Young AA, Vine W, Beeley NRA, Prickett K;
XX	XX		XX	XX	
DR	XX	WPI; 1999-527332/44.	DR	XX	WPI; 1999-527332/44.
XX	XX		XX	XX	
PT	XX	Increasing urine flow by administering peptides or peptide agonists.	PT	XX	Increasing urine flow by administering peptides or peptide agonists.
XX	XX		XX	XX	
PS	XX	Example 24; Page 42; 94pp; English.	PS	XX	Example 24; Page 42; 94pp; English.
XX	XX		XX	XX	
CC	XX	The invention relates to new methods of increasing urine flow that	CC	XX	The invention relates to new methods of increasing urine flow that
CC	XX	comprises administering an exendin or exendin agonist, or a GLP-1	CC	XX	comprises administering an exendin or exendin agonist, or a GLP-1
CC	XX	(glucagon-like peptide) or GLP-1 agonist. The new methods using an	CC	XX	(glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC	XX	exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for	CC	XX	exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC	XX	increasing urine flow, decreasing potassium concentration in urine,	CC	XX	increasing urine flow, decreasing potassium concentration in urine,
CC	XX	preventing or alleviating a disorder associated with toxic hypervolemia	CC	XX	preventing or alleviating a disorder associated with toxic hypervolemia
CC	XX	(renal failure, congestive heart failure, nephrotic syndrome, pulmonary	CC	XX	(renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC	XX	edema, cirrhosis, or hypertension). They can also be used for inducing	CC	XX	edema, cirrhosis, or hypertension). They can also be used for inducing
CC	XX	rapid diuresis, preparing an individual for surgical procedure,	CC	XX	rapid diuresis, preparing an individual for surgical procedure,
CC	XX	increasing renal plasma flow and glomerular filtration rate, treating pre	CC	XX	increasing renal plasma flow and glomerular filtration rate, treating pre
CC	XX	-eclampsia or eclampsia of pregnancy, and increasing a condition/	CC	XX	-eclampsia or eclampsia of pregnancy, and increasing a condition/
CC	XX	disorder that can be alleviated by increasing cardiac contractility	CC	XX	disorder that can be alleviated by increasing cardiac contractility
CC	XX	(congestive heart failure, pulmonary edema, systemic edema or renal	CC	XX	(congestive heart failure, pulmonary edema, systemic edema or renal
CC	XX	failure). Unlike prior art diuretics, the new methods increase urine	CC	XX	failure). Unlike prior art diuretics, the new methods increase urine
CC	XX	excretion and sodium excretion without increasing potassium loss, and are	CC	XX	excretion and sodium excretion without increasing potassium loss, and are
CC	XX	fast acting. They have a prolonged duration of action, are inotropic,	CC	XX	fast acting. They have a prolonged duration of action, are inotropic,
CC	XX	have a low toxicity, and are easily administered intravenously. Sequences	CC	XX	have a low toxicity, and are easily administered intravenously. Sequences
CC	XX	AAV31505-560 represent examples of exendin agonists compounds	CC	XX	AAV31505-560 represent examples of exendin agonists compounds
XX	XX		XX	XX	
SQ	XX	Sequence 28 AA;	SQ	XX	Sequence 28 AA;
AAV31525	Length: 28	February 4, 2005 13:19	AAV31526	Length: 28	February 4, 2005 13:19
Type: P	Check: 9975		Type: P	Check: 9991	
Found using 'seq4' (mohamed337.key)			Found using 'seq4' (mohamed337.key)		
1	1	HGEGFTTSDLSKQLEEEAVRLFIEFAN	1	1	HGEGFTTSDLSKQLEEEAVRLFIEFAN
28	28		28	28	
-----	-----		-----	-----	
1 match found in sequence:	1 match found in sequence:		1 match found in sequence:	1 match found in sequence:	
ay31526 ; Exendin agonist peptide.	ay31526 ; Exendin agonist peptide.		ay31527 ; Exendin agonist peptide.	ay31527 ; Exendin agonist peptide.	
(from "seq4ags.pep")	(from "seq4ags.pep")		(from "seq4ags.pep")	(from "seq4ags.pep")	
TOIG of: aay31526 check: 9991 from: 1 to: 28	TOIG of: aay31526 check: 9991 from: 1 to: 28		TOIG of: aay31527 check: 9897 from: 1 to: 28	TOIG of: aay31527 check: 9897 from: 1 to: 28	
ID	AY31526 standard; peptide; 28 AA.		ID	AY31527 standard; peptide; 28 AA.	
XX			XX		
AC	AY31526;		AC	AY31527;	
XX			XX		
DT	08-NOV-1999 (first entry)		DT	08-NOV-1999 (first entry	

DE Exendin agonist peptide.
 XX
 KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 28 /note= "C-terminal amide"
 FT
 XX WO9940788-A1.
 XX
 XX 19-AUG-1999.
 XX
 XX 05-FEB-1999; 99WO-US002554.
 XX
 XX 13-FEB-1998; 98US-0075122P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Vine W, Beeley NRA, Prickett K;
 XX WPI; 1999-527332/44.
 XX
 XX Increasing urine flow by administering peptides or peptide agonists.
 PT
 XX Example 26; Page 43; 94pp; English.
 XX
 XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 28 AA;
 AAY31527 Length: 28 February 4, 2005 13:19 Type: P Check: 9897 ..
 Found using 'seq4' (mohamed337.key)

```

1  |-----|
  1 HGEFTSLSKQLEEAARLFIKLA
    28

```

 1 match found in sequence:
 aay31528 ; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31528 check: 6333 from: 1 to: 38

ID AAY31528 standard; peptide; 38 AA.
 XX
 AC AAY31528;
 XX
 DT 08-NOV-1999 (first entry)
 XX

DE Exendin agonist peptide.
 XX
 KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 38 /note= "C-terminal amide"
 FT
 XX WO9940788-A1.
 XX
 XX 19-AUG-1999.
 XX
 XX 05-FEB-1999; 99WO-US002554.
 XX
 XX 13-FEB-1998; 98US-0075122P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Vine W, Beeley NRA, Prickett K;
 XX WPI; 1999-527332/44.
 XX
 XX Increasing urine flow by administering peptides or peptide agonists.
 PT
 XX Example 27; Page 44; 94pp; English.
 XX
 XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 38 AA;
 AAY31528 Length: 38 February 4, 2005 13:19 Type: P Check: 6333 ..
 Found using 'seq4' (mohamed337.key)

```

1  |-----|
  1 HGEFTSLSKQMEEAARLFIKNGKGGSSGAPPP
    28

```

 1 match found in sequence:
 aay31529 ; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31529 check: 5894 from: 1 to: 38

ID AAY31529 standard; peptide; 38 AA.
 XX
 AC AAY31529;
 XX
 DT 08-NOV-1999 (first entry)
 XX

```
DE      Extensin agonist peptide.
XX
KW      Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
FH      Key      Location/Qualifiers
FT      Modified-site 38
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 28; Page 45; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an extensin or extensin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of extensin agonists compounds
XX
XX      Sequence 38 AA;
XX
AAY31529 Length: 38 February 4, 2005 13:19 Type: P Check: 5894
Found using 'seq4' (mohamed337.key)

1      HCGFTTDLKQLEEAVALRFLFKNGGPGSGAPP
      |-----|
      1
      HCGFTTDLKQLEEAVALRFLFKNGGPGSGAPP
      28

-----
1 match found in sequence:
aay31530 ; Extensin agonist peptide.
(from "seq4ags pep")
TOIG of: aay31530 check: 3293 from: 1 to: 37

ID      AAY31530 standard; peptide; 37 AA.
XX
AC      AAY31530;
XX
XX      08-NOV-1999 (first entry)
XX
```

```
DE      Extensin agonist peptide.
XX
KW      Extensin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
FH      Key      Location/Qualifiers
FT      Modified-site 38
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 28; Page 45; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an extensin or extensin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      extensin, extensin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of extensin agonists compounds
XX
XX      Sequence 38 AA;
XX
AAY31529 Length: 38 February 4, 2005 13:19 Type: P Check: 5894
Found using 'seq4' (mohamed337.key)

1      HCGFTTDLKQLEEAVALRFLFKNGGPGSGAPP
      |-----|
      1
      HCGFTTDLKQLEEAVALRFLFKNGGPGSGAPP
      28

-----
1 match found in sequence:
aay31530 ; Extensin agonist peptide.
(from "seq4ags pep")
TOIG of: aay31530 check: 3293 from: 1 to: 37

ID      AAY31530 standard; peptide; 37 AA.
XX
AC      AAY31530;
XX
XX      08-NOV-1999 (first entry)
XX
```

```

DE  Extending agonist peptide.
XX
KW  Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  hypertension; urine flow.
XX
OS  Synthetic.
OS  Heloderma sp.
XX
PH  Key
FT  Modified-site 38
FT  /note= "C-terminal amide"
XX
PN  W09940788-A1.
XX
PD  19-AUG-1999.
XX
PF  05-FEB-1999; 99WO-US002554.
XX
PR  13-FEB-1998; 98US-0075122P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Young AA, Vine W, Beeley NRA, Prickett K;
XX  WPI; 1999-527332/44.
XX
PT  Increasing urine flow by administering peptides or peptide agonists.
XX
PS  Example 30; Page 46; 94pp; English.
XX
CC  The invention relates to new methods of increasing urine flow that
CC  comprises administering an extendin or extendin agonist, or a GLP-1
CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
CC  increasing urine flow, decreasing potassium concentration in urine,
CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  rapid diuresis, preparing an individual for surgical procedure,
CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  disorder that can be alleviated by increasing cardiac contractility
CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  excretion and sodium excretion without increasing potassium loss, and are
CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  AAY31505-560 represent examples of extendin agonists compounds
XX
SQ  Sequence 37 AA;

AAY31531 Length: 37 February 4, 2005 13:19 Type: P Check: 2854
Found using 'seq4' (mohamed337.key)

1  HCGGTFTSLSKQLEEAVALRFLFKNGPSSGAPP 28
|-----|
1 match found in sequence:
aay31532 ; Extending agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31532 check: 333 from: 1 to: 36

ID  AAY31532 standard; peptide; 36 AA.
XX
AC  AAY31532;
XX
XX  08-NOV-1999 (first entry)
XX

```

```

DE  Extending agonist peptide.
XX
KW  Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  hypertension; urine flow.
XX
OS  Synthetic.
OS  Heloderma sp.
XX
PH  Key
FT  Modified-site 38
FT  /note= "C-terminal amide"
XX
PN  W09940788-A1.
XX
PD  19-AUG-1999.
XX
PF  05-FEB-1999; 99WO-US002554.
XX
PR  13-FEB-1998; 98US-0075122P.
XX
PA  (AMYL-) AMYLIN PHARM INC.
XX
PI  Young AA, Vine W, Beeley NRA, Prickett K;
XX  WPI; 1999-527332/44.
XX
PT  Increasing urine flow by administering peptides or peptide agonists.
XX
PS  Example 31; Page 46; 94pp; English.
XX
CC  The invention relates to new methods of increasing urine flow that
CC  comprises administering an extendin or extendin agonist, or a GLP-1
CC  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC  extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
CC  increasing urine flow, decreasing potassium concentration in urine,
CC  preventing or alleviating a disorder associated with toxic hypervolemia
CC  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC  edema, cirrhosis, or hypertension). They can also be used for inducing
CC  rapid diuresis, preparing an individual for surgical procedure,
CC  increasing renal plasma flow and glomerular filtration rate, treating pre
CC  -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC  disorder that can be alleviated by increasing cardiac contractility
CC  (congestive heart failure, pulmonary edema, systemic edema or renal
CC  failure). Unlike prior art diuretics, the new methods increase urine
CC  excretion and sodium excretion without increasing potassium loss, and are
CC  fast acting. They have a prolonged duration of action, are inotropic,
CC  have a low toxicity, and are easily administered intravenously. Sequences
CC  AAY31505-560 represent examples of extendin agonists compounds
XX
SQ  Sequence 36 AA;

AAY31532 Length: 36 February 4, 2005 13:19 Type: P Check: 333
Found using 'seq4' (mohamed337.key)

1  HCGGTFTSLSKQLEEAVALRFLFKNGPSSGAPP 28
|-----|
1 match found in sequence:
aay31533 ; Extending agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31533 check: 9894 from: 1 to: 36

ID  AAY31533 standard; peptide; 36 AA.
XX
AC  AAY31533;
XX
XX  08-NOV-1999 (first entry)
XX

```

```

DE      Extending agonist peptide.
XX
KW      Extending; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site 36
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 32; Page 47; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
XX      comprises administering an extendin or extendin agonist, or a GLP-1
XX      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX      extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
XX      increasing urine flow, decreasing potassium concentration in urine,
XX      preventing or alleviating a disorder associated with toxic hypervolemia
XX      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX      edema, cirrhosis, or hypertension). They can also be used for inducing
XX      rapid diuresis, preparing an individual for surgical procedure,
XX      increasing renal plasma flow and glomerular filtration rate, treating pre
XX      -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX      disorder that can be alleviated by increasing cardiac contractility
XX      (congestive heart failure, pulmonary edema, systemic edema or renal
XX      failure). Unlike prior art diuretics, the new methods increase urine
XX      excretion and sodium excretion without increasing potassium loss, and are
XX      fast acting. They have a prolonged duration of action, are inotropic,
XX      have a low toxicity, and are easily administered intravenously. Sequences
XX      AAY31505-560 represent examples of extendin agonists compounds
XX
XX      Sequence 36 AA;
XX
XX      AAY31533 Length: 36 February 4, 2005 13:19 Type: P Check: 9894 ..
XX      Found using 'seq4' (mohamed337.key)
XX
XX      1 HGEFTTSDLSKQLEBEAVRLFIEFLKNGPSSGAP
XX      28
XX
XX      -----
XX      1 match found in sequence:
XX      aay31534 ; Extending agonist peptide.
XX      (from "seq4ags.pap")
XX      TOIG of: aay31534 check: 7453 from: 1 to: 35
XX
XX      ID AAY31534 standard; peptide; 35 AA.
XX      AC AAY31534;
XX      XX
XX      DT 08-NOV-1999 (first entry)
XX      XX

```

```
DE      Extendin agonist peptide.
XX
XX      Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX      hypertension; urine flow.
XX
XX      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site 35
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
PI      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
PT
XX
XX      Example 34; Page 48; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
CC      comprises administering an extendin or extendin agonist, or a GLP-1
CC      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC      extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
CC      increasing urine flow, decreasing potassium concentration in urine,
CC      preventing or alleviating a disorder associated with toxic hypervolemia
CC      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC      edema, cirrhosis, or hypertension). They can also be used for inducing
CC      rapid diuresis, preparing an individual for surgical procedure,
CC      increasing renal plasma flow and glomerular filtration rate, treating pre
CC      -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC      disorder that can be alleviated by increasing cardiac contractility
CC      (congestive heart failure, pulmonary edema, systemic edema or renal
CC      failure). Unlike prior art diuretics, the new methods increase urine
CC      excretion and sodium excretion without increasing potassium loss, and are
CC      fast acting. They have a prolonged duration of action, are inotropic,
CC      have a low toxicity, and are easily administered intravenously. Sequences
CC      AAY31505-560 represent examples of extendin agonists compounds
XX
XX      Sequence 35 AA;
SQ
AAY31535 Length: 35 February 4, 2005 13:19 Type: P Check: 7014
Found using 'seq4' (mohamed337.key)
1      HGEFTFTDLSKQLEEEAVRLFIEFLKNGGPSSGA
1      -----|
1      28
-----
1 match found in sequence:
aay31536 ; Extendin agonist peptide.
(from "seqtags.pep")
TOIG of: aay31536 check: 5178 from: 1 to: 34
ID      AAY31536 standard; peptide; 34 AA.
XX
XX      AC      AAY31536;
XX
XX      DT      08-NOV-1999 (first entry)
XX
```

```
DE      Extendin agonist peptide.
XX
XX      Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX      hypertension; urine flow.
XX
XX      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site 34
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX
XX      13-FEB-1998; 98US-0075122P.
XX
XX      (AMYL-) AMYLIN PHARM INC.
XX
XX      Young AA, Vine W, Beeley NRA, Prickett K;
PI      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
PT
XX
XX      Example 35; Page 48; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
CC      comprises administering an extendin or extendin agonist, or a GLP-1
CC      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC      extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
CC      increasing urine flow, decreasing potassium concentration in urine,
CC      preventing or alleviating a disorder associated with toxic hypervolemia
CC      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC      edema, cirrhosis, or hypertension). They can also be used for inducing
CC      rapid diuresis, preparing an individual for surgical procedure,
CC      increasing renal plasma flow and glomerular filtration rate, treating pre
CC      -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC      disorder that can be alleviated by increasing cardiac contractility
CC      (congestive heart failure, pulmonary edema, systemic edema or renal
CC      failure). Unlike prior art diuretics, the new methods increase urine
CC      excretion and sodium excretion without increasing potassium loss, and are
CC      fast acting. They have a prolonged duration of action, are inotropic,
CC      have a low toxicity, and are easily administered intravenously. Sequences
CC      AAY31505-560 represent examples of extendin agonists compounds
XX
XX      Sequence 34 AA;
SQ
AAY31536 Length: 34 February 4, 2005 13:19 Type: P Check: 5178
Found using 'seq4' (mohamed337.key)
1      HGEFTFTDLSKQMEEEAVRLFIEFLKNGGPSSG
1      -----|
1      28
-----
1 match found in sequence:
aay31537 ; Extendin agonist peptide.
(from "seqtags.pep")
TOIG of: aay31537 check: 4739 from: 1 to: 34
ID      AAY31537 standard; peptide; 34 AA.
XX
XX      AC      AAY31537;
XX
XX      DT      08-NOV-1999 (first entry)
XX
```

DE Exendin agonist peptide.
 XX
 KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 34 /note= "C-terminal amide"
 FT
 XX WO9940788-A1.
 XX
 XX 19-AUG-1999.
 XX
 XX 05-FEB-1999; 99WO-US002554.
 XX
 XX 13-FEB-1998; 98US-0075122P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Vine W, Beeley NRA, Prickett K;
 XX WPI; 1999-527332/44.
 XX
 PT Increasing urine flow by administering peptides or peptide agonists.
 XX
 XX Example 36; Page 49; 94pp; English.
 XX
 CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 34 AA;
 AAY31537 Length: 34 February 4, 2005 13:19 Type: P Check: 4739 ..
 Found using 'seq4' (mohamed337.key)

1 HCGEFTTDLKQLEEEAVRLFIEFLKNGPSSG
 1
 28

 1 match found in sequence:
 aay31538 ; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31538 check: 2764 from: 1 to: 33

ID AAY31538 standard; peptide; 33 AA.
 XX
 AC AAY31538;
 XX
 DT 08-NOV-1999 (first entry)
 XX

DE Exendin agonist peptide.
 XX
 KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 33 /note= "C-terminal amide"
 FT
 XX WO9940788-A1.
 XX
 XX 19-AUG-1999.
 XX
 XX 05-FEB-1999; 99WO-US002554.
 XX
 XX 13-FEB-1998; 98US-0075122P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Vine W, Beeley NRA, Prickett K;
 XX WPI; 1999-527332/44.
 XX
 PT Increasing urine flow by administering peptides or peptide agonists.
 XX
 XX Example 37; Page 49; 94pp; English.
 XX
 CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 33 AA;
 AAY31538 Length: 33 February 4, 2005 13:19 Type: P Check: 2764 ..
 Found using 'seq4' (mohamed337.key)

1 HCGEFTTDLKQMEEEAVRLFIEFLKNGGPSS
 1
 28

 1 match found in sequence:
 aay31539 ; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31539 check: 2325 from: 1 to: 33

ID AAY31539 standard; peptide; 33 AA.
 XX
 AC AAY31539;
 XX
 DT 08-NOV-1999 (first entry)
 XX

```
DE      Extentin agonist peptide.
XX
XX      Extentin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX      hypertension; urine flow.
OS      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site 33
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX      13-FEB-1998; 98US-0075122P.
XX      (AMYL-) AMYLIN PHARM INC.
XX      PA
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 38; Page 50; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
CC      comprises administering an extentin or extentin agonist, or a GLP-1
CC      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC      extentin, extentin agonist, GLP-1 or GLP-1 agonist are useful for
CC      increasing urine flow, decreasing potassium concentration in urine,
CC      preventing or alleviating a disorder associated with toxic hypervolemia
CC      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC      edema, cirrhosis, or hypertension). They can also be used for inducing
CC      rapid diuresis, preparing an individual for surgical procedure,
CC      increasing renal plasma flow and glomerular filtration rate, treating pre
CC      -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC      disorder that can be alleviated by increasing cardiac contractility
CC      (congestive heart failure, pulmonary edema, systemic edema or renal
CC      failure). Unlike prior art diuretics, the new methods increase urine
CC      excretion and sodium excretion without increasing potassium loss, and are
CC      fast acting. They have a prolonged duration of action, are inotropic,
CC      have a low toxicity, and are easily administered intravenously. Sequences
CC      AAY31505-560 represent examples of extentin agonists compounds
XX
XX      SQ      Sequence 33 AA;
XX
XX      AAY31539 Length: 33 February 4, 2005 13:19 Type: P Check: 2325
XX      Found using 'seq4' (mohamed337.key)
XX
XX      1      HCEGFTSDLSKQLBEEAVRLFIEFLKNGGPS
XX      1      28
XX
XX      -----
XX      1 match found in sequence:
XX      aay31540 : Extentin agonist peptide.
XX      (from "seq4ags.pep")
XX      TOIG of: aay31540 check: 25 from: 1 to: 32
XX
XX      ID      AAY31540 standard; peptide; 32 AA.
XX      AC      AAY31540;
XX      XX      08-NOV-1999 (first entry)
XX      DT
XX      XX
```

```
DE      Extentin agonist peptide.
XX
XX      Extentin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX      hypertension; urine flow.
OS      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site 33
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
XX      19-AUG-1999.
XX
XX      05-FEB-1999; 99WO-US002554.
XX      13-FEB-1998; 98US-0075122P.
XX      (AMYL-) AMYLIN PHARM INC.
XX      PA
XX      Young AA, Vine W, Beeley NRA, Prickett K;
XX      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
XX
XX      Example 38; Page 50; 94pp; English.
XX
XX      The invention relates to new methods of increasing urine flow that
CC      comprises administering an extentin or extentin agonist, or a GLP-1
CC      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC      extentin, extentin agonist, GLP-1 or GLP-1 agonist are useful for
CC      increasing urine flow, decreasing potassium concentration in urine,
CC      preventing or alleviating a disorder associated with toxic hypervolemia
CC      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC      edema, cirrhosis, or hypertension). They can also be used for inducing
CC      rapid diuresis, preparing an individual for surgical procedure,
CC      increasing renal plasma flow and glomerular filtration rate, treating pre
CC      -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC      disorder that can be alleviated by increasing cardiac contractility
CC      (congestive heart failure, pulmonary edema, systemic edema or renal
CC      failure). Unlike prior art diuretics, the new methods increase urine
CC      excretion and sodium excretion without increasing potassium loss, and are
CC      fast acting. They have a prolonged duration of action, are inotropic,
CC      have a low toxicity, and are easily administered intravenously. Sequences
CC      AAY31505-560 represent examples of extentin agonists compounds
XX
XX      SQ      Sequence 33 AA;
XX
XX      AAY31539 Length: 33 February 4, 2005 13:19 Type: P Check: 2325
XX      Found using 'seq4' (mohamed337.key)
XX
XX      1      HCEGFTSDLSKQLBEEAVRLFIEFLKNGGPS
XX      1      28
XX
XX      -----
XX      1 match found in sequence:
XX      aay31540 : Extentin agonist peptide.
XX      (from "seq4ags.pep")
XX      TOIG of: aay31540 check: 25 from: 1 to: 32
XX
XX      ID      AAY31540 standard; peptide; 32 AA.
XX      AC      AAY31540;
XX      XX      08-NOV-1999 (first entry)
XX      DT
XX      XX
```

```

DE  Exendin agonist peptide.
XX
KW  Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  hypertension; urine flow.
XX
OS  Synthetic.
OS  Heloderma sp.
XX
XX  Key      Location/Qualifiers
FH  Modified-site 32
FT  /note= "C-terminal amide"
XX
XX  WO9940788-A1.
XX
XX  19-AUG-1999.
XX
XX  05-FEB-1999; 99WO-US002554.
XX
XX  13-FEB-1998; 98US-0075122P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Young AA, Vine W, Beeley NRA, Prickett K;
XX  WPI; 1999-527332/44.
XX
XX  Increasing urine flow by administering peptides or peptide agonists.
XX
XX  Example 40; Page 51; 94pp; English.
XX
XX  The invention relates to new methods of increasing urine flow that
XX  comprises administering an exendin or exendin agonist, or a GLP-1
XX  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX  exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX  increasing urine flow, decreasing potassium concentration in urine,
XX  preventing or alleviating a disorder associated with toxic hypervolemia
XX  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX  edema, cirrhosis, or hypertension). They can also be used for inducing
XX  rapid diuresis, preparing an individual for surgical procedure,
XX  increasing renal plasma flow and glomerular filtration rate, treating pre
XX  -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX  disorder that can be alleviated by increasing cardiac contractility
XX  (congestive heart failure, pulmonary edema, systemic edema or renal
XX  failure). Unlike prior art diuretics, the new methods increase urine
XX  excretion and sodium excretion without increasing potassium loss, and are
XX  fast acting. They have a prolonged duration of action, are inotropic,
XX  have a low toxicity, and are easily administered intravenously. Sequences
XX  CC  AAY31505-560 represent examples of exendin agonists compounds
XX
XX  Sequence 32 AA;
SQ

AAY31541 Length: 32 February 4, 2005 13:19 Type: P Check: 9586
Found using 'seq4' (mohamed337.key)

1  HGEGETSLSKQLEEEAVRLFIEFLKNGSPS
  1  -----|-----
  28

-----|
1 match found in sequence:
aay31542 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31542 check: 7369 from: 1 to: 31

ID  AAY31542 standard; peptide; 31 AA.
XX
XX  AAY31542;
AC
XX
XX  08-NOV-1999 (first entry)
DT
XX

```

```

DE  Exendin agonist peptide.
XX
KW  Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  hypertension; urine flow.
XX
OS  Synthetic.
OS  Heloderma sp.
XX
XX  Key      Location/Qualifiers
FH  Modified-site 31
FT  /note= "C-terminal amide"
XX
XX  WO9940788-A1.
XX
XX  19-AUG-1999.
XX
XX  05-FEB-1999; 99WO-US002554.
XX
XX  13-FEB-1998; 98US-0075122P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Young AA, Vine W, Beeley NRA, Prickett K;
XX  WPI; 1999-527332/44.
XX
XX  Increasing urine flow by administering peptides or peptide agonists.
XX
XX  Example 41; Page 51; 94pp; English.
XX
XX  The invention relates to new methods of increasing urine flow that
XX  comprises administering an exendin or exendin agonist, or a GLP-1
XX  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX  exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX  increasing urine flow, decreasing potassium concentration in urine,
XX  preventing or alleviating a disorder associated with toxic hypervolemia
XX  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX  edema, cirrhosis, or hypertension). They can also be used for inducing
XX  rapid diuresis, preparing an individual for surgical procedure,
XX  increasing renal plasma flow and glomerular filtration rate, treating pre
XX  -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX  disorder that can be alleviated by increasing cardiac contractility
XX  (congestive heart failure, pulmonary edema, systemic edema or renal
XX  failure). Unlike prior art diuretics, the new methods increase urine
XX  excretion and sodium excretion without increasing potassium loss, and are
XX  fast acting. They have a prolonged duration of action, are inotropic,
XX  have a low toxicity, and are easily administered intravenously. Sequences
XX  CC  AAY31505-560 represent examples of exendin agonists compounds
XX
XX  Sequence 31 AA;
SQ

AAY31542 Length: 31 February 4, 2005 13:19 Type: P Check: 7369
Found using 'seq4' (mohamed337.key)

1  HGEGETSLSKQMEEEAVRLFIEFLKNGGP
  1  -----|-----
  28

-----|
1 match found in sequence:
aay31543 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31543 check: 6930 from: 1 to: 31

ID  AAY31543 standard; peptide; 31 AA.
XX
XX  AAY31543;
AC
XX
XX  08-NOV-1999 (first entry)
DT
XX

```

```

DE  Exendin agonist peptide.
XX
KW  Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  hypertension; urine flow.
XX
OS  Synthetic.
OS  Heloderma sp.
XX
FH  Key                      Location/Qualifiers
FT  Modified-site 31
FT  /note= "C-terminal amide"
XX
XX  WO9940788-A1.
XX
XX  19-AUG-1999.
XX
XX  05-FEB-1999; 99WO-US002554.
XX
XX  13-FEB-1998; 98US-0075122P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Young AA, Vine W, Beeley NRA, Prickett K;
XX  WPI; 1999-527332/44.
XX
XX  Increasing urine flow by administering peptides or peptide agonists.
XX
XX  Example 42; Page 52; 94pp; English.
XX
XX  The invention relates to new methods of increasing urine flow that
XX  comprises administering an exendin or exendin agonist, or a GLP-1
XX  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX  exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX  increasing urine flow, decreasing potassium concentration in urine,
XX  preventing or alleviating a disorder associated with toxic hypervolemia
XX  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX  edema, cirrhosis, or hypertension). They can also be used for inducing
XX  rapid diuresis, preparing an individual for surgical procedure,
XX  increasing renal plasma flow and glomerular filtration rate, treating pre
XX  -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX  disorder that can be alleviated by increasing cardiac contractility
XX  (congestive heart failure, pulmonary edema, systemic edema or renal
XX  failure). Unlike prior art diuretics, the new methods increase urine
XX  excretion and sodium excretion without increasing potassium loss, and are
XX  fast acting. They have a prolonged duration of action, are inotropic,
XX  have a low toxicity, and are easily administered intravenously. Sequences
XX  AAY31505-560 represent examples of exendin agonists compounds
XX
XX  Sequence 31 AA;
SQ

AAY31543 Length: 31 February 4, 2005 13:19 Type: P Check: 6930
Found using 'seq4' (mohamed337.key)

1  HCGFTFTSLSKQLEEEAVRLFIKNGG 28
|-----|
1 match found in sequence:
aay31544 : Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31544 check: 4450 from: 1 to: 30

ID  AAY31544 standard; peptide; 30 AA.
XX
XX  AAY31544;
AC
XX
XX  08-NOV-1999 (first entry)
DT
XX

```

```

DE  Exendin agonist peptide.
XX
KW  Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW  diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW  eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW  congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW  hypertension; urine flow.
XX
OS  Synthetic.
OS  Heloderma sp.
XX
FH  Key                      Location/Qualifiers
FT  Modified-site 30
FT  /note= "C-terminal amide"
XX
XX  WO9940788-A1.
XX
XX  19-AUG-1999.
XX
XX  05-FEB-1999; 99WO-US002554.
XX
XX  13-FEB-1998; 98US-0075122P.
XX
XX  (AMYL-) AMYLIN PHARM INC.
XX
XX  Young AA, Vine W, Beeley NRA, Prickett K;
XX  WPI; 1999-527332/44.
XX
XX  Increasing urine flow by administering peptides or peptide agonists.
XX
XX  Example 43; Page 52-53; 94pp; English.
XX
XX  The invention relates to new methods of increasing urine flow that
XX  comprises administering an exendin or exendin agonist, or a GLP-1
XX  (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX  exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX  increasing urine flow, decreasing potassium concentration in urine,
XX  preventing or alleviating a disorder associated with toxic hypervolemia
XX  (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX  edema, cirrhosis, or hypertension). They can also be used for inducing
XX  rapid diuresis, preparing an individual for surgical procedure,
XX  increasing renal plasma flow and glomerular filtration rate, treating pre
XX  -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX  disorder that can be alleviated by increasing cardiac contractility
XX  (congestive heart failure, pulmonary edema, systemic edema or renal
XX  failure). Unlike prior art diuretics, the new methods increase urine
XX  excretion and sodium excretion without increasing potassium loss, and are
XX  fast acting. They have a prolonged duration of action, are inotropic,
XX  have a low toxicity, and are easily administered intravenously. Sequences
XX  AAY31505-560 represent examples of exendin agonists compounds
XX
XX  Sequence 30 AA;
SQ

AAY31544 Length: 30 February 4, 2005 13:19 Type: P Check: 4450
Found using 'seq4' (mohamed337.key)

1  HCGFTFTSLSKQLEEEAVRLFIKNGG 28
|-----|
1 match found in sequence:
aay31545 : Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31545 check: 2759 from: 1 to: 29

ID  AAY31545 standard; peptide; 29 AA.
XX
XX  AAY31545;
AC
XX
XX  08-NOV-1999 (first entry)
DT
XX

```

```
DE      Exendin agonist peptide.
XX
KW      Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site 29
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
PN
XX      19-AUG-1999.
PD
XX      05-FEB-1999; 99WO-US002554.
PF
XX      13-FEB-1998; 98US-0075122P.
PR
XX      (AMYL-) AMYLIN PHARM INC.
PA
XX      Young AA, Vine W, Beeley NRA, Prickett K;
PI      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
PT
XX      Example 44; Page 53; 94pp; English.
PS
XX      The invention relates to new methods of increasing urine flow that
CC      comprises administering an exendin or exendin agonist, or a GLP-1
CC      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC      exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC      increasing urine flow, decreasing potassium concentration in urine,
CC      preventing or alleviating a disorder associated with toxic hypervolemia
CC      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC      edema, cirrhosis, or hypertension). They can also be used for inducing
CC      rapid diuresis, preparing an individual for surgical procedure,
CC      increasing renal plasma flow and glomerular filtration rate, treating pre
CC      -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC      disorder that can be alleviated by increasing cardiac contractility
CC      (congestive heart failure, pulmonary edema, systemic edema or renal
CC      failure). Unlike prior art diuretics, the new methods increase urine
CC      excretion and sodium excretion without increasing potassium loss, and are
CC      fast acting. They have a prolonged duration of action, are inotropic,
CC      have a low toxicity, and are easily administered intravenously. Sequences
CC      AAY31505-560 represent examples of exendin agonists compounds
XX
SQ      Sequence 29 AA;
AAY31545 Length: 29 February 4, 2005 13:19 Type: P Check: 2759
Found using 'seq4' (mohamed337.key)
1      HGEGETSDLSKQMEEEAVRLFIWELKNG
1      28
-----
1 match found in sequence:
aay31546 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31546 check: 2320 from: 1 to: 29
ID      AAY31546 standard; peptide; 29 AA.
XX
AC      AAY31546;
XX
DT      08-NOV-1999 (first entry)
XX

DE      Exendin agonist peptide.
XX
KW      Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW      diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW      eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW      congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW      hypertension; urine flow.
XX
OS      Synthetic.
OS      Heloderma sp.
XX
XX      Key      Location/Qualifiers
FH      Modified-site 29
FT      /note= "C-terminal amide"
XX
XX      WO9940788-A1.
PN
XX      19-AUG-1999.
PD
XX      05-FEB-1999; 99WO-US002554.
PF
XX      13-FEB-1998; 98US-0075122P.
PR
XX      (AMYL-) AMYLIN PHARM INC.
PA
XX      Young AA, Vine W, Beeley NRA, Prickett K;
PI      WPI; 1999-527332/44.
XX
XX      Increasing urine flow by administering peptides or peptide agonists.
PT
XX      Example 45; Page 54; 94pp; English.
PS
XX      The invention relates to new methods of increasing urine flow that
CC      comprises administering an exendin or exendin agonist, or a GLP-1
CC      (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC      exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC      increasing urine flow, decreasing potassium concentration in urine,
CC      preventing or alleviating a disorder associated with toxic hypervolemia
CC      (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC      edema, cirrhosis, or hypertension). They can also be used for inducing
CC      rapid diuresis, preparing an individual for surgical procedure,
CC      increasing renal plasma flow and glomerular filtration rate, treating pre
CC      -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC      disorder that can be alleviated by increasing cardiac contractility
CC      (congestive heart failure, pulmonary edema, systemic edema or renal
CC      failure). Unlike prior art diuretics, the new methods increase urine
CC      excretion and sodium excretion without increasing potassium loss, and are
CC      fast acting. They have a prolonged duration of action, are inotropic,
CC      have a low toxicity, and are easily administered intravenously. Sequences
CC      AAY31505-560 represent examples of exendin agonists compounds
XX
SQ      Sequence 29 AA;
AAY31546 Length: 29 February 4, 2005 13:19 Type: P Check: 2320
Found using 'seq4' (mohamed337.key)
1      HGEGETSDLSKQLEEEAVRLFELKNG
1      28
-----
1 match found in sequence:
aay31547 ; Exendin agonist peptide.
(from "seq4ags.pep")
TOIG of: aay31547 check: 7469 from: 1 to: 38
ID      AAY31547 standard; peptide; 38 AA.
XX
AC      AAY31547;
XX
DT      08-NOV-1999 (first entry)
XX
```

DE Exendin agonist peptide.
 XX
 KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 XX diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 31 /note= "thioproline"
 FT Modified-site 36 /note= "thioproline"
 FT Modified-site 37 /note= "thioproline"
 FT Modified-site 38 /note= "thioproline"
 FT Modified-site 38 /note= "thioproline; C-terminal amide"
 XX
 PN WO9940788-A1.
 XX
 PD 19-AUG-1999.
 XX
 PF 05-FEB-1999; 99WO-US002554.
 XX
 PR 13-FEB-1998; 98US-0075122P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Vine W, Beeley NRA, Prickett K;
 PI WPI; 1999-527332/44.
 XX
 DR Increasing urine flow by administering peptides or peptide agonists.
 XX
 PT Example 46; Page 54; 94pp; English.
 XX
 CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 38 AA;
 AAY31547 Length: 38 February 4, 2005 13:19 Type: P Check: 7469 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQMBEEAVRLFTIWLKNGKSSGAXXX
 28

1 match found in sequence:
 aay31548; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31548 check: 7221 from: 1 to: 38

ID AAY31548 standard; peptide; 38 AA.
 XX
 AC AAY31548;
 XX
 DT 08-NOV-1999 (first entry)
 XX
 DE Exendin agonist peptide.
 XX
 KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 36 /note= "thioproline"
 FT Modified-site 37 /note= "thioproline"
 FT Modified-site 38 /note= "thioproline"
 FT Modified-site 38 /note= "thioproline; C-terminal amide"
 XX
 PN WO9940788-A1.
 XX
 PD 19-AUG-1999.
 XX
 PF 05-FEB-1999; 99WO-US002554.
 XX
 PR 13-FEB-1998; 98US-0075122P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Vine W, Beeley NRA, Prickett K;
 PI WPI; 1999-527332/44.
 XX
 DR Increasing urine flow by administering peptides or peptide agonists.
 XX
 PT Example 47; Page 55; 94pp; English.
 XX
 CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 38 AA;
 AAY31548 Length: 38 February 4, 2005 13:19 Type: P Check: 7221 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQMBEEAVRLFTIWLKNGKSSGAXXX
 28

1 match found in sequence:

ay31549 ; Exendin agonist peptide.

(from "seq4ags.pep")
TOIG of: ay31549 check: 3541 from: 1 to: 37

ID AAY31549 standard; peptide; 37 AA.

XX AC AAY31549;
XX
DT 08-NOV-1999 (first entry)
XX
DE Exendin agonist peptide.
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "N-methyl alanine"
FT Modified-site 37 /note= "C-terminal amide"
FT
FT
FT
PN WO9940788-A1.
XX
PD 19-AUG-1999.
XX
PF 05-FEB-1999; 99WO-US002554.
XX
PR 13-FEB-1998; 98US-0075122P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
PT Increasing urine flow by administering peptides or peptide agonists.
XX
PS Example 48; Page 55; 94pp; English.
XX
CC The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC increasing urine flow, decreasing potassium concentration in urine,
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure,
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine
CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,
CC have a low toxicity, and are easily administered intravenously. Sequences
CC AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 37 AA;

AAY31549 Length: 37 February 4, 2005 13:19 Type: P Check: 3541 ..

Found using 'seq4' (mohamed337.key)

1 HGBGTFSDLSKQMBEAVRLFTEWLKNGXSGSGAPP
28

1 match found in sequence:

ay31550 ; Exendin agonist peptide.
(from "seq4ags.pep")

TOIG of: ay31550 check: 4125 from: 1 to: 37

ID AAY31550 standard; peptide; 37 AA.

XX AC AAY31550;
XX
DT 08-NOV-1999 (first entry)
XX
DE Exendin agonist peptide.
XX
KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
KW hypertension; urine flow.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "N-methyl alanine"
FT Modified-site 36 /note= "N-methyl alanine"
FT Modified-site 37 /note= "N-methyl alanine"
FT
FT
FT
PN WO9940788-A1.
XX
PD 19-AUG-1999.
XX
PF 05-FEB-1999; 99WO-US002554.
XX
PR 13-FEB-1998; 98US-0075122P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
PT Increasing urine flow by administering peptides or peptide agonists.
XX
PS Example 49; Page 56; 94pp; English.
XX
CC The invention relates to new methods of increasing urine flow that
CC comprises administering an exendin or exendin agonist, or a GLP-1
CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
CC increasing urine flow, decreasing potassium concentration in urine,
CC preventing or alleviating a disorder associated with toxic hypervolemia
CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
CC edema, cirrhosis, or hypertension). They can also be used for inducing
CC rapid diuresis, preparing an individual for surgical procedure,
CC increasing renal plasma flow and glomerular filtration rate, treating pre
CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
CC disorder that can be alleviated by increasing cardiac contractility
CC (congestive heart failure, pulmonary edema, systemic edema or renal
CC failure). Unlike prior art diuretics, the new methods increase urine
CC excretion and sodium excretion without increasing potassium loss, and are
CC fast acting. They have a prolonged duration of action, are inotropic,
CC have a low toxicity, and are easily administered intravenously. Sequences
CC AAY31505-560 represent examples of exendin agonists compounds
XX
SQ Sequence 37 AA;

AAY31550 Length: 37 February 4, 2005 13:19 Type: P Check: 4125 ..

Found using 'seq4' (mohamed337.key)

```

1 HGGTFTSLSKQMEEEAVRLFIEWLKNGKSSGAXX
  1
  -----|-----
  1 match found in sequence:
  aay31551; Exendin agonist peptide.
  (from "seq4ags.pep")
  TOIG of: aay31551 check: 3293 from: 1 to: 37

ID AAY31551 standard; peptide; 37 AA.
XX AC AAY31551;
XX DT 08-NOV-1999 (first entry)
XX DE Exendin agonist peptide.
XX KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
XX KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
XX KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
XX KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX KW hypertension; urine flow.
XX OS Synthetic.
XX OS Heloderma sp.
XX FH Key Location/Qualifiers
XX FT Modified-site 31 /note= "hydroxyproline"
XX FT Modified-site 36 /note= "hydroxyproline"
XX FT Modified-site 37 /note= "hydroxyproline; C-terminal amide"
XX PN WO9940788-A1.
XX PD 19-AUG-1999.
XX PF 05-FEB-1999; 99WO-US002554.
XX PR 13-FEB-1998; 98US-0075122P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Vine W, Beeley NRA, Prickett K;
XX PI WPI; 1999-527332/44.
XX PT Increasing urine flow by administering peptides or peptide agonists.
XX PS Example 50; Page 56; 94pp; English.
XX CC The invention relates to new methods of increasing urine flow that
XX CC comprises administering an exendin or exendin agonist, or a GLP-1
XX CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX CC increasing urine flow, decreasing potassium concentration in urine,
XX CC preventing or alleviating a disorder associated with toxic hypervolemia
XX CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX CC edema, cirrhosis, or hypertension). They can also be used for inducing
XX CC rapid diuresis, preparing an individual for surgical procedure,
XX CC increasing renal plasma flow and glomerular filtration rate, treating pre
XX CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX CC disorder that can be alleviated by increasing cardiac contractility
XX CC (congestive heart failure, pulmonary edema, systemic edema or renal
XX CC failure). Unlike prior art diuretics, the new methods increase urine
XX CC excretion and sodium excretion without increasing potassium loss, and are
XX CC fast acting. They have a prolonged duration of action, are inotropic,
XX CC have a low toxicity, and are easily administered intravenously. Sequences
XX CC AAY31505-560 represent examples of exendin agonists compounds
XX CC Sequence 37 AA;

```

```

1 HGGTFTSLSKQMEEEAVRLFIEWLKNGGSSGAPP
  1
  -----|-----
  1 match found in sequence:
  aay31552; Exendin agonist peptide.
  (from "seq4ags.pep")
  TOIG of: aay31552 check: 333 from: 1 to: 36

ID AAY31552 standard; peptide; 36 AA.
XX AC AAY31552;
XX DT 08-NOV-1999 (first entry)
XX DE Exendin agonist peptide.
XX KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
XX KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
XX KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
XX KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX KW hypertension; urine flow.
XX OS Synthetic.
XX OS Heloderma sp.
XX FH Key Location/Qualifiers
XX FT Modified-site 31 /note= "hydroxyproline"
XX FT Modified-site 36 /note= "hydroxyproline; C-terminal amide"
XX PN WO9940788-A1.
XX PD 19-AUG-1999.
XX PF 05-FEB-1999; 99WO-US002554.
XX PR 13-FEB-1998; 98US-0075122P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Vine W, Beeley NRA, Prickett K;
XX PI WPI; 1999-527332/44.
XX PT Increasing urine flow by administering peptides or peptide agonists.
XX PS Example 51; Page 57; 94pp; English.
XX CC The invention relates to new methods of increasing urine flow that
XX CC comprises administering an exendin or exendin agonist, or a GLP-1
XX CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX CC increasing urine flow, decreasing potassium concentration in urine,
XX CC preventing or alleviating a disorder associated with toxic hypervolemia
XX CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX CC edema, cirrhosis, or hypertension). They can also be used for inducing
XX CC rapid diuresis, preparing an individual for surgical procedure,
XX CC increasing renal plasma flow and glomerular filtration rate, treating pre
XX CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX CC disorder that can be alleviated by increasing cardiac contractility
XX CC (congestive heart failure, pulmonary edema, systemic edema or renal
XX CC failure). Unlike prior art diuretics, the new methods increase urine
XX CC excretion and sodium excretion without increasing potassium loss, and are
XX CC fast acting. They have a prolonged duration of action, are inotropic,
XX CC have a low toxicity, and are easily administered intravenously. Sequences
XX CC AAY31505-560 represent examples of exendin agonists compounds
XX CC

```

```
XX      SQ      Sequence 36 AA;
AAY31552 Length: 36 February 4, 2005 13:19 Type: P Check: 333
Found using 'seq4' (mohamed337.key)

1  HEGGTFSDLSKQMEEEAVRLFIWLKNGPSSGAP
   1 -----|-----|
   28

-----
1 match found in sequence:
aay31553 ; Exendin agonist peptide.
  (from "seq4ags.pep")
TOIG of: aay31553 check: 7463 from: 1 to: 35

ID AAY31553 standard; peptide; 35 AA.
XX
XX AC AAY31553;
XX
XX DT 08-NOV-1999 (first entry)
XX
XX DE Exendin agonist peptide.
XX
XX KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
XX KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
XX KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
XX KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX KW hypertension; urine flow.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 35 /note= "C-terminal amide"
XX FT
XX PN WO9940788-A1.
XX
XX PD 19-AUG-1999.
XX
XX PF 05-FEB-1999; 99WO-US002554.
XX
XX PR 13-FEB-1998; 98US-0075122P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX PT Increasing urine flow by administering peptides or peptide agonists.
XX PS Example 52; Page 57; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are isotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
```

```
XX      SQ      Sequence 35 AA;
AAY31553 Length: 35 February 4, 2005 13:19 Type: P Check: 7463
Found using 'seq4' (mohamed337.key)

1  RGGGTFSDLSKQMEEEAVRLFIWLKNGPSSGA
   1 -----|-----|
   28

-----
1 match found in sequence:
aay31554 ; Exendin agonist peptide.
  (from "seq4ags.pep")
TOIG of: aay31554 check: 4886 from: 1 to: 30

ID AAY31554 standard; peptide; 30 AA.
XX
XX AC AAY31554;
XX
XX DT 08-NOV-1999 (first entry)
XX
XX DE Exendin agonist peptide.
XX
XX KW Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
XX KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
XX KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
XX KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
XX KW hypertension; urine flow.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 30 /note= "C-terminal amide"
XX FT
XX PN WO9940788-A1.
XX
XX PD 19-AUG-1999.
XX
XX PF 05-FEB-1999; 99WO-US002554.
XX
XX PR 13-FEB-1998; 98US-0075122P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Vine W, Beeley NRA, Prickett K;
XX WPI; 1999-527332/44.
XX
XX PT Increasing urine flow by administering peptides or peptide agonists.
XX PS Example 53; Page 58; 94pp; English.
XX
XX The invention relates to new methods of increasing urine flow that
XX comprises administering an exendin or exendin agonist, or a GLP-1
XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an
XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
XX increasing urine flow, decreasing potassium concentration in urine,
XX preventing or alleviating a disorder associated with toxic hypervolemia
XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
XX edema, cirrhosis, or hypertension). They can also be used for inducing
XX rapid diuresis, preparing an individual for surgical procedure,
XX increasing renal plasma flow and glomerular filtration rate, treating pre
XX -eclampsia or eclampsia of pregnancy, and increasing a condition/
XX disorder that can be alleviated by increasing cardiac contractility
XX (congestive heart failure, pulmonary edema, systemic edema or renal
XX failure). Unlike prior art diuretics, the new methods increase urine
XX excretion and sodium excretion without increasing potassium loss, and are
XX fast acting. They have a prolonged duration of action, are isotropic,
XX have a low toxicity, and are easily administered intravenously. Sequences
XX AAY31505-560 represent examples of exendin agonists compounds
```

CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 SQ Sequence 28 AA;
 AAY31555 Length: 28 February 4, 2005 13:19 Type: P Check: 369
 Found using 'seq4' (mohamed337.key)
 1 |-----|
 1 HGEGTFTSDLSKQLEEAVALRFLFIEFLKN 28

 1 match found in sequence:
 aay31555 ; Extendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31555 check: 693 from: 1 to: 28
 ID AAY31555 standard; peptide; 28 AA.
 XX
 AC AAY31555;
 XX
 DT 08-NOV-1999 (first entry)
 XX
 DE Extendin agonist peptide.
 XX
 KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 28
 FT Modified-site /note= "C-terminal amide"
 FT
 XX WO9940788-A1.
 XX PD 19-AUG-1999.
 XX PF 05-FEB-1999; 99WO-US002554.
 XX PR 13-FEB-1998; 98US-0075122P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Young AA, Vine W, Beeley NRA, Prickett K;
 XX WPI; 1999-527332/44.
 XX
 PT Increasing urine flow by administering peptides or peptide agonists.
 XX
 PS Example 55; Page 59; 94pp; English.
 XX
 CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,

XX
 SQ Sequence 30 AA;
 AAY31554 Length: 30 February 4, 2005 13:19 Type: P Check: 4886
 Found using 'seq4' (mohamed337.key)
 1 |-----|
 1 HGDGFTFTSDLSKQMBEEAVALRFLFIEFLKNGG 28

 1 match found in sequence:
 aay31555 ; Extendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31555 check: 369 from: 1 to: 28
 ID AAY31555 standard; peptide; 28 AA.
 XX
 AC AAY31555;
 XX
 DT 08-NOV-1999 (first entry)
 XX
 DE Extendin agonist peptide.
 XX
 KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 6
 FT Modified-site /note= "Naphthylalanine"
 FT Modified-site 28
 FT Modified-site /note= "C-terminal amide"
 FT
 XX WO9940788-A1.
 XX PD 19-AUG-1999.
 XX PF 05-FEB-1999; 99WO-US002554.
 XX PR 13-FEB-1998; 98US-0075122P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Young AA, Vine W, Beeley NRA, Prickett K;
 XX WPI; 1999-527332/44.
 XX
 PT Increasing urine flow by administering peptides or peptide agonists.
 XX
 PS Example 54; Page 58; 94pp; English.
 XX
 CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,

CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 SQ Sequence 28 AA;

AAY31556 Length: 28 February 4, 2005 13:19 Type: P Check: 693 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFSSDLSKQMBEEAVRLFIEWLKN 28
 |-----|

1 match found in sequence:
 aay31557; Extendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31557 check: 701 from: 1 to: 28

ID AAY31557 standard; peptide; 28 AA.

XX AC AAY31557;

XX DT 08-NOV-1999 (first entry)

XX DE Extendin agonist peptide.

XX KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX OS Synthetic.
 OS Heloderma sp.

XX FH Key Location/Qualifiers
 FT Modified-site 28

FT FT /note= "C-terminal amide"

XX PN WO9940788-A1.

XX PD 19-AUG-1999.

XX PF 05-FEB-1999; 99WO-US002554.

XX PR 13-FEB-1998; 98US-0075122P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Vine W, Beeley NRA, Prickett K;

XX DR WPI; 1999-527332/44.

XX PT Increasing urine flow by administering peptides or peptide agonists.

XX PS Example 56; Page 59; 94pp; English.

XX CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,

CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 SQ Sequence 28 AA;

AAY31557 Length: 28 February 4, 2005 13:19 Type: P Check: 701 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFSTDLKQMBEEAVRLFIEWLKN 28
 |-----|

1 match found in sequence:
 aay31558; Extendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31558 check: 649 from: 1 to: 28

ID AAY31558 standard; peptide; 28 AA.

XX AC AAY31558;

XX DT 08-NOV-1999 (first entry)

XX DE Extendin agonist peptide.

XX KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX OS Synthetic.
 OS Heloderma sp.

XX FH Key Location/Qualifiers
 FT Modified-site 28

FT FT /note= "C-terminal amide"

XX PN WO9940788-A1.

XX PD 19-AUG-1999.

XX PF 05-FEB-1999; 99WO-US002554.

XX PR 13-FEB-1998; 98US-0075122P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Vine W, Beeley NRA, Prickett K;

XX DR WPI; 1999-527332/44.

XX PT Increasing urine flow by administering peptides or peptide agonists.

XX PS Example 57; Page 60; 94pp; English.

XX CC The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,

CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 SQ Sequence 28 AA;

AAY31558 Length: 28 February 4, 2005 13:19 Type: P Check: 649
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTSELSKQMAEEAVRLFIEFLKN
 28

 1 match found in sequence:
 aay31559 ; Extendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31559 check: 211 from: 1 to: 28

ID AAY31559 standard; peptide; 28 AA.

XX AAY31559;

AC AAY31559;

DT 08-NOV-1999 (first entry)

DE Extendin agonist peptide.

KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.

OS Heloderma sp.

XX Key

FT Modified-site 10 Location/Qualifiers

FT Modified-site 28 /note= "pentylglycine"

FT Modified-site 28 /note= "C-terminal amide"

XX WO9940788-A1.

XX 19-AUG-1999.

XX 05-FEB-1999; 99WO-US002554.

XX 13-FEB-1998; 98US-0075122P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

XX WPI; 1999-527332/44.

XX Increasing urine flow by administering peptides or peptide agonists.

XX Example 58; Page 60; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine

CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 SQ Sequence 28 AA;

AAY31559 Length: 28 February 4, 2005 13:19 Type: P Check: 211
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTSDGSKQLEEEAVRLFIEFLKN
 28

 1 match found in sequence:
 aay31560 ; Extendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31560 check: 657 from: 1 to: 28

ID AAY31560 standard; peptide; 28 AA.

XX AAY31560;

AC AAY31560;

DT 08-NOV-1999 (first entry)

DE Extendin agonist peptide.

KW Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.

OS Heloderma sp.

XX Key

FT Modified-site 22 Location/Qualifiers

FT Modified-site 28 /note= "Naphthyl alanine"

FT Modified-site 28 /note= "C-terminal amide"

XX WO9940788-A1.

XX 19-AUG-1999.

XX 05-FEB-1999; 99WO-US002554.

XX 13-FEB-1998; 98US-0075122P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

XX WPI; 1999-527332/44.

XX Increasing urine flow by administering peptides or peptide agonists.

XX Example 59; Page 61; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility

CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 28 AA;

AAY31560 Length: 28 February 4, 2005 13:19 Type: P Check: 657 ..
 Found using 'seq4' (mohamed337.key)

```

1 HGEGETFTSDLSKQLEEEAVRLXIEFLKN 28
  |-----|
  |-----|

```

1 match found in sequence:
 aay31561; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31561 check: 1045 from: 1 to: 28

ID AAY31561 standard; peptide; 28 AA.

XX AAY31561;

AC AAY31562;

XX 08-NOV-1999 (first entry)

DT Exendin agonist peptide.

XX Exendin agonist peptide.

XX Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

PH Modified-site 23 /note= "tButylglycine"

FT Modified-site 28

FT Modified-site /note= "C-terminal amide"

FT Modified-site /note= "C-terminal amide"

XX WO9940788-A1.

PN 19-AUG-1999.

XX 05-FEB-1999; 99WO-US002554.

XX 13-FEB-1998; 98US-0075122P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

XX WPI; 1999-527332/44.

XX Increasing urine flow by administering peptides or peptide agonists.

XX Example 60; Page 61; 94pp; English.

XX The invention relates to new methods of increasing urine flow that

XX comprises administering an exendin or exendin agonist, or a GLP-1

XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an

XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for

XX increasing urine flow, decreasing potassium concentration in urine,

XX preventing or alleviating a disorder associated with toxic hypervolemia

XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary

XX edema, cirrhosis, or hypertension). They can also be used for inducing

XX rapid diuresis, preparing an individual for surgical procedure,

XX increasing renal plasma flow and glomerular filtration rate, treating pre

CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX

SQ Sequence 28 AA;

AAY31561 Length: 28 February 4, 2005 13:19 Type: P Check: 1045 ..
 Found using 'seq4' (mohamed337.key)

```

1 HGEGETFTSDLSKQLEEEAVRLXIEFLKN 28
  |-----|
  |-----|

```

1 match found in sequence:
 aay31562; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31562 check: 237 from: 1 to: 28

ID AAY31562 standard; peptide; 28 AA.

XX AAY31562;

XX 08-NOV-1999 (first entry)

DT Exendin agonist peptide.

XX Exendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;

KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

PH Modified-site 28 /note= "C-terminal amide"

FT Modified-site 28 /note= "C-terminal amide"

FT Modified-site 28 /note= "C-terminal amide"

XX WO9940788-A1.

PN 19-AUG-1999.

XX 05-FEB-1999; 99WO-US002554.

XX 13-FEB-1998; 98US-0075122P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

XX WPI; 1999-527332/44.

XX Increasing urine flow by administering peptides or peptide agonists.

XX Example 61; Page 62; 94pp; English.

XX The invention relates to new methods of increasing urine flow that

XX comprises administering an exendin or exendin agonist, or a GLP-1

XX (glucagon-like peptide) or GLP-1 agonist. The new methods using an

XX exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for

XX increasing urine flow, decreasing potassium concentration in urine,

XX preventing or alleviating a disorder associated with toxic hypervolemia

XX (renal failure, congestive heart failure, nephrotic syndrome, pulmonary

XX edema, cirrhosis, or hypertension). They can also be used for inducing

XX rapid diuresis, preparing an individual for surgical procedure,

XX increasing renal plasma flow and glomerular filtration rate, treating pre

CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 28 AA;

AAY31562 Length: 28 February 4, 2005 13:19 Type: P Check: 237 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGTFTSLSKQLEEEAVRLFIDFLKN 28
 1

 1 match found in sequence:
 aay31563 ; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31563 check: 2215 from: 1 to: 33

ID AAY31563 standard; peptide; 33 AA.

XX AAY31563;

AC AAY31563;

DT 08-NOV-1999 (first entry)

XX Exendin agonist peptide.

XX Exendin agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

FT Modified-site 28 /note= "C-terminal amide"

XX WO9940788-A1.

PN 19-AUG-1999.

PD 05-FEB-1999; 99WO-US002554.

PF 13-FEB-1998; 98US-0075122P.

PR (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

PI WPI; 1999-527332/44.

DR Increasing urine flow by administering peptides or peptide agonists.

XX Example 62; Page 62; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre

CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of exendin agonists compounds
 XX
 SQ Sequence 33 AA;

AAY31563 Length: 33 February 4, 2005 13:19 Type: P Check: 2215 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGTFTSDASKQLEEEAVRLFIFLKNQGPSS 28
 1

 1 match found in sequence:
 aay31564 ; Exendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31564 check: 2649 from: 1 to: 29

ID AAY31564 standard; peptide; 29 AA.

XX AAY31564;

AC AAY31564;

DT 08-NOV-1999 (first entry)

XX Exendin agonist peptide.

XX Exendin agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

FT Modified-site 29 /note= "C-terminal amide"

XX WO9940788-A1.

PN 19-AUG-1999.

PD 05-FEB-1999; 99WO-US002554.

PF 13-FEB-1998; 98US-0075122P.

PR (AMYL-) AMYLIN PHARM INC.

XX Young AA, Vine W, Beeley NRA, Prickett K;

PI WPI; 1999-527332/44.

DR Increasing urine flow by administering peptides or peptide agonists.

XX Example 63; Page 63; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an exendin or exendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC exendin, exendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing
 CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre

CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 XX Sequence 29 AA;

AAAY31564 Length: 29 February 4, 2005 13:19 Type: P Check: 2649 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGTTSDASKQMEEEAVRLFIEWLKNG
 1
 -----|-----
 28

 1 match found in sequence:
 aay31565 ; Extendin agonist peptide.
 (from "seq4ags.pep")
 TOIG of: aay31565 check: 3183 from: 1 to: 37
 ID AAY31565 standard; peptide; 37 AA.

XX AC AAY31565;
 XX DT 08-NOV-1999 (first entry)
 XX DE Extendin agonist peptide.
 XX DE Extendin; agonist; GLP-1; glucagon-like peptide; toxic hypervolemia;
 KW diuresis; renal plasma flow; glomerular filtration rate; pre-eclampsia;
 KW eclampsia of pregnancy; cardiac contractility; renal failure; diuretic;
 KW congestive heart failure; nephrotic syndrome; pulmonary edema; cirrhosis;
 KW hypertension; urine flow.

XX OS Synthetic.
 OS Heloderma sp.
 XX FH Key Location/Qualifiers
 FT Modified-site 36
 FT Modified-site 37 /note= "hydroxyproline"
 FT Modified-site 37 /note= "hydroxyproline; C-terminal amide"
 XX WO9940788-A1.

XX PN 19-AUG-1999.
 XX PP 05-FEB-1999; 99WO-US002554.
 XX PR 13-FEB-1998; 98US-0075122P.

XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Young AA, Vine W, Beeley NRA, Prickett K;
 XX WPI; 1999-527332/44.

XX Increasing urine flow by administering peptides or peptide agonists.
 XX Example 65; Page 64; 94pp; English.

XX The invention relates to new methods of increasing urine flow that
 CC comprises administering an extendin or extendin agonist, or a GLP-1
 CC (glucagon-like peptide) or GLP-1 agonist. The new methods using an
 CC extendin, extendin agonist, GLP-1 or GLP-1 agonist are useful for
 CC increasing urine flow, decreasing potassium concentration in urine,
 CC preventing or alleviating a disorder associated with toxic hypervolemia
 CC (renal failure, congestive heart failure, nephrotic syndrome, pulmonary
 CC edema, cirrhosis, or hypertension). They can also be used for inducing

CC rapid diuresis, preparing an individual for surgical procedure,
 CC increasing renal plasma flow and glomerular filtration rate, treating pre
 CC -eclampsia or eclampsia of pregnancy, and increasing a condition/
 CC disorder that can be alleviated by increasing cardiac contractility
 CC (congestive heart failure, pulmonary edema, systemic edema or renal
 CC failure). Unlike prior art diuretics, the new methods increase urine
 CC excretion and sodium excretion without increasing potassium loss, and are
 CC fast acting. They have a prolonged duration of action, are inotropic,
 CC have a low toxicity, and are easily administered intravenously. Sequences
 CC AAY31505-560 represent examples of extendin agonists compounds
 XX
 XX Sequence 37 AA;

AAAY31565 Length: 37 February 4, 2005 13:19 Type: P Check: 3183 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGTTSDASKQMEEEAVRLFIEWLKNGPSSGAPP
 1
 -----|-----
 28

 1 match found in sequence:
 aay76998 ; Extendin peptide.
 (from "seq4ags.pep")
 TOIG of: aay76998 check: 7617 from: 1 to: 31

ID AAY76998 standard; peptide; 31 AA.
 XX AC AAY76998;
 XX DT 01-JUN-2000 (first entry)
 XX DE Extendin peptide.
 XX DE Extendin; GLP-1; agonist; glucagon like peptide-1; insulin synthesis;
 KW impaired glucose tolerance; IGT; non-insulin requiring type II diabetes;
 KW insulin requiring type II diabetes.

XX OS Unidentified.
 XX FH Key Location/Qualifiers
 FT Misc-difference 31 /label= Pro, Tyr
 FT WO200007617-A1.
 XX PD 17-FEB-2000.

XX PF 29-JUL-1999; 99WO-DK000424.
 XX PR 31-JUL-1998; 98DK-00000998.
 XX PR 12-AUG-1998; 98DK-00001025.
 XX PA (NOVO) NOVO-NORDISK AS.
 XX PI Nielsen JH, Friedrichsen BN, Rugh S, Tronholt N, Bjorn S;
 XX PI Knudsen LB, Sturis J;
 XX WPI; 2000-205569/18.

XX Use of GLP-1, its analogs, derivatives and agonists for increasing
 PT insulin synthesis, delaying progression of impaired glucose tolerance or
 PT non-insulin requiring type II diabetes to insulin requiring type II
 PT diabetes.

XX Disclosure; Page 4; 68pp; English.

XX This sequence represents an extendin peptide, and is a GLP-1 agonist. The
 CC invention relates to the use of a glucagon like peptide-1 (GLP-1), its
 CC analogues, derivative, or a GLP-1 agonist for the preparation of a
 CC medicament for delaying the progression of impaired glucose tolerance
 CC (IGT) or non-insulin requiring type II diabetes to insulin requiring type
 CC II diabetes. The invention also relates to the use of GLP-1, its

CC analogues, derivatives and agonists for increasing the insulin synthesis
 CC capability of a subject. The GLP-1 derivative is Arg34, Lys26(N-epsilon-
 CC (gamma-Glu(N-alpha-hexadecanoyl))-GLP-1(7-37)). The GLP-1 agonist is
 CC particularly GLP-1(7-37) and GLP-1(7-36)amide and the corresponding Thr8,
 CC Met8, Gly8 and Val8 analogues. The method is used for delaying
 CC progression of impaired glucose tolerance or non-insulin requiring type
 CC II diabetes to insulin requiring type II diabetes and for increasing
 CC insulin synthesis
 XX Sequence 31 AA;
 SQ
 AAY76998 Length: 31 February 4, 2005 13:19 Type: P Check: 7617 ..
 Found using 'seq4' (mohamed337.key)
 1 |-----|
 1 HGEFTSLSKQMBEEAVRLFIEWLKNGGX 28

 1 match found in sequence:
 aay78957 ; Extendin-4 (1-39) active fragment.
 (from "seq4ags.pep")
 TOIG of: aay78957 check: 9570 from: 1 to: 39
 ID AAY78957 standard; peptide; 39 AA.
 XX
 AC AAY78957;
 XX
 DT 05-JUN-2000 (first entry)
 XX
 DE Extendin-4 (1-39) active fragment.
 XX
 KW Extendin-4; Gila Monster lizard; insulin producing cell; insulin;
 KW amylose; diabetes mellitus type 1; human; livestock; pet.
 XX
 OS Heloderma suspectum.
 XX
 PN WO200009666-A2.
 XX
 PD 24-FEB-2000.
 XX
 PF 10-AUG-1999; 99WO-US018099.
 XX
 PR 10-AUG-1998; 98US-0095917P.
 XX
 PS (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PA Egan J, Perfetti R, Passaniti A, Greig N, Holloway H;
 PI WPI; 2000-205999/18.
 DR
 PT Differentiation of non-insulin producing cells into insulin-producing
 PT cells by glucagon-like peptide-1 or extendin-4, used to treat diabetes
 PT mellitus.
 XX
 PS Disclosure; Page 17; 119pp; English.
 XX
 CC This sequence represents an extendin-4 active fragment peptide sequence.
 CC Extendin-4 is a peptide produced in the salivary gland of the Gila
 CC Monster lizard. Extendin-4 has been shown to promote insulin secretion,
 CC and given in equimolar quantities, is more potent than glucagon-like
 CC protein-1 (GLP-1) at causing insulin release from insulin producing
 CC cells. GLP-1 is a hormone normally secreted by neuroendocrine cells of
 CC the gut, in response to food. GLP-1 fragments or Extendin-4 growth factor
 CC fragments can be used in the production of a population of insulin-
 CC producing cells from a population of non-insulin producing cells. The
 CC methods may also be used to promote pancreatic amylase producing cells to
 CC produce both insulin and amylase. The methods are used to treat diabetes
 CC mellitus (type 1) in humans, domesticated animals, livestock and pets
 XX Sequence 39 AA;
 SQ
 AAY78957 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..

Found using 'seq4' (mohamed337.key)
 1 |-----|
 1 HGEFTSLSKQMBEEAVRLFIEWLKNGGSSGAPPPS 28

 1 match found in sequence:
 aay78958 ; Extendin-4 (1-38) active fragment amino acid sequence.
 (from "seq4ags.pep")
 TOIG of: aay78958 check: 6333 from: 1 to: 38
 ID AAY78958 standard; peptide; 38 AA.
 XX
 AC AAY78958;
 XX
 DT 05-JUN-2000 (first entry)
 XX
 DE Extendin-4 (1-38) active fragment amino acid sequence.
 XX
 KW Extendin-4; Gila Monster lizard; insulin producing cell; insulin;
 KW amylose; diabetes mellitus type 1; human; livestock; pet.
 XX
 OS Heloderma suspectum.
 XX
 PN WO200009666-A2.
 XX
 PD 24-FEB-2000.
 XX
 PF 10-AUG-1999; 99WO-US018099.
 XX
 PR 10-AUG-1998; 98US-0095917P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Egan J, Perfetti R, Passaniti A, Greig N, Holloway H;
 DR WPI; 2000-205999/18.
 XX
 PT Differentiation of non-insulin producing cells into insulin-producing
 PT cells by glucagon-like peptide-1 or extendin-4, used to treat diabetes
 PT mellitus.
 XX
 PS Disclosure; Page 17; 119pp; English.
 XX
 CC This sequence represents an extendin-4 active fragment peptide sequence.
 CC Extendin-4 is a peptide produced in the salivary gland of the Gila
 CC Monster lizard. Extendin-4 has been shown to promote insulin secretion,
 CC and given in equimolar quantities, is more potent than glucagon-like
 CC protein-1 (GLP-1) at causing insulin release from insulin producing
 CC cells. GLP-1 is a hormone normally secreted by neuroendocrine cells of
 CC the gut, in response to food. GLP-1 fragments or Extendin-4 growth factor
 CC fragments can be used in the production of a population of insulin-
 CC producing cells from a population of non-insulin producing cells. The
 CC methods may also be used to promote pancreatic amylase producing cells to
 CC produce both insulin and amylase. The methods are used to treat diabetes
 CC mellitus (type 1) in humans, domesticated animals, livestock and pets
 XX Sequence 38 AA;
 SQ
 AAY78958 Length: 38 February 4, 2005 13:20 Type: P Check: 6333 ..
 Found using 'seq4' (mohamed337.key)
 1 |-----|
 1 HGEFTSLSKQMBEEAVRLFIEWLKNGGSSGAPPP 28

 1 match found in sequence:
 aay78959 ; Extendin-4 (1-37) active fragment amino acid sequence.
 (from "seq4ags.pep")
 TOIG of: aay78959 check: 3293 from: 1 to: 37 ..

```

ID AAY78959 standard; peptide; 37 AA.
XX AC AAY78959;
XX DT 05-JUN-2000 (first entry)
XX DE Extendin-4 (1-37) active fragment amino acid sequence.
XX KW Extendin-4; Gila Monster lizard; insulin producing cell; insulin;
XX KW amylase; diabetes mellitus type 1; human; livestock; pet.
XX OS Heloderma suspectum.
XX PN WO200009666-A2.
XX PD 24-FEB-2000.
XX PF 10-AUG-1999; 99WO-US018099.
XX PR 10-AUG-1998; 98US-0095917P.
XX PS 10-AUG-1998; 98US-0095917P.
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX PI Egan J, Perfetti R, Passaniti A, Greig N, Holloway H;
XX WPI; 2000-205999/18.
XX DR Differentiation of non-insulin producing cells into insulin-producing
XX PT cells by glucagon-like peptide-1 or extendin-4, used to treat diabetes
XX PT mellitus.
XX PS Disclosure; Page 17; 119pp; English.
XX CC This sequence represents an extendin-4 active fragment peptide sequence.
XX CC Extendin-4 is a peptide produced in the salivary gland of the Gila
XX CC Monster lizard. Extendin-4 has been shown to promote insulin secretion,
XX CC and given in equimolar quantities, is more potent than glucagon-like
XX CC protein-1 (GLP-1) at causing insulin release from insulin producing
XX CC cells. GLP-1 is a hormone normally secreted by neuroendocrine cells of
XX CC the gut, in response to food. GLP-1 fragments or Extendin-4 growth factor
XX CC fragments can be used in the production of a population of insulin-
XX CC producing cells from a population of non-insulin producing cells. The
XX CC methods may also be used to promote pancreatic amylase producing cells to
XX CC produce both insulin and amylase. The methods are used to treat diabetes
XX CC mellitus (type 1) in humans, domesticated animals, livestock and pets
XX SQ Sequence 37 AA;
XX
AAY78959 Length: 37 February 4, 2005 13:20 Type: P Check: 3293 ..
Found using 'seq4' (mohamed337.key)
1 HGGGFTTDLKQMBEEAVRLFIEWLKNKGPPSSGAPP
1 |-----|
28
-----
1 match found in sequence:
aay78960 ; Extendin-4 (1-36) active fragment amino acid sequence.
(from "seq4ags pep")
TOIG of: aay78960 check: 333 from: 1 to: 36
ID AAY78960 standard; peptide; 36 AA.
XX AC AAY78960;
XX DT 05-JUN-2000 (first entry)
XX DE Extendin-4 (1-36) active fragment amino acid sequence.
XX KW Extendin-4; Gila Monster lizard; insulin producing cell; insulin;
XX KW amylase; diabetes mellitus type 1; human; livestock; pet.
XX OS Heloderma suspectum.
XX PN WO200009666-A2.
XX PD 24-FEB-2000.
XX PF 10-AUG-1999; 99WO-US018099.
XX PR 10-AUG-1998; 98US-0095917P.
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX PI Egan J, Perfetti R, Passaniti A, Greig N, Holloway H;
XX WPI; 2000-205999/18.
XX DR Differentiation of non-insulin producing cells into insulin-producing
XX PT cells by glucagon-like peptide-1 or extendin-4, used to treat diabetes
XX PT mellitus.
XX PS Disclosure; Page 17; 119pp; English.
XX CC This sequence represents an extendin-4 active fragment peptide sequence.
XX CC Extendin-4 is a peptide produced in the salivary gland of the Gila
XX CC Monster lizard. Extendin-4 has been shown to promote insulin secretion,
XX CC and given in equimolar quantities, is more potent than glucagon-like
XX CC protein-1 (GLP-1) at causing insulin release from insulin producing
XX CC cells. GLP-1 is a hormone normally secreted by neuroendocrine cells of
XX CC the gut, in response to food. GLP-1 fragments or Extendin-4 growth factor
XX CC fragments can be used in the production of a population of insulin-
XX CC producing cells from a population of non-insulin producing cells. The
XX CC methods may also be used to promote pancreatic amylase producing cells to
XX CC produce both insulin and amylase. The methods are used to treat diabetes
XX CC mellitus (type 1) in humans, domesticated animals, livestock and pets
XX SQ Sequence 37 AA;
XX
AAY78959 Length: 37 February 4, 2005 13:20 Type: P Check: 3293 ..
Found using 'seq4' (mohamed337.key)
1 HGGGFTTDLKQMBEEAVRLFIEWLKNKGPPSSGAPP
1 |-----|
28
-----
1 match found in sequence:
aay78960 ; Extendin-4 (1-36) active fragment amino acid sequence.
(from "seq4ags pep")
TOIG of: aay78960 check: 333 from: 1 to: 36
ID AAY78960 standard; peptide; 36 AA.
XX AC AAY78960;
XX DT 05-JUN-2000 (first entry)
XX DE Extendin-4 (1-36) active fragment amino acid sequence.
XX KW Extendin-4; Gila Monster lizard; insulin producing cell; insulin;
XX KW amylase; diabetes mellitus type 1; human; livestock; pet.
XX OS Heloderma suspectum.

```

```

XX PN WO200009666-A2.
XX PD 24-FEB-2000.
XX PF 10-AUG-1999; 99WO-US018099.
XX PR 10-AUG-1998; 98US-0095917P.
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX PI Egan J, Perfetti R, Passaniti A, Greig N, Holloway H;
XX WPI; 2000-205999/18.
XX DR Differentiation of non-insulin producing cells into insulin-producing
XX PT cells by glucagon-like peptide-1 or extendin-4, used to treat diabetes
XX PT mellitus.
XX PS Disclosure; Page 17; 119pp; English.
XX CC This sequence represents an extendin-4 active fragment peptide sequence.
XX CC Extendin-4 is a peptide produced in the salivary gland of the Gila
XX CC Monster lizard. Extendin-4 has been shown to promote insulin secretion,
XX CC and given in equimolar quantities, is more potent than glucagon-like
XX CC protein-1 (GLP-1) at causing insulin release from insulin producing
XX CC cells. GLP-1 is a hormone normally secreted by neuroendocrine cells of
XX CC the gut, in response to food. GLP-1 fragments or Extendin-4 growth factor
XX CC fragments can be used in the production of a population of insulin-
XX CC producing cells from a population of non-insulin producing cells. The
XX CC methods may also be used to promote pancreatic amylase producing cells to
XX CC produce both insulin and amylase. The methods are used to treat diabetes
XX CC mellitus (type 1) in humans, domesticated animals, livestock and pets
XX SQ Sequence 36 AA;
XX
AAY78960 Length: 36 February 4, 2005 13:20 Type: P Check: 333 ..
Found using 'seq4' (mohamed337.key)
1 HGGGFTTDLKQMBEEAVRLFIEWLKNKGPPSSGAPP
1 |-----|
28
-----
1 match found in sequence:
aay78961 ; Extendin-4 (1-35) active fragment amino acid sequence.
(from "seq4ags pep")
TOIG of: aay78961 check: 7453 from: 1 to: 35
ID AAY78961 standard; peptide; 35 AA.
XX AC AAY78961;
XX DT 05-JUN-2000 (first entry)
XX DE Extendin-4 (1-35) active fragment amino acid sequence.
XX KW Extendin-4; Gila Monster lizard; insulin producing cell; insulin;
XX KW amylase; diabetes mellitus type 1; human; livestock; pet.
XX OS Heloderma suspectum.
XX PN WO200009666-A2.
XX PD 24-FEB-2000.
XX PF 10-AUG-1999; 99WO-US018099.
XX PR 10-AUG-1998; 98US-0095917P.
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX PI Egan J, Perfetti R, Passaniti A, Greig N, Holloway H;

```

```

XX DR WPI; 2000-205999/18.
XX CC
XX PT Differentiation of non-insulin producing cells into insulin-producing
XX PT cells by glucagon-like peptide-1 or extendin-4, used to treat diabetes
XX PT mellitus.
XX PS Disclosure; Page 17; 119pp; English.
XX CC
XX CC This sequence represents an extendin-4 active fragment peptide sequence.
XX CC Extendin-4 is a peptide produced in the salivary gland of the Gila
XX CC Monster lizard. Extendin-4 has been shown to promote insulin secretion,
XX CC and given in equimolar quantities, is more potent than glucagon-like
XX CC protein-1 (GLP-1) at causing insulin release from insulin producing
XX CC cells. GLP-1 is a hormone normally secreted by neuroendocrine cells of
XX CC the gut, in response to food. GLP-1 fragments or extendin-4 growth factor
XX CC fragments can be used in the production of a population of insulin-
XX CC producing cells from a population of non-insulin producing cells. The
XX CC methods may also be used to promote pancreatic amylase producing cells to
XX CC produce both insulin and amylase. The methods are used to treat diabetes
XX CC mellitus (type 1) in humans, domesticated animals, livestock and pets
XX SQ Sequence 35 AA;

AAY78961 Length: 35 February 4, 2005 13:20 Type: P Check: 7453
Found using 'seq4' (mohamed337.key)

1 HEGTFTDLSKQMEEAARLFIWLKNGPSSGA
  1 -----|-----|
  28

-----
1 match found in sequence:
aay78962 : Extendin-4 (1-34) active fragment amino acid sequence.
(from "seq4ags.pep")
TOIG of: aay78962 check: 5178 from: 1 to: 34

ID AAY78962 standard; peptide; 34 AA.
XX
XX AC AAY78962;
XX
XX DT 05-JUN-2000 (first entry)
XX
XX DE Extendin-4 (1-34) active fragment amino acid sequence.
XX
XX KW Extendin-4; Gila Monster lizard; insulin producing cell; insulin;
XX KW amylase; diabetes mellitus type 1; human; livestock; pet.
XX
XX OS Heloderma suspectum.
XX
XX PN WO200009666-A2..
XX
XX PD 24-FEB-2000.
XX
XX DT 05-JUN-2000 (first entry)
XX
XX DE Extendin-4 (1-34) active fragment amino acid sequence.
XX
XX KW Extendin-4; Gila Monster lizard; insulin producing cell; insulin;
XX KW amylase; diabetes mellitus type 1; human; livestock; pet.
XX
XX OS Heloderma suspectum.
XX
XX PN WO200009666-A2..
XX
XX PD 24-FEB-2000.
XX
XX PF 10-AUG-1999; 99WO-US018099.
XX
XX PR 10-AUG-1998; 98US-0095917P.
XX
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
XX PI Egan J, Perfetti R, Passaniti A, Greig N, Holloway H;
XX
XX DR WPI; 2000-205999/18.
XX
XX PT Differentiation of non-insulin producing cells into insulin-producing
XX PT cells by glucagon-like peptide-1 or extendin-4, used to treat diabetes
XX PT mellitus.
XX
XX PS Disclosure; Page 17; 119pp; English.
XX
XX CC This sequence represents an extendin-4 active fragment peptide sequence.
XX CC Extendin-4 is a peptide produced in the salivary gland of the Gila
XX CC Monster lizard. Extendin-4 has been shown to promote insulin secretion,
XX CC and given in equimolar quantities, is more potent than glucagon-like
XX CC protein-1 (GLP-1) at causing insulin release from insulin producing
XX CC cells. GLP-1 is a hormone normally secreted by neuroendocrine cells of
XX CC the gut, in response to food. GLP-1 fragments or extendin-4 growth factor
XX CC fragments can be used in the production of a population of insulin-
XX CC producing cells from a population of non-insulin producing cells. The
XX CC methods may also be used to promote pancreatic amylase producing cells to
XX CC produce both insulin and amylase. The methods are used to treat diabetes
XX CC mellitus (type 1) in humans, domesticated animals, livestock and pets
XX SQ Sequence 35 AA;

```

```

CC and given in equimolar quantities, is more potent than glucagon-like
CC protein-1 (GLP-1) at causing insulin release from insulin producing
CC cells. GLP-1 is a hormone normally secreted by neuroendocrine cells of
CC the gut, in response to food. GLP-1 fragments or extendin-4 growth factor
CC fragments can be used in the production of a population of insulin-
CC producing cells from a population of non-insulin producing cells. The
CC methods may also be used to promote pancreatic amylase producing cells to
CC produce both insulin and amylase. The methods are used to treat diabetes
CC mellitus (type 1) in humans, domesticated animals, livestock and pets
XX SQ Sequence 34 AA;

AAY78962 Length: 34 February 4, 2005 13:20 Type: P Check: 5178
Found using 'seq4' (mohamed337.key)

1 HEGTFTDLSKQMEEAARLFIWLKNGPSSG
  1 -----|-----|
  28

-----
1 match found in sequence:
aay78963 : Extendin-4 (1-33) active fragment amino acid sequence.
(from "seq4ags.pep")
TOIG of: aay78963 check: 2764 from: 1 to: 33

ID AAY78963 standard; peptide; 33 AA.
XX
XX AC AAY78963;
XX
XX DT 05-JUN-2000 (first entry)
XX
XX DE Extendin-4 (1-33) active fragment amino acid sequence.
XX
XX KW Extendin-4; Gila Monster lizard; insulin producing cell; insulin;
XX KW amylase; diabetes mellitus type 1; human; livestock; pet.
XX
XX OS Heloderma suspectum.
XX
XX PN WO200009666-A2.
XX
XX PD 24-FEB-2000.
XX
XX PF 10-AUG-1999; 99WO-US018099.
XX
XX PR 10-AUG-1998; 98US-0095917P.
XX
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
XX PI Egan J, Perfetti R, Passaniti A, Greig N, Holloway H;
XX
XX DR WPI; 2000-205999/18.
XX
XX PT Differentiation of non-insulin producing cells into insulin-producing
XX PT cells by glucagon-like peptide-1 or extendin-4, used to treat diabetes
XX PT mellitus.
XX
XX PS Disclosure; Page 17; 119pp; English.
XX
XX CC This sequence represents an extendin-4 active fragment peptide sequence.
XX CC Extendin-4 is a peptide produced in the salivary gland of the Gila
XX CC Monster lizard. Extendin-4 has been shown to promote insulin secretion,
XX CC and given in equimolar quantities, is more potent than glucagon-like
XX CC protein-1 (GLP-1) at causing insulin release from insulin producing
XX CC cells. GLP-1 is a hormone normally secreted by neuroendocrine cells of
XX CC the gut, in response to food. GLP-1 fragments or extendin-4 growth factor
XX CC fragments can be used in the production of a population of insulin-
XX CC producing cells from a population of non-insulin producing cells. The
XX CC methods may also be used to promote pancreatic amylase producing cells to
XX CC produce both insulin and amylase. The methods are used to treat diabetes
XX CC mellitus (type 1) in humans, domesticated animals, livestock and pets
XX SQ Sequence 33 AA;

```



```
PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using exendin, an exendin agonist, a modified
XX exendin or a modified exendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Example 1; Fig 2; 96pp; English.
XX
XX The present sequence represents an extendin-4 peptide. Extendins are
XX found in the salivary glands of the Gila monster and Mexican Beaded
XX lizard, and have sequence similarity to glucagon-like peptides. It is
XX used in the method of the invention. The specification describes a method
XX for lowering plasma glucagon, comprising administering an exendin, an
XX exendin agonist, a modified exendin or a modified exendin agonist. These
XX compounds lower plasma glucagon level. The method is useful for lowering
XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX erythema or glucagonoma. The method is also useful for treating
XX hyperglucagonemia and other conditions that would benefit from reduced
XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
XX Sequence 39 AA;
XX
AAAY94011 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HCGGTFTSLSKQMEAEAVRLFIEFLKNGGPPSGAPPPS
1 |-----|
28
-----
1 match found in sequence:
aay94013 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94013 check: 9131 from: 1 to: 39
ID AAY94013 standard; peptide; 39 AA.
XX
XX AC
XX
XX DT
XX
XX DE
XX
XX KW
XX
XX KW
XX
XX OS
XX
XX OS
XX
XX PN
XX
XX PD
XX
XX PF
XX
XX PR
XX
XX PR
XX
XX PR
XX
XX PA
XX
XX PI
XX
XX DR
XX
XX PT
XX
XX PT
XX
XX PA
XX
XX PS
XX
XX CC
XX

PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using exendin, an exendin agonist, a modified
XX exendin or a modified exendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Example 1; Fig 2; 96pp; English.
XX
XX The present sequence represents an extendin-4 peptide. Extendins are
XX found in the salivary glands of the Gila monster and Mexican Beaded
XX lizard, and have sequence similarity to glucagon-like peptides. It is
XX used in the method of the invention. The specification describes a method
XX for lowering plasma glucagon, comprising administering an exendin, an
XX exendin agonist, a modified exendin or a modified exendin agonist. These
XX compounds lower plasma glucagon level. The method is useful for lowering
XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX erythema or glucagonoma. The method is also useful for treating
XX hyperglucagonemia and other conditions that would benefit from reduced
XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
XX Sequence 39 AA;
XX
AAAY94011 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)
1 HCGGTFTSLSKQMEAEAVRLFIEFLKNGGPPSGAPPPS
1 |-----|
28
-----
1 match found in sequence:
aay94013 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94013 check: 9131 from: 1 to: 39
ID AAY94013 standard; peptide; 39 AA.
XX
XX AC
XX
XX DT
XX
XX DE
XX
XX KW
XX
XX KW
XX
XX OS
XX
XX OS
XX
XX PN
XX
XX PD
XX
XX PF
XX
XX PR
XX
XX PR
XX
XX PR
XX
XX PA
XX
XX PI
XX
XX DR
XX
XX PT
XX
XX PT
XX
XX PA
XX
XX PS
XX
XX CC
XX

Lowering plasma glucagon using exendin, an exendin agonist, a modified
exendin or a modified exendin agonist, useful for treating
hyperglucagonemia and diabetes.
Disclosure; Fig 3A; 96pp; English.
AAAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
are found in the salivary glands of the Gila monster and Mexican Beaded
lizard, and have sequence similarity to glucagon-like peptides. They are
used in the method of the invention. The specification describes a method
for lowering plasma glucagon, comprising administering an exendin, an
exendin agonist, a modified exendin or a modified exendin agonist. These
compounds lower plasma glucagon level. The method is useful for lowering
plasma glucagon in subjects, preferably humans, suffering from necrolytic
erythema or glucagonoma. The method is also useful for treating
hyperglucagonemia and other conditions that would benefit from reduced
glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
diabetes
Sequence 39 AA;
AAAY94013 Length: 39 February 4, 2005 13:20 Type: P Check: 9131 ..
Found using 'seq4' (mohamed337.key)
1 HCGGTFTSLSKQLEAEAVRLFIEFLKNGGPPSGAPPPS
1 |-----|
28
-----
1 match found in sequence:
aay94014 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94014 check: 9556 from: 1 to: 39
ID AAY94014 standard; peptide; 39 AA.
XX
XX AC
XX
XX DT
XX
XX DE
XX
XX KW
XX
XX KW
XX
XX OS
XX
XX OS
XX
XX PN
XX
XX PD
XX
XX PF
XX
XX PR
XX
XX PR
XX
XX PR
XX
XX PA
XX
XX PI
XX
XX DR
XX
XX PT
XX
XX PT
XX
XX PA
XX
XX PS
XX
XX CC
XX

Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
hyperglucagonemia; diabetes.
Synthetic.
Heloderma sp.
WO200041548-A2.
20-JUL-2000.
14-JAN-2000; 2000WO-US0000942.
14-JAN-1999; 99US-0116380P.
30-APR-1999; 99US-0132017P.
10-JAN-2000; 2000US-0175365P.
(AMYL-) AMYLIN PHARM INC.
Young A, Gedulin B;
WPI; 2000-490999/43.
Lowering plasma glucagon using exendin, an exendin agonist, a modified
exendin or a modified exendin agonist, useful for treating
hyperglucagonemia and diabetes.
Disclosure; Fig 3A; 96pp; English.
AAAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
are found in the salivary glands of the Gila monster and Mexican Beaded
```

CC lizard, and have sequence similarity to glucagon-like peptides. They are
 CC used in the method of the invention. The specification describes a method
 CC for lowering plasma glucagon, comprising administering an extendin, an
 CC extendin agonist, a modified extendin or a modified extendin agonist. These
 CC compounds lower plasma glucagon level. The method is useful for lowering
 CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
 CC erythema or glucagonoma. The method is also useful for treating
 CC hyperglucagonemia and other conditions that would benefit from reduced
 CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes
 XX
 SQ Sequence 39 AA;
 AAY94014 Length: 39 February 4, 2005 13:20 Type: P Check: 9556 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGTFTSDLSKQLEEAVERLFIETLKNKGPSGAPPPS
 28
 1

 1 match found in sequence:
 aay94015 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94015 check: 9145 from: 1 to: 39
 ID AAY94015 standard; peptide; 39 AA.
 XX
 AC AAY94015;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO200041548-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Gedulin B;
 XX
 DR WPI; 2000-490999/43.
 XX
 PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 PS Disclosure; Fig 3A; 96pp; English.
 XX
 CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendsins
 CC are found in the salivary glands of the Gila monster and Mexican Beaded
 CC lizard, and have sequence similarity to glucagon-like peptides. They are
 CC used in the method of the invention. The specification describes a method
 CC for lowering plasma glucagon, comprising administering an extendin, an
 CC extendin agonist, a modified extendin or a modified extendin agonist. These
 CC compounds lower plasma glucagon level. The method is useful for lowering
 CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
 CC erythema or glucagonoma. The method is also useful for treating
 CC hyperglucagonemia and other conditions that would benefit from reduced
 CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes
 XX
 SQ Sequence 39 AA;
 AAY94016 Length: 39 February 4, 2005 13:20 Type: P Check: 9587 ..
 Found using 'seq4' (mohamed337.key)

CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes
 XX
 SQ Sequence 39 AA;
 AAY94015 Length: 39 February 4, 2005 13:20 Type: P Check: 9145 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGTFTSDLSKQMEEAVERLFIETLKNKGPSGAPPPS
 28
 1

 1 match found in sequence:
 aay94016 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94016 check: 9587 from: 1 to: 39
 ID AAY94016 standard; peptide; 39 AA.
 XX
 AC AAY94016;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 PN WO200041548-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Gedulin B;
 XX
 DR WPI; 2000-490999/43.
 XX
 PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 PS Disclosure; Fig 3A; 96pp; English.
 XX
 CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendsins
 CC are found in the salivary glands of the Gila monster and Mexican Beaded
 CC lizard, and have sequence similarity to glucagon-like peptides. They are
 CC used in the method of the invention. The specification describes a method
 CC for lowering plasma glucagon, comprising administering an extendin, an
 CC extendin agonist, a modified extendin or a modified extendin agonist. These
 CC compounds lower plasma glucagon level. The method is useful for lowering
 CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
 CC erythema or glucagonoma. The method is also useful for treating
 CC hyperglucagonemia and other conditions that would benefit from reduced
 CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes
 XX
 SQ Sequence 39 AA;
 AAY94016 Length: 39 February 4, 2005 13:20 Type: P Check: 9587 ..
 Found using 'seq4' (mohamed337.key)

```
1 YGEGTFTSLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
1 -----
1 match found in sequence:
aay94017 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94017 check: 9804 from: 1 to: 39

ID AAY94017 standard; peptide; 39 AA.
XX AC AAY94017;
XX XX
XX DT 20-OCT-2000 (first entry)
XX XX
XX DE Amino acid sequence of an extendin agonist.
XX XX
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX KW hyperglucagonemia; diabetes.
XX OS Synthetic.
XX OS Heloderma sp.
XX XX
XX PN WO200041548-A2.
XX PD 20-JUL-2000.
XX XX
XX PF 14-JAN-2000; 2000WO-US000942.
XX XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Gedulin B;
XX XX
XX DR WPI; 2000-490999/43.
XX XX
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX PT extendin or a modified extendin agonist, useful for treating
XX PT hyperglucagonemia and diabetes.
XX XX
XX PS Disclosure; Fig 3A; 96pp; English.
XX XX
XX CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX CC are found in the salivary glands of the Gila monster and Mexican Beaded
XX CC lizard, and have sequence similarity to glucagon-like peptides. They are
XX CC used in the method of the invention. The specification describes a method
XX CC for lowering plasma glucagon, comprising administering an extendin, an
XX CC extendin agonist, a modified extendin or a modified extendin agonist. These
XX CC compounds lower plasma glucagon level. The method is useful for lowering
XX CC erythema or glucagonoma. The method is also useful for treating
XX CC hyperglucagonemia and other conditions that would benefit from reduced
XX CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX CC diabetes
XX SQ Sequence 39 AA;
XX XX
XX AAY94018 Length: 39 February 4, 2005 13:20 Type: P Check: 9567 ..
Found using 'seq4' (mohamed337.key)
1 HEGGTFTSLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
1 -----
1 match found in sequence:
aay94019 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94019 check: 9678 from: 1 to: 39

ID AAY94019 standard; peptide; 39 AA.
XX AC AAY94019;
XX XX
XX DT 20-OCT-2000 (first entry)
XX XX
```

```

DE Amino acid sequence of an extendin agonist.
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FH Modified-site 6
FT /note= "naphthylalanine"
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, Gedulin B;
PI WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3A; 96pp; English.
XX
XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC diabetes
XX
XX Sequence 39 AA;
SQ
AAY94019 Length: 39 February 4, 2005 13:20 Type: P Check: 9678 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEGTXTSLSKQMBEEAVRLFIEWLKNKGPPSSGAPPPS
28
-----
1 match found in sequence:
aay94020 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94020 check: 9563 from: 1 to: 39
ID AAY94020 standard; peptide; 39 AA.
XX
XX AAY94020;
AC
XX 20-OCT-2000 (first entry)
DT
XX
XX Amino acid sequence of an extendin agonist.
DE
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, Gedulin B;
PI WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3A; 96pp; English.
XX
XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC diabetes
XX
XX Sequence 39 AA;
SQ
AAY94020 Length: 39 February 4, 2005 13:20 Type: P Check: 9563 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEGTFTSLSKQMBEEAVRLFIEWLKNKGPPSSGAPPPS
28
-----
1 match found in sequence:
aay94021 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94021 check: 9571 from: 1 to: 39
ID AAY94021 standard; peptide; 39 AA.
XX
XX AAY94021;
AC
XX 20-OCT-2000 (first entry)
DT
XX
XX Amino acid sequence of an extendin agonist.
DE
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX

```

```

KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, Gedulin B;
PI WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3A; 96pp; English.
XX
XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC diabetes
XX
XX Sequence 39 AA;
SQ
AAY94020 Length: 39 February 4, 2005 13:20 Type: P Check: 9563 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEGTFTSLSKQMBEEAVRLFIEWLKNKGPPSSGAPPPS
28
-----
1 match found in sequence:
aay94021 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94021 check: 9571 from: 1 to: 39
ID AAY94021 standard; peptide; 39 AA.
XX
XX AAY94021;
AC
XX 20-OCT-2000 (first entry)
DT
XX
XX Amino acid sequence of an extendin agonist.
DE
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX

```

```

XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 30-APR-1999; 99US-0132017P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3A; 96pp; English.
XX
XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX are found in the salivary glands of the Gila monster and Mexican Beaded
XX lizard, and have sequence similarity to glucagon-like peptides. They are
XX used in the method of the invention. The specification describes a method
XX for lowering plasma glucagon, comprising administering an extendin, an
XX extendin agonist, a modified extendin or a modified extendin agonist. These
XX compounds lower plasma glucagon level. The method is useful for lowering
XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX erythema or glucagonoma. The method is also useful for treating
XX hyperglucagonemia and other conditions that would benefit from reduced
XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
XX Sequence 39 AA;
XX
XX AAY94021 Length: 39 February 4, 2005 13:20 Type: P Check: 9571 ..
XX Found using 'seq4' (mohamed337.key)
XX
1 |-----|
1 HGEFTTDLKQMEEEAVRLFIEWLKNGSPSSGAPPPS
28
-----
1 match found in sequence:
aay94022 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94022 check: 9578 from: 1 to: 39
ID AAY94022 standard; peptide; 39 AA.
XX
XX AAY94022;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
XX Heloderma sp.
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 30-APR-1999; 99US-0132017P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX (AMYL-) AMYLIN PHARM INC.

```

```

XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3A; 96pp; English.
XX
XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX are found in the salivary glands of the Gila monster and Mexican Beaded
XX lizard, and have sequence similarity to glucagon-like peptides. They are
XX used in the method of the invention. The specification describes a method
XX for lowering plasma glucagon, comprising administering an extendin, an
XX extendin agonist, a modified extendin or a modified extendin agonist. These
XX compounds lower plasma glucagon level. The method is useful for lowering
XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX erythema or glucagonoma. The method is also useful for treating
XX hyperglucagonemia and other conditions that would benefit from reduced
XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
XX Sequence 39 AA;
XX
XX AAY94022 Length: 39 February 4, 2005 13:20 Type: P Check: 9578 ..
XX Found using 'seq4' (mohamed337.key)
XX
1 |-----|
1 HGEFTTDLKQMEEEAVRLFIEWLKNGSPSSGAPPPS
28
-----
1 match found in sequence:
aay94023 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94023 check: 9579 from: 1 to: 39
ID AAY94023 standard; peptide; 39 AA.
XX
XX AAY94023;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
XX Heloderma sp.
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX
XX 30-APR-1999; 99US-0132017P.
XX
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX (AMYL-) AMYLIN PHARM INC.

```

XX Disclosure; Fig 3A; 96pp; English.
 XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extends
 CC are found in the salivary glands of the Gila monster and Mexican Beaded
 CC lizard, and have sequence similarity to glucagon-like peptides. They are
 CC used in the method of the invention. The specification describes a method
 CC for lowering plasma glucagon, comprising administering an extendin, an
 CC extendin agonist, a modified extendin or a modified extendin agonist. These
 CC compounds lower plasma glucagon level. The method is useful for lowering
 CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
 CC erythema or glucagonoma. The method is also useful for treating
 CC hyperglucagonemia and other conditions that would benefit from reduced
 CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes
 XX Sequence 39 AA;
 SQ
 AAY94023 Length: 39 February 4, 2005 13:20 Type: P Check: 9579 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGTFTSLSKQMBEEAVRLFIEWLKNGSPSSGAPPPS
 28

 1 match found in sequence:
 aay94024 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94024 check: 9690 from: 1 to: 39

 ID AAY94024 standard; peptide; 39 AA.
 XX AC AAY94024;
 XX DT 20-OCT-2000 (first entry)
 XX DE Amino acid sequence of an extendin agonist.
 XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX OS Synthetic.
 OS Heloderma sp.
 XX FH Key Location/Qualifiers
 FT Modified-site 10 /note= "pentyl-glycine"
 FT WO200041548-A2.
 XX PN 20-JUL-2000.
 XX PD 14-JAN-2000; 2000WO-US000942.
 XX PF 14-JAN-1999; 99US-0116380P.
 XX PR 30-APR-1999; 99US-0132017P.
 XX PR 10-JAN-2000; 2000US-0175365P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Young A, Gedulin B;
 XX DR WPI; 2000-490999/43.
 XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX PS Disclosure; Fig 3A; 96pp; English.
 XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extends

CC are found in the salivary glands of the Gila monster and Mexican Beaded
 CC lizard, and have sequence similarity to glucagon-like peptides. They are
 CC used in the method of the invention. The specification describes a method
 CC for lowering plasma glucagon, comprising administering an extendin, an
 CC extendin agonist, a modified extendin or a modified extendin agonist. These
 CC compounds lower plasma glucagon level. The method is useful for lowering
 CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
 CC erythema or glucagonoma. The method is also useful for treating
 CC hyperglucagonemia and other conditions that would benefit from reduced
 CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes
 XX Sequence 39 AA;
 SQ
 AAY94024 Length: 39 February 4, 2005 13:20 Type: P Check: 9690 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGTFTSLSKQMBEEAVRLFIEWLKNGSPSSGAPPPS
 28

 1 match found in sequence:
 aay94025 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94025 check: 9251 from: 1 to: 39

 ID AAY94025 standard; peptide; 39 AA.
 XX AC AAY94025;
 XX DT 20-OCT-2000 (first entry)
 XX DE Amino acid sequence of an extendin agonist.
 XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX OS Synthetic.
 OS Heloderma sp.
 XX FH Key Location/Qualifiers
 FT Modified-site 10 /note= "pentyl-glycine"
 FT WO200041548-A2.
 XX PN 20-JUL-2000.
 XX PD 14-JAN-2000; 2000WO-US000942.
 XX PF 14-JAN-1999; 99US-0116380P.
 XX PR 30-APR-1999; 99US-0132017P.
 XX PR 10-JAN-2000; 2000US-0175365P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Young A, Gedulin B;
 XX DR WPI; 2000-490999/43.
 XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX PS Disclosure; Fig 3A; 96pp; English.
 XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extends
 CC are found in the salivary glands of the Gila monster and Mexican Beaded
 CC lizard, and have sequence similarity to glucagon-like peptides. They are
 CC used in the method of the invention. The specification describes a method
 CC for lowering plasma glucagon, comprising administering an extendin, an

CC extendin agonist, a modified extendin or a modified extendin agonist. These
 CC compounds lower plasma glucagon level. The method is useful for lowering
 CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
 CC erythema or glucagonoma. The method is also useful for treating
 CC hyperglucagonemia and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes
 XX Sequence 39 AA;

AAAY94025 Length: 39 February 4, 2005 13:20 Type: P Check: 9251 ..
 Found using 'seq4' (mohamed337.key)

```

1  HGEFTTDXSKQLEEEAVRLFTFLKNGGSSGAPPPS
  1  -----|-----
  28

```

 1 match found in sequence:
 aay94026 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94026 check: 9724 from: 1 to: 39

ID AAY94026 standard; peptide; 39 AA.
 XX
 AC AAY94026;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.

XX
 FH Key Location/Qualifiers
 FT Modified-site 14
 FT /note= "pentyl-glycine"
 XX
 XX WO200041548-A2.
 XX
 XX 20-JUL-2000.
 XX
 XX 14-JAN-2000; 2000WO-US000942.
 XX
 XX 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, Gedulin B;
 PI
 XX WPI; 2000-490999/43.
 XX
 XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 XX Disclosure; Fig 3A; 96pp; English.
 XX

CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendsins
 CC are found in the salivary glands of the Gila monster and Mexican Beaded
 CC lizard, and have sequence similarity to glucagon-like peptides. They are
 CC used in the method of the invention. The specification describes a method
 CC for lowering plasma glucagon, comprising administering an extendin, an
 CC extendin agonist, a modified extendin or a modified extendin agonist. These
 CC compounds lower plasma glucagon level. The method is useful for lowering
 CC erythema or glucagonoma. The method is also useful for treating
 CC hyperglucagonemia and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes

CC hyperglucagonemia and other conditions that would benefit from reduced
 CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes
 XX Sequence 39 AA;
 SQ
 AAY94026 Length: 39 February 4, 2005 13:20 Type: P Check: 9724 ..
 Found using 'seq4' (mohamed337.key)

```

1  HGEFTTDLXKQLEEEAVRLFIWLKNGGSSGAPPPS
  1  -----|-----
  28

```

 1 match found in sequence:
 aay94027 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94027 check: 9299 from: 1 to: 39

ID AAY94027 standard; peptide; 39 AA.
 XX
 AC AAY94027;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.

XX
 FH Key Location/Qualifiers
 FT Modified-site 14
 FT /note= "pentyl-glycine"
 XX
 XX WO200041548-A2.
 XX
 XX 20-JUL-2000.
 XX
 XX 14-JAN-2000; 2000WO-US000942.
 XX
 XX 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, Gedulin B;
 PI
 XX WPI; 2000-490999/43.
 XX
 XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 XX Disclosure; Fig 3A; 96pp; English.
 XX

CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendsins
 CC are found in the salivary glands of the Gila monster and Mexican Beaded
 CC lizard, and have sequence similarity to glucagon-like peptides. They are
 CC used in the method of the invention. The specification describes a method
 CC for lowering plasma glucagon, comprising administering an extendin, an
 CC extendin agonist, a modified extendin or a modified extendin agonist. These
 CC compounds lower plasma glucagon level. The method is useful for lowering
 CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
 CC erythema or glucagonoma. The method is also useful for treating
 CC hyperglucagonemia and other conditions that would benefit from reduced
 CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
 CC diabetes

SQ Sequence 39 AA;

AA94027 Length: 39 February 4, 2005 13:20 Type: P Check: 9299 ..
Found using 'seq4' (mohamed337.key)

1 HEGFTSLSKQEEAEVRLFIETLKNKGSSGAPPPS
28

1 match found in sequence:

aay94028 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")

TOIG of: aay94028 check: 9966 from: 1 to: 39

ID AAY94028 standard; peptide; 39 AA.

XX AC AAY94028;

DT 20-OCT-2000 (first entry)

DE Amino acid sequence of an extendin agonist.

KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.

XX OS Synthetic.

OS Heloderma sp.

FH Key Location/Qualifiers

FT Modified-site 22

FT /note= "naphthylalanine"

PN WO200041548-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000942.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 30-APR-1999; 99US-0132017P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, Gedulin B;

XX PS WPI; 2000-490999/43.

XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.

XX Disclosure; Fig 3A; 96pp; English.

XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC diabetes

XX SQ Sequence 39 AA;

AA94028 Length: 39 February 4, 2005 13:20 Type: P Check: 9966 ..

Found using 'seq4' (mohamed337.key)

1 HEGFTSLSKQEEAEVRLFIETLKNKGSSGAPPPS
28

1 match found in sequence:

aay94029 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")

TOIG of: aay94029 check: 9869 from: 1 to: 39

ID AAY94029 standard; peptide; 39 AA.

XX AC AAY94029;

DT 20-OCT-2000 (first entry)

DE Amino acid sequence of an extendin agonist.

KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.

XX OS Synthetic.

OS Heloderma sp.

XX WO200041548-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000942.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 30-APR-1999; 99US-0132017P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, Gedulin B;

XX WPI; 2000-490999/43.

XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.

XX Disclosure; Fig 3A; 96pp; English.

XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC diabetes

XX SQ Sequence 39 AA;

AA94029 Length: 39 February 4, 2005 13:20 Type: P Check: 9869 ..

Found using 'seq4' (mohamed337.key)

1 HEGFTSLSKQEEAEVRLFIETLKNKGSSGAPPPS
28

1 match found in sequence:

aay94030 ; Amino acid sequence of an extendin agonist.

```

(from "seq4ags.pep")
TOIG of: aay94030 check: 9430 from: 1 to: 39

ID AAY94030 standard; peptide; 39 AA.
XX AC AAY94030;
XX DT 20-OCT-2000 (first entry)
XX DE Amino acid sequence of an extendin agonist.
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX KW hyperglucagonemia; diabetes.
XX OS Synthetic.
XX OS Heloderma sp.
XX PN WO200041548-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000942.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Gedulin B;
XX PI WPI; 2000-490999/43.
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX PT extendin or a modified extendin agonist, useful for treating
XX PT hyperglucagonemia and diabetes.
XX PS Disclosure; Fig 3A; 96pp; English.
XX CC AAY94031-43 represent extendin agonists, derived from AAY94012. Extendins
XX CC are found in the salivary glands of the Gila monster and Mexican Beaded
XX CC lizard, and have sequence similarity to glucagon-like peptides. They are
XX CC used in the method of the invention. The specification describes a method
XX CC for lowering plasma glucagon, comprising administering an extendin, an
XX CC extendin agonist, a modified extendin or a modified extendin agonist. These
XX CC compounds lower plasma glucagon level. The method is useful for lowering
XX CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX CC erythema or glucagonoma. The method is also useful for treating
XX CC hyperglucagonemia and other conditions that would benefit from reduced
XX CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX CC diabetes
XX SQ Sequence 39 AA;

AAY94030 Length: 39 February 4, 2005 13:20 Type: P Check: 9430 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSLSKQLEEEAVRLFVFLKNGPSSGAPPPS
1 28
-----
1 match found in sequence:
aay94031; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94031 check: 9915 from: 1 to: 39

ID AAY94031 standard; peptide; 39 AA.
XX AC AAY94031;
XX DT 20-OCT-2000 (first entry)
XX DE Amino acid sequence of an extendin agonist.
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;

```

```

XX DE Amino acid sequence of an extendin agonist.
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX KW hyperglucagonemia; diabetes.
XX OS Synthetic.
XX OS Heloderma sp.
XX Key Location/Qualifiers
XX Modified-site 23
XX /note= "tertiary-butyl glycine"
XX PN WO200041548-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000942.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Gedulin B;
XX PI WPI; 2000-490999/43.
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX PT extendin or a modified extendin agonist, useful for treating
XX PT hyperglucagonemia and diabetes.
XX PS Disclosure; Fig 3B; 96pp; English.
XX CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX CC are found in the salivary glands of the Gila monster and Mexican Beaded
XX CC lizard, and have sequence similarity to glucagon-like peptides. They are
XX CC used in the method of the invention. The specification describes a method
XX CC for lowering plasma glucagon, comprising administering an extendin, an
XX CC extendin agonist, a modified extendin or a modified extendin agonist. These
XX CC compounds lower plasma glucagon level. The method is useful for lowering
XX CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX CC erythema or glucagonoma. The method is also useful for treating
XX CC hyperglucagonemia and other conditions that would benefit from reduced
XX CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX CC diabetes
XX SQ Sequence 39 AA;

AAY94031 Length: 39 February 4, 2005 13:20 Type: P Check: 9915 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSLSKQLEEEAVRLFVFLKNGPSSGAPPPS
1 28
-----
1 match found in sequence:
aay94032; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94032 check: 9476 from: 1 to: 39

ID AAY94032 standard; peptide; 39 AA.
XX AC AAY94032;
XX DT 20-OCT-2000 (first entry)
XX DE Amino acid sequence of an extendin agonist.
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;

```

```
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 23
FT /note="tertiary-butyl glycine"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
DR
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3B; 96pp; English.
XX
CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC diabetes
XX
SQ Sequence 39 AA;
AAY94032 Length: 39 February 4, 2005 13:20 Type: P Check: 9476 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQLBEEAVRLFKEFLKNGSPSSGAPPPS
1 |-----|
1 match found in sequence:
aay94033 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94033 check: 9546 from: 1 to: 39
ID AAY94033 standard; peptide; 39 AA.
XX
AC AAY94033;
XX
XX 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
```

```
OS Heloderma sp.
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
DR
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3B; 96pp; English.
XX
CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC diabetes
XX
SQ Sequence 39 AA;
AAY94033 Length: 39 February 4, 2005 13:20 Type: P Check: 9546 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQLBEEAVRLFIDWLKNGSPSSGAPPPS
1 |-----|
1 match found in sequence:
aay94034 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94034 check: 9131 from: 1 to: 39
ID AAY94034 standard; peptide; 39 AA.
XX
AC AAY94034;
XX
XX 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
```

```

PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
PS Disclosure; Fig 3B; 96pp; English.
XX
CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
SQ Sequence 39 AA;

AAY94034 Length: 39 February 4, 2005 13:20 Type: P Check: 9131 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFTSLSKQLEEEAVRLFIEFLKNGGPGSSGAPPPS
1 |-----|
28

-----
1 match found in sequence:
aay94035 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94035 check: 706 from: 1 to: 39

ID AAY94035 standard; peptide; 39 AA.
XX
AC AAY94035;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
XX Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 31
FT /note= "thioprolin"
FT Modified-site 36
FT /note= "thioprolin"
FT Modified-site 37
FT /note= "thioprolin"
FT Modified-site 38
FT /note= "thioprolin"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX

PR 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
PS Disclosure; Fig 3B; 96pp; English.
XX
CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
SQ Sequence 39 AA;

AAY94035 Length: 39 February 4, 2005 13:20 Type: P Check: 706 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTFTSLSKQLEEEAVRLFIEFLKNGGSSGAXXS
1 |-----|
28

-----
1 match found in sequence:
aay94036 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94036 check: 458 from: 1 to: 39

ID AAY94036 standard; peptide; 39 AA.
XX
AC AAY94036;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
XX Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 36
FT /note= "thioprolin"
FT Modified-site 37
FT /note= "thioprolin"
FT Modified-site 38
FT /note= "thioprolin"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX

```

```

PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 3B; 96pp; English.
XX
CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC diabetes
XX
SQ Sequence 39 AA;

AAY94036 Length: 39 February 4, 2005 13:20 Type: P Check: 458 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTSLSKQMBEEAVRLFIEWLKNKGSPSSGAXXXS
1 |-----|
28

-----
1 match found in sequence:
aay94037 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94037 check: 706 from: 1 to: 39

ID AAY94037 standard; peptide; 39 AA.
XX
AC AAY94037;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "homoproline"
FT Modified-site 36 /note= "homoproline"
FT Modified-site 37 /note= "homoproline"
FT Modified-site 37 /note= "homoproline"
FT Modified-site 38 /note= "homoproline"
FT Modified-site 38 /note= "homoproline"
XX
PN WO200041548-A2.
XX

PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 3B; 96pp; English.
XX
CC AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
CC are found in the salivary glands of the Gila monster and Mexican Beaded
CC lizard, and have sequence similarity to glucagon-like peptides. They are
CC used in the method of the invention. The specification describes a method
CC for lowering plasma glucagon, comprising administering an extendin, an
CC extendin agonist, a modified extendin or a modified extendin agonist. These
CC compounds lower plasma glucagon level. The method is useful for lowering
CC plasma glucagon in subjects, preferably humans, suffering from necrolytic
CC erythema or glucagonoma. The method is also useful for treating
CC hyperglucagonemia and other conditions that would benefit from reduced
CC glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
CC diabetes
XX
SQ Sequence 39 AA;

AAY94037 Length: 39 February 4, 2005 13:20 Type: P Check: 706 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTSLSKQMBEEAVRLFIEWLKNKGSSGAXXXS
1 |-----|
28

-----
1 match found in sequence:
aay94038 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94038 check: 458 from: 1 to: 39

ID AAY94038 standard; peptide; 39 AA.
XX
AC AAY94038;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 36 /note= "homoproline"
FT Modified-site 37 /note= "homoproline"
FT Modified-site 38 /note= "homoproline"
FT Modified-site 38 /note= "homoproline"
XX
PN WO200041548-A2.
XX

```

```

PD 20-JUL-2000.
XX
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3B; 96pp; English.
XX
XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX are found in the salivary glands of the Gila monster and Mexican Beaded
XX lizard, and have sequence similarity to glucagon-like peptides. They are
XX used in the method of the invention. The specification describes a method
XX for lowering plasma glucagon, comprising administering an extendin, an
XX extendin agonist, a modified extendin or a modified extendin agonist. These
XX compounds lower plasma glucagon level. The method is useful for lowering
XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX erythema or glucagonoma. The method is also useful for treating
XX hyperglucagonemia and other conditions that would benefit from reduced
XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
XX Sequence 39 AA;
SQ
AAY94038 Length: 39 February 4, 2005 13:20 Type: P Check: 458 ..
Found using 'seq4' (mohamed337.key)

1 HCGEFTSLSKQMEEEAVRLFIEFLKNGGPPSGAXXXS
1 28
-----
1 match found in sequence:
aay94039 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94039 check: 267 from: 1 to: 39

ID AAY94039 standard; peptide; 39 AA.
XX
XX AAY94039;
AC
XX
XX 20-OCT-2000 (first entry)
DT
XX
XX Amino acid sequence of an extendin agonist.
DE
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS
XX Heloderma sp.
XX
XX Key Location/Qualifiers
FH Modified-site 31 /note= "thioprolin"
FT Modified-site 36 /note= "thioprolin"
FT Modified-site 37 /note= "thioprolin"
FT Modified-site 38 /note= "thioprolin"
FT
XX

```

```

PN WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC..
XX
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3B; 96pp; English.
XX
XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX are found in the salivary glands of the Gila monster and Mexican Beaded
XX lizard, and have sequence similarity to glucagon-like peptides. They are
XX used in the method of the invention. The specification describes a method
XX for lowering plasma glucagon, comprising administering an extendin, an
XX extendin agonist, a modified extendin or a modified extendin agonist. These
XX compounds lower plasma glucagon level. The method is useful for lowering
XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX erythema or glucagonoma. The method is also useful for treating
XX hyperglucagonemia and other conditions that would benefit from reduced
XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
XX Sequence 39 AA;
SQ
AAY94039 Length: 39 February 4, 2005 13:20 Type: P Check: 267 ..
Found using 'seq4' (mohamed337.key)

1 HCGEFTSLSKQLEEEAVRLFIEFLKNGGSSGAXXXS
1 28
-----
1 match found in sequence:
aay94040 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94040 check: 267 from: 1 to: 39

ID AAY94040 standard; peptide; 39 AA.
XX
XX AAY94040;
AC
XX
XX 20-OCT-2000 (first entry)
DT
XX
XX Amino acid sequence of an extendin agonist.
DE
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS
XX Heloderma sp.
XX
XX Key Location/Qualifiers
FH Modified-site 31 /note= "homoprolin"
FT Modified-site 36 /note= "homoprolin"
FT Modified-site 37 /note= "homoprolin"
FT Modified-site 38 /note= "homoprolin"
FT
XX

```

```

FT XX /note= "homoproline"
PN XX WO200041548-A2.
XX XX 20-JUL-2000.
XX XX
XX XX 14-JAN-2000; 2000WO-US000942.
XX XX 14-JAN-1999; 99US-0116380P.
XX XX 30-APR-1999; 99US-0132017P.
XX XX 10-JAN-2000; 2000US-0175365P.
XX XX (AMYL-) AMYLIN PHARM INC.
XX XX
XX XX Young A, Gedulin B;
XX XX WPI; 2000-490999/43.
XX XX
XX XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX XX extendin or a modified extendin agonist, useful for treating
XX XX hyperglucagonemia and diabetes.
XX XX Disclosure; Fig 3B; 96pp; English.
XX XX
XX XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX XX are found in the salivary glands of the Gila monster and Mexican Beaded
XX XX lizard, and have sequence similarity to glucagon-like peptides. They are
XX XX used in the method of the invention. The specification describes a method
XX XX for lowering plasma glucagon, comprising administering an extendin, an
XX XX extendin agonist, a modified extendin or a modified extendin agonist. These
XX XX compounds lower plasma glucagon level. The method is useful for lowering
XX XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX XX erythema or glucagonoma. The method is also useful for treating
XX XX hyperglucagonemia and other conditions that would benefit from reduced
XX XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX XX diabetes
XX XX Sequence 39 AA;
XX XX
XX XX AAY94040 Length: 39 February 4, 2005 13:20 Type: P Check: 267 ..
XX XX Found using 'seq4' (mohamed337.key)
XX XX
1 HGEFTSLSKQLEEEAVRLFIEFLKNGXSGAXXXS
1 1
-----
1 match found in sequence:
aay94041 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94041 check: 706 from: 1 to: 39
ID AAY94041 standard; peptide; 39 AA.
XX XX
XX XX AAY94041;
XX XX
XX XX 20-OCT-2000 (first entry)
XX XX
XX XX Amino acid sequence of an extendin agonist.
XX XX
XX XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX XX hyperglucagonemia; diabetes.
XX XX
XX XX Synthetic.
XX XX Heloderma sp.
XX XX
XX XX Key Location/Qualifiers
XX XX Modified-site 31 /note= "N-methylalanine"
XX XX
XX XX FT Modified-site 36 /note= "N-methylalanine"
XX XX
XX XX FT Modified-site 37
XX XX

```

```

FT XX /note= "N-methylalanine"
FT XX 38
FT XX /note= "N-methylalanine"
XX XX
XX XX WO200041548-A2.
XX XX
XX XX 20-JUL-2000.
XX XX
XX XX 14-JAN-2000; 2000WO-US000942.
XX XX 14-JAN-1999; 99US-0116380P.
XX XX 30-APR-1999; 99US-0132017P.
XX XX 10-JAN-2000; 2000US-0175365P.
XX XX (AMYL-) AMYLIN PHARM INC.
XX XX
XX XX Young A, Gedulin B;
XX XX WPI; 2000-490999/43.
XX XX
XX XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX XX extendin or a modified extendin agonist, useful for treating
XX XX hyperglucagonemia and diabetes.
XX XX Disclosure; Fig 3B; 96pp; English.
XX XX
XX XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX XX are found in the salivary glands of the Gila monster and Mexican Beaded
XX XX lizard, and have sequence similarity to glucagon-like peptides. They are
XX XX used in the method of the invention. The specification describes a method
XX XX for lowering plasma glucagon, comprising administering an extendin, an
XX XX extendin agonist, a modified extendin or a modified extendin agonist. These
XX XX compounds lower plasma glucagon level. The method is useful for lowering
XX XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX XX erythema or glucagonoma. The method is also useful for treating
XX XX hyperglucagonemia and other conditions that would benefit from reduced
XX XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX XX diabetes
XX XX Sequence 39 AA;
XX XX
XX XX AAY94041 Length: 39 February 4, 2005 13:20 Type: P Check: 706 ..
XX XX Found using 'seq4' (mohamed337.key)
XX XX
1 HGEFTSLSKQLEEEAVRLFIEFLKNGXSGAXXXS
1 1
-----
1 match found in sequence:
aay94042 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94042 check: 458 from: 1 to: 39
ID AAY94042 standard; peptide; 39 AA.
XX XX
XX XX AAY94042;
XX XX
XX XX 20-OCT-2000 (first entry)
XX XX
XX XX Amino acid sequence of an extendin agonist.
XX XX
XX XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX XX hyperglucagonemia; diabetes.
XX XX
XX XX Synthetic.
XX XX Heloderma sp.
XX XX
XX XX Key Location/Qualifiers
XX XX Modified-site 36 /note= "N-methylalanine"
XX XX
XX XX FT Modified-site 37
XX XX

```

```

FT Modified-site /note= "N-methylalanine"
FT 38
FT /note= "N-methylalanine"
XX 38
XX /note= "N-methylalanine"
PN WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using exendin, an exendin agonist, a modified
XX exendin or a modified exendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3B; 96pp; English.
XX
XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX are found in the salivary glands of the Gila monster and Mexican Beaded
XX lizard, and have sequence similarity to glucagon-like peptides. They are
XX used in the method of the invention. The specification describes a method
XX for lowering plasma glucagon, comprising administering an extendin, an
XX exendin agonist, a modified exendin or a modified exendin agonist. These
XX compounds lower plasma glucagon level. The method is useful for lowering
XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX erythema or glucagonoma. The method is also useful for treating
XX hyperglucagonemia and other conditions that would benefit from reduced
XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
XX Sequence 39 AA;
XX
AAY94042 Length: 39 February 4, 2005 13:20 Type: P Check: 458 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQMEEEAVRLFIEMKNGSPSSGAXXXS
1 |-----|
1 HGEFTSDLSKQMEEEAVRLFIEMKNGSPSSGAXXXS
28
-----
1 match found in sequence:
aay94043 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94043 check: 267 from: 1 to: 39
ID AAY94043 standard; peptide; 39 AA.
XX
XX AAY94043;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
XX Heloderma sp.
XX
XX Key Location/Qualifiers
XX Modified-site 31
XX /note= "N-methylalanine"
XX Modified-site 36

```

```

FT Modified-site /note= "N-methylalanine"
FT 37
FT /note= "N-methylalanine"
FT 38
FT /note= "N-methylalanine"
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using exendin, an exendin agonist, a modified
XX exendin or a modified exendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 3B; 96pp; English.
XX
XX AAY94013-43 represent extendin agonists, derived from AAY94012. Extendins
XX are found in the salivary glands of the Gila monster and Mexican Beaded
XX lizard, and have sequence similarity to glucagon-like peptides. They are
XX used in the method of the invention. The specification describes a method
XX for lowering plasma glucagon, comprising administering an extendin, an
XX exendin agonist, a modified exendin or a modified exendin agonist. These
XX compounds lower plasma glucagon level. The method is useful for lowering
XX plasma glucagon in subjects, preferably humans, suffering from necrolytic
XX erythema or glucagonoma. The method is also useful for treating
XX hyperglucagonemia and other conditions that would benefit from reduced
XX glucagon levels and/or suppression of glucagon, e.g. type 1 and type 2
XX diabetes
XX
XX Sequence 39 AA;
XX
AAY94043 Length: 39 February 4, 2005 13:20 Type: P Check: 267 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQLEEEAVRLFIEMKNGKSSGAXXXS
1 |-----|
1 HGEFTSDLSKQLEEEAVRLFIEMKNGKSSGAXXXS
28
-----
1 match found in sequence:
aay94044 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94044 check: 4889 from: 1 to: 30
ID AAY94044 standard; peptide; 30 AA.
XX
XX AAY94044;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
XX Heloderma sp.
XX
XX Key Location/Qualifiers
XX Modified-site 30

```

```
FT XX /note= "amidated residue"
PN XX
XX WO200041548-A2.
XX
PD 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 30 AA;
SQ
AAAY94044 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEEEAVRLFIEWLKNGG
1 28
-----
1 match found in sequence:
aay94045 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94045 check: 700 from: 1 to: 28
-----
ID AAY94045 standard; peptide; 28 AA.
XX
XX AAY94045;
AC
XX
XX 20-OCT-2000 (first entry)
DT
XX
XX Amino acid sequence of an extendin agonist.
DE
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "amidated residue"
FT
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 28 AA;
SQ
AAAY94045 Length: 28 February 4, 2005 13:20 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEEEAVRLFIEWLKNG
1 28
-----
1 match found in sequence:
aay94046 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94046 check: 261 from: 1 to: 28
-----
ID AAY94046 standard; peptide; 28 AA.
XX
XX AAY94046;
AC
XX
XX 20-OCT-2000 (first entry)
DT
XX
XX Amino acid sequence of an extendin agonist.
DE
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "amidated residue"
FT
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX
```

```

PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 28 AA;
SQ
AAAY94046 Length: 28 February 4, 2005 13:20 Type: P Check: 261
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTSLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay94047; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94047 check: 249 from: 1 to: 28
ID AAY94047 standard; peptide; 28 AA.
XX
AC AAY94047;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 28 /note= "amidated residue"
FT
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX

```

```

PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 28 AA;
SQ
AAAY94047 Length: 28 February 4, 2005 13:20 Type: P Check: 249
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HAEGTFTSLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aay94048; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94048 check: 166 from: 1 to: 28
ID AAY94048 standard; peptide; 28 AA.
XX
AC AAY94048;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 28 /note= "amidated residue"
FT
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX

```

DR WPI; 2000-490999/43.
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 4A; 96pp; English.
XX
CC The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
SQ Sequence 28 AA;
AAAY94048 Length: 28 February 4, 2005 13:20 Type: P Check: 166 ..
Found using 'seq4' (mohamed337.key)
1 HGEAGTSDLSKQLEEEAVRLFIEFLKN 28
-----|-----
1 match found in sequence:
aay94049 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94049 Check: 231 from: 1 to: 28

ID AAY94049 standard; peptide; 28 AA.
XX
AC AAY94049;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "amidated residue"
FT
XX WO2000041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US0000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating

PT hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 4A; 96pp; English.
XX
CC The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
SQ Sequence 28 AA;
AAAY94049 Length: 28 February 4, 2005 13:20 Type: P Check: 231 ..
Found using 'seq4' (mohamed337.key)
1 HGEAGTSDLSKQLEEEAVRLFIEFLKN 28
-----|-----
1 match found in sequence:
aay94050 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94050 Check: 117 from: 1 to: 28

ID AAY94050 standard; peptide; 28 AA.
XX
AC AAY94050;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28 /note= "amidated residue"
FT
XX WO2000041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US0000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 4A; 96pp; English.
XX

CC The present sequence represents a modified extendin or extendin agonist.
 CC Extending are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX Sequence 28 AA;
 SQ
 AAY94050 Length: 28 February 4, 2005 13:20 Type: P Check: 117 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTADLSKQLEEEAVRLFIEFLKN 28
 |-----|
 1 match found in sequence:
 aay94051 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94051 check: 151 from: 1 to: 28

 ID AAY94051 standard; peptide; 28 AA.
 XX
 AC AAY94051;
 AC
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extending; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.
 FH Key Location/Qualifiers
 FT Modified-site 28
 FT /note= "amidated residue"
 XX
 PN WO200041548-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Gedulin B;
 XX
 DR WPI; 2000-490999/43.
 XX
 PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 PS Disclosure; Fig 4A; 96pp; English.
 XX
 CC The present sequence represents a modified extendin or extendin agonist.
 CC Extending are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification

CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX Sequence 28 AA;
 SQ
 AAY94051 Length: 28 February 4, 2005 13:20 Type: P Check: 151 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTDASKQLEEEAVRLFIEFLKN 28
 |-----|
 1 match found in sequence:
 aay94052 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94052 check: 63 from: 1 to: 28

 ID AAY94052 standard; peptide; 28 AA.
 XX
 AC AAY94052;
 AC
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extending; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.
 FH Key Location/Qualifiers
 FT Modified-site 28
 FT /note= "amidated residue"
 XX
 PN WO200041548-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Gedulin B;
 XX
 DR WPI; 2000-490999/43.
 XX
 PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 PS Disclosure; Fig 4A; 96pp; English.
 XX
 CC The present sequence represents a modified extendin or extendin agonist.
 CC Extending are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX Sequence 28 AA;
 SQ

CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX
 SQ Sequence 28 AA;

AAV94052 Length: 28 February 4, 2005 13:20 Type: P Check: 63 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLAQLLEEAVRLFIEFLKN
 1 28

 1 match found in sequence:
 aay94053 ; Amino acid sequence of an extendin agonist.
 (from "seqtags.pep")
 TOIG of: aay94053 check: 141 from: 1 to: 28

ID AAY94053 standard; peptide; 28 AA.
 XX
 AC AAY94053;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 28 /note= "amidated residue"
 FT
 XX
 PN WO200041548-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Gedulin B;
 XX
 DR WPI; 2000-490999/43.
 XX

Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.

PS Disclosure; Fig 4A; 96pp; English.

XX The present sequence represents a modified extendin or extendin agonist.
 CC Extendins are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes

XX Sequence 28 AA;
 SQ

AAV94053 Length: 28 February 4, 2005 13:20 Type: P Check: 141 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLAQLLEEAVRLFIEFLKN
 1 28

 1 match found in sequence:
 aay94054 ; Amino acid sequence of an extendin agonist.
 (from "seqtags.pep")
 TOIG of: aay94054 check: 53 from: 1 to: 28

ID AAY94054 standard; peptide; 28 AA.
 XX
 AC AAY94054;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 28 /note= "amidated residue"
 FT
 XX
 PN WO200041548-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Gedulin B;
 XX
 DR WPI; 2000-490999/43.
 XX

Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.

PS Disclosure; Fig 4A; 96pp; English.

XX The present sequence represents a modified extendin or extendin agonist.
 CC Extendins are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes

XX Sequence 28 AA;
 SQ

AAV94054 Length: 28 February 4, 2005 13:20 Type: P Check: 53 ..

```
Found using 'seq4' (mohamed337.key)
-----|-----
1 HEGTFTSDLSKALEEAVRLFIEFLKN 28
1
-----|-----
1 match found in sequence:
aay94055 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94055 check: 107 from: 1 to: 28

ID AAY94055 standard; peptide; 28 AA.
XX
XX AC AAY94055;
XX
XX DT 20-OCT-2000 (first entry)
XX
XX DE Amino acid sequence of an extendin agonist.
XX
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "amidated residue"
XX
XX PN WO200041548-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000942.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, Gedulin B;
XX
XX DR WPI; 2000-490999/43.
XX
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX PS Disclosure; Fig 4A; 96pp; English.
XX
XX CC The present sequence represents a modified extendin or extendin agonist.
XX CC Extendins are found in the salivary glands of the Gila monster and
XX CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX CC peptides. They are used in the method of the invention. The specification
XX CC describes a method for lowering plasma glucagon, comprising administering
XX CC an extendin, an extendin agonist, a modified extendin or a modified extendin
XX CC agonist. These compounds lower plasma glucagon level. The method is
XX CC useful for lowering plasma glucagon in subjects, preferably humans,
XX CC suffering from necrolytic erythema or glucagonoma. The method is also
XX CC useful for treating hyperglucagonemia and other conditions that would
XX CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX CC type 1 and type 2 diabetes
XX
XX SQ Sequence 28 AA;
AAY94055 Length: 28 February 4, 2005 13:20 Type: P Check: 107 ..
Found using 'seq4' (mohamed337.key)
-----|-----
1 HEGTFTSDLSKALEEAVRLFIEFLKN 28
1
-----|-----
1 match found in sequence:
aay94055 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94055 check: 107 from: 1 to: 28

ID AAY94055 standard; peptide; 28 AA.
XX
XX AC AAY94055;
XX
XX DT 20-OCT-2000 (first entry)
XX
XX DE Amino acid sequence of an extendin agonist.
XX
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "amidated residue"
XX
XX PN WO200041548-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000942.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, Gedulin B;
XX
XX DR WPI; 2000-490999/43.
XX
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX PS Disclosure; Fig 4A; 96pp; English.
XX
XX CC The present sequence represents a modified extendin or extendin agonist.
XX CC Extendins are found in the salivary glands of the Gila monster and
XX CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX CC peptides. They are used in the method of the invention. The specification
XX CC describes a method for lowering plasma glucagon, comprising administering
XX CC an extendin, an extendin agonist, a modified extendin or a modified extendin
XX CC agonist. These compounds lower plasma glucagon level. The method is
XX CC useful for lowering plasma glucagon in subjects, preferably humans,
XX CC suffering from necrolytic erythema or glucagonoma. The method is also
XX CC useful for treating hyperglucagonemia and other conditions that would
XX CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX CC type 1 and type 2 diabetes
XX
XX SQ Sequence 28 AA;
AAY94055 Length: 28 February 4, 2005 13:20 Type: P Check: 107 ..
Found using 'seq4' (mohamed337.key)
-----|-----
1 HEGTFTSDLSKALEEAVRLFIEFLKN 28
1
-----|-----
1 match found in sequence:
aay94056 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94056 check: 201 from: 1 to: 28

ID AAY94056 standard; peptide; 28 AA.
XX
XX AC AAY94056;
XX
XX DT 20-OCT-2000 (first entry)
XX
XX DE Amino acid sequence of an extendin agonist.
XX
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "amidated residue"
XX
XX PN WO200041548-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000942.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, Gedulin B;
XX
XX DR WPI; 2000-490999/43.
XX
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX PS Disclosure; Fig 4A; 96pp; English.
XX
XX CC The present sequence represents a modified extendin or extendin agonist.
XX CC Extendins are found in the salivary glands of the Gila monster and
XX CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX CC peptides. They are used in the method of the invention. The specification
XX CC describes a method for lowering plasma glucagon, comprising administering
XX CC an extendin, an extendin agonist, a modified extendin or a modified extendin
XX CC agonist. These compounds lower plasma glucagon level. The method is
XX CC useful for lowering plasma glucagon in subjects, preferably humans,
XX CC suffering from necrolytic erythema or glucagonoma. The method is also
XX CC useful for treating hyperglucagonemia and other conditions that would
XX CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX CC type 1 and type 2 diabetes
XX
XX SQ Sequence 28 AA;
AAY94056 Length: 28 February 4, 2005 13:20 Type: P Check: 201 ..
Found using 'seq4' (mohamed337.key)
-----|-----
1 HEGTFTSDLSKALEEAVRLFIEFLKN 28
1
-----|-----
1 match found in sequence:
aay94056 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94056 check: 201 from: 1 to: 28

ID AAY94056 standard; peptide; 28 AA.
XX
XX AC AAY94056;
XX
XX DT 20-OCT-2000 (first entry)
XX
XX DE Amino acid sequence of an extendin agonist.
XX
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 28
XX FT /note= "amidated residue"
XX
XX PN WO200041548-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000942.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, Gedulin B;
XX
XX DR WPI; 2000-490999/43.
XX
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX PS Disclosure; Fig 4A; 96pp; English.
XX
XX CC The present sequence represents a modified extendin or extendin agonist.
XX CC Extendins are found in the salivary glands of the Gila monster and
XX CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX CC peptides. They are used in the method of the invention. The specification
XX CC describes a method for lowering plasma glucagon, comprising administering
XX CC an extendin, an extendin agonist, a modified extendin or a modified extendin
XX CC agonist. These compounds lower plasma glucagon level. The method is
XX CC useful for lowering plasma glucagon in subjects, preferably humans,
XX CC suffering from necrolytic erythema or glucagonoma. The method is also
XX CC useful for treating hyperglucagonemia and other conditions that would
XX CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX CC type 1 and type 2 diabetes
XX
XX SQ Sequence 28 AA;
AAY94056 Length: 28 February 4, 2005 13:20 Type: P Check: 201 ..
Found using 'seq4' (mohamed337.key)
-----|-----
1 HEGTFTSDLSKALEEAVRLFIEFLKN 28
1
-----|-----
1 match found in sequence:
```

aay94057 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94057 check: 197 from: 1 to: 28

ID AAY94057 standard; peptide; 28 AA.

XX AAY94057;

DT 20-OCT-2000 (first entry)

DE Amino acid sequence of an extendin agonist.

XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;

KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;

KW hyperglucagonemia; diabetes.

XX Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

FH Modified-site 28

FT /note= "amidated residue"

XX WO200041548-A2.

PD 20-JUL-2000.

PF 14-JAN-2000; 2000WO-US000942.

PR 14-JAN-1999; 99US-0116380P.

PR 30-APR-1999; 99US-0132017P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, Gedulin B;

PI WPI; 2000-490999/43.

DR Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.

XX Disclosure; Fig 4A; 96pp; English.

CC The present sequence represents a modified extendin or extendin agonist.
CC Extensins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes

XX Sequence 28 AA;

AAY94057 Length: 28 February 4, 2005 13:20 Type: P Check: 197 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSLSKQLEAAVRLPIEFLEKN 28
1

1 match found in sequence:

aay94058 ; Amino acid sequence of an extendin agonist.

(from "seq4ags.pep")

TOIG of: aay94058 check: 193 from: 1 to: 28

ID AAY94058 standard; peptide; 28 AA.

XX AAY94058;

DT 20-OCT-2000 (first entry)

DE Amino acid sequence of an extendin agonist.

XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;

KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;

KW hyperglucagonemia; diabetes.

XX Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

FH Modified-site 28

FT /note= "amidated residue"

XX WO200041548-A2.

PD 20-JUL-2000.

PF 14-JAN-2000; 2000WO-US000942.

PR 14-JAN-1999; 99US-0116380P.

PR 30-APR-1999; 99US-0132017P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, Gedulin B;

PI WPI; 2000-490999/43.

DR Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.

XX Disclosure; Fig 4A; 96pp; English.

CC The present sequence represents a modified extendin or extendin agonist.
CC Extensins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes

XX Sequence 28 AA;

AAY94058 Length: 28 February 4, 2005 13:20 Type: P Check: 193 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSLSKQLEAAVRLPIEFLEKN 28
1

1 match found in sequence:

aay94059 ; Amino acid sequence of an extendin agonist.

(from "seq4ags.pep")

TOIG of: aay94059 check: 9862 from: 1 to: 28

ID AAY94059 standard; peptide; 28 AA.

XX AAY94059;

XX

```

DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "amidated residue"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 4A; 96pp; English.
XX
CC The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
SQ Sequence 28 AA;

AAY94059 Length: 28 February 4, 2005 13:20 Type: P Check: 9862
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAARLFIEFLKN 28
-----
1 match found in sequence:
aay94060 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94060 check: 9921 from: 1 to: 28

ID AAY94060 standard; peptide; 28 AA.
XX
AC AAY94060;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "amidated residue"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 4A; 96pp; English.
XX
CC The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
SQ Sequence 28 AA;

AAY94060 Length: 28 February 4, 2005 13:20 Type: P Check: 9921
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEEEAARLFIEFLKN 28
-----
1 match found in sequence:
aay94061 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94061 check: 30 from: 1 to: 28

ID AAY94061 standard; peptide; 28 AA.
XX
AC AAY94061;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "amidated residue"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 4A; 96pp; English.
XX
CC The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
SQ Sequence 28 AA;

AAY94060 Length: 28 February 4, 2005 13:20 Type: P Check: 9921
Found using 'seq4' (mohamed337.key)

```

```

OS Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 28
FT /note= "amidated residue"
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for treating hyperglucagonemia and other conditions that would
XX benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
XX Sequence 28 AA;
XX
AA94061 Length: 28 February 4, 2005 13:20 Type: P Check: 30 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQLSEEAARVAFIEFLKN 28
1
-----
1 match found in sequence:
aay94062 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94062 check: 165 from: 1 to: 28
-----
ID AAY94062 standard; peptide; 28 AA.
XX
XX AC AAY94062;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
XX Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 28
FT /note= "amidated residue"
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX useful for treating hyperglucagonemia and other conditions that would
XX benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
XX Sequence 28 AA;
XX
AA94062 Length: 28 February 4, 2005 13:20 Type: P Check: 165 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQLSEEAARVAFIEFLKN 28
1
-----
1 match found in sequence:
aay94063 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94063 check: 136 from: 1 to: 28
-----
ID AAY94063 standard; peptide; 28 AA.
XX
XX AC AAY94063;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
XX Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 28
FT /note= "amidated residue"
XX
XX WO200041548-A2.
XX

```

```

XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000942.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Gedulin B;
XX PI WPI; 2000-490999/43.
XX PT Lowering plasma glucagon using exendin, an exendin agonist, a modified
XX PT exendin or a modified exendin agonist, useful for treating
XX PT hyperglucagonemia and diabetes.
XX PS Disclosure; Fig 4A; 96pp; English.
XX CC The present sequence represents a modified exendin or exendin agonist.
XX CC Extensins are found in the salivary glands of the Gila monster and
XX CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX CC peptides. They are used in the method of the invention. The specification
XX CC describes a method for lowering plasma glucagon, comprising administering
XX CC an exendin, an exendin agonist, a modified exendin or a modified exendin
XX CC agonist. These compounds lower plasma glucagon level. The method is
XX CC useful for lowering plasma glucagon in subjects, preferably humans,
XX CC suffering from necrolytic erythema or glucagonoma. The method is also
XX CC useful for treating hyperglucagonemia and other conditions that would
XX CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX CC type 1 and type 2 diabetes
XX SQ Sequence 28 AA;
AAAY94063 Length: 28 February 4, 2005 13:20 Type: P Check: 136 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQLEEEAVRLFIEALKN 28
-----|
1 match found in sequence:
aay94064; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94064 check: 9975 from: 1 to: 28
-----
ID AAY94064 standard; peptide; 28 AA.
XX AC AAY94064;
XX DT 20-OCT-2000 (first entry)
XX DE Amino acid sequence of an extendin agonist.
XX KW Extending; Gila monster lizard; Mexican Beaded lizard; agonist;
XX KW Glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX KW hyperglucagonemia; diabetes.
XX OS Synthetic.
XX OS Heloderma sp.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "amidated residue"
XX FT FT
XX PN WO200041548-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000942.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.

```

```

XX PD 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Gedulin B;
XX PI WPI; 2000-490999/43.
XX PT Lowering plasma glucagon using exendin, an exendin agonist, a modified
XX PT exendin or a modified exendin agonist, useful for treating
XX PT hyperglucagonemia and diabetes.
XX PS Disclosure; Fig 4A; 96pp; English.
XX CC The present sequence represents a modified exendin or exendin agonist.
XX CC Extensins are found in the salivary glands of the Gila monster and
XX CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX CC peptides. They are used in the method of the invention. The specification
XX CC describes a method for lowering plasma glucagon, comprising administering
XX CC an exendin, an exendin agonist, a modified exendin or a modified exendin
XX CC agonist. These compounds lower plasma glucagon level. The method is
XX CC useful for lowering plasma glucagon in subjects, preferably humans,
XX CC suffering from necrolytic erythema or glucagonoma. The method is also
XX CC useful for treating hyperglucagonemia and other conditions that would
XX CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX CC type 1 and type 2 diabetes
XX SQ Sequence 28 AA;
AAAY94064 Length: 28 February 4, 2005 13:20 Type: P Check: 9975 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQLEEEAVRLFIEAFKN 28
-----|
1 match found in sequence:
aay94065; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94065 check: 9991 from: 1 to: 28
-----
ID AAY94065 standard; peptide; 28 AA.
XX AC AAY94065;
XX DT 20-OCT-2000 (first entry)
XX DE Amino acid sequence of an extendin agonist.
XX KW Extending; Gila monster lizard; Mexican Beaded lizard; agonist;
XX KW Glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX KW hyperglucagonemia; diabetes.
XX OS Synthetic.
XX OS Heloderma sp.
XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "amidated residue"
XX FT FT
XX PN WO200041548-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000942.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.

```

```
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX useful for treating hyperglucagonemia and other conditions that would
XX benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
XX Sequence 28 AA;
XX
XX AAY94065 Length: 28 February 4, 2005 13:20 Type: P Check: 9991
XX Found using 'seq4' (mohamed337.key)
1 -----|
1 HGEFTFTSLSKQLEEEAVRLFIEFLAN 28
-----|
1 match found in sequence:
aay94066 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94066 check: 9897 from: 1 to: 28
-----|
ID AAY94066 standard; peptide; 28 AA.
XX
XX AAY94066;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
XX Heloderma sp.
XX
XX Key Location/Qualifiers
XX Modified-site 28 /note= "amidated residue"
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX useful for treating hyperglucagonemia and other conditions that would
XX benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
XX Sequence 28 AA;
XX
XX AAY94066 Length: 28 February 4, 2005 13:20 Type: P Check: 9897
XX Found using 'seq4' (mohamed337.key)
```

```
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX useful for treating hyperglucagonemia and other conditions that would
XX benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
XX Sequence 28 AA;
XX
XX AAY94066 Length: 28 February 4, 2005 13:20 Type: P Check: 9897
XX Found using 'seq4' (mohamed337.key)
1 -----|
1 HGEFTFTSLSKQLEEEAVRLFIEFLKA 28
-----|
1 match found in sequence:
aay94067 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94067 check: 6333 from: 1 to: 38
-----|
ID AAY94067 standard; peptide; 38 AA.
XX
XX AAY94067;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX Synthetic.
XX Heloderma sp.
XX
XX Key Location/Qualifiers
XX Modified-site 38 /note= "amidated residue"
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
```

PT extendin or a modified extendin agonist, useful for treating
 XX hyperglucagonemia and diabetes.
 PS Disclosure; Fig 4A; 96pp; English.
 CC The present sequence represents a modified extendin or extendin agonist.
 CC Extendins are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX Sequence 38 AA;
 SQ
 AAY94067 Length: 38 February 4, 2005 13:20 Type: P Check: 6333 ..
 Found using 'seq4' (mohamed337.key)

1 HGGFTFTDLSKQEEAVRLFIEFLKNGGPPSSGAPPP
 28

 1 match found in sequence:
 aay94068 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94068 check: 5894 from: 1 to: 38

ID AAY94068 standard; peptide; 38 AA.
 XX
 AC AAY94068;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 38
 FT /note= "amidated residue"
 XX
 PN WO200041548-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Gedulin B;
 XX
 DR WPI; 2000-490999/43.
 XX
 PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 PS Disclosure; Fig 4A; 96pp; English.

XX The present sequence represents a modified extendin or extendin agonist.
 CC Extendins are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX Sequence 38 AA;
 SQ
 AAY94068 Length: 38 February 4, 2005 13:20 Type: P Check: 5894 ..
 Found using 'seq4' (mohamed337.key)

1 HGGFTFTDLSKQEEAVRLFIEFLKNGGPPSSGAPPP
 28

 1 match found in sequence:
 aay94069 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94069 check: 3293 from: 1 to: 37

ID AAY94069 standard; peptide; 37 AA.
 XX
 AC AAY94069;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 37
 FT /note= "amidated residue"
 XX
 PN WO200041548-A2.
 XX
 PD 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young A, Gedulin B;
 XX
 DR WPI; 2000-490999/43.
 XX
 PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 PS Disclosure; Fig 4A; 96pp; English.
 XX
 CC The present sequence represents a modified extendin or extendin agonist.
 CC Extendins are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like

CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX
 SQ Sequence 37 AA;

AAAY94069 Length: 37 February 4, 2005 13:20 Type: P Check: 3293 ..
 Found using 'seq4' (mohamed337.key)

1 HGGFTTSDLSKQMBEEAVRLFIEFLKNGCPSSGAPP
 28

 1 match found in sequence:
 aay94070 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94070 check: 2854 from: 1 to: 37

ID AAY94070 standard; peptide; 37 AA.
 XX
 AC AAY94070;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.

OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 37 /note= "amidated residue"
 FT

XX WO200041548-A2.
 XX 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US0000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX

PA (AMYL-) AMYLIN PHARM INC.

XX Young A, Gedulin B;
 XX WPI; 2000-490999/43.
 XX

PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.

XX Disclosure; Fig 4A; 96pp; English.

CC The present sequence represents a modified extendin or extendin agonist.
 CC Extending are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes

CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX
 SQ Sequence 37 AA;

AAAY94070 Length: 37 February 4, 2005 13:20 Type: P Check: 2854 ..
 Found using 'seq4' (mohamed337.key)

1 HGGFTTSDLSKQMBEEAVRLFIEFLKNGCPSSGAPP
 28

 1 match found in sequence:
 aay94071 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94071 check: 333 from: 1 to: 36

ID AAY94071 standard; peptide; 36 AA.
 XX
 AC AAY94071;
 XX
 DT 20-OCT-2000 (first entry)
 XX
 DE Amino acid sequence of an extendin agonist.
 XX
 KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.

OS Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 36 /note= "amidated residue"
 FT

XX WO200041548-A2.
 XX 20-JUL-2000.
 XX
 PF 14-JAN-2000; 2000WO-US0000942.
 XX
 PR 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX

PA (AMYL-) AMYLIN PHARM INC.

XX Young A, Gedulin B;
 XX WPI; 2000-490999/43.
 XX

PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.

XX Disclosure; Fig 4A; 96pp; English.

CC The present sequence represents a modified extendin or extendin agonist.
 CC Extending are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes

CC type 1 and type 2 diabetes
XX Sequence 36 AA;
SQ

AA94071 Length: 36 February 4, 2005 13:20 Type: P Check: 333 ..
Found using 'seq4' (mohamed337.key)

1 HEGTFTSLSKQEEAVRLFIEWLKNGPSSGAP
28
-----|

1 match found in sequence:
aay94072 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94072 check: 9894 from: 1 to: 36

ID AAY94072 standard; peptide; 36 AA.
XX
AC AAY94072;
XX
XX 20-OCT-2000 (first entry)
DE
XX Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 36 /note= "amidated residue"
XX
XX WO200041548-A2.
PN
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, Gedulin B;
PI
XX WPI; 2000-490999/43.
DR
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 36 AA;
SQ

AA94072 Length: 36 February 4, 2005 13:20 Type: P Check: 9894 ..
Found using 'seq4' (mohamed337.key)

1 HEGTFTSLSKQEEAVRLFIEFLKNGPSSGAP
28
-----|

1 match found in sequence:
aay94073 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94073 check: 7453 from: 1 to: 35

ID AAY94073 standard; peptide; 35 AA.
XX
AC AAY94073;
XX
XX 20-OCT-2000 (first entry)
DE
XX Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 35 /note= "amidated residue"
XX
XX WO200041548-A2.
PN
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, Gedulin B;
PI
XX WPI; 2000-490999/43.
DR
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 35 AA;
SQ

AA94073 Length: 35 February 4, 2005 13:20 Type: P Check: 7453 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTTSDLSKQMBEEAVRLFIEFLKNGGPSSGA
28

1 match found in sequence:
aay94074 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94074 check: 7014 from: 1 to: 35

ID AAY94074 standard; peptide; 35 AA.
XX
AC AAY94074;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 35 /note= "amidated residue"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 4A; 96pp; English.
XX
CC The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
SQ Sequence 35 AA;

AAY94074 Length: 35 February 4, 2005 13:20 Type: P Check: 7014 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTTSDLSKQMBEEAVRLFIEFLKNGGPSSGA
28

1 match found in sequence:
aay94075 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94075 check: 5178 from: 1 to: 34

ID AAY94075 standard; peptide; 34 AA.
XX
AC AAY94075;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 34 /note= "amidated residue"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
PS Disclosure; Fig 4A; 96pp; English.
XX
CC The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
SQ Sequence 34 AA;

AAY94075 Length: 34 February 4, 2005 13:20 Type: P Check: 5178 ..
Found using 'seq4' (mohamed337.key)

1 HEGGTTSDLSKQMBEEAVRLFIEFLKNGGPSSG
28

1 match found in sequence:
aay94076 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94076 check: 4739 from: 1 to: 34

```

ID AAY94076 standard; peptide; 34 AA.
AC AAY94076;
XX
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 34 /note= "amidated residue"
FT
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extending are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 34 AA;
SQ
AAY94076 Length: 34 February 4, 2005 13:20 Type: P Check: 4739 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQLEBAVRLFIETLKNKGPPSS
1 28
-----
1 match found in sequence:
aay94077 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94077 check: 2764 from: 1 to: 33

ID AAY94077 standard; peptide; 33 AA.
XX
XX AAY94077;

```

```

XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 33 /note= "amidated residue"
FT
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extending are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 33 AA;
SQ
AAY94077 Length: 33 February 4, 2005 13:20 Type: P Check: 2764 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTDLSKQMBEAVRLFIETLKNKGPPSS
1 28
-----
1 match found in sequence:
aay94078 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94078 check: 2325 from: 1 to: 33

ID AAY94078 standard; peptide; 33 AA.
XX
XX AAY94078;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.

```

```

XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FH Modified-site 33
FT /note= "amidated residue"
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 33 AA;
SQ
AAY94078 Length: 33 February 4, 2005 13:20 Type: P Check: 2325 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQLEBEAVRLFIEPLKNGPSS
  1 28
-----
1 match found in sequence:
aay94079 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94079 check: 25 from: 1 to: 32

ID AAY94079 standard; peptide; 32 AA.
XX
AC AAY94079;
XX
XX 20-OCT-2000 (first entry)
DT
DE Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.

```

```

XX Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FH Modified-site 32
FT /note= "amidated residue"
XX
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4A; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 32 AA;
SQ
AAY94079 Length: 32 February 4, 2005 13:20 Type: P Check: 25 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEEAVRLFIEWLKNGGPPS
  1 28
-----
1 match found in sequence:
aay94080 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94080 check: 9586 from: 1 to: 32

ID AAY94080 standard; peptide; 32 AA.
XX
AC AAY94080;
XX
XX 20-OCT-2000 (first entry)
DT
DE Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS Heloderma sp.
XX

```



```

PF 14-JAN-2000; 2000WO-US000942.
PR 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
PA Young A, Gedulin B;
XX WPI; 2000-490999/43.
PI Lowering plasma glucagon using exendin, an exendin agonist, a modified
XX extendin or a modified exendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX Disclosure; Fig 4A; 96pp; English.
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an exendin, an exendin agonist, a modified exendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX Sequence 31 AA;
SQ
AAAY94082 Length: 31 February 4, 2005 13:20 Type: P Check: 6930 ..
Found using 'seq4' (mohamed337.key)
1 HEGFTSDLSKQLEEA VRLFI EFLKNGG
1 28
-----
1 match found in sequence:
aay94083 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94083 check: 4450 from: 1 to: 30
ID AAY94083 standard; peptide; 30 AA.
XX AC AAY94083;
XX DT 20-OCT-2000 (first entry)
XX DE Amino acid sequence of an extendin agonist.
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX KW hyperglucagonemia; diabetes.
XX OS Synthetic.
XX OS Heloderma sp.
XX FH Key Location/Qualifiers
XX FT Modified-site 30
XX FT /note= "amidated residue"
XX PN WO200041548-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000942.
XX PD 20-JUL-2000.
XX PR 14-JAN-1999; 99US-0116380P.
XX PF 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX

```

```

PR 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX Lowering plasma glucagon using exendin, an exendin agonist, a modified
PT extendin or a modified exendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX Disclosure; Fig 4A; 96pp; English.
XX The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an exendin, an exendin agonist, a modified exendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX Sequence 30 AA;
SQ
AAAY94083 Length: 30 February 4, 2005 13:20 Type: P Check: 4450 ..
Found using 'seq4' (mohamed337.key)
1 HEGFTSDLSKQLEEA VRLFI EFLKNGG
1 28
-----
1 match found in sequence:
aay94084 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94084 check: 2759 from: 1 to: 29
ID AAY94084 standard; peptide; 29 AA.
XX AC AAY94084;
XX DT 20-OCT-2000 (first entry)
XX DE Amino acid sequence of an extendin agonist.
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX KW hyperglucagonemia; diabetes.
XX OS Synthetic.
XX OS Heloderma sp.
XX FH Key Location/Qualifiers
XX FT Modified-site 29
XX FT /note= "amidated residue"
XX PN WO200041548-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000942.
XX PD 20-JUL-2000.
XX PR 14-JAN-1999; 99US-0116380P.
XX PF 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX

```


DR WPI; 2000-490999/43.
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX Disclosure; Fig 4B; 96pp; English.
XX
CC The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
SQ Sequence 38 AA;
AAAY94086 Length: 38 February 4, 2005 13:20 Type: P Check: 6333 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMEEEAVRLFIEWLKNGPSSGAPPP 28
-----|-----|
1 match found in sequence:
aay94087 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94087 Check: 6333 from: 1 to: 38
ID AAY94087 standard; peptide; 38 AA.
XX
AC AAY94087;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 36 /note= "thioprolin"
FT Modified-site 37 /note= "thioprolin"
FT Modified-site 38 /note= "amidated thioprolin"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX Disclosure; Fig 4B; 96pp; English.
XX
CC The present sequence represents a modified extendin or extendin agonist.
CC Extendins are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
SQ Sequence 38 AA;
AAAY94087 Length: 38 February 4, 2005 13:20 Type: P Check: 6333 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMEEEAVRLFIEWLKNGPSSGAPPP 28
-----|-----|
1 match found in sequence:
aay94088 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94088 Check: 3541 from: 1 to: 37
ID AAY94088 standard; peptide; 37 AA.
XX
AC AAY94088;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 31 /note= "N-methylalanine"
FT Modified-site 37 /note= "amidated residue"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
DR WPI; 2000-490999/43.
XX

PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 PS Disclosure; Fig 4B; 96pp; English.
 XX
 CC The present sequence represents a modified extendin or extendin agonist.
 CC Extendins are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX
 SQ Sequence 37 AA;

AA94088 Length: 37 February 4, 2005 13:20 Type: P Check: 3541 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTSLSKQMEEEAVRLFIEWLKNKGXSSGAPP
 1 28

 1 match found in sequence:
 aay94089 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94089 check: 4125 from: 1 to: 37

ID AAY94089 standard; peptide; 37 AA.
 XX
 AC AAY94089;
 XX
 XX
 DT 20-OCT-2000 (first entry)
 XX
 XX Amino acid sequence of an extendin agonist.
 DE
 XX
 XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 XX Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 31 /note= "N-methylalanine"
 FT Modified-site 36 /note= "N-methylalanine"
 FT Modified-site 37 /note= "amidated N-methylalanine"
 FT
 XX WO200041548-A2.
 PN
 XX
 XX
 PD 20-JUL-2000.
 XX
 XX 14-JAN-2000; 2000WO-US000942.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, Gedulin B;
 PI
 XX WPI; 2000-490999/43.
 DR
 XX

PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 PT extendin or a modified extendin agonist, useful for treating
 PT hyperglucagonemia and diabetes.
 XX
 PS Disclosure; Fig 4B; 96pp; English.
 XX
 CC The present sequence represents a modified extendin or extendin agonist.
 CC Extendins are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes
 XX
 SQ Sequence 37 AA;

AA94089 Length: 37 February 4, 2005 13:20 Type: P Check: 4125 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTSLSKQMEEEAVRLFIEWLKNKGXSSGAXX
 1 28

 1 match found in sequence:
 aay94090 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94090 check: 3293 from: 1 to: 37

ID AAY94090 standard; peptide; 37 AA.
 XX
 AC AAY94090;
 XX
 XX
 DT 20-OCT-2000 (first entry)
 XX
 XX Amino acid sequence of an extendin agonist.
 DE
 XX
 XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.
 XX
 XX Synthetic.
 OS Heloderma sp.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 31 /note= "homoproline"
 FT Modified-site 36 /note= "homoproline"
 FT Modified-site 37 /note= "amidated homoproline"
 FT
 XX WO200041548-A2.
 PN
 XX
 XX
 PD 20-JUL-2000.
 XX
 XX 14-JAN-2000; 2000WO-US000942.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR 30-APR-1999; 99US-0132017P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, Gedulin B;
 PI
 XX WPI; 2000-490999/43.
 DR
 XX

```

PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX
XX Disclosure; Fig 4B; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX useful for treating hyperglucagonemia and other conditions that would
XX benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
XX Sequence 37 AA;
SQ
AAY94090 Length: 37 February 4, 2005 13:20 Type: P Check: 3293 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSLSKQMBEEAVRLFIEWLKNGPSSGAPP
1
-----|-----|
1 match found in sequence:
aay94091 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94091 check: 333 from: 1 to: 36
ID AAY94091 standard; peptide; 36 AA.
XX
XX AC AAY94091;
XX
XX DT 20-OCT-2000 (first entry)
XX
XX DE Amino acid sequence of an extendin agonist.
XX
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX FH Key Location/Qualifiers
FT Modified-site 31
FT Modified-site /note= "homoproline"
FT Modified-site 36
FT /note= "amidated homoproline"
XX
XX PN WO2000041548-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US0000942.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, Gedulin B;
XX
XX DR WPI; 2000-490999/43.
XX
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating

```

```

PT hyperglucagonemia and diabetes.
XX
XX PS Disclosure; Fig 4B; 96pp; English.
XX
XX CC The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX useful for treating hyperglucagonemia and other conditions that would
XX benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
XX Sequence 36 AA;
SQ
AAY94091 Length: 36 February 4, 2005 13:20 Type: P Check: 333 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSLSKQMBEEAVRLFIEWLKNGPSSGAP
1
-----|-----|
1 match found in sequence:
aay94092 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94092 check: 7463 from: 1 to: 35
ID AAY94092 standard; peptide; 35 AA.
XX
XX AC AAY94092;
XX
XX DT 20-OCT-2000 (first entry)
XX
XX DE Amino acid sequence of an extendin agonist.
XX
XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
XX glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
XX
XX OS Synthetic.
XX OS Heloderma sp.
XX
XX PN WO2000041548-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US0000942.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, Gedulin B;
XX
XX DR WPI; 2000-490999/43.
XX
XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX PS Disclosure; Fig 4B; 96pp; English.
XX
XX CC The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification

```


CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes

SQ Sequence 28 AA;

AAy94094 Length: 28 February 4, 2005 13:20 Type: P Check: 369 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTSTSDLSKQLEBAVRLFIETLKN 28
 -----|-----|

1 match found in sequence:
 aay94095 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94095 check: 693 from: 1 to: 28

ID AAY94095 standard; peptide; 28 AA.
 XX AC AAY94095;
 XX AC AAY94095;
 XX DT 20-OCT-2000 (first entry)
 XX DE Amino acid sequence of an extendin agonist.
 XX DE Amino acid sequence of an extendin agonist.
 XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 XX KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 XX KW hyperglucagonemia; diabetes.
 XX OS Synthetic.
 XX OS Heloderma sp.
 XX FH Key Location/Qualifiers
 XX FT Modified-site 28 /note= "amidated residue"
 XX FT
 XX PN WO200041548-A2.
 XX PD 20-JUL-2000.
 XX PF 14-JAN-2000; 2000WO-US000942.
 XX PR 14-JAN-1999; 99US-0116380P.
 XX PR 30-APR-1999; 99US-0132017P.
 XX PR 10-JAN-2000; 2000US-0175365P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Young A, Gedulin B;
 XX PI WPI; 2000-490999/43.
 XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 XX PT extendin or a modified extendin agonist, useful for treating
 XX PT hyperglucagonemia and diabetes.
 XX PS Disclosure; Fig 4B; 96pp; English.
 XX PS

XX The present sequence represents a modified extendin or extendin agonist.
 CC Extendins are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes

SQ Sequence 28 AA;

AAy94095 Length: 28 February 4, 2005 13:20 Type: P Check: 693 ..
 Found using 'seq4' (mohamed337.key)

1 HGGTFSSDLSKQMBEBAVRLFIETLKN 28
 -----|-----|

1 match found in sequence:
 aay94096 ; Amino acid sequence of an extendin agonist.
 (from "seq4ags.pep")
 TOIG of: aay94096 check: 701 from: 1 to: 28

ID AAY94096 standard; peptide; 28 AA.
 XX AC AAY94096;
 XX AC AAY94096;
 XX DT 20-OCT-2000 (first entry)
 XX DE Amino acid sequence of an extendin agonist.
 XX DE Amino acid sequence of an extendin agonist.
 XX KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 XX KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 XX KW hyperglucagonemia; diabetes.
 XX OS Synthetic.
 XX OS Heloderma sp.
 XX FH Key Location/Qualifiers
 XX FT Modified-site 28 /note= "amidated residue"
 XX FT
 XX PN WO200041548-A2.
 XX PD 20-JUL-2000.
 XX PF 14-JAN-2000; 2000WO-US000942.
 XX PR 14-JAN-1999; 99US-0116380P.
 XX PR 30-APR-1999; 99US-0132017P.
 XX PR 10-JAN-2000; 2000US-0175365P.
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX PI Young A, Gedulin B;
 XX PI WPI; 2000-490999/43.
 XX PT Lowering plasma glucagon using extendin, an extendin agonist, a modified
 XX PT extendin or a modified extendin agonist, useful for treating
 XX PT hyperglucagonemia and diabetes.
 XX PS Disclosure; Fig 4B; 96pp; English.
 XX PS

XX The present sequence represents a modified extendin or extendin agonist.
 CC Extendins are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes

SQ Sequence 28 AA;

AAy94096 Length: 28 February 4, 2005 13:20 Type: P Check: 701 ..
 Found using 'seq4' (mohamed337.key)


```
(from "seq4ags.pep")
TOIG of: aay94101 check: 237 from: 1 to: 28
```

```

ID AAY94101 standard; peptide; 28 AA.
XX
AC AAY94101;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "amidated residue"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4B; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
SQ Sequence 28 AA;
AAY94101 Length: 28 February 4, 2005 13:20 Type: P Check: 237 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQLEEEAVRLFIDFLKN
1 28
-----
1 match found in sequence:
aay94102; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94102 check: 2215 from: 1 to: 33
ID AAY94102 standard; peptide; 33 AA.
XX
AC AAY94102;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 33
FT /note= "amidated residue"
XX
PN WO200041548-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000942.
XX
PR 14-JAN-1999; 99US-0116380P.
PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4B; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
SQ Sequence 33 AA;
AAY94102 Length: 33 February 4, 2005 13:20 Type: P Check: 2215 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSDASKQLEEEAVRLFIFLKN
1 28
-----
1 match found in sequence:
aay94103; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94103 check: 2649 from: 1 to: 29
ID AAY94103 standard; peptide; 29 AA.
XX
AC AAY94103;
XX
DT 20-OCT-2000 (first entry)
XX
DE Amino acid sequence of an extendin agonist.
XX

```

```
KW Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX hyperglucagonemia; diabetes.
OS Synthetic.
OS Heloderma sp.
XX
FH Key Location/Qualifiers
FT Modified-site 29 /note= "amidated residue"
FT FT
XX WO200041548-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4B; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX useful for treating hyperglucagonemia and other conditions that would
XX benefit from reduced hyperglucagonemia and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
XX Sequence 29 AA;
SQ
AA94103 Length: 29 February 4, 2005 13:20 Type: P Check: 2649 ..
Found using 'seq4' (mohamed337.key)
1 HEGTFTSDASKQMEEEAVRLFIEWLKNG
1 |-----|
1 HEGTFTSDASKQMEEEAVRLFIEWLKNG 28
-----
1 match found in sequence:
aay94104 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94104 check: 3183 from: 1 to: 37
ID AAY94104 standard; peptide; 37 AA.
XX
XX AAY94104;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
```

```
OS Synthetic.
OS Heloderma sp.
XX
XX Key Location/Qualifiers
FT Modified-site 31 /note= "homoproline"
FT FT
XX 14-JAN-1999; 99US-0116380P.
XX 30-APR-1999; 99US-0132017P.
XX 10-JAN-2000; 2000US-0175365P.
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
XX extendin or a modified extendin agonist, useful for treating
XX hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4B; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
XX Extendins are found in the salivary glands of the Gila monster and
XX Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX peptides. They are used in the method of the invention. The specification
XX describes a method for lowering plasma glucagon, comprising administering
XX an extendin, an extendin agonist, a modified extendin or a modified extendin
XX agonist. These compounds lower plasma glucagon level. The method is
XX useful for lowering plasma glucagon in subjects, preferably humans,
XX suffering from necrolytic erythema or glucagonoma. The method is also
XX useful for treating hyperglucagonemia and other conditions that would
XX benefit from reduced hyperglucagonemia and/or suppression of glucagon, e.g.
XX type 1 and type 2 diabetes
XX
XX Sequence 37 AA;
SQ
AA94104 Length: 37 February 4, 2005 13:20 Type: P Check: 3183 ..
Found using 'seq4' (mohamed337.key)
1 HEGTFTSDASKQMEEEAVRLFIEWLKNGPSSGAPP
1 |-----|
1 HEGTFTSDASKQMEEEAVRLFIEWLKNGPSSGAPP 28
-----
1 match found in sequence:
aay94114 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94114 check: 249 from: 1 to: 28
ID AAY94114 standard; peptide; 28 AA.
XX
XX AAY94114;
XX
XX 20-OCT-2000 (first entry)
XX
XX Amino acid sequence of an extendin agonist.
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
```

KW hyperglucagonemia; diabetes.

XX Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

FT Modified-site 28

FT /note= "amidated residue"

XX WO200041548-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000942.

XX 14-JAN-1999; 99US-0116380P.

XX 30-APR-1999; 99US-0132017P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, Gedulin B;

XX WPI; 2000-490999/43.

XX Lowering plasma glucagon using extendin, an extendin agonist, a modified

PT extendin or a modified extendin agonist, useful for treating

PT hyperglucagonemia and diabetes.

PS Disclosure; Fig 4E; 96pp; English.

XX The present sequence represents a modified extendin or extendin agonist.
 CC Extending are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes

XX Sequence 28 AA;

XX AAY94114 Length: 28 February 4, 2005 13:20 Type: P Check: 249 ..

Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGAGTFTSLSKQLEBEAVRLFIEFLKN 28

1 match found in sequence:

aay94118 ; Amino acid sequence of an extendin agonist.

(from "seq4ags.pep")

TOIG of: aay94118 check: 688 from: 1 to: 28

ID AAY94118 standard; peptide; 28 AA.

XX AAY94118;

XX 20-OCT-2000 (first entry)

XX Amino acid sequence of an extendin agonist.

XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.

XX Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers
 FT Modified-site 28
 FT /note= "amidated residue"

XX WO200041548-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000942.

XX 14-JAN-1999; 99US-0116380P.

XX 30-APR-1999; 99US-0132017P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, Gedulin B;

XX WPI; 2000-490999/43.

XX Lowering plasma glucagon using extendin, an extendin agonist, a modified

PT extendin or a modified extendin agonist, useful for treating

PT hyperglucagonemia and diabetes.

XX Disclosure; Fig 4E; 96pp; English.

XX The present sequence represents a modified extendin or extendin agonist.
 CC Extending are found in the salivary glands of the Gila monster and
 CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
 CC peptides. They are used in the method of the invention. The specification
 CC describes a method for lowering plasma glucagon, comprising administering
 CC an extendin, an extendin agonist, a modified extendin or a modified extendin
 CC agonist. These compounds lower plasma glucagon level. The method is
 CC useful for lowering plasma glucagon in subjects, preferably humans,
 CC suffering from necrolytic erythema or glucagonoma. The method is also
 CC useful for treating hyperglucagonemia and other conditions that would
 CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
 CC type 1 and type 2 diabetes

XX Sequence 28 AA;

XX AAY94118 Length: 28 February 4, 2005 13:20 Type: P Check: 688 ..

Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGAGTFTSLSKQLEBEAVRLFIEFLKN 28

1 match found in sequence:

aay94121 ; Amino acid sequence of an extendin agonist.

(from "seq4ags.pep")

TOIG of: aay94121 check: 590 from: 1 to: 28

ID AAY94121 standard; peptide; 28 AA.

XX AAY94121;

XX 20-OCT-2000 (first entry)

XX Amino acid sequence of an extendin agonist.

XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
 KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
 KW hyperglucagonemia; diabetes.

XX Synthetic.

OS Heloderma sp.

XX Key Location/Qualifiers

FT Modified-site 28

FT /note= "amidated residue"


```

PR 30-APR-1999; 99US-0132017P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, Gedulin B;
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4G; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extending are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 35 AA;
SQ
AAY94186 Length: 35 February 4, 2005 13:20 Type: P Check: 7002 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTDLSKQLEEEAVRLFIEFLKNGPSSGA
1 28
-----
1 match found in sequence:
aay94190 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94190 check: 9574 from: 1 to: 32

ID AAY94190 standard; peptide; 32 AA.
XX
XX AAY94190;
AC
XX
XX 20-OCT-2000 (first entry)
DT
XX
XX Amino acid sequence of an extendin agonist.
DE
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS
XX Heloderma sp.
OS
XX Key Location/Qualifiers
FH Modified-site 32
FT Modified-site /note= "amidated residue"
FT
FT
XX WO2000041548-A2.
PN
XX
XX 20-JUL-2000.
PD
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 30-APR-1999; 99US-0132017P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA

```

```

XX Young A, Gedulin B;
PI
XX
XX WPI; 2000-490999/43.
XX
XX Lowering plasma glucagon using extendin, an extendin agonist, a modified
PT extendin or a modified extendin agonist, useful for treating
PT hyperglucagonemia and diabetes.
XX
XX Disclosure; Fig 4G; 96pp; English.
XX
XX The present sequence represents a modified extendin or extendin agonist.
CC Extending are found in the salivary glands of the Gila monster and
CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
CC peptides. They are used in the method of the invention. The specification
CC describes a method for lowering plasma glucagon, comprising administering
CC an extendin, an extendin agonist, a modified extendin or a modified extendin
CC agonist. These compounds lower plasma glucagon level. The method is
CC useful for lowering plasma glucagon in subjects, preferably humans,
CC suffering from necrolytic erythema or glucagonoma. The method is also
CC useful for treating hyperglucagonemia and other conditions that would
CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
CC type 1 and type 2 diabetes
XX
XX Sequence 32 AA;
SQ
AAY94190 Length: 32 February 4, 2005 13:20 Type: P Check: 9574 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTDLSKQLEEEAVRLFIEFLKNGGPS
1 28
-----
1 match found in sequence:
aay94194 ; Amino acid sequence of an extendin agonist.
(from "seq4ags.pep")
TOIG of: aay94194 check: 6321 from: 1 to: 38

ID AAY94194 standard; peptide; 38 AA.
XX
XX AAY94194;
AC
XX
XX 20-OCT-2000 (first entry)
DT
XX
XX Amino acid sequence of an extendin agonist.
DE
XX
XX Extendin; Gila monster lizard; Mexican Beaded lizard; agonist;
KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
KW hyperglucagonemia; diabetes.
XX
XX Synthetic.
OS
XX Heloderma sp.
OS
XX Key Location/Qualifiers
FH Modified-site 31
FT Modified-site /note= "thioprolin"
FT Modified-site 36
FT Modified-site /note= "thioprolin"
FT Modified-site 37
FT Modified-site /note= "thioprolin"
FT Modified-site 38
FT Modified-site /note= "amidated thioprolin"
XX
XX WO2000041548-A2.
PN
XX
XX 20-JUL-2000.
PD
XX
XX 14-JAN-2000; 2000WO-US000942.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 30-APR-1999; 99US-0132017P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA

```

```

XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Gedulin B;
XX PT WPI; 2000-490999/43.
XX DR Lowering plasma glucagon using exendin, an exendin agonist, a modified
XX PT exendin or a modified exendin agonist, useful for treating
XX PT hyperglucagonemia and diabetes.
XX PS Disclosure; Fig 4G; 96pp; English.
XX CC The present sequence represents a modified exendin or exendin agonist.
XX CC Extending are found in the salivary glands of the Gila monster and
XX CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX CC peptides. They are used in the method of the invention. The specification
XX CC describes a method for lowering plasma glucagon, comprising administering
XX CC an exendin, an exendin agonist, a modified exendin or a modified exendin
XX CC agonist. These compounds lower plasma glucagon level. The method is
XX CC useful for lowering plasma glucagon in subjects, preferably humans,
XX CC suffering from necrolytic erythema or glucagonoma. The method is also
XX CC useful for treating hyperglucagonemia and other conditions that would
XX CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX CC type 1 and type 2 diabetes
XX SQ Sequence 38 AA;
AAAY94194 Length: 38 February 4, 2005 13:20 Type: P Check: 6321 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTSDLSKQMEEEAVRLFIWLKNGSPSGAPP
1 28
-----
1 match found in sequence:
aay94198 ; Amino acid sequence of an exendin agonist.
(from "seq4ags.pep")
TOIG of: aay94198 check: 7441 from: 1 to: 35
ID AAY94198 standard; peptide; 35 AA.
XX AC AAY94198;
XX DT 20-OCT-2000 (first entry)
XX DE Amino acid sequence of an exendin agonist.
XX KW Extending; Gila monster lizard; Mexican Beaded lizard; agonist;
XX KW glucagon-like peptide; plasma glucagon; necrolytic erythema; glucagonoma;
XX KW hyperglucagonemia; diabetes.
XX OS Synthetic.
XX OS Heloderma sp.
XX FH Key Location/Qualifiers
XX FT Modified-site 35 /note= "amidated residue"
XX FT
XX WO2000041548-A2.
XX PN 20-JUL-2000.
XX PD 14-JAN-2000; 2000WO-US0000942.
XX PF 14-JAN-1999; 99US-0116380P.
XX PR 30-APR-1999; 99US-0132017P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, Gedulin B;

```

```

XX DR WPI; 2000-490999/43.
XX PT Lowering plasma glucagon using exendin, an exendin agonist, a modified
XX PT exendin or a modified exendin agonist, useful for treating
XX PT hyperglucagonemia and diabetes.
XX PS Disclosure; Fig 4G; 96pp; English.
XX CC The present sequence represents a modified exendin or exendin agonist.
XX CC Extending are found in the salivary glands of the Gila monster and
XX CC Mexican Beaded lizard, and have sequence similarity to glucagon-like
XX CC peptides. They are used in the method of the invention. The specification
XX CC describes a method for lowering plasma glucagon, comprising administering
XX CC an exendin, an exendin agonist, a modified exendin or a modified exendin
XX CC agonist. These compounds lower plasma glucagon level. The method is
XX CC useful for lowering plasma glucagon in subjects, preferably humans,
XX CC suffering from necrolytic erythema or glucagonoma. The method is also
XX CC useful for treating hyperglucagonemia and other conditions that would
XX CC benefit from reduced glucagon levels and/or suppression of glucagon, e.g.
XX CC type 1 and type 2 diabetes
XX SQ Sequence 35 AA;
AAAY94198 Length: 35 February 4, 2005 13:20 Type: P Check: 7441 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTSDLSKQMEEEAVRLFIWLKNGSPSSGA
1 28
-----
1 match found in sequence:
abb07149 ; Gila monster venom exendin 3 fragment.
(from "seq4ags.pep")
TOIG of: abb07149 check: 9591 from: 1 to: 39
ID ABB07149 standard; peptide; 39 AA.
XX AC ABB07149;
XX DT 13-MAR-2002 (first entry)
XX DE Gila monster venom exendin 3 fragment.
XX KW GLP-1; glucagon-like-peptide-1; growth-hormone releasing factor; GRF;
XX KW parathyroid hormone; PTH; antidiabetic; anorectic; cerebroprotective;
XX KW vasotropic; anti-inflammatory; antiarteriosclerotic; hepatotropic;
XX KW tranquilizer; vulnery; osteopathic; gila monster; exendin.
XX OS Heloderma suspectum.
XX FH Key Location/Qualifiers
XX FT Modified-site 39 /note= "C-terminal amide"
XX FT
XX WO200187322-A2.
XX PN 22-NOV-2001.
XX PD 17-MAY-2001; 2001WO-US015872.
XX PF 17-MAY-2000; 2000US-0205377P.
XX PR 19-MAY-2000; 2000US-0205262P.
XX PR (BION-) BIONEERASKA INC.
XX PA Holmquist B, Dormady DC;
XX PI WPI; 2002-082941/11.
XX DR New peptide formulation for treating disease e.g. diabetes, obesity,
XX PT ischemia comprises peptides, an acid having a specified dissociation

```

PT constant and an excipient.
 XX
 PS Disclosure; Page 10; 34pp; English.
 XX
 CC The invention provides a pharmaceutical composition that comprises a
 CC molecule selected from a glucagon-like-peptide-1 (GLP-1) molecule, growth
 CC -hormone releasing factor (GRF) molecule or a parathyroid hormone (PTH)
 CC molecule. The composition further includes a weak acid such as acetic
 CC acid. The pH of the composition is 3 - 5. The composition can be used for
 CC the treatment of a disease or condition selected from diabetes, excess
 CC appetite, obesity, stroke, ischemia, reperfusion injury, disturbed
 CC glucose metabolism, surgery, coma, shock, gastrointestinal disease,
 CC digestive hormone disease, atherosclerosis, vascular disease, gestational
 CC diabetes, liver disease and cirrhosis, glucocorticoid excess, Cushing's
 CC disease, the presence of activated counter regulatory hormones that occur
 CC after trauma or a disease, hypertriglyceridemia, chronic pancreatitis,
 CC the need for parenteral feeding, and a catabolic state following surgery
 CC or injury. Sequences ABB07149-155 represent peptide fragments from gila
 CC monster venoms that are homologous to GLP-1 molecules and can be included
 CC in the composition
 XX
 CC Sequence 39 AA;
 SQ

ABB07149 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGTFSDLSKQMEEAARLFIWLNKNGPSSGAPPPS
 1 28

1 match found in sequence:
 abb07151; Gila monster venom extendin 4 peptide (residues 1-39).
 (from "seq4ags.pep")
 TOIG of: abb07151 check: 9570 from: 1 to: 39

ID ABB07151 standard; peptide; 39 AA.
 XX
 AC ABB07151;
 XX
 DT 13-MAR-2002 (first entry)
 XX
 DE Gila monster venom extendin 4 peptide (residues 1-39).
 XX
 KW GLP-1; glucagon-like-peptide-1; growth-hormone releasing factor; GRF;
 KW parathyroid hormone; PTH; antidiabetic; anorectic; cerebroprotective;
 KW vasotropic; anti-inflammatory; antiarteriosclerotic; hepatotropic;
 KW tranquilizer; vulnerary; osteopathic; gila monster; extendin.
 XX
 OS Heloderma suspectum.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 PN WO200187322-A2.
 XX
 PD 22-NOV-2001.
 XX
 PF 17-MAY-2001; 2001WO-US015872.
 XX
 PR 17-MAY-2000; 2000US-0205377P.
 PR 19-MAY-2000; 2000US-0205262P.
 XX
 PA (BION-) BIONEERASKA INC.
 XX
 PI Holmquist B, Dormady DC;
 XX
 DR WPI; 2002-082941/11.
 XX
 XX New peptide formulation for treating disease e.g. diabetes, obesity,
 PT ischemia comprises peptides, an acid having a specified dissociation
 PT constant and an excipient.

XX
 PS Disclosure; Page 11; 34pp; English.
 XX
 CC The invention provides a pharmaceutical composition that comprises a
 CC molecule selected from a glucagon-like-peptide-1 (GLP-1) molecule, growth
 CC -hormone releasing factor (GRF) molecule or a parathyroid hormone (PTH)
 CC molecule. The composition further includes a weak acid such as acetic
 CC acid. The pH of the composition is 3 - 5. The composition can be used for
 CC the treatment of a disease or condition selected from diabetes, excess
 CC appetite, obesity, stroke, ischemia, reperfusion injury, disturbed
 CC glucose metabolism, surgery, coma, shock, gastrointestinal disease,
 CC digestive hormone disease, atherosclerosis, vascular disease, gestational
 CC diabetes, liver disease and cirrhosis, glucocorticoid excess, Cushing's
 CC disease, the presence of activated counter regulatory hormones that occur
 CC after trauma or a disease, hypertriglyceridemia, chronic pancreatitis,
 CC the need for parenteral feeding, and a catabolic state following surgery
 CC or injury. Sequences ABB07149-155 represent peptide fragments from gila
 CC monster venoms that are homologous to GLP-1 molecules and can be included
 CC in the composition
 XX
 CC Sequence 39 AA;
 SQ

ABB07151 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGTFSDLSKQMEEAARLFIWLNKNGPSSGAPPPS
 1 28

1 match found in sequence:
 abb80100; Glucagon like peptide-1 (GLP-1) extendin 3.
 (from "seq4ags.pep")
 TOIG of: abb80100 check: 9591 from: 1 to: 39

ID ABB80100 standard; peptide; 39 AA.
 XX
 AC ABB80100;
 XX
 DT 02-OCT-2002 (first entry)
 XX
 DE Glucagon like peptide-1 (GLP-1) extendin 3.
 XX
 KW Glucagon like peptide-1; GLP-1; extendin 3; cardiant; antidiabetic;
 KW vasotropic; hibernating myocardium; congestive heart failure;
 KW ischaemic cardiomyopathy; diabetic cardiomyopathy.
 XX
 OS Heloderma suspectum.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 PN WO200234285-A2.
 XX
 PD 02-MAY-2002.
 XX
 PF 22-OCT-2001; 2001WO-US032559.
 XX
 PR 20-OCT-2000; 2000US-0241834P.
 PR 23-OCT-2000; 2000US-0242139P.
 PR 03-NOV-2000; 2000US-0245234P.
 XX
 PA (COOL/) COOLIDGE T R.
 XX
 PI Ehlers M;
 XX
 DR WPI; 2002-426545/45.
 XX
 XX Treatment of hibernating myocardium involves administering GLP-1
 PT molecule.
 XX
 PS Disclosure; Page 13; 25pp; English.

XX The invention relates to the treatment of hibernating myocardium by
 CC administering a GLP-1 (glucagon like peptide-1) molecule. GLP-1 activity
 CC may be described as, cardiant, antidiabetic and vasotropic. GLP-1 may be
 CC used for treating, hibernating myocardium, congestive heart failure,
 CC ischaemic cardiomyopathy and diabetic cardiomyopathy. GLP-1 reduces
 CC plasma or heart norepinephrine level in a patient. The current sequence
 CC represents the glucagon like peptide-1 (GLP-1) known as extendin 3
 XX Sequence 39 AA;
 SQ

ABB80100 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSLSKQMBEEAVRLFIEWLKGSGSSGAPPPS
 1

 1 match found in sequence:
 abm79779 ; H suspectum extendin-3 peptide.
 (from "seq4ags.pep")
 TOIG of: abm79779 check: 9591 from: 1 to: 39

1 HSDGFTSLSKQMBEEAVRLFIEWLKGSGSSGAPPPS
 28

 1 match found in sequence:
 abm79779 ; H suspectum extendin-3 peptide.
 (from "seq4ags.pep")
 TOIG of: abm79779 check: 9570 from: 1 to: 39

1 HSDGFTSLSKQMBEEAVRLFIEWLKGSGSSGAPPPS
 28

 1 match found in sequence:
 abm79780 ; H suspectum extendin-4 peptide.
 (from "seq4ags.pep")
 TOIG of: abm79780 check: 9570 from: 1 to: 39

1 HSDGFTSLSKQMBEEAVRLFIEWLKGSGSSGAPPPS
 28

 1 match found in sequence:
 abm79780 ; H suspectum extendin-4 peptide.
 (from "seq4ags.pep")
 TOIG of: abm79780 check: 9570 from: 1 to: 39

ID ABB83059 standard; peptide; 39 AA.
 XX
 AC ABB83059;
 XX
 DT 02-OCT-2002 (first entry)
 XX
 DE Glucagon like peptide-1 (GLP-1) extendin 4 #2.
 XX
 KW Glucagon like peptide-1; GLP-1; extendin 4; cardiant; antidiabetic;
 KW vasotropic; hibernating myocardium; congestive heart failure;
 KW ischaemic cardiomyopathy; diabetic cardiomyopathy.
 XX
 OS Heloderma suspectum.
 XX
 PI Dimarchi RD, Smiley DL, Zhang L;
 XX WPI; 2004-062204/06.
 XX
 DR Novel glucagon-like peptide-1 compound comprising glucagon-like peptide-1
 FT modified with reactive group that reacts with thiol group on blood
 FT component to form covalent bond, useful for treating obesity, stroke.
 XX
 PN WO200234285-A2.
 XX
 PD 02-MAY-2002.
 XX
 PF 22-OCT-2001; 2001WO-US032559.
 XX
 PR 20-OCT-2000; 2000US-0241834P.
 PR 23-OCT-2000; 2000US-0242139P.
 PR 03-NOV-2000; 2000US-0245234P.
 XX
 XX (COOL/) COOLIDGE T R.
 PA Ehlers M;
 XX WPI; 2002-426545/45.
 XX
 DR Treatment of hibernating myocardium involves administering GLP-1
 PT molecule.
 PT
 PS Disclosure; Page 13; 25pp; English.
 XX
 CC The invention relates to the treatment of hibernating myocardium by
 CC administering a GLP-1 (glucagon like peptide-1) molecule. GLP-1 activity
 CC may be described as; cardiant, antidiabetic and vasotropic. GLP-1 may be
 CC used for treating, hibernating myocardium, congestive heart failure,
 CC ischaemic cardiomyopathy and diabetic cardiomyopathy. GLP-1 reduces
 CC plasma or heart norepinephrine level in a patient. The current sequence
 CC represents the glucagon like peptide-1 (GLP-1) known as extendin 4
 XX Sequence 39 AA;
 SQ

ABB83059 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSLSKQMBEEAVRLFIEWLKGSGSSGAPPPS
 1

 1 match found in sequence:
 abm79779 ; H suspectum extendin-3 peptide.
 (from "seq4ags.pep")
 TOIG of: abm79779 check: 9591 from: 1 to: 39

ID ABB79779 standard; peptide; 39 AA.
 XX
 AC ABB79779;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE H suspectum extendin-3 peptide.
 XX
 KW Glucagon-like peptide-1; analogue; GLP-1; antidiabetic; anorectic;
 KW cerebroprotective; cardiant.
 XX
 OS Heloderma suspectum.
 XX
 PN WO2003103572-A2.
 XX
 PD 18-DEC-2003.
 XX
 PF 02-JUN-2003; 2003WO-US015395.
 XX
 PR 04-JUN-2002; 2002US-0385927P.
 XX
 PA (ELIL) LILLY & CO ELI.
 XX
 PI Dimarchi RD, Smiley DL, Zhang L;
 XX WPI; 2004-062204/06.
 XX
 DR Novel glucagon-like peptide-1 compound comprising glucagon-like peptide-1
 PT modified with reactive group that reacts with thiol group on blood
 PT component to form covalent bond, useful for treating obesity, stroke.
 XX
 PS Disclosure; Page 123; 124pp; English.
 XX
 CC The present invention relates to analogues of glucagon-like peptide-1,
 CC comprising glucagon-like peptide-1 (GLP-1) modified with a reactive group
 CC that reacts with a thiol group on a blood component to form a covalent
 CC bond, where the reactive group is chosen from an activated disulfide bond
 CC group or an S-sulfonate. The analogues are useful for manufacturing
 CC medicament and treating non-insulin dependent diabetes, obesity, stroke,
 CC myocardial infraction, stress-induced hyperglycaemia or irritable bowel
 CC syndrome. The present sequence is a peptide shown in the exemplification
 CC of the invention
 XX Sequence 39 AA;
 SQ

ABB79779 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSLSKQMBEEAVRLFIEWLKGSGSSGAPPPS
 1

 1 match found in sequence:
 abm79780 ; H suspectum extendin-4 peptide.
 (from "seq4ags.pep")
 TOIG of: abm79780 check: 9570 from: 1 to: 39

ID ABB79780 standard; peptide; 39 AA.
 XX

```
AC ABM79780;
XX
XX DT 22-APR-2004 (first entry)
XX DE H suspectum extendin-4 peptide.
XX
XX KW Glucagon-like peptide-1; analogue; GLP-1; antidiabetic; anorectic;
XX KW cerebroprotective; cardiant.
XX OS Heloderma suspectum.
XX PN WO2003103572-A2.
XX
XX PD 18-DEC-2003.
XX
XX PF 02-JUN-2003; 2003WO-US015395.
XX
XX PR 04-JUN-2002; 2002US-0385927P.
XX
XX PA (ELIL ) LILLY & CO ELI.
XX
XX PI Dimarchi RD, Smiley DL, Zhang L;
XX
XX DR WPI; 2004-062204/06.
XX
XX PT Novel glucagon-like peptide-1 compound comprising glucagon-like peptide-1
XX PT modified with reactive group that reacts with thiol group on blood
XX PT component to form covalent bond, useful for treating obesity, stroke.
XX
XX PS Disclosure; Page 123-124; 124pp; English.
XX
XX CC The present invention relates to analogues of glucagon-like peptide-1,
XX CC comprising glucagon-like peptide-1 (GLP-1) modified with a reactive group
XX CC that reacts with a thiol group on a blood component to form a covalent
XX CC bond, where the reactive group is chosen from an activated disulfide bond
XX CC group or an S-sulfonate. The analogues are useful for manufacturing
XX CC medicament and treating non-insulin dependent diabetes, obesity, stroke,
XX CC myocardial infarction, stress-induced hyperglycaemia or irritable bowel
XX CC syndrome. The present sequence is a peptide shown in the exemplification
XX CC of the invention
XX
XX SQ Sequence 39 AA;

ABM79780 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGGFTSDLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
    28

-----
1 match found in sequence:
  abp58578 ; Mexican beaded lizard extendin-4.
  (from "seq4ags.pep")
  TOIG of: abp58578 check: 9570 from: 1 to: 39

ID ABP58578 standard; peptide; 39 AA.
XX
XX AC ABP58578;
XX
XX DT 28-MAR-2003 (first entry)
XX
XX DE Mexican beaded lizard extendin-4.
XX
XX KW Extendin-4; Mexican beaded lizard; extendin-4 analogue; antidiabetic;
XX KW insulin secretagogue; type 2 diabetes.
XX
XX OS Heloderma horridum.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 39
XX FT /note= "C-terminal amide"
XX
```

```
PN WO200290388-A1.
XX
XX PD 14-NOV-2002.
XX
XX PF 08-MAY-2002; 2002WO-CN000316.
XX
XX PR 10-MAY-2001; 2001CN-00112856.
XX
XX PA (SHAN-) SHANGHAI HUAYI BIO LAB.
XX
XX PI Sun Y, Wu D, Zhu Z, Yu G, Shen C, Zhao S, Zhou J;
XX
XX DR WPI; 2003-120527/11.
XX
XX PT Polypeptide extendin-4 derivatives, useful for promoting insulin secretion
XX PT and reducing blood sugar, for treating diabetes type 2.
XX
XX PS Disclosure; Page 2; 24pp; Chinese.
XX
XX CC The invention relates to novel analogues of extendin-4 (ABP58572-
XX CC ABP58576) or their pharmaceutically acceptable salts. The invention also
XX CC encompasses a procedure for preparing the extendin-4 analogues. Extendin-4
XX CC (ABP58578) is a polypeptide obtained from the Mexican beaded lizard
XX CC (Heloderma horridum) which acts as an agonist of glucagon-like peptide 1
XX CC (GLP-1; see ABP58577). Like extendin-4 itself, the extendin-4 analogues of
XX CC the invention have antidiabetic activity, being able to promote the
XX CC secretion of insulin and reduce blood sugar, and are thus applicable in
XX CC treating type 2 diabetes. 0.1 micrograms of an extendin-4 analogue was
XX CC demonstrated to be able to reduce blood sugar to approximately 20% of its
XX CC former value after one hour, and its effects lasted 30 minutes longer
XX CC than 4 micrograms of insulin. The extendin-4 analogues of the invention
XX CC can be synthesised either chemically or by recombinant methods, thereby
XX CC permitting large-scale production. The present sequence represents wild-
XX CC type extendin-4 which is referred to in the disclosure of the invention
XX
XX SQ Sequence 39 AA;

ABP58578 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
  1 HGGFTSDLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
    28

-----
1 match found in sequence:
  abu66208 ; Gila monster extendin-4.
  (from "seq4ags.pep")
  TOIG of: abu66208 check: 9570 from: 1 to: 39

ID ABU66208 standard; peptide; 39 AA.
XX
XX AC ABU66208;
XX
XX DT 20-MAY-2003 (first entry)
XX
XX DE Gila monster extendin-4.
XX
XX KW Glucagon-like peptide-1; GLP_1; extendin-4; antidiabetic; stroke;
XX KW nootropic; neuroprotective; antiparkinsonian; anticonvulsant;
XX KW cerebroprotective; neuronal death; neuronal differentiation;
XX KW neuronal proliferation; neuronal process growth; amyloid protein;
XX KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
XX KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
XX KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
XX KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
XX
XX OS Heloderma suspectum.
XX
XX PN WO2003011892-A2.
XX
XX PD 13-FEB-2003.
XX
```

```

PF 30-JUL-2002; 2002WO-US024141.
XX
XX
PR 31-JUL-2001; 2001US-0309076P.
XX
XX
PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
XX
PI Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
XX
XX WPI; 2003-268106/26.
XX
XX
XX New Glucagon-like peptide-1 or exendin-2 polypeptides, or their
PT analogues, useful for treating a subject with diabetes or a
PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
PT sclerosis or brain injury).
XX
XX Claim 27; Fig 1; 119pp; English.
XX
XX The invention relates to a purified polypeptide, which comprises the
CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
CC Exendin-4 or an exendin analogue with a spacer between the amino acid
CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
CC Also include are: (1) reducing neuronal death, promoting neuronal
CC differentiation or proliferation, or promoting growth of neuronal
CC processes, by contacting one or more neurons with the polypeptide; and
CC (2) reducing formation or accumulation of amyloid protein by contacting
CC one or more neurons with the polypeptide, which affects amyloid precursor
CC protein metabolism. The polypeptides are useful for treating a subject
CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
CC injury, spinal chord injury or peripheral neuropathy), as well as for
CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
CC polypeptides are also useful for treating a subject with neurotoxic
CC injury or neurodegenerative condition, or for reducing the symptom(s) of
CC neurotoxic injury or neurodegenerative condition in a subject. The
CC present sequence is wild-type Gila-monster lizard exendin-4
XX
XX Sequence 39 AA;
SQ
ABU66208 Length: 39 February 4, 2005 13:20 Type: P Check: 9570
Found using 'seq4' (mohamed337.key)
1 HEGTFTSDLSKQMEEEAVRLFIEWLKNKGSPSGAPPPS
1 28
-----
1 match found in sequence:
abu66216 ; Glucagon-like peptide 1/exendin-4 analogue #1.
(from "seq4ags.pep")
TOIG of: abu66216 check: 9558 from: 1 to: 39
ID ABU66216 standard; peptide; 39 AA.
XX
XX AC ABU66216;
XX
XX DT 23-OCT-2003 (revised)
XX
XX DE 20-MAY-2003 (first entry)
XX
XX DE Glucagon-like peptide 1/exendin-4 analogue #1.
XX
XX Glucagon-like peptide-1; GLP 1; exendin-4; antidiabetic; stroke; human;
KW nootropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
KW neuronal proliferation; neuronal process growth; amyloid protein;
KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
XX
XX OS Homo sapiens.
XX
XX OS Heloderma suspectum.
XX
XX OS Chimeric.

```

```

XX WO2003011892-A2.
XX
XX PD 13-FEB-2003.
XX
XX PF 30-JUL-2002; 2002WO-US024141.
XX
XX PR 31-JUL-2001; 2001US-0309076P.
XX
XX PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
XX
XX WPI; 2003-268106/26.
XX
XX New Glucagon-like peptide-1 or exendin-2 polypeptides, or their
PT analogues, useful for treating a subject with diabetes or a
PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
PT sclerosis or brain injury).
XX
XX Claim 27; Fig 1; 119pp; English.
XX
XX The invention relates to a purified polypeptide, which comprises the
CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
CC Exendin-4 or an exendin analogue with a spacer between the amino acid
CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
CC Also include are: (1) reducing neuronal death, promoting neuronal
CC differentiation or proliferation, or promoting growth of neuronal
CC processes, by contacting one or more neurons with the polypeptide; and
CC (2) reducing formation or accumulation of amyloid protein by contacting
CC one or more neurons with the polypeptide, which affects amyloid precursor
CC protein metabolism. The polypeptides are useful for treating a subject
CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
CC injury, spinal chord injury or peripheral neuropathy), as well as for
CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
CC polypeptides are also useful for treating a subject with neurotoxic
CC injury or neurodegenerative condition, or for reducing the symptom(s) of
CC neurotoxic injury or neurodegenerative condition in a subject. The
CC present sequence is a human GLP-1/Gila-monster lizard exendin-4
CC chimeric analogue peptide. (Updated on 23-OCT-2003 to standardise OS
CC field)
XX
XX Sequence 39 AA;
SQ
ABU66216 Length: 39 February 4, 2005 13:20 Type: P Check: 9558
Found using 'seq4' (mohamed337.key)
1 HEGTFTSDLSKQMEEEAVRLFIEWLKNKGSPSGAPPPS
1 28
-----
1 match found in sequence:
abu66217 ; Gila monster exendin-4 analogue #1.
(from "seq4ags.pep")
TOIG of: abu66217 check: 4877 from: 1 to: 30
ID ABU66217 standard; peptide; 30 AA.
XX
XX AC ABU66217;
XX
XX DT 20-MAY-2003 (first entry)
XX
XX DE Gila monster exendin-4 analogue #1.
XX
XX Glucagon-like peptide-1; GLP 1; exendin-4; antidiabetic; stroke;
KW nootropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
KW neuronal proliferation; neuronal process growth; amyloid protein;
KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
KW peripheral neuropathy; neurotoxic injury; Huntington's disease;
KW Alzheimer's disease; Huntington's disease;

```

KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
 OS Heloderma suspectum.
 OS Synthetic.

XX WO2003011892-A2.

XX 13-FEB-2003.

XX 30-JUL-2002; 2002WO-US024141.

XX 31-JUL-2001; 2001US-0309076P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;

XX WPI; 2003-268106/26.

XX New Glucagon-like peptide-1 or exendin-2 polypeptides, or their
 PT analogues, useful for treating a subject with diabetes or a
 PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 PT sclerosis or brain injury).

XX Claim 27; Fig 1; 119pp; English.

XX The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Exendin-4 or an exendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor
 CC protein metabolism. The polypeptides are useful for treating a subject
 CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
 CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
 CC injury, spinal chord injury or peripheral neuropathy), as well as for
 CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
 CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a Gila-monster lizard exendin-4 analogue

XX Sequence 30 AA;

ABU66217 Length: 30 February 4, 2005 13:20 Type: P Check: 4877 ..
 Found using 'seq4' (mohamed337.key)

1 HARGTFTSLSKQMEERAVRLFIEWLKNKG
 1 28

1 match found in sequence:

abu66218 ; Gila monster exendin-4 analogue #2.
 (from "seq4ags.pep")

TOIG of: abu66218 check: 3293 from: 1 to: 37

ID ABU66218 standard; peptide; 37 AA.

XX ABU66218;

XX 20-MAY-2003 (first entry)

DE Gila monster exendin-4 analogue #2.

XX Glucagon-like peptide-1; GLP 1; exendin-4; antidiabetic; stroke;
 KW norepinephrine; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
 KW cerebroprotective; neuronal death; neuronal differentiation; mutin;

KW neuronal proliferation; neuronal process growth; amyloid protein;
 KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
 KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.

XX Heloderma suspectum.

OS Synthetic.

XX WO2003011892-A2.

XX 13-FEB-2003.

XX 30-JUL-2002; 2002WO-US024141.

XX 31-JUL-2001; 2001US-0309076P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;

XX WPI; 2003-268106/26.

XX New Glucagon-like peptide-1 or exendin-2 polypeptides, or their
 PT analogues, useful for treating a subject with diabetes or a
 PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 PT sclerosis or brain injury).

XX Claim 27; Fig 1; 119pp; English.

XX The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Exendin-4 or an exendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor
 CC protein metabolism. The polypeptides are useful for treating a subject
 CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
 CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
 CC injury, spinal chord injury or peripheral neuropathy), as well as for
 CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
 CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a Gila-monster lizard exendin-4 analogue

XX Sequence 37 AA;

ABU66218 Length: 37 February 4, 2005 13:20 Type: P Check: 3293 ..
 Found using 'seq4' (mohamed337.key)

1 HARGTFTSLSKQMEERAVRLFIEWLKNKGPSGAPP
 1 28

1 match found in sequence:

abu66219 ; Gila monster exendin-4 analogue #3.
 (from "seq4ags.pep")

TOIG of: abu66219 check: 7453 from: 1 to: 35

ID ABU66219 standard; peptide; 35 AA.

XX ABU66219;

XX 20-MAY-2003 (first entry)

DE Gila monster exendin-4 analogue #3.

KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; stroke;
 KW neurotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
 KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
 KW neuronal proliferation; neuronal process growth; amyloid protein;
 KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
 KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX WO2003011892-A2.
 XX 13-FEB-2003.
 XX 30-JUL-2002; 2002WO-US024141.
 XX 31-JUL-2001; 2001US-0309076P.
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
 XX WPI; 2003-268106/26.
 DR
 XX New Glucagon-like peptide-1 or exendin-2 polypeptides, or their
 XX analogues, useful for treating a subject with diabetes or a
 XX neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 XX sclerosis or brain injury).
 XX
 PS Claim 27; Fig 1; 119pp; English.
 XX
 CC The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Exendin-4 or an exendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor
 CC protein metabolism. The polypeptides are useful for treating a subject
 CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
 CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
 CC injury, spinal chord injury or peripheral neuropathy), as well as for
 CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
 CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a Gila-monster lizard exendin-4 analogue
 XX
 SQ Sequence 35 AA;
 ABU66219 Length: 35 February 4, 2005 13:20 Type: P Check: 7453 ..
 Found using 'seq4' (mohamed337.key)
 1- |-----|
 1 HEGGFTSDLSKQMEEEAVRLFIWLKNGPSSGA
 28

 1 match found in sequence:
 abu66220 ; Gila monster exendin-4 analogue #4.
 (from "seq4ags.pep")
 TOIG of: abu66220 check: 2764 from: 1 to: 33
 ID ABU66220 standard; peptide; 33 AA.
 AC ABU66220;
 XX
 DT 20-MAY-2003 (first entry)

XX Gila monster exendin-4 analogue #4.
 DE
 XX
 KW Glucagon-like peptide-1; GLP-1; exendin-4; antidiabetic; stroke;
 KW neurotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
 KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
 KW neuronal proliferation; neuronal process growth; amyloid protein;
 KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
 KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
 XX
 OS Heloderma suspectum.
 OS Synthetic.
 XX WO2003011892-A2.
 XX 13-FEB-2003.
 XX 30-JUL-2002; 2002WO-US024141.
 XX 31-JUL-2001; 2001US-0309076P.
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
 XX WPI; 2003-268106/26.
 DR
 XX New Glucagon-like peptide-1 or exendin-2 polypeptides, or their
 XX analogues, useful for treating a subject with diabetes or a
 XX neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 XX sclerosis or brain injury).
 XX
 PS Claim 27; Fig 1; 119pp; English.
 XX
 CC The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Exendin-4 or an exendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor
 CC protein metabolism. The polypeptides are useful for treating a subject
 CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
 CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
 CC injury, spinal chord injury or peripheral neuropathy), as well as for
 CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
 CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a Gila-monster lizard exendin-4 analogue
 XX
 SQ Sequence 33 AA;
 ABU66220 Length: 33 February 4, 2005 13:20 Type: P Check: 2764 ..
 Found using 'seq4' (mohamed337.key)
 1- |-----|
 1 HEGGFTSDLSKQMEEEAVRLFIWLKNGPSS
 28

 1 match found in sequence:
 abu66221 ; Gila monster exendin-4 analogue #5.
 (from "seq4ags.pep")
 TOIG of: abu66221 check: 700 from: 1 to: 28
 ID ABU66221 standard; peptide; 28 AA.
 XX

AC ABU66221;
 XX 20-MAY-2003 (first entry)
 XX Gila monster extendin-4 analogue #5.
 DE Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
 XX neurotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
 KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
 KW neuronal proliferation; neuronal process growth; amyloid protein;
 KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
 KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
 XX Heloderma suspectum.
 OS Synthetic.
 OS WO2003011892-A2.
 XX 13-FEB-2003.
 XX 30-JUL-2002; 2002WO-US024141.
 XX 31-JUL-2001; 2001US-0309076P.
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
 XX WPI; 2003-268106/26.
 XX New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
 PT analogues, useful for treating a subject with diabetes or a
 PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 PT sclerosis or brain injury).
 XX Claim 27; Fig 1; 119pp; English.
 XX The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Extendin-4 or an extendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor
 CC protein metabolism. The polypeptides are useful for treating a subject
 CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
 CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
 CC injury, spinal chord injury or peripheral neuropathy), as well as for
 CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
 CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a Gila-monster lizard extendin-4 analogue
 XX Sequence 28 AA;
 ABU66221 Length: 28 February 4, 2005 13:20 Type: P Check: 700 ..
 Found using 'seq4' (mohamed337.key)

ID AC ABU66237;
 XX 20-MAY-2003 (first entry)
 XX Gila monster extendin-4 analogue #11.
 DE Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
 XX neurotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
 KW cerebroprotective; neuronal death; neuronal differentiation; mutein;
 KW neuronal proliferation; neuronal process growth; amyloid protein;
 KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
 KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
 KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
 KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.
 XX Heloderma suspectum.
 OS Synthetic.
 OS WO2003011892-A2.
 XX 13-FEB-2003.
 XX 30-JUL-2002; 2002WO-US024141.
 XX 31-JUL-2001; 2001US-0309076P.
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX Greig NH, Egan J, Doyle M, Holloway H, Perry TA;
 XX WPI; 2003-268106/26.
 XX New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
 PT analogues, useful for treating a subject with diabetes or a
 PT neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
 PT sclerosis or brain injury).
 XX Example 2; Fig 1; 119pp; English.
 XX The invention relates to a purified polypeptide, which comprises the
 CC amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
 CC Extendin-4 or an extendin analogue with a spacer between the amino acid
 CC residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
 CC Also include are: (1) reducing neuronal death, promoting neuronal
 CC differentiation or proliferation, or promoting growth of neuronal
 CC processes, by contacting one or more neurons with the polypeptide; and
 CC (2) reducing formation or accumulation of amyloid protein by contacting
 CC one or more neurons with the polypeptide, which affects amyloid precursor
 CC protein metabolism. The polypeptides are useful for treating a subject
 CC with diabetes (particularly type 2 diabetes) or a neurodegenerative
 CC condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
 CC disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
 CC injury, spinal chord injury or peripheral neuropathy), as well as for
 CC reducing the symptom(s) of neurodegenerative conditions in a subject. The
 CC polypeptides are also useful for treating a subject with neurotoxic
 CC injury or neurodegenerative condition, or for reducing the symptom(s) of
 CC neurotoxic injury or neurodegenerative condition in a subject. The
 CC present sequence is a Gila-monster lizard extendin-4 analogue
 XX Sequence 30 AA;
 ABU66237 Length: 30 February 4, 2005 13:20 Type: P Check: 5219 ..
 Found using 'seq4' (mohamed337.key)

1 match found in sequence:
 abu66237 ; Gila monster extendin-4 analogue #11.
 (from "seq4ags.pep")
 TOIG of: abu66237 check: 5219 from: 1 to: 30

1 HGGGTFTSLSKQMEEEAVRLFIEWLKNGR
 1
 1 match found in sequence:

abu66238 ; Gila monster extendin-4 analogue #12.
(from "seq4ags.pep")
TOIG of: abu66238 check: 5123 from: 1 to: 30

ID ABU66238 standard; peptide; 30 AA.

AC ABU66238;

DT 20-MAY-2003 (first entry)

DE Gila monster extendin-4 analogue #12.

KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
KW neurotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
KW cerebroprotective; neuronal death; neuronal differentiation; mutant;
KW neuronal proliferation; neuronal process growth; amyloid protein;
KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.

OS Heloderma suspectum.

OS Synthetic.

PN WO2003011892-A2.

PD 13-FEB-2003.

PF 30-JUL-2002; 2002WO-US024141.

PR 31-JUL-2001; 2001US-0309076P.

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

PI Greig NH, Egan J, Doyle M, Holloway H, Perry TA;

DR WPI; 2003-268106/26.

XX New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
XX analogues, useful for treating a subject with diabetes or a
XX neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
XX sclerosis or brain injury).

PS Example 2; Fig 1; 119pp; English.

XX The invention relates to a purified polypeptide, which comprises the
XX amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
XX Extendin-4 or an extendin analogue with a spacer between the amino acid
XX residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
XX Also include are: (1) reducing neuronal death, promoting neuronal
XX differentiation or proliferation, or promoting growth of neuronal
XX processes, by contacting one or more neurons with the polypeptide; and
XX (2) reducing formation or accumulation of amyloid protein by contacting
XX one or more neurons with the polypeptide, which affects amyloid precursor
XX protein metabolism. The polypeptides are useful for treating a subject
XX with diabetes (particularly type 2 diabetes) or a neurodegenerative
XX condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
XX disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
XX injury, spinal chord injury or peripheral neuropathy), as well as for
XX reducing the symptom(s) of neurodegenerative conditions in a subject. The
XX polypeptides are also useful for treating a subject with neurotoxic
XX injury or neurodegenerative condition, or for reducing the symptom(s) of
XX neurotoxic injury or neurodegenerative condition in a subject. The
XX present sequence is a Gila-monster lizard extendin-4 analogue

XX Sequence 30 AA;

ABU66238 Length: 30 February 4, 2005 13:20 Type: P Check: 5123 ..
Found using 'seq4' (mohamed337.key)

1 HGGFTTDLKQMEBEAVRLFIAMJKNR
28

1 match found in sequence:

abu66255 ; Gila monster extendin-4 analogue #14.
(from "seq4ags.pep")
TOIG of: abu66255 check: 333 from: 1 to: 36

ID ABU66255 standard; peptide; 36 AA.

XX AC ABU66255;

XX DT 20-MAY-2003 (first entry)

XX DE Gila monster extendin-4 analogue #14.

KW Glucagon-like peptide-1; GLP-1; extendin-4; antidiabetic; stroke;
KW neurotropic; neuroprotective; antiparkinsonian; anticonvulsant; mutant;
KW cerebroprotective; neuronal death; neuronal differentiation; mutant;
KW neuronal proliferation; neuronal process growth; amyloid protein;
KW diabetes; type 2 diabetes; neurodegenerative condition; brain injury;
KW Alzheimer's disease; Parkinson's disease; Huntington's disease;
KW amyotrophic lateral sclerosis; multiple sclerosis; spinal chord injury;
KW peripheral neuropathy; neurotoxic injury; Gila-monster lizard.

OS Heloderma suspectum.

OS Synthetic.

PN WO2003011892-A2.

PD 13-FEB-2003.

PF 30-JUL-2002; 2002WO-US024141.

PR 31-JUL-2001; 2001US-0309076P.

PA (USSH) US DEPT HEALTH & HUMAN SERVICES.

PI Greig NH, Egan J, Doyle M, Holloway H, Perry TA;

DR WPI; 2003-268106/26.

XX New Glucagon-like peptide-1 or extendin-2 polypeptides, or their
XX analogues, useful for treating a subject with diabetes or a
XX neurodegenerative condition (e.g. Alzheimer's disease, stroke, multiple
XX sclerosis or brain injury).

PS Example 9; Page 37; 119pp; English.

XX The invention relates to a purified polypeptide, which comprises the
XX amino acid sequence of Glucagon-like peptide-1 (GLP-1), a GLP-1 analogue,
XX Extendin-4 or an extendin analogue with a spacer between the amino acid
XX residues comparable to residues 7 and 8, or residues 8 and 9 of GLP-1.
XX Also include are: (1) reducing neuronal death, promoting neuronal
XX differentiation or proliferation, or promoting growth of neuronal
XX processes, by contacting one or more neurons with the polypeptide; and
XX (2) reducing formation or accumulation of amyloid protein by contacting
XX one or more neurons with the polypeptide, which affects amyloid precursor
XX protein metabolism. The polypeptides are useful for treating a subject
XX with diabetes (particularly type 2 diabetes) or a neurodegenerative
XX condition (e.g. Alzheimer's disease, Parkinson's disease, Huntington's
XX disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis, brain
XX injury, spinal chord injury or peripheral neuropathy), as well as for
XX reducing the symptom(s) of neurodegenerative conditions in a subject. The
XX polypeptides are also useful for treating a subject with neurotoxic
XX injury or neurodegenerative condition, or for reducing the symptom(s) of
XX neurotoxic injury or neurodegenerative condition in a subject. The
XX present sequence is a Gila-monster lizard extendin-4 analogue

XX Sequence 36 AA;

ABU66255 Length: 36 February 4, 2005 13:20 Type: P Check: 333 ..
Found using 'seq4' (mohamed337.key)

```

1 1-----|
  HGEGTFTDLSKQMEEEAVRLFIEWLKNKGPPSSGAP
  1
-----
1 match found in sequence:
  (from "seq4ags.pep")
  TOIG of: ABU91974 Check: 9570 from: 1 to: 39

ID ABU91974 standard; peptide; 39 AA.
AC ABU91974;
XX
XX 14-JUL-2003 (first entry)
XX
XX Glia monster extendin peptide.
XX
XX Adenoviral vector; glucagon-like peptide 1; GLP-1; GIP; obesity;
KW glucose-dependent insulinotropic peptide; type II diabetes;
KW in vivo expression; dipeptidyl peptidase IV inhibitor; DPP-IV;
KW GLP-1 variant; extendin; antidiabetic; anorectic; gene therapy.
XX
XX Unidentified.
XX
XX WO2003030946-A1.
XX
XX 17-APR-2003.
XX
XX 09-OCT-2002; 2002WO-US032051.
XX
XX 09-OCT-2001; 2001US-0328116P.
XX
XX (NOVS ) NOVARTIS AG.
XX
XX Connelly S, Golightly D, Hughes T, Kaleko M, Pattison S;
PI Sakhuja K;
XX
XX WPI; 2003-381685/36.
XX
XX N-PSDB; ACA92262.
XX
XX New viral vectors comprising a sequence encoding glucagons-like peptide 1
PT or glucose-dependent insulinotropic peptide, a sequence encoding a signal
PT sequence, and a polyadenylation signal, for treating e.g. diabetes or
PT obesity.
XX
XX Disclosure; Page 17; 62pp; English.
XX
XX The present invention relates to an adenoviral vector comprising a
CC polynucleotide sequence encoding glucagon-like peptide 1 (GLP-1) or
CC glucose-dependent insulinotropic peptide (GIP), a polynucleotide sequence
CC encoding a signal sequence upstream of it, and a polyadenylation signal
CC downstream of it. The viral vector is useful in gene therapy for treating
CC type II diabetes, obesity and related conditions by in vivo expression of
CC GLP-1, and/or GIP. The treatment may be combined with the administration
CC of dipeptidyl peptidase IV (DPP-IV) inhibitors. ABU91969-ABU91975
CC represent GLP-1, GLP-1 variant, extendin or GIP peptides
XX
XX Sequence 39 AA;
SQ
ABU91974 Length: 39 February 4, 2005 13:20 Type: P Check: 9570
Found using 'seq4' (mohamed337.key)

1 1-----|
  HGEGTFTDLSKQMEEEAVRLFIEWLKNKGPPSSGAPPS
  1
-----
1 match found in sequence:
  (from "seq4ags.pep")
  TOIG of: ada44870 check: 9591 from: 1 to: 39

ADA44870 standard; peptide; 39 AA.
ADA44870;
XX
XX 20-NOV-2003 (first entry)
XX
XX Glia monster extendin 3 peptide SEQ ID NO: 7.
XX
XX polycystic ovary syndrome; PCOS; glucagon-like peptide-1; GLP-1;
XX gynaecological; antidiabetic; anorectic; hypotensive; antilipaeamic;
XX antifertility; depilatory; andocrine-gen.; antiseborrheic;
KW dermatological; plasma glucose regulator; insulin secretion stimulator;
KW insulin resistance; hyperinsulinaemia; type-2 diabetes; obesity;
KW hypertension; hyperlipidaemia; anovulation; irregular ovulation;
KW infertility; hyperandrogenism; hirsutism; alopecia; acne;
KW enlarged multifollicular ovaries; abnormal uterine bleeding;
KW spontaneous abortion; insulin sensitivity; Gila monster; extendin 3.
XX
XX Heloderma suspectum.
XX
XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
FT
XX
XX WO2003061362-A2.
XX
XX 31-JUL-2003.
XX
XX 14-JAN-2003; 2003WO-US001109.
XX
XX 22-JAN-2002; 2002US-0350395P.
XX
XX 11-DEC-2002; 2002US-00317126.
XX
XX (REST-) RESTORAGEN INC.
XX
XX Hathaway DR;
XX
XX WPI; 2003-663337/62.
XX
XX Treating polycystic ovary syndrome and associated symptoms e.g. insulin
PT resistance comprises administering glucagon-like peptide-1 molecule.
XX
XX Disclosure; Page 9; 11pp; English.
XX
XX The invention relates to a method for treating polycystic ovary syndrome
CC (PCOS). The method comprises administering a glucagon-like peptide-1 (GLP
CC -1) molecule. The method of the invention has gynaecological,
CC antidiabetic, anorectic, hypotensive, antilipaeamic, antifertility,
CC depilatory, andocrine-gen., antiseborrheic, and dermatological activity.
CC A GLP-1 molecule of the invention acts as a plasma glucose regulator, or
CC insulin secretion stimulator. The method is useful for treating
CC polycystic ovary syndrome (PCOS) and its symptoms, particularly insulin
CC resistance, hyperinsulinaemia, type-2 diabetes, obesity, hypertension,
CC hyperlipidaemia, anovulation or irregular ovulation, infertility,
CC hyperandrogenism, hirsutism, alopecia, acne, enlarged multifollicular
CC ovaries, abnormal uterine bleeding and spontaneous abortion, and for
CC restoring regular menses, ovulation and fertility. A GLP-1 molecule
CC reduces insulin resistance or increases insulin sensitivity. The present
CC sequence represents a Gila monster venom peptide, extendin 3, which shows
CC homology to GLP-1.
XX
XX Sequence 39 AA;
SQ
ADA44870 Length: 39 February 4, 2005 13:20 Type: P Check: 9591
Found using 'seq4' (mohamed337.key)

1 1-----|
  HSDGTFTDLSKQMEEEAVRLFIEWLKNKGPPSSGAPPS
  1
-----
1 match found in sequence:
  (from "seq4ags.pep")
  TOIG of: ada44872 ; Gila monster extendin 4 peptide SEQ ID NO: 9.

```

(from "seq4ags.pep")
TOIG of: ada44872 check: 9570 from: 1 to: 39

ID ADA44872 standard; peptide; 39 AA.
XX ADA44872;
AC
XX
DT 20-NOV-2003 (first entry)
XX
DE Gila monster venom extendin 4.
XX
KW polycystic ovary syndrome; PCOS; glucagon-like peptide-1; GLP-1;
KW gynaecological; antidiabetic; anorectic; hypotensive; antilipaeic;
KW antifertility; depilatory; andocrine-gen.; antiseborrheic;
KW dermatological; plasma glucose regulator; insulin secretion stimulator;
KW insulin resistance; hyperinsulinaemia; type-2 diabetes; obesity;
KW hypertension; hyperlipidaemia; anovulation; irregular ovulation;
KW infertility; hyperandrogenism; hirsutism; alopecia; acne;
KW enlarged multifollicular ovaries; abnormal uterine bleeding;
KW spontaneous abortion; insulin sensitivity; Gila monster; extendin 4.

XX Heloderma suspectum.
OS
XX WO2003061362-A2.
PN
XX
XX
XX 31-JUL-2003.
PD
XX
XX 14-JAN-2003; 2003WO-US001109.
PF
XX
XX 22-JAN-2002; 2002US-0350395P.
PR
XX 11-DEC-2002; 2002US-00317126.
PR
XX (REST-) RESTORAGEN INC.
PA
XX Hathaway DR;
PI
XX WPI; 2003-663337/62.
DR
XX
XX Treating polycystic ovary syndrome and associated symptoms e.g. insulin
PT resistance comprises administering glucagon-like peptide-1 molecule.
PT
XX
XX Disclosure; Page 9; 1lpp; English.

XX The invention relates to a method for treating polycystic ovary syndrome
CC (PCOS). The method comprises administering a glucagon-like peptide-1 (GLP
CC -1) molecule. The method of the invention has gynecological,
CC antidiabetic, anorectic, hypotensive, antilipaeic, antifertility,
CC depilatory, andocrine-gen., antiseborrheic, and dermatological activity.
CC A GLP-1 molecule of the invention acts as a plasma glucose regulator, or
CC insulin secretion stimulator. The method is useful for treating
CC polycystic ovary syndrome (PCOS) and its symptoms, particularly insulin
CC resistance, hyperinsulinaemia, type-2 diabetes, obesity, hypertension,
CC hyperlipidaemia, anovulation or irregular ovulation, infertility,
CC hyperandrogenism, hirsutism, alopecia, acne, enlarged multifollicular
CC ovaries, abnormal uterine bleeding and spontaneous abortion, and for
CC restoring regular menses, ovulation and fertility. A GLP-1 molecule
CC reduces insulin resistance or increases insulin sensitivity. The present
CC sequence represents a Gila monster venom peptide, extendin 4, which shows
CC homology to GLP-1.

XX Sequence 39 AA;

ADA44872 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HEGTFTSLSKQMEAEVRLFIWLNKGPGSSGAPPPS
28

1 match found in sequence:
adb84203; Gila monster venom extendin 3.
(from "seq4ags.pep")

TOIG of: adb84203 check: 9591 from: 1 to: 39
ADB84203 standard; peptide; 39 AA.

ID ADB84203;
XX
AC
XX
DT 04-DEC-2003 (first entry)
XX
DE Gila monster venom extendin 3.
XX
KW vasotropic; intermittent claudication; skeletal muscle injury; ischaemia;
KW glucagon-like peptide-1; GLP-1; peripheral vascular disease;
KW glucose oxidation; fatty acid oxidation reduction; Gila monster venom;
KW extendin 3.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Misc-difference 39 /note= "C-terminal amide"
FT
XX

US2003073626-A1.

PD 17-APR-2003.

XX 05-MAR-2002; 2002US-00091258.

XX 30-APR-1999; 99US-00302596.

XX 09-MAY-2001; 2001US-00851738.

XX (HATH/) HATHAWAY D R.

XX (COOL/) COOLIDGE T R.

XX Hathaway DR, Coolidge TR;

XX WPI; 2003-677986/64.

XX Method for the treatment or prevention of intermittent claudication or
PT skeletal muscle injury caused by ischemia and/or reperfusion in a human
PT subject, comprises administration of a glucagon-like peptide-1 molecule.
XX
XX Disclosure; Page 4; 12pp; English.

XX The invention describes a method for the treatment or prevention of
CC intermittent claudication or skeletal muscle injury caused by ischaemia
CC and/or reperfusion in a human subject, comprising the administration of a
CC glucagon-like peptide-1 (GLP-1) molecule. The method is useful for
CC treating or preventing intermittent claudication or skeletal muscle
CC injury caused by ischaemia and/or reperfusion in a human subject
CC suffering from peripheral vascular disease (PVD). Administration of GLP-1
CC in a subject improves skeletal muscle performance by promoting glucose
CC oxidation and reducing fatty acid oxidation. This is the amino acid
CC sequence of a mammalian glucagon-like peptide-1 peptide GLP-1(1-37) that
CC can be used in the method of the invention.

XX Sequence 39 AA;

ADB84203 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)

1 HSDGTFTSLSKQMEAEVRLFIWLNKGPGSSGAPPPS
28

1 match found in sequence:
adb84205; Gila monster venom extendin 4.
(from "seq4ags.pep")
TOIG of: adb84205 check: 9570 from: 1 to: 39

ID ADB84205 standard; peptide; 39 AA.
XX
AC ADB84205;

XX 04-DEC-2003 (first entry)
 XX Gila monster venom exendin 4.
 XX vasotropic; intermittent claudication; skeletal muscle injury; ischaemia;
 KW glucagon-like peptide-1; GLP-1; peripheral vascular disease;
 KW glucose oxidation; fatty acid oxidation reduction; Gila monster venom;
 KW exendin 4.
 XX Heloderma suspectum.
 OS
 XX Key Location/Qualifiers
 FH Misc-difference 39
 FT /note= "C-terminal amide"
 XX
 XX US2003073626-A1.
 XX 17-APR-2003.
 XX 05-MAR-2002; 2002US-00091258.
 XX 30-APR-1999; 99US-00302596.
 PR 09-MAY-2001; 2001US-00851738.
 XX (HATH/) HATHWAY D R.
 PA (COOL/) COOLIDGE T R.
 XX Hathaway DR, Coolidge TR;
 XX WPI; 2003-677986/64;
 XX Method for the treatment or prevention of intermittent claudication or
 PT skeletal muscle injury caused by ischemia and/or reperfusion in a human
 PT subject, comprises administration of a glucagon-like peptide-1 molecule.
 XX Disclosure; Page 4; 12pp; English.
 XX The invention describes a method for the treatment or prevention of
 CC intermittent claudication or skeletal muscle injury caused by ischaemia
 CC and/or reperfusion in a human subject, comprising the administration of a
 CC glucagon-like peptide-1 (GLP-1) molecule. The method is useful for
 CC treating or preventing intermittent claudication or skeletal muscle
 CC injury caused by ischaemia and/or reperfusion in a human subject
 CC suffering from peripheral vascular disease (PVD). Administration of GLP-1
 CC in a subject improves skeletal muscle performance by promoting glucose
 CC oxidation and reducing fatty acid oxidation. This is the amino acid
 CC sequence of a mammalian glucagon-like peptide-1 (1-37) that
 CC can be used in the method of the invention.
 XX Sequence 39 AA;
 SQ
 ADB84205 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEFTFTDLSKQMBEEAVRLFIEWLKNGGPGSSGAPPPS
 28

 1 match found in sequence:
 add02757; Exendin-4 amino acid sequence SEQ ID NO:4.
 (from "seq4ags.pep")
 TOIG of: add02757 check: 9570 from: 1 to: 39
 ID ADD02757 standard; peptide; 39 AA.
 XX
 AC ADD02757;
 XX
 XX 01-JAN-2004 (first entry)
 XX Exendin-4 amino acid sequence SEQ ID NO:4.
 DE
 XX

KW insulin-secreting cell; glucagon-like peptide-1; GLP-1; diabetes; human;
 KW exendin-4.
 XX Homo sapiens.
 OS
 XX WO2003078462-A2.
 XX 25-SEP-2003.
 XX 11-MAR-2003; 2003WO-US007210.
 XX 12-MAR-2002; 2002US-00097230.
 PR (CEDA-) CEDARS SINAI MEDICAL CENT.
 PA Perfetti R, Hui H;
 PI WPI; 2003-779115/73.
 XX New insulin-secreting cell comprising an insulin-secreting cell
 PT transfected with a nucleotide sequence encoding a protein selected from
 PT glucagons-like peptide-1 (GLP) and its analog, useful for treating
 PT diabetes.
 XX Claim 7; SEQ ID NO 4; 45pp; English.
 XX The present invention describes an insulin-secreting cell comprising an
 CC insulin-secreting cell transfected with a nucleotide sequence encoding a
 CC protein selected from glucagon-like peptide-1 (GLP-1) and its analogue.
 CC Also described: (i) constructing an insulin-dependent glucose-secreting
 CC cell comprising: (a) providing an insulin-secreting cell; (b) isolating
 CC from a proglucagon a minigene construct comprising a nucleotide sequence
 CC comprising the coding region for a protein; (c) providing a plasmid; (d)
 CC transfecting the plasmid with the minigene construct; and (e) including
 CC the plasmid in the insulin-secreting cell; (2) determining the ability of
 CC a drug to stimulate cells to secrete insulin comprising: (a) providing an
 CC insulin by providing the insulin-secreting cell; (b) exposing the cell to
 CC the drug; and (c) measuring the amount of insulin secreted by the cell;
 CC and (3) supplying insulin to a mammal comprising: (a) providing the
 CC insulin-secreting cells; (b) exposing the cells to a body fluid of the
 CC mammal, the body fluid providing an indication of glucose level; and (c)
 CC transferring to the mammal insulin secreted from the cells. The insulin-
 CC secreting cell and methods are useful for treating diabetes. The cells
 CC are also useful for investigating the development and function of the
 CC pancreas, the cell that constitutes it, and the secretion it produces.
 CC The present sequence represents exendin-4, which is a GLP-1 receptor
 CC agonist used in the exemplification of the present invention.
 XX Sequence 39 AA;
 SQ
 ADD02757 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)
 1 HGEFTFTDLSKQMBEEAVRLFIEWLKNGGPGSSGAPPPS
 28

 1 match found in sequence:
 add12855; Exendin derivative parent peptide #1.
 (from "seq4ags.pep")
 TOIG of: add12855 check: 7617 from: 1 to: 31
 ID ADD12855 standard; peptide; 31 AA.
 XX
 AC ADD12855;
 XX
 XX 01-JAN-2004 (first entry)
 XX Exendin derivative parent peptide #1.
 XX GLP-1; glucagon-like peptide-1; exendin; antidiabetic; anti-obesity;
 KW insulinotropic; hypoglycaemic; insulin secretion; glucagon suppressor;
 KW

```

KW gastric emptying inhibitor; pancreatic secretion inhibitor;
KW non-insulin-dependent diabetes mellitus;
KW insulin-dependent diabetes mellitus; obesity; hyperglycaemia.
OS Synthetic.
XX
XX
XX Key Location/Qualifiers
XX Misc-difference 31
XX /label= Pro, Tyr
XX
XX
XX WO9843708-A1.
XX
XX 02-SEP-1999.
XX
XX 25-FEB-1999; 99WO-DK000086.
XX
XX 27-FEB-1998; 98DK-00000274.
XX 05-MAY-1998; 98US-0084357P.
XX
XX (NOVO ) NOVO-NORDISK AS.
XX
XX Knudsen LB, Huusfeldt PO, Nielsen PF, Madsen K;
XX
XX WPI; 1999-540562/45.
XX
XX New derivatives of glucagon-like peptide-1 and exendin containing
XX lipophilic substituent, for treating diabetes and obesity.
XX
XX Claim 82; Page 61; 69pp; English.
XX
XX The present invention describes derivatives (A1) of GLP-1 (glucagon-like
XX peptide-1) (7-c) (with c = 35 or 36) having just one lipophilic
XX substituent (LS) attached to the C-terminal amino acid (aa) and
XX derivatives (A2) of exendin with LS attached to at least one aa of the
XX parent peptide. A1 excludes compounds Arg26, Arg34, Lys36-(N-
XX epsilon(omega-carboxyl)-GLP-1(7-36)-OH, where X = nonadecanoyl,
XX heptadecanoyl, undecanoyl or heptanoyl. Also described are compositions
XX containing A1 and A2 plus a vehicle or carrier. A1 and A2 have
XX antidiabetic, anti-obesity, insulinotropic and hypoglycaemic activities.
XX A1 stimulates secretion of insulin but suppresses that of glucagon. They
XX also inhibit gastric emptying and pancreatic secretion and may reduce
XX food intake. A1 and A2 are used to treat (non-)insulin-dependent diabetes
XX mellitus and obesity, and also to prevent hyperglycaemia. A1 and A2 have
XX a greater persistence in vivo than corresponding peptides without LS
XX (because of reduced sensitivity to dipeptidyl peptidases). When
XX formulated with other antidiabetic agents, they often produce a
XX synergistic effect. The present sequence represents an exendin derivative
XX parent peptide, which is used in the exemplification of the present
XX invention.
XX
XX Sequence 31 AA;
XX
XX ADD12855 Length: 31 February 4, 2005 13:19 Type: P Check: 7617 ..
XX Found using 'seq4' (mohamed337.key)
XX
1 HSGTGFTSDLSKQMEEEAVRLFIEWLKNGGX
1 28
-----|
1 match found in sequence:
1 adf44966 ; H. horridum exendin-3 peptide fragment.
1 (from "seq4ags.pep")
1 TOIG of: adf44966 check: 9591 from: 1 to: 39
-----|
ID ADF44966 standard; peptide; 39 AA.
XX
XX ADF44966;
XX
XX 12-FEB-2004 (first entry)
XX
XX H. horridum exendin-3 peptide fragment.
XX
XX

```

```

KW detection; EST; expressed sequence tag library; conserved structure;
KW pharmaceutical; drug target; mexican bearded lizard; natriuretic peptide;
KW bradykinin; angiotensin-converting enzyme; ss; exendin-3.
XX
XX Heloderma horridum.
XX
XX WO2003071268-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-EP001765.
XX
XX 20-FEB-2002; 2002DE-01008187.
XX
XX (PAIO-) PATON GMBH.
XX
XX Schleuning W, Schulz T;
XX
XX WPI; 2003-697652/66.
XX
XX Identifying substances with a specific activity in target organisms,
XX useful for drug development, by detecting compounds with related activity
XX in reference organisms.
XX
XX Example 1; Page 28; 76pp; German.
XX
XX This invention describes a novel method for discovering a substance that
XX is pharmaceutically active in a target organism. The method comprises
XX generating an EST (expressed sequence tag) library from the reference
XX organism or tissue and identifying active compounds in the reference
XX material, particularly by structure/sequence comparison between the EST
XX library and sequence information on the target organism. Particularly at
XX least two reference organisms are used, to allow identification of
XX conserved structures, which are then used to identify orthologous
XX structures in the target. Optionally the orthologous structures are then
XX modified, e.g. by structure-based optimisation of the required
XX properties. The method is used to identify polypeptides which are then
XX used optionally after optimisation of properties, as pharmaceuticals, or
XX after validation as a drug target, for development of ligands, also
XX potential pharmaceuticals. Polypeptides and nucleic acids encoding them,
XX can also be used for identification and validation of drug targets and
XX for identifying lead structures for pharmaceutical development. The
XX method facilitates discovery of agents that are biologically active,
XX specifically in humans, and should reduce the time between discovery and
XX development of new drugs, since previous understanding of molecular
XX mechanisms of pathology or of the structures involved in drug design are
XX not necessary. The identified drugs will usually be very specific, with
XX reduced side effects. Sequencing of a cDNA bank from the mexican bearded
XX lizard Heloderma horridum indicated a 736 bp sequence that, by comparison
XX with sequences in published databases, encoded a 196 amino acid precursor
XX of natriuretic peptide. Analysis of corresponding sequences from other
XX reptiles showed that the N-terminal region of the new sequence probably
XX encodes peptides that potentiate the effect of bradykinin and inhibit
XX angiotensin-converting enzyme.
XX
XX Sequence 39 AA;
XX
XX ADF44966 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
XX Found using 'seq4' (mohamed337.key)
XX
1 HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGSSGAPPPS
1 28
-----|
1 match found in sequence:
1 adg73288 ; Glucagon-like peptide-1-related Exendin-3 peptide.
1 (from "seq4ags.pep")
1 TOIG of: adg73288 check: 9591 from: 1 to: 39
-----|
ID ADG73288 standard; peptide; 39 AA.
XX
XX ADG73288;
XX

```

```

XX 11-MAR-2004 (first entry)
XX Glucagon-like peptide-1-related Extendin-3 peptide.
XX
XX GLP-1; glucagon-like peptide-1; antidiabetic; anorectic;
XX cerebroprotective; cardiant; antiinflammatory; gastrointestinal;
XX vasotrophic; insulin-dependent diabetes; obesity; stroke;
XX myocardial infarction; catabolic change; surgery; functional dyspepsia;
XX irritable bowel syndrome; oral administration; Extendin-3.
XX
XX Unidentified.
XX
XX Key Location/Qualifiers
XX Modified-site 39 /note= "C-terminal amide"
XX
XX WO2003072195-A2.
XX
XX 04-SEP-2003.
XX
XX 07-FEB-2003; 2003WO-US003111.
XX
XX 20-FEB-2002; 2002US-0358184P.
XX
XX (ELIL ) LILLY & CO ELI.
XX Khan MA;
XX
XX WPI; 2003-731576/69.
XX
XX Pharmaceutical formulation, useful e.g. for the treatment of non-insulin-
XX dependent diabetes, obesity, stroke or myocardial infarction, comprises
XX glucagon-like peptide-1 and a delivery agent.
XX
XX Claim 2; SEQ ID NO 10; 72pp; English.
XX
XX The invention relates to a novel pharmaceutical formulation comprising a
XX GLP-1 (glucagon-like peptide-1) compound and a delivery agent. The
XX formulation of the invention demonstrates antidiabetic, anorectic,
XX cerebroprotective, cardiant, antiinflammatory, gastrointestinal and
XX vasotrophic activities and may be useful for the treatment of insulin-
XX dependent diabetes, obesity, stroke, myocardial infarction, catabolic
XX changes after surgery, functional dyspepsia and irritable bowel syndrome.
XX When formulated with a delivery agent the GLP-1 compound can cross
XX intestinal membranes while remaining active, allowing oral
XX administration. The current sequence is that of the glucagon-like peptide
XX -1-related Extendin-3 peptide of the invention.
XX
XX Sequence 39 AA;
XX
ADG73288 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HSGGFTTSLSKQMEEEAVRLFIWLKNGPSSGAPPPS
28
-----
1 match found in sequence:
adg73289; Glucagon-like peptide-1-related Extendin-4 peptide.
(from "seq4ags.pep")
TOIG of: adg73289 check: 9570 from: 1 to: 39

ID ADG73289 standard; peptide; 39 AA.
XX
XX AC ADG73289;
XX
XX 11-MAR-2004 (first entry)
XX
XX Glucagon-like peptide-1-related Extendin-4 peptide.
XX
XX GLP-1; glucagon-like peptide-1; antidiabetic; anorectic;

```

```

KW cerebroprotective; cardiant; antiinflammatory; gastrointestinal;
KW vasotrophic; insulin-dependent diabetes; obesity; stroke;
KW myocardial infarction; catabolic change; surgery; functional dyspepsia;
KW irritable bowel syndrome; oral administration; Extendin-4.
XX
XX Unidentified.
XX
XX Key Location/Qualifiers
XX Modified-site 39 /note= "C-terminal amide"
XX
XX WO2003072195-A2.
XX
XX 04-SEP-2003.
XX
XX 07-FEB-2003; 2003WO-US003111.
XX
XX 20-FEB-2002; 2002US-0358184P.
XX
XX (ELIL ) LILLY & CO ELI.
XX Khan MA;
XX
XX WPI; 2003-731576/69.
XX
XX Pharmaceutical formulation, useful e.g. for the treatment of non-insulin-
XX dependent diabetes, obesity, stroke or myocardial infarction, comprises
XX glucagon-like peptide-1 and a delivery agent.
XX
XX Claim 2; SEQ ID NO 11; 72pp; English.
XX
XX The invention relates to a novel pharmaceutical formulation comprising a
XX GLP-1 (glucagon-like peptide-1) compound and a delivery agent. The
XX formulation of the invention demonstrates antidiabetic, anorectic,
XX cerebroprotective, cardiant, antiinflammatory, gastrointestinal and
XX vasotrophic activities and may be useful for the treatment of insulin-
XX dependent diabetes, obesity, stroke, myocardial infarction, catabolic
XX changes after surgery, functional dyspepsia and irritable bowel syndrome.
XX When formulated with a delivery agent the GLP-1 compound can cross
XX intestinal membranes while remaining active, allowing oral
XX administration. The current sequence is that of the glucagon-like peptide
XX -1-related Extendin-4 peptide of the invention.
XX
XX Sequence 39 AA;
XX
ADG73289 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HCGGFTTSLSKQMEEEAVRLFIWLKNGPSSGAPPPS
28
-----
1 match found in sequence:
adh21336; Human albumin/extendin fragment fusion protein, SEQ ID NO:133.
(from "seq4ags.pep")
TOIG of: adh21336 check: 1808 from: 1 to: 648

ID ADH21336 standard; protein; 648 AA.
XX
XX AC ADH21336;
XX
XX 11-MAR-2004 (first entry)
XX
XX Human albumin/extendin fragment fusion protein, SEQ ID NO:133.
XX
XX Fusion protein; human serum albumin; HSA; therapeutic protein;
XX shelf-life; in vitro biological activity; in vivo biological activity;
XX metabolic disorder; endocrine disorder; diabetes; type 1; type 2;
XX diabetes-related condition; hyperglycaemia; neural disorder; neuropathy;
XX retinopathy; cardiovascular disorder; heart disease; renal disorder;
XX obesity; glucose level maintenance; weight loss; antidiabetic; cardiant;
XX anorectic; ophthalmological; gene therapy.

```

```

XX OS Chimeric.
XX OS Homo sapiens.
XX PN WO2003059934-A2.
XX XX 24-JUL-2003.
XX PF 23-DEC-2002; 2002WO-US040892.
XX XX
XX PR 21-DEC-2001; 2001US-0341811P.
XX PR 24-JAN-2002; 2002US-0350358P.
XX PR 26-FEB-2002; 2002US-0359370P.
XX PR 28-FEB-2002; 2002US-0360000P.
XX PR 27-MAR-2002; 2002US-0367500P.
XX PR 08-APR-2002; 2002US-0370227P.
XX PR 10-MAY-2002; 2002US-0378950P.
XX PR 24-JUL-2002; 2002US-0398008P.
XX PR 09-AUG-2002; 2002US-0402131P.
XX PR 13-AUG-2002; 2002US-0402708P.
XX PR 18-SEP-2002; 2002US-0411353P.
XX PR 02-OCT-2002; 2002US-0411355P.
XX PR 02-OCT-2002; 2002US-0414984P.
XX PR 11-OCT-2002; 2002US-0417611P.
XX PR 23-OCT-2002; 2002US-0420246P.
XX PR 05-NOV-2002; 2002US-0423623P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX XX
XX PI Rosen CA, Haseltine WA;
XX XX WPI; 2003-598501/56.
XX DR
XX PT New albumin fusion protein, useful for preparing a composition for
XX PS treating diabetes mellitus.
XX XX
XX CC The invention relates to fusion proteins comprising human serum albumin
XX CC (ADH21530) and a therapeutic polypeptide such as a therapeutic protein,
XX CC antibody or peptide or their variants or fragments. The therapeutic
XX CC protein may be fused to the N-terminus, the C-terminus or both termini of
XX CC albumin via a linker. The albumin component of the fusion proteins
XX CC prolongs the shelf-life and the in vitro and vivo biological activity of
XX CC the proteins compared with those of the corresponding therapeutic
XX CC proteins on their own. The invention also relates to nucleic acids
XX CC encoding albumin fusion proteins, vectors and host cells comprising an
XX CC albumin fusion protein nucleic acid, compositions and kits comprising an
XX CC albumin fusion protein, the method of extending the shelf-life of a
XX CC therapeutic protein by fusion with albumin, and the treatment of disease
XX CC using an albumin fusion protein. The albumin fusion proteins may be used
XX CC in the treatment of metabolic/endocrine disorders, diabetes and diabetes-
XX CC related to the invention.
XX SQ Sequence 648 AA;
ADH21336 Length: 648 February 4, 2005 13:20 Type: P Check: 1808 ..
Found using 'seq4' (mohamed337.key)
...
560 KPKATKEQLKAVMDPPAFAFVEKCKADKRETCFAEGRKKLVAASQAALGHGEGTFTSDL
610
-----|-----
620 SKQMEEAERVLFIENLKNKGPPSGAPPPS
637

```

1 match found in sequence:
adh21337 ; Human albumin/extendin fragment fusion protein, SEQ ID NO:134.
(from "seq4ags pep")
TOIG of: adh21337 check: 7050 from: 1 to: 648

ID ADH21337 standard; protein; 648 AA.
XX AC ADH21337;
XX DT 11-MAR-2004 (first entry)
XX DE Human albumin/extendin fragment fusion protein, SEQ ID NO:134.
XX KW Fusion protein; human serum albumin; HSA; therapeutic protein;
XX KW shelf-life; in vitro biological activity; in vivo biological activity;
XX KW metabolic disorder; endocrine disorder; diabetes; type 1; type 2;
XX KW diabetes-related condition; hyperglycaemia; neural disorder; neuropathy;
XX KW retinopathy; cardiovascular disorder; heart disease; renal disorder;
XX KW obesity; glucose level maintenance; weight loss; antidiabetic; cardiant;
XX KW anorectic; ophthalmological; gene therapy.
XX OS Chimeric.
XX OS Homo sapiens.
XX XX WO2003059934-A2.
XX XX 24-JUL-2003.
XX PF 23-DEC-2002; 2002WO-US040892.
XX XX
XX PR 21-DEC-2001; 2001US-0341811P.
XX PR 24-JAN-2002; 2002US-0350358P.
XX PR 26-FEB-2002; 2002US-0359370P.
XX PR 28-FEB-2002; 2002US-0360000P.
XX PR 27-MAR-2002; 2002US-0367500P.
XX PR 08-APR-2002; 2002US-0370227P.
XX PR 10-MAY-2002; 2002US-0378950P.
XX PR 24-JUL-2002; 2002US-0398008P.
XX PR 09-AUG-2002; 2002US-0402131P.
XX PR 13-AUG-2002; 2002US-0402708P.
XX PR 18-SEP-2002; 2002US-0411353P.
XX PR 02-OCT-2002; 2002US-0414984P.
XX PR 11-OCT-2002; 2002US-0417611P.
XX PR 23-OCT-2002; 2002US-0420246P.
XX PR 05-NOV-2002; 2002US-0423623P.
XX PA (HUMA-) HUMAN GENOME SCI INC.
XX XX
XX PI Rosen CA, Haseltine WA;
XX XX WPI; 2003-598501/56.
XX DR
XX PT New albumin fusion protein, useful for preparing a composition for
XX PS treating diabetes mellitus.
XX XX
XX CC The invention relates to fusion proteins comprising human serum albumin
XX CC (ADH21530) and a therapeutic polypeptide such as a therapeutic protein,
XX CC antibody or peptide or their variants or fragments. The therapeutic
XX CC protein may be fused to the N-terminus, the C-terminus or both termini of
XX CC albumin via a linker. The albumin component of the fusion proteins
XX CC prolongs the shelf-life and the in vitro and vivo biological activity of
XX CC the proteins compared with those of the corresponding therapeutic
XX CC proteins on their own. The invention also relates to nucleic acids
XX CC encoding albumin fusion proteins, vectors and host cells comprising an
XX CC albumin fusion protein nucleic acid, compositions and kits comprising an
XX CC albumin fusion protein, the method of extending the shelf-life of a
XX CC therapeutic protein by fusion with albumin, and the treatment of disease
XX CC using an albumin fusion protein. The albumin fusion proteins may be used
XX CC in the treatment of metabolic/endocrine disorders, diabetes and diabetes-
XX CC related to the invention.
XX SQ Sequence 648 AA;
ADH21336 Length: 648 February 4, 2005 13:20 Type: P Check: 1808 ..
Found using 'seq4' (mohamed337.key)
...
560 KPKATKEQLKAVMDPPAFAFVEKCKADKRETCFAEGRKKLVAASQAALGHGEGTFTSDL
610
-----|-----
620 SKQMEEAERVLFIENLKNKGPPSGAPPPS
637

CC related conditions. Specifically the albumin fusion proteins may be used
 CC to treat type 1 and type 2 diabetes, hyperglycaemia, neural disorders
 CC (especially neuropathy), retinopathy, cardiovascular disorders
 CC (especially heart disease, renal disorders and obesity. The proteins may
 CC also be used in a method of maintaining a basal glucose level in a
 CC patient and in a method for losing weight. The present sequence is
 CC related to the invention.
 XX Sequence 648 AA;

ADH21337 Length: 648 February 4, 2005 13:20 Type: P Check: 7050
 Found using 'seq4' (mohamed337.key)

1 MKWVSFISLLFLFSSAYSRLKRGEGTFTSDLSKQMEAEAVRLFIEWLKNKGSPSSGAP
 25

61 PPSDAHKSEVAHRFKDLGEENFKALVLIAPQYLOQCPFDH

...

1 match found in sequence:
 adh21405 ; Human extendin fragment, SEQ ID NO:202.
 (from "seq4ags.pep")
 TOIG of: adh21405 check: 973 from: 1 to: 87

ID ADH21405 standard; protein; 87 AA.

XX AC ADH21405;

XX DT 11-MAR-2004 (first entry)

XX DE Human extendin fragment, SEQ ID NO:202.

XX KW Fusion protein; human serum albumin; HSA; therapeutic protein;
 KW shelf-life; in vitro biological activity; in vivo biological activity;
 KW metabolic disorder; endocrine disorder; diabetes; type 1; type 2;
 KW diabetes-related condition; hyperglycaemia; neural disorder; neuropathy;
 KW retinopathy; cardiovascular disorder; heart disease; renal disorder;
 KW obesity; glucose level maintenance; weight loss; antidiabetic; cardiant;
 KW anorectic; ophthalmological; gene therapy.

XX OS Homo sapiens.

XX PN WO2003059934-A2.

XX PD 24-JUL-2003.

XX PF 23-DEC-2002; 2002WO-US040892.

XX PR 21-DEC-2001; 2001US-034181P.

XX PR 24-JAN-2002; 2002US-0350358P.

XX PR 26-FEB-2002; 2002US-0359370P.

XX PR 28-FEB-2002; 2002US-0360000P.

XX PR 27-MAR-2002; 2002US-0367500P.

XX PR 08-APR-2002; 2002US-0370227P.

XX PR 10-MAY-2002; 2002US-0378950P.

XX PR 24-JUL-2002; 2002US-0398008P.

XX PR 09-AUG-2002; 2002US-0402131P.

XX PR 13-AUG-2002; 2002US-0402708P.

XX PR 18-SEP-2002; 2002US-0411355P.

XX PR 02-OCT-2002; 2002US-0417611P.

XX PR 23-OCT-2002; 2002US-0420246P.

XX PR 05-NOV-2002; 2002US-0423623P.

XX PA (HUMA-) HUMAN GENOME SCI INC.

XX PT New albumin fusion protein, useful for preparing a composition for
 treating diabetes mellitus.

XX PS Disclosure; SEQ ID NO 202; 1086pp; English.

CC The invention relates to fusion proteins comprising human serum albumin
 CC (ADH21530) and a therapeutic polypeptide such as a therapeutic protein,
 CC antibody or peptide or their variants or fragments. The therapeutic
 CC protein may be fused to the N-terminus, the C-terminus or both termini of
 CC albumin via a linker. The albumin component of the fusion proteins
 CC prolongs the shelf-life and the in vitro and vivo biological activity of
 CC the proteins compared with those of the corresponding therapeutic
 CC proteins on their own. The invention also relates to nucleic acids
 CC encoding albumin fusion proteins, vectors and host cells comprising an
 CC albumin fusion protein nucleic acid, compositions and kits comprising an
 CC albumin fusion protein, the method of extending the shelf-life of a
 CC therapeutic protein by fusion with albumin, and the treatment of disease
 CC using an albumin fusion protein. The albumin fusion proteins may be used
 CC in the treatment of metabolic/endocrine disorders, diabetes and diabetes-
 CC related conditions. Specifically the albumin fusion proteins may be used
 CC to treat type 1 and type 2 diabetes, hyperglycaemia, neural disorders
 CC (especially neuropathy), retinopathy, cardiovascular disorders
 CC (especially heart disease, renal disorders and obesity. The proteins may
 CC also be used in a method of maintaining a basal glucose level in a
 CC patient and in a method for losing weight. The present sequence is
 CC related to the invention.

XX SQ Sequence 87 AA;

ADH21405 Length: 87 February 4, 2005 13:20 Type: P Check: 973
 Found using 'seq4' (mohamed337.key)

1 MKIILWLCVGLFLATLFPISWQMPVESGLSSEDSASSESPASKIKRGEGTFTSDLSKQ
 48

61 MEAEAVRLFIEWLKNKGSPSSGAPPSG
 75

1 match found in sequence:
 adh21406 ; Human extendin fragment, SEQ ID NO:203.
 (from "seq4ags.pep")
 TOIG of: adh21406 check: 973 from: 1 to: 87

ID ADH21406 standard; protein; 87 AA.

XX AC ADH21406;

XX DT 11-MAR-2004 (first entry)

XX DE Human extendin fragment, SEQ ID NO:203.

XX KW Fusion protein; human serum albumin; HSA; therapeutic protein;
 KW shelf-life; in vitro biological activity; in vivo biological activity;
 KW metabolic disorder; endocrine disorder; diabetes; type 1; type 2;
 KW diabetes-related condition; hyperglycaemia; neural disorder; neuropathy;
 KW retinopathy; cardiovascular disorder; heart disease; renal disorder;
 KW obesity; glucose level maintenance; weight loss; antidiabetic; cardiant;
 KW anorectic; ophthalmological; gene therapy.

XX OS Homo sapiens.

XX PN WO2003059934-A2.

XX PD 24-JUL-2003.

XX PF 23-DEC-2002; 2002WO-US040892.

XX PR 21-DEC-2001; 2001US-034181P.

XX PR 24-JAN-2002; 2002US-0350358P.

```
PR 26-FEB-2002; 2002US-0359370P.
PR 28-FEB-2002; 2002US-0360000P.
PR 27-MAR-2002; 2002US-0367500P.
PR 08-APR-2002; 2002US-0370227P.
PR 10-MAY-2002; 2002US-0378950P.
PR 24-JUL-2002; 2002US-0398008P.
PR 09-AUG-2002; 2002US-0402131P.
PR 13-AUG-2002; 2002US-0402708P.
PR 18-SEP-2002; 2002US-0411355P.
PR 02-OCT-2002; 2002US-0414984P.
PR 11-OCT-2002; 2002US-0417611P.
PR 23-OCT-2002; 2002US-0420246P.
PR 05-NOV-2002; 2002US-0423623P.
XX
XX (HUMA-) HUMAN GENOME SCI INC.
XX
XX Rosen CA, Haseltine WA;
XX
XX WPI; 2003-598501/56.
XX DR N-PSDB; ADH22126.
XX
XX New albumin fusion protein, useful for preparing a composition for
XX treating diabetes mellitus.
XX
XX Disclosure; SEQ ID NO 203; 1086pp; English.
XX
XX The invention relates to fusion proteins comprising human serum albumin
XX (ADH21530) and a therapeutic polypeptide such as a therapeutic protein,
XX antibody or peptide or their variants or fragments. The therapeutic
XX protein may be fused to the N-terminus, the C-terminus or both termini of
XX albumin via a linker. The albumin component of the fusion proteins
XX prolongs the shelf-life and the in vitro and vivo biological activity of
XX the proteins compared with those of the corresponding therapeutic
XX proteins on their own. The invention also relates to nucleic acids
XX encoding albumin fusion proteins, vectors and host cells comprising an
XX albumin fusion protein nucleic acid, compositions and kits comprising an
XX albumin fusion protein, the method of extending the shelf-life of a
XX therapeutic protein by fusion with albumin, and the treatment of disease
XX using an albumin fusion protein. The albumin fusion proteins may be used
XX in the treatment of metabolic/endocrine disorders, diabetes and diabetes-
XX related conditions. Specifically the albumin fusion proteins may be used
XX to treat type 1 and type 2 diabetes, hyperglycaemia, neural disorders
XX (especially neuropathy), retinopathy, cardiovascular disorders
XX (especially heart disease, renal disorders and obesity). The proteins may
XX also be used in a method of maintaining a basal glucose level in a
XX patient and in a method for losing weight. The present sequence is
XX related to the invention.
XX
XX Sequence 87 AA;
XX
ADH21406 Length: 87 February 4, 2005 13:20 Type: P Check: 973 ..
Found using 'seq4' (mohamed337.key)
1 MKILLWLCVGLFLATLFLPISQMPVESGLSSDSASSFSASKIKRHHGFTTSDLSQK
48
61 MEEAVRLFIEWLKGKGPSSGAPPPSG
75
-----|-----
1 match found in sequence:
adh22131; Exendin peptide, an insulintropic GLP-1 compound.
(from "seq4ags.pep")
TOIG of: adh22131 check: 7617 from: 1 to: 31
ID ADH22131 standard; peptide; 31 AA.
XX
XX ADH22131;
XX
XX 11-MAR-2004 (first entry)
XX
XX
```

```
DE Exendin peptide, an insulintropic GLP-1 compound.
XX
XX Type 1 diabetes; Latent Autoimmune Diabetes in the Adult; LADA; CD3;
XX GLP-1; beta-cell; glycaemic control; exendin; insulintropic;
XX immunosuppressive; antidiabetic.
XX
XX Unidentified.
XX
XX Key Location/Qualifiers
XX Misc-difference 31 /label= Pro, Tyr
XX
XX WO2003105897-A1.
XX
XX 24-DEC-2003.
XX
XX 12-JUN-2003; 2003WO-DK000387.
XX
XX 14-JUN-2002; 2002DK-00000909.
XX
XX (NOVO ) NOVO NORDISK AS.
XX
XX Michelsen BK, Sturis J;
XX
XX WPI; 2004-090758/09.
XX
XX Preventing and intervening of Type 1 diabetes and latent autoimmune
XX diabetes in the adult, comprising administering a modulator of CD3 and a
XX GLP-1 compound to a patient.
XX
XX Disclosure; Page 8; 24pp; English.
XX
XX This invention relates to a novel method for the prevention and
XX intervention into Type 1 diabetes and Latent Autoimmune Diabetes in the
XX Adult (LADA). Specifically, it refers to the administration of a
XX modulator derived from a CD3 and GLP-1 compound. This combined treatment
XX provides a synergistic effect and can attenuate the further destruction
XX of beta-cells, hence improving glycaemic control in diabetic patients.
XX Furthermore, it can be used as a prophylactic for people at high risk for
XX the development of type 1 diabetes and can provide an improved prognosis
XX with respect to microvascular and macrovascular complications. The
XX present invention describes exendin, a GLP-1 compound that is
XX insulintropic, as well as analogues and fragments derived thereof that
XX can be used to modulate beta cell function. Accordingly, the compositions
XX of this invention exhibit immunosuppressive and antidiabetic activities.
XX This peptide sequence is a GLP-1 compound, the exendin peptide of the
XX invention.
XX
XX Sequence 31 AA;
XX
ADH22131 Length: 31 February 4, 2005 13:20 Type: P Check: 7617 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTTSDLSKQMEEEAVRLFIEWLKGKX
28
-----|-----
1 match found in sequence:
adh73029; Glucagon like peptide-1 related exendin peptide 1.
(from "seq4ags.pep")
TOIG of: adh73029 check: 7617 from: 1 to: 31
ID ADH73029 standard; peptide; 31 AA.
XX
XX ADH73029;
XX
XX 25-MAR-2004 (first entry)
XX
XX Glucagon like peptide-1 related exendin peptide 1.
XX
XX cardiac disease; cardiovascular disease; diabetic patient;
XX non-diabetic patient; glucagon like peptide-1; GLP 1; cardiant;
```

KW cardiovascular-Gen; antiarrhythmic; antianginal; antiarteriosclerotic;
 KW vasotropic; hypotensive; glucose metabolism;
 KW cardiovascular haemodynamic regulator; left ventricular hypertrophy;
 KW coronary artery disease; essential hypertension;
 KW acute hypotensive emergency; cardiomyopathy; heart insufficiency;
 KW exercise tolerance; chronic heart failure; arrhythmia;
 KW cardiac dysrhythmia; syncope; atherosclerosis;
 KW mild chronic heart failure; angina pectoris; cardiac bypass reocclusion;
 KW intermittent claudication; atherosclerosis obliterans;
 KW diastolic dysfunction; systolic dysfunction; brain natriuretic peptide;
 KW BNP; myocardial infarction; acute coronary syndrome; unstable angina;
 KW non-Q-wave cardiac necrosis; Q-wave myocardial infarct; stroke.

XX Unidentified.

XX Key Location/Qualifiers
 XX Misc-difference 31
 FT /label= Pro, Tyr

XX WO2003084563-A1.

XX 16-OCT-2003.

XX 02-APR-2003; 2003WO-DK000216.

XX 04-APR-2002; 2002DK-00000499.

XX 23-APR-2002; 2002US-0375255P.

XX (NOVO) NOVO NORDISK AS.

XX Knudsen LB, Rolin BC, Carr RD, Selmer J, Larsen J, Elbrond B;
 PI Nielsen LB, Christoffersen C;
 XX WPI; 2004-022543/02.

XX Use of a glucagon like peptide-1 agonist or its salt for the preparation
 PT of a pharmaceutical composition for the treatment or prevention of an
 PT early cardiac or early cardiovascular disease in a diabetic or non-
 PT diabetic patient.

XX Disclosure; Page 7; 14pp; English.

XX This invention relates to a novel method for the treatment or prevention
 CC of an early cardiac or early cardiovascular disease in a diabetic or non-
 CC diabetic patient where a glucagon like peptide-1 (GLP 1) agonist or its
 CC salt is used. The invention may be useful for the development of
 CC compounds with a cardiant, cardiovascular-Gen, antiarrhythmic,
 CC antianginal, antiarteriosclerotic, vasotropic or hypotensive activity
 CC through action as glucose metabolism regulators or cardiovascular
 CC haemodynamics regulators. The invention may be used for the treatment or
 CC prevention of an early cardiac or early cardiovascular disease (for
 CC example left ventricular hypertrophy, coronary artery disease, essential
 CC hypertension, acute hypertensive emergency, cardiomyopathy, heart
 CC insufficiency, exercise tolerance, chronic heart failure, arrhythmia,
 CC cardiac dysrhythmia, syncope, atherosclerosis, mild chronic heart
 CC failure, angina pectoris, cardiac bypass reocclusion, intermittent
 CC claudication (for example atherosclerosis obliterans), diastolic
 CC dysfunction (for example dysfunction) in a diabetic or non-diabetic
 CC patient; for the preparation of a pharmaceutical composition for reducing
 CC the level of brain natriuretic peptide (BNP) in plasma and/or heart
 CC tissue in a diabetic or non-diabetic patient. The invention may also be
 CC useful for the treatment of myocardial infarction, acute coronary
 CC syndrome, unstable angina, non-Q-wave cardiac necrosis, Q-wave myocardial
 CC infarct and morbidity after stroke. The GLP-1 agonists are in the form of
 CC stable derivatives and exhibit a protracted profile of action compared to
 CC the corresponding other GLP-1 analogues. The GLP-1 analogues lower the
 CC brain natriuretic peptide (BNP) in the plasma and/or heart tissue, in
 CC addition to lowering blood glucose and plasma lipids. The present
 CC sequence is that of an exendin peptide which is related to the invention.

XX Sequence 31 AA;

ADH73029 Length: 31 February 4, 2005 13:20 Type: P Check: 7617

Found using 'seq4' (mohamed337.key)

1 HEGTFTSLSKQMBEEAVRLFIEWLKGGX
 1 28

1 match found in sequence:

ad124854; Exendin-4 as active moiety for pharmacologically active peptide.

(from "seq4ags.pep")

TOIG of: ad124854 check: 9570 from: 1 to: 39

ID AD124854 standard; peptide; 39 AA.

XX AC AD124854;

XX DT 15-APR-2004 (first entry)

XX DE Exendin-4 as active moiety for pharmacologically active peptide.

XX KW pharmacologically active peptide conjugate; enzymatic cleavage; pain;
 KW HIV; cancer; diabetes; incontinence; hypertension; amnesia;
 KW Alzheimer's disease; fever; depression; sex hormone regulation;
 KW eating disorder; schizophrenia; osteoporosis; insomnia;
 KW Central nervous system disorder; contraceptive.

XX OS Synthetic.

XX Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "amidated C-terminus"

XX PN WO9946283-A1.

XX PD 16-SEP-1999.

XX PF 09-MAR-1999; 99WO-DK000118.

XX PR 09-MAR-1998; 98DK-00000317.

XX PA (ZEAL-) ZEALAND PHARM AS.

XX PI Larsen BD;

XX WPI; 1999-561659/47.

XX New peptide conjugates used for treating, e.g. pain, HIV, depression,
 PT schizophrenia, osteoporosis or insomnia.

XX Claim 24; Page 91; 113pp; English.

XX The invention relates to a novel pharmacologically active peptide
 CC conjugate having a reduced tendency towards enzymatic cleavage comprises
 CC X and Z, where: (a) X is a pharmacologically active peptide sequence; and
 CC (b) Z is a stabilising peptide sequence of 4-20 amino acid units
 CC covalently bound to X, where each amino acid unit in the stabilizing
 CC peptide sequence, Z being selected from Ala, Leu, Ser, Thr, Tyr, Asn,
 CC Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of formula -
 CC NH-C(R1)(R2)-C(=O)- (1), where: R1 and R2 are H, 1-6C alkyl, phenyl, and
 CC phenyl-methyl, where 1-6C-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfonyl, and carboxy, and phenyl and phenyl-methyl are optionally
 CC substituted with 1-3 substituents selected from 1-6C-alkyl, 2-6C-alkenyl,
 CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R1 and R2
 CC 2 together with the C atom to which they are bound form a cyclopentyl,
 CC cyclohexyl or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid; the ratio between the half-life of the peptide
 CC conjugate and the half-life of the corresponding active peptide sequence,
 CC X, when treated with carboxypeptidase A or leucine aminopeptidase in
 CC about 50 mM phosphate buffer solution at about pH 7.4 and about 37 deg C
 CC or in serum or plasma is at least about 2 (preferably at least about 10),
 CC or when the pharmacologically active peptide X is not orally absorbed,
 CC the conjugate is adsorbed, or a salt, with the proviso that the

CC pharmacologically active peptide conjugate is not selected from sequences
 CC (AD124837)-(AD124841). The peptide conjugates can be used for treating
 CC e.g. pain, HIV, cancer, diabetes, incontinence, hypertension, amnesia,
 CC Alzheimer's disease, fever, depression, sex hormone regulation, eating
 CC disorders, schizophrenia, osteoporosis or insomnia. They can also be used
 CC for treating e.g. CNS disorders and as contraceptives. The conjugated
 CC peptides are less susceptible to degradation by proteases compared to the
 CC corresponding free pharmacologically active peptides. This sequence
 CC represents a pharmacologically active peptide as the X part of the
 CC peptide of the invention.

XX Sequence 39 AA;

AD124854 Length: 39 February 4, 2005 13:19 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGSGSPGAPPPS
 28

 1 match found in sequence:

ad124855 ; Exendin-3 as active moiety for pharmacologically active peptide.
 (from "seq4ags.pep")
 TOIG of: ad124855 check: 9591 from: 1 to: 39

ID AD124855 standard; peptide; 39 AA.

XX AC AD124855;

XX DT 15-APR-2004 (first entry)

XX DE Exendin-3 as active moiety for pharmacologically active peptide.

XX KW pharmacologically active peptide conjugate; enzymatic cleavage; pain;

XX KW HIV; cancer; diabetes; incontinence; hypertension; amnesia;

XX KW Alzheimer's disease; fever; depression; sex hormone regulation;

XX KW eating disorder; schizophrenia; osteoporosis; insomnia;

XX KW Central nervous system disorder; contraceptive.

XX OS Synthetic.

XX PN WO9946283-A1.

XX PD 16-SEP-1999.

XX PF 09-MAR-1999; 99WO-DK000119.

XX PR 09-MAR-1998; 98DK-00000317.

XX PA (ZEAL-) ZEALAND PHARM AS.

XX PI Larsen BD;

XX DR WPI; 1999-561659/47.

XX PT New peptide conjugates used for treating, e.g. pain, HIV, depression,
 PT schizophrenia, osteoporosis or insomnia.

XX PS Claim 24; Page 91; 113pp; English.

XX CC The invention relates to a novel pharmacologically active peptide
 CC conjugate having a reduced tendency towards enzymatic cleavage comprises
 CC X and Z, where: (a) X is a pharmacologically active peptide sequence; and
 CC (b) Z is a stabilising peptide sequence of 4-20 amino acid units
 CC covalently bound to X, where each amino acid unit in the stabilizing
 CC peptide sequence, Z being selected from Ala, Leu, Ser, Thr, Tyr, Asn,
 CC Gln, Asp, Glu, Lys, Arg, His, Met, Orn, and amino acid units of formula -
 CC NH-C(R1)(R2)-C(=O)- (I), where: R1 and R2 are H, 1-6C alkyl, phenyl, and
 CC phenyl-methyl, where 1-6C-alkyl is optionally substituted with 1-3
 CC substituents selected from halogen, hydroxy, amino, cyano, nitro,
 CC sulfono, and carboxy, and phenyl and phenyl-methyl are optionally
 CC substituted with 1-3 substituents selected from 1-6C-alkyl, 2-6C-alkenyl,

CC halogen, hydroxy, amino, cyano, nitro, sulfono, and carboxy, or R1 and R2
 CC 2 together with the C atom to which they are bound form a cyclopentyl,
 CC cyclohexyl or cycloheptyl ring, e.g. 2,4-diaminobutanoic acid and 2,3-
 CC diaminopropanoic acid; the ratio between the half-life of the peptide
 CC conjugate and the half-life of the corresponding active peptide sequence,
 CC X, when treated with carboxypeptidase A or leucine aminopeptidase in
 CC about 50 mM phosphate buffer solution at about pH 7.4 and about 37 deg C
 CC or in serum or plasma is at least about 2 (preferably at least about 10),
 CC or when the pharmacologically active peptide X is not orally absorbed,
 CC the conjugate is adsorbed, or a salt, with the proviso that the
 CC pharmacologically active peptide conjugate is not selected from sequences
 CC (AD124837)-(AD124841). The peptide conjugates can be used for treating
 CC e.g. pain, HIV, cancer, diabetes, incontinence, hypertension, amnesia,
 CC Alzheimer's disease, fever, depression, sex hormone regulation, eating
 CC disorders, schizophrenia, osteoporosis or insomnia. They can also be used
 CC for treating e.g. CNS disorders and as contraceptives. The conjugated
 CC peptides are less susceptible to degradation by proteases compared to the
 CC corresponding free pharmacologically active peptides. This sequence
 CC represents a pharmacologically active peptide as the X part of the
 CC peptide of the invention.

XX Sequence 39 AA;

AD124855 Length: 39 February 4, 2005 13:19 Type: P Check: 9591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGSGSPGAPPPS
 28

 1 match found in sequence:

ad166122 ; Exendin agonist peptide, SEQ ID No 1.
 (from "seq4ags.pep")
 TOIG of: ad166122 check: 9591 from: 1 to: 39

ID ADL66122 standard; peptide; 39 AA.

XX AC ADL66122;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 1.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;

XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;

XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;

XX KW dyslipidaemia; cardiovascular; Mexican beaded lizard.

XX OS Heloderma horridum.

XX FH Key Location/Qualifiers

XX FT Modified-site 39 /note= "C-terminal amide"

XX FT WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT exendin or an exendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 1; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an

CC extendin (agonist) peptide in an extended-release formulation. The

CC formulation is capable of releasing the peptide over a predetermined

CC release period, the period being at least one hour, and in an amount such

CC that, when the composition is administered to a human, an average

CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%

CC of the predetermined release period. The composition has antidiabetic,

CC anorectic, and antilipaeamic activities. The novel composition and method

CC are useful in treating diabetes and conditions that would be benefited by

CC lowering plasma glucose or delaying and/or slowing gastric emptying or

CC inhibiting food intake, such as impaired glucose tolerance, obesity,

CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence

CC represents an extendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66122 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..

Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGSPSSGAPPPS
28

1 match found in sequence:

adl66123 ; Extendin agonist peptide, SEQ ID No 2.

(from "seq4ags.pep")

TOIG of: adl66123 check: 9570 from: 1 to: 39

ID ADL66123 standard; peptide; 39 AA.

XX AC ADL66123;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 2.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;

XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;

XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;

XX KW dyslipidaemia; cardiovascular; gila monster.

XX OS Heloderma suspectum.

XX FH Key Location/Qualifiers

FT Modified-site 39 /note= "C-terminal amide"

FT FT

XX WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX The invention relates to a novel pharmaceutical composition comprising an

CC extendin (agonist) peptide in an extended-release formulation. The

CC formulation is capable of releasing the peptide over a predetermined

CC release period, the period being at least one hour, and in an amount such

CC that, when the composition is administered to a human, an average

CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%

CC of the predetermined release period. The composition has antidiabetic,

CC anorectic, and antilipaeamic activities. The novel composition and method

CC are useful in treating diabetes and conditions that would be benefited by

CC lowering plasma glucose or delaying and/or slowing gastric emptying or

CC inhibiting food intake, such as impaired glucose tolerance, obesity,

CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence

CC represents an extendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66123 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..

Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGSPSSGAPPPS
28

1 match found in sequence:

adl66126 ; Extendin agonist peptide, SEQ ID No 6.

(from "seq4ags.pep")

TOIG of: adl66126 check: 4889 from: 1 to: 30

ID ADL66126 standard; peptide; 30 AA.

XX AC ADL66126;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 6.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;

XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;

XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;

XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose

CC tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an

CC extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 2; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an

CC extendin (agonist) peptide in an extended-release formulation. The

CC formulation is capable of releasing the peptide over a predetermined

CC represents an extendin agonist peptide of the invention.

XX Sequence 30 AA;

ADL66126 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1 HEGTFTSDLSKQMEEEAVRLFIEWLKNGG
28

1 match found in sequence:
adl66127 ; Extendin agonist peptide, SEQ ID No 7.
(from "seq4ags.pep")
TOIG of: adl66127 check: 4889 from: 1 to: 30

ID ADL66127 standard; peptide; 30 AA.

XX AC ADL66127;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 7.

XX OS extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 30 /note= "C-terminal amide"

XX FT

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 7; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 30 AA;

ADL66127 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..

Found using 'seq4' (mohamed337.key)

1 HEGTFTSDLSKQMEEEAVRLFIEWLKNGG
28

1 match found in sequence:
adl66128 ; Extendin agonist peptide, SEQ ID No 8.
(from "seq4ags.pep")
TOIG of: adl66128 check: 151 from: 1 to: 28

ID ADL66128 standard; peptide; 28 AA.

XX AC ADL66128;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 8.

XX OS extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 8; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66128 Length: 28 February 4, 2005 13:20 Type: P Check: 151 ..
Found using 'seq4' (mohamed337.key)

1 HEGTFTSDLSKQMEEEAVRLFIEWLKNGG
28

1 match found in sequence:
adl66129 ; Exendin agonist peptide, SEQ ID No 9.
(from "seq4ags.pep")
TOIG of: adl66129 check: 9131 from: 1 to: 39

ID ADL66129 standard; peptide; 39 AA.

XX ADL66129;

AC ADL66129;

XX 20-MAY-2004 (first entry)

DT 20-MAY-2004 (first entry)

DE Exendin agonist peptide, SEQ ID No 9.
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

OS Synthetic.

XX Key Location/Qualifiers

FH Modified-site 39
FT /note= "C-terminal amide"

PN WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID No 9; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66129 Length: 39 February 4, 2005 13:20 Type: P Check: 9131 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSLSKQLEEAARVLFIEFKNGPSSGAPPPS
28
1

1 match found in sequence:
adl66130 ; Exendin agonist peptide, SEQ ID No 10.
(from "seq4ags.pep")

TOIG of: adl66130 check: 9556 from: 1 to: 39

ID ADL66130 standard; peptide; 39 AA.

XX ADL66130;

XX 20-MAY-2004 (first entry)

DT 20-MAY-2004 (first entry)

DE Exendin agonist peptide, SEQ ID No 10.

KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

OS Synthetic.

XX Key Location/Qualifiers

FH Modified-site 39
FT /note= "C-terminal amide"

PN WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID No 10; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66130 Length: 39 February 4, 2005 13:20 Type: P Check: 9556 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSLSKQLEEAARVLFIEFKNGPSSGAPPPS
28
1

1 match found in sequence:
adl66131 ; Exendin agonist peptide, SEQ ID No 11.
(from "seq4ags.pep")
TOIG of: adl66131 check: 9145 from: 1 to: 39

ID ADL66131 standard; peptide; 39 AA.

XX ADL66131;

XX 20-MAY-2004 (first entry)
 XX Extendin agonist peptide, SEQ ID No 11.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 PN WO2003099314-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 28-MAY-2003; 2003WO-US016699.
 XX
 PR 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX
 PT Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 PS Disclosure; SEQ ID NO 11; 173pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;
 ADL66131 Length: 39 February 4, 2005 13:20 Type: P Check: 9145 ..
 Found using 'seq4' (mohamed337.key)
 1 HEGGFTSDLSKQMBEEAVRLFIEFLKNGPSSGAPPPS
 28

 1 match found in sequence:
 adl66132 ; Extendin agonist peptide, SEQ ID No 12.
 (from "seq4ags.pep")
 TOIG of: adl66132 check: 9587 from: 1 to: 39

 ID ADL66132 standard; peptide; 39 AA.
 XX
 AC ADL66132;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 XX Extendin agonist peptide, SEQ ID No 12.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 PN WO2003099314-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 28-MAY-2003; 2003WO-US016699.
 XX
 PR 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX
 PT Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 PS Disclosure; SEQ ID NO 12; 173pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;
 ADL66132 Length: 39 February 4, 2005 13:20 Type: P Check: 9587 ..
 Found using 'seq4' (mohamed337.key)
 1 YGEGFTSDLSKQMBEEAVRLFIEFLKNGPSSGAPPPS
 28

 1 match found in sequence:
 adl66133 ; Extendin agonist peptide, SEQ ID No 13.
 (from "seq4ags.pep")
 TOIG of: adl66133 check: 9804 from: 1 to: 39

 ID ADL66133 standard; peptide; 39 AA.
 XX
 AC ADL66133;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 XX Extendin agonist peptide, SEQ ID No 13.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

```
OS Synthetic.
XX Key Location/Qualifiers
FH Modified-site 39 /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 13; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
SQ
ADL66134 Length: 39 February 4, 2005 13:20 Type: P Check: 9804 ..
Found using 'seq4' (mohamed337.key)
1 HGEGETSLSKQMEEEAVRLFIEWLKNGSPSGAPPPY
1 28
-----
1 match found in sequence:
adl66134 ; Extendin agonist peptide, SEQ ID No 14.
(from "seq4ags pep")
TOIG of: adl66134 check: 9567 from: 1 to: 39
ID ADL66134 standard; peptide; 39 AA.
XX
XX AC ADL66134;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 14.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 39 /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 13; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
SQ
ADL66134 Length: 39 February 4, 2005 13:20 Type: P Check: 9567 ..
Found using 'seq4' (mohamed337.key)
1 HGEGETSLSKQMEEEAVRLFIEWLKNGSPSGAPPPS
1 28
-----
1 match found in sequence:
adl66135 ; Extendin agonist peptide, SEQ ID No 15.
(from "seq4ags pep")
TOIG of: adl66135 check: 9678 from: 1 to: 39
ID ADL66135 standard; peptide; 39 AA.
XX
XX AC ADL66135;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 15.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 39 /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
```

```
PF 28-MAY-2003; 2003WO-US016699.
XX
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 15; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
ADL66135 Length: 39 February 4, 2005 13:20 Type: P Check: 9678 ..
Found using 'seq4' (mohamed337.key)
1 HEGGTXDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
1 28
-----
1 match found in sequence:
adl66136 ; Extendin agonist peptide, SEQ ID No 16.
(from "seq4tags.pep")
TOIG of: adl66136 check: 9563 from: 1 to: 39
-----
ID ADL66136 standard; peptide; 39 AA.
XX
XX AC ADL66136;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 16.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 39
XX /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
```

```
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 16; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
ADL66136 Length: 39 February 4, 2005 13:20 Type: P Check: 9563 ..
Found using 'seq4' (mohamed337.key)
1 HEGGTFSSDLSKQMEEEAVRLFIEWLKNGPSSGAPPPS
1 28
-----
1 match found in sequence:
adl66137 ; Extendin agonist peptide, SEQ ID No 17.
(from "seq4tags.pep")
TOIG of: adl66137 check: 9571 from: 1 to: 39
-----
ID ADL66137 standard; peptide; 39 AA.
XX
XX AC ADL66137;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 17.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 39
XX /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
```

PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 17; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66137 Length: 39 February 4, 2005 13:20 Type: P Check: 9571 ..
Found using 'seq4' (mohamed337.key)

1 HEGCTFTDLSKQMEEEAVRLFIWLKNGPSSGAPPPS
1
-----|-----|-----|
28

1 match found in sequence:
adl66138 ; Extendin agonist peptide, SEQ ID No 18.
(from "seq4ags.pep")
TOIG of: adl66138 check: 9578 from: 1 to: 39

ID ADL66138 standard; peptide; 39 AA.

XX
AC ADL66138;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 18.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 18; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66138 Length: 39 February 4, 2005 13:20 Type: P Check: 9578 ..
Found using 'seq4' (mohamed337.key)

1 HEGCTFTDLSKQMEEEAVRLFIWLKNGPSSGAPPPS
1
-----|-----|-----|
28

1 match found in sequence:
adl66139 ; Extendin agonist peptide, SEQ ID No 19.
(from "seq4ags.pep")
TOIG of: adl66139 check: 9579 from: 1 to: 39

ID ADL66139 standard; peptide; 39 AA.

XX

AC ADL66139;

XX

DT 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 19.

XX extendin; extended-release formulation; plasma level; antidiabetic;

KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;

KW inhibiting food intake; tolerance; obesity; hyperglycaemia;

KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

FH Modified-site 39

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 19; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such

CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;

ADL66139 Length: 39 February 4, 2005 13:20 Type: P Check: 9579 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTTSLSKQMBEEAVRLFIEWLKNGGPPSGAPPPS
 28

 1 match found in sequence:
 adl66140 ; Extendin agonist peptide, SEQ ID No 20.
 (from "seq4ags.pep")
 TOIG of: adl66140 check: 9690 from: 1 to: 39

ID ADL66140 standard; peptide; 39 AA.
 XX
 AC ADL66140;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 20.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT Modified-site 10 /note= "Pentylglycine"
 FT Modified-site 39 /note= "C-terminal amide"
 FT
 XX WO2003099314-A1.
 XX
 PD 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young AA, Kolterman OG;
 XX
 DR WPI; 2004-042706/04.

XX
 PT Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 PS Disclosure; SEQ ID NO 20; 173pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;

CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;

ADL66140 Length: 39 February 4, 2005 13:20 Type: P Check: 9690 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTTSDXSKQMBEEAVRLFIEWLKNGGPPSGAPPPS
 28

 1 match found in sequence:
 adl66141 ; Extendin agonist peptide, SEQ ID No 21.
 (from "seq4ags.pep")
 TOIG of: adl66141 check: 9251 from: 1 to: 39

ID ADL66141 standard; peptide; 39 AA.
 XX
 AC ADL66141;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 21.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT Modified-site 10 /note= "Pentylglycine"
 FT Modified-site 39 /note= "C-terminal amide"
 FT
 XX WO2003099314-A1.
 XX
 PD 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 PA (AMYL-) AMYLIN PHARM INC.
 XX
 PI Young AA, Kolterman OG;
 XX
 DR WPI; 2004-042706/04.

XX
 PT Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX
 PS Disclosure; SEQ ID NO 21; 173pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX
 SQ Sequence 39 AA;

CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX
 SQ Sequence 39 AA;

ADL66141 Length: 39 February 4, 2005 13:20 Type: P Check: 9251 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQEEAVRLFIEWLNKGSPSSGAPPPS
 1
 28

1 match found in sequence:
 adl66142 ; Extendin agonist peptide, SEQ ID No 22.
 (from "seq4ags.pep")
 TOIG of: adl66142 check: 9724 from: 1 to: 39

ID ADL66142 standard; peptide; 39 AA.

XX
 AC ADL66142;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 22.

XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
 FH Modified-site 14
 FT /note= "Pentylglycine"

FT Modified-site 39
 FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 22; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX
 SQ Sequence 39 AA;

ADL66142 Length: 39 February 4, 2005 13:20 Type: P Check: 9724 ..
 Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQEEAVRLFIEWLNKGSPSSGAPPPS
 1
 28

1 match found in sequence:
 adl66143 ; Extendin agonist peptide, SEQ ID No 23.
 (from "seq4ags.pep")
 TOIG of: adl66143 check: 9299 from: 1 to: 39

ID ADL66143 standard; peptide; 39 AA.

XX
 AC ADL66143;

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 23.

XX extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
 FH Modified-site 14
 FT /note= "Pentylglycine"

FT Modified-site 39
 FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 23; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66143 Length: 39 February 4, 2005 13:20 Type: P Check: 9299 ..
Found using 'seq4' (mohamed337.key)

1 HEGFTSLSKQXBEAVRLFIEFLKNGSPSSGAPPPS
28

1 match found in sequence:
adl66144 ; Exendin agonist peptide, SEQ ID No 24.
(from "seq4ags.pep")
TOIG of: adl66144 check: 9966 from: 1 to: 39

ID ADL66144 standard; peptide; 39 AA.

XX AC ADL66144;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 24.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 22 /note= "Naphthylalanine"

XX FT Modified-site 39 /note= "C-terminal amide"

XX FT WO2003099314-A1.

XX PN 04-DEC-2003.

XX PD 28-MAY-2003; 2003WO-US016699.

XX PF 28-MAY-2002; 2002US-00157224.

XX PR (AMYL-) AMYLIN PHARM INC.

XX PA Young AA, Kolterman OG;

XX PI WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an exendin or an exendin agonist peptide in an extended-release formulation.

XX PT Disclosure; SEQ ID No 24; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an exendin (agonist) peptide in an extended-release formulation. The formulation is capable of releasing the peptide over a predetermined release period, the period being at least one hour, and in an amount such that, when the composition is administered to a human, an average sustained plasma level of at least 5 pg/ml is achieved for at least 25% of the predetermined release period. The composition has antidiabetic, anorectic, and antilipaeamic activities. The novel composition and method are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake, such as impaired glucose tolerance, obesity, hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence represents an exendin agonist peptide of the invention.

XX SQ Sequence 39 AA;

ADL66144 Length: 39 February 4, 2005 13:20 Type: P Check: 9966 ..
Found using 'seq4' (mohamed337.key)

1 HEGFTSLSKQMEEAVALXIEWLKGSPSSGAPPPS
28

1 match found in sequence:
adl66145 ; Exendin agonist peptide, SEQ ID No 25.
(from "seq4ags.pep")
TOIG of: adl66145 check: 9869 from: 1 to: 39

ID ADL66145 standard; peptide; 39 AA.

XX AC ADL66145;

XX DT 20-MAY-2004 (first entry)

XX DE Exendin agonist peptide, SEQ ID No 25.

XX KW exendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 39 /note= "C-terminal amide"

XX FT WO2003099314-A1.

XX PN 04-DEC-2003.

XX PD 28-MAY-2003; 2003WO-US016699.

XX PF 28-MAY-2002; 2002US-00157224.

XX PR (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an exendin or an exendin agonist peptide in an extended-release formulation.

XX PT Disclosure; SEQ ID No 25; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an exendin (agonist) peptide in an extended-release formulation. The formulation is capable of releasing the peptide over a predetermined release period, the period being at least one hour, and in an amount such that, when the composition is administered to a human, an average sustained plasma level of at least 5 pg/ml is achieved for at least 25% of the predetermined release period. The composition has antidiabetic, anorectic, and antilipaeamic activities. The novel composition and method are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake, such as impaired glucose tolerance, obesity, hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence represents an exendin agonist peptide of the invention.

XX SQ Sequence 39 AA;

ADL66145 Length: 39 February 4, 2005 13:20 Type: P Check: 9869 ..
Found using 'seq4' (mohamed337.key)

1 HEGFTSLSKQMEEAVALXIEWLKGSPSSGAPPPS
28

1 match found in sequence:
adl66146 ; Exendin agonist peptide, SEQ ID No 26.
(from "seq4ags.pep")
TOIG of: adl66146 check: 9430 from: 1 to: 39

ID ADL66146 standard; peptide; 39 AA.

AC ADL66146;

DT 20-MAY-2004 (first entry)

DE Exendin agonist peptide, SEQ ID No 26.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

OS Synthetic.

XX Key Location/Qualifiers

FT Modified-site 39 /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID No 26; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an exendin (agonist) peptide in an extended-release formulation. The formulation is capable of releasing the peptide over a predetermined release period, the period being at least one hour, and in an amount such that, when the composition is administered to a human, an average sustained plasma level of at least 5 pg/ml is achieved for at least 25% of the predetermined release period. The composition has antidiabetic, anorectic, and antilipaeamic activities. The novel composition and method are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake, such as impaired glucose tolerance, obesity, hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence represents an exendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66146 Length: 39 February 4, 2005 13:20 Type: P Check: 9430 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTSDLSKQLEBEAVRLFVEFLKNGGPGSSGAPPPS
28

1 match found in sequence:
adl66147 ; Exendin agonist peptide, SEQ ID No 27.
(from "seq4ags.pep")
TOIG of: adl66147 check: 9915 from: 1 to: 39

ID ADL66147 standard; peptide; 39 AA.

AC ADL66147;

DT 20-MAY-2004 (first entry)

DE Exendin agonist peptide, SEQ ID No 27.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

OS Synthetic.

XX Key Location/Qualifiers

FT Modified-site 23 /note= "Tertiary-butylglycine"

FT Modified-site 39 /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID No 27; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an exendin (agonist) peptide in an extended-release formulation. The formulation is capable of releasing the peptide over a predetermined release period, the period being at least one hour, and in an amount such that, when the composition is administered to a human, an average sustained plasma level of at least 5 pg/ml is achieved for at least 25% of the predetermined release period. The composition has antidiabetic, anorectic, and antilipaeamic activities. The novel composition and method are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake, such as impaired glucose tolerance, obesity, hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence represents an exendin agonist peptide of the invention.

XX Sequence 39 AA;

ADL66147 Length: 39 February 4, 2005 13:20 Type: P Check: 9915 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTFTSDLSKQMBEAVRLFEXWLKNGGPGSSGAPPPS
28

1 match found in sequence:
adl66148 ; Exendin agonist peptide, SEQ ID No 28.
(from "seq4ags.pep")
TOIG of: adl66148 check: 9476 from: 1 to: 39

ID ADL66148 standard; peptide; 39 AA.

XX ADL66148;


```

KW dyslipidaemia; cardiovascular.
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FT Modified-site 39 /note= "C-terminal amide"
FT
FT
XX WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX PS Disclosure; SEQ ID NO 30; 173pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
ADL66150 Length: 39 February 4, 2005 13:20 Type: P Check: 9119 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HAEGTFTSLSKQLEEEAVRLFIETLKNGSPSGAPPPS
28
-----
1 match found in sequence:
adl66151; Extendin agonist peptide, SEQ ID No 31.
(from "seq4ags.pep")
TOIG of: adl66151 check: 706 from: 1 to: 39
ID ADL66151 standard; peptide; 39 AA.
XX
XX AC ADL66151;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 31.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 36.38
FT
FT
XX Modified-site 31 /note= "Thioproline"
XX Modified-site 36.38
XX Modified-site 39 /note= "Thioproline"
XX Modified-site 39 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX PS Disclosure; SEQ ID NO 31; 173pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
ADL66151 Length: 39 February 4, 2005 13:20 Type: P Check: 706 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HEGTFTSLSKQMBEEAVRLFIETLKNGSGGAXXXS
28
-----
1 match found in sequence:
adl66152; Extendin agonist peptide, SEQ ID No 32.
(from "seq4ags.pep")
TOIG of: adl66152 check: 458 from: 1 to: 39
ID ADL66152 standard; peptide; 39 AA.
XX
XX AC ADL66152;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 32.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 36.38

```

```

FT Modified-site 39 /note= "Thioproline"
FT FT 39 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX DR
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 32; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 39 AA;
ADL66152 Length: 39 February 4, 2005 13:20 Type: P Check: 458 ..
Found using 'seq4' (mohamed337.key)
1 HGEGFTSDLSQMEEAVRLFIEWLKNGGSPSSGAXXXS
1 -----|-----|
1 HGEGFTSDLSQMEEAVRLFIEWLKNGGSPSSGAXXXS
28
-----|
1 match found in sequence:
adl66153 ; Extendin agonist peptide, SEQ ID No 33.
(from "seq4ags.pep")
TOIG of: adl66153 check: 706 from: 1 to: 39
ID ADL66153 standard; peptide; 39 AA.
XX AC
XX ADL66153;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DE
XX DE Extendin agonist peptide, SEQ ID No 33.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS
XX Synthetic.
XX FH Key Location/Qualifiers
FH Modified-site 31
FT Modified-site /note= "Homoproline"
FT Modified-site 36.38
FT Modified-site /note= "Homoproline"
FT Modified-site 39
FT Modified-site /note= "C-terminal amide"
XX

```

```

FT Modified-site 39 /note= "Thioproline"
FT FT 39 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX DR
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 32; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 39 AA;
ADL66153 Length: 39 February 4, 2005 13:20 Type: P Check: 458 ..
Found using 'seq4' (mohamed337.key)
1 HGEGFTSDLSQMEEAVRLFIEWLKNGGSPSSGAXXXS
1 -----|-----|
1 HGEGFTSDLSQMEEAVRLFIEWLKNGGSPSSGAXXXS
28
-----|
1 match found in sequence:
adl66153 ; Extendin agonist peptide, SEQ ID No 33.
(from "seq4ags.pep")
TOIG of: adl66153 check: 706 from: 1 to: 39
ID ADL66153 standard; peptide; 39 AA.
XX AC
XX ADL66153;
XX AC
XX DT 20-MAY-2004 (first entry)
XX DE
XX DE Extendin agonist peptide, SEQ ID No 33.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS
XX Synthetic.
XX FH Key Location/Qualifiers
FH Modified-site 31
FT Modified-site /note= "Homoproline"
FT Modified-site 36.38
FT Modified-site /note= "Homoproline"
FT Modified-site 39
FT Modified-site /note= "C-terminal amide"
XX

```

```
PN WO2003099314-A1.
XX 04-DEC-2003.
PD
XX
XX
XX 28-MAY-2003; 2003WO-US016699.
PF
XX
XX 28-MAY-2002; 2002US-00157224.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young AA, Kolterman OG;
PI
XX
XX WPI; 2004-042706/04.
DR
XX
XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 34; 173pp; English.
PS
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
SQ
ADL66154 Length: 39 February 4, 2005 13:20 Type: P Check: 458 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQMBEEAVRLFIEFLKNGGPGSSGAXXXS
1 28
-----
1 match found in sequence:
adl66155 ; Extendin agonist peptide, SEQ ID No 35.
(from "seq4ags.pep")
TOIG of: adl66155 check: 267 from: 1 to: 39
ID ADL66155 standard; peptide; 39 AA.
XX
XX AC ADL66155;
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Extendin agonist peptide, SEQ ID No 35.
DE
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 31 /note= "Thioprolin"
FT Modified-site 36.38
FT Modified-site 36.38
FT Modified-site 39 /note= "Thioprolin"
FT Modified-site 39 /note= "C-terminal amide"
FT
XX WO2003099314-A1.
PN
```

```
XX 04-DEC-2003.
PD
XX
XX
XX 28-MAY-2003; 2003WO-US016699.
PF
XX
XX 28-MAY-2002; 2002US-00157224.
PR
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX
XX Young AA, Kolterman OG;
PI
XX
XX WPI; 2004-042706/04.
DR
XX
XX
PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 35; 173pp; English.
PS
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 39 AA;
SQ
ADL66155 Length: 39 February 4, 2005 13:20 Type: P Check: 267 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLSKQMBEEAVRLFIEFLKNGGPGSSGAXXXS
1 28
-----
1 match found in sequence:
adl66156 ; Extendin agonist peptide, SEQ ID No 36.
(from "seq4ags.pep")
TOIG of: adl66156 check: 267 from: 1 to: 39
ID ADL66156 standard; peptide; 39 AA.
XX
XX AC ADL66156;
XX
XX 20-MAY-2004 (first entry)
DT
XX
XX Extendin agonist peptide, SEQ ID No 36.
DE
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 31 /note= "Homoprolin"
FT Modified-site 36.38
FT Modified-site 36.38
FT Modified-site 39 /note= "Homoprolin"
FT Modified-site 39 /note= "C-terminal amide"
FT
XX WO2003099314-A1.
PN
```

```
PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX FI WPI; 2004-042706/04.
XX DR
XX XX Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 36; 173pp; English.
XX XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 39 AA;
ADL66156 Length: 39 February 4, 2005 13:20 Type: P Check: 267 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLKQLEEEAVRLFIETFLKNGXSGAXXXS
1 |-----|
1 HGEFTFTSLKQLEEEAVRLFIETFLKNGXSGAXXXS
28
-----
1 match found in sequence:
adl66157 ; Extendin agonist peptide, SEQ ID No 37.
(from "seq4ags.pep")
TOIG of: adl66157 check: 706 from: 1 to: 39
ID ADL66157 standard; peptide; 39 AA.
XX
XX AC ADL66157;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 37.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 31 /note= "N-methylalanine"
XX FT Modified-site 36..38
XX FT Modified-site /note= "N-methylalanine"
XX FT Modified-site 39 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX FI WPI; 2004-042706/04.
XX DR
XX XX Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 36; 173pp; English.
XX XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 39 AA;
ADL66157 Length: 39 February 4, 2005 13:20 Type: P Check: 706 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLKQLEEEAVRLFIETFLKNGXSGAXXXS
1 |-----|
1 HGEFTFTSLKQLEEEAVRLFIETFLKNGXSGAXXXS
28
-----
1 match found in sequence:
adl66158 ; Extendin agonist peptide, SEQ ID No 38.
(from "seq4ags.pep")
TOIG of: adl66158 check: 458 from: 1 to: 39
ID ADL66158 standard; peptide; 39 AA.
XX
XX AC ADL66158;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 38.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 36..38 /note= "N-methylalanine"
XX FT Modified-site 39 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX FI WPI; 2004-042706/04.
XX DR
XX XX Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 37; 173pp; English.
XX XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 39 AA;
ADL66157 Length: 39 February 4, 2005 13:20 Type: P Check: 706 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTFTSLKQLEEEAVRLFIETFLKNGXSGAXXXS
1 |-----|
1 HGEFTFTSLKQLEEEAVRLFIETFLKNGXSGAXXXS
28
-----
1 match found in sequence:
adl66158 ; Extendin agonist peptide, SEQ ID No 38.
(from "seq4ags.pep")
TOIG of: adl66158 check: 458 from: 1 to: 39
ID ADL66158 standard; peptide; 39 AA.
XX
XX AC ADL66158;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 38.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 36..38 /note= "N-methylalanine"
XX FT Modified-site 39 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX FI WPI; 2004-042706/04.
XX DR
XX XX Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 37; 173pp; English.
XX XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 39 AA;
```


DR WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 40; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ . Sequence 28 AA;
ADL66160 Length: 28 February 4, 2005 13:20 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)
1 HCGEGFTSDLSKQMEEEAVRLFIEWLNK 28
|-----|
1 match found in sequence:
adl66161 ; Exendin agonist peptide, SEQ ID No 41.
(from "seq4ags.pep")
TOIG of: adl66161 check: 261 from: 1 to: 28

ID ADL66161 standard; peptide; 28 AA.
XX
XX AC ADL66161;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Exendin agonist peptide, SEQ ID No 41.
XX
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 41; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ . Sequence 28 AA;
ADL66161 Length: 28 February 4, 2005 13:20 Type: P Check: 261 ..
Found using 'seq4' (mohamed337.key)
1 HCGEGFTSDLSKQMEEEAVRLFIEWLNK 28
|-----|
1 match found in sequence:
adl66162 ; Exendin agonist peptide, SEQ ID No 42.
(from "seq4ags.pep")
TOIG of: adl66162 check: 249 from: 1 to: 28

ID ADL66162 standard; peptide; 28 AA.
XX
XX AC ADL66162;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Exendin agonist peptide, SEQ ID No 42.
XX
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 42; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The

CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66162 Length: 28 February 4, 2005 13:20 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HAEGFTSDLSKQLEEAARLFIETLKN 28

1 match found in sequence:
adl66163 ; Extendin agonist peptide, SEQ ID NO 43.
(from "seq4ags.pep")
TOIG of: adl66163 check: 166 from: 1 to: 28

ID ADL66163 standard; peptide; 28 AA.

XX AC

XX AC

XX AC

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID NO 43.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 28

FT /note= "C-terminal amide"

XX WO2003099314-A1.

PN 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 43; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,

CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66163 Length: 28 February 4, 2005 13:20 Type: P Check: 166 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HCEGFTSDLSKQLEEAARLFIETLKN 28

1 match found in sequence:
adl66164 ; Extendin agonist peptide, SEQ ID NO 44.
(from "seq4ags.pep")
TOIG of: adl66164 check: 231 from: 1 to: 28

ID ADL66164 standard; peptide; 28 AA.

XX AC

XX AC

XX AC

DT 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID NO 44.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 28

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 44; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence

CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66164 Length: 28 February 4, 2005 13:20 Type: P Check: 231

Found using 'seq4' (mohamed337.key)

```

1 |-----|
  |HGGTATSDLSKQLBEEAVRLFIEFLKN|
  |1                               |
  |28                             |

```

1 match found in sequence:

adl66165 ; Extendin agonist peptide, SEQ ID No 45.
(from "seq4ags.pep")
TOIG of: adl66165 check: 117 from: 1 to: 28

ID ADL66165 standard; peptide; 28 AA.

XX AC ADL66165;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 45.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 28

XX FT /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX XX WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.

XX DR Disclosure; SEQ ID NO 45; 173pp; English.

XX PS The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66165 Length: 28 February 4, 2005 13:20 Type: P Check: 117

Found using 'seq4' (mohamed337.key)

```

1 |-----|
  |HGGTFTADLSKQLBEEAVRLFIEFLKN|
  |1                               |
  |28                             |

```

1 match found in sequence:

adl66166 ; Extendin agonist peptide, SEQ ID No 46.
(from "seq4ags.pep")
TOIG of: adl66166 check: 151 from: 1 to: 28

ID ADL66166 standard; peptide; 28 AA.

XX AC ADL66166;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 46.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 28

XX FT /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX XX WPI; 2004-042706/04.

XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.

XX DR Disclosure; SEQ ID NO 46; 173pp; English.

XX PS The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.

XX SQ Sequence 28 AA;

ADL66166 Length: 28 February 4, 2005 13:20 Type: P Check: 151
Found using 'seq4' (mohamed337.key)

```

1 |-----|
  |HGGTFTDASKQLBEEAVRLFIEFLKN|
  |1                               |
  |28                             |

```

1 match found in sequence:
adl66167 ; Exendin agonist peptide, SEQ ID No 47.
(from "seq4ags.pep")
TOIG of: adl66167 check: 63 from: 1 to: 28

ID ADL66167 standard; peptide; 28 AA.
XX
AC ADL66167;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 47.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 47; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
XX
ADL66167 Length: 28 February 4, 2005 13:20 Type: P Check: 63 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTFTSLAKLEAEVRLFIETLKN 28

1 match found in sequence:
adl66168 ; Exendin agonist peptide, SEQ ID No 48.
(from "seq4ags.pep")
TOIG of: adl66168 check: 141 from: 1 to: 28

ID ADL66168 standard; peptide; 28 AA.
XX
AC ADL66168;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 48.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 48; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
XX
ADL66168 Length: 28 February 4, 2005 13:20 Type: P Check: 141 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTFTSLAKLEAEVRLFIETLKN 28

1 match found in sequence:
adl66169 ; Exendin agonist peptide, SEQ ID No 49.
(from "seq4ags.pep")
TOIG of: adl66169 check: 53 from: 1 to: 28

ID ADL66169 standard; peptide; 28 AA.
XX
AC ADL66169;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 49.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 49; 173pp; English.
XX
CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 28 AA;
XX
ADL66169 Length: 28 February 4, 2005 13:20 Type: P Check: 141 ..
Found using 'seq4' (mohamed337.key)

1 |-----|
1 HGEFTFTSLAKLEAEVRLFIETLKN 28

XX 20-MAY-2004 (first entry)
XX Extendin agonist peptide, SEQ ID No 49.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 49; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
ADL66169 Length: 28 February 4, 2005 13:20 Type: P Check: 53 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKALBEEAVRLFIEFLKN 28

1 match found in sequence:
adl66170 ; Extendin agonist peptide, SEQ ID No 50.
(from "seq4ags.pep")
TOIG of: adl66170 check: 107 from: 1 to: 28

ID ADL66170 standard; peptide; 28 AA.
XX
XX ADL66170;
AC
XX 20-MAY-2004 (first entry)
DT
XX Extendin agonist peptide, SEQ ID No 50.
DE
XX

KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
FT
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 50; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
ADL66170 Length: 28 February 4, 2005 13:20 Type: P Check: 107 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTSDLSKQAEAEAVRLFIEFLKN 28

1 match found in sequence:
adl66171 ; Extendin agonist peptide, SEQ ID No 51.
(from "seq4ags.pep")
TOIG of: adl66171 check: 201 from: 1 to: 28

ID ADL66171 standard; peptide; 28 AA.
XX
XX ADL66171;
AC
XX 20-MAY-2004 (first entry)
DT
XX Extendin agonist peptide, SEQ ID No 51.
DE
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX

```
OS Synthetic.
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 51; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66171 Length: 28 February 4, 2005 13:20 Type: P Check: 201
Found using 'seq4' (mohamed337.key)
1 HGGFTTSDLSKQLAEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
adl66172 ; Extendin agonist peptide, SEQ ID No 52.
(from "seq4ags pep")
TOIG of: adl66172 check: 197 from: 1 to: 28
-----
ID ADL66172 standard; peptide; 28 AA.
XX
XX AC ADL66172;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 52.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 51; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
SQ
ADL66172 Length: 28 February 4, 2005 13:20 Type: P Check: 197
Found using 'seq4' (mohamed337.key)
1 HGGFTTSDLSKQLAEAVRLFIEFLKN 28
1
-----
1 match found in sequence:
adl66173 ; Extendin agonist peptide, SEQ ID No 53.
(from "seq4ags pep")
TOIG of: adl66173 check: 193 from: 1 to: 28
-----
ID ADL66173 standard; peptide; 28 AA.
XX
XX AC ADL66173;
XX
XX 20-MAY-2004 (first entry)
XX
XX Extendin agonist peptide, SEQ ID No 53.
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
```

```

XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 54; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX
XX Sequence 28 AA;
XX
ADL66174 Length: 28 February 4, 2005 13:20 Type: P Check: 9862 ..
Found using 'seq4' (mohamed337.key)
-----|
HGGGTFSTDLSKQLSEEAARLFIEFLKN
1 28
-----|
match found in sequence:
ADL66175 ; Extendin agonist peptide, SEQ ID No 55.
(from "seq4ags.pep")
TOIG of: ADL66175 check: 9921 from: 1 to: 28
-----|
ID ADL66175 standard; peptide; 28 AA.
XX
XX AC ADL66175;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 55.
XX
XX exendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX Key Location/Qualifiers
XX Modified-site 28
XX FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PP 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX

```

PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
PS Disclosure; SEQ ID NO 55; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66175 Length: 28 February 4, 2005 13:20 Type: P Check: 9921 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQLEEEAVAFIEFLKN 28
|-----|
(from "seq4ags.pep")

1 match found in sequence:
adl66176 ; Extendin agonist peptide, SEQ ID No 56.
(from "seq4ags.pep")
TOIG of: adl66176 check: 30 from: 1 to: 28

ID ADL66176 standard; peptide; 28 AA.

XX ADL66176;

XX 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 56.

XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 28 /note= "C-terminal amide"

FT WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 56; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66176 Length: 28 February 4, 2005 13:20 Type: P Check: 30 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTSDLSKQLEEEAVAFIEFLKN 28
|-----|
(from "seq4ags.pep")

1 match found in sequence:
adl66177 ; Extendin agonist peptide, SEQ ID No 57.
(from "seq4ags.pep")
TOIG of: adl66177 check: 165 from: 1 to: 28

ID ADL66177 standard; peptide; 28 AA.

XX ADL66177;

XX 20-MAY-2004 (first entry)

DE Extendin agonist peptide, SEQ ID No 57.

XX extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers

FT Modified-site 28 /note= "C-terminal amide"

FT WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 57; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such

CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66177 Length: 28 February 4, 2005 13:20 Type: P Check: 165 ..

Found using 'seq4' (mohamed337.key)

1 HGGCTFTSDLSKQLBEEAVRLFIATLKN 28
|-----|
1

1 match found in sequence:
adl66178 ; Extendin agonist peptide, SEQ ID No 58.
(from "seq4ags.pep")
TOIG of: adl66178 check: 136 from: 1 to: 28

ID ADL66178 standard; peptide; 28 AA.

XX AC

XX ADL66178;

DT 20-MAY-2004 (first entry)

XX DE

DE Extendin agonist peptide, SEQ ID No 58.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS

OS Synthetic.

XX FH

FH Key Location/Qualifiers

FT Modified-site 28 /note= "C-terminal amide"

FT

XX WO2003099314-A1.

XX PN

XX 04-DEC-2003.

XX PD

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX PS WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 58; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by

CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66178 Length: 28 February 4, 2005 13:20 Type: P Check: 136 ..

Found using 'seq4' (mohamed337.key)

1 HGGCTFTSDLSKQLBEEAVRLFIATLKN 28
|-----|
1

1 match found in sequence:
adl66179 ; Extendin agonist peptide, SEQ ID No 59.
(from "seq4ags.pep")
TOIG of: adl66179 check: 9975 from: 1 to: 28

ID ADL66179 standard; peptide; 28 AA.

XX AC

XX ADL66179;

XX DT 20-MAY-2004 (first entry)

XX DE

DE Extendin agonist peptide, SEQ ID No 59.

XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX OS

OS Synthetic.

XX FH

FH Key Location/Qualifiers

FT Modified-site 28 /note= "C-terminal amide"

FT

XX WO2003099314-A1.

XX PD

PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX PS WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID NO 59; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX

SQ Sequence 28 AA;

ADL66179 Length: 28 February 4, 2005 13:20 Type: P Check: 9975 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLEEAARLFIETFAKN 28
1

1 match found in sequence:
adl66180 ; Exendin agonist peptide, SEQ ID No 60.
(from "seq4ags.pep")
TOIG of: adl66180 check: 9991 from: 1 to: 28

ID ADL66180 standard; peptide; 28 AA.

XX AC ADL66180;

XX 20-MAY-2004 (first entry)

XX Exendin agonist peptide, SEQ ID No 60.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 28

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 60; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66180 Length: 28 February 4, 2005 13:20 Type: P Check: 9991 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLEEAARLFIETFLAN 28
1

1 match found in sequence:
adl66181 ; Exendin agonist peptide, SEQ ID No 61.
(from "seq4ags.pep")
TOIG of: adl66181 check: 9897 from: 1 to: 28

ID ADL66181 standard; peptide; 28 AA.

XX AC ADL66181;

XX 20-MAY-2004 (first entry)

XX Exendin agonist peptide, SEQ ID No 61.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 28

FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 61; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66181 Length: 28 February 4, 2005 13:20 Type: P Check: 9897 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLEEAARLFIETFLKA 28
1

1 match found in sequence:
adl66182 ; Exendin agonist peptide, SEQ ID No 62.
(from "seq4ags.pep")
TOIG of: adl66182 check: 6333 from: 1 to: 38

ID ADL66182 standard; peptide; 38 AA.
XX AC ADL66182;
XX XX
DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 62.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 38 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PP 28-MAY-2002; 2002US-00157224.
XX PR (AMYL-) AMYLIN PHARM INC.
XX PA Young AA, Kolterman OG;
XX PI WPI; 2004-042706/04.
XX DR Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID No 62; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 38 AA;

ADL66182 Length: 38 February 4, 2005 13:20 Type: P Check: 6333 ..
Found using 'seq4' (mohamed337.key)

1 HEGFTSLSKQMEAEVRLFIWLNKGPSGAPP
28

1 match found in sequence:
adl66183 ; Exendin agonist peptide, SEQ ID No 63.
(from "seq4ags.pep")
TOIG of: adl66183 check: 5894 from: 1 to: 38

ID ADL66183 standard; peptide; 38 AA.
XX AC ADL66183;
XX XX
DT 20-MAY-2004 (first entry)
XX DE Exendin agonist peptide, SEQ ID No 63.
XX KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
FT Modified-site 38 /note= "C-terminal amide"
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PP 28-MAY-2002; 2002US-00157224.
XX PR (AMYL-) AMYLIN PHARM INC.
XX PA Young AA, Kolterman OG;
XX PI WPI; 2004-042706/04.
XX DR Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT exendin or an exendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID No 63; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX SQ Sequence 38 AA;

ADL66183 Length: 38 February 4, 2005 13:20 Type: P Check: 5894 ..
Found using 'seq4' (mohamed337.key)

1 HEGFTSLSKQMEAEVRLFIWLNKGPSGAPP
28

1 match found in sequence:
adl66184 ; Exendin agonist peptide, SEQ ID No 64.
(from "seq4ags.pep")
TOIG of: adl66184 check: 3293 from: 1 to: 37

ID ADL66184 standard; peptide; 37 AA.
XX AC ADL66184;
XX XX
DT 20-MAY-2004 (first entry)

```

XX DE      Exendin agonist peptide, SEQ ID No 64.
XX KW      exendin; extended-release formulation; plasma level; antidiabetic;
XX KW      anorectic; antilipidaemic; diabetes; glucose; gastric emptying;
KW KW      inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW KW      dyslipidaemia; cardiovascular.
XX OS      Synthetic.
XX FH      Key                               Location/Qualifiers
XX FT      Modified-site 37
XX FT      /note= "C-terminal amide"
XX PN      WO2003099314-A1.
XX PD      04-DEC-2003.
XX PF      28-MAY-2003; 2003WO-US016699.
XX PR      28-MAY-2002; 2002US-00157224.
XX PA      (AMYL-) AMYLIN PHARM INC.
XX PI      Young AA, Kolterman OG;
XX PI      WPI; 2004-042706/04.
XX DR      Pharmaceutical composition for treating diabetes, impaired glucose
XX PT      tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT      exendin or an exendin agonist peptide in an extended-release formulation.
XX PS      Disclosure; SEQ ID No 64; 173pp; English.
XX CC      The invention relates to a novel pharmaceutical composition comprising an
XX CC      exendin (agonist) peptide in an extended-release formulation. The
XX CC      formulation is capable of releasing the peptide over a predetermined
XX CC      release period, the period being at least one hour, and in an amount such
XX CC      that, when the composition is administered to a human, an average
XX CC      sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC      of the predetermined release period. The composition has antidiabetic,
XX CC      anorectic, and antilipaeamic activities. The novel composition and method
XX CC      are useful in treating diabetes and conditions that would be benefited by
XX CC      lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC      inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC      hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC      represents an exendin agonist peptide of the invention.
XX SQ      Sequence 37 AA;
ADL66184 Length: 37 February 4, 2005 13:20 Type: P Check: 3293 ..
Found using 'seq4' (mohamed337.key)
1 1 HGEFTPTDLSKQMEEEAVRLFIEFLKNGPSSGAPP
  28
-----
1 match found in sequence:
adl66185 ; Exendin agonist peptide, SEQ ID No 65.
(from "seq4ags.pep")
TOIG of: adl66185 check: 2854 from: 1 to: 37
-----
ID ADL66185 standard; peptide; 37 AA.
XX AC
XX ADL66185;
XX AC
XX 20-MAY-2004 (first entry)
XX DT
XX DE      Exendin agonist peptide, SEQ ID No 65.
XX KW      exendin; extended-release formulation; plasma level; antidiabetic;
XX KW      anorectic; antilipidaemic; diabetes; glucose; gastric emptying;
KW KW      inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW KW      dyslipidaemia; cardiovascular.
XX OS      Synthetic.

```

```

KW KW      inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW KW      dyslipidaemia; cardiovascular.
XX OS      Synthetic.
XX FH      Key                               Location/Qualifiers
XX FT      Modified-site 37
XX FT      /note= "C-terminal amide"
XX PN      WO2003099314-A1.
XX PD      04-DEC-2003.
XX PF      28-MAY-2003; 2003WO-US016699.
XX PR      28-MAY-2002; 2002US-00157224.
XX PA      (AMYL-) AMYLIN PHARM INC.
XX PI      Young AA, Kolterman OG;
XX PI      WPI; 2004-042706/04.
XX DR      Pharmaceutical composition for treating diabetes, impaired glucose
XX PT      tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT      exendin or an exendin agonist peptide in an extended-release formulation.
XX PS      Disclosure; SEQ ID No 65; 173pp; English.
XX CC      The invention relates to a novel pharmaceutical composition comprising an
XX CC      exendin (agonist) peptide in an extended-release formulation. The
XX CC      formulation is capable of releasing the peptide over a predetermined
XX CC      release period, the period being at least one hour, and in an amount such
XX CC      that, when the composition is administered to a human, an average
XX CC      sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC      of the predetermined release period. The composition has antidiabetic,
XX CC      anorectic, and antilipaeamic activities. The novel composition and method
XX CC      are useful in treating diabetes and conditions that would be benefited by
XX CC      lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC      inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC      hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC      represents an exendin agonist peptide of the invention.
XX SQ      Sequence 37 AA;
ADL66185 Length: 37 February 4, 2005 13:20 Type: P Check: 2854 ..
Found using 'seq4' (mohamed337.key)
1 1 HGEFTPTDLSKQLEEEAVRLFIEFLKNGPSSGAPP
  28
-----
1 match found in sequence:
adl66186 ; Exendin agonist peptide, SEQ ID No 66.
(from "seq4ags.pep")
TOIG of: adl66186 check: 333 from: 1 to: 36
-----
ID ADL66186 standard; peptide; 36 AA.
XX AC
XX ADL66186;
XX AC
XX 20-MAY-2004 (first entry)
XX DT
XX DE      Exendin agonist peptide, SEQ ID No 66.
XX KW      exendin; extended-release formulation; plasma level; antidiabetic;
XX KW      anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW KW      inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW KW      dyslipidaemia; cardiovascular.
XX OS      Synthetic.

```

PH Key Location/Qualifiers
FT Modified-site 36
XX /note= "C-terminal amide"
PN WO2003099314-A1.
XX
XX
PD 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
PI Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
FT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 66; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 36 AA;
SQ
ADL66186 Length: 36 February 4, 2005 13:20 Type: P Check: 333
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQMEBEAVRLFIEFLKNGGPGSSGAP
28

1 match found in sequence:
adl66187 ; Extendin agonist peptide, SEQ ID No 67.
(from "seq4ags.pep")
TOIG of: adl66187 check: 9894 from: 1 to: 36

ID ADL66187 standard; peptide; 36 AA.
XX
XX ADL66187;
AC
XX 20-MAY-2004 (first entry)
DT
XX
XX Extendin agonist peptide, SEQ ID No 67.
DE
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FT Modified-site 36
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.

XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
PI Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
FT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 67; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX
XX Sequence 36 AA;
SQ
ADL66187 Length: 36 February 4, 2005 13:20 Type: P Check: 9894
Found using 'seq4' (mohamed337.key)
1 HGEFTSLSKQLEBEAVRLFIEFLKNGGPGSSGAP
28

1 match found in sequence:
adl66188 ; Extendin agonist peptide, SEQ ID No 68.
(from "seq4ags.pep")
TOIG of: adl66188 check: 7453 from: 1 to: 35

ID ADL66188 standard; peptide; 35 AA.
XX
XX ADL66188;
AC
XX 20-MAY-2004 (first entry)
DT
XX
XX Extendin agonist peptide, SEQ ID No 68.
DE
XX
XX extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FT Modified-site 35
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX

PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 70; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 34 AA;

ADL66190 Length: 34 February 4, 2005 13:20 Type: P Check: 5178 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQMBEEAVRLFIWLNKGPPSSG
 1 28

 1 match found in sequence:
 adl66191; Extendin agonist peptide, SEQ ID NO 71.
 (from "seq4ags.pep")
 TOIG of: adl66191 check: 4739 from: 1 to: 34

ID ADL66191 standard; peptide; 34 AA.

XX AC ADL66191;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID NO 71.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
 FT Modified-site 34
 FT /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX The invention relates to a novel pharmaceutical composition comprising an
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 71; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an

CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipaeamic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.

XX Sequence 34 AA;

ADL66191 Length: 34 February 4, 2005 13:20 Type: P Check: 4739 ..
 Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQMBEEAVRLFIWLNKGPPSSG
 1 28

 1 match found in sequence:
 adl66192; Extendin agonist peptide, SEQ ID NO 72.
 (from "seq4ags.pep")
 TOIG of: adl66192 check: 2764 from: 1 to: 33

ID ADL66192 standard; peptide; 33 AA.

XX AC ADL66192;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID NO 72.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
 FT Modified-site 33
 FT /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID NO 72; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%

CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 33 AA;

ADL66192 Length: 33 February 4, 2005 13:20 Type: P Check: 2764 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQMBEEAVRLFIELKNGGPSS
1 28

1 match found in sequence:
adl66193 ; Extendin agonist peptide, SEQ ID No 73.
(from "seq4ags.pap")
TOIG of: adl66193 check: 2325 from: 1 to: 33

ID ADL66193 standard; peptide; 33 AA.

XX AC ADL66193;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 73.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 33 /note= "C-terminal amide"

XX FT

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 73; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,

CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 33 AA;

ADL66193 Length: 33 February 4, 2005 13:20 Type: P Check: 2325 ..
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQMBEEAVRLFIELKNGGPSS
1 28

1 match found in sequence:
adl66194 ; Extendin agonist peptide, SEQ ID No 74.
(from "seq4ags.pap")
TOIG of: adl66194 check: 25 from: 1 to: 32

ID ADL66194 standard; peptide; 32 AA.

XX AC ADL66194;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 74.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 32 /note= "C-terminal amide"

XX FT

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.

XX PS Disclosure; SEQ ID No 74; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.

XX Sequence 32 AA;

SQ

ADL66194 Length: 32 February 4, 2005 13:20 Type: P Check: 25 ..
Found using 'seq4' (mohamed337.key)

1 HGGFTSLSKQMEEEAVRLFIEWLKNGGPS
28

1 match found in sequence:
adl66195 ; Exendin agonist peptide, SEQ ID No 75.
(from "seq4ags.pep")
TOIG of: adl66195 check: 9586 from: 1 to: 32

ID ADL66195 standard; peptide; 32 AA.
XX
AC ADL66195;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 75.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.

XX Key Location/Qualifiers
FH Modified-site 32
FT /note= "C-terminal amide"

XX WO2003099314-A1.
XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID No 75; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 32 AA;

ADL66195 Length: 32 February 4, 2005 13:20 Type: P Check: 9586 ..
Found using 'seq4' (mohamed337.key)

1 HGGFTSLSKQLEEEAVRLFIEWLKNGGPS

1 28

1 match found in sequence:
adl66196 ; Exendin agonist peptide, SEQ ID No 76.
(from "seq4ags.pep")
TOIG of: adl66196 check: 7369 from: 1 to: 31

ID ADL66196 standard; peptide; 31 AA.
XX
AC ADL66196;
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 76.

XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.

XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 31
FT /note= "C-terminal amide"

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.

XX Disclosure; SEQ ID No 76; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.

XX Sequence 31 AA;

ADL66196 Length: 31 February 4, 2005 13:20 Type: P Check: 7369 ..
Found using 'seq4' (mohamed337.key)

1 HGGFTSLSKQMEEEAVRLFIEWLKNGGP
28

1 match found in sequence:
adl66197 ; Exendin agonist peptide, SEQ ID No 77.

(from "seq4ags.pep")
TOIG of: adl66197 check: 6930 from: 1 to: 31

ID ADL66197 standard; peptide; 31 AA.
XX
AC ADL66197;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 77.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.

XX Key Location/Qualifiers
FH Modified-site 31
FT /note= "C-terminal amide"
FT

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 77; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 31 AA;

ADL66197 Length: 31 February 4, 2005 13:20 Type: P Check: 6930
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLBEEAVRLFIEFLKNGP
28

1 match found in sequence:

adl66198 ; Extendin agonist peptide, SEQ ID No 78.
(from "seq4ags.pep")
TOIG of: adl66198 check: 4450 from: 1 to: 30

ID ADL66198 standard; peptide; 30 AA.

XX

AC ADL66198;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 78.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.

XX Key Location/Qualifiers
FH Modified-site 30
FT /note= "C-terminal amide"
FT

XX WO2003099314-A1.

XX 04-DEC-2003.

XX 28-MAY-2003; 2003WO-US016699.

XX 28-MAY-2002; 2002US-00157224.

XX (AMYL-) AMYLIN PHARM INC.

XX Young AA, Kolterman OG;

XX WPI; 2004-042706/04.

XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 78; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 30 AA;

ADL66198 Length: 30 February 4, 2005 13:20 Type: P Check: 4450
Found using 'seq4' (mohamed337.key)

1 HGGTFTSDLSKQLBEEAVRLFIEFLKNGG
28

1 match found in sequence:

adl66199 ; Extendin agonist peptide, SEQ ID No 79.
(from "seq4ags.pep")
TOIG of: adl66199 check: 2759 from: 1 to: 29

ID ADL66199 standard; peptide; 29 AA.

XX ADL66199;

XX 20-MAY-2004 (first entry)

XX Extendin agonist peptide, SEQ ID No 79.

```
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 29 /note= "C-terminal amide"
XX FT
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX PS WPI; 2004-042706/04.
XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 79; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 29 AA;
ADL66199 Length: 29 February 4, 2005 13:20 Type: P Check: 2759 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTFTSLSKQMEAEVRLFIETWLNKG 28
-----
1 match found in sequence:
adl66200 ; Extendin agonist peptide, SEQ ID No 80.
(from "seq4ags.pep")
TOIG of: adl66200 check: 2320 from: 1 to: 29
ID ADL66200 standard; peptide; 29 AA.
XX AC ADL66200;
XX DT 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 80.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
```

```
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 29 /note= "C-terminal amide"
XX FT
XX PN WO2003099314-A1.
XX PD 04-DEC-2003.
XX PF 28-MAY-2003; 2003WO-US016699.
XX PR 28-MAY-2002; 2002US-00157224.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young AA, Kolterman OG;
XX PS WPI; 2004-042706/04.
XX PS Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 80; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX SQ Sequence 29 AA;
ADL66200 Length: 29 February 4, 2005 13:20 Type: P Check: 2320 ..
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGEFTFTSLSKQLEAEVRLFIETWLNKG 28
-----
1 match found in sequence:
adl66201 ; Extendin agonist peptide, SEQ ID No 81.
(from "seq4ags.pep")
TOIG of: adl66201 check: 7469 from: 1 to: 38
ID ADL66201 standard; peptide; 38 AA.
XX AC ADL66201;
XX DT 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 81.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 31
```

```

FT Modified-site 36 /note= "Thioprolin"
FT 36..38
FT /note= "Thioprolin"
FT 38
FT Modified-site 38 /note= "C-terminal amide"
FT 38
XX WO2003099314-A1.
XX 04-DEC-2003.
XX 28-MAY-2003; 2003WO-US016699.
XX 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 81; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX SQ Sequence 38 AA;
ADL66201 Length: 38 February 4, 2005 13:20 Type: P Check: 7469
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEEEAVRLFIEWLKNGXSGAXXX
1
-----
1 match found in sequence:
adl66202; Extendin agonist peptide, SEQ ID No 82.
(from "seq4ags.pep")
TOIG of: adl66202 check: 7221 from: 1 to: 38
ID ADL66202 standard; peptide; 38 AA.
XX AC ADL66202;
XX 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 82.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 36..38
XX FT /note= "Thioprolin"
XX FT

```

```

FT Modified-site 38 /note= "C-terminal amide"
FT 38
XX WO2003099314-A1.
XX 04-DEC-2003.
XX 28-MAY-2003; 2003WO-US016699.
XX 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX extendin or an extendin agonist peptide in an extended-release formulation.
XX PS Disclosure; SEQ ID NO 82; 173pp; English.
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX extendin (agonist) peptide in an extended-release formulation. The
XX formulation is capable of releasing the peptide over a predetermined
XX release period, the period being at least one hour, and in an amount such
XX that, when the composition is administered to a human, an average
XX sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX of the predetermined release period. The composition has antidiabetic,
XX anorectic, and antilipaeamic activities. The novel composition and method
XX are useful in treating diabetes and conditions that would be benefited by
XX lowering plasma glucose or delaying and/or slowing gastric emptying or
XX inhibiting food intake, such as impaired glucose tolerance, obesity,
XX hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX represents an extendin agonist peptide of the invention.
XX SQ Sequence 38 AA;
ADL66202 Length: 38 February 4, 2005 13:20 Type: P Check: 7221
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDLSKQMEEEAVRLFIEWLKNGGSSGAXXX
1
-----
1 match found in sequence:
adl66203; Extendin agonist peptide, SEQ ID No 83.
(from "seq4ags.pep")
TOIG of: adl66203 check: 3541 from: 1 to: 37
ID ADL66203 standard; peptide; 37 AA.
XX AC ADL66203;
XX 20-MAY-2004 (first entry)
XX DE Extendin agonist peptide, SEQ ID No 83.
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT Modified-site 31
XX FT /note= "N-methylalanine"
XX FT Modified-site 37
XX FT /note= "C-terminal amide"
XX FT

```



```
PD 04-DEC-2003.
XX
XX PF
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX PS Disclosure; SEQ ID NO 85; 173pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX
XX SQ Sequence 37 AA;
ADL66205 Length: 37 February 4, 2005 13:20 Type: P Check: 4125 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTPTSLSKQMEEEAVRLFIEWLKNGKXSSGAXX
1 28
-----
1 match found in sequence:
1 adl66206 ; Extendin agonist peptide, SEQ ID No 86.
(from "seq4ags.pep")
TOIG of: adl66206 check: 869 from: 1 to: 36
ID ADL66206 standard; peptide; 36 AA.
XX
XX AC ADL66206;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 86.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 31 /note= "Homoproline"
XX FT Modified-site 36 /note= "Homoproline residue with C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX PT Pharmaceutical composition for treating diabetes, impaired glucose
XX PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
XX PT extendin or an extendin agonist peptide in an extended-release formulation.
XX
XX PS Disclosure; SEQ ID NO 85; 173pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX
XX SQ Sequence 37 AA;
ADL66206 Length: 36 February 4, 2005 13:20 Type: P Check: 869 ..
Found using 'seq4' (mohamed337.key)
1 HGEFTPTSLSKQMEEEAVRLFIEWLKNGKXSSGAXX
1 28
-----
1 match found in sequence:
1 adl66207 ; Extendin agonist peptide, SEQ ID No 87.
(from "seq4ags.pep")
TOIG of: adl66207 check: 7463 from: 1 to: 35
ID ADL66207 standard; peptide; 35 AA.
XX
XX AC ADL66207;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 87.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 35 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
```

PI Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 87; 173pp; English.
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX Sequence 35 AA;
 SQ
 ADL66207 Length: 35 February 4, 2005 13:20 Type: P Check: 7463 ..
 Found using 'seq4' (mohamed337.key)
 1 RRGTTTSLSKQMEEEAVRLFIEWLKNGGPPSSGA
 28

 1 match found in sequence:
 adl66208 ; Extendin agonist peptide, SEQ ID No 88.
 (from "seq4ags.pep")
 TOIG of: adl66208 check: 4886 from: 1 to: 30
 ID ADL66208 standard; peptide; 30 AA.
 XX
 AC ADL66208;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 88.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 30 /note= "C-terminal amide"
 FT
 FT
 PN WO2003099314-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX Pharmaceutical composition for treating diabetes, impaired glucose

PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 88; 173pp; English.
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX Sequence 30 AA;
 SQ
 ADL66208 Length: 30 February 4, 2005 13:20 Type: P Check: 4886 ..
 Found using 'seq4' (mohamed337.key)
 1 HGDGTTSLSKQMEEEAVRLFIEWLKNGG
 28

 1 match found in sequence:
 adl66209 ; Extendin agonist peptide, SEQ ID No 89.
 (from "seq4ags.pep")
 TOIG of: adl66209 check: 369 from: 1 to: 28
 ID ADL66209 standard; peptide; 28 AA.
 XX
 AC ADL66209;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 89.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 6 /note= "Naphthylalanine"
 FT Modified-site 28 /note= "C-terminal amide"
 FT
 FT
 PN WO2003099314-A1.
 XX
 XX 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 XX
 XX Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX

PS Disclosure; SEQ ID NO 89; 173pp; English.

XX The invention relates to a novel pharmaceutical composition comprising an

CC extendin (agonist) peptide in an extended-release formulation. The

CC formulation is capable of releasing the peptide over a predetermined

CC release period, the period being at least one hour, and in an amount such

CC that, when the composition is administered to a human, an average

CC sustained plasma level of at least 5 pg/ml is achieved for at least 25*

CC of the predetermined release period. The composition has antidiabetic,

CC anorectic, and antilipaeamic activities. The novel composition and method

CC are useful in treating diabetes and conditions that would be benefited by

CC lowering plasma glucose or delaying and/or slowing gastric emptying or

CC inhibiting food intake, such as impaired glucose tolerance, obesity,

CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence

CC represents an extendin agonist peptide of the invention.

XX

SQ Sequence 28 AA;

ADL66209 Length: 28 February 4, 2005 13:20 Type: P Check: 369 ..

Found using 'seq4' (mohamed337.key)

1 HEGTXXDLSKQLEEEAVRLFIEFLKN 28

1 match found in sequence:

adl66210 ; Extendin agonist peptide, SEQ ID No 90.

(from "seq4ags.pep")

TOIG of: adl66210 check: 693 from: 1 to: 28

ID ADL66210 standard; peptide; 28 AA.

XX

AC ADL66210;

XX

DT 20-MAY-2004 (first entry)

XX

DE Extendin agonist peptide, SEQ ID No 90.

XX

KW extendin; extended-release formulation; plasma level; antidiabetic;

XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;

KW inhibiting food intake; tolerance; obesity; hyperglycaemia;

KW dyslipidaemia; cardiovascular.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 28

FT /note= "C-terminal amide"

XX

PN WO2003099314-A1.

XX

PD 04-DEC-2003.

XX

PF 28-MAY-2003; 2003WO-US016699.

XX

PR 28-MAY-2002; 2002US-00157224.

XX

PA (AMYL-) AMYLIN PHARM INC.

XX

PI Young AA, Kolterman OG;

XX

DR WPI; 2004-042706/04.

XX

PT Pharmaceutical composition for treating diabetes, impaired glucose

PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an

PT extendin or an extendin agonist peptide in an extended-release formulation.

XX

PS Disclosure; SEQ ID NO 90; 173pp; English.

XX

CC The invention relates to a novel pharmaceutical composition comprising an

CC extendin (agonist) peptide in an extended-release formulation. The

CC formulation is capable of releasing the peptide over a predetermined

CC release period, the period being at least one hour, and in an amount such

CC that, when the composition is administered to a human, an average

CC sustained plasma level of at least 5 pg/ml is achieved for at least 25*

CC of the predetermined release period. The composition has antidiabetic,

CC anorectic, and antilipaeamic activities. The novel composition and method

CC are useful in treating diabetes and conditions that would be benefited by

CC lowering plasma glucose or delaying and/or slowing gastric emptying or

CC inhibiting food intake, such as impaired glucose tolerance, obesity,

CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence

CC represents an extendin agonist peptide of the invention.

XX

SQ Sequence 28 AA;

ADL66210 Length: 28 February 4, 2005 13:20 Type: P Check: 693 ..

Found using 'seq4' (mohamed337.key)

1 HEGTFFSDLSKQMBEEAVRLFIEFLKN 28

1 match found in sequence:

adl66211 ; Extendin agonist peptide, SEQ ID No 91.

(from "seq4ags.pep")

TOIG of: adl66211 check: 701 from: 1 to: 28

ID ADL66211 standard; peptide; 28 AA.

XX

AC ADL66211;

XX

DT 20-MAY-2004 (first entry)

XX

DE Extendin agonist peptide, SEQ ID No 91.

XX

KW extendin; extended-release formulation; plasma level; antidiabetic;

XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;

KW inhibiting food intake; tolerance; obesity; hyperglycaemia;

KW dyslipidaemia; cardiovascular.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 28

FT /note= "C-terminal amide"

XX

PN WO2003099314-A1.

XX

PD 04-DEC-2003.

XX

PF 28-MAY-2003; 2003WO-US016699.

XX

PR 28-MAY-2002; 2002US-00157224.

XX

PA (AMYL-) AMYLIN PHARM INC.

XX

PI Young AA, Kolterman OG;

XX

DR WPI; 2004-042706/04.

XX

PT Pharmaceutical composition for treating diabetes, impaired glucose

PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an

PT extendin or an extendin agonist peptide in an extended-release formulation.

XX

PS Disclosure; SEQ ID NO 91; 173pp; English.

XX

CC The invention relates to a novel pharmaceutical composition comprising an

CC extendin (agonist) peptide in an extended-release formulation. The

CC formulation is capable of releasing the peptide over a predetermined

CC release period, the period being at least one hour, and in an amount such

CC that, when the composition is administered to a human, an average

CC sustained plasma level of at least 5 pg/ml is achieved for at least 25*

CC of the predetermined release period. The composition has antidiabetic,

CC anorectic, and antilipaeamic activities. The novel composition and method

CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66211 Length: 28 February 4, 2005 13:20 Type: P Check: 701 ..
Found using 'seq4' (mohamed337.key)

1 HEGFTSTDLKQMEAEAVRLFIEWLKN
1 28

1 match found in sequence:
adl66212 ; Extendin agonist peptide, SEQ ID No 92.
(from "seq4ags.pep")
TOIG of: adl66212 check: 649 from: 1 to: 28

ID ADL66212 standard; peptide; 28 AA.

XX AC ADL66212;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 92.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 92; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66212 Length: 28 February 4, 2005 13:20 Type: P Check: 649 ..
Found using 'seq4' (mohamed337.key)

1 HEGFTTSELKQMAEAEAVRLFIEWLKN
1 28

1 match found in sequence:
adl66213 ; Extendin agonist peptide, SEQ ID No 93.
(from "seq4ags.pep")
TOIG of: adl66213 check: 381 from: 1 to: 28

ID ADL66213 standard; peptide; 28 AA.

XX AC ADL66213;

XX DT 20-MAY-2004 (first entry)

XX DE Extendin agonist peptide, SEQ ID No 93.

XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.

XX OS Synthetic.

XX FH Key Location/Qualifiers
XX FT Modified-site 10 /note= "Pentylglycine"
XX FT Modified-site 28 /note= "C-terminal amide"

XX PN WO2003099314-A1.

XX PD 04-DEC-2003.

XX PF 28-MAY-2003; 2003WO-US016699.

XX PR 28-MAY-2002; 2002US-00157224.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young AA, Kolterman OG;

XX DR WPI; 2004-042706/04.

XX PT Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.

PS Disclosure; SEQ ID NO 93; 173pp; English.

XX CC The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.

XX Sequence 28 AA;

ADL66213 Length: 28 February 4, 2005 13:20 Type: P Check: 381 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEBEEAVRLFIEFLKN 28
1

1 match found in sequence:
adl66214; Exendin agonist peptide, SEQ ID No 94.
(from "seq4ags.pep")
TOIG of: adl66214 check: 657 from: 1 to: 28

ID ADL66214 standard; peptide; 28 AA.
XX
AC ADL66214;
AC
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 94.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 22
FT Modified-site 28 /note= "Naphthylalanine"
FT Modified-site 28 /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
DR WPI; 2004-042706/04.
XX

Pharmaceutical composition for treating diabetes, impaired glucose tolerance, obesity, dyslipidemia or cardiovascular disease comprises an exendin or an exendin agonist peptide in an extended-release formulation.

Disclosure; SEQ ID NO 94; 173pp; English.

The invention relates to a novel pharmaceutical composition comprising an exendin (agonist) peptide in an extended-release formulation. The formulation is capable of releasing the peptide over a predetermined release period, the period being at least one hour, and in an amount such that, when the composition is administered to a human, an average sustained plasma level of at least 5 pg/ml is achieved for at least 25% of the predetermined release period. The composition has antidiabetic, anorectic, and antilipaeamic activities. The novel composition and method are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake, such as impaired glucose tolerance, obesity, hyperglycaemia, dyslipidemia or cardiovascular disease. This sequence represents an exendin agonist peptide of the invention.

Sequence 28 AA;

ADL66214 Length: 28 February 4, 2005 13:20 Type: P Check: 657 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEBEEAVRLFIEFLKN 28
1

1 match found in sequence:
adl66215; Exendin agonist peptide, SEQ ID No 95.
(from "seq4ags.pep")
TOIG of: adl66215 check: 1045 from: 1 to: 28

ID ADL66215 standard; peptide; 28 AA.
XX
AC ADL66215;
AC
XX
DT 20-MAY-2004 (first entry)
XX
DE Exendin agonist peptide, SEQ ID No 95.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 23
FT Modified-site 28 /note= "Tertiary-butylglycine"
FT Modified-site 28 /note= "C-terminal amide"
XX
PN WO2003099314-A1.
XX
PD 04-DEC-2003.
XX
PF 28-MAY-2003; 2003WO-US016699.
XX
PR 28-MAY-2002; 2002US-00157224.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young AA, Kolterman OG;
XX
DR WPI; 2004-042706/04.
XX

Pharmaceutical composition for treating diabetes, impaired glucose tolerance, obesity, dyslipidemia or cardiovascular disease comprises an exendin or an exendin agonist peptide in an extended-release formulation.

Disclosure; SEQ ID NO 95; 173pp; English.

The invention relates to a novel pharmaceutical composition comprising an exendin (agonist) peptide in an extended-release formulation. The formulation is capable of releasing the peptide over a predetermined release period, the period being at least one hour, and in an amount such that, when the composition is administered to a human, an average sustained plasma level of at least 5 pg/ml is achieved for at least 25% of the predetermined release period. The composition has antidiabetic, anorectic, and antilipaeamic activities. The novel composition and method are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhibiting food intake, such as impaired glucose tolerance, obesity, hyperglycaemia, dyslipidemia or cardiovascular disease. This sequence represents an exendin agonist peptide of the invention.

Sequence 28 AA;

ADL66215 Length: 28 February 4, 2005 13:20 Type: P Check: 1045 ..
Found using 'seq4' (mohamed337.key)

1 HEGGFTSDLSKQLEBEEAVRLFIEFLKN 28
1

2000

AC ADL66218;

```
XX 20-MAY-2004 (first entry)
XX Exendin agonist peptide, SEQ ID No 98.
DE
XX
XX exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 29 /note= "C-terminal amide"
FT
FT
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 98; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 29 AA;
ADL66218 Length: 29 February 4, 2005 13:20 Type: P Check: 2649 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDASKQMBEEAVRLFIEWLKGKNG 28
1 -----|
1 match found in sequence:
adl66219 ; Exendin agonist peptide, SEQ ID No 99.
(from "seq4ags.pep")
TOIG of: adl66219 check: 4015 from: 1 to: 37
ID ADL66219 standard; peptide; 37 AA.
XX
XX AC ADL66219;
XX
XX 20-MAY-2004 (first entry)
XX
XX Exendin agonist peptide, SEQ ID No 99.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 29 /note= "C-terminal amide"
FT
FT
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 98; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 29 AA;
ADL66219 Length: 29 February 4, 2005 13:20 Type: P Check: 2649 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDASKQMBEEAVRLFIEWLKGKNG 28
1 -----|
1 match found in sequence:
adl66219 ; Exendin agonist peptide, SEQ ID No 99.
(from "seq4ags.pep")
TOIG of: adl66219 check: 4015 from: 1 to: 37
ID ADL66219 standard; peptide; 37 AA.
XX
XX AC ADL66219;
XX
XX 20-MAY-2004 (first entry)
XX
XX Exendin agonist peptide, SEQ ID No 99.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH Modified-site 31 /note= "Homoproline"
FT Modified-site 36.37 /note= "Homoproline"
FT Modified-site 37 /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX
XX 04-DEC-2003.
XX
XX 28-MAY-2003; 2003WO-US016699.
XX
XX 28-MAY-2002; 2002US-00157224.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young AA, Kolterman OG;
XX
XX WPI; 2004-042706/04.
XX
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT exendin or an exendin agonist peptide in an extended-release formulation.
XX
XX Disclosure; SEQ ID NO 99; 173pp; English.
XX
XX The invention relates to a novel pharmaceutical composition comprising an
CC exendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an exendin agonist peptide of the invention.
XX
SQ Sequence 37 AA;
ADL66219 Length: 37 February 4, 2005 13:20 Type: P Check: 4015 ..
Found using 'seq4' (mohamed337.key)
1 HEGGFTSDASKQMBEEAVRLFIEWLKGKNGSGXGX 28
1 -----|
1 match found in sequence:
adl66221 ; Exendin agonist peptide, SEQ ID No 101.
(from "seq4ags.pep")
TOIG of: adl66221 check: 249 from: 1 to: 28
ID ADL66221 standard; peptide; 28 AA.
XX
XX AC ADL66221;
XX
XX 20-MAY-2004 (first entry)
XX
XX Exendin agonist peptide, SEQ ID No 101.
XX
KW exendin; extended-release formulation; plasma level; antidiabetic;
```

KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX Synthetic.
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX 04-DEC-2003.
XX 28-MAY-2003; 2003WO-US016699.
XX 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 101; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX Sequence 28 AA;
ADL66221 Length: 28 February 4, 2005 13:20 Type: P Check: 249 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTSDLSKQLEEAVALRFLTEFLKN 28

1 match found in sequence:
adl66225 ; Extendin agonist peptide, SEQ ID No 105.
(from "seq4ags.pep")
TOIG of: adl66225 check: 688 from: 1 to: 28

ID ADL66225 standard; peptide; 28 AA.
XX
AC ADL66225;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 105.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX Synthetic.

XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX
XX WO2003099314-A1.
XX 04-DEC-2003.
XX 28-MAY-2003; 2003WO-US016699.
XX 28-MAY-2002; 2002US-00157224.
XX (AMYL-) AMYLIN PHARM INC.
XX Young AA, Kolterman OG;
XX WPI; 2004-042706/04.
XX Pharmaceutical composition for treating diabetes, impaired glucose
PT tolerance, obesity, dyslipidaemia or cardiovascular disease comprises an
PT extendin or an extendin agonist peptide in an extended-release formulation.
XX Disclosure; SEQ ID NO 105; 173pp; English.
XX The invention relates to a novel pharmaceutical composition comprising an
CC extendin (agonist) peptide in an extended-release formulation. The
CC formulation is capable of releasing the peptide over a predetermined
CC release period, the period being at least one hour, and in an amount such
CC that, when the composition is administered to a human, an average
CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
CC of the predetermined release period. The composition has antidiabetic,
CC anorectic, and antilipaeamic activities. The novel composition and method
CC are useful in treating diabetes and conditions that would be benefited by
CC lowering plasma glucose or delaying and/or slowing gastric emptying or
CC inhibiting food intake, such as impaired glucose tolerance, obesity,
CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
CC represents an extendin agonist peptide of the invention.
XX Sequence 28 AA;
ADL66225 Length: 28 February 4, 2005 13:20 Type: P Check: 688 ..
Found using 'seq4' (mohamed337.key)
1 HGAGTFTSDLSKQLEEAVALRFLTEFLKN 28

1 match found in sequence:
adl66228 ; Extendin agonist peptide, SEQ ID No 108.
(from "seq4ags.pep")
TOIG of: adl66228 check: 590 from: 1 to: 28

ID ADL66228 standard; peptide; 28 AA.
XX
AC ADL66228;
XX
DT 20-MAY-2004 (first entry)
XX
DE Extendin agonist peptide, SEQ ID No 108.
XX
KW extendin; extended-release formulation; plasma level; antidiabetic;
KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
KW dyslipidaemia; cardiovascular.
XX Synthetic.
XX Key Location/Qualifiers
FH Modified-site 28
FT /note= "C-terminal amide"
XX

```
PN WO2003099314-A1.
XX
XX
PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX PS
XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX
XX SQ Sequence 28 AA;
ADL66228 Length: 28 February 4, 2005 13:20 Type: P Check: 590
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGTFTSDASKQMEAEVRLFIENLKN 28
-----
1 match found in sequence:
adl66288; Extendin agonist peptide, SEQ ID No 168.
(from "seq4ags.pep")
TOIG of: adl66288 check: 5882 from: 1 to: 38
-----
ID ADL66288 standard; peptide; 38 AA.
XX
XX AC ADL66288;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 168.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 38 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX PS
XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX
XX SQ Sequence 28 AA;
ADL66228 Length: 28 February 4, 2005 13:20 Type: P Check: 590
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGTFTSDASKQMEAEVRLFIENLKN 28
-----
1 match found in sequence:
adl66288; Extendin agonist peptide, SEQ ID No 168.
(from "seq4ags.pep")
TOIG of: adl66288 check: 5882 from: 1 to: 38
-----
ID ADL66288 standard; peptide; 38 AA.
XX
XX AC ADL66288;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 168.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 38 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young AA, Kolterman OG;
XX
XX DR WPI; 2004-042706/04.
XX
XX PS
XX
XX CC The invention relates to a novel pharmaceutical composition comprising an
XX CC extendin (agonist) peptide in an extended-release formulation. The
XX CC formulation is capable of releasing the peptide over a predetermined
XX CC release period, the period being at least one hour, and in an amount such
XX CC that, when the composition is administered to a human, an average
XX CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
XX CC of the predetermined release period. The composition has antidiabetic,
XX CC anorectic, and antilipaeamic activities. The novel composition and method
XX CC are useful in treating diabetes and conditions that would be benefited by
XX CC lowering plasma glucose or delaying and/or slowing gastric emptying or
XX CC inhibiting food intake, such as impaired glucose tolerance, obesity,
XX CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
XX CC represents an extendin agonist peptide of the invention.
XX
XX SQ Sequence 38 AA;
ADL66288 Length: 38 February 4, 2005 13:20 Type: P Check: 5882
Found using 'seq4' (mohamed337.key)
1 |-----|
1 HGGTFTSDLSKQLEAEVRLFIENLKN 28
-----
1 match found in sequence:
adl66293; Extendin agonist peptide, SEQ ID No 173.
(from "seq4ags.pep")
TOIG of: adl66293 check: 7002 from: 1 to: 35
-----
ID ADL66293 standard; peptide; 35 AA.
XX
XX AC ADL66293;
XX
XX DT 20-MAY-2004 (first entry)
XX
XX DE Extendin agonist peptide, SEQ ID No 173.
XX
XX KW extendin; extended-release formulation; plasma level; antidiabetic;
XX KW anorectic; antilipaeamic; diabetes; glucose; gastric emptying;
XX KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
XX KW dyslipidaemia; cardiovascular.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX FT Modified-site 35 /note= "C-terminal amide"
XX
XX PN WO2003099314-A1.
XX
XX PD 04-DEC-2003.
XX
XX PF 28-MAY-2003; 2003WO-US016699.
XX
XX PR 28-MAY-2002; 2002US-00157224.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
```

PI Young AA, Kolterman OG;
 XX WPI; 2004-042706/04.
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 173; 173pp; English.
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX Sequence 35 AA;
 SQ
 ADL66293 Length: 35 February 4, 2005 13:20 Type: P Check: 7002 ..
 Found using 'seq4' (mohamed337.key)
 1 HGAGTFTSLSKQLEEEAVRLFIEFLKNGPSSGA
 28

 1 match found in sequence:
 adl66297; Extendin agonist peptide, SEQ ID No 177.
 (from "seq4ags.pep")
 TOIG of: adl66297 check: 9574 from: 1 to: 32
 ID ADL66297 standard; peptide; 32 AA.
 XX
 AC ADL66297;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 177.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 32 /note= "C-terminal amide"
 FT
 FT WO2003099314-A1.
 PN
 XX
 PD 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young AA, Kolterman OG;
 PI
 XX WPI; 2004-042706/04.
 DR
 XX Pharmaceutical composition for treating diabetes, impaired glucose

PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an
 PT extendin or an extendin agonist peptide in an extended-release formulation.
 XX Disclosure; SEQ ID NO 177; 173pp; English.
 XX The invention relates to a novel pharmaceutical composition comprising an
 CC extendin (agonist) peptide in an extended-release formulation. The
 CC formulation is capable of releasing the peptide over a predetermined
 CC release period, the period being at least one hour, and in an amount such
 CC that, when the composition is administered to a human, an average
 CC sustained plasma level of at least 5 pg/ml is achieved for at least 25%
 CC of the predetermined release period. The composition has antidiabetic,
 CC anorectic, and antilipemic activities. The novel composition and method
 CC are useful in treating diabetes and conditions that would be benefited by
 CC lowering plasma glucose or delaying and/or slowing gastric emptying or
 CC inhibiting food intake, such as impaired glucose tolerance, obesity,
 CC hyperglycaemia, dyslipidaemia or cardiovascular disease. This sequence
 CC represents an extendin agonist peptide of the invention.
 XX Sequence 32 AA;
 SQ
 ADL66297 Length: 32 February 4, 2005 13:20 Type: P Check: 9574 ..
 Found using 'seq4' (mohamed337.key)
 1 HGAGTFTSLSKQLEEEAVRLFIEFLKNGGPPS
 28

 1 match found in sequence:
 adl66301; Extendin agonist peptide, SEQ ID No 181.
 (from "seq4ags.pep")
 TOIG of: adl66301 check: 7457 from: 1 to: 38
 ID ADL66301 standard; peptide; 38 AA.
 XX
 AC ADL66301;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 DE Extendin agonist peptide, SEQ ID No 181.
 XX
 KW extendin; extended-release formulation; plasma level; antidiabetic;
 KW anorectic; antilipemic; diabetes; glucose; gastric emptying;
 KW inhibiting food intake; tolerance; obesity; hyperglycaemia;
 KW dyslipidaemia; cardiovascular.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 31 /note= "Thioproline"
 FT Modified-site 36..38 /note= "Thioproline"
 FT Modified-site 38 /note= "C-terminal amide"
 FT
 FT WO2003099314-A1.
 PN
 XX
 PD 04-DEC-2003.
 XX
 XX 28-MAY-2003; 2003WO-US016699.
 XX
 XX 28-MAY-2002; 2002US-00157224.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young AA, Kolterman OG;
 PI
 XX WPI; 2004-042706/04.
 DR
 XX Pharmaceutical composition for treating diabetes, impaired glucose
 PT tolerance, obesity, dyslipidemia or cardiovascular disease comprises an

CC produced by a recombinant host cell. The novel method involves selecting
 CC a cell comprising a first nucleic acid encoding a leader peptide and a
 CC second nucleic acid fragment encoding the desired (poly)peptide. The
 CC first and second fragments are within the same open reading frame of the
 CC first nucleic acid and the leader peptide is functionally equivalent to
 CC an N-terminal leader peptide found with the pre-peptide of a lantibiotic.
 CC The host cells and nucleic acids are useful for producing, harvesting and
 CC post-translational modification of polypeptides. The polypeptides may be
 CC used in the production of pharmaceuticals, e.g. as antigen for vaccine or
 CC immunogenic composition. This sequence represents a polypeptide relating
 CC to the novel method of the invention.

XX SQ Sequence 39 AA;

ADL92031 Length: 39 February 4, 2005 13:20 Type: P Check: 9661 ..
 Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HSDGTFITSLSKQMEEEAVRLFIEWLKNKGPPSGGCPPPS
 28

 1 match found in sequence:
 adl92153 ; Extensin-4 protein sequence.
 (from "seq4ags.pep")
 TOIG of: adl92153 check: 7609 from: 1 to: 64

ID ADL92153 standard; protein; 64 AA.

XX AC ADL92153;

XX DT 20-MAY-2004 (first entry)

XX DE Extensin-4 protein sequence.

XX KW harvesting; recombinant; host cell; N-terminal leader peptide;
 KW pre-peptide; lantibiotic; post-translational modification;
 KW pharmaceuticals; vaccine; immunogenic.

XX OS Unidentified.

XX PN WO2003099862-A1.

XX PD 04-DEC-2003.

XX PF 26-MAY-2003; 2003WO-NL000389.

XX PR 24-MAY-2002; 2002EP-00077060.

XX PR 07-FEB-2003; 2003US-00360101.

XX PA (NANO-) APPLIED NANOSYSTEMS BV.

XX PI Moll GN, Leenhouts CJ, Kuipers OP, Driessen AJM;

XX DR WPI; 2004-042770/04.

XX PT Harvesting a desired polypeptide produced by a recombinant host cell, for
 PT producing pharmaceuticals, comprises selecting a recombinant nucleic acid
 PT comprising nucleic acid fragments encoding a leader peptide and the
 PT polypeptide.

XX PS Claim 4; Page 68; 109pp; English.

XX CC The invention relates to a novel method for harvesting a (poly)peptide
 CC produced by a recombinant host cell. The novel method involves selecting
 CC a cell comprising a first nucleic acid encoding a leader peptide and a
 CC second nucleic acid fragment encoding the desired (poly)peptide. The
 CC first and second fragments are within the same open reading frame of the
 CC first nucleic acid and the leader peptide is functionally equivalent to
 CC an N-terminal leader peptide found with the pre-peptide of a lantibiotic.
 CC The host cells and nucleic acids are useful for producing, harvesting and
 CC post-translational modification of polypeptides. The polypeptides may be
 CC used in the production of pharmaceuticals, e.g. as antigen for vaccine or

CC immunogenic composition. This sequence represents a polypeptide relating
 CC to the novel method of the invention.

XX SQ Sequence 64 AA;

ADL92153 Length: 64 February 4, 2005 13:20 Type: P Check: 7609 ..
 Found using 'seq4' (mohamed337.key)

1 |-----|
 1 MPVESGLSSSEDSASSSEFASKIKRHCGETFTSDLSKQMEEEAVRLFIEWLKNKGPPSSGAP
 25

61 PPSG

 1 match found in sequence:

adm41356 ; Extensin 4, glucagon-like peptide 1 receptor agonist (antidiabetic)
 (from "seq4ags.pep")
 TOIG of: adm41356 check: 9570 from: 1 to: 39

ID ADM41356 standard; peptide; 39 AA.

XX AC ADM41356;

XX DT 03-JUN-2004 (first entry)

XX DE Extensin 4, glucagon-like peptide 1 receptor agonist (antidiabetic).

XX KW Glucagon-like peptide 1; GLP-1; human; receptor; agonist; antidiabetic;
 KW immunosuppressive; anorectic; antiarteriosclerotic; hypotensive;
 KW antilipaemic; extensin-4.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers
 XX Modified-site 39

XX FT note= "C-terminal amide"

XX PN WO2004022004-A2.

XX PD 18-MAR-2004.

XX PF 04-SEP-2003; 2003WO-US028093.

XX PR 06-SEP-2002; 2002US-0408696P.

XX PR 09-JAN-2003; 2003US-043369P.

XX PA (FARB) BAYER PHARM CORP.

XX PI Pan C, Whelan JP;

XX DR WPI; 2004-282764/26.

XX PT Novel glucagon-like peptide-1 receptor agonist or modified GLP-1 receptor
 PT agonist, useful for treating diabetes, impaired glucose tolerance,
 PT metabolic syndrome or pre-diabetic state.

XX PS Example 1; SEQ ID NO 3; 56pp; English.

XX CC The present sequence is that of extensin 4, an example of a glucagon-like
 CC peptide 1 (GLP-1) receptor agonist. Modified GLP-1 receptor agonists of
 CC the invention comprise a GLP-1 receptor agonist such as the present
 CC peptide linked to a polyethylene glycol polymer having a molecular weight
 CC of greater than 30 kDa. The modified GLP-1 receptor agonists are useful
 CC for treating type 1 diabetes, type 2 diabetes, maturity onset diabetes of
 CC the young, latent autoimmune diabetes adult, gestational diabetes and
 CC Syndrome X (all claimed). They can also be used to treat hyperglycaemia,
 CC impaired glucose tolerance, impaired fasting glucose and obesity caused
 CC by inducing glucose-dependent insulin secretion. They may also be
 CC effective in the treatment of obesity, atherosclerotic disease,
 CC hyperlipidaemia, hypercholesterolaemia, low high density lipoprotein
 CC levels, hypertension, cardiovascular disease (including atherosclerosis,
 CC coronary heart disease and hypertension), cerebrovascular disease,

CC peripheral vessel disease, physiological disorders and the secondary
 CC causes of diabetes. The modified GLP-1 receptor agonists can be prepared
 CC by synthetic or recombinant methods. They induce glucose-dependent
 CC insulin secretion without reducing gastrointestinal motility, thereby
 CC lessening the gastrointestinal side-effects associated with previous GLP-
 CC 1 receptor agonists.

XX
 SQ Sequence 39 AA;

ADM41356 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..

Found using 'seq4' (mohamed337.key)

```

1  HGGTFTSLSKQMEEEAVRLFIEWLKNGSPSGAPPPS
    |-----|
    28
  
```

 1 match found in sequence:

adm41384 ; Exendin-4, glucagon-like peptide 1 receptor agonist (antidiabetic).
 (from "seq4ags.pep")
 TOIG of: adm41384 check: 2250 from: 1 to: 40

ID ADM41384 standard; peptide; 40 AA.

XX
 AC ADM41384;

DT 03-JUN-2004 (first entry)

DE Exendin-4, glucagon-like peptide 1 receptor agonist (antidiabetic).

XX Glucagon-like peptide 1; GLP-1; human; receptor; agonist; antidiabetic;
 KW immunosuppressive; anorectic; antiarteriosclerotic; hypotensive;
 KW antilipemic; excendin-4.

XX Homo sapiens.

XX Key Location/Qualifiers
 FH Modified-site 40
 FT /note= "PEGylated amino acid residue"

XX WO2004022004-A2.
 PN 18-MAR-2004.

XX 04-SEP-2003; 2003WO-US028093.
 XX 06-SEP-2002; 2002US-0408596P.
 PR 09-JAN-2003; 2003US-0439369P.

XX (FARB) BAYER PHARM CORP.
 PA Pan C, Whelan JP;
 PI WPI; 2004-282764/26.

XX Novel glucagon-like peptide-1 receptor agonist or modified GLP-1 receptor

PT agonist, useful for treating diabetes, impaired glucose tolerance,
 PT metabolic syndrome or pre-diabetic state.
 XX Claim 1; SEQ ID NO 31; 56pp; English.

XX The present sequence is that of an exendin-4 peptide modified to include
 CC a PEGylated C-terminal Cys residue. This is an example of a modified
 CC glucagon-like peptide 1 (GLP-1) receptor agonist of the invention
 CC comprising a GLP-1 receptor agonist peptide linked to a polyethylene
 CC glycol (PEG) polymer having a molecular weight of greater than 30 kDa.
 CC Modified GLP-1 receptor agonists are useful for treating type 1 diabetes,
 CC type 2 diabetes, maturity onset diabetes of the young, latent autoimmune
 CC diabetes adult, gestational diabetes and Syndrome X (all claimed). They
 CC can also be used to treat hyperglycaemia, impaired glucose tolerance,
 CC impaired fasting glucose and obesity caused by inducing glucose-dependent
 CC insulin secretion. They may also be effective in the treatment of
 CC obesity, atherosclerotic disease, hyperlipidaemia, hypercholesterolaemia,

CC low high density lipoprotein levels, hypertension, cardiovascular disease
 CC (including atherosclerosis, coronary heart disease and hypertension),
 CC cerebrovascular disease, peripheral vessel disease, physiological
 CC disorders and the secondary causes of diabetes. The modified GLP-1
 CC receptor agonists can be prepared by synthetic or recombinant methods.
 CC They induce glucose-dependent insulin secretion without reducing
 CC gastrointestinal motility, thereby lessening the gastrointestinal side-
 CC effects associated with previous GLP-1 receptor agonists.

XX Sequence 40 AA;

ADM41384 Length: 40 February 4, 2005 13:20 Type: P Check: 2250 ..

Found using 'seq4' (mohamed337.key)

```

1  HGGTFTSLSKQMEEEAVRLFIEWLKNGSPSGAPPPSC
    |-----|
    28
  
```

 1 match found in sequence:

adm16852 ; Fermentation-derived product exendin-4 analogue ZP10 peptide.
 (from "seq4ags.pep")
 TOIG of: adm16852 check: 5122 from: 1 to: 44

ID ADN16852 standard; peptide; 44 AA.

XX
 AC ADN16852;

DT 01-JUL-2004 (first entry)

DE Fermentation-derived product exendin-4 analogue ZP10 peptide.

XX Fermentation-derived product; microfiltration; fermentation broth;
 KW exendin-4 analogue; ZP10 peptide.

XX Unidentified.

XX Key Location/Qualifiers
 FH Misc-difference 44
 FT /note= "C-terminal amide"

XX WO2004029076-A2.

XX 08-APR-2004.

XX 25-SEP-2003; 2003WO-DK000627.

XX 25-SEP-2002; 2002DK-00001422.

XX (NOVO) NOVO NORDISK AS.

XX Christensen LH, Nielsen TK;

XX WPI; 2004-375439/35.

XX Purifying fermentation-derived product such as interleukins, insulin,
 PT albumin, involves microfiltration of fermentation broth containing
 PT fermentation-derived product at specific microfiltration temperature and
 PT isolating final product.

XX Claim 25; Page 17; 20pp; English.

XX This invention relates to a novel method of purifying a fermentation-
 CC derived product, which involves microfiltration of a fermentation broth
 CC containing the fermentation-derived product at a microfiltration
 CC temperature within the range from 66-90 degrees C and isolating the final
 CC product. The method of the invention is efficient in purifying a
 CC fermentation-derived product with an improved microfiltration process
 CC comprising elevated temperatures. The present sequence is that of an
 CC exendin-4 analogue ZP10 peptide which is a fermentation-derived product
 CC to which the method of the invention may be applied.

XX Sequence 44 AA;

ADN16852 Length: 44 February 4, 2005 13:20 Type: P Check: 5122 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEAVRLFIEWLKNGPSSGAPPSKKKKK
28

1 match found in sequence:
ad055979 ; Human extendin-4 peptide related to diabetes treatment.
(from "seq4ags.pep")
TOIG of: ad055979 check: 9570 from: 1 to: 39

ID AD055979 standard; peptide; 39 AA.
XX
AC AD055979;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human extendin-4 peptide related to diabetes treatment.
XX
KW diabetes; beta-cell proliferation; beta-cell apoptosis; antidiabetic;
KW immunosuppressive; protein kinase; Akt1; p44WAPK; caspase-3; extendin-4;
KW human.
XX
OS Homo sapiens.
XX
PN CA2389462-A1.
XX
PD 21-DEC-2003.
XX
PF 21-JUN-2002; 2002CA-02389462.
XX
PR 21-JUN-2002; 2002US-00111111.
XX
PW (WANG/) WANG Q Q.
PA (BRUB/) BRUBAKER P L.
XX
PI Wang QQ, Brubaker PL;
XX WPI; 2004-099536/11.
XX
DR Preventing and/or delaying diabetes in a subject in need, involves
XX administering to subject a compound that increases beta-cell
XX proliferation and/or reduces beta cell apoptosis in subject.
XX
PS Disclosure; SEQ ID NO 2; 43pp; English.
XX
CC This invention relates to a novel method of preventing and/or delaying
CC diabetes in a subject in need, which involves administering to the
CC subject an effective amount of a compound that increases beta-cell
CC proliferation and/or reduces beta-cell apoptosis in the subject. The
CC invention may be useful for the production of compounds with an
CC antidiabetic or immunosuppressive activity by increasing expression of
CC protein kinase (Akt1 and/or p44WAPK) in the beta-cells and decreasing
CC caspase-3 activation. The method is useful for preventing and/or delaying
CC diabetes in a subject. The present sequence is that of a human extendin-4
CC peptide which is related to the method of the invention.
XX
SQ Sequence 39 AA;

AD055979 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEAVRLFIEWLKNGPSSGAPPS
28

1 match found in sequence:
ad058913 ; Extendin-4 peptide.
(from "seq4ags.pep")

TOIG of: ad058913 check: 9570 from: 1 to: 39
AD058913 standard; peptide; 39 AA.

ID AD058913;
AC
XX
DT 29-JUL-2004 (first entry)
XX
DE Extendin-4 peptide.

XX neurological disorder; Glitide peptide; memory disorder;
KW neurodegenerative disorder; seizures; stroke; brain ischaemia; epilepsy;
KW Parkinson's disease; Alzheimer's disease; Huntington's disease; ALS;
KW blood glucose; glucose-metabolism disorder; obesity; diabetes;
KW anorexia nervosa; hypercholesterolaemia; atherosclerosis; extendin-4.
XX
OS Synthetic.
XX
PN US2004092432-A1.
XX
PD 13-MAY-2004.
XX
PF 01-APR-2003; 2003US-00405090.
XX
PR 24-AUG-2000; 2000US-0227631P.
PR 24-AUG-2001; 2001US-00939472.
PR 01-APR-2002; 2002US-0369249P.
XX
PW (UYJE-) UNIV JEFFERSON THOMAS.
XX
PI During MJ, Haile CN, Cao L;
XX WPI; 2004-374977/35.
XX
PT Ameliorating a neurological disorder, e.g. stroke, Parkinson's disease,
PT Alzheimer's disease or Huntington's disease, comprises administering
PT Glitide peptide.
XX
PS Disclosure; Page 12; 67pp; English.

XX The invention relates to a method of ameliorating a neurological disorder
XX is in a subject, which comprises administering a therapeutical amount of
XX a Glitide peptide or its functional analogue, where the administration
XX of the Glitide peptide or its functional analogue inhibits or delays the
XX onset of the neurological disorder. Also described is the Glitide
XX peptide and encoding nucleic acid. The methods, composition, the nucleic
XX acid and the encoded peptide are useful in preventing or delaying the
XX onset of a memory disorder and in treating a neurological disorder, i.e.
XX a neurodegenerative disorder, e.g. seizures, strokes, brain ischaemia or
XX epilepsy. Other diseases include Parkinson's disease, Alzheimer's
XX disease, Huntington's disease or ALS. The peptides are also useful in
XX modulating blood glucose and in preventing and treating glucose-
XX metabolism disorders, e.g. obesity, diabetes, anorexia nervosa,
XX hypercholesterolaemia or atherosclerosis. The present sequence represents
XX an extendin-4 peptide used as a Glitide peptide of the invention.
XX
SQ Sequence 39 AA;

AD058913 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HGEFTTSDLSKQMBEAVRLFIEWLKNGPSSGAPPS
28

1 match found in sequence:
adp20988 ; Gila monster lizard venom isolated 39 amino acid extendin-4 peptide.
(from "seq4ags.pep")
TOIG of: adp20988 check: 9570 from: 1 to: 39

ID ADP20988 standard; peptide; 39 AA.
XX

AC ADP20988;
 XX 09-SEP-2004 (first entry)
 XX
 DE Gila monster lizard venom isolated 39 amino acid exendin-4 peptide.
 XX
 DE diabetes; exendin-4; thiazolidinedione; insulin sensitizer; antidiabetic;
 KW immunosuppressive; cytosaratic; anorectic; antilipaeamic; hypotensive;
 KW antiarteriosclerotic; ophthalmological; nephrotropic; neuroprotective;
 KW type 1 diabetes; type 2; hyperglycaemia; latent autoimmune;
 KW maturity onset; polycystic ovarian syndrome; gestational; obesity;
 KW dyslipidaemia; hyperlipidaemia; hypertriglyceridaemia;
 KW hyperlipoproteinaemia; hypercholesterolaemia; hypertension;
 KW arteriosclerosis; atherosclerosis; cardiovascular disease;
 KW diabetic retinopathy; background retinopathy; proliferative retinopathy;
 KW diabetic nephropathy; neuropathy; beta-cell; venom; Gila monster lizard;
 KW GLP-1 receptor agonist.
 XX
 OS Heloderma suspectum.
 XX
 PN WO2004050115-A2.
 XX
 PD 17-JUN-2004.
 XX
 XX 01-DEC-2003; 2003WO-DK000824.
 PF
 XX 03-DEC-2002; 2002DK-00001864.
 PR
 PR 09-DEC-2002; 2002US-0431999P.
 XX
 XX (NOVO) NOVO NORDISK AS.
 PA
 XX Knudsen LB;
 XX
 XX WPI; 2004-480530/45.
 DR
 XX Treating or preventing diabetes or diabetes-related disease by
 PT administering exendin-4 compound and thiazolidinedione insulin sensitizer
 PT to patient.
 XX
 PS Claim 7; SEQ ID NO 1; 3lpp; English.
 XX
 XX The invention relates to a novel method for treating or preventing
 CC diabetes or a diabetes-related disease, which involves administering an
 CC exendin-4 compound and thiazolidinedione insulin sensitizer to the
 CC patient. The invention further comprises the use of exendin-4 compound
 CC and thiazolidinedione insulin sensitizer for the preparation of one or
 CC more medicaments for carrying out the method; and a pharmaceutical
 CC composition comprising exendin-4 compound and thiazolidinedione
 CC preservative. The compositions and method have the following activities:
 CC antidiabetic, immunosuppressive, cytostatic, anorectic, antilipaeamic,
 CC hypotensive, antiarteriosclerotic, ophthalmological, nephrotropic, and
 CC neuroprotective. The method is useful for treating or preventing diabetes
 CC or a diabetes related disease chosen from type 1 diabetes, type 2
 CC diabetes, hyperglycaemia, latent autoimmune diabetes in adults, maturity
 CC onset diabetes, polycystic ovarian syndrome, gestational diabetes,
 CC obesity, dyslipidaemia, hyperlipidaemia, hypertriglyceridaemia,
 CC hyperlipoproteinaemia, hypercholesterolaemia, hypertension,
 CC arteriosclerosis, atherosclerosis, cardiovascular disease, diabetic
 CC retinopathy, background retinopathy, proliferative retinopathy, diabetic
 CC nephropathy, neuropathy and diabetic neuropathy, where the patient is
 CC human. The method is useful for increasing the number of beta-cells in a
 CC patient. The insulin sensitizer is useful for the preparation of one or
 CC more medicaments for carrying out the method. This sequence represents a
 CC 39 amino acid exendin-4 peptide isolated from the venom of the Gila
 CC monster lizard, Heloderma suspectum. This peptide is used to act as a
 CC potent GLP-1 receptor agonist for stimulating insulin release relating to
 CC the method of the invention.
 XX
 SQ Sequence 39 AA;

ADP20988 Length: 39 February 4, 2005 13:20 Type: P Check: 9570
 Found using 'seq4' (mohamed337.key)

1 HGEFTFTSLSQMEEEAVRLFIEWLKNKGSPSSGAPPPS
 1 28

 1 match found in sequence:
 adp48978 ; Gila monster amidated exendin-3 peptide.
 (from "seq4ags.pep")
 TOIG of: adp48978 check: 9591 from: 1 to: 39

 ID ADP48978 standard; peptide; 39 AA.
 XX
 AC ADP48978;
 XX
 DT 09-SEP-2004 (first entry)
 XX
 DE Gila monster amidated exendin-3 peptide.
 XX
 KW polycystic ovary syndrome; PCOS; exendin; type-2 diabetes; ovulation;
 KW fertility; spontaneous abortion; gene therapy; insulin resistance;
 KW menses; Gila monster; exendin-3.
 XX
 OS Heloderma suspectum.
 XX
 FH Key Location/Qualifiers
 FT Modified-site 39
 FT /note= "C-terminal amide"
 XX
 PN WO2004052390-A1.
 XX
 XX 24-JUN-2004.
 PD
 XX 30-JUL-2003; 2003WO-US023715.
 PF
 XX 11-DEC-2002; 2002US-00317126.
 PR
 PR 14-JAN-2003; 2003WO-US001109.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Beely NRA, Prickett K, Young A, Hathaway DR;
 PI
 XX WPI; 2004-468706/44.
 DR
 XX Treating a subject suffering from polycystic ovary syndrome (PCOS) for
 CC reducing insulin resistance, restoring fertility or preventing
 CC spontaneous abortion by administering a compound consisting of exendin or
 CC its agonist or analog.
 PT
 XX Disclosure; SEQ ID NO 7; 65pp; English.
 PS
 XX The invention relates to a novel method for treating a subject suffering
 CC from polycystic ovary syndrome (PCOS). The method comprises administering
 CC a compound consisting of exendin, or its agonists or analogues, having a
 CC sequence given in the specification, where the subject exhibits at least
 CC one symptom of PCOS. The invention further relates to: reducing insulin
 CC resistance in a subject suffering from PCOS; preventing the onset of type
 CC -2 diabetes in a subject suffering from PCOS; restoring regular menses in
 CC a subject suffering from PCOS; restoring regular ovulation in a subject
 CC suffering from PCOS; restoring fertility in a subject suffering from PCOS. The
 CC novel compounds of the invention may be used in gene therapy to treat
 CC PCOS. The method is useful in treating a subject suffering from
 CC polycystic ovary syndrome (PCOS) for reducing insulin resistance,
 CC preventing the onset of type-2 diabetes; restoring regular menses,
 CC restoring regular ovulation and fertility or preventing spontaneous
 CC abortion in a subject. This sequence represents an exendin peptide used
 CC in the treatment of polycystic ovary syndrome of the invention.
 XX
 SQ Sequence 39 AA;

ADP48978 Length: 39 February 4, 2005 13:20 Type: P Check: 9591
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNGSPSSGAPPPS
28

1 match found in sequence:
adp48980 ; Gila monster amidated exendin-4 peptide, SEQ ID 9.
(from "seq4ags.pep")
TOIG of: adp48980 check: 9570 from: 1 to: 39

ID ADP48980 standard; peptide; 39 AA.
XX
AC ADP48980;
XX
DT 09-SEP-2004 (first entry)
XX
DE Gila monster amidated exendin-4 peptide, SEQ ID 9.
XX
KW polycystic ovary syndrome; PCOS; exendin; type-2 diabetes; ovulation;
KW fertility; spontaneous abortion; gene therapy; insulin resistance;
KW menses; Gila monster; exendin-4.
XX
OS Heloderma suspectum.

Key Location/Qualifiers
FH Modified-site 39
FT /note= "C-terminal amide"
XX
XX WO2004052390-A1.
XX
XX 24-JUN-2004.
XX
XX 30-JUL-2003; 2003WO-US023715.
XX
XX 11-DEC-2002; 2002US-00317126.
XX
XX 14-JAN-2003; 2003WO-US001109.
XX
XX (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett K, Young A, Hathaway DR;
XX WPI; 2004-468706/44.
XX
XX Treating a subject suffering from polycystic ovary syndrome (PCOS) for
XX reducing insulin resistance, restoring fertility or preventing
XX spontaneous abortion by administering a compound consisting of exendin or
XX its agonist or analog.
XX
XX Disclosure; SEQ ID NO 9; 65pp; English.

XX The invention relates to a novel method for treating a subject suffering
XX from polycystic ovary syndrome (PCOS). The method comprises administering
XX a compound consisting of exendin, or its agonists or analogues, having a
XX sequence given in the specification, where the subject exhibits at least
XX one symptom of PCOS. The invention further relates to: reducing insulin
XX resistance in a subject suffering from PCOS; preventing the onset of type
XX -2 diabetes in a subject suffering from PCOS; restoring regular menses in
XX a subject suffering from PCOS; restoring regular ovulation in a subject
XX suffering from PCOS; restoring fertility in a subject suffering from PCOS
XX ; preventing spontaneous abortion in a subject suffering from PCOS. The
XX novel compounds of the invention may be used in gene therapy to treat
XX PCOS. The method is useful in treating a subject suffering from
XX polycystic ovary syndrome (PCOS) for reducing insulin resistance,
XX preventing the onset of type-2 diabetes; restoring regular menses,
XX restoring regular ovulation and fertility or preventing spontaneous
XX abortion in a subject. This sequence represents an exendin peptide used
XX in the treatment of polycystic ovary syndrome of the invention.

XX Sequence 39 AA;

ADP48980 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

1 HSGGFTSDLSKQMEEEAVRLFIEWLKNGSPSSGAPPPS
28

1 match found in sequence:
adp48985 ; Gila monster exendin-4 peptide (1-30).
(from "seq4ags.pep")
TOIG of: adp48985 check: 4889 from: 1 to: 30

ID ADP48985 standard; peptide; 30 AA.
XX
AC ADP48985;
XX
DT 09-SEP-2004 (first entry)
XX
DE Gila monster exendin-4 peptide (1-30).
XX
KW polycystic ovary syndrome; PCOS; exendin; type-2 diabetes; ovulation;
KW fertility; spontaneous abortion; gene therapy; insulin resistance;
KW menses; Gila monster; exendin-4.
XX
OS Heloderma suspectum.

FN WO2004052390-A1.
XX
XX 24-JUN-2004.
XX
XX 30-JUL-2003; 2003WO-US023715.
XX
XX 11-DEC-2002; 2002US-00317126.
XX
XX 14-JAN-2003; 2003WO-US001109.
XX
XX (AMYL-) AMYLIN PHARM INC.

XX Beeley NRA, Prickett K, Young A, Hathaway DR;
XX WPI; 2004-468706/44.
XX
XX Treating a subject suffering from polycystic ovary syndrome (PCOS) for
XX reducing insulin resistance, restoring fertility or preventing
XX spontaneous abortion by administering a compound consisting of exendin or
XX its agonist or analog.

XX Claim 1; SEQ ID NO 14; 65pp; English.

XX The invention relates to a novel method for treating a subject suffering
XX from polycystic ovary syndrome (PCOS). The method comprises administering
XX a compound consisting of exendin, or its agonists or analogues, having a
XX sequence given in the specification, where the subject exhibits at least
XX one symptom of PCOS. The invention further relates to: reducing insulin
XX resistance in a subject suffering from PCOS; preventing the onset of type
XX -2 diabetes in a subject suffering from PCOS; restoring regular menses in
XX a subject suffering from PCOS; restoring regular ovulation in a subject
XX suffering from PCOS; restoring fertility in a subject suffering from PCOS
XX ; preventing spontaneous abortion in a subject suffering from PCOS. The
XX novel compounds of the invention may be used in gene therapy to treat
XX PCOS. The method is useful in treating a subject suffering from
XX polycystic ovary syndrome (PCOS) for reducing insulin resistance,
XX preventing the onset of type-2 diabetes; restoring regular menses,
XX restoring regular ovulation and fertility or preventing spontaneous
XX abortion in a subject. This sequence represents an exendin peptide used
XX in the treatment of polycystic ovary syndrome of the invention.

XX Sequence 30 AA;

ADP48985 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1 HSGGFTSDLSKQMEEEAVRLFIEWLKNGG
28

1 match found in sequence:
adp48986 : Gila monster amidated extendin-4 peptide (1-30).
(from "seq4ags.pep")
TOIG of: adp48986 check: 4889 from: 1 to: 30

ID ADP48986 standard; peptide; 30 AA.
XX
AC ADP48986;
XX
DT 09-SEP-2004 (first entry)
XX
DE Gila monster amidated extendin-4 peptide (1-30).
XX
KW polycystic ovary syndrome; PCOS; extendin; type-2 diabetes; ovulation;
KW fertility; spontaneous abortion; gene therapy; insulin resistance;
KW menses; Gila monster; extendin-4.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX
PN WO2004052390-A1.
XX
PD 24-JUN-2004.
XX
PF 30-JUL-2003; 2003WO-US023715.
XX
PR 11-DEC-2002; 2002US-00317126.
PR 14-JAN-2003; 2003WO-US001109.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett K, Young A, Hathaway DR;
XX
WPI; 2004-468706/44.
XX
PT Treating a subject suffering from polycystic ovary syndrome (PCOS) for
PT reducing insulin resistance, restoring fertility or preventing
PT spontaneous abortion by administering a compound consisting of extendin or
PT its agonist or analog.
XX
PS Claim 1; SEQ ID NO 15; 65pp; English.
XX
CC The invention relates to a novel method for treating a subject suffering
CC from polycystic ovary syndrome (PCOS). The method comprises administering
CC a compound consisting of extendin, or its agonists or analogues, having a
CC sequence given in the specification, where the subject exhibits at least
CC one symptom of PCOS. The invention further relates to: reducing insulin
CC resistance in a subject suffering from PCOS; preventing the onset of type
CC -2 diabetes in a subject suffering from PCOS; preventing regular menses in
CC a subject suffering from PCOS; restoring regular ovulation in a subject
CC suffering from PCOS; restoring fertility in a subject suffering from PCOS
CC ; preventing spontaneous abortion in a subject suffering from PCOS. The
CC novel compounds of the invention may be used in gene therapy to treat
CC PCOS. The method is useful in treating a subject suffering from
CC polycystic ovary syndrome (PCOS) for reducing insulin resistance,
CC preventing the onset of type-2 diabetes; restoring regular menses,
CC restoring regular ovulation and fertility or preventing spontaneous
CC abortion in a subject. This sequence represents an extendin peptide used
CC in the treatment of polycystic ovary syndrome of the invention.
XX
SQ Sequence 30 AA;
ADP48986 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1 HGEGTFSDLSKQMBEEAVRLPIEWLKN 28
-----|

1 match found in sequence:
adp48987 : Gila monster amidated extendin-4 peptide (1-28).
(from "seq4ags.pep")
TOIG of: adp48987 check: 700 from: 1 to: 28

ID ADP48987 standard; peptide; 28 AA.
XX
AC ADP48987;
XX
DT 09-SEP-2004 (first entry)
XX
DE Gila monster amidated extendin-4 peptide (1-28).
XX
KW polycystic ovary syndrome; PCOS; extendin; type-2 diabetes; ovulation;
KW fertility; spontaneous abortion; gene therapy; insulin resistance;
KW menses; Gila monster; extendin-4.
XX
OS Heloderma suspectum.
XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX
PN WO2004052390-A1.
XX
PD 24-JUN-2004.
XX
PF 30-JUL-2003; 2003WO-US023715.
XX
PR 11-DEC-2002; 2002US-00317126.
PR 14-JAN-2003; 2003WO-US001109.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Beeley NRA, Prickett K, Young A, Hathaway DR;
XX
WPI; 2004-468706/44.
XX
PT Treating a subject suffering from polycystic ovary syndrome (PCOS) for
PT reducing insulin resistance, restoring fertility or preventing
PT spontaneous abortion by administering a compound consisting of extendin or
PT its agonist or analog.
XX
PS Claim 1; SEQ ID NO 16; 65pp; English.
XX
CC The invention relates to a novel method for treating a subject suffering
CC from polycystic ovary syndrome (PCOS). The method comprises administering
CC a compound consisting of extendin, or its agonists or analogues, having a
CC sequence given in the specification, where the subject exhibits at least
CC one symptom of PCOS. The invention further relates to: reducing insulin
CC resistance in a subject suffering from PCOS; preventing the onset of type
CC -2 diabetes in a subject suffering from PCOS; preventing regular menses in
CC a subject suffering from PCOS; restoring regular ovulation in a subject
CC suffering from PCOS; restoring fertility in a subject suffering from PCOS
CC ; preventing spontaneous abortion in a subject suffering from PCOS. The
CC novel compounds of the invention may be used in gene therapy to treat
CC PCOS. The method is useful in treating a subject suffering from
CC polycystic ovary syndrome (PCOS) for reducing insulin resistance,
CC preventing the onset of type-2 diabetes; restoring regular menses,
CC restoring regular ovulation and fertility or preventing spontaneous
CC abortion in a subject. This sequence represents an extendin peptide used
CC in the treatment of polycystic ovary syndrome of the invention.
XX
SQ Sequence 28 AA;
ADP48987 Length: 28 February 4, 2005 13:20 Type: P Check: 700 ..
Found using 'seq4' (mohamed337.key)

1 HGEGTFSDLSKQMBEEAVRLPIEWLKN 28
-----|

Sequence 39 AA;

CC preventing the onset of type-2 diabetes; restoring regular menses,
 CC restoring regular ovulation and fertility or preventing spontaneous
 CC abortion in a subject. This sequence represents an extendin peptide used
 CC in the treatment of polycystic ovary syndrome of the invention.
 XX
 SQ Sequence 28 AA;
 ADP48989 Length: 28 February 4, 2005 13:20 Type: P Check: 261 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGFTFTSLSKQLEEEAVRLAIEFLKN 28
 |-----|
 1 match found in sequence:
 adp48990 ; Gila monster amidated 14-Leu, 22-Ala, 25-Phe extendin-4 (1-28) pepti
 (from "seq4ags.pep")
 TOIG of: adp48990 check: 151 from: 1 to: 28
 ID ADP48990 standard; peptide; 28 AA.
 XX AC ADP48990;
 XX DT 09-SEP-2004 (first entry)
 XX DE Gila monster amidated 14-Leu, 22-Ala, 25-Phe extendin-4 (1-28) peptide.
 XX KW polycystic ovary syndrome; PCOS; extendin; type-2 diabetes; ovulation;
 KW fertility; spontaneous abortion; gene therapy; insulin resistance;
 KW menses; Gila monster; extendin-4; mutant; mutein.
 XX OS Heloderma suspectum.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT Misc-difference 14 /note= "The wild-type residue has been substituted by
 FT Leu"
 FT Misc-difference 22 /note= "The wild-type residue has been substituted by
 FT Ala"
 FT Misc-difference 25 /note= "The wild-type residue has been substituted by
 FT Phe"
 FT Modified-site 28 /note= "C-terminal amide"
 FT FT
 XX WO2004052390-A1.
 XX PN 24-JUN-2004.
 XX PD
 XX PF 30-JUL-2003; 2003WO-US023715.
 XX PR 11-DEC-2002; 2002US-00317126.
 XX PR 14-JAN-2003; 2003WO-US001109.
 XX XX
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX XX
 XX PI Beeley NRA, Prickett K, Young A, Hathaway DR;
 XX XX WPI; 2004-468706/44.
 XX XX
 XX PT Treating a subject suffering from polycystic ovary syndrome (PCOS) for
 PT reducing insulin resistance, restoring fertility or preventing
 PT spontaneous abortion by administering a compound consisting of extendin or
 PT its agonist or analog.
 XX PS Claim 1; SEQ ID NO 19; 65pp; English.
 XX CC The invention relates to a novel method for treating a subject suffering
 CC from polycystic ovary syndrome (PCOS). The method comprises administering
 CC a compound consisting of extendin, or its agonists or analogues, having a

CC sequence given in the specification, where the subject exhibits at least
 CC one symptom of PCOS. The invention further relates to: reducing insulin
 CC resistance in a subject suffering from PCOS; preventing the onset of type
 CC -2 diabetes in a subject suffering from PCOS; restoring regular menses in
 CC a subject suffering from PCOS; restoring regular ovulation in a subject
 CC suffering from PCOS; restoring fertility in a subject suffering from PCOS. The
 CC ; preventing spontaneous abortion in a subject suffering from PCOS. The
 CC novel compounds of the invention may be used in gene therapy to treat
 CC PCOS. The method is useful in treating a subject suffering from
 CC polycystic ovary syndrome (PCOS) for reducing insulin resistance,
 CC preventing the onset of type-2 diabetes; restoring regular menses,
 CC restoring regular ovulation and fertility or preventing spontaneous
 CC abortion in a subject. This sequence represents an extendin peptide used
 CC in the treatment of polycystic ovary syndrome of the invention.
 XX
 SQ Sequence 28 AA;
 ADP48990 Length: 28 February 4, 2005 13:20 Type: P Check: 151 ..
 Found using 'seq4' (mohamed337.key)
 1 HGGFTFTSLSKQLEEEAVRLAIEFLKN 28
 |-----|
 1 match found in sequence:
 adp86539 ; Extendin-3 peptide SEQ ID NO:12.
 (from "seq4ags.pep")
 TOIG of: adp86539 check: 9591 from: 1 to: 39
 ID ADP86539 standard; peptide; 39 AA.
 XX AC ADP86539;
 XX DT 23-SEP-2004 (first entry)
 XX DE Extendin-3 peptide SEQ ID NO:12.
 XX KW incretin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
 KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
 KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
 KW hypertension.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT Modified-site 39 /note= "amidated"
 FT FT
 XX WO2004056317-A2.
 XX PN 08-JUL-2004.
 XX PD
 XX PF 19-DEC-2003; 2003WO-US040713.
 XX PR 19-DEC-2002; 2002US-00741534.
 XX PR 17-DEC-2003; 2003US-00740146.
 XX XX
 XX PA (AMYL-) AMYLIN PHARM INC.
 XX XX
 XX PI Baron AD, Hathaway DR, Mistry M, Roman RJ;
 XX XX WPI; 2004-507586/48.
 XX XX
 XX PT Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
 PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
 PT of a medicament for the prevention or treatment of nephropathy.
 XX PS Disclosure; SEQ ID NO 12; 50pp; English.
 XX CC The present invention describes an incertin, a glucagon-like peptide-1
 CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
 CC their agonist, analogue, derivative or variant or fragment (i), that is

CC used in the manufacture of a medicament for the prevention or treatment
 CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive
 CC activities. (I) can be used in the manufacture of a medicament for the
 CC prevention or treatment of nephropathy; preventing progression of
 CC nephropathy to end stage renal disease (ESRD); improving endothelial
 CC function in the treatment of reduced vasodilatory capacity; reducing
 CC proteinuria; and preventing or slowing progression of glomerulosclerosis
 CC associated with insulin resistance, diabetes and hypertension. The
 CC compounds act in part by facilitating glucose oxidation; including that by
 CC endothelial cells in the kidney and by other cells, rather by oxidation
 CC of free fatty acids; and so leads to an enhanced production of Arp for
 CC use by the cells and reduces oxidative stress on the affected tissue. The
 CC present sequence represents an extendin-3 peptide, which is given in the
 CC exemplification of the present invention.

XX Sequence 39 AA;

ADP86539 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGFTSDLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
 28

1 match found in sequence:

adp86541; Extendin-4 peptide SEQ ID NO:14.
 (from "seq4ags.pep")
 TOIG of: adp86541 check: 9570 from: 1 to: 39

ID ADP86541 standard; peptide; 39 AA.

XX AC ADP86541;

XX DT 23-SEP-2004 (first entry)

XX DE Extendin-4 peptide SEQ ID NO:14.

XX incretin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
 KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
 KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
 KW hypertension.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 39 /note= "amidated"

XX PN WO2004056317-A2.

XX PD 08-JUL-2004.

XX PF 19-DEC-2003; 2003WO-US040713.

XX PR 19-DEC-2002; 2002US-00741534.

XX PR 17-DEC-2003; 2003US-00740146.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Baron AD, Hathaway DR, Mistry M, Roman RJ;

XX DR WPI; 2004-507586/48.

XX Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
 PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
 PT of a medicament for the prevention or treatment of nephropathy.

XX PS Disclosure; SEQ ID NO 14; 50pp; English.

XX The present invention describes an incertin, a glucagon-like peptide-1
 CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or

CC their agonist, analogue, derivative or variant or fragment (I), that is
 CC used in the manufacture of a medicament for the prevention or treatment
 CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive
 CC activities. (I) can be used in the manufacture of a medicament for the
 CC prevention or treatment of nephropathy; preventing progression of
 CC nephropathy to end stage renal disease (ESRD); improving endothelial
 CC function in the treatment of reduced vasodilatory capacity; reducing
 CC proteinuria; and preventing or slowing progression of glomerulosclerosis
 CC associated with insulin resistance, diabetes and hypertension. The
 CC compounds act in part by improving glucose oxidation; including that by
 CC endothelial cells in the kidney and by other cells, rather by oxidation
 CC of free fatty acids; and so leads to an enhanced production of Arp for
 CC use by the cells and reduces oxidative stress on the affected tissue. The
 CC present sequence represents an extendin-4 peptide, which is given in the
 CC exemplification of the present invention.

XX Sequence 39 AA;

ADP86541 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)

1 HSGFTSDLSKQMEEEAVRLFIEWLKNKGPPSSGAPPPS
 28

1 match found in sequence:

adp86546; Extendin-4 analogue peptide SEQ ID NO:19.
 (from "seq4ags.pep")
 TOIG of: adp86546 check: 4889 from: 1 to: 30

ID ADP86546 standard; peptide; 30 AA.

XX AC ADP86546;

XX DT 23-SEP-2004 (first entry)

XX DE Extendin-4 analogue peptide SEQ ID NO:19.

XX incretin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
 KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
 KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
 KW hypertension.

XX OS Synthetic.

XX PN WO2004056317-A2.

XX PD 08-JUL-2004.

XX PF 19-DEC-2003; 2003WO-US040713.

XX PR 19-DEC-2002; 2002US-00741534.

XX PR 17-DEC-2003; 2003US-00740146.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Baron AD, Hathaway DR, Mistry M, Roman RJ;

XX DR WPI; 2004-507586/48.

XX Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
 PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
 PT of a medicament for the prevention or treatment of nephropathy.

XX PS Disclosure; SEQ ID NO 19; 50pp; English.

XX The present invention describes an incertin, a glucagon-like peptide-1
 CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
 CC their agonist, analogue, derivative or variant or fragment (I), that is
 CC used in the manufacture of a medicament for the prevention or treatment
 CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive

CC activities. (I) can be used in the manufacture of a medicament for the
 CC prevention or treatment of nephropathy; preventing progression of
 CC nephropathy to end stage renal disease (ESRD); improving endothelial
 CC function in the treatment of reduced vasodilatory capacity; reducing
 CC proteinuria; and preventing or slowing progression of glomerulosclerosis
 CC associated with insulin resistance, diabetes and hypertension. The
 CC compounds act in part by improving insulin resistance, cation balance,
 CC hypertension and/or by facilitating glucose oxidation; including that by
 CC endothelial cells in the kidney and by other cells, rather by oxidation
 CC of free fatty acids; and so leads to an enhanced production of ATP for
 CC use by the cells and reduces oxidative stress on the affected tissue. The
 CC present sequence represents an extendin analogue peptide, which is given
 CC in the exemplification of the present invention.

XX Sequence 30 AA;

ADP86546 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
 Found using 'seq4' (mohamed337.key)

1 HGGCTFTSLSKQMBEEAVRLFIEWLKNGG 28
 |-----|

1 match found in sequence:
 adp86547 ; Extendin-4 analogue peptide SEQ ID NO:20.
 (from "seq4ags.pep")
 TOIG of: adp86547 check: 4889 from: 1 to: 30

ID ADP86547 standard; peptide; 30 AA.

XX AC ADP86547;

XX DT 23-SEP-2004 (first entry)

XX DE Extendin-4 analogue peptide SEQ ID NO:20.

XX KW incretin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
 KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
 KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
 KW hypertension.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 30

XX FT /note= "amidated"

XX PN WO2004056317-A2.

XX PD 08-JUL-2004.

XX PF 19-DEC-2003; 2003WO-US040713.

XX PR 19-DEC-2002; 2002US-00741534.

XX PR 17-DEC-2003; 2003US-00740146.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Baron AD, Hathaway DR, Mistry M, Roman RJ;

XX DR WPI; 2004-507586/48.

XX PT Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
 PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
 PT of a medicament for the prevention or treatment of nephropathy.

XX PS Disclosure; SEQ ID NO 20; 50pp; English.

XX CC The present invention describes an incretin, a glucagon-like peptide-1
 CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
 CC their agonist, analogue, derivative or variant or fragment (I), that is
 CC used in the manufacture of a medicament for the prevention or treatment

CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive
 CC activities. (I) can be used in the manufacture of a medicament for the
 CC prevention or treatment of nephropathy; preventing progression of
 CC nephropathy to end stage renal disease (ESRD); improving endothelial
 CC function in the treatment of reduced vasodilatory capacity; reducing
 CC proteinuria; and preventing or slowing progression of glomerulosclerosis
 CC associated with insulin resistance, diabetes and hypertension. The
 CC compounds act in part by improving insulin resistance, cation balance,
 CC hypertension and/or by facilitating glucose oxidation; including that by
 CC endothelial cells in the kidney and by other cells, rather by oxidation
 CC of free fatty acids; and so leads to an enhanced production of ATP for
 CC use by the cells and reduces oxidative stress on the affected tissue. The
 CC present sequence represents an extendin analogue peptide, which is given
 CC in the exemplification of the present invention.

XX Sequence 30 AA;

ADP86547 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
 Found using 'seq4' (mohamed337.key)

1 HGGCTFTSLSKQMBEEAVRLFIEWLKNGG 28
 |-----|

1 match found in sequence:
 adp86548 ; Extendin-4 analogue peptide SEQ ID NO:21.
 (from "seq4ags.pep")
 TOIG of: adp86548 check: 700 from: 1 to: 28

ID ADP86548 standard; peptide; 28 AA.

XX AC ADP86548;

XX DT 23-SEP-2004 (first entry)

XX DE Extendin-4 analogue peptide SEQ ID NO:21.

XX KW incretin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
 KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
 KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
 KW hypertension.

XX OS Synthetic.

XX FH Key Location/Qualifiers

XX FT Modified-site 28

XX FT /note= "amidated"

XX PN WO2004056317-A2.

XX PD 08-JUL-2004.

XX PF 19-DEC-2003; 2003WO-US040713.

XX PR 19-DEC-2002; 2002US-00741534.

XX PR 17-DEC-2003; 2003US-00740146.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Baron AD, Hathaway DR, Mistry M, Roman RJ;

XX DR WPI; 2004-507586/48.

XX PT Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
 PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
 PT of a medicament for the prevention or treatment of nephropathy.

XX PS Disclosure; SEQ ID NO 21; 50pp; English.

XX CC The present invention describes an incretin, a glucagon-like peptide-1
 CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
 CC their agonist, analogue, derivative or variant or fragment (I), that is

used in the manufacture of a medicament for the prevention or treatment of nephropathy. (i) has nephrotropic, antidiabetic and hypotensive activities. (ii) can be used in the manufacture of a medicament for the prevention or treatment of nephropathy; preventing progression of nephropathy to end stage renal disease (ESRD); improving endothelial function in the treatment of reduced vasodilatory capacity; reducing proteinuria; and preventing or slowing progression of glomerulosclerosis associated with insulin resistance, diabetes and hypertension. The compounds act in part by improving insulin resistance, cation balance, hypertension and/or by facilitating glucose oxidation, including that by endothelial cells in the kidney and by other cells, rather by oxidation of free fatty acids; and so leads to an enhanced production of ATP for use by the cells and reduces oxidative stress on the affected tissue. The present sequence represents an exendin analogue peptide, which is given in the exemplification of the present invention.

their agonist, analogue, derivative or variant or fragment (I), that is used in the manufacture of a medicament for the prevention or treatment of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive activities. (I) can be used in the manufacture of a medicament for the prevention or treatment of nephropathy; preventing progression of nephropathy to end stage renal disease (ESRD); improving endothelial function in the treatment of reduced vasodilatory capacity; reducing proteinuria; and preventing or slowing progression of glomerulosclerosis associated with insulin resistance, diabetes and hypertension. The compounds act in part by improving insulin resistance, cation balance, hypertension and/or by facilitating glucose oxidation, including that by endothelial cells in the kidney and by other cells, rather by oxidation of free fatty acids; and so leads to an enhanced production of ATP for use by the cells and reduces oxidative stress on the affected tissue. The present sequence represents an exendin analogue peptide, which is given in the exemplification of the present invention.

ADP86548 Length: 28 February 4, 2005 13:20 Type: P Check: 700 : :
Found using 'seq4', (mohamed337.key)

CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
 CC their agonist, analogue, derivative or variant or fragment (I), that is
 CC used in the manufacture of a medicament for the prevention or treatment
 CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive
 CC activities. (I) can be used in the manufacture of a medicament for the
 CC prevention or treatment of nephropathy; preventing progression of
 CC nephropathy to end stage renal disease (ESRD); improving endothelial
 CC function in the treatment of reduced vasodilatory capacity; reducing
 CC proteinuria; and preventing or slowing progression of glomerulosclerosis
 CC associated with insulin resistance, diabetes and hypertension. The
 CC compounds act in part by improving insulin resistance, cation balance,
 CC hypertension and/or by facilitating glucose oxidation; including that by
 CC endothelial cells in the kidney and by other cells, rather by oxidation
 CC of free fatty acids; and so leads to an enhanced production of ATP for
 CC use by the cells and reduces oxidative stress on the affected tissue. The
 CC present sequence represents an extendin analogue peptide, which is given
 CC in the exemplification of the present invention.
 XX
 SQ Sequence 28 AA;

ADP86550 Length: 28 February 4, 2005 13:20 Type: P Check: 261
 Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGEFTFTDLSKQLEEEAVRLAIEFLKN 28

1 match found in sequence:
 adp86551 ; Extendin-4 analogue peptide SEQ ID NO:24.
 (from "seq4ags.pep")
 TOIG of: adp86551 check: 151 from: 1 to: 28

ID ADP86551 standard; peptide; 28 AA.

XX AC ADP86551;

XX DT 23-SEP-2004 (first entry)

XX DE Extendin-4 analogue peptide SEQ ID NO:24.

XX KW incretin; glucagon-like peptide-1; GLP-1; extendin; nephropathy;
 XX KW nephrotropic; antidiabetic; hypotensive; end stage renal disease; ESRD;
 XX KW proteinuria; glomerulosclerosis; insulin resistance; diabetes;
 XX KW hypertension.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT Modified-site 28

FT /note= "amidated"

XX WO2004056317-A2.

XX PD 08-JUL-2004.

XX PF 19-DEC-2003; 2003WO-US040713.

XX PR 19-DEC-2002; 2002US-00741534.

XX PR 17-DEC-2003; 2003US-00740146.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Baron AD, Hathaway DR, Mistry M, Roman RJ;

XX DR WPI; 2004-507586/48.

XX PT Use of an incertin, a glucagon-like peptide-1, an extendin or a compound
 XX PT that binds to a receptor for glucagon-like peptide-1, in the manufacture
 XX PT of a medicament for the prevention or treatment of nephropathy.

XX PS Disclosure; SEQ ID NO 24; 50pp; English.

CC The present invention describes an incretin, a glucagon-like peptide-1
 CC (GLP-1), an extendin or a compound that binds to a receptor for GLP-1, or
 CC their agonist, analogue, derivative or variant or fragment (I), that is
 CC used in the manufacture of a medicament for the prevention or treatment
 CC of nephropathy. (I) has nephrotropic, antidiabetic and hypotensive
 CC activities. (I) can be used in the manufacture of a medicament for the
 CC prevention or treatment of nephropathy; preventing progression of
 CC nephropathy to end stage renal disease (ESRD); improving endothelial
 CC function in the treatment of reduced vasodilatory capacity; reducing
 CC proteinuria; and preventing or slowing progression of glomerulosclerosis
 CC associated with insulin resistance, diabetes and hypertension. The
 CC compounds act in part by improving insulin resistance, cation balance,
 CC hypertension and/or by facilitating glucose oxidation; including that by
 CC endothelial cells in the kidney and by other cells, rather by oxidation
 CC of free fatty acids; and so leads to an enhanced production of ATP for
 CC use by the cells and reduces oxidative stress on the affected tissue. The
 CC present sequence represents an extendin analogue peptide, which is given
 CC in the exemplification of the present invention.
 XX
 SQ Sequence 28 AA;

ADP86551 Length: 28 February 4, 2005 13:20 Type: P Check: 151

Found using 'seq4' (mohamed337.key)

1 |-----|
 1 HGEFTFTDLSKQLEEEAVRLAIEFLKN 28

1 match found in sequence:
 adq28641 ; Extendin-3, useful as antiarrhythmic.
 (from "seq4ags.pep")
 TOIG of: adq28641 check: 9591 from: 1 to: 39

ID ADQ28641 standard; peptide; 39 AA.

XX AC ADQ28641;

XX DT 23-SEP-2004 (first entry)

XX DE Extendin-3, useful as antiarrhythmic.

XX KW Extendin-3; antiarrhythmic; cardiovascular-gen.; vasotropic.

XX OS Heloderma horridum.

XX FH Key Location/Qualifiers

FT Modified-site 39

FT /note= "C-terminal amide"

XX WO2004056313-A2.

XX PD 08-JUL-2004.

XX PF 17-DEC-2003; 2003WO-US040504.

XX PR 17-DEC-2002; 2002US-0434508P.

XX PR 19-DEC-2002; 2002US-0434888P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Hathaway DR, Baron AD;

XX DR WPI; 2004-507584/48.

XX PT Use of an incertin, a glucagon-like peptide-1, an extendin, or a compound
 XX PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
 XX PT cardiac arrhythmias by metabolic intervention.

XX PS Disclosure; SEQ ID NO 12; 49pp; English.

XX The present sequence is that of the extendin-3 peptide of Heloderma
 CC harridum. This is a glucose-dependent insulinotropic peptide that

CC enhances peripheral glucose uptake without inducing dangerous
 CC hyperglycaemia. The present invention provides methods and compositions
 CC for preventing and treating cardiac arrhythmias. The compositions
 CC comprise exendin, GLP-1, an incretin, a compound that binds to a receptor
 CC for GLP-1, or an agonist, analogue, derivative or variant of these
 CC compounds or their biologically active fragments. These compounds enhance
 CC peripheral glucose uptake by potentiating insulin secretion without
 CC inducing dangerous hypoglycaemia. They are effective at maintaining the
 CC electrochemical gradient across cardiac cellular membranes, thereby
 CC reducing the likelihood of arrhythmias developing. They also strongly
 CC suppress glucagon secretion, independent of its insulinotropic action,
 CC and thereby reduce plasma free fatty acid (FFA) levels substantially more
 CC than can be accomplished with insulin. High FFA levels have been
 CC implicated as a major toxic mechanism during myocardial ischaemia. The
 CC compounds can be administered by injection following an ischaemic event
 CC or a cardiac intervention such as angioplasty, coronary bypass grafting
 CC or placement of an intracoronary stent, and can be used to treat or
 CC prevent ventricular arrhythmias such as cardiac ischaemia, cardiac
 CC ischaemia-reperfusion and congestive heart failure.
 XX
 SQ Sequence 39 AA;

ADQ28641 Length: 39 February 4, 2005 13:20 Type: P Check: 9591 ..
 Found using 'seq4' (mohamed337.key)

1 HSDGTFSTLSKQMEBEAVRLFIEWLKNKGPSGAPPPS
 1 28

 1 match found in sequence:
 adq28643 ; Exendin-4, useful as antiarrhythmic.
 (from "seq4ags.pep")
 TOIG of: adq28643 check: 9570 from: 1 to: 39

ID ADQ28643 standard; peptide; 39 AA.
 XX
 AC ADQ28643;
 XX
 DT 23-SEP-2004 (first entry)
 XX
 DE Exendin-4, useful as antiarrhythmic.
 XX
 KW Exendin-4; antiarrhythmic; cardiovascular-gen.; vasotropic.
 XX
 OS Heloderma suspectum.
 XX

FH Key Location/Qualifiers
 FT Modified-site 39 /note= "C-terminal amide"
 FT
 XX WO2004056313-A2.
 XX
 XX 08-JUL-2004.
 XX
 XX 17-DEC-2003; 2003WO-US040504.
 XX
 XX 17-DEC-2002; 2002US-0434508P.
 PR
 PR 19-DEC-2002; 2002US-0434888P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Hathaway DR, Baron AD;
 XX
 XX WPI; 2004-507584/48.
 DR
 XX

XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
 PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
 PT cardiac arrhythmias by metabolic intervention.
 PT
 XX Disclosure; SEQ ID NO 14; 49pp; English.
 PS
 XX The present sequence is that of exendin-4 of Heloderma suspectum. This is

CC a glucose-dependent insulinotropic peptide that enhances peripheral
 CC glucose uptake without inducing dangerous hyperglycaemia. The present
 CC invention provides methods and compositions for preventing and treating
 CC cardiac arrhythmias. The compositions comprise exendin, GLP-1, an
 CC incretin, a compound that binds to a receptor for GLP-1, or an agonist,
 CC analogue, derivative or variant of these compounds or their biologically
 CC active fragments. These compounds enhance peripheral glucose uptake by
 CC potentiating insulin secretion without inducing dangerous hypoglycaemia.
 CC They are effective at maintaining the electrochemical gradient across
 CC cardiac cellular membranes, thereby reducing the likelihood of
 CC arrhythmias developing. They also strongly suppress glucagon secretion,
 CC independent of its insulinotropic action, and thereby reduce plasma free
 CC fatty acid (FFA) levels substantially more than can be accomplished with
 CC insulin. High FFA levels have been implicated as a major toxic mechanism
 CC during myocardial ischaemia. The compounds can be administered by
 CC injection following an ischaemic event or a cardiac intervention such as
 CC angioplasty, coronary bypass grafting or placement of an intracoronary
 CC stent, and can be used to treat or prevent ventricular arrhythmias such
 CC as cardiac ischaemia, cardiac ischaemia-reperfusion and congestive heart
 CC failure.
 XX
 SQ Sequence 39 AA;

ADQ28643 Length: 39 February 4, 2005 13:20 Type: P Check: 9570 ..
 Found using 'seq4' (mohamed337.key)

1 HCEGTFTSLSKQMEBEAVRLFIEWLKNKGPSGAPPPS
 1 28

 1 match found in sequence:
 adq28648 ; Exendin-4 (1-30) peptide, useful as antiarrhythmic.
 (from "seq4ags.pep")
 TOIG of: adq28648 check: 4889 from: 1 to: 30

ID ADQ28648 standard; peptide; 30 AA.
 XX
 AC ADQ28648;
 XX
 DT 23-SEP-2004 (first entry)
 XX
 DE Exendin-4 (1-30) peptide, useful as antiarrhythmic.
 XX
 KW Exendin-4 (1-30); antiarrhythmic; cardiovascular-gen.; vasotropic.
 XX
 OS Heloderma suspectum.
 XX
 PN WO2004056313-A2.
 XX
 XX 08-JUL-2004.
 XX
 XX 17-DEC-2003; 2003WO-US040504.
 XX
 XX 17-DEC-2002; 2002US-0434508P.
 PR
 PR 19-DEC-2002; 2002US-0434888P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Hathaway DR, Baron AD;
 XX
 XX WPI; 2004-507584/48.
 DR
 XX

XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
 PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
 PT cardiac arrhythmias by metabolic intervention.
 PT
 XX Disclosure; SEQ ID NO 19; 49pp; English.
 PS
 XX The present sequence is that of exendin-4 (1-30) peptide derived from
 CC Heloderma suspectum exendin-4 ADQ28643. It is an example of exendin
 CC analogues of the invention. The present invention provides methods and
 CC compositions for preventing and treating cardiac arrhythmias. The

CC compositions comprise exendin, GLP-1, an incretin, a compound that binds
CC to a receptor for GLP-1, or an agonist, analogue, derivative or variant
CC of these compounds or their biologically active fragments. These
CC compounds enhance peripheral glucose uptake by potentiating insulin
CC secretion without inducing dangerous hypoglycaemia. They are effective at
CC maintaining the electrochemical gradient across cardiac cellular
CC membranes, thereby reducing the likelihood of arrhythmias developing.
CC They also strongly suppress glucagon secretion, independent of its
CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
CC levels substantially more than can be accomplished with insulin. High FFA
CC levels have been implicated as a major toxic mechanism during myocardial
CC ischaemia. The compounds can be administered by injection following an
CC ischaemic event or a cardiac intervention such as angioplasty, coronary
CC bypass grafting or placement of an intracoronary stent, and can be used
CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
CC cardiac ischaemia-reperfusion and congestive heart failure.

XX Sequence 30 AA;

ADQ28648 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1 HGGGFTSDLSKQMBEEAVRLFIEWLKNGG
1 28

1 match found in sequence:

adq28649 ; Exendin-4 (1-30) amide, useful as antiarrhythmic.
(from "seq4ags.pep")

TOIG of: adq28649 check: 4889 from: 1 to: 30

ID ADQ28649 standard; peptide; 30 AA.
XX
AC ADQ28649;
XX
XX
DT 23-SEP-2004 (first entry)
XX
DE Exendin-4 (1-30) amide, useful as antiarrhythmic.
XX
KW Exendin-4 (1-30); antiarrhythmic; cardiovascular-gen.; vasotropic.
XX
OS Heloderma suspectum.

XX
FH Key Location/Qualifiers
FT Modified-site 30
FT /note= "C-terminal amide"
XX

PN WO2004056313-A2.

XX 08-JUL-2004.

XX 17-DEC-2003; 2003WO-US040504.

XX 17-DEC-2002; 2002US-0434508P.

PR 19-DEC-2002; 2002US-0434888P.

XX (AMYL-) AMYLIN PHARM INC.

XX Hathaway DR, Baron AD;

XX WPI; 2004-507584/48.

XX Use of an incretin, a glucagon-like peptide-1, an exendin, or a compound
PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
PT cardiac arrhythmias by metabolic intervention.

XX Disclosure; SEQ ID NO 20; 49pp; English.

XX The present sequence is that of exendin-4 (1-30) amide derived from
CC Heloderma suspectum exendin-4 ADQ28643. It is an example of exendin
CC analogues of the invention. The present invention provides methods and
CC compositions for preventing and treating cardiac arrhythmias. The

CC compositions comprise exendin, GLP-1, an incretin, a compound that binds
CC to a receptor for GLP-1, or an agonist, analogue, derivative or variant
CC of these compounds or their biologically active fragments. These
CC compounds enhance peripheral glucose uptake by potentiating insulin
CC secretion without inducing dangerous hypoglycaemia. They are effective at
CC maintaining the electrochemical gradient across cardiac cellular
CC membranes, thereby reducing the likelihood of arrhythmias developing.
CC They also strongly suppress glucagon secretion, independent of its
CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
CC levels substantially more than can be accomplished with insulin. High FFA
CC levels have been implicated as a major toxic mechanism during myocardial
CC ischaemia. The compounds can be administered by injection following an
CC ischaemic event or a cardiac intervention such as angioplasty, coronary
CC bypass grafting or placement of an intracoronary stent, and can be used
CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
CC cardiac ischaemia-reperfusion and congestive heart failure.

XX Sequence 30 AA;

ADQ28649 Length: 30 February 4, 2005 13:20 Type: P Check: 4889 ..
Found using 'seq4' (mohamed337.key)

1 HGGGFTSDLSKQMBEEAVRLFIEWLKNGG
1 28

1 match found in sequence:

adq28650 ; Exendin-4 (1-28) amide, useful as antiarrhythmic.
(from "seq4ags.pep")

TOIG of: adq28650 check: 700 from: 1 to: 28

ID ADQ28650 standard; peptide; 28 AA.
XX
AC ADQ28650;
XX
XX
DT 23-SEP-2004 (first entry)
XX
DE Exendin-4 (1-28) amide, useful as antiarrhythmic.
XX
KW Exendin-4 (1-28); antiarrhythmic; cardiovascular-gen.; vasotropic.
XX
OS Heloderma suspectum.

XX
FH Key Location/Qualifiers
FT Modified-site 28
FT /note= "C-terminal amide"
XX

PN WO2004056313-A2.

XX 08-JUL-2004.

XX 17-DEC-2003; 2003WO-US040504.

XX 17-DEC-2002; 2002US-0434508P.

PR 19-DEC-2002; 2002US-0434888P.

XX (AMYL-) AMYLIN PHARM INC.

XX Hathaway DR, Baron AD;

XX WPI; 2004-507584/48.

XX Use of an incretin, a glucagon-like peptide-1, an exendin, or a compound
PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
PT cardiac arrhythmias by metabolic intervention.

XX Disclosure; SEQ ID NO 21; 49pp; English.

XX The present sequence is that of exendin-4 (1-28) amide derived from
CC Heloderma suspectum exendin-4 ADQ28643. It is an example of exendin
CC analogues of the invention. The present invention provides methods and
CC compositions for preventing and treating cardiac arrhythmias. The

CC compositions comprise exendin, GLP-1, an incretin, a compound that binds
 CC to a receptor for GLP-1, or an agonist, analogue, derivative or variant
 CC of these compounds or their biologically active fragments. These
 CC compounds enhance peripheral glucose uptake by potentiating insulin
 CC secretion without inducing dangerous hypoglycaemia. They are effective at
 CC maintaining the electrochemical gradient across cardiac cellular
 CC membranes, thereby reducing the likelihood of arrhythmias developing.
 CC They also strongly suppress glucagon secretion, independent of its
 CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
 CC levels substantially more than can be accomplished with insulin. High FFA
 CC levels have been implicated as a major toxic mechanism during myocardial
 CC ischaemia. The compounds can be administered by injection following an
 CC ischaemic event or a cardiac intervention such as angioplasty, coronary
 CC bypass grafting or placement of an intracoronary stent, and can be used
 CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
 CC cardiac ischaemia-reperfusion and congestive heart failure.
 XX
 SQ Sequence 28 AA;

ADQ28650 Length: 28 February 4, 2005 13:20 Type: P Check: 700 ..
 Found using 'seq4' (mohamed337.key)

1 HCEGFTSDLSKQMEAEVRLFIWLNKX
 1
 28

 1 match found in sequence:
 adq28651 ; 14Leu,25Phe exendin-4 amide, useful as antiarrhythmic.
 (from "seq4ags.pep")
 TOIG of: adq28651 check: 9131 from: 1 to: 39

ID ADQ28651 standard; peptide; 39 AA.
 AC ADQ28651;
 XX
 XX
 DT 23-SEP-2004 (first entry)
 XX
 DE 14Leu,25Phe exendin-4 amide, useful as antiarrhythmic.
 XX
 KW Exendin-4; antiarrhythmic; cardiovascular-gen.; vasotropic.
 XX
 OS Heloderma suspectum.

XX Key Location/Qualifiers
 FH Misc-difference 14 /note= "Wild-type Met substituted by Leu"
 FT Misc-difference 25 /note= "Wild-type Trp substituted by Phe"
 FT Modified-site 39 /note= "C-terminal amide"
 FT
 XX

WO2004056313-A2.

XX
 XX
 PD 08-JUL-2004.

XX 17-DEC-2003; 2003WO-US040504.

XX 17-DEC-2002; 2002US-0434508P.

PR 19-DEC-2002; 2002US-0434888P.

XX (AMYL-) AMYLIN PHARM INC.

XX Hathaway DR, Baron AD;

XX WPI; 2004-507584/48.

XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
 PT that binds to a receptor for glucagon-like peptide-1 in the treatment of
 PT cardiac arrhythmias by metabolic intervention.

XX Disclosure; SEQ ID NO 22; 49pp; English.

CC The present sequence is that of 14Leu,25Phe exendin-4 amide derived from
 CC Heloderma suspectum exendin-4 ADQ28643. It is an example of exendin
 CC analogues of the invention. The present invention provides methods and
 CC compositions for preventing and treating cardiac arrhythmias. The
 CC compositions comprise exendin, GLP-1, an incretin, a compound that binds
 CC to a receptor for GLP-1, or an agonist, analogue, derivative or variant
 CC of these compounds or their biologically active fragments. These
 CC compounds enhance peripheral glucose uptake by potentiating insulin
 CC secretion without inducing dangerous hypoglycaemia. They are effective at
 CC maintaining the electrochemical gradient across cardiac cellular
 CC membranes, thereby reducing the likelihood of arrhythmias developing.
 CC They also strongly suppress glucagon secretion, independent of its
 CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)
 CC levels substantially more than can be accomplished with insulin. High FFA
 CC levels have been implicated as a major toxic mechanism during myocardial
 CC ischaemia. The compounds can be administered by injection following an
 CC ischaemic event or a cardiac intervention such as angioplasty, coronary
 CC bypass grafting or placement of an intracoronary stent, and can be used
 CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,
 CC cardiac ischaemia-reperfusion and congestive heart failure.
 XX
 SQ Sequence 39 AA;

ADQ28651 Length: 39 February 4, 2005 13:20 Type: P Check: 9131 ..
 Found using 'seq4' (mohamed337.key)

1 HCEGFTSDLSKQLEAEVRLFIELKNGSPSSGAPPPS
 1
 28

 1 match found in sequence:

adq28652 ; 14Leu,25Phe exendin-4 (1-28) amide, useful as antiarrhythmic.
 (from "seq4ags.pep")
 TOIG of: adq28652 check: 261 from: 1 to: 28

ID ADQ28652 standard; peptide; 28 AA.

XX AC ADQ28652;

XX DT 23-SEP-2004 (first entry)

XX DE 14Leu,25Phe exendin-4 (1-28) amide, useful as antiarrhythmic.

XX KW Exendin-4; antiarrhythmic; cardiovascular-gen.; vasotropic.

XX OS Heloderma suspectum.

XX Key Location/Qualifiers

FH Misc-difference 14 /note= "Wild-type Met substituted by Leu"

FT Misc-difference 25 /note= "Wild-type Trp substituted by Phe"

FT Modified-site 28 /note= "C-terminal amide"

FT
 XX

WO2004056313-A2.

XX 08-JUL-2004.

XX 17-DEC-2003; 2003WO-US040504.

XX 17-DEC-2002; 2002US-0434508P.

PR 19-DEC-2002; 2002US-0434888P.

XX (AMYL-) AMYLIN PHARM INC.

XX Hathaway DR, Baron AD;

XX WPI; 2004-507584/48.

XX Use of an incertin, a glucagon-like peptide-1, an exendin, or a compound
 PT that binds to a receptor for glucagon-like peptide-1 in the treatment of

PT cardiac arrhythmias by metabolic intervention.

XX

PS Disclosure; SEQ ID NO 23; 49pp; English.

XX

CC The present sequence is that of 14Leu,25Phe extendin-4 (1-28) amide

CC derived from Heloderma suspectum extendin-4 ADO28643. It is an example of

CC extendin analogues of the invention. The present invention provides

CC methods and compositions for preventing and treating cardiac arrhythmias.

CC The compositions comprise extendin, GLP-1, an incretin, a compound that

CC binds to a receptor for GLP-1, or an agonist, analogue, derivative or

CC variant of these compounds or their biologically active fragments. These

CC compounds enhance peripheral glucose uptake by potentiating insulin

CC secretion without inducing dangerous hypoglycaemia. They are effective at

CC maintaining the electrochemical gradient across cardiac cellular

CC membranes, thereby reducing the likelihood of arrhythmias developing.

CC They also strongly suppress glucagon secretion, independent of its

CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)

CC levels substantially more than can be accomplished with insulin. High FFA

CC ischaemic event or a cardiac intervention such as angioplasty, coronary

CC bypass grafting or placement of an intracoronary stent, and can be used

CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,

CC cardiac ischaemia-reperfusion and congestive heart failure.

XX

XX Sequence 28 AA;

ADQ28652 Length: 28 February 4, 2005 13:20 Type: P Check: 261 ..

Found using 'seq4' (mohamed337.key)

1 |-----|

1 HGGGTTSDLSKQLEEEAVRLTFEFLKN 28

1 match found in sequence:

adq28653 ; 14Leu,22Ala,25Phe extendin-4 (1-28) amide, useful as antiarrhythmic.

(from "seq4ags pep")

TOIG of: adq28653 check: 151 from: 1 to: 28

ID ADQ28653 standard; peptide; 28 AA.

XX

AC ADQ28653;

XX

DT 23-SEP-2004 (first entry)

DE 14Leu,22Ala,25Phe extendin-4 (1-28) amide, useful as antiarrhythmic.

XX

XX Extendin-4; antiarrhythmic; cardiovascular-gen.; vasotropic.

XX

OS Heloderma suspectum.

XX

XX Key Location/Qualifiers

FT Misc-difference 14

FT /note= "Wild-type Met substituted by Leu"

FT Misc-difference 22

FT /note= "Wild-type Phe substituted by Ala"

FT Misc-difference 25

FT /note= "Wild-type Trp substituted by Phe"

FT Modified-site 28

FT /note= "C-terminal amide"

XX

XX WO2004056313-A2.

XX

XX 08-JUL-2004.

XX

XX 17-DEC-2003; 2003WO-US040504.

XX

XX 17-DEC-2002; 2002US-0434508P.

PR

XX 19-DEC-2002; 2002US-0434888P.

XX

XX (AWYL-) AMYLIN PHARM INC.

PA

XX

PI Hathaway DR, Baron AD;

XX

DR WPI; 2004-507584/48.

XX

XX Use of an incertin, a glucagon-like peptide-1, an extendin, or a compound

PT that binds to a receptor for glucagon-like peptide-1 in the treatment of

PT cardiac arrhythmias by metabolic intervention.

XX

PS Disclosure; SEQ ID NO 24; 49pp; English.

XX

CC The present sequence is that of 14Leu,22Ala, 25Phe extendin-4 (1-28) amide

CC derived from Heloderma suspectum extendin-4 ADO28643. It is an example of

CC extendin analogues of the invention. The present invention provides

CC methods and compositions for preventing and treating cardiac arrhythmias.

CC The compositions comprise extendin, GLP-1, an incretin, a compound that

CC binds to a receptor for GLP-1, or an agonist, analogue, derivative or

CC variant of these compounds or their biologically active fragments. These

CC compounds enhance peripheral glucose uptake by potentiating insulin

CC secretion without inducing dangerous hypoglycaemia. They are effective at

CC maintaining the electrochemical gradient across cardiac cellular

CC membranes, thereby reducing the likelihood of arrhythmias developing.

CC They also strongly suppress glucagon secretion, independent of its

CC insulinotropic action, and thereby reduce plasma free fatty acid (FFA)

CC levels substantially more than can be accomplished with insulin. High FFA

CC ischaemic event or a cardiac intervention such as angioplasty, coronary

CC bypass grafting or placement of an intracoronary stent, and can be used

CC to treat or prevent ventricular arrhythmias such as cardiac ischaemia,

CC cardiac ischaemia-reperfusion and congestive heart failure.

XX

XX Sequence 28 AA;

ADQ28653 Length: 28 February 4, 2005 13:20 Type: P Check: 151 ..

Found using 'seq4' (mohamed337.key)

1 |-----|

1 HGGGTTSDLSKQLEEEAVRLTFEFLKN 28

-- Search Statistics --

Times: CPU 00:00:01.09 Total Elapsed 00:00:18.00

Number of sequences searched: 955

Number of sequence hits: 955

Number of separate matches: 955

Number of sequence hits saved: 0

```

> O <
> O | O IntelliGenetics
> O <

Quest - Quick User-directed Expression Search Tool
Release 5.4

-- Outline of search "seq4_pir" --

Selected search type is key against sequence data banks or files.
Selected scope is Sequence.
Selected sequence key from "mohamed337.key":
seq4 (AA) ID seq4 AA preliminary pattern
followed by
1 h or r or y
2 s or g or a or t
2 a or d or e
2 g
2 a or t
2 any character
2 t or s
2 a or s or t
2 d or e
2 any character
2 a or s
2 a or k
2 a or q
2 any character
2 a or e
2 a or e
2 a or v
2 a or r
2 a or l
2 any character
2 any character
2 a or e or d
2 any character
2 a or l
2 a or k
2 a or n

Selected files:
File : seq4pir.pep

-- Output Parameters --

Format Options:
Nucleic acid code matching Exact Indirect file
Find non-matching hits only No Sequence or key file
Report key used Yes List of hits
Note position of hit Yes Hit display
Display full annotations Yes Name and annotations
Sequence context 50

-- Run Parameters --

Run mode Batch
Time to start comparison now
Notify at end of run No

-----
1 match found in sequence:
hwgh3z ; TOIG of: hwgh3z check: 9591 from: 1 to: 39
(from "seq4pir.pep")
TOIG of: hwgh3z check: 9591 from: 1 to: 39

Pl:HWGH3Z - exendin-3 - Mexican beaded lizard
C:Species: Heloderma horridum (Mexican beaded lizard)
C:Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 09-Jul-2004

C:Accession: A23674
R:Eng, J.; Andrews, P.C.; Kleinman, W.A.; Singh, L.; Raufman, J.P.
J. Biol. Chem. 265, 20259-20262, 1990
A:Title: Purification and structure of exendin-3, a new pancreatic secretagogue
isolated from Heloderma horridum venom.
A:Reference number: A23674; MUID:91056067; PMID:1700785
A:Accession: A23674
A:Molecule type: protein
A:Residues: 1-39 <ENG>
A:CROSS-references: UNIPROT:P20394
C:Comment: Exendins are venom components that are thought to bind to receptors
for vasoactive intestinal peptide and/or secretin on pancreatic acinar cells
and to activate adenylate cyclase, resulting in secretion of amylase.
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; duplication; secretagogue; venom
P:39/Modified site: amidated carboxyl end (Ser) #status experimental

HWGH3Z Length: 39 February 4, 2005 13:30 Type: P Check: 9591 ..
Found using 'seq4' (mohamed337.key)

-----
1 HSDGFTSDLSKQMEEAARLFIWLKNGSPSSGAPPPS
28

-----
1 match found in sequence:
hwgh4g ; TOIG of: hwgh4g check: 9570 from: 1 to: 39
(from "seq4pir.pep")
TOIG of: hwgh4g check: 9570 from: 1 to: 39

Pl:HWGH4G - exendin-4 - Gila monster
C:Species: Heloderma suspectum (Gila monster)
C:Date: 31-Mar-1993 #sequence_revision 31-Mar-1993 #text_change 09-Jul-2004
C:Accession: A42486
R:Eng, J.; Kleinman, W.A.; Singh, L.; Singh, G.; Raufman, J.P.
J. Biol. Chem. 267, 7402-7405, 1992
A:Title: Isolation and characterization of exendin-4, an exendin-3 analogue,
from Heloderma suspectum venom. Further evidence for an exendin receptor on
dispersed acini from guinea pig pancreas.
A:Reference number: A42486; MUID:92218391; PMID:1313797
A:Accession: A42486
A:Molecule type: protein
A:Residues: 1-39 <ENG>
A:CROSS-references: UNIPROT:P26349
C:Comment: Exendin-4 does not stimulate amylase secretion by pancreatic acinar
cells.
C:Superfamily: glucagon
C:Keywords: amidated carboxyl end; duplication; venom
P:39/Modified site: amidated carboxyl end (Ser) #status experimental

HWGH4G Length: 39 February 4, 2005 13:30 Type: P Check: 9570 ..
Found using 'seq4' (mohamed337.key)

-----
1 HEGTFTSDLSKQMEEAARLFIWLKNGSPSSGAPPPS
28

-----
-- Search Statistics --

Times: CPU Total Elapsed
00:00:00.00 00:00:00.00

Number of sequences searched: 2
Number of sequence hits: 2
Number of separate matches: 2
Number of sequence hits saved: 0

```


RX PubMed=11693627; DOI=10.1021/b1010902g;
RA Neidigh J.W., Fesinmeyer R.M., Prickett K.S., Andersen N.H.;
RT "Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in
the solution and micelle-associated states";
RL Biochemistry 40:13188-13200(2001)
CC -!- FUNCTION: Has a VIP/secretin-like biological activity. Interacts
CC with the exendin receptor.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC -!- SIMILARITY: Belongs to the glucagon family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL Outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; U77613; AAB51130.1; -
DR PIR; A42486; HWGH4G.
DR PDB; 1URJ; NMR; A=48-86.
DR InterPro: IPR000532; Glucagon.
DR Pfam; PF00123; Hormone_2; 1.
DR SMART; SM00070; Hormone_2; 1.
DR PROSITE; PS00260; GLUCAG; 1.
KW 3D-structure; Amidation; Direct protein sequencing; Glucagon family;
KW Signal; Toxin.
FT SIGNAL 1 23 Potential.
FT PROPEP 24 47
FT PEPTIDE 48 86 Exendin-4.
FT MOD_RES 86 86 Serine amide (G-87 provides amide group).
FT TURN 52 53
FT HELIX 54 74
FT TURN 75 76
FT TURN 77 79
FT HELIX 77 79
SQ SEQUENCE 87 AA; 9479 MW; 656BA6E3D87454A2 CRC64;

EXE4 HELSU Length: 87 February 4, 2005 13:30 Type: P Check: 973 ..
Found using 'seq4' (mohamed337.key)

1 MKIILWLCVFGGLFLATLFPVSWQMPVESGLSSEDSASSSFASKIKRHSDGTFTSDLSKQ
48

61 MEEAVRLFIWLNKGPPSSGAPPPSG
75

1 match found in sequence:
q7szu6 : Exendin 3 precursor.
(from "seq4uni.pep")
TOIG of: q7szu6 Check: 1771 from: 1 to: 87

ID Q7SZU6 PRELIMINARY; PRT; 87 AA.
AC Q7SZU6;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-MAR-2004 (TrEMBLrel. 26, Last annotation update)
DE Exendin 3 precursor.
GN Name=exendin;
OS Heloderma horridum (Mexican beaded lizard).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidodonta; Squamata; Scleroglossa; Anguimorpha; Helodermatidae;
OC Heloderma.
OX NCBI_TaxID=8551;
RN [1]
RP SEQUENCE FROM N.A.
RC TISSUE=Venom;
RA Chen T., Kwok H., Shaw C.;
RL Submitted (AUG-2003) to the EMBL/GenBank/DBJ databases.
DR EMBL; AJ580309; CAE30483.1; -

DR HSP; P26349; 1URJ.
DR GO; GO:0005576; C:extracellular; IEA.
DR GO; GO:0005179; F:hormone activity; IEA.
DR InterPro: IPR000532; Glucagon.
DR Pfam; PF00123; Hormone_2; 1.
DR SMART; SM00070; GLUCAG; 1.
DR PROSITE; PS00260; GLUCAG; 1.
KW Signal.
FT SIGNAL 1 21 Potential.
FT CHAIN 48 86 exendin 3.
SQ SEQUENCE 87 AA; 9481 MW; E66FA6F15AE5F127 CRC64;

Q7SZU6 Length: 87 February 4, 2005 13:30 Type: P Check: 1771 ..
Found using 'seq4' (mohamed337.key)

1 MKIILWLCVFGGLFLATLFPVSWQMPVESGLSSEDSASSSFASKIKRHSDGTFTSDLSKQ
48

61 MEEAVRLFIWLNKGPPSSGAPPPSG
75

-- Search Statistics --

Times: CPU 00:00:00.00 Total Elapsed
00:00:00.00

Number of sequences searched: 3
Number of sequence hits: 3
Number of separate matches: 3
Number of sequence hits saved: 0

```
> O <
O| O| Intelligenetics
> O <

Quest - Quick User-directed Expression Search Tool
Release 5.4

-- Outline of search "seq4_uni" --

Selected search type is key against sequence data banks or files.
Selected scope is Sequence.
Selected sequence key from "mohamed337.key":
seq4 (AA) ID seq4 AA preliminary pattern
1 followed by
2 h or r or y
2 s or g or a or t
2 a or d or e
2 g
2 a or t
2 any character
2 t or s
2 a or s or t
2 d or e
2 any character
2 a or s
2 a or k
2 a or q
2 any character
2 a or e
2 a or e
2 a or e
2 a or v
2 a or i
2 any character
2 any character
2 a or e or d
2 any character
2 a or l
2 a or k
2 a or n

Selected files:
File : seq4uni.pep

-- Output Parameters --

Format Options:
Nucleic acid code matching Exact Indirect file
Find non-matching hits only No Sequence or key file
Report key used Yes List of hits
Note position of hit Yes Hit display
Display full annotations Yes Name and annotations
Sequence context 50

-- Run Parameters --

Run mode Batch
Time to start comparison now
Notify at end of run No

-----
1 match found in sequence:
exe3helho ; Exendin-3.
(from "seq4uni.pep")
TOIG of: exe3helho check: 9591 from: 1 to: 39

ID EXE3 HELHO STANDARD; PRT; 39 AA.
AC P20394;
DT 01-FEB-1991 (Rel. 17, Created)

-----
1 match found in sequence:
exe4helsu ; Exendin-4 precursor.
(from "seq4uni.pep")
TOIG of: exe4helsu check: 973 from: 1 to: 87

ID EXE4 HELSU STANDARD; PRT; 87 AA.
AC P26349;
DT 01-MAY-1992 (Rel. 22, Created)
DT 15-JUL-1998 (Rel. 36, Last sequence update)
DT 25-OCT-2004 (Rel. 45, Last annotation update)
DE Exendin-4 precursor.
OS Heloderma suspectum (Gila monster).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Lepidosauria; Squamata; Scleroglossa; Anguimorpha; Helodermatidae;
OC Heloderma.
OX NCBI_TaxID=8554;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=97172477; PubMed=9020121; DOI=10.1074/jbc.272.7.4335;
RA Chen Y.E., Drucker D.J.;
RT "Tissue-specific expression of unique mRNAs that encode proglucagon-
derived peptides or exendin 4 in the lizard.";
RL J. Biol. Chem. 272:4108-4115(1997).
RN [2]
RP SEQUENCE OF 48-86.
RX TISSUE=Venom;
RC MEDLINE=92218391; PubMed=1313797;
RA Eng J., Kleinman W.A., Singh L., Kaufman J.-P.;
RT "Isolation and characterization of exendin-4, an exendin-3 analogue,
from Heloderma suspectum venom. Further evidence for an exendin
receptor on dispersed acini from guinea pig pancreas.";
RL J. Biol. Chem. 267:7402-7405(1992).
RN [3]
RP STRUCTURE BY NMR OF 48-86.
```



```
> O <
> O | O IntelliGenetics
> O <

Quest - Quick User-directed Expression Search Tool
Release 5.4

-- Outline of search "seq5_ags" --

Selected search type is key against sequence data banks or files.
Selected scope is Sequence.
Selected sequence key from "mohamed337.key":
seq5 (AA) ID seq5 AA preliminary pattern
followed by
1 any character
2 s or g or a or t
2 a or d or e
2 any character
2 a or t
2 any character
2 t or s
2 a or s or t
2 any character
2 any character
2 a or s
2 a or k
2 a or q
2 any character
2 a or e
2 a or e
2 a
2 a or v
2 a or l
2 any character
2 any character
2 a or e or d
2 any character
2 a or l
2 a or k
2 a or n

Selected files:
File : seq5ags.pep

-- Output Parameters --

Format Options:
Nucleic acid code matching Exact Indirect file
Find non-matching hits only No Sequence or key file
Report key used Yes List of hits
Note position of hit Yes Hit display
Display full annotations Yes Name and annotations
Sequence context 50

Run mode Batch
Time to start comparison now
Notify at end of run No

-- Run Parameters --

1 match found in sequence:
aabl1126 ; extendin agonist SEQ ID NO 6.
(from "seq5ags.pep")
TOIG of: aabl1126 check: 4889 from: 1 to: 30

ID AABL1126 standard; peptide; 30 AA.
XX
AC AABL1126;
XX
XX 20-FEB-2001 (first entry)
DE extendin agonist SEQ ID NO 7.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX WO2000041546-A2.
PN
XX 20-JUL-2000.
PD
XX 14-JAN-2000; 2000WO-US000902.
PF
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
PA (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
PI
XX WPI; 2000-514584/46.
DR
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
PT
XX
XX Disclosure; Page 25; 281pp; English.
PS
XX
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 30 AA;
SQ

AABL1126 Length: 30 February 4, 2005 13:32 Type: P Check: 4889 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTFTSDLSKQMBEEAVRLFIEWLKNGG
1 28
-----
1 match found in sequence:
aabl1127 ; extendin agonist SEQ ID NO 7.
(from "seq5ags.pep")
TOIG of: aabl1127 check: 4889 from: 1 to: 30

ID AABL1127 standard; peptide; 30 AA.
XX
XX AABL1127;
AC
XX
XX 20-FEB-2001 (first entry)
DE extendin agonist SEQ ID NO 7.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX WO2000041546-A2.
PN
XX 20-JUL-2000.
PD
XX 14-JAN-2000; 2000WO-US000902.
PF
XX
```

DR WPI; 2000-514584/46.
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 49; Page 127; 281pp; English.
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
SQ
AAB11134 Length: 28 February 4, 2005 13:32 Type: P Check: 249 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HAEGFTSDLSKQLEEEAVRLFIEFLKN 28

1 match found in sequence:
aabl1135 ; extendin agonist peptide SEQ ID NO 43.
(from "seq5ags.pep")
TOIG of: aabl1135 check: 166 from: 1 to: 28
ID AAB11135 standard; peptide; 28 AA.
XX
XX AC AAB11135;
XX
XX 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 43.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 50; Page 128; 281pp; English.
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX

SQ Sequence 28 AA;
AAB11135 Length: 28 February 4, 2005 13:32 Type: P Check: 166 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HAEGFTSDLSKQLEEEAVRLFIEFLKN 28

1 match found in sequence:
aabl1136 ; extendin agonist peptide SEQ ID NO 44.
(from "seq5ags.pep")
TOIG of: aabl1136 check: 231 from: 1 to: 28
ID AAB11136 standard; peptide; 28 AA.
XX
XX AC AAB11136;
XX
XX 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 44.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 51; Page 129; 281pp; English.
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
SQ
AAB11136 Length: 28 February 4, 2005 13:32 Type: P Check: 231 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
1 HAEGFTSDLSKQLEEEAVRLFIEFLKN 28

1 match found in sequence:
aabl1137 ; extendin agonist peptide SEQ ID NO 45.
(from "seq5ags.pep")
TOIG of: aabl1137 check: 117 from: 1 to: 28
ID AAB11137 standard; peptide; 28 AA.

CC This invention describes a novel formulation (I) comprising an exendin or
 CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The exendin or exendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 CC
 XX Sequence 28 AA;

AAB11139 Length: 28 February 4, 2005 13:32 Type: P Check: 63 ..
 Found using 'seq5' (mohamed337.key)

1 HEGTFTSLAKLSEEAARLFIETFLKN 28
 |-----|

1 match found in sequence:
 aab11140 ; exendin agonist peptide SEQ ID NO 48.
 (from "seq5ags.pep")
 TOIG of: aab11140 check: 141 from: 1 to: 28

ID AAB11140 standard; peptide; 28 AA.

XX
 AC AAB11140;

XX
 DT 20-FEB-2001 (first entry)

XX
 DE exendin agonist peptide SEQ ID NO 48.

XX
 KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX
 OS Synthetic.

XX
 PN WO200041546-A2.

XX
 PD 20-JUL-2000.

XX
 PF 14-JAN-2000; 2000WO-US000902.

XX
 PR 14-JAN-1999; 99US-0116380P.

XX
 PR 10-JAN-2000; 2000US-0175365P.

XX
 PA (AMYL-) AMYLIN PHARM INC.

XX
 PI Young A, L'italien JJ, Kolterman O;

XX
 DR WPI; 2000-514584/46.

XX
 PT New formulations comprising an exendin or exendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX
 PS Example 55; Page 132; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
 CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The exendin or exendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 CC
 XX Sequence 28 AA;

AAB11140 Length: 28 February 4, 2005 13:32 Type: P Check: 141 ..
 Found using 'seq5' (mohamed337.key)

1 HEGTFTSLAKLSEEAARLFIETFLKN
 |-----|

1 28
 |-----|
 1 match found in sequence:
 aab11141 ; exendin agonist peptide SEQ ID NO 49.
 (from "seq5ags.pep")
 TOIG of: aab11141 check: 53 from: 1 to: 28

ID AAB11141 standard; peptide; 28 AA.

XX
 AC AAB11141;

XX
 DT 20-FEB-2001 (first entry)

XX
 DE exendin agonist peptide SEQ ID NO 49.

XX
 KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX
 OS Synthetic.

XX
 PN WO200041546-A2.

XX
 PD 20-JUL-2000.

XX
 PF 14-JAN-2000; 2000WO-US000902.

XX
 PR 14-JAN-1999; 99US-0116380P.

XX
 PR 10-JAN-2000; 2000US-0175365P.

XX
 PA (AMYL-) AMYLIN PHARM INC.

XX
 PI Young A, L'italien JJ, Kolterman O;

XX
 DR WPI; 2000-514584/46.

XX
 PT New formulations comprising an exendin or exendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX
 PS Example 56; Page 133; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
 CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The exendin or exendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 CC
 XX Sequence 28 AA;

AAB11141 Length: 28 February 4, 2005 13:32 Type: P Check: 53 ..
 Found using 'seq5' (mohamed337.key)

1 HEGTFTSLAKLSEEAARLFIETFLKN 28
 |-----|

1 match found in sequence:
 aab11142 ; exendin agonist peptide SEQ ID NO 50.
 (from "seq5ags.pep")
 TOIG of: aab11142 check: 107 from: 1 to: 28

ID AAB11142 standard; peptide; 28 AA.

XX
 AC AAB11142;

XX
 DT 20-FEB-2001 (first entry)

XX
 DE exendin agonist peptide SEQ ID NO 50.


```
CC or reducing food intake
XX Sequence 28 AA;
SQ
AAB11144 Length: 28 February 4, 2005 13:32 Type: P Check: 197 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  HEGGFTSDLSKQLAEAAVRLFIIEFLKN 28
  1
-----
1 match found in sequence:
aabl1145 ; extendin agonist peptide SEQ ID NO 53.
(from "seq5ags.pep")
TOIG of: aabl1145 check: 193 from: 1 to: 28

ID AAB11145 standard; peptide; 28 AA.
XX
AC AAB11145;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 53.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 60; Page 136; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;
AAB11145 Length: 28 February 4, 2005 13:32 Type: P Check: 193 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  HEGGFTSDLSKQLAEAAVRLFIIEFLKN 28
  1
-----
1 match found in sequence:
aabl1146 ; extendin agonist peptide SEQ ID NO 54.
(from "seq5ags.pep")
TOIG of: aabl1146 check: 9862 from: 1 to: 28

ID AAB11146 standard; peptide; 28 AA.
XX
AC AAB11146;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 54.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 61; Page 137; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 28 AA;
AAB11146 Length: 28 February 4, 2005 13:32 Type: P Check: 9862 ..
Found using 'seq5' (mohamed337.key)
1 |-----|
  HEGGFTSDLSKQLAEAAVRLFIIEFLKN 28
  1
-----
1 match found in sequence:
aabl1147 ; extendin agonist peptide SEQ ID NO 55.
(from "seq5ags.pep")
TOIG of: aabl1147 check: 9921 from: 1 to: 28

ID AAB11147 standard; peptide; 28 AA.
XX
AC AAB11147;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 55.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
```

KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

PN WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

PA Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an exendin or exendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 57; Page 133-134; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
 CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The exendin or exendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 28 AA;

AAB11142 Length: 28 February 4, 2005 13:32 Type: P Check: 107 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLAEAAVRLFIETFLKN 28
 1

1 match found in sequence:
 aab11143 ; exendin agonist peptide SEQ ID NO 51.
 (from "seq5ags.pep")
 TOIG of: aab11143 check: 201 from: 1 to: 28

ID AAB11143 standard; peptide; 28 AA.

AC AAB11143;

XX 20-FEB-2001 (first entry)

XX exendin agonist peptide SEQ ID NO 51.

KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

PN WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX

PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an exendin or exendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 58; Page 134; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
 CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The exendin or exendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 28 AA;

AAB11143 Length: 28 February 4, 2005 13:32 Type: P Check: 201 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLAEAAVRLFIETFLKN 28
 1

1 match found in sequence:
 aab11144 ; exendin agonist peptide SEQ ID NO 52.
 (from "seq5ags.pep")
 TOIG of: aab11144 check: 197 from: 1 to: 28

ID AAB11144 standard; peptide; 28 AA.

AC AAB11144;

XX 20-FEB-2001 (first entry)

XX exendin agonist peptide SEQ ID NO 52.

KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

PN WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

PI Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an exendin or exendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 59; Page 135; 281pp; English.

XX This invention describes a novel formulation (I) comprising an exendin or
 CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The exendin or exendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying

```
1 HEGTFTSLSKQLEEEAVRLFIAFLKN 28
-----
1 match found in sequence:
aabl1150 ; extendin agonist peptide SEQ ID NO 58.
(from "seq5ags.pep")
TOIG of: aabl1150 check: 136 from: 1 to: 28

ID AAB11150 standard; peptide; 28 AA.
XX
AC AAB11150;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 58.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PS 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 65; Page 140; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
or reducing food intake
XX
SQ Sequence 28 AA;

AAB11150 Length: 28 February 4, 2005 13:32 Type: P Check: 136 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQLEEEAVRLFIAFLKN 28
-----
1 match found in sequence:
aabl1151 ; extendin agonist peptide SEQ ID NO 59.
(from "seq5ags.pep")
TOIG of: aabl1151 check: 9975 from: 1 to: 28

ID AAB11151 standard; peptide; 28 AA.
XX
AC AAB11151;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 59.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PS 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 65; Page 140; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
or reducing food intake
XX
SQ Sequence 28 AA;

AAB11150 Length: 28 February 4, 2005 13:32 Type: P Check: 136 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQLEEEAVRLFIAFLKN 28
-----
1 match found in sequence:
aabl1151 ; extendin agonist peptide SEQ ID NO 59.
(from "seq5ags.pep")
TOIG of: aabl1151 check: 9975 from: 1 to: 28

ID AAB11151 standard; peptide; 28 AA.
XX
AC AAB11151;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 59.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PS 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 66; Page 140; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
or reducing food intake
XX
SQ Sequence 28 AA;

AAB11151 Length: 28 February 4, 2005 13:32 Type: P Check: 9975 ..
Found using 'seq5' (mohamed337.key)

1 HEGTFTSLSKQLEEEAVRLFIAFLKN 28
-----
1 match found in sequence:
aabl1152 ; extendin agonist peptide SEQ ID NO 60.
(from "seq5ags.pep")
TOIG of: aabl1152 check: 9991 from: 1 to: 28

ID AAB11152 standard; peptide; 28 AA.
XX
AC AAB11152;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 60.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PS 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PT New formulations comprising an extendin or extendin agonist peptide used
for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 66; Page 140; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
extendin agonist peptide, a buffer and an iso-osmolality modifier which
has a pH of 3-7. The products of the invention have antidiabetic
activity. The extendin or extendin agonist is used to increase the
sensitivity of a subject to insulin to treat diabetes and disorders which
would benefit from agents which lower plasma glucose levels and disorders
or reducing food intake
XX
SQ Sequence 28 AA;
```

PD 20-JUL-2000.
XX
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Young A, L'italien JJ, Kolterman O;
XX
XX
XX WPI; 2000-514584/46.
XX
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX
PS Example 62; Page 137; 281pp; English.
XX
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX
SQ Sequence 28 AA;
XX
XX
AAB1147 Length: 28 February 4, 2005 13:32 Type: P Check: 9921 ..
Found using 'seq5' (mohamed337.key)
1 1 HGEFTSDLSKQLEEEAVRAFIETLKN 28

1 match found in sequence:
aab1148 ; extendin agonist peptide SEQ ID NO 56.
(from "seq5ags.pep")
TOIG of: aab1148 check: 30 from: 1 to: 28

ID AAB1148 standard; peptide; 28 AA.
XX
XX
AC AAB1148;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 56.
XX
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX
OS Synthetic.
XX
XX
PN WO200041546-A2.
XX
XX
PD 20-JUL-2000.
XX
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Young A, L'italien JJ, Kolterman O;
XX
XX
XX WPI; 2000-514584/46.
XX
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX

PS Example 63; Page 138; 281pp; English.
XX
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX
SQ Sequence 28 AA;
XX
XX
AAB1148 Length: 28 February 4, 2005 13:32 Type: P Check: 30 ..
Found using 'seq5' (mohamed337.key)
1 1 HGEFTSDLSKQLEEEAVRAFIETLKN 28

1 match found in sequence:
aab1149 ; extendin agonist peptide SEQ ID NO 57.
(from "seq5ags.pep")
TOIG of: aab1149 check: 165 from: 1 to: 28

ID AAB1149 standard; peptide; 28 AA.
XX
XX
AC AAB1149;
XX
XX
DT 20-FEB-2001 (first entry)
XX
XX
DE extendin agonist peptide SEQ ID NO 57.
XX
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX
OS Synthetic.
XX
XX
PN WO200041546-A2.
XX
XX
PD 20-JUL-2000.
XX
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
XX
PR 14-JAN-1999; 99US-0116380P.
PR 10-JAN-2000; 2000US-0175365P.
XX
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
XX
PI Young A, L'italien JJ, Kolterman O;
XX
XX
XX WPI; 2000-514584/46.
XX
XX
PT New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX
PS Example 64; Page 139; 281pp; English.
XX
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX
SQ Sequence 28 AA;
XX
XX
AAB1149 Length: 28 February 4, 2005 13:32 Type: P Check: 165 ..
Found using 'seq5' (mohamed337.key)

```

(from "seq5ags.pep")
TOIG of: aab11155 check: 5894 from: 1 to: 38
ID AAB11155 standard; peptide; 38 AA.
XX
AC AAB11155;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 63.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PS New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 70; Page 143; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 38 AA;
AAB11155 Length: 38 February 4, 2005 13:32 Type: P Check: 5894 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTSDLSKQLEBEAVRLFIEPLKNGGPPSGAPP
1 28
-----
1 match found in sequence:
aab11156 ; extendin agonist peptide SEQ ID NO 64.
(from "seq5ags.pep")
TOIG of: aab11156 check: 3293 from: 1 to: 37
ID AAB11156 standard; peptide; 37 AA.
XX
AC AAB11156;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 64.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PS New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 70; Page 143; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 37 AA;
AAB11157 Length: 37 February 4, 2005 13:32 Type: P Check: 3293 ..
Found using 'seq5' (mohamed337.key)
1 HEGGFTSDLSKQMEEEAVRLFIEWLKNGGPPSGAPP
1 28
-----
1 match found in sequence:
aab11157 ; extendin agonist peptide SEQ ID NO 65.
(from "seq5ags.pep")
TOIG of: aab11157 check: 2854 from: 1 to: 37
ID AAB11157 standard; peptide; 37 AA.
XX
AC AAB11157;
XX
DT 20-FEB-2001 (first entry)
XX
DE extendin agonist peptide SEQ ID NO 65.
XX
KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
OS Synthetic.
XX
PN WO200041546-A2.
XX
PD 20-JUL-2000.
XX
PF 14-JAN-2000; 2000WO-US000902.
XX
PR 14-JAN-1999; 99US-0116380P.
XX
PR 10-JAN-2000; 2000US-0175365P.
XX
PA (AMYL-) AMYLIN PHARM INC.
XX
PI Young A, L'italien JJ, Kolterman O;
XX
DR WPI; 2000-514584/46.
XX
PS New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
PS Example 71; Page 144; 281pp; English.
XX
CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 37 AA;

```

PA (AMYL-) AMYLIN PHARM INC.
 XX Young A, L'italien JJ, Kolterman O;
 PI WPI; 2000-514584/46.
 DR
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 PS Example 67; Page 141; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 28 AA;
 SQ
 AAB1152 Length: 28 February 4, 2005 13:32 Type: P Check: 9991 ..
 Found using 'seq5' (mohamed337.key)
 1 HGEFTFTDLSKQLEEEAVRLFIEFLAN 28
 1 match found in sequence:
 aab11153 ; extendin agonist peptide SEQ ID NO 61.
 (from "seq5ags.pep")
 TOIG of: aab11153 check: 9897 from: 1 to: 28
 ID AAB1153 standard; peptide; 28 AA.
 XX
 AC AAB11153;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 61.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX Synthetic.
 OS
 XX WO2000041546-A2.
 PN
 XX 20-JUL-2000.
 PD
 XX 14-JAN-2000; 2000WO-US000902.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR
 XX 10-JAN-2000; 2000US-0175365P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, L'italien JJ, Kolterman O;
 PI WPI; 2000-514584/46.
 DR
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 PS Example 68; Page 142; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which

CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 28 AA;
 SQ
 AAB1153 Length: 28 February 4, 2005 13:32 Type: P Check: 9897 ..
 Found using 'seq5' (mohamed337.key)
 1 HGEFTFTDLSKQLEEEAVRLFIEFLKA 28
 1 match found in sequence:
 aab11154 ; extendin agonist peptide SEQ ID NO 62.
 (from "seq5ags.pep")
 TOIG of: aab11154 check: 6333 from: 1 to: 38
 ID AAB1154 standard; peptide; 38 AA.
 XX
 AC AAB11154;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 62.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX Synthetic.
 OS
 XX WO2000041546-A2.
 PN
 XX 20-JUL-2000.
 PD
 XX 14-JAN-2000; 2000WO-US000902.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR
 XX 10-JAN-2000; 2000US-0175365P.
 PR
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, L'italien JJ, Kolterman O;
 PI WPI; 2000-514584/46.
 DR
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 PS Example 69; Page 143; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 38 AA;
 SQ
 AAB1154 Length: 38 February 4, 2005 13:32 Type: P Check: 6333 ..
 Found using 'seq5' (mohamed337.key)
 1 HGEFTFTDLSKQLEEEAVRLFIEWLKNGPSSGAPPP 28
 1 match found in sequence:
 aab11155 ; extendin agonist peptide SEQ ID NO 63.

```
DT 20-FEB-2001 (first entry)
XX extendin agonist peptide SEQ ID NO 68.
DE
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX WO200041546-A2.
XX
XX
XX 20-JUL-2000.
PD
XX
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
XX
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 75; Page 147; 281pp; English.
PS
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 35 AA;
SQ
AAB1160 Length: 35 February 4, 2005 13:32 Type: P Check: 7453
Found using 'seq5' (mohamed337.key)
1 HGEFTSDLSKQMEEEAVRLFIEWLKNGPSSGA
|-----|
1 28
-----
1 match found in sequence:
aab1161; extendin agonist peptide SEQ ID NO 69.
(from "seq5ags.pep")
TOIG of: aab1161 check: 7014 from: 1 to: 35
ID AAB1161 standard; peptide; 35 AA.
XX
XX AAB1161;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 69.
DE
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX WO200041546-A2.
XX
XX
XX 20-JUL-2000.
PD
XX
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 14-JAN-2000; 2000US-0116380P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
XX
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 77; Page 149; 281pp; English.
PS
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 35 AA;
SQ
AAB1161 Length: 35 February 4, 2005 13:32 Type: P Check: 7014
Found using 'seq5' (mohamed337.key)
1 HGEFTSDLSKQLEEBEAVRLFIEFLKNGPSSGA
|-----|
1 28
-----
1 match found in sequence:
aab1162; extendin agonist peptide SEQ ID NO 70.
(from "seq5ags.pep")
TOIG of: aab1162 check: 5178 from: 1 to: 34
ID AAB1162 standard; peptide; 34 AA.
XX
XX AAB1162;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 70.
DE
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX WO200041546-A2.
XX
XX
XX 20-JUL-2000.
PD
XX
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
XX
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 77; Page 149; 281pp; English.
PS
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
```

```
PR 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 76; Page 148; 281pp; English.
PS
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 35 AA;
SQ
AAB1161 Length: 35 February 4, 2005 13:32 Type: P Check: 7014
Found using 'seq5' (mohamed337.key)
1 HGEFTSDLSKQLEEBEAVRLFIEFLKNGPSSGA
|-----|
1 28
-----
1 match found in sequence:
aab1162; extendin agonist peptide SEQ ID NO 70.
(from "seq5ags.pep")
TOIG of: aab1162 check: 5178 from: 1 to: 34
ID AAB1162 standard; peptide; 34 AA.
XX
XX AAB1162;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX extendin agonist peptide SEQ ID NO 70.
DE
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
OS
XX WO200041546-A2.
XX
XX
XX 20-JUL-2000.
PD
XX
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
PR
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
PA
XX Young A, L'italien JJ, Kolterman O;
PI WPI; 2000-514584/46.
XX
XX
XX New formulations comprising an extendin or extendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 77; Page 149; 281pp; English.
PS
XX This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
```

PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX
 PS
 CC Example 72; Page 145; 281pp; English.

CC This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 37 AA;

AAB11157 Length: 37 February 4, 2005 13:32 Type: P Check: 2854 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIEFLKNGGPGSSGAPP
 28

1 match found in sequence:
 aab11158 ; extendin agonist peptide SEQ ID NO 66.
 (from "seq5ags.pep")
 TOIG of: aab11158 check: 333 from: 1 to: 36

ID AAB11158 standard; peptide; 36 AA.

XX
 AC AAB11158;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 66.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX
 OS Synthetic.

XX WO200041546-A2.

PN 14-JAN-1999; 99US-0116380P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX
 PD 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

PS Example 73; Page 146; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 36 AA;

AAB11158 Length: 36 February 4, 2005 13:32 Type: P Check: 333 ..

Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIEFLKNGGPGSSGAPP
 28

1 match found in sequence:
 aab11159 ; extendin agonist peptide SEQ ID NO 67.
 (from "seq5ags.pep")
 TOIG of: aab11159 check: 9894 from: 1 to: 36

ID AAB11159 standard; peptide; 36 AA.

XX
 AC AAB11159;

XX DT 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 67.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

XX Synthetic.

XX WO200041546-A2.

XX 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

XX 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

XX Young A, L'italien JJ, Kolterman O;

XX WPI; 2000-514584/46.

XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 74; Page 146-147; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX
 SQ Sequence 36 AA;

AAB11159 Length: 36 February 4, 2005 13:32 Type: P Check: 9894 ..
 Found using 'seq5' (mohamed337.key)

1 HGGTFTSDLSKQLEEEAVRLFIEFLKNGGPGSSGAPP
 28

1 match found in sequence:
 aab11160 ; extendin agonist peptide SEQ ID NO 68.
 (from "seq5ags.pep")
 TOIG of: aab11160 check: 7453 from: 1 to: 35

ID AAB11160 standard; peptide; 35 AA.

XX
 AC AAB11160;

XX

```

OS Synthetic.
XX WO200041546-A2.
XX
XX
XX
XX
XX 14-JAN-2000; 2000WO-US000902.
XX PF
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young A, L'italien JJ, Kolterman O;
XX PI
XX WPI; 2000-514584/46.
XX DR
XX
XX New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 80; Page 151; 281pp; English.
XX PS
XX This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC
XX Sequence 33 AA;
SQ

AAB11165 Length: 33 February 4, 2005 13:32 Type: P Check: 2325 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTSLSKQEEAVRLFIEFLKNGGPS
  1 28
  -----|
  HGEFTSLSKQEEAVRLFIEFLKNGGPS
  1 28
  -----|
  1 match found in sequence:
  aab11166 ; exendin agonist peptide SEQ ID NO 74.
  (from "seq5ags.pep")
  TOIG of: aab11166 check: 25 from: 1 to: 32

ID AAB11166 standard; peptide; 32 AA.
XX
XX
XX AAB11166;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX exendin agonist peptide SEQ ID NO 74.
DE
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX PN
XX 20-JUL-2000.
XX PD
XX
XX 14-JAN-2000; 2000WO-US000902.
XX PF
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young A, L'italien JJ, Kolterman O;
XX PI
XX WPI; 2000-514584/46.
XX DR
XX
XX New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 80; Page 151; 281pp; English.
XX PS
XX This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC
XX Sequence 33 AA;
SQ

AAB11165 Length: 33 February 4, 2005 13:32 Type: P Check: 2325 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTSLSKQEEAVRLFIEFLKNGGPS
  1 28
  -----|
  HGEFTSLSKQEEAVRLFIEFLKNGGPS
  1 28
  -----|
  1 match found in sequence:
  aab11166 ; exendin agonist peptide SEQ ID NO 74.
  (from "seq5ags.pep")
  TOIG of: aab11166 check: 25 from: 1 to: 32

ID AAB11166 standard; peptide; 32 AA.
XX
XX
XX AAB11166;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX exendin agonist peptide SEQ ID NO 74.
DE
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX PN
XX 20-JUL-2000.
XX PD
XX
XX 14-JAN-2000; 2000WO-US000902.
XX PF
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young A, L'italien JJ, Kolterman O;
XX PI
XX WPI; 2000-514584/46.
XX DR

```

```

XX New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 81; Page 152; 281pp; English.
XX PS
XX This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC
XX Sequence 32 AA;
SQ

AAB11166 Length: 32 February 4, 2005 13:32 Type: P Check: 25 ..
Found using 'seq5' (mohamed337.key)

1 HGEFTSLSKQEEAVRLFIEFLKNGGPS
  1 28
  -----|
  HGEFTSLSKQEEAVRLFIEFLKNGGPS
  1 28
  -----|
  1 match found in sequence:
  aab11167 ; exendin agonist peptide SEQ ID NO 75.
  (from "seq5ags.pep")
  TOIG of: aab11167 check: 9586 from: 1 to: 32

ID AAB11167 standard; peptide; 32 AA.
XX
XX
XX AAB11167;
AC
XX
XX 20-FEB-2001 (first entry)
DT
XX
XX exendin agonist peptide SEQ ID NO 75.
DE
XX
XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX PN
XX 20-JUL-2000.
XX PD
XX
XX 14-JAN-2000; 2000WO-US000902.
XX PF
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young A, L'italien JJ, Kolterman O;
XX PI
XX WPI; 2000-514584/46.
XX DR
XX
XX New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 82; Page 153; 281pp; English.
XX PS
XX This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC
XX Sequence 32 AA;
SQ

```

CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
SQ Sequence 34 AA;

AAB11162 Length: 34 February 4, 2005 13:32 Type: P Check: 5178 ..
Found using 'seq5' (mohamed337.key)

1 HGGFTTSDLSKQMEEEAVRLFIEWLKNGPSSG
28

1 match found in sequence:
aabl1163 ; exendin agonist peptide SEQ ID NO 71.
(from "seq5ags.pep")
TOIG of: aabl1163 check: 4739 from: 1 to: 34

ID AAB11163 standard; peptide; 34 AA.

XX AC AAB11163;

XX DT 20-FEB-2001 (first entry)

XX DE exendin agonist peptide SEQ ID NO 71.

XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 78; Page 149-150; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake

XX SQ Sequence 34 AA;

AAB11163 Length: 34 February 4, 2005 13:32 Type: P Check: 4739 ..
Found using 'seq5' (mohamed337.key)

1 HGGFTTSDLSKQLEEEAVRLFIEFLKNGPSSG
28

1 match found in sequence:
aabl1164 ; exendin agonist peptide SEQ ID NO 72.
(from "seq5ags.pep")
TOIG of: aabl1164 check: 2764 from: 1 to: 33

ID AAB11164 standard; peptide; 33 AA.

XX AC AAB11164;

XX DT 20-FEB-2001 (first entry)

XX DE exendin agonist peptide SEQ ID NO 72.

XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX OS Synthetic.

XX PN WO200041546-A2.

XX PD 20-JUL-2000.

XX PF 14-JAN-2000; 2000WO-US000902.

XX PR 14-JAN-1999; 99US-0116380P.

XX PR 10-JAN-2000; 2000US-0175365P.

XX PA (AMYL-) AMYLIN PHARM INC.

XX PI Young A, L'italien JJ, Kolterman O;

XX DR WPI; 2000-514584/46.

XX PT New formulations comprising an exendin or exendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX PS Example 79; Page 150; 281pp; English.

XX CC This invention describes a novel formulation (I) comprising an exendin or
XX CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The exendin or exendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake

XX SQ Sequence 33 AA;

AAB11164 Length: 33 February 4, 2005 13:32 Type: P Check: 2764 ..
Found using 'seq5' (mohamed337.key)

1 HGGFTTSDLSKQMEEEAVRLFIEWLKNGPSS
28

1 match found in sequence:
aabl1165 ; exendin agonist peptide SEQ ID NO 73.
(from "seq5ags.pep")
TOIG of: aabl1165 check: 2325 from: 1 to: 33

ID AAB11165 standard; peptide; 33 AA.

XX AC AAB11165;

XX DT 20-FEB-2001 (first entry)

XX DE exendin agonist peptide SEQ ID NO 73.

XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.

XX 14-JAN-1999; 99US-0116380P.
 PR 10-JAN-2000; 2000US-0175365P.
 XX (AMYL-) AMYLIN PHARM INC.
 XX Young A, L'italien JJ, Kolterman O;
 PI WPI; 2000-514584/46.
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX Example 85; Page 155; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 30 AA;
 SQ
 AAB11170 Length: 30 February 4, 2005 13:32 Type: P Check: 4450 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGTFTSDLSKQLEEEAVRLFIEFLKNG 28
 1 match found in sequence:
 aab11171; extendin agonist peptide SEQ ID NO 79.
 (from "seq5ags.pep")
 TOIG of: aab11171 check: 2759 from: 1 to: 29
 ID AAB11171 standard; peptide; 29 AA.
 XX
 AC AAB11171;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 79.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX Synthetic.
 OS
 XX WO2000041546-A2.
 PN
 XX 20-JUL-2000.
 PD
 XX 14-JAN-2000; 2000WO-US000902.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR
 XX 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, L'italien JJ, Kolterman O;
 PI WPI; 2000-514584/46.
 XX
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX Example 86; Page 156; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or

CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 29 AA;
 SQ
 AAB11171 Length: 29 February 4, 2005 13:32 Type: P Check: 2759 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGTFTSDLSKQLEEEAVRLFIEFLKNG 28
 1 match found in sequence:
 aab11172; extendin agonist peptide SEQ ID NO 80.
 (from "seq5ags.pep")
 TOIG of: aab11172 check: 2320 from: 1 to: 29
 ID AAB11172 standard; peptide; 29 AA.
 XX
 AC AAB11172;
 XX
 DT 20-FEB-2001 (first entry)
 XX
 DE extendin agonist peptide SEQ ID NO 80.
 XX
 KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.
 XX Synthetic.
 OS
 XX WO2000041546-A2.
 PN
 XX 20-JUL-2000.
 PD
 XX 14-JAN-2000; 2000WO-US000902.
 PF
 XX 14-JAN-1999; 99US-0116380P.
 PR
 XX 10-JAN-2000; 2000US-0175365P.
 XX
 XX (AMYL-) AMYLIN PHARM INC.
 PA
 XX Young A, L'italien JJ, Kolterman O;
 PI WPI; 2000-514584/46.
 XX
 XX New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.
 XX Example 87; Page 156; 281pp; English.
 XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 29 AA;
 SQ
 AAB11172 Length: 29 February 4, 2005 13:32 Type: P Check: 2320 ..
 Found using 'seq5' (mohamed337.key)
 1 HEGTFTSDLSKQLEEEAVRLFIEFLKNG 28

```

AAB11167 Length: 32 February 4, 2005 13:32 Type: P Check: 9586 ..
Found using 'seq5' (mohamed337.key)

1 1 HGGFTFTSDLSKQLEEEAVRLFIEFLKNGGFS
  1 28
-----
1 match found in sequence:
aabl1168 ; extendin agonist peptide SEQ ID NO 76.
(from "seq5ags.pep")
TOIG of: aabl1168 check: 7369 from: 1 to: 31

ID AAB11168 standard; peptide; 31 AA.
XX
XX AC AAB11168;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 76.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PS 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 83; Page 153; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 31 AA;

AAB11168 Length: 31 February 4, 2005 13:32 Type: P Check: 7369 ..
Found using 'seq5' (mohamed337.key)

1 1 HGGFTFTSDLSKQMEEEAVRLFIEFLKNGGP
  1 28
-----
1 match found in sequence:
aabl1169 ; extendin agonist peptide SEQ ID NO 77.
(from "seq5ags.pep")
TOIG of: aabl1169 check: 6930 from: 1 to: 31

ID AAB11169 standard; peptide; 31 AA.
XX

```

```

AAB11169;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 77.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX
XX PS 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX
XX DR WPI; 2000-514584/46.
XX
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX PS Example 84; Page 154; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX SQ Sequence 31 AA;

AAB11169 Length: 31 February 4, 2005 13:32 Type: P Check: 6930 ..
Found using 'seq5' (mohamed337.key)

1 1 HGGFTFTSDLSKQLEEEAVRLFIEFLKNGGP
  1 28
-----
1 match found in sequence:
aabl1170 ; extendin agonist peptide SEQ ID NO 78.
(from "seq5ags.pep")
TOIG of: aabl1170 check: 4450 from: 1 to: 30

ID AAB11170 standard; peptide; 30 AA.
XX
XX AC AAB11170;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE extendin agonist peptide SEQ ID NO 78.
XX
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PS 14-JAN-2000; 2000WO-US000902.

```



```

XX CC This invention describes a novel formulation (I) comprising an extendin or
CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The extendin or extendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders which
CC would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX CC Sequence 30 AA;
SQ
AAB1180 Length: 30 February 4, 2005 13:32 Type: P Check: 4886 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aabl1181 ; extendin agonist peptide SEQ ID NO 89.
(from "seq5ags.pep")
TOIG of: aabl1181 check: 231 from: 1 to: 28

ID AAB11181 standard; peptide; 28 AA.
XX AC AAB11181;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 89.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX XX 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX XX (AMYL-) AMYLIN PHARM INC.
XX PA Young A, L'italien JJ, Kolterman O;
XX PI WPI; 2000-514584/46.
XX DR New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 96; Page 163-164; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC Sequence 28 AA;
SQ
AAB1181 Length: 28 February 4, 2005 13:32 Type: P Check: 231 ..
Found using 'seq5' (mohamed337.key)

```

```

1 HGGTFTSDLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aabl1182 ; extendin agonist peptide SEQ ID NO 90.
(from "seq5ags.pep")
TOIG of: aabl1182 check: 693 from: 1 to: 28

ID AAB11182 standard; peptide; 28 AA.
XX AC AAB11182;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 90.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX XX 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX XX (AMYL-) AMYLIN PHARM INC.
XX PA Young A, L'italien JJ, Kolterman O;
XX PI WPI; 2000-514584/46.
XX DR New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 97; Page 164; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC Sequence 28 AA;
SQ
AAB1182 Length: 28 February 4, 2005 13:32 Type: P Check: 693 ..
Found using 'seq5' (mohamed337.key)
1 HGGTFTSDLSKQLEEEAVRLFIEFLKN 28
-----
1 match found in sequence:
aabl1183 ; extendin agonist peptide SEQ ID NO 91.
(from "seq5ags.pep")
TOIG of: aabl1183 check: 701 from: 1 to: 28

ID AAB11183 standard; peptide; 28 AA.
XX AC AAB11183;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 91.

```

```

ID AAB11178 standard; peptide; 36 AA.
XX AC
XX AAB11178;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 86.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX PI WPI; 2000-514584/46.
XX DR
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 93; Page 161; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC Sequence 36 AA;
XX AC
XX AAB11178 Length: 36 February 4, 2005 13:32 Type: P Check: 333 ..
XX DT Found using 'seq5' (mohamed337.key)
XX DE
XX DE 1 HGEFTSLSKQMBEEAVRLFIEWLKNGPSSGAP
XX DE 28
XX DE
-----
1 match found in sequence:
XX DE aab11179; extendin agonist peptide SEQ ID NO 87.
XX DE (from "seq5ags.pep")
XX DE TOIG of: aab11179 check: 7463 from: 1 to: 35
XX ID AAB11179 standard; peptide; 35 AA.
XX AC
XX AAB11179;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 87.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX PI WPI; 2000-514584/46.
XX DR
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 95; Page 163; 281pp; English.

```

```

XX 14-JAN-2000; 2000WO-US000902.
XX PF
XX 14-JAN-1999; 99US-0116380P.
XX PR
XX 10-JAN-2000; 2000US-0175365P.
XX PR
XX (AMYL-) AMYLIN PHARM INC.
XX PA
XX Young A, L'italien JJ, Kolterman O;
XX PI
XX WPI; 2000-514584/46.
XX DR
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 94; Page 162; 281pp; English.
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX CC has a pH of 3-7. The products of the invention have antidiabetic
XX CC activity. The extendin or extendin agonist is used to increase the
XX CC sensitivity of a subject to insulin to treat diabetes and disorders which
XX CC would benefit from agents which lower plasma glucose levels and disorders
XX CC which would benefit from agents that delay and/or slow gastric emptying
XX CC or reducing food intake
XX CC Sequence 35 AA;
XX AC
XX AAB11179 Length: 35 February 4, 2005 13:32 Type: P Check: 7463 ..
XX DT Found using 'seq5' (mohamed337.key)
XX DE
XX DE 1 RGEFTSLSKQMBEEAVRLFIEWLKNGPSSGA
XX DE 28
XX DE
-----
1 match found in sequence:
XX DE aab11180; extendin agonist peptide SEQ ID NO 88.
XX DE (from "seq5ags.pep")
XX DE TOIG of: aab11180 check: 4886 from: 1 to: 30
XX ID AAB11180 standard; peptide; 30 AA.
XX AC
XX AAB11180;
XX DT 20-FEB-2001 (first entry)
XX DE extendin agonist peptide SEQ ID NO 88.
XX KW Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX KW plasma glucose; gastric emptying; food intake.
XX OS Synthetic.
XX PN WO200041546-A2.
XX PD 20-JUL-2000.
XX PF 14-JAN-2000; 2000WO-US000902.
XX PR 14-JAN-1999; 99US-0116380P.
XX PR 10-JAN-2000; 2000US-0175365P.
XX PA (AMYL-) AMYLIN PHARM INC.
XX PI Young A, L'italien JJ, Kolterman O;
XX PI WPI; 2000-514584/46.
XX DR
XX PT New formulations comprising an extendin or extendin agonist peptide used
XX PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX PS Example 95; Page 163; 281pp; English.

```

CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake
 XX Sequence 28 AA;

AAB11185 Length: 28 February 4, 2005 13:32 Type: P Check: 211 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTSDLSKQLEEAARLPIEFLKN 28
 1

1 match found in sequence:
 aab11186 ; extendin agonist peptide SEQ ID NO 94.
 (from "seq5ags.pep")
 TOIG of: aab11186 Check: 151 from: 1 to: 28

ID AAB11186 standard; peptide; 28 AA.

XX AAB11186;

AC AAB11187;

DT 20-FEB-2001 (first entry)

XX extendin agonist peptide SEQ ID NO 94.

DE Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 XX plasma glucose; gastric emptying; food intake.

OS Synthetic.

XX WO200041546-A2.

PN 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

PA Young A, L'italien JJ, Kolterman O;
 XX WPI; 2000-514584/46.

DR New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 101; Page 167; 281pp; English.

PS This invention describes a novel formulation (I) comprising an extendin or
 XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 28 AA;

AAB11186 Length: 28 February 4, 2005 13:32 Type: P Check: 151 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTSDLSKQLEEAARLPIEFLKN 28
 1

1 match found in sequence:
 aab11187 ; extendin agonist peptide SEQ ID NO 95.
 (from "seq5ags.pep")

TOIG of: aab11187 check: 654 from: 1 to: 28

ID AAB11187 standard; peptide; 28 AA.

XX AAB11187;

AC 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 95.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

XX WO200041546-A2.

PN 20-JUL-2000.

XX 14-JAN-2000; 2000WO-US000902.

XX 14-JAN-1999; 99US-0116380P.

PR 10-JAN-2000; 2000US-0175365P.

XX (AMYL-) AMYLIN PHARM INC.

PA Young A, L'italien JJ, Kolterman O;
 XX WPI; 2000-514584/46.

DR New formulations comprising an extendin or extendin agonist peptide used
 PT for increasing the sensitivity of a subject to insulin to treat diabetes.

XX Example 102; Page 168; 281pp; English.

XX This invention describes a novel formulation (I) comprising an extendin or
 CC extendin agonist peptide, a buffer and an iso-osmolality modifier which
 CC has a pH of 3-7. The products of the invention have antidiabetic
 CC activity. The extendin or extendin agonist is used to increase the
 CC sensitivity of a subject to insulin to treat diabetes and disorders which
 CC would benefit from agents which lower plasma glucose levels and disorders
 CC which would benefit from agents that delay and/or slow gastric emptying
 CC or reducing food intake

XX Sequence 28 AA;

AAB11187 Length: 28 February 4, 2005 13:32 Type: P Check: 654 ..
 Found using 'seq5' (mohamed337.key)

1 HGEFTSDLSKQLEEAARLPIEFLKN 28
 1

1 match found in sequence:
 aab11188 ; extendin agonist peptide SEQ ID NO 96.
 (from "seq5ags.pep")
 TOIG of: aab11188 check: 237 from: 1 to: 28

ID AAB11188 standard; peptide; 28 AA.

XX AAB11188;

AC 20-FEB-2001 (first entry)

DE extendin agonist peptide SEQ ID NO 96.

XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
 KW plasma glucose; gastric emptying; food intake.

OS Synthetic.

XX WO200041546-A2.

```

XX Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
KW plasma glucose; gastric emptying; food intake.
XX Synthetic.
OS
PN WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 98; Page 165; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders
CC which would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
XX
XX AAB1183 Length: 28 February 4, 2005 13:32 Type: P Check: 701 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX -----|-----|
XX 1 HGEGETFSTLKSQMAEEAVRLFIEWLKN 28
XX
XX -----|-----|
XX 1 match found in sequence:
XX aab1184; exendin agonist peptide SEQ ID NO 92.
XX (from "seq5ags.pep")
XX TOIG of: aab1184 check: 649 from: 1 to: 28
XX
XX ID AAB1184 standard; peptide; 28 AA.
XX
XX AC AAB1184;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE exendin agonist peptide SEQ ID NO 92.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 98; Page 165; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders
CC which would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
XX
XX AAB1183 Length: 28 February 4, 2005 13:32 Type: P Check: 701 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX -----|-----|
XX 1 HGEGETFSTLKSQMAEEAVRLFIEWLKN 28
XX
XX -----|-----|
XX 1 match found in sequence:
XX aab1184; exendin agonist peptide SEQ ID NO 92.
XX (from "seq5ags.pep")
XX TOIG of: aab1184 check: 649 from: 1 to: 28
XX
XX ID AAB1184 standard; peptide; 28 AA.
XX
XX AC AAB1184;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE exendin agonist peptide SEQ ID NO 92.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.

```

```

XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 99; Page 166; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders
CC which would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake
XX
XX Sequence 28 AA;
XX
XX AAB1184 Length: 28 February 4, 2005 13:32 Type: P Check: 649 ..
XX Found using 'seq5' (mohamed337.key)
XX
XX -----|-----|
XX 1 HGEGETFSTLKSQMAEEAVRLFIEWLKN 28
XX
XX -----|-----|
XX 1 match found in sequence:
XX aab1185; exendin agonist peptide SEQ ID NO 93.
XX (from "seq5ags.pep")
XX TOIG of: aab1185 check: 211 from: 1 to: 28
XX
XX ID AAB1185 standard; peptide; 28 AA.
XX
XX AC AAB1185;
XX
XX DT 20-FEB-2001 (first entry)
XX
XX DE exendin agonist peptide SEQ ID NO 93.
XX
XX KW Exendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX OS Synthetic.
XX
XX PN WO200041546-A2.
XX
XX PD 20-JUL-2000.
XX
XX PF 14-JAN-2000; 2000WO-US000902.
XX
XX PR 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX PA (AMYL-) AMYLIN PHARM INC.
XX
XX PI Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an exendin or exendin agonist peptide used
PT for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 100; Page 167; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an exendin or
CC exendin agonist peptide, a buffer and an iso-osmolality modifier which
CC has a pH of 3-7. The products of the invention have antidiabetic
CC activity. The exendin or exendin agonist is used to increase the
CC sensitivity of a subject to insulin to treat diabetes and disorders
CC which would benefit from agents which lower plasma glucose levels and disorders
CC which would benefit from agents that delay and/or slow gastric emptying
CC or reducing food intake

```



```
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 103; Page 168; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 28 AA;
XX
AAB11188 Length: 28 February 4, 2005 13:32 Type: P Check: 237 ..
Found using 'seq5' (mohamed337.key)
1 HEGTFTDLSKQLEEAVALRFLFIDFLKN 28
1 -----|
1 match found in sequence:
aabl1189 ; extendin agonist peptide SEQ ID NO 97.
(from "seq5ags.pep")
TOIG of: aabl1189 check: 2215 from: 1 to: 33
ID AAB11189 standard; peptide; 33 AA.
XX
XX AC AAB11189;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 97.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
```

```
XX
XX PS Example 104; Page 170; 281pp; English.
XX
XX CC This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 33 AA;
XX
AAB11189 Length: 33 February 4, 2005 13:32 Type: P Check: 2215 ..
Found using 'seq5' (mohamed337.key)
1 HEGTFTDASKQLSEEAVALRFLFIEFLKNGPSS 33
1 -----|
1 match found in sequence:
aabl1190 ; extendin agonist peptide SEQ ID NO 98.
(from "seq5ags.pep")
TOIG of: aabl1190 check: 2649 from: 1 to: 29
ID AAB11190 standard; peptide; 29 AA.
XX
XX AC AAB11190;
XX
XX 20-FEB-2001 (first entry)
XX
XX extendin agonist peptide SEQ ID NO 98.
XX
XX Extendin; agonist; treatment; antidiabetic; insulin sensitivity; diabetes;
XX plasma glucose; gastric emptying; food intake.
XX
XX Synthetic.
XX
XX WO200041546-A2.
XX
XX 20-JUL-2000.
XX
XX 14-JAN-2000; 2000WO-US000902.
XX
XX 14-JAN-1999; 99US-0116380P.
XX 10-JAN-2000; 2000US-0175365P.
XX
XX (AMYL-) AMYLIN PHARM INC.
XX
XX Young A, L'italien JJ, Kolterman O;
XX WPI; 2000-514584/46.
XX
XX New formulations comprising an extendin or extendin agonist peptide used
XX for increasing the sensitivity of a subject to insulin to treat diabetes.
XX
XX Example 105; Page 170; 281pp; English.
XX
XX This invention describes a novel formulation (I) comprising an extendin or
XX extendin agonist peptide, a buffer and an iso-osmolality modifier which
XX has a pH of 3-7. The products of the invention have antidiabetic
XX activity. The extendin or extendin agonist is used to increase the
XX sensitivity of a subject to insulin to treat diabetes and disorders which
XX would benefit from agents which lower plasma glucose levels and disorders
XX which would benefit from agents that delay and/or slow gastric emptying
XX or reducing food intake
XX
XX Sequence 29 AA;
XX
AAB11190 Length: 29 February 4, 2005 13:32 Type: P Check: 2649 ..
Found using 'seq5' (mohamed337.key)
```